OBJECTIVE O
: O
To O
test O
the O
hypothesis O
that O
tumor O
necrosis O
factor O
( O
TNF) O
- O
alpha O
may O
mediate O
the O
loss O
and O
the O
dedifferentiation O
of O
subcutaneous O
fat O
tissue O
in O
the O
insulin I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
lipoatrophies I-Effect
of O
a O
diabetic I-Treat_Disorder
patient O
who O
presented O
extensive O
lesions O
. O

An O
evaluation O
of O
ovarian O
structure O
and O
function O
should O
be O
considered O
in O
women I-Subject.Gender
of I-Subject
reproductive I-Subject.Age
age I-Subject.Age
being O
treated O
with O
valproate I-Treatment.Drug
for I-Treatment
epilepsy I-Treatment.Treat_Disorder
, O
especially O
if O
they O
develop I-Adverse_event.Trigger
menstrual I-Effect
cycle I-Effect
disturbances I-Effect
during O
treatment O
. O

Phenobarbital I-Treatment.Drug
hepatotoxicity I-Effect
in I-Adverse_event.Trigger
an I-Subject
8 I-Subject.Age
- I-Subject.Age
month I-Subject.Age
- I-Subject.Age
old I-Subject.Age
infant I-Subject.Age
. O

The O
authors O
report O
a O
case O
of O
Balint I-Effect
syndrome I-Effect
with I-Effect
irreversible I-Effect
posterior I-Effect
leukoencephalopathy I-Effect
on I-Effect
MRI I-Effect
following I-Adverse_event.Trigger
intrathecal I-Treatment.Route
methotrexate I-Treatment.Combination.Drug
and I-Treatment
cytarabine I-Treatment.Combination.Drug
. O

According O
to O
the O
Naranjo O
probability O
scale O
, O
flecainide I-Treatment.Drug
was O
the O
probable O
cause I-Adverse_event.Trigger
of O
the I-Subject
patient I-Subject
's O
delirium I-Effect
; O
the O
Horn O
Drug O
Interaction O
Probability O
Scale O
indicates O
a O
possible O
pharmacokinetic O
drug O
interaction O
between O
flecainide I-Combination.Drug
and O
paroxetine I-Combination.Drug
. O

Contact I-Effect
dermatitis I-Effect
due I-Adverse_event.Trigger
to O
budesonide I-Treatment.Drug
: O
report O
of O
five O
cases O
and O
review O
of O
the O
Japanese O
literature O
. O

Prolongation I-Effect
of I-Effect
the I-Effect
QT I-Effect
interval I-Effect
observed O
in O
a I-Subject
Japanese I-Subject.Race
patient I-Subject
with I-Subject
vivax I-Treat_Disorder
malaria I-Treat_Disorder
following I-Adverse_event.Trigger
treatment O
with O
halofantrine I-Treatment.Drug
. O

We O
report O
three I-Subject.Population
cases I-Subject
of O
severe I-Effect
hepatotoxicity I-Effect
related I-Adverse_event.Trigger
to O
benzarone I-Treatment.Drug
, O
a O
benzofuran O
derivative O
. O

Four I-Subject.Population
patients I-Subject
who O
manifested O
symptoms I-Adverse_event.Trigger
of I-Adverse_event.Trigger
the O
antiepileptic I-Treatment.Drug
drug I-Treatment.Drug
( I-Treatment.Drug
AED I-Treatment.Drug
) I-Treatment.Drug
hypersensitivity I-Effect
syndrome I-Effect
during I-Treatment
therapy I-Treatment
with I-Treatment
carbamazepine I-Treatment.Drug
are O
reported O
. O

Minocycline I-Treatment.Drug
as O
a O
cause O
of O
drug O
- O
induced I-Adverse_event.Trigger
autoimmune I-Effect
hepatitis I-Effect
. O

Secondary I-Effect
acute I-Effect
myeloid I-Effect
leukemia I-Effect
after I-Adverse_event.Trigger
etoposide I-Treatment.Drug
therapy I-Treatment
for O
haemophagocytic I-Treat_Disorder
lymphohistiocytosis I-Treat_Disorder
. O

Allergic I-Effect
contact I-Effect
angioedema I-Effect
to I-Adverse_event.Trigger
benzoyl I-Treatment.Drug
peroxide I-Treatment.Drug
. O

A I-Subject
60 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
white I-Subject.Race
man I-Subject.Gender
with I-Subject
chronic I-Subject.Sub_Disorder
bronchitis I-Subject.Sub_Disorder
was O
noted O
to O
develop I-Adverse_event.Trigger
acute I-Effect
respiratory I-Effect
failure I-Effect
and I-Effect
metabolic I-Effect
acidosis I-Effect
four I-Time_elapsed
days I-Time_elapsed
after I-Time_elapsed
being O
started O
on O
methazolamide I-Treatment.Drug
( I-Treatment
Neptazane I-Treatment
) I-Treatment
for O
an O
ophthalmologic I-Treat_Disorder
problem I-Treat_Disorder
. O

L I-Treatment
- I-Treatment
DOPA I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
excessive O
daytime I-Effect
sleepiness I-Effect
in O
PD O
: O
a O
placebo O
- O
controlled O
case O
with O
MSLT O
assessment O
. O

CONCLUSIONS O
: O
It O
is O
probable O
that O
foscarnet I-Treatment.Drug
contributed I-Adverse_event.Trigger
to O
the O
electrolyte I-Effect
disorders I-Effect
and I-Effect
symptomatology I-Effect
in O
this I-Subject
patient I-Subject
. O

Acute I-Effect
drug I-Effect
induced I-Effect
hepatitis I-Effect
due I-Adverse_event.Trigger
to O
erlotinib I-Treatment.Drug
. O

We O
observed O
3 I-Subject.Population
diabetic I-Treat_Disorder
patients I-Subject
with O
intolerable I-Effect
dizziness I-Effect
followed I-Effect
by I-Effect
nausea I-Effect
and I-Effect
vomiting I-Effect
immediately O
after I-Adverse_event.Trigger
an I-Treatment
initial I-Treatment
administration I-Treatment
of I-Treatment
the I-Treatment
alpha I-Treatment
- I-Treatment
glucosidase I-Treatment
inhibitor I-Treatment
, I-Treatment
voglibose I-Treatment.Drug
. O

Although O
risk O
factors O
for O
MTX I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
pulmonary I-Effect
toxicity I-Effect
are O
poorly O
understood O
, O
the I-Subject
presence I-Subject
in I-Subject
3 I-Subject.Population
out I-Subject.Population
of I-Subject.Population
5 I-Subject.Population
of I-Subject
our I-Subject
patients I-Subject
of I-Subject
pre I-Subject.Sub_Disorder
- I-Subject.Sub_Disorder
existing I-Subject.Sub_Disorder
lung I-Subject.Sub_Disorder
disease I-Subject.Sub_Disorder
, I-Subject.Sub_Disorder
represented I-Subject.Sub_Disorder
by I-Subject.Sub_Disorder
diffuse I-Subject.Sub_Disorder
interstitial I-Subject.Sub_Disorder
changes I-Subject.Sub_Disorder
on I-Subject.Sub_Disorder
chest I-Subject.Sub_Disorder
X I-Subject.Sub_Disorder
- I-Subject.Sub_Disorder
ray I-Subject.Sub_Disorder
, I-Subject.Sub_Disorder
and I-Subject.Sub_Disorder
mild I-Subject.Sub_Disorder
bronchial I-Subject.Sub_Disorder
asthma I-Subject.Sub_Disorder
in I-Subject.Sub_Disorder
two I-Subject.Sub_Disorder
RA I-Subject.Sub_Disorder
patients I-Subject.Sub_Disorder
and I-Subject.Sub_Disorder
by I-Subject.Sub_Disorder
pulmonary I-Subject.Sub_Disorder
silicosis I-Subject.Sub_Disorder
in I-Subject.Sub_Disorder
the I-Subject.Sub_Disorder
patient I-Subject.Sub_Disorder
with I-Subject.Sub_Disorder
PsA I-Subject.Sub_Disorder
may O
account O
for O
a O
predisposition O
to O
the O
development O
of O
MTX O
pneumonitis O
. O

Acute O
esmolol I-Treatment.Drug
toxicity I-Effect
may O
be I-Adverse_event.Trigger
self O
- O
limiting O
because O
of O
its O
extremely O
short O
half O
- O
life O
. O

The O
association O
with I-Adverse_event.Trigger
prolonged I-Treatment.Duration
unopposed I-Treatment
estrogen I-Treatment
- I-Treatment
like I-Treatment
stimulation I-Treatment
with I-Treatment
tamoxifen I-Treatment.Drug
as O
a O
possible O
factor O
in O
the O
development I-Effect
of I-Effect
ovarian I-Effect
endometrioid I-Effect
carcinoma I-Effect
is O
discussed O
. O

The I-Subject
other I-Subject
woman I-Subject.Gender
had I-Subject
rheumatoid I-Treat_Disorder
arthritis I-Treat_Disorder
and O
developed I-Adverse_event.Trigger
acute I-Effect
tubular I-Effect
necrosis I-Effect
after O
treatment O
with O
gentamicin I-Treatment.Combination.Drug
and I-Treatment
cefoxitin I-Treatment.Combination.Drug
. O

One I-Subject.Population
patient I-Subject
who O
received O
clindamycin I-Treatment.Drug
had I-Adverse_event.Trigger
liver O
biopsy O
findings O
of O
marked I-Effect
cholestasis I-Effect
, I-Effect
portal I-Effect
inflammation I-Effect
, I-Effect
bile I-Effect
duct I-Effect
injury I-Effect
and I-Effect
bile I-Effect
duct I-Effect
paucity I-Effect
( I-Effect
ductopenia I-Effect
) I-Effect
. O

A O
MEDLINE O
search O
( O
1966 O
- O
January O
2009 O
) O
revealed O
one O
in O
vivo O
pharmacokinetic O
study O
on O
the O
interaction O
between O
flecainide O
, O
a O
CYP2D6 O
substrate O
, O
and O
paroxetine O
, O
a O
CYP2D6 O
inhibitor O
, O
as O
well O
as O
3 I-Subject.Population
case I-Subject
reports I-Subject
of O
flecainide I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
delirium I-Effect
. O

As O
these O
cases O
revealed O
, O
close O
monitoring O
of O
blood O
chemistry O
is O
mandatory O
after O
starting O
spironolactone I-Treatment.Drug
, O
and O
patients I-Subject
should O
be O
advised O
to O
stop O
spironolactone O
immediately O
if O
diarrhoea I-Effect
develops I-Adverse_event.Trigger
. O

When O
these O
cells O
are O
exposed O
to O
nicotinic I-Treatment.Drug
acid I-Treatment.Drug
, O
an O
exaggerated I-Effect
immune I-Effect
response I-Effect
is O
produced I-Adverse_event.Trigger
that O
may O
lead O
to O
pain I-Effect
, I-Effect
redness I-Effect
, I-Effect
and I-Effect
swelling I-Effect
at I-Effect
the I-Effect
injection I-Effect
site I-Effect
. O

A O
case O
of O
heatstroke I-Effect
is O
reported I-Adverse_event.Trigger
in O
a I-Subject
32 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
man I-Subject.Gender
diagnosed I-Subject
with I-Subject
schizophrenia I-Treat_Disorder
and O
on O
clozapine I-Treatment.Drug
monotherapy I-Treatment
. O

Paraplegia I-Effect
following I-Adverse_event.Trigger
intrathecal I-Treatment.Route
cytosine I-Treatment.Drug
arabinoside I-Treatment.Drug
. O

Cimetidine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
fever I-Effect
. O

This I-Subject
case I-Subject
report O
illustrates O
the O
neurotoxicity I-Effect
unique I-Effect
to I-Adverse_event.Trigger
HDARAC I-Treatment.Drug
. O

Agranulocytosis I-Effect
associated I-Adverse_event.Trigger
with O
ticlopidine I-Treatment.Drug
: O
a O
possible O
benefit O
with O
filgastim O
. O

Since O
SS O
is O
a O
clinical O
diagnosis O
, O
heightened O
clinician O
awareness O
of O
the O
possibility O
of O
SS O
among O
patients I-Subject
receiving O
SSRI I-Treatment.Combination.Drug
or I-Treatment
mirtazapine I-Treatment.Combination.Drug
in I-Treatment
combination I-Treatment
with I-Treatment
opioids I-Treatment.Combination.Drug
may O
lead I-Adverse_event.Trigger
to I-Adverse_event.Trigger
earlier O
detection O
and O
avoidance O
of O
potentially I-Effect
lethal I-Effect
consequences I-Effect
. O

The O
mechanism O
by O
which O
sunitinib I-Treatment.Drug
induces I-Adverse_event.Trigger
gynaecomastia I-Effect
is O
thought O
to O
be O
associated O
with O
an O
unknown O
direct O
action O
on O
breast O
hormonal O
receptors O
. O

Some I-Subject.Population
patients I-Subject
develop I-Adverse_event.Trigger
hypersensitivity I-Effect
rash I-Effect
in O
response O
to O
HCQ I-Treatment.Drug
. O

To O
report O
a O
case O
of O
serotonin I-Effect
toxicity I-Effect
, O
presenting O
in O
the O
postoperative O
period O
, O
caused I-Adverse_event.Trigger
by O
an O
interaction O
between O
paroxetine I-Treatment.Combination.Drug
( O
a O
selective O
serotonin O
reuptake O
inhibitor O
, O
SSRI O
) O
and O
fentanyl I-Treatment.Combination.Drug
( O
a O
phenylpiperidine O
opioid O
) O
. O

However O
, O
to O
our O
knowledge O
, O
in O
newborns I-Subject.Age
there O
have O
been O
no O
reported O
cases O
to O
date O
of O
thrombocytosis I-Effect
induced I-Adverse_event.Trigger
by O
enoxaparin I-Treatment.Drug
. O

The O
case O
presented O
here O
documents O
adverse I-Effect
cardiac I-Effect
effects I-Effect
in O
a O
28 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
man I-Subject.Gender
who O
intentionally O
ingested I-Adverse_event.Trigger
24 I-Treatment.Dosage
mg I-Treatment.Dosage
of I-Treatment
risperidone I-Treatment.Drug
- O
- O
4 O
times O
the O
recommended O
dose O
. O

Anaphylaxis I-Effect
to I-Adverse_event.Trigger
cisplatin I-Treatment.Drug
following I-Treatment
nine I-Treatment.Duration
previous I-Treatment.Duration
uncomplicated I-Treatment.Duration
cycles I-Treatment.Duration
. O

To O
the O
best O
of O
the O
authors O
' O
knowledge O
, O
this O
is O
the O
first O
reported O
case O
of O
Propecia I-Treatment.Drug
- O
associated I-Adverse_event.Trigger
cataract I-Effect
. O

Serotonin I-Effect
syndrome I-Effect
caused I-Adverse_event.Trigger
by O
interaction O
between O
citalopram I-Treatment.Combination.Drug
and I-Treatment
fentanyl I-Treatment.Combination.Drug
. O

We O
report O
on O
three O
observations O
of O
parkinsonian I-Subject.Sub_Disorder
patients I-Subject
with O
levo O
- O
dopa O
- O
induced O
diphasic O
dyskinesias O
, O
who O
received O
subcutaneous I-Treatment.Route
apomorphine I-Treatment.Drug
to O
reduce I-Potential_therapeutic_event.Trigger
the O
duration O
of O
abnormal I-Treat_Disorder
movements I-Treat_Disorder
. O

We O
report O
on O
three O
observations O
of O
parkinsonian I-Subject.Sub_Disorder
patients I-Subject
with O
levo I-Treatment.Drug
- I-Treatment.Drug
dopa I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
diphasic I-Effect
dyskinesias I-Effect
, O
who O
received O
subcutaneous O
apomorphine O
to O
reduce O
the O
duration O
of O
abnormal O
movements O
. O

This O
report O
presents O
a O
case O
of O
acute I-Effect
lung I-Effect
injury I-Effect
developing O
within I-Time_elapsed
hours I-Time_elapsed
after I-Adverse_event.Trigger
administration I-Treatment
of I-Treatment
mefloquine I-Treatment.Drug
for I-Treatment
a I-Treatment
low I-Treatment.Treat_Disorder
- I-Treatment.Treat_Disorder
level I-Treatment.Treat_Disorder
Plasmodium I-Treatment.Treat_Disorder
falciparum I-Treatment.Treat_Disorder
malaria I-Treatment.Treat_Disorder
, O
which O
was O
persistent I-Effect
despite I-Effect
halofantrine I-Treatment.Drug
therapy I-Treatment
. O

Warfarin I-Treatment.Drug
- O
associated I-Adverse_event.Trigger
bleeding I-Effect
generally O
is O
considered O
deleterious O
; O
however O
, O
in O
our O
patient O
it O
unmasked O
an O
early O
stage O
of O
colon O
cancer O
and O
thus O
may O
have O
saved O
the O
patient O
's O
life O
. O

The O
clinical O
use O
of O
itraconazole I-Treatment.Combination.Drug
in O
patients I-Subject
receiving I-Treatment
multiple I-Treatment.Dosage
doses I-Treatment.Dosage
of I-Treatment
oxycodone I-Treatment.Combination.Drug
for O
pain I-Treat_Disorder
relief I-Treat_Disorder
may O
increase I-Adverse_event.Trigger
the O
risk O
of O
opioid I-Effect
- I-Effect
associated I-Effect
adverse I-Effect
effects I-Effect
. O

Three I-Subject.Population
cases I-Subject
of O
gold I-Treatment.Drug
- O
related I-Adverse_event.Trigger
neuropathy I-Effect
are O
reported O
. O

We O
report O
the O
case O
of O
a I-Subject
man I-Subject.Gender
, O
treated O
with O
mesalazine I-Treatment.Drug
for O
Crohn I-Treat_Disorder
's I-Treat_Disorder
disease I-Treat_Disorder
who O
developed I-Adverse_event.Trigger
drug I-Effect
- I-Effect
induced I-Effect
pericarditis I-Effect
. O

We O
report O
the O
occurrence I-Adverse_event.Trigger
of O
spontaneous I-Effect
intracranial I-Effect
bleeding I-Effect
in O
an I-Subject
human I-Subject
immunodeficiency I-Treat_Disorder
virus I-Treat_Disorder
( I-Treat_Disorder
HIV) I-Treat_Disorder
- I-Treat_Disorder
infected I-Treat_Disorder
adolescent I-Treat_Disorder
with I-Treat_Disorder
hemophilia I-Treat_Disorder
A I-Treat_Disorder
who O
was O
receiving O
amprenavir I-Treatment.Drug
( I-Treatment.Drug
APV I-Treatment.Drug
) I-Treatment.Drug
. O

Under O
the O
suspicion O
of O
amiodarone I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
acute I-Effect
pancreatitis I-Effect
, O
amiodarone O
was O
substituted O
by O
propafenone O
. O

Evidence O
is O
shown O
in O
this O
report O
that O
adenosine I-Treatment.Drug
was O
associated I-Adverse_event.Trigger
with O
dangerous I-Effect
worsening I-Effect
of I-Effect
arrhythmia I-Effect
in O
patients I-Subject
with I-Subject
atrial I-Treat_Disorder
flutter I-Treat_Disorder
. I-Treat_Disorder

Salicylate I-Treatment.Drug
hepato I-Effect
toxicity I-Effect
in O
rheumatic I-Treat_Disorder
fever I-Treat_Disorder
. O

A O
case O
of O
serotonin I-Effect
syndrome I-Effect
that O
developed I-Adverse_event.Trigger
during O
concurrent I-Treatment
linezolid I-Treatment.Combination.Drug
and I-Treatment
fluoxetine I-Treatment.Combination.Drug
is O
presented O
. O

Herein O
we O
report O
four I-Subject.Population
patients I-Subject
who I-Subject
underwent I-Subject
liver I-Subject.Sub_Disorder
transplantation I-Subject.Sub_Disorder
and O
developed I-Adverse_event.Trigger
neutropenia I-Effect
while O
receiving O
MMF I-Treatment.Drug
. O

A O
study O
of O
in O
vitro O
reactivity O
to O
L O
- O
T4 O
, O
as O
assessed O
by O
peripheral O
blood O
lymphocyte O
transformation O
, O
was O
carried O
out O
in O
a I-Subject
patient I-Subject
with I-Subject
Hashimoto I-Treat_Disorder
's I-Treat_Disorder
disease I-Treat_Disorder
who O
developed I-Adverse_event.Trigger
leukopenia I-Effect
during O
treatment O
with O
L I-Treatment.Drug
- I-Treatment.Drug
T4 I-Treatment.Drug
. O

Methemoglobinemia I-Effect
is O
another O
common O
finding O
among O
patients I-Subject
receiving I-Adverse_event.Trigger
dapsone I-Treatment.Drug
therapy I-Treatment
, O
but O
rarely O
does O
it O
result O
in O
prominent O
symptoms O
other O
than O
transient I-Effect
pallor I-Effect
. O

During O
the O
first O
treatment O
, O
dysarthria I-Effect
and I-Effect
ataxia I-Effect
were O
seen I-Adverse_event.Trigger
after O
completion O
of O
the I-Subject
patient I-Subject
's I-Subject
eighth O
and O
final O
dose O
of O
HDARAC I-Treatment.Drug
. O

Four O
weeks O
earlier O
she I-Subject.Gender
had O
developed I-Adverse_event.Trigger
hepatopathy I-Effect
during O
a O
regimen O
of O
carbamazepine I-Treatment.Drug
, I-Treatment
lynestrenol I-Treatment.Drug
and I-Treatment
sodium I-Treatment.Drug
valproate I-Treatment.Drug
. O

We O
consider O
asterixis I-Effect
to O
be O
an O
easily O
overlooked O
sign O
of O
neurotoxicity O
, O
which O
may O
occur I-Adverse_event.Trigger
even I-Treatment
at I-Treatment
low I-Treatment.Dosage
or I-Treatment.Dosage
moderate I-Treatment.Dosage
dosage I-Treatment.Dosage
levels I-Treatment
, O
if O
certain I-Treatment
drugs I-Treatment
as I-Treatment
lithium I-Treatment.Combination.Drug
or I-Treatment
clozapine I-Treatment.Combination.Drug
are I-Treatment
used I-Treatment
in I-Treatment
combination I-Treatment
with I-Treatment
CBZ I-Treatment.Combination.Drug
. O

We O
report O
here O
a I-Subject
rare I-Subject
case I-Subject
of O
pleuropericarditis I-Effect
due I-Adverse_event.Trigger
to O
methotrexate I-Treatment.Drug
. O

A O
case O
of O
phenytoin I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
hepatitis I-Effect
with I-Effect
mononucleosis I-Effect
is O
reported O
, O
and O
syndromes O
associated O
with O
phenytoin O
hypersensitivity O
reactions O
are O
discussed O
. O

We O
also O
discuss O
whether O
screening O
for O
DPD O
deficiency O
is O
warranted O
to O
identify O
patients I-Subject
at O
risk I-Adverse_event.Trigger
for O
severe I-Effect
toxicities I-Effect
from O
5 I-Treatment.Drug
- I-Treatment.Drug
FU I-Treatment.Drug
treatment I-Treatment
. O

We O
report O
a O
case O
of O
reversible I-Effect
encephalopathy I-Effect
syndrome I-Effect
in O
a I-Subject
16 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
girl I-Subject.Gender
with I-Subject
acute I-Treat_Disorder
myelogenous I-Treat_Disorder
leukemia I-Treat_Disorder
( I-Subject
AML I-Subject
) I-Subject
, O
who O
is O
undergoing I-Adverse_event.Trigger
during O
consolidation I-Treatment
chemotherapy I-Treatment
composed I-Treatment
of I-Treatment
BH I-Treatment.Combination.Drug
- I-Treatment.Combination.Drug
AC I-Treatment.Combination.Drug
( I-Treatment
N4 I-Treatment
- I-Treatment
behenoyl I-Treatment
- I-Treatment
1 I-Treatment
- I-Treatment
beta I-Treatment
- I-Treatment
D I-Treatment
- I-Treatment
arabinofuranosyl I-Treatment
cytosine I-Treatment
) I-Treatment
and I-Treatment
idarubicin I-Treatment.Combination.Drug
. O

Concurrent O
use O
of O
vismodegib I-Treatment.Combination.Drug
and I-Treatment
warfarin I-Treatment.Combination.Drug
was O
deemed O
the O
probable O
cause I-Adverse_event.Trigger
of O
acute I-Effect
INR I-Effect
elevation I-Effect
in O
this O
case O
, O
suggesting O
the O
need O
for O
close O
monitoring O
of O
INR O
values O
in O
patients O
receiving O
this O
combination O
of O
drugs O
. O

Captopril I-Treatment.Drug
is O
an O
angiotensin O
- O
converting O
enzyme O
( O
ACE O
) O
inhibitor O
and O
their O
cutaneous I-Effect
side I-Effect
- I-Effect
effects I-Effect
are O
documented I-Adverse_event.Trigger
, O
but O
little O
has O
been O
published O
concerning O
the O
usefulness O
of O
patch O
test O
when O
they O
occur O
. O

High I-Treatment.Drug
- I-Treatment.Drug
dose I-Treatment.Drug
methylprednisolone I-Treatment.Drug
in O
a I-Subject
pregnant I-Subject.Age
woman I-Subject.Gender
with I-Subject
Crohn I-Treat_Disorder
's I-Treat_Disorder
disease I-Treat_Disorder
and O
adrenal I-Effect
suppression I-Effect
in I-Effect
her I-Effect
newborn I-Effect
. O

Cardiac I-Effect
hypersensitivity I-Effect
and I-Effect
myopericarditis I-Effect
have O
been O
reported I-Adverse_event.Trigger
during O
long I-Treatment.Duration
- I-Treatment.Duration
term I-Treatment.Duration
treatment I-Treatment
with I-Treatment
mesalazine I-Treatment.Drug
. O

It O
is O
concluded O
that O
' O
cerebral I-Effect
atrophy I-Effect
' O
on O
CT O
scans O
may O
represent I-Adverse_event.Trigger
an O
accumulative O
effect O
of O
ACTH I-Treatment.Drug
and O
that O
ACTH I-Drug
should O
be O
given O
with O
the O
utmost O
discretion O
, O
and O
in O
as O
low O
a O
dose O
as O
possible O
. O

Two O
cases O
of O
polymorphic I-Effect
ventricular I-Effect
tachycardia I-Effect
induced I-Adverse_event.Trigger
by O
the O
administration O
of O
verapamil I-Treatment.Drug
against O
paroxysmal I-Treat_Disorder
supraventricular I-Treat_Disorder
tachycardia I-Treat_Disorder
. O

Fatal I-Effect
acute I-Effect
encephalomyelitis I-Effect
after I-Adverse_event.Trigger
a O
single I-Treatment.Dosage
dose I-Treatment.Dosage
of I-Treatment
intrathecal I-Treatment.Route
methotrexate I-Treatment.Drug
. O

The O
authors O
report O
one I-Subject
case I-Subject
of O
incomplete I-Effect
posterior I-Effect
hyaloid I-Effect
detachment I-Effect
( I-Effect
PHD I-Effect
) I-Effect
following I-Adverse_event.Trigger
intravitreal I-Treatment.Route
pegaptanib I-Treatment.Drug
to O
treat O
DME I-Treat_Disorder
. O

Pulmonary I-Effect
edema I-Effect
as O
a O
delayed O
complication I-Adverse_event.Trigger
of O
ritodrine I-Treatment.Drug
therapy O
. O

Carbamazepine I-Effect
toxicity I-Effect
following I-Adverse_event.Trigger
Oxybutynin I-Treatment.Combination.Drug
and I-Treatment
Dantrolene I-Treatment.Combination.Drug
administration O
: O
a O
case O
report O
. O

Multiple I-Effect
seizures I-Effect
after I-Adverse_event.Trigger
bupropion I-Treatment.Drug
overdose I-Treatment.Dosage
in O
a I-Subject
small I-Subject.Age
child I-Subject.Age
. O

Sorafenib I-Treatment.Drug
, O
a I-Treatment
multitargeted I-Treatment
kinase I-Treatment
inhibitor I-Treatment
used O
for O
the O
treatment I-Potential_therapeutic_event.Trigger
of O
unresectable I-Treat_Disorder
hepatocellular I-Treat_Disorder
carcinoma I-Treat_Disorder
and O
advanced I-Treat_Disorder
renal I-Treat_Disorder
cell I-Treat_Disorder
carcinomas I-Treat_Disorder
, O
received O
FDA O
approval O
in O
2005 O
. O

Triiodothyronine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
thyrotoxicosis I-Effect
in O
ophthalmic I-Treat_Disorder
Graves I-Treat_Disorder
disease O
. O

Bleomycin I-Treatment.Drug
induced I-Adverse_event.Trigger
hyperpigmentation I-Effect
with I-Effect
yolk I-Effect
sac I-Effect
tumor I-Effect
. O

PURPOSE O
: O
To O
describe O
bilateral I-Effect
corneal I-Effect
endothelial I-Effect
dysfunction I-Effect
in I-Adverse_event.Trigger
a I-Subject
patient I-Subject
with I-Subject
Parkinson I-Treat_Disorder
disease I-Treat_Disorder
who O
was O
treated O
with O
long I-Treatment.Duration
- I-Treatment.Duration
term I-Treatment.Duration
amantadine I-Treatment.Drug
. O

A O
case O
of O
severe O
acute I-Effect
hepatitis I-Effect
caused I-Adverse_event.Trigger
by O
cyproterone I-Treatment.Drug
acetate I-Treatment.Drug
in O
a I-Subject
71 I-Subject.Age
year I-Subject.Age
old I-Subject.Age
man I-Subject.Gender
with I-Subject
prostatic I-Treat_Disorder
carcinoma I-Treat_Disorder
is O
reported O
with O
a O
review O
of O
the O
literature O
on O
hepatic O
reactions O
to O
this O
drug O
. O

Insulin I-Effect
- I-Effect
dependent I-Effect
diabetes I-Effect
mellitus I-Effect
associated I-Adverse_event.Trigger
with O
danazol I-Treatment.Drug
. O

CONCLUSIONS O
: O
Topical I-Treatment.Route
brimonidine I-Treatment.Drug
may O
be O
associated I-Adverse_event.Trigger
with O
central I-Effect
nervous I-Effect
system I-Effect
depression I-Effect
in O
infants I-Subject.Age
. O

Flecainide I-Treatment.Drug
- O
associated I-Adverse_event.Trigger
pneumonitis I-Effect
with I-Effect
acute I-Effect
respiratory I-Effect
failure I-Effect
in O
a I-Subject
patient I-Subject
with I-Subject
the I-Subject
LEOPARD I-Treat_Disorder
syndrome I-Treat_Disorder
. I-Treat_Disorder

Seizure I-Effect
with I-Effect
hyponatremia I-Effect
in I-Adverse_event.Trigger
a I-Subject
child I-Subject.Age
prescribed O
desmopressin I-Treatment.Drug
for O
nocturnal I-Treat_Disorder
enuresis I-Treat_Disorder
. O

Risks O
and O
benefits O
of O
co O
- O
treatment O
should O
be O
carefully O
considered O
and O
therapeutic I-Treatment
alternatives I-Treatment
to I-Treatment
NSAIDs I-Treatment.Drug
should O
be O
recommended I-Potential_therapeutic_event.Trigger
to O
patients I-Subject
with I-Subject
central I-Treat_Disorder
DI I-Treat_Disorder
in I-Effect
order I-Effect
to I-Effect
improve I-Effect
DDAVP I-Effect
safety I-Effect
. O

She I-Subject
had O
been O
treated I-Potential_therapeutic_event.Trigger
by O
Carbamazepine I-Treatment.Drug
1000 I-Treatment.Dosage
mg I-Treatment.Dosage
/ I-Treatment.Dosage
day I-Treatment.Dosage
for O
neuropathic I-Treat_Disorder
pain I-Treat_Disorder
for O
2 I-Time_elapsed
years I-Time_elapsed
without O
clinical O
or O
laboratory O
signs O
of O
toxicity O
. O

The O
chemotherapeutics I-Treatment
, I-Treatment
including I-Treatment
vincristine I-Treatment.Combination.Drug
, I-Treatment
actinomycin I-Treatment.Combination.Drug
D I-Treatment.Combination.Drug
, I-Treatment
and I-Treatment
epirubicin I-Treatment.Combination.Drug
in O
case O
1 O
and O
vincristine O
and O
actinomycin O
D O
in O
case O
2 O
, O
were O
given I-Adverse_event.Trigger
before O
the O
hepatotoxicity I-Effect
developed I-Effect
. O

The O
chemotherapeutics O
, O
including O
vincristine O
, O
actinomycin O
D O
, O
and O
epirubicin O
in O
case O
1 O
and O
vincristine I-Treatment.Combination.Drug
and I-Treatment
actinomycin I-Treatment.Combination.Drug
D I-Treatment.Combination.Drug
in O
case O
2 O
, O
were O
given I-Adverse_event.Trigger
before O
the O
hepatotoxicity I-Effect
developed I-Effect
. O

After O
a O
second I-Treatment
dose I-Treatment
of I-Treatment
metoclopramide I-Treatment.Drug
, O
these O
symptoms O
recurred O
and O
were O
associated I-Adverse_event.Trigger
with O
confusion I-Effect
, I-Effect
agitation I-Effect
, I-Effect
fever I-Effect
, I-Effect
diaphoresis I-Effect
, I-Effect
tachypnea I-Effect
, I-Effect
tachycardia I-Effect
, I-Effect
and I-Effect
hypertension I-Effect
. O

We O
report O
the O
first O
case O
of O
tuberculous I-Effect
uveitis I-Effect
due I-Adverse_event.Trigger
to I-Adverse_event.Trigger
etanercept I-Treatment.Drug
. O

Acute I-Effect
hyperphosphatemia I-Effect
caused I-Adverse_event.Trigger
by O
sodium I-Treatment.Drug
phosphate I-Treatment.Drug
enema I-Treatment.Route
in O
a I-Subject
patient I-Subject
with I-Subject
liver I-Subject.Sub_Disorder
dysfunction I-Subject.Sub_Disorder
and I-Subject.Sub_Disorder
chronic I-Subject.Sub_Disorder
renal I-Subject.Sub_Disorder
failure I-Subject.Sub_Disorder
. O

We O
discuss O
the O
association I-Adverse_event.Trigger
between O
carbamazepine I-Treatment.Drug
and O
hyponatremia I-Effect
and O
the O
causes O
of O
hyponatremia O
after O
cardiopulmonary O
bypass O
. O

Use O
of O
the O
Naranjo O
adverse O
drug O
reaction O
probability O
algorithm O
indicated O
a I-Adverse_event.Trigger
probable I-Adverse_event.Trigger
relationship I-Adverse_event.Trigger
between I-Adverse_event.Trigger
serotonin I-Effect
syndrome I-Effect
and O
treatment I-Treatment
with I-Treatment
lithium I-Treatment.Combination.Drug
and I-Treatment
venlafaxine I-Treatment.Combination.Drug
. O

The O
exact O
mechanism O
of O
IVIG I-Treatment.Drug
- O
associated I-Adverse_event.Trigger
acute I-Effect
renal I-Effect
failure I-Effect
remains O
unclear O
. O

We O
report O
on O
7 I-Subject.Population
patients I-Subject
( I-Subject
2 I-Subject
women I-Subject
, I-Subject
5 I-Subject
men I-Subject
) I-Subject
with I-Subject
chronic I-Subject.Sub_Disorder
renal I-Subject.Sub_Disorder
failure I-Subject.Sub_Disorder
, O
who O
developed I-Adverse_event.Trigger
under O
a I-Treatment
high I-Treatment
dosage I-Treatment
of I-Treatment
the I-Treatment
new I-Treatment
diuretic I-Treatment.Drug
muzolimine I-Treatment.Drug
( I-Treatment
range I-Treatment.Dosage
240 I-Treatment.Dosage
to I-Treatment.Dosage
1440 I-Treatment.Dosage
mg I-Treatment.Dosage
per I-Treatment.Freq
day I-Treatment.Freq
) I-Treatment
fatal I-Effect
neuromyeloencephalopathy I-Effect
. O

Two I-Subject.Population
renal I-Subject.Sub_Disorder
transplant I-Subject.Sub_Disorder
patients I-Subject
developed I-Adverse_event.Trigger
anemia I-Effect
during O
treatment O
of O
hypertension I-Treat_Disorder
with O
enalapril I-Treatment.Drug
medication I-Treatment
. O

Sotalol I-Treat_Disorder
- I-Treat_Disorder
induced I-Treat_Disorder
bradycardia I-Treat_Disorder
reversed I-Potential_therapeutic_event.Trigger
by O
glucagon I-Treatment.Drug
. O

Sotalol I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
bradycardia I-Effect
reversed O
by O
glucagon O
. O

The O
development I-Adverse_event.Trigger
of O
cutaneous I-Effect
ecchymosis I-Effect
associated O
with O
a I-Effect
sudden I-Effect
fall I-Effect
in I-Effect
hemoglobin I-Effect
after O
the O
administration O
of O
alteplase I-Treatment.Drug
should O
strongly O
suggest O
the O
possibility O
of O
diffuse I-Effect
subfascial I-Effect
hematoma I-Effect
. O

We O
report O
a O
case O
of O
papillary I-Effect
necrosis I-Effect
in O
a I-Subject
patient I-Subject
treated I-Adverse_event.Trigger
with O
indinavir I-Treatment.Drug
. O

Generalized I-Effect
maculopapular I-Effect
and I-Effect
papular I-Effect
purpuric I-Effect
eruptions I-Effect
are O
perhaps O
the O
most O
common O
thionamide I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
reactions I-Effect
. O

Imidazoline I-Treatment
intoxication I-Effect
due I-Adverse_event.Trigger
to O
overdose I-Treatment.Dosage
or I-Treatment.Dosage
accidental I-Treatment.Dosage
ingestion I-Treatment.Route
but I-Treatment.Dosage
also I-Treatment.Dosage
after I-Treatment.Dosage
normal I-Treatment.Dosage
therapeutic I-Treatment.Dosage
usage I-Treatment.Dosage
is O
frequent O
in O
children I-Subject.Age
. O

A O
50 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
diabetic I-Subject.Sub_Disorder
and I-Subject.Sub_Disorder
hypertensive I-Subject.Sub_Disorder
male I-Subject.Gender
patient I-Subject
is O
reported O
who O
had O
ticlopidine I-Treat_Disorder
- I-Treat_Disorder
induced I-Treat_Disorder
marrow I-Treat_Disorder
aplasia I-Treat_Disorder
partially O
responsive O
to O
colony O
- O
stimulating O
factors O
and O
corticosteroids O
, O
but O
experienced I-Effect
complete I-Effect
recovery I-Effect
with I-Potential_therapeutic_event.Trigger
cyclosporine I-Treatment.Drug
. O

A O
50 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
diabetic I-Subject.Sub_Disorder
and I-Subject.Sub_Disorder
hypertensive I-Subject.Sub_Disorder
male I-Subject.Gender
patient I-Subject
is O
reported O
who O
had O
ticlopidine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
marrow I-Effect
aplasia I-Effect
partially O
responsive O
to O
colony O
- O
stimulating O
factors O
and O
corticosteroids O
, O
but O
experienced O
complete O
recovery O
with O
cyclosporine O
. O

A I-Subject
patient I-Subject
with I-Subject
intracranial I-Treat_Disorder
osteosarcoma I-Treat_Disorder
that I-Subject
arose I-Subject
16 I-Subject
years I-Subject
after I-Subject
radiation I-Subject
therapy I-Subject
for I-Subject
hereditary I-Subject.Sub_Disorder
retinoblastoma I-Subject.Sub_Disorder
developed I-Adverse_event.Trigger
fatal O
cerebral I-Effect
edema I-Effect
and I-Effect
brainstem I-Effect
herniation I-Effect
after O
she O
received O
a I-Treatment.Freq
single I-Treatment.Freq
dose I-Treatment.Freq
of I-Treatment
intravenous I-Treatment.Route
methotrexate I-Treatment.Drug
. O

Neutropenia I-Effect
is O
an O
infrequent O
complication O
following I-Adverse_event.Trigger
administration O
of O
the I-Treatment
angiotensin I-Treatment
- I-Treatment
converting I-Treatment
enzyme I-Treatment
( I-Treatment
ACE I-Treatment
) I-Treatment
inhibitor I-Treatment
, I-Treatment
captopril I-Treatment.Drug
. O

INTRODUCTION O
: O
We O
describe O
the O
neurointensive O
care O
( O
NIC O
) O
management O
of O
a O
patient I-Subject
with O
severe I-Effect
cerebral I-Effect
swelling I-Effect
and I-Effect
raised I-Effect
intracranial I-Effect
pressure I-Effect
( I-Effect
ICP I-Effect
) I-Effect
after I-Adverse_event.Trigger
severe O
sodium I-Treatment.Drug
valproic I-Treatment.Drug
acid I-Treatment.Drug
( I-Treatment
VPA I-Treatment
) I-Treatment
intoxication I-Effect
. O

Lithium I-Treatment
therapy O
was O
discontinued O
because I-Adverse_event.Trigger
of O
poor O
compliance O
to O
the O
medication O
and O
intolerable O
polyuria I-Effect
. O

Both O
PAN I-Treatment.Combination.Drug
and I-Treatment
methotrexate I-Treatment.Combination.Drug
have O
been O
independently O
demonstrated O
to O
cause I-Adverse_event.Trigger
sensorineural I-Effect
hearing I-Effect
loss I-Effect
. O

CONCLUSION O
: O
A I-Subject
26 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
man I-Subject.Gender
with I-Subject
bipolar I-Treat_Disorder
disorder I-Treat_Disorder
developed I-Adverse_event.Trigger
hyperammonemia I-Effect
three I-Treatment.Time_elapsed
weeks I-Treatment.Time_elapsed
after I-Treatment
initiating I-Treatment
carbamazepine I-Treatment.Drug
therapy I-Treatment
. O

We O
report O
two I-Subject.Population
adults I-Subject.Age
who O
received O
gabapentin I-Treatment.Drug
( I-Treatment
GBP I-Treatment
) I-Treatment
and O
subsequently O
developed I-Adverse_event.Trigger
behavioural I-Effect
side I-Effect
effects I-Effect
. O

Atrial I-Effect
fibrillation I-Effect
was O
induced I-Adverse_event.Trigger
by O
diltiazem I-Treatment.Drug
in O
two I-Subject.Population
patients I-Subject
and O
verapamil O
induced O
syncope O
in O
one O
patient O
. O

Atrial O
fibrillation O
was O
induced O
by O
diltiazem O
in O
two O
patients O
and O
verapamil I-Treatment.Drug
induced I-Adverse_event.Trigger
syncope I-Effect
in O
one I-Subject.Population
patient I-Subject
. O

We O
can O
conclude O
that O
in O
this I-Subject
case I-Subject
, O
as O
in O
many O
others O
, O
akathisia I-Effect
as O
a O
possible O
adverse I-Adverse_event.Trigger
effect I-Adverse_event.Trigger
of O
psychopharmacs I-Treatment.Drug
was O
very O
hard O
to O
identify O
. O

Although O
HAART I-Treatment.Drug
is O
very O
important O
in O
the O
treatment O
of O
HIV I-Treat_Disorder
, O
its O
side I-Adverse_event.Trigger
effects I-Adverse_event.Trigger
are O
responsible O
for O
patients I-Subject
' O
non I-Effect
- I-Effect
adherence I-Effect
to I-Effect
medications I-Effect
. O

A O
case O
of O
acute I-Effect
subdural I-Effect
haematoma I-Effect
originating O
spontaneously O
from O
an I-Subject
angiomatous I-Subject
meningioma I-Subject
in I-Subject
a I-Subject
patient I-Subject
receiving O
prophylactic O
aspirin I-Treatment.Drug
therapy O
is O
presented I-Adverse_event.Trigger
. O

Long O
known O
to O
psychiatrists O
, O
monoamine I-Treatment.Drug
oxidase I-Treatment.Drug
inhibitors I-Treatment.Drug
( I-Treatment
MAOIs I-Treatment
) I-Treatment
and O
complications O
of O
their O
use O
may O
be O
unfamiliar O
to O
medical O
and O
surgical O
practitioners O
who O
may O
thus O
unwittingly O
precipitate I-Adverse_event.Trigger
a O
hypertensive I-Effect
crisis I-Effect
or I-Effect
serotonin I-Effect
syndrome I-Effect
. O

According O
to O
the O
Naranjo O
adverse O
drug O
reaction O
probability O
scale O
, O
the O
likelihood O
that O
temozolomide I-Treatment.Drug
was O
responsible O
for O
the O
adverse I-Adverse_event.Trigger
drug I-Adverse_event.Trigger
reaction I-Adverse_event.Trigger
of O
fever I-Effect
was O
probable O
( O
score O
of O
6 O
) O
. O

OBJECTIVE O
: O
To O
describe O
the O
development O
of O
valproate I-Treatment.Drug
- O
related I-Adverse_event.Trigger
reproductive I-Effect
endocrine I-Effect
disorders I-Effect
in O
women I-Subject.Gender
with I-Subject
epilepsy I-Treat_Disorder
. O

Alprazolam I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
mania I-Effect
: O
two I-Subject.Population
clinical I-Subject
cases I-Subject
. O

Bronchiolitis I-Effect
obliterans I-Effect
organising I-Effect
pneumonia I-Effect
associated I-Adverse_event.Trigger
with I-Adverse_event.Trigger
the O
use I-Treatment
of I-Treatment
nitrofurantoin I-Treatment.Drug
. O

To O
our O
knowledge O
, O
this O
recurrence O
of O
amiodarone I-Treatment.Drug
pulmonary I-Effect
toxicity I-Effect
has O
not O
been O
reported O
previously O
. O

A I-Subject
patient I-Subject
treated I-Potential_therapeutic_event.Trigger
with O
itraconazole I-Treatment.Drug
( I-Treatment
ITCZ I-Treatment
) I-Treatment
under O
the O
diagnosis O
of O
Aspergillus I-Treat_Disorder
flavus I-Treat_Disorder
- I-Treat_Disorder
induced I-Treat_Disorder
chronic I-Treat_Disorder
hypertrophic I-Treat_Disorder
pachymeningitis I-Treat_Disorder
is O
presented O
. O

Severe I-Effect
autoimmune I-Effect
hemolytic I-Effect
anemia I-Effect
following I-Adverse_event.Trigger
rituximab I-Treatment.Drug
therapy I-Treatment
in O
a I-Subject
patient I-Subject
with I-Subject
a I-Subject
lymphoproliferative I-Treat_Disorder
disorder I-Treat_Disorder
. O

The O
renal O
consequences O
of O
indinavir I-Treatment.Drug
- O
associated I-Adverse_event.Trigger
nephrotoxicity I-Effect
are O
uncertain O
. O

BACKGROUND O
: O
reports O
on O
delated I-Effect
cutaneous I-Effect
reactions I-Effect
to O
captopril I-Treatment.Drug
have O
been O
seldom O
reported I-Adverse_event.Trigger
. O

Bismuth I-Treatment.Drug
subsalicylate I-Treatment.Drug
30 I-Treatment.Dosage
mL I-Treatment.Dosage
every I-Treatment.Freq
4 I-Treatment.Freq
hours I-Treatment.Freq
was O
prescribed I-Potential_therapeutic_event.Trigger
for O
diarrhea I-Treat_Disorder
. O

A O
drug O
interaction O
between O
the O
alpha(2) O
- O
adrenergic O
agonist O
medetomidine O
and O
lignocaine O
is O
suspected O
and O
highlights O
the O
potential O
for O
seizures I-Effect
following I-Adverse_event.Trigger
the O
subcutaneous I-Treatment.Route
administration I-Treatment
of I-Treatment
relatively I-Treatment
large I-Treatment
doses I-Treatment
of I-Treatment
lignocaine I-Treatment.Combination.Drug
under I-Treatment
medetomidine I-Treatment.Combination.Drug
sedation I-Treatment
. O

Oesophageal I-Effect
ulceration I-Effect
due I-Adverse_event.Trigger
to I-Adverse_event.Trigger
emepronium I-Treatment.Drug
bromide I-Treatment.Drug
. O

Development I-Adverse_event.Trigger
of O
sarcoidosis I-Effect
during O
interferon I-Treatment.Combination.Drug
alpha I-Treatment.Combination.Drug
2b I-Treatment.Combination.Drug
and I-Treatment
ribavirin I-Treatment.Combination.Drug
combination O
therapy O
for O
chronic I-Treat_Disorder
hepatitis I-Treat_Disorder
C I-Treat_Disorder
-- O
a O
case O
report O
and O
review O
of O
the O
literature O
. O

CONCLUSION O
: O
The O
findings O
in O
these O
two I-Subject.Population
patients I-Subject
suggest O
that O
colchicine I-Treatment.Drug
may O
delay I-Effect
corneal I-Treat_Disorder
wound I-Treat_Disorder
healing I-Effect
. O

Gemcitabine I-Treatment.Drug
- O
associated I-Adverse_event.Trigger
hemolytic I-Effect
- I-Effect
uremic I-Effect
syndrome I-Effect
. O

Case O
study O
: O
adverse I-Effect
response I-Effect
to I-Adverse_event.Trigger
clonidine I-Treatment.Drug
. O

In O
this O
report O
, O
a I-Subject
patient I-Subject
who O
had O
undergone I-Treatment
a I-Treatment
renal I-Treatment
transplantation I-Treatment
as I-Treatment
a I-Treatment
result I-Treatment
of I-Treatment
malignant I-Treatment
hypertension I-Treatment
, O
and O
who O
was O
on I-Treatment
immunosuppressive I-Treatment
therapy I-Treatment
consisting I-Treatment
of I-Treatment
cyclosporin I-Treatment.Combination.Drug
, I-Treatment
prednisone I-Treatment.Combination.Drug
and I-Treatment
azathioprine I-Treatment.Combination.Drug
, O
developed I-Adverse_event.Trigger
thrombosis I-Effect
of I-Effect
the I-Effect
central I-Effect
retinal I-Effect
vein I-Effect
5 I-Time_elapsed
years I-Time_elapsed
following O
the O
transplantation O
. O

In O
each O
of O
the O
three I-Subject.Population
reported I-Subject
patients I-Subject
, O
alteration I-Effect
of I-Effect
eyelid I-Effect
appearance I-Effect
with I-Effect
deepening I-Effect
of I-Effect
the I-Effect
lid I-Effect
sulcus I-Effect
was O
evident I-Adverse_event.Trigger
as O
the O
result O
of O
topical I-Treatment
bimatoprost I-Treatment.Drug
therapy O
. O

PURPOSE O
: O
To O
report O
a O
case O
of O
traumatic I-Effect
flap I-Effect
dehiscence I-Effect
and I-Effect
Enterobacter I-Effect
keratitis I-Effect
34 I-Treatment.Time_elapsed
months I-Treatment.Time_elapsed
after I-Treatment.Time_elapsed
LASIK I-Treatment
. O

CONCLUSIONS O
: O
The O
risk O
of O
drug O
- O
induced O
rhabdomyolysis I-Effect
due I-Adverse_event.Trigger
to O
the O
potential O
interaction O
between O
lovastatin I-Treatment.Combination.Drug
and O
azithromycin I-Treatment.Combination.Drug
or O
clarithromycin I-Treatment.Combination.Drug
should O
be O
considered O
before O
the O
concomitant O
use O
of O
these O
agents O
. O

Ten O
years O
of O
behavioral O
data O
are O
presented O
to O
support O
the O
hypothesis O
that O
phenobarbital I-Treatment.Drug
was O
exacerbating I-Adverse_event.Trigger
maladaptive I-Effect
behaviors I-Effect
. O

Terbinafine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
cholestatic I-Effect
liver I-Effect
disease I-Effect
. I-Effect

The O
proteasome I-Treatment
inhibitor I-Treatment
Bortezomib I-Treatment.Drug
has I-Treatment
been I-Treatment
identified I-Treatment
as I-Treatment
a I-Treatment
potent I-Treatment
enhancer I-Treatment
of I-Treatment
TRAIL I-Treatment
- O
induced I-Potential_therapeutic_event.Trigger
apoptosis I-Effect
in I-Effect
several I-Effect
human I-Effect
cancers I-Effect
. O

METHODS O
: O
A O
retrospective O
report O
of O
the O
first O
case O
of O
gemcitabine I-Treatment.Drug
- O
related I-Adverse_event.Trigger
HUS I-Effect
, O
in O
a I-Subject
patient I-Subject
with I-Subject
metastatic I-Treat_Disorder
pancreatic I-Treat_Disorder
adenocarcinoma I-Treat_Disorder
, I-Treat_Disorder
treated O
with O
a O
variety O
of O
standard O
therapies O
in O
addition O
to O
rituximab O
is O
presented O
. O

Their I-Subject
parkinsonism I-Treat_Disorder
improved I-Potential_therapeutic_event.Trigger
on O
discontinuation I-Treatment
of I-Treatment
metoclopramide I-Treatment.Drug
therapy I-Treatment
. O

Lichen I-Effect
planus I-Effect
induced I-Adverse_event.Trigger
by O
hepatitis I-Treatment.Drug
B I-Treatment.Drug
vaccination I-Treatment.Drug
: O
a O
new O
case O
and O
review O
of O
the O
literature O
. O

A O
total O
of O
40 I-Subject.Population
healthy I-Subject
volunteers I-Subject
were O
planned O
to O
start I-Potential_therapeutic_event.Trigger
with O
600 I-Treatment.Dosage
mg I-Treatment.Dosage
rifampicin I-Treatment.Drug
once I-Treatment.Freq
daily I-Treatment.Freq
from I-Treatment
days I-Treatment
1 I-Treatment
- I-Treatment
5 I-Treatment
. O

Skin I-Effect
necrosis I-Effect
secondary I-Adverse_event.Trigger
to I-Adverse_event.Trigger
low I-Treatment.Drug
- I-Treatment.Drug
molecular I-Treatment.Drug
weight I-Treatment.Drug
heparin I-Treatment.Drug
in O
a I-Subject
patient I-Subject
with I-Subject
antiphospholipid I-Treat_Disorder
antibody I-Treat_Disorder
syndrome I-Treat_Disorder
. O

Exacerbation O
of O
anthracycline I-Treatment.Combination.Drug
- O
induced I-Adverse_event.Trigger
early I-Effect
chronic I-Effect
cardiomyopathy I-Effect
with I-Treatment
ATRA I-Treatment.Combination.Drug
: O
role O
of O
B O
- O
type O
natriuretic O
peptide O
as O
an O
indicator O
of O
cardiac O
dysfunction O
. O

Fixed I-Effect
drug I-Effect
eruption I-Effect
in I-Effect
hands I-Effect
caused I-Adverse_event.Trigger
by O
omeprazole I-Treatment.Drug
. O

FK506 I-Treatment.Drug
, I-Treatment
which I-Treatment
began I-Treatment
to I-Treatment
be I-Treatment
administered I-Treatment
12 I-Treatment.Time_elapsed
days I-Treatment.Time_elapsed
earlier I-Treatment.Time_elapsed
, I-Treatment
rose I-Treatment
to I-Treatment
a I-Treatment
level I-Treatment
of I-Treatment
44 I-Treatment
ng I-Treatment
/ I-Treatment
mL I-Treatment
( I-Treatment
normal I-Treatment
range I-Treatment
, I-Treatment
10 I-Treatment
- I-Treatment
20 I-Treatment
ng I-Treatment
/ I-Treatment
mL I-Treatment
) I-Treatment
1 O
day O
before I-Adverse_event.Trigger
neurologic I-Effect
abnormalities I-Effect
began I-Effect
. O

Sweet I-Effect
's I-Effect
syndrome I-Effect
is I-Effect
an I-Effect
acute I-Effect
febrile I-Effect
neutrophilic I-Effect
dermatosis I-Effect
that O
is O
a O
known O
complication O
of O
the O
administration O
of O
filgrastim I-Treatment.Drug
, O
a O
drug O
that O
causes I-Adverse_event.Trigger
increased I-Effect
neutrophil I-Effect
proliferation I-Effect
and I-Effect
differentiation I-Effect
. O

Although O
it O
would O
be O
expected O
that O
, O
like O
other O
type O
IA O
toxicities O
, O
diphenhydramine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
cardiotoxicity I-Effect
could O
be O
responsive O
to O
hypertonic O
sodium O
bicarbonate O
, O
this O
finding O
is O
largely O
unappreciated O
. O

Although O
it O
would O
be O
expected O
that O
, O
like O
other O
type O
IA O
toxicities O
, O
diphenhydramine I-Treat_Disorder
- I-Treat_Disorder
induced I-Treat_Disorder
cardiotoxicity I-Treat_Disorder
could O
be O
responsive I-Potential_therapeutic_event.Trigger
to O
hypertonic I-Treatment.Drug
sodium I-Treatment.Drug
bicarbonate I-Treatment.Drug
, O
this O
finding O
is O
largely O
unappreciated O
. O

We O
describe O
a I-Subject
patient I-Subject
who O
experienced I-Adverse_event.Trigger
chronic I-Effect
nausea I-Effect
and I-Effect
an I-Effect
episode I-Effect
of I-Effect
confusion I-Effect
while O
treated O
with O
a I-Treatment
small I-Treatment.Dosage
, I-Treatment.Dosage
stable I-Treatment.Dosage
dose I-Treatment.Dosage
of I-Treatment
oral I-Treatment.Route
morphine I-Treatment.Drug
in O
the O
setting O
of O
mild I-Sub_Disorder
renal I-Sub_Disorder
insufficiency I-Sub_Disorder
. O

Bulbar I-Effect
and I-Effect
pseudobulbar I-Effect
palsy I-Effect
complicating I-Adverse_event.Trigger
therapy O
with O
high I-Treatment.Dosage
- I-Treatment.Dosage
dose I-Treatment.Dosage
cytosine I-Treatment.Drug
arabinoside I-Treatment.Drug
in O
children I-Subject.Age
with I-Subject
leukemia I-Treat_Disorder
. O

The O
development I-Effect
of I-Effect
erythroid I-Effect
leukemia I-Effect
plus I-Effect
carcinoma I-Effect
in O
these O
two I-Subject.Population
men I-Subject.Gender
suggests I-Adverse_event.Trigger
mutagenic I-Effect
change I-Effect
secondary O
to O
cyclophosphamide I-Treatment.Drug
therapy I-Treatment
. O

Administration O
of O
thiazide I-Treatment.Drug
diuretics I-Treatment.Drug
also O
has O
been O
the O
cause I-Adverse_event.Trigger
of O
hyponatremia I-Effect
. O

Serotonin I-Treat_Disorder
syndrome I-Treat_Disorder
is O
a O
potentially O
lethal O
adverse O
drug O
reaction O
that O
may O
occur I-Adverse_event.Trigger
in O
patients I-Subject
taking O
proserotoninergic I-Treatment.Drug
medications I-Treatment
. O

However O
, O
there O
remain O
questions O
concerning O
whether O
these O
drugs O
, O
especially O
methimazole I-Treatment.Drug
( I-Drug
MMI I-Drug
) I-Drug
, O
may O
be O
associated I-Adverse_event.Trigger
with O
aplasia I-Effect
cutis I-Effect
congenita I-Effect
( O
ACC O
) O
and O
how O
best O
to O
avoid O
impairment O
of O
fetal O
thyroid O
function O
during O
their O
use O
. O

An I-Subject
18 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
man I-Subject.Gender
with I-Subject
attention I-Subject.Sub_Disorder
- I-Subject.Sub_Disorder
deficit I-Subject.Sub_Disorder
- I-Subject.Sub_Disorder
hyperactivity I-Subject.Sub_Disorder
disorder I-Subject.Sub_Disorder
( I-Subject.Sub_Disorder
ADHD I-Subject.Sub_Disorder
) I-Subject.Sub_Disorder
was O
prescribed I-Potential_therapeutic_event.Trigger
varenicline I-Treatment.Drug
for O
smoking I-Treat_Disorder
cessation I-Treat_Disorder
. O

The O
condition O
should O
be O
suspected O
in O
patients I-Subject
who O
develop I-Adverse_event.Trigger
unexplained I-Effect
abdominal I-Effect
pain I-Effect
or I-Effect
collapse I-Effect
following O
vasopressin I-Treatment.Drug
treatment O
. O

The O
present O
observation O
suggests O
, O
that O
a O
batch O
of O
different O
testing O
doses O
, O
including O
lower O
testing O
doses O
may O
help O
to O
differentiate O
between O
an I-Effect
allergic I-Effect
type I-Effect
of I-Effect
contact I-Effect
dermatitis I-Effect
and O
an I-Effect
irritant I-Effect
type I-Effect
of I-Effect
reaction I-Effect
after I-Adverse_event.Trigger
treatment I-Adverse_event.Trigger
with O
calcipotriol I-Treatment.Drug
. O

Acute I-Effect
erythroid I-Effect
leukemia I-Effect
after I-Adverse_event.Trigger
cyclophosphamide I-Treatment.Drug
therapy I-Treatment
for O
multiple I-Treat_Disorder
myeloma I-Treat_Disorder
: O
report O
of O
two I-Subject.Population
cases I-Subject
. O

A O
combination O
of O
behavioural O
and O
cognitive O
adverse O
effects O
is O
illustrated O
in O
this O
case O
report O
of O
a O
recurrent O
triazolam I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
eating I-Effect
disorder I-Effect
. O

5 I-Treatment.Drug
- I-Treatment.Drug
fluorouracil I-Treatment.Drug
( O
5 O
- O
FU) O
- O
associated I-Adverse_event.Trigger
peripheral I-Effect
neuropathy I-Effect
is O
an O
uncommon O
event O
. O

Insulin I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
lipoatrophy I-Effect
in O
type I-Treat_Disorder
I I-Treat_Disorder
diabetes I-Treat_Disorder
. O

This O
article O
describes O
a I-Subject
patient I-Subject
with O
suspected O
ciprofloxacin I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
interstitial I-Effect
nephritis I-Effect
. O

We O
report O
3 I-Subject.Population
cases I-Subject
of I-Subject
HIV I-Treat_Disorder
- I-Treat_Disorder
1 I-Treat_Disorder
infected I-Subject
patients I-Subject
who O
experienced I-Adverse_event.Trigger
symptomatic I-Effect
angiolipomas I-Effect
shortly O
after O
starting O
antiretroviral I-Treatment
therapy I-Treatment
including I-Treatment
the I-Treatment
protease I-Treatment
inhibitor I-Treatment
indinavir I-Treatment.Drug
. O

Depressive I-Effect
symptoms I-Effect
disappeared O
after I-Adverse_event.Trigger
interferon I-Treatment.Drug
therapy I-Treatment
was O
stopped O
. O

Coumarin I-Treatment.Drug
is O
reported I-Adverse_event.Trigger
to O
elevate I-Effect
liver I-Effect
function I-Effect
tests I-Effect
( I-Effect
LFT I-Effect
) I-Effect
values I-Effect
. O

Decreased I-Effect
plasma I-Effect
cortisol I-Effect
level I-Effect
during I-Adverse_event.Trigger
alprazolam I-Treatment.Drug
treatment O
of O
panic I-Treat_Disorder
disorder I-Treat_Disorder
: O
a O
case O
report O
. O

Severe O
diffuse I-Effect
interstitial I-Effect
pneumonitis I-Effect
induced I-Adverse_event.Trigger
by O
carmustine I-Treatment.Drug
( I-Treatment
BCNU I-Treatment
) I-Treatment
. O

Fever I-Effect
, I-Effect
pulmonary I-Effect
infiltrates I-Effect
, I-Effect
and I-Effect
pleural I-Effect
effusion I-Effect
following I-Adverse_event.Trigger
acyclovir I-Treatment.Drug
therapy I-Treatment
for I-Treatment
herpes I-Treatment.Treat_Disorder
zoster I-Treatment.Treat_Disorder
ophthalmicus I-Treatment.Treat_Disorder
. O

We O
propose O
a O
mechanism O
of O
vancomycin I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
mast I-Effect
cell I-Effect
degranulation I-Effect
and I-Effect
subsequent I-Effect
release I-Effect
of I-Effect
eosinophil I-Effect
chemotactic I-Effect
factor I-Effect
as I-Effect
a I-Effect
cause I-Effect
of I-Effect
CSFE I-Effect
. O

Within I-Treatment.Time_elapsed
3 I-Treatment.Time_elapsed
weeks I-Treatment.Time_elapsed
of I-Treatment.Time_elapsed
beginning I-Treatment.Time_elapsed
continuous I-Treatment
daily I-Treatment.Freq
isoniazid I-Treatment.Combination.Drug
and I-Treatment
rifampin I-Treatment.Combination.Drug
therapy O
for O
pulmonary I-Treat_Disorder
tuberculosis I-Treat_Disorder
, O
a I-Subject
patient I-Subject
developed I-Adverse_event.Trigger
acute I-Effect
renal I-Effect
failure I-Effect
. O

We O
report O
four I-Subject.Population
cases I-Subject
of O
severe O
corneal I-Effect
ulceration I-Effect
in I-Adverse_event.Trigger
methamphetamine I-Treatment.Drug
abusers O
. O

Diagnosis O
: O
practolol I-Treatment.Drug
induced I-Adverse_event.Trigger
sclerosing I-Effect
peritonitis I-Effect
. O

We O
report O
the O
first O
biopsy O
confirmed O
occurrence I-Adverse_event.Trigger
of O
acute I-Effect
interstitial I-Effect
nephritis I-Effect
in O
a O
patient I-Subject
receiving O
treatment O
with O
Sunitinib I-Treatment.Drug
for O
metastatic I-Treat_Disorder
renal I-Treat_Disorder
cell I-Treat_Disorder
cancer I-Treat_Disorder
. O

Multiple I-Effect
pulmonary I-Effect
nodules I-Effect
: O
an O
unusual O
presentation I-Adverse_event.Trigger
of O
fludarabine I-Treatment.Drug
pulmonary O
toxicity O
: O
case O
report O
and O
review O
of O
literature O
. O

Clozapine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
tardive I-Effect
dyskinesia I-Effect
in O
schizophrenic I-Treat_Disorder
patients I-Subject
taking O
clozapine O
as O
a O
first O
- O
line O
antipsychotic O
drug O
. O

Recently O
, O
her I-Subject.Gender
serum O
theophylline I-Effect
levels I-Effect
had I-Effect
increased I-Effect
to I-Effect
the I-Effect
toxic I-Effect
range I-Effect
( O
133.2 O
micromol O
/ O
L O
[ O
24 O
microg O
/ O
mL O
] O
) O
shortly O
after I-Adverse_event.Trigger
the O
addition O
of O
zafirlukast I-Treatment.Drug
( O
Accolate O
, O
Zeneca O
Pharmaceuticals O
, O
Wilmington O
, O
Del O
) O
to O
her O
regimen O
. O

Withdrawal I-Effect
emergent I-Effect
syndrome I-Effect
in O
an I-Subject
infant I-Subject.Age
associated I-Adverse_event.Trigger
with O
maternal I-Treatment.Route
haloperidol I-Treatment.Drug
therapy I-Treatment
. O

Diphenylhydantoin I-Treatment.Drug
apparently O
adversely I-Effect
affected I-Effect
both I-Effect
the I-Effect
clinical I-Effect
and I-Effect
biochemical I-Effect
parameters I-Effect
of I-Effect
the I-Effect
acute I-Effect
intermittent I-Effect
porphyria I-Effect
. O

Successful O
recovery O
from O
interstitial I-Effect
pneumonitis I-Effect
, O
induced I-Adverse_event.Trigger
by O
bicalutamide I-Treatment.Combination.Drug
and I-Treatment
leuprorelin I-Treatment.Combination.Drug
acetate I-Treatment.Combination.Drug
given O
as O
treatment O
for O
prostate I-Treat_Disorder
cancer I-Treat_Disorder
. O

Gold I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
pneumonitis I-Effect
. O

OBJECTIVE O
: O
To O
report O
a O
case O
of O
significant I-Effect
hepatic I-Effect
and I-Effect
renal I-Effect
failure I-Effect
with O
the O
use I-Adverse_event.Trigger
of O
argatroban I-Treatment.Drug
in O
a I-Subject
patient I-Subject
with I-Subject
heparin I-Subject.Sub_Disorder
- I-Subject.Sub_Disorder
induced I-Subject.Sub_Disorder
thrombocytopenia I-Subject.Sub_Disorder
( I-Subject.Sub_Disorder
HIT I-Subject.Sub_Disorder
) I-Subject.Sub_Disorder
requiring I-Subject
continuous I-Subject
veno I-Subject
- I-Subject
veno I-Subject
hemodialysis I-Subject
( I-Subject
CVVHD I-Subject
) I-Subject
. O

OBJECTIVE O
: O
To O
report O
a O
case O
of O
significant O
hepatic O
and O
renal O
failure O
with O
the O
use O
of O
argatroban O
in O
a O
patient O
with O
heparin I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
thrombocytopenia I-Effect
( O
HIT O
) O
requiring O
continuous O
veno O
- O
veno O
hemodialysis O
( O
CVVHD O
) O
. O

Visceral I-Effect
leishmaniasis I-Effect
and I-Effect
macrophagic I-Effect
activation I-Effect
syndrome I-Effect
in O
a I-Subject
patient I-Subject
with I-Subject
rheumatoid I-Treat_Disorder
arthritis I-Treat_Disorder
under I-Adverse_event.Trigger
treatment O
with O
adalimumab I-Treatment.Drug
. O

He I-Subject.Gender
was O
diagnosed O
with O
possible I-Effect
serotonin I-Effect
syndrome I-Effect
; O
his O
symptoms O
resolved I-Adverse_event.Trigger
after O
clomipramine O
was O
stopped O
but O
before O
clozapine I-Treatment.Drug
was O
restarted O
eight O
days O
later O
. O

Disseminated I-Effect
intravascular I-Effect
coagulation I-Effect
associated I-Effect
with I-Effect
acute I-Effect
hemoglobinemia I-Effect
or I-Effect
hemoglobinuria I-Effect
following I-Adverse_event.Trigger
Rh(0)(D I-Treatment.Drug
) I-Treatment.Drug
immune I-Treatment.Drug
globulin I-Treatment.Drug
intravenous I-Treatment.Route
administration O
for O
immune I-Treat_Disorder
thrombocytopenic I-Treat_Disorder
purpura I-Treat_Disorder
. O

Two O
patients O
had O
ampicillin I-Treatment.Drug
- O
associated I-Adverse_event.Trigger
seizures I-Effect
. O

A I-Subject
patient I-Subject
developed I-Adverse_event.Trigger
restless I-Effect
legs I-Effect
symptoms I-Effect
paralleling O
the O
course O
of O
interferon I-Treatment.Drug
- I-Treatment.Drug
alpha I-Treatment.Drug
( I-Treatment
IFN I-Treatment
alpha I-Treatment
) I-Treatment
therapy I-Treatment
for O
chronic I-Treat_Disorder
hepatitis I-Treat_Disorder
C. I-Treat_Disorder

While O
many O
can O
benefit O
from O
coadministration I-Treatment
of I-Treatment
serotonergic I-Treatment.Combination.Drug
antidepressants I-Treatment.Combination.Drug
and I-Treatment
opioids I-Treatment.Combination.Drug
, O
it O
appears O
that O
some I-Subject
individuals I-Subject
are O
at O
increased O
risk I-Adverse_event.Trigger
for O
SS I-Effect
. O

Stomatitis I-Effect
, O
diarrhea I-Effect
, O
dermatitis I-Effect
, O
and O
myelosuppression I-Effect
are O
the O
main O
toxicities I-Adverse_event.Trigger
of O
5 I-Treatment.Drug
- I-Treatment.Drug
FU I-Treatment.Drug
. O

After O
treatment O
with O
cimetidine I-Treatment.Drug
, O
there O
was I-Adverse_event.Trigger
a I-Effect
rapid I-Effect
deterioration I-Effect
with I-Effect
decreased I-Effect
oxygen I-Effect
saturation I-Effect
and I-Effect
arterial I-Effect
PO2 I-Effect
values I-Effect
. O

We O
describe O
a I-Subject
case I-Subject
of I-Subject
advanced I-Treat_Disorder
ovarian I-Treat_Disorder
carcinoma I-Treat_Disorder
who O
developed I-Adverse_event.Trigger
difficulty I-Effect
walking I-Effect
because I-Effect
of I-Effect
marked I-Effect
pain I-Effect
in I-Effect
the I-Effect
lower I-Effect
extremities I-Effect
and I-Effect
loss I-Effect
of I-Effect
proprioception I-Effect
25 I-Treatment.Time_elapsed
days I-Treatment.Time_elapsed
after I-Treatment
treatment I-Treatment
with I-Treatment
weekly I-Treatment.Freq
taxol I-Treatment.Drug
( I-Treatment
80 I-Treatment.Dosage
mg I-Treatment.Dosage
/ I-Treatment.Dosage
m(2)x3 I-Treatment.Dosage
) I-Treatment
. O

Agranulocytosis I-Effect
and I-Effect
granulocytopenia I-Effect
associated I-Adverse_event.Trigger
with O
quetiapine I-Treatment.Drug
. O

The O
multiple I-Effect
comedones I-Effect
and I-Effect
ruptured I-Effect
epidermoid I-Effect
cysts I-Effect
are O
newly O
reported I-Adverse_event.Trigger
adverse O
effects O
of O
imiquimod I-Treatment.Drug
therapy I-Treatment
. O

We O
conclude O
that O
neurosurgeons O
and O
neurologists O
should O
be O
aware O
of O
calcium I-Treatment
antagonist I-Treatment
-- O
related I-Adverse_event.Trigger
ileus I-Effect
in O
patients I-Subject
treated O
with O
nimodipine I-Treatment.Drug
. O

Hyperpigmentation I-Effect
during I-Adverse_event.Trigger
interferon I-Treatment.Drug
- I-Treatment.Drug
alpha I-Treatment.Drug
therapy I-Treatment
for O
chronic I-Treat_Disorder
hepatitis I-Treat_Disorder
C I-Treat_Disorder
virus I-Treat_Disorder
infection I-Treat_Disorder
. O

Chlorambucil I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
chromosome I-Effect
damage I-Effect
to O
human O
lymphocytes O
is O
dose O
- O
dependent O
and O
cumulative O
. O

Carbamazepine I-Treatment.Drug
hypersensitivity I-Effect
syndrome I-Effect
is I-Adverse_event.Trigger
a O
rare O
, O
life O
- O
threatening O
condition O
. O

Case O
report O
: O
dapsone I-Treatment.Drug
hypersensitivity I-Effect
syndrome I-Effect
associated I-Adverse_event.Trigger
with O
treatment O
of O
the O
bite O
of O
a O
brown O
recluse O
spider O
. O

Acute I-Effect
asymptomatic I-Effect
hepatitis I-Effect
in O
a I-Subject
healthy I-Subject
normal I-Subject
volunteer I-Subject
exposed I-Adverse_event.Trigger
to O
2 I-Treatment.Dosage
oral I-Treatment.Route
doses I-Treatment
of I-Treatment
amodiaquine I-Treatment.Combination.Drug
and I-Treatment
artesunate I-Treatment.Combination.Drug
. O

The O
authors O
report O
a O
case O
of O
focal I-Effect
myocardial I-Effect
necrosis I-Effect
, I-Effect
presenting I-Effect
clinically I-Effect
as I-Effect
an I-Effect
acute I-Effect
myocardial I-Effect
infarction I-Effect
during I-Adverse_event.Trigger
the O
administration O
of O
the O
antineoplastic O
drug O
, O
amsacrine I-Treatment.Drug
, O
in O
a I-Subject
patient I-Subject
without I-Subject
coronary I-Subject
artery I-Subject
disease I-Subject
. O

Baclofen I-Treatment.Combination.Drug
and O
oxazepam I-Treatment.Combination.Drug
were O
prescribed I-Potential_therapeutic_event.Trigger
secondary O
to O
right I-Treat_Disorder
- I-Treat_Disorder
sided I-Treat_Disorder
hemiparesis I-Treat_Disorder
contractures I-Treat_Disorder
. O

DISCUSSION O
: O
A O
review O
of O
the O
cases O
of O
SS I-Effect
with O
implication I-Adverse_event.Trigger
of I-Adverse_event.Trigger
mirtazapine I-Treatment.Drug
as O
the O
cause O
was O
performed O
. O

A O
small O
number O
of O
oxaliplatin I-Treatment.Drug
- O
related I-Adverse_event.Trigger
hemolytic I-Effect
and/or I-Effect
thrombocytopenic I-Effect
reactions I-Effect
have O
been O
reported O
. O

CASE O
SUMMARY O
: O
A I-Subject
39 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
white I-Subject.Race
Jewish I-Subject.Race
schizophrenic I-Treat_Disorder
man I-Subject.Gender
treated O
with O
olanzapine I-Treatment.Drug
developed I-Adverse_event.Trigger
an I-Effect
elevated I-Effect
serum I-Effect
CK I-Effect
concentration I-Effect
with O
a O
peak O
concentration O
of O
4000 O
IU O
/ O
L O
( O
normal O
< O
230 O
) O
. O

Severe I-Effect
water I-Effect
intoxication I-Effect
secondary I-Adverse_event.Trigger
to I-Adverse_event.Trigger
the I-Treatment
concomitant I-Treatment
intake I-Treatment
of I-Treatment
non I-Treatment.Combination.Drug
- I-Treatment.Combination.Drug
steroidal I-Treatment.Combination.Drug
anti I-Treatment.Combination.Drug
- I-Treatment.Combination.Drug
inflammatory I-Treatment.Combination.Drug
drugs I-Treatment.Combination.Drug
and I-Treatment
desmopressin I-Treatment.Combination.Drug
: O
a O
case O
report O
and O
review O
of O
the O
literature O
. O

An O
apparent O
link O
is O
described O
between O
the O
use O
of O
MMF I-Treatment.Combination.Drug
with I-Treatment
prednisone I-Treatment.Combination.Drug
to I-Treatment
treat I-Treatment
pemphigus I-Treatment.Treat_Disorder
vulgaris I-Treatment.Treat_Disorder
and O
the O
development I-Adverse_event.Trigger
of O
red I-Effect
blood I-Effect
cell I-Effect
anemia I-Effect
. O

Other O
potential O
causes O
of O
renal O
failure O
were O
not O
present O
in O
our I-Subject
patient I-Subject
and O
his I-Effect
renal I-Effect
function I-Effect
gradually I-Effect
recovered I-Effect
with O
the O
cessation I-Treatment.Dosage
of I-Treatment
suramin I-Treatment.Drug
treatment I-Treatment
. O

Massive I-Treatment
CBZ I-Treatment.Drug
OD I-Treatment.Dosage
may O
produce I-Adverse_event.Trigger
a O
reversible I-Effect
encephalopathy I-Effect
that I-Effect
includes I-Effect
cortical I-Effect
hyperexcitability I-Effect
, I-Effect
a I-Effect
profound I-Effect
burst I-Effect
- I-Effect
suppression I-Effect
EEG I-Effect
pattern I-Effect
, I-Effect
and I-Effect
cranial I-Effect
nerve I-Effect
areflexia I-Effect
. O

This O
is O
the O
first O
report O
of O
a O
fluoxetine I-Treatment.Drug
- O
related I-Adverse_event.Trigger
death I-Effect
in O
a I-Subject
child I-Subject.Age
with I-Subject
a I-Subject
confirmed I-Subject
genetic I-Subject.Sub_Disorder
polymorphism I-Subject.Sub_Disorder
of I-Subject.Sub_Disorder
the I-Subject.Sub_Disorder
CYP2D6 I-Subject.Sub_Disorder
gene I-Subject.Sub_Disorder
that I-Subject.Sub_Disorder
results I-Subject.Sub_Disorder
in I-Subject.Sub_Disorder
impaired I-Subject.Sub_Disorder
drug I-Subject.Sub_Disorder
metabolism I-Subject.Sub_Disorder
. O

We O
report O
a O
case O
of O
reversible I-Effect
DKA I-Effect
and I-Effect
new I-Effect
- I-Effect
onset I-Effect
DM I-Effect
that O
developed I-Adverse_event.Trigger
in O
a O
demented I-Treat_Disorder
patient I-Subject
who O
was O
treated O
with O
quetiapine I-Treatment.Drug
for I-Treatment
14 I-Treatment.Duration
days I-Treatment.Duration
. O

We O
describe O
3 I-Subject.Population
cases I-Subject
of O
diphenhydramine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
cardiac I-Effect
toxicity I-Effect
that O
were O
responsive O
to O
bicarbonate O
. O

We O
describe O
3 I-Subject.Population
cases I-Subject
of O
diphenhydramine I-Treat_Disorder
- I-Treat_Disorder
induced I-Treat_Disorder
cardiac I-Treat_Disorder
toxicity I-Treat_Disorder
that O
were O
responsive I-Potential_therapeutic_event.Trigger
to O
bicarbonate I-Treatment.Drug
. O

The O
patient I-Subject
's I-Subject
arthritis I-Effect
flared I-Effect
after I-Adverse_event.Trigger
the O
second I-Treatment.Time_elapsed
infusion I-Treatment.Route
of I-Treatment
infliximab I-Treatment.Drug
, O
which O
was O
discontinued O
. O

CONCLUSION O
: O
Marked I-Effect
visual I-Effect
field I-Effect
constriction I-Effect
appears O
to O
be O
associated I-Adverse_event.Trigger
with O
vigabatrin I-Treatment.Drug
therapy I-Treatment
. O

Possible O
serotonin I-Effect
syndrome I-Effect
associated I-Effect
with I-Effect
clomipramine I-Drug
after I-Adverse_event.Trigger
withdrawal I-Treatment
of I-Treatment
clozapine I-Treatment.Drug
. O

A I-Subject
14 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
female I-Subject.Gender
developed I-Adverse_event.Trigger
systemic I-Effect
lupus I-Effect
erythematosus I-Effect
( I-Effect
SLE) I-Effect
- I-Effect
like I-Effect
symptoms I-Effect
, I-Effect
rash I-Effect
, I-Effect
fever I-Effect
, I-Effect
leukopenia I-Effect
and I-Effect
positive I-Effect
anti I-Effect
- I-Effect
nuclear I-Effect
antibody I-Effect
( I-Effect
ANA I-Effect
) I-Effect
two O
weeks O
after O
administration I-Treatment
of I-Treatment
carbamazepine I-Treatment.Drug
( I-Treatment
CBZ I-Treatment
; I-Treatment
Tegretol I-Treatment
) I-Treatment
used I-Treatment
against I-Treatment
benign I-Treatment.Treat_Disorder
Rolandic I-Treatment.Treat_Disorder
epilepsy I-Treatment.Treat_Disorder
. O

There O
was O
a I-Adverse_event.Trigger
clear I-Adverse_event.Trigger
relationship I-Adverse_event.Trigger
between O
restarting O
the O
Accutane I-Treatment.Drug
and O
recurrence I-Effect
of I-Effect
the I-Effect
transient I-Effect
myopia I-Effect
. O

Graves I-Effect
' I-Effect
hyperthyroidism I-Effect
following I-Effect
transient I-Effect
thyrotoxicosis I-Effect
during I-Adverse_event.Trigger
interferon I-Treatment.Drug
therapy I-Treatment.Drug
for O
chronic I-Treat_Disorder
hepatitis I-Treat_Disorder
type I-Treat_Disorder
C. I-Treat_Disorder

Masculinization I-Effect
of I-Effect
a I-Effect
female I-Effect
fetus I-Effect
occurred O
in O
5 I-Subject.Population
of I-Subject.Population
39 I-Subject.Population
( I-Subject.Population
12.8 I-Subject.Population
% I-Subject.Population
) I-Subject.Population
exposed I-Adverse_event.Trigger
to O
norethisterone I-Treatment.Drug
; O
all O
were O
cases O
of O
clitoral I-Effect
hypertrophy I-Effect
not O
requiring O
surgical O
treatment O
. O

She I-Subject.Gender
continued I-Treatment
taking I-Treatment
verapamil I-Treatment.Drug
for I-Treatment.Duration
6 I-Treatment.Duration
months I-Treatment.Duration
, I-Treatment
then I-Treatment
, I-Treatment
on I-Treatment
her I-Treatment
own I-Treatment
, I-Treatment
stopped I-Treatment
all I-Treatment
medications I-Treatment
including I-Treatment
the I-Treatment
sustained I-Treatment
- I-Treatment
release I-Treatment
verapamil I-Treatment
, O
and O
her O
asthma I-Treat_Disorder
symptoms O
disappeared I-Potential_therapeutic_event.Trigger
. O

Two O
patients O
with O
ovarian I-Treat_Disorder
cancer I-Treat_Disorder
who O
had O
received O
multiple O
courses O
of O
cisplatin O
without O
complications O
experienced O
hypersensitivity O
reactions I-Adverse_event.Trigger
to O
cisplatin I-Treatment.Drug
: O
one I-Subject
, O
involving I-Treatment
intrahepatic I-Treatment.Route
artery I-Treatment.Route
infusion I-Treatment.Route
, O
manifested I-Effect
general I-Effect
erythema I-Effect
, I-Effect
dyspnea I-Effect
, I-Effect
and I-Effect
hypotension I-Effect
; O
the O
other O
, O
involving O
intravenous O
infusion O
, O
manifested O
abdominal O
pain O
, O
general O
erythema O
, O
and O
fever O
. O

Two O
patients O
with O
ovarian O
cancer O
who O
had O
received O
multiple O
courses O
of O
cisplatin O
without O
complications O
experienced O
hypersensitivity O
reactions I-Adverse_event.Trigger
to O
cisplatin I-Treatment.Drug
: O
one O
, O
involving O
intrahepatic O
artery O
infusion O
, O
manifested O
general O
erythema O
, O
dyspnea O
, O
and O
hypotension O
; O
the I-Subject
other I-Subject
, O
involving I-Treatment
intravenous I-Treatment.Route
infusion I-Treatment.Route
, O
manifested I-Effect
abdominal I-Effect
pain I-Effect
, I-Effect
general I-Effect
erythema I-Effect
, I-Effect
and I-Effect
fever I-Effect
. O

CONCLUSION O
: O
There O
are O
only O
a O
few O
confirmed O
cases O
of O
gemcitabine I-Treatment.Drug
- O
associated I-Adverse_event.Trigger
HUS I-Effect
despite O
the O
widespread O
use O
of O
the O
drug O
. O

In O
these I-Subject
patients I-Subject
, O
long I-Treatment
- I-Treatment
acting I-Treatment
octreotide I-Treatment.Drug
may O
trigger I-Adverse_event.Trigger
serious I-Effect
hypoglycemia I-Effect
. O

Usefulness O
of O
antiplatelet O
drugs O
in O
the O
management O
of O
heparin I-Treatment.Drug
- O
associated I-Adverse_event.Trigger
thrombocytopenia I-Effect
and I-Effect
thrombosis I-Effect
. O

Usefulness I-Potential_therapeutic_event.Trigger
of O
antiplatelet I-Treatment.Drug
drugs I-Treatment.Drug
in O
the O
management O
of O
heparin I-Treat_Disorder
- I-Treat_Disorder
associated I-Treat_Disorder
thrombocytopenia I-Treat_Disorder
and I-Treat_Disorder
thrombosis I-Treat_Disorder
. O

An O
intertrigo I-Effect
- I-Effect
like I-Effect
eruption I-Effect
from I-Adverse_event.Trigger
pegylated I-Treatment
liposomal I-Treatment
doxorubicin I-Treatment.Drug
. O

We O
report O
a O
case O
of O
NEH I-Effect
masquerading I-Effect
as I-Effect
cutaneous I-Effect
vasculitis I-Effect
in I-Adverse_event.Trigger
a I-Subject
woman I-Subject.Gender
receiving O
cyclophosphamide I-Treatment.Drug
for I-Subject
lupus I-Treat_Disorder
nephritis I-Treat_Disorder
. I-Treat_Disorder

The O
diagnosis O
of O
hypothermia I-Treat_Disorder
was O
delayed O
until O
it O
was O
apparent O
for O
several O
days O
but O
resolved I-Potential_therapeutic_event.Trigger
with O
the O
discontinuation I-Treatment
of I-Treatment
risperidone I-Treatment.Drug
and I-Treatment
continuation I-Treatment
of I-Treatment
clozapine I-Treatment.Drug
. O

Unaccountable I-Effect
severe I-Effect
hypercalcemia I-Effect
in O
a O
patient I-Subject
treated I-Adverse_event.Trigger
for O
hypoparathyroidism I-Treat_Disorder
with O
dihydrotachysterol I-Treatment.Drug
. O

Anaphylaxis I-Effect
to I-Adverse_event.Trigger
calcitonin I-Treatment.Drug
. O

However O
, O
he I-Subject.Gender
developed I-Adverse_event.Trigger
acute I-Effect
renal I-Effect
failure I-Effect
, I-Effect
hyperkalemia I-Effect
, I-Effect
and I-Effect
hyperuricemia I-Effect
30 I-Time_elapsed
d I-Time_elapsed
after O
receiving O
the O
sorafenib I-Treatment.Drug
treatment O
. O

Mycobacterium I-Treat_Disorder
marinum I-Treat_Disorder
infection I-Treat_Disorder
complicating I-Treat_Disorder
Crohn I-Treat_Disorder
's I-Treat_Disorder
disease I-Treat_Disorder
, O
treated I-Potential_therapeutic_event.Trigger
with O
infliximab I-Treatment.Drug
. O

Current I-Treatment
immunosuppressive I-Treatment.Drug
therapies I-Treatment
are O
effective O
but O
can O
be O
associated I-Adverse_event.Trigger
with O
significant I-Effect
adverse I-Effect
reactions I-Effect
. I-Effect

This O
report O
describes O
the O
first O
association O
( O
exclusive O
of O
drug O
overdose O
) O
of O
symptomatic I-Effect
torsades I-Effect
de I-Effect
pointes I-Effect
occurring I-Adverse_event.Trigger
with O
the O
use O
of O
terfenadine I-Treatment.Combination.Drug
in O
a I-Subject
patient I-Subject
who O
was O
taking I-Treatment
the I-Treatment
recommended I-Treatment
prescribed I-Treatment
dose I-Treatment
of I-Treatment
this I-Treatment
drug I-Treatment
in I-Treatment
addition I-Treatment
to I-Treatment
cefaclor I-Treatment.Combination.Drug
, I-Treatment
ketoconazole I-Treatment.Combination.Drug
, I-Treatment
and I-Treatment
medroxyprogesterone I-Treatment.Combination.Drug
. O

Tamoxifen I-Treatment.Drug
is O
suggested I-Adverse_event.Trigger
to O
be O
carcinogenic I-Effect
both I-Effect
through I-Effect
direct I-Effect
genotoxic I-Effect
and I-Effect
epigenetic I-Effect
mechanisms I-Effect
. O

DISCUSSION O
: O
Colchicine I-Treatment.Drug
, O
the O
most O
important O
drug O
in O
treatment O
of O
FMF I-Treat_Disorder
, O
can O
cause I-Adverse_event.Trigger
myopathy I-Effect
in O
patients I-Subject
with I-Subject
impaired I-Subject.Sub_Disorder
renal I-Subject.Sub_Disorder
and I-Subject.Sub_Disorder
hepatic I-Subject.Sub_Disorder
function I-Subject.Sub_Disorder
. O

In O
the O
presented O
case O
fluvoxamine I-Subject
- I-Subject
induced I-Subject
akathisia I-Treat_Disorder
in I-Subject
an I-Subject
OCD I-Treat_Disorder
patient I-Subject
was O
partially O
resistant O
to O
the O
anticholinergic O
agent O
biperiden O
, O
and O
was O
successfully O
treated I-Potential_therapeutic_event.Trigger
with O
the O
5 I-Treatment
- I-Treatment
HT2A/5 I-Treatment
- I-Treatment
HT2C I-Treatment
antagonist I-Treatment
mianserin I-Treatment.Drug
. O

SUBSEQUENT O
COURSE O
: O
The O
nephrosis I-Treat_Disorder
resolved I-Potential_therapeutic_event.Trigger
almost O
completely O
once O
the O
interferon I-Treatment.Drug
was I-Treatment
stopped I-Treatment
and I-Treatment
after I-Treatment
immunosuppressive I-Treatment.Drug
treatment I-Treatment
. O

In I-Subject
two I-Subject.Population
patients I-Subject
, O
apomorphine I-Treatment.Drug
remained O
effective O
in O
the O
morning O
, O
but O
increased I-Adverse_event.Trigger
the O
intensity I-Effect
of I-Effect
the I-Effect
dyskinesias I-Effect
in I-Effect
the I-Effect
afternoon I-Effect
. O

Transient I-Effect
asymptomatic I-Effect
bradycardia I-Effect
in O
patients I-Subject
on I-Adverse_event.Trigger
infusional I-Treatment.Route
5 I-Treatment.Drug
- I-Treatment.Drug
fluorouracil I-Treatment.Drug
. I-Treatment

In O
2006 O
, O
he I-Subject.Population
was O
diagnosed O
with O
deep I-Treat_Disorder
vein I-Treat_Disorder
thrombosis I-Treat_Disorder
and I-Treat_Disorder
pulmonary I-Treat_Disorder
embolism I-Treat_Disorder
and O
was O
started I-Potential_therapeutic_event.Trigger
on O
warfarin I-Treatment.Drug
. O

Scleritis I-Effect
complicating I-Adverse_event.Trigger
zoledronic I-Treatment.Drug
acid I-Treatment.Drug
infusion I-Treatment.Route
. O

A I-Subject
22 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
black I-Subject.Race
man I-Subject.Gender
developed I-Adverse_event.Trigger
fever I-Effect
, I-Effect
chills I-Effect
, I-Effect
fatigue I-Effect
, I-Effect
night I-Effect
sweats I-Effect
, I-Effect
tender I-Effect
lymphadenopathy I-Effect
, I-Effect
and I-Effect
a I-Effect
generalized I-Effect
, I-Effect
pruritic I-Effect
, I-Effect
macular I-Effect
eruption I-Effect
3 I-Time_elapsed
weeks I-Time_elapsed
after O
starting O
minocycline I-Treatment.Drug
therapy I-Treatment
for O
acne I-Treat_Disorder
. O

Ticlopidine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
aplastic I-Effect
anemia I-Effect
: O
two O
new O
case O
reports O
, O
review O
, O
and O
meta O
- O
analysis O
of O
55 O
additional O
cases O
. O

This O
is O
the O
second O
report O
of O
acute I-Effect
lung I-Effect
injury I-Effect
and I-Effect
diffuse I-Effect
alveolar I-Effect
damage I-Effect
caused I-Adverse_event.Trigger
by O
mefloquine I-Treatment.Drug
. O

A O
case O
of O
Erythema I-Effect
Multiforme I-Effect
Bullosum I-Effect
in O
patient I-Subject
of I-Subject
lepromatous I-Treat_Disorder
leprosy I-Treat_Disorder
with I-Subject
pulmonary I-Treat_Disorder
tuberculosis I-Treat_Disorder
due I-Adverse_event.Trigger
to I-Adverse_event.Trigger
Rifampicin I-Treatment.Drug
is O
described O
. O

Life I-Effect
- I-Effect
threatening I-Effect
alterations I-Effect
in I-Effect
heart I-Effect
rate I-Effect
after I-Adverse_event.Trigger
the O
use O
of O
adenosine I-Treatment.Drug
in O
atrial O
flutter O
. O

We O
report O
a O
case O
of O
pancytopenia I-Effect
in O
a I-Subject
23 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
man I-Subject.Gender
with I-Subject
Crohn I-Treat_Disorder
's I-Treat_Disorder
disease I-Treat_Disorder
who O
was O
treated I-Adverse_event.Trigger
with I-Adverse_event.Trigger
5 I-Treatment.Drug
- I-Treatment.Drug
aminosalicylic I-Treatment.Drug
acid I-Treatment.Drug
( I-Treatment
Pentasa I-Treatment.Drug
; I-Treatment
Nisshin I-Treatment
, I-Treatment
Tokyo I-Treatment
, I-Treatment
Japan I-Treatment
) I-Treatment
3.0 I-Treatment.Dosage
g I-Treatment.Dosage
/ I-Treatment.Dosage
day I-Treatment.Dosage
. O

The I-Effect
ampicillin I-Treatment.Drug
rash I-Effect
occurring I-Adverse_event.Trigger
in O
cases O
of O
infectious I-Treat_Disorder
mononucleosis I-Treat_Disorder
is O
well O
documented O
. O

The O
major O
side O
effect O
of I-Adverse_event.Trigger
infliximab I-Treatment.Drug
is O
infection I-Effect
. O

An I-Subject
asymptomatic I-Subject
HIV I-Treat_Disorder
- I-Subject
infected I-Subject
woman I-Subject.Gender
experienced I-Adverse_event.Trigger
right I-Effect
- I-Effect
sided I-Effect
renal I-Effect
colicky I-Effect
pain I-Effect
during O
treatment O
with O
indinavir I-Treatment.Drug
. O

The O
case O
resembles O
two O
previously O
reported O
cases O
of O
optic I-Effect
neuropathy I-Effect
which O
occurred I-Adverse_event.Trigger
in O
patients I-Subject
with I-Subject
Wilson I-Treat_Disorder
's I-Treat_Disorder
disease I-Treat_Disorder
who O
were O
receiving O
penicillamine I-Treatment.Drug
. O

Cutaneous I-Effect
ulceration I-Effect
: O
an O
unusual O
complication I-Adverse_event.Trigger
of O
intravenous I-Treatment.Route
pentamidine I-Treatment.Drug
therapy O
. O

Pulmonary I-Effect
hemorrhage I-Effect
is O
an O
uncommon O
feature O
in O
the O
HUS O
, O
and O
seems O
to O
appear I-Adverse_event.Trigger
especially O
in O
the O
HUS O
associated O
with O
MMC I-Treatment.Drug
therapy O
. O

Immunosuppression O
elicited O
by O
the O
extensive I-Treatment
administration I-Treatment
of I-Treatment
prednisolone I-Treatment.Drug
was O
suspected O
for O
the O
initiation O
of O
the O
generalized I-Adverse_event.Trigger
mite I-Effect
infestation I-Effect
. O

The I-Effect
episode I-Effect
appeared I-Effect
to I-Effect
have I-Effect
been I-Effect
precipitated I-Effect
by I-Effect
toxicity I-Effect
due I-Adverse_event.Trigger
to O
ingestion I-Route
of O
a I-Treatment
large I-Treatment.Dosage
amount I-Treatment.Dosage
of I-Treatment
phenytoin I-Treatment.Drug
. I-Treatment

Cardiopulmonary I-Effect
arrest I-Effect
following I-Adverse_event.Trigger
intravenous I-Treatment.Route
phenytoin I-Treatment.Drug
loading I-Treatment
. O

Although O
taxol I-Treatment.Drug
has O
shown O
significant O
activity O
in O
advanced O
ovarian O
cancer O
, O
peripheral I-Effect
neuropathy I-Effect
is O
likely O
to O
become O
the O
major O
dose O
- O
limiting O
toxicity I-Adverse_event.Trigger
. O

Syringotropic I-Effect
hypersensitivity I-Effect
reaction I-Effect
associated I-Adverse_event.Trigger
with O
infliximab I-Treatment.Combination.Drug
and I-Treatment
leflunomide I-Treatment.Combination.Drug
combination I-Treatment
therapy I-Treatment
in O
a I-Subject
child I-Subject.Age
with I-Subject
psoriatic I-Treat_Disorder
arthritis I-Treat_Disorder
. O

Corticosteroid I-Treatment.Drug
therapy O
was O
continued O
for I-Treatment.Duration
8 I-Treatment.Duration
months I-Treatment.Duration
since O
there O
was O
still O
improvement I-Potential_therapeutic_event.Trigger
of O
pulmonary I-Treat_Disorder
function I-Treat_Disorder
studies O
. O

OBJECTIVE O
: O
To O
describe O
a O
case O
of O
sertraline I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
rhabdomyolysis I-Effect
in O
an I-Subject
elderly I-Subject.Age
patient I-Subject
with I-Subject
dementia I-Treat_Disorder
and I-Subject
comorbidities I-Treat_Disorder
. O

Beyond O
the O
predictable O
pharmacokinetic O
drug O
- O
drug O
interaction O
requiring O
a O
significant O
warfarin O
dose O
reduction O
, O
the O
iodine I-Treatment.Drug
- I-Treatment.Drug
rich I-Treatment.Drug
amiodarone I-Treatment.Drug
affects O
the O
thyroid O
gland O
, O
causing I-Adverse_event.Trigger
overt I-Effect
hypothyroidism I-Effect
or I-Effect
thyrotoxicosis I-Effect
in O
14% O
- O
18 O
% O
of O
cases O
. O

Toxic I-Effect
epidermal I-Effect
necrolysis I-Effect
associated I-Adverse_event.Trigger
with O
interleukin I-Treatment.Drug
- I-Treatment.Drug
2 I-Treatment.Drug
. O

The O
pulmonary I-Effect
toxicity I-Effect
of O
gold I-Treatment.Drug
salts I-Treatment
is O
an O
uncommon O
cause I-Adverse_event.Trigger
of O
life I-Effect
- I-Effect
threatening I-Effect
respiratory I-Effect
failure I-Effect
. O

With O
its O
characteristics O
, O
tizanidine I-Treatment.Combination.Drug
has O
the O
potential O
to O
compromise I-Effect
hemodynamic I-Effect
stability I-Effect
during I-Treatment
concomitant I-Treatment
angiotensin I-Treatment.Combination.Drug
- I-Treatment.Combination.Drug
converting I-Treatment.Combination.Drug
enzyme I-Treatment.Combination.Drug
inhibitor I-Treatment.Combination.Drug
use I-Treatment
. O

Premature I-Effect
closure I-Effect
of I-Effect
the I-Effect
ductus I-Effect
arteriosus I-Effect
: O
variable O
response O
among O
monozygotic I-Subject
twins I-Subject
after I-Adverse_event.Trigger
in I-Treatment.Route
utero I-Treatment.Route
exposure I-Treatment.Route
to I-Treatment
indomethacin I-Treatment.Drug
. O

Possible O
mechanisms O
by O
which O
clonidine I-Treatment.Drug
decreases O
spasticity O
are O
described O
, O
probable O
mechanisms O
of O
induced I-Adverse_event.Trigger
bradycardia I-Effect
are O
reviewed O
, O
and O
specific O
treatment O
recommendations O
for O
the O
use O
of O
clonidine O
in O
spinal I-Treat_Disorder
cord I-Treat_Disorder
injured I-Treat_Disorder
patients O
are O
presented O
. O

This O
is O
the O
first O
report O
of O
a O
possible O
association I-Adverse_event.Trigger
between O
an I-Effect
acute I-Effect
cardiovascular I-Effect
event I-Effect
and O
venlafaxine I-Treatment.Drug
. O

Since O
early O
symptoms O
of O
the O
toxic O
effects O
of O
theophylline O
can O
mimic O
peptic O
ulcer O
disease O
, O
cimetidine I-Treatment.Drug
might O
be O
prescribed I-Potential_therapeutic_event.Trigger
for O
the O
gastrointestinal I-Treat_Disorder
symptoms I-Treat_Disorder
with O
subsequent O
worsening O
of O
theophylline O
poisoning O
. O

Acute I-Effect
renal I-Effect
failure I-Effect
in I-Adverse_event.Trigger
a I-Subject
patient I-Subject
receiving O
treatment O
with O
suramin I-Treatment.Drug
. O

A O
further O
case O
of O
anaphylactoid I-Effect
reaction I-Effect
to I-Adverse_event.Trigger
methylprednisolone I-Treatment.Drug
is O
reported O
. O

Pulmonary I-Effect
hemorrhage I-Effect
as O
a O
clinical O
manifestation O
of O
hemolytic I-Effect
- I-Effect
uremic I-Effect
syndrome I-Effect
associated I-Adverse_event.Trigger
with O
mitomycin I-Treatment.Drug
C I-Treatment.Drug
therapy I-Treatment
. O

EEG I-Effect
abnormalities I-Effect
were O
observed I-Adverse_event.Trigger
in O
two I-Subject.Population
of I-Subject.Population
the I-Subject.Population
nine I-Subject.Population
children I-Subject.Age
during O
chlorambucil I-Treatment.Drug
therapy O
. O

Discontinuation O
of O
the O
itraconazole I-Treatment.Drug
caused I-Adverse_event.Trigger
resolution O
of O
the O
drug I-Effect
eruption I-Effect
. O

The I-Treatment
addition I-Treatment
of I-Treatment
intrathecal I-Treatment
methotrexate I-Treatment.Drug
to I-Treatment
treatment I-Treatment
protocols I-Treatment
has O
increased O
survival O
rates O
in I-Subject
children I-Subject.Age
with I-Subject
acute I-Treat_Disorder
lymphoblastic I-Treat_Disorder
leukemia I-Treat_Disorder
but O
is O
also O
associated I-Adverse_event.Trigger
with O
varying I-Effect
degrees I-Effect
of I-Effect
neurotoxicity I-Effect
. O

We O
conclude O
that O
the O
presence O
of O
this I-Subject
metabolic I-Subject.Sub_Disorder
defect I-Subject.Sub_Disorder
combined O
with O
topical I-Treatment.Route
5 I-Treatment.Drug
- I-Treatment.Drug
FU I-Treatment.Drug
( I-Treatment
a I-Treatment
drug I-Treatment
demonstrating I-Treatment
a I-Treatment
narrow I-Treatment
therapeutic I-Treatment
index I-Treatment
) I-Treatment
results I-Adverse_event.Trigger
in I-Adverse_event.Trigger
the O
unusual I-Effect
presentation I-Effect
of I-Effect
life I-Effect
- I-Effect
threatening I-Effect
toxicity I-Effect
after O
treatment O
with O
a O
topical O
drug O
. O

Six I-Subject.Population
patients I-Subject
with I-Subject
rheumatoid I-Treat_Disorder
arthritis I-Treat_Disorder
developed I-Adverse_event.Trigger
a O
syndrome I-Effect
resembling I-Effect
lupus I-Effect
erythematosus I-Effect
while O
being O
treated O
with O
penicillamine I-Treatment.Drug
. O

This O
case O
highlights O
the O
need O
to O
monitor O
liver O
enzymes O
in O
patients I-Subject
treated I-Subject
with I-Subject
6 I-Subject
- I-Subject
TG I-Subject
and O
identifies O
the O
need O
for O
additional O
research O
focused O
on O
the O
mechanism O
of O
thiopurine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
hepatic I-Effect
injury I-Effect
. O

During I-Treatment.Time_elapsed
clarithromycin I-Treatment.Combination.Drug
coadministration I-Treatment
, O
four I-Subject.Population
out I-Subject.Population
of I-Subject.Population
the I-Subject.Population
seven I-Subject.Population
patients I-Subject
developed I-Adverse_event.Trigger
moderate I-Effect
- I-Effect
to I-Effect
- I-Effect
severe I-Effect
toxic I-Effect
symptoms I-Effect
of I-Effect
carbamazepine I-Treatment.Combination.Drug
, I-Effect
such I-Effect
as I-Effect
drowsiness I-Effect
, I-Effect
dizziness I-Effect
, I-Effect
and I-Effect
ataxia I-Effect
, O
which O
resolved O
within O
5 O
days O
after O
clarithromycin O
discontinuation O
. O

During O
clarithromycin O
coadministration O
, O
four O
out O
of O
the O
seven O
patients O
developed O
moderate I-Treat_Disorder
- I-Treat_Disorder
to I-Treat_Disorder
- I-Treat_Disorder
severe I-Treat_Disorder
toxic I-Treat_Disorder
symptoms I-Treat_Disorder
of I-Treat_Disorder
carbamazepine I-Treat_Disorder
, I-Treat_Disorder
such I-Treat_Disorder
as I-Treat_Disorder
drowsiness I-Treat_Disorder
, I-Treat_Disorder
dizziness I-Treat_Disorder
, I-Treat_Disorder
and I-Treat_Disorder
ataxia I-Treat_Disorder
, O
which O
resolved I-Potential_therapeutic_event.Trigger
within O
5 I-Treatment
days I-Treatment
after I-Treatment
clarithromycin I-Treatment.Drug
discontinuation I-Treatment
. O

5 I-Treatment.Drug
- I-Treatment.Drug
Fluorouracil I-Treatment.Drug
( I-Treatment.Drug
5 I-Treatment.Drug
- I-Treatment.Drug
FU I-Treatment.Drug
) I-Treatment.Drug
is I-Treatment
an I-Treatment
analogue I-Treatment
of I-Treatment
pyrimidine I-Treatment
nucleosides I-Treatment
that O
is O
widely O
used I-Potential_therapeutic_event.Trigger
in O
the O
treatment O
of O
head I-Treat_Disorder
and I-Treat_Disorder
neck I-Treat_Disorder
, I-Treat_Disorder
breast I-Treat_Disorder
, I-Treat_Disorder
ovarian I-Treat_Disorder
, I-Treat_Disorder
and I-Treat_Disorder
colon I-Treat_Disorder
cancer I-Treat_Disorder
. O

Fulminant I-Effect
fatal I-Effect
cardiotoxicity I-Effect
following I-Adverse_event.Trigger
cyclophosphamide I-Treatment.Drug
therapy O
. O

The O
reaction I-Treat_Disorder
in O
our O
patient I-Subject
appeared O
after O
tizanidine O
initiation O
and O
improved I-Potential_therapeutic_event.Trigger
after O
both I-Treatment
lisinopril I-Treatment.Combination.Drug
and I-Treatment
tizanidine I-Treatment.Combination.Drug
were O
discontinued O
. O

The O
reaction I-Effect
in O
our O
patient I-Subject
appeared O
after I-Adverse_event.Trigger
tizanidine I-Treatment.Drug
initiation I-Treatment
and O
improved O
after O
both O
lisinopril O
and O
tizanidine O
were O
discontinued O
. O

We O
describe O
the O
exceptional O
development I-Adverse_event.Trigger
of O
AML I-Effect
and O
lung I-Effect
cancer I-Effect
in O
a I-Subject
patient I-Subject
with I-Subject
previously I-Subject
diagnosed I-Subject
CLL I-Treat_Disorder
in I-Treat_Disorder
minimal I-Treat_Disorder
residual I-Treat_Disorder
disease I-Treat_Disorder
status I-Treat_Disorder
after O
fludarabine I-Treatment.Combination.Drug
treatment O
followed O
by O
autologous I-Treatment.Combination.Drug
peripheral I-Treatment.Combination.Drug
blood I-Treatment.Combination.Drug
stem I-Treatment.Combination.Drug
- I-Treatment.Combination.Drug
cell I-Treatment.Combination.Drug
transplantation I-Treatment.Route
. O

Valproate I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
hyperammonemia I-Effect
as O
a O
cause O
of O
altered I-Effect
mental I-Effect
status I-Effect
. O

We O
report O
5 O
cases O
of O
acute I-Effect
reversible I-Effect
renal I-Effect
failure I-Effect
coinciding O
with O
the O
onset I-Adverse_event.Trigger
of I-Adverse_event.Trigger
treatment I-Adverse_event.Trigger
with O
captopril I-Treatment.Drug
in O
patients I-Subject
with I-Subject
severe I-Treat_Disorder
drug I-Treat_Disorder
- I-Treat_Disorder
resistant I-Treat_Disorder
hypertension I-Treat_Disorder
. O

We O
report O
a O
case O
of O
contact I-Effect
dermatitis I-Effect
due I-Adverse_event.Trigger
to O
sodium I-Treatment.Drug
bisulfite I-Treatment.Drug
in O
Tathion O
eye O
drops O
. O

The I-Subject
first I-Subject
patient I-Subject
is O
undergoing O
hemodialysis O
and O
, O
though O
responding O
to O
sunitinib I-Treatment.Drug
, O
is O
having I-Adverse_event.Trigger
significant I-Effect
fatigue I-Effect
and I-Effect
hypertension I-Effect
. O

CCBs I-Treatment.Drug
should O
be O
considered O
in O
the O
treatment I-Potential_therapeutic_event.Trigger
of O
5 O
- O
FU O
or O
capecitabine O
- O
induced O
headaches I-Treat_Disorder
. O

Furosemide I-Treatment.Drug
, I-Treatment
spironolactone I-Treatment.Drug
, I-Treatment
allopurinol I-Treatment.Drug
, I-Treatment
and I-Treatment
hydroxyurea I-Treatment.Drug
were O
considered O
possible O
causes I-Adverse_event.Trigger
of O
the O
reaction I-Effect
and O
were O
discontinued O
. O

PATIENTS O
: O
One I-Subject.Population
patient I-Subject
with O
mucositis I-Effect
secondary I-Adverse_event.Trigger
to O
chemotherapy I-Treatment.Route
. O

A I-Subject
patient I-Subject
with I-Subject
monocular I-Treat_Disorder
open I-Treat_Disorder
- I-Treat_Disorder
angle I-Treat_Disorder
glaucoma I-Treat_Disorder
had I-Adverse_event.Trigger
trichiasis I-Effect
, O
a O
condition O
associated O
with O
the O
use O
of O
a I-Treatment
prostaglandin I-Treatment.Drug
analog I-Treatment.Drug
. O

A I-Subject
53 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
African I-Subject.Race
American I-Subject.Race
male I-Subject.Gender
with I-Subject
HIV I-Subject.Sub_Disorder
was O
prescribed I-Potential_therapeutic_event.Trigger
warfarin I-Treatment.Drug
5 I-Treatment.Dosage
mg I-Treatment.Dosage
/ I-Treatment.Dosage
day I-Treatment.Dosage
for I-Treatment
12 I-Treatment.Duration
months I-Treatment.Duration
after O
diagnosis O
of O
idiopathic I-Treat_Disorder
deep I-Treat_Disorder
vein I-Treat_Disorder
thrombosis I-Treat_Disorder
and I-Treat_Disorder
bilateral I-Treat_Disorder
pulmonary I-Treat_Disorder
emboli I-Treat_Disorder
( O
target O
INR O
2.5 O
[ O
range O
2.0 O
- O
3.0 O
] O
) O
. O

After O
treatment O
with O
a I-Treatment
beta I-Treatment
- I-Treatment
sympathomimetic I-Treatment
drug I-Treatment
( I-Treatment
Partusisten I-Treatment.Drug
) I-Treatment
one I-Subject
fetus I-Subject.Age
developed I-Adverse_event.Trigger
supraventricular I-Effect
tachycardia I-Effect
. I-Effect

Serotonin I-Effect
syndrome I-Effect
developed I-Adverse_event.Trigger
in O
a I-Subject
patient I-Subject
taking O
concurrent I-Treatment
linezolid I-Treatment.Combination.Drug
and I-Treatment
fluoxetine I-Treatment.Combination.Drug
. O

RESULTS O
: O
A I-Subject
male I-Subject.Gender
and I-Subject
a I-Subject
female I-Subject.Gender
patient I-Subject
with I-Subject
spasticity I-Treat_Disorder
treated I-Adverse_event.Trigger
with O
intrathecal I-Treatment.Route
baclofen I-Treatment.Drug
were O
recognized O
to O
have O
sexual I-Effect
dysfunction I-Effect
side O
effects O
from O
treatment O
. O

OBJECTIVE O
: O
To O
describe O
a O
patient I-Subject
with O
ifosfamide I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
nonconvulsive I-Effect
status I-Effect
epilepticus I-Effect
. O

Upper I-Effect
gastrointestinal I-Effect
haemorrhage I-Effect
is O
a O
serious O
complication I-Adverse_event.Trigger
of O
aspirin I-Treatment
and I-Treatment
clopidogrel I-Treatment
( I-Treatment
dual I-Treatment
) I-Treatment
anti O
- O
platelet O
therapy O
with O
a O
high O
morbidity O
and O
mortality O
. O

Flecainide I-Treatment.Drug
overdose I-Treatment.Dosage
can O
rapidly O
result I-Adverse_event.Trigger
in O
profound I-Effect
cardiovascular I-Effect
collapse I-Effect
, I-Effect
and I-Effect
is I-Effect
associated I-Effect
with I-Effect
a I-Effect
relatively I-Effect
high I-Effect
mortality I-Effect
. O

Sulfasalazine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
lupus I-Effect
erythematosus I-Effect
. O

Reye I-Effect
syndrome I-Effect
( I-Effect
RS I-Effect
) I-Effect
is O
believed O
to O
occur I-Adverse_event.Trigger
infrequently O
among O
children I-Subject.Age
receiving O
long I-Treatment
- I-Treatment
term I-Treatment
aspirin I-Treatment.Drug
therapy O
. O

Propecia I-Treatment.Drug
- O
associated I-Adverse_event.Trigger
bilateral I-Effect
cataract I-Effect
. O

After I-Adverse_event.Trigger
39 I-Time_elapsed
hours I-Time_elapsed
on O
argatroban I-Treatment.Drug
, O
the O
infusion O
was O
stopped O
when O
minor I-Effect
bleeding I-Effect
was I-Effect
observed I-Effect
with I-Effect
a I-Effect
concurrent I-Effect
activated I-Effect
partial I-Effect
thromboplastin I-Effect
time I-Effect
( I-Effect
aPTT I-Effect
) I-Effect
of I-Effect
100 I-Effect
seconds I-Effect
. O

Anaphylactoid I-Effect
reaction I-Effect
to I-Adverse_event.Trigger
methylprednisolone I-Treatment.Drug
pulsed I-Treatment
therapy I-Treatment
for O
multiple I-Treat_Disorder
sclerosis I-Treat_Disorder
. O

Warfarin O
- O
induced O
skin O
necrosis O
and O
heparin I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
thrombocytopenia I-Effect
following O
mitral O
valve O
replacement O
for O
marantic I-Treat_Disorder
endocarditis I-Treat_Disorder
. O

Warfarin I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
skin I-Effect
necrosis I-Effect
and O
heparin O
- O
induced O
thrombocytopenia O
following O
mitral O
valve O
replacement O
for O
marantic O
endocarditis O
. O

Surprisingly O
, O
we O
found O
that O
three I-Subject.Population
patients I-Subject
appeared O
to O
develop I-Adverse_event.Trigger
tardive I-Effect
OGC I-Effect
while O
taking O
clozapine I-Treatment.Drug
. O

We O
report O
a O
fatal O
case O
of O
toxic I-Effect
epidermal I-Effect
necrolysis I-Effect
( I-Effect
TEN I-Effect
) I-Effect
resulting I-Adverse_event.Trigger
from I-Adverse_event.Trigger
a O
high I-Treatment.Dosage
dose I-Treatment.Dosage
of I-Treatment
cytosine I-Treatment.Drug
arabinoside I-Treatment.Drug
( I-Treatment.Drug
ARA I-Treatment.Drug
- I-Treatment.Drug
C I-Treatment.Drug
) I-Treatment.Drug
. O

On O
the I-Time_elapsed
fifth I-Time_elapsed
day I-Time_elapsed
after O
administration O
of O
a O
high I-Treatment.Dosage
dose I-Treatment.Dosage
of I-Treatment
ARA I-Treatment.Drug
- I-Treatment.Drug
C I-Treatment.Drug
( O
2 I-Dosage
g I-Dosage
/ I-Dosage
m2 I-Dosage
intravenously O
every O
12 I-Freq
hours I-Freq
) O
, O
she O
developed I-Adverse_event.Trigger
bullous I-Effect
lesions I-Effect
on I-Effect
the I-Effect
hands I-Effect
and I-Effect
soles I-Effect
that I-Effect
disseminated I-Effect
, I-Effect
evolving I-Effect
to I-Effect
necrosis I-Effect
, I-Effect
sepsis I-Effect
, I-Effect
and I-Effect
death I-Effect
on O
the I-Time_elapsed
22nd I-Time_elapsed
day I-Time_elapsed
. O

We O
describe O
2 I-Subject.Population
patients I-Subject
with I-Subject
cutaneous I-Treat_Disorder
lupus I-Treat_Disorder
erythematosus I-Treat_Disorder
who O
developed O
severe I-Effect
dapsone I-Drug
reaction I-Effect
after I-Adverse_event.Trigger
low I-Treatment.Dosage
dose I-Treatment.Dosage
therapy I-Treatment
, O
with I-Effect
a I-Effect
fatal I-Effect
outcome I-Effect
in I-Effect
one I-Effect
. O

A I-Subject
patient I-Subject
with I-Subject
ulcerative I-Treat_Disorder
colitis I-Treat_Disorder
developed I-Adverse_event.Trigger
skin I-Effect
pigmentation I-Effect
and I-Effect
diffuse I-Effect
pulmonary I-Effect
shadowing I-Effect
without I-Effect
respiratory I-Effect
symptomatology I-Effect
, O
while O
taking O
sulfasalazine I-Treatment.Drug
. O

This O
is O
a O
case O
report O
involving O
a I-Subject
patient I-Subject
who O
was O
treated O
with O
topical I-Treatment.Route
5 I-Treatment.Drug
- I-Treatment.Drug
FU I-Treatment.Drug
cream I-Treatment
and O
subsequently O
developed I-Adverse_event.Trigger
a I-Effect
severe I-Effect
case I-Effect
of I-Effect
angioedema I-Effect
. O

Cessation I-Treatment
of I-Treatment
D I-Treatment.Drug
- I-Treatment.Drug
Pen I-Treatment.Drug
and I-Treatment
the I-Treatment
start I-Treatment
of I-Treatment
corticosteroid I-Treatment.Drug
therapy I-Treatment
were O
followed I-Potential_therapeutic_event.Trigger
by O
recovery I-Effect
from I-Effect
bicytopenia I-Treat_Disorder
. O

Prevention I-Potential_therapeutic_event.Trigger
of O
infection I-Treat_Disorder
by O
immunization I-Treatment
, I-Treatment
together I-Treatment
with I-Treatment
early I-Treatment
recognition I-Treatment
and I-Treatment
prompt I-Treatment
antiviral I-Treatment
treatment I-Treatment
are O
critical O
. O

A I-Subject
case I-Subject
of O
normotensive I-Effect
scleroderma I-Effect
renal I-Effect
crisis I-Effect
after I-Adverse_event.Trigger
high I-Treatment.Dosage
- I-Treatment.Dosage
dose I-Treatment.Dosage
methylprednisolone I-Treatment.Drug
treatment I-Treatment
. O

OBJECTIVES O
: O
A O
delayed I-Effect
stroke I-Effect
- I-Effect
like I-Effect
leukoencephalopathy I-Effect
has I-Adverse_event.Trigger
been I-Adverse_event.Trigger
observed I-Adverse_event.Trigger
in O
patients I-Subject
receiving O
methotrexate I-Treatment.Drug
( I-Treatment
MTX I-Treatment
) I-Treatment
for O
childhood I-Treat_Disorder
leukemia I-Treat_Disorder
. O

Duloxetine I-Treatment.Combination.Drug
- O
induced I-Adverse_event.Trigger
hyponatremia I-Effect
in O
an I-Subject
elderly I-Subject.Age
patient I-Subject
treated I-Subject
with I-Subject
thiazide I-Combination.Drug
diuretics I-Combination.Drug
. O

The O
following O
is O
a O
case O
report O
analysis O
intended O
to O
draw O
attention O
to O
the O
need O
for O
better O
care O
coordination O
by O
describing O
the O
observed O
relationship I-Adverse_event.Trigger
of O
olanzapine I-Treatment.Drug
to O
metabolic I-Effect
changes I-Effect
manifested I-Effect
as I-Effect
uncontrolled I-Effect
diabetes I-Effect
mellitus I-Effect
and I-Effect
weight I-Effect
gain I-Effect
. O

Arsenic I-Treatment.Drug
trioxide I-Treatment.Drug
has O
recently O
been O
introduced O
as O
a O
promising O
new O
agent O
to O
treat I-Potential_therapeutic_event.Trigger
refractory I-Treat_Disorder
acute I-Treat_Disorder
promyelocytic I-Treat_Disorder
leukemia I-Treat_Disorder
( O
APL O
) O
. O

Although O
the I-Effect
t I-Effect
- I-Effect
AML I-Effect
developed I-Adverse_event.Trigger
following O
oral I-Treatment.Route
etoposide I-Treatment.Combination.Drug
therapy I-Treatment
, O
the I-Subject
child I-Subject.Age
had O
previously O
received O
high I-Treatment.Dosage
- I-Treatment.Dosage
dose I-Treatment.Dosage
, I-Treatment
multiagent I-Treatment
chemotherapy I-Treatment.Combination.Drug
, O
and O
rearrangement O
of O
the O
MLL O
gene O
was O
not O
demonstrated O
. O

Heat I-Effect
stroke I-Effect
in O
schizophrenia I-Treat_Disorder
during I-Adverse_event.Trigger
clozapine I-Treatment.Drug
treatment O
: O
rapid O
recognition O
and O
management O
. O

The O
same I-Effect
symptoms I-Effect
recurred O
few I-Treatment.Time_elapsed
days I-Treatment.Time_elapsed
after I-Treatment.Time_elapsed
taking I-Adverse_event.Trigger
nitrendipine I-Treatment.Drug
. O

The O
authors O
report O
two I-Subject.Population
cases I-Subject
of O
acute I-Effect
dystonic I-Effect
reactions I-Effect
( I-Effect
ADRs I-Effect
) I-Effect
as O
a O
side O
effect I-Adverse_event.Trigger
of O
lamivudine I-Treatment.Drug
. O

Isoniazid I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
anaphylaxis I-Effect
. O

Histopathology O
of O
the O
thyroid O
in O
amiodarone I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
hypothyroidism I-Effect
. O

Deepening I-Effect
of I-Effect
lid I-Effect
sulcus I-Effect
from I-Adverse_event.Trigger
topical O
bimatoprost I-Treatment.Drug
therapy O
. O

Gastro I-Effect
- I-Effect
oesophageal I-Effect
reflux I-Effect
associated I-Adverse_event.Trigger
with O
nifedipine I-Treatment.Drug
. O

CASE O
SUMMARY O
: O
A I-Subject
68 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
woman I-Subject.Gender
developed O
a I-Effect
dry I-Effect
, I-Effect
irritating I-Effect
cough I-Effect
within I-Time_elapsed
one I-Time_elapsed
month I-Time_elapsed
of O
starting I-Adverse_event.Trigger
quinapril I-Treatment.Drug
therapy I-Treatment
for O
the O
treatment O
of O
essential I-Treat_Disorder
hypertension I-Treat_Disorder
. O

Sertraline I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
rhabdomyolysis I-Effect
in O
an I-Subject
elderly I-Subject.Age
patient I-Subject
with I-Subject
dementia I-Subject.Sub_Disorder
and I-Subject
comorbidities I-Subject.Sub_Disorder
. O

After I-Treatment
the I-Treatment
dose I-Treatment
of I-Treatment
methylprednisolone I-Treatment.Drug
was I-Treatment
reduced I-Treatment.Dosage
from I-Treatment.Dosage
40 I-Treatment.Dosage
mg I-Treatment.Dosage
to I-Treatment.Dosage
20 I-Treatment.Dosage
mg I-Treatment.Dosage
i.v I-Treatment.Dosage
. I-Treatment.Dosage
q6h I-Treatment.Dosage
and I-Treatment
shifted I-Treatment
to I-Treatment
other I-Treatment
anti I-Treatment
- I-Treatment
asthma I-Treatment
treatment I-Treatment
by I-Treatment
procaterol I-Treatment
metered I-Treatment
dose I-Treatment
inhaler I-Treatment
via I-Treatment
spacer I-Treatment.Route
, O
the O
psychotic I-Treat_Disorder
reaction I-Treat_Disorder
disappeared I-Potential_therapeutic_event.Trigger
a I-Treatment.Time_elapsed
few I-Treatment.Time_elapsed
hours I-Treatment.Time_elapsed
later I-Treatment
. O

Sirolimus I-Treatment.Drug
works I-Treatment
differently I-Treatment
from I-Treatment
the I-Treatment
immunosuppressants I-Treatment.Drug
currently I-Treatment
available I-Treatment
, O
and O
except O
for I-Adverse_event.Trigger
increased I-Effect
lipid I-Effect
levels I-Effect
, O
the O
adverse O
reaction O
profile O
of O
sirolimus I-Drug
does O
not O
appear O
to O
overlap O
to O
any O
great O
extent O
with O
that O
associated O
with O
cyclosporine I-Drug
or O
tacrolimus I-Drug
. O

Patient O
was O
on O
warfarin I-Treatment.Drug
for I-Potential_therapeutic_event.Trigger
a I-Treat_Disorder
prior I-Treat_Disorder
deep I-Treat_Disorder
venous I-Treat_Disorder
thrombosis I-Treat_Disorder
. O

Quetiapine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
myoclonus I-Effect
. O

Dyspnea I-Effect
possibly O
associated I-Adverse_event.Trigger
with O
controlled I-Treatment.Dosage
- I-Treatment.Dosage
release I-Treatment.Dosage
morphine I-Treatment.Drug
sulfate I-Treatment.Drug
tablets I-Treatment.Route
. O

The O
incidence O
of O
ARE I-Effect
suddenly O
exceeded O
10 O
% O
of O
the O
patients I-Subject
treated O
by I-Adverse_event.Trigger
melarsoprol I-Treatment.Drug
during O
August I-Duration
1992 I-Duration
and I-Duration
September I-Duration
1993 I-Duration
. O

A I-Subject
patient I-Subject
with I-Subject
disseminated I-Treat_Disorder
herpes I-Treat_Disorder
zoster I-Treat_Disorder
developed I-Adverse_event.Trigger
a O
syndrome I-Effect
of I-Effect
inappropriate I-Effect
antidiuretic I-Effect
hormone I-Effect
and I-Effect
profound I-Effect
hyponatremia I-Effect
secondary O
to O
the O
administration O
of O
adenine I-Treatment.Drug
arabinoside I-Treatment.Drug
. O

One I-Subject.Population
patient I-Subject
with I-Subject
systemic I-Subject.Sub_Disorder
lupus I-Subject.Sub_Disorder
erythematosus I-Subject.Sub_Disorder
developed O
erythema I-Effect
multiforme I-Effect
after I-Adverse_event.Trigger
taking O
griseofulvin I-Treatment.Drug
. O

We O
report O
a O
rare O
case O
of O
colonic I-Effect
mucosal I-Effect
necrosis I-Effect
following I-Adverse_event.Trigger
Kalimate I-Treatment.Drug
( I-Treatment.Drug
calcium I-Treatment.Drug
polystryrene I-Treatment.Drug
sulfonate I-Treatment.Drug
) I-Treatment.Drug
, I-Treatment
an I-Treatment
analogue I-Treatment
of I-Treatment
Kayexalate I-Treatment.Drug
without I-Treatment
sorbitol I-Treatment
in O
a I-Subject
34 I-Subject.Age
- I-Subject.Age
yr I-Subject.Age
- I-Subject.Age
old I-Subject.Age
man I-Subject.Gender
. O

Bilateral I-Effect
anterior I-Effect
uveitis I-Effect
associated I-Adverse_event.Trigger
with O
clomiphene I-Treatment.Drug
citrate I-Treatment.Drug
. O

Progressive I-Effect
anemia I-Effect
following I-Adverse_event.Trigger
combination I-Treatment
therapy I-Treatment
with I-Treatment
interferon I-Treatment.Combination.Drug
- I-Treatment.Combination.Drug
alpha I-Treatment.Combination.Drug
and I-Treatment
interleukin I-Treatment.Combination.Drug
- I-Treatment.Combination.Drug
2 I-Treatment.Combination.Drug
in O
a I-Subject
patient I-Subject
with I-Subject
metastatic I-Treat_Disorder
renal I-Treat_Disorder
cell I-Treat_Disorder
carcinoma I-Treat_Disorder
. O

Metoclopramide I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
parkinsonism I-Effect
. O

A O
12 I-Subject.Age
year I-Subject.Age
old I-Subject.Age
patient I-Subject
with I-Subject
atrial I-Treat_Disorder
flutter I-Treat_Disorder
is O
presented O
, O
in O
whom O
intravenous I-Treatment.Route
adenosine I-Treatment.Drug
was O
followed I-Adverse_event.Trigger
by I-Adverse_event.Trigger
acceleration I-Effect
of I-Effect
the I-Effect
heart I-Effect
rate I-Effect
to I-Effect
a I-Effect
potentially I-Effect
dangerous I-Effect
arrhythmia I-Effect
. O

Similar O
to O
reports O
in O
patients I-Subject
receiving I-Adverse_event.Trigger
gefitinib I-Treatment.Drug
, O
those O
with O
pathologic O
findings O
of O
UIP O
on O
resected O
lung O
specimens O
or O
known O
pulmonary O
fibrosis O
may O
be O
at O
particular O
risk O
for O
erlotinib I-Effect
pulmonary I-Effect
toxicity I-Effect
. I-Effect

Eleven I-Treatment.Time_elapsed
days I-Treatment.Time_elapsed
after I-Treatment
increase I-Treatment
of I-Treatment
the I-Treatment
trimipramine I-Treatment.Drug
dosage I-Treatment
to I-Treatment
100 I-Treatment.Dosage
mg I-Treatment.Dosage
/ I-Treatment.Dosage
d I-Treatment.Dosage
, O
she I-Subject.Gender
was O
hospitalized I-Adverse_event.Trigger
because O
of O
seizures I-Effect
suggesting I-Effect
a I-Effect
secondary I-Effect
generalized I-Effect
grand I-Effect
- I-Effect
mal I-Effect
episode I-Effect
. O

AIM O
: O
To O
report O
a O
patient I-Subject
with I-Subject
diabetic I-Treat_Disorder
rubeosis I-Treat_Disorder
who O
suffered I-Adverse_event.Trigger
from O
acute I-Effect
retinal I-Effect
ischemic I-Effect
change I-Effect
and I-Effect
stroke I-Effect
after O
intravitreal I-Treatment.Route
injection I-Treatment.Route
of I-Treatment
bevacizumab I-Treatment.Drug
. O

Stevens I-Effect
- I-Effect
Johnson I-Effect
syndrome I-Effect
caused I-Adverse_event.Trigger
by I-Adverse_event.Trigger
the O
antiretroviral I-Treatment
drug I-Treatment
nevirapine I-Treatment.Drug
. O

From O
these O
data O
, O
acute I-Effect
generalized I-Effect
dystonia I-Effect
with I-Effect
brainstem I-Effect
and I-Effect
thalamic I-Effect
lesions I-Effect
may O
occur O
in O
WD I-Treat_Disorder
patients I-Subject
after I-Adverse_event.Trigger
an I-Treatment
initial I-Treatment
d I-Treatment.Drug
- I-Treatment.Drug
penicillamine I-Treatment.Drug
therapy I-Treatment
. O

Although O
this O
combination O
agent O
has O
been O
associated O
with O
a O
hypersensitivity O
syndrome O
involving O
cutaneous O
skin O
eruptions O
, O
pediatric I-Subject.Age
cases I-Subject
of O
TMP I-Treatment.Drug
- I-Treatment.Drug
SMX I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
hepatotoxicity I-Effect
are O
rare O
. O

Drug I-Treat_Disorder
resistant I-Treat_Disorder
tuberculosis I-Treat_Disorder
requires I-Potential_therapeutic_event.Trigger
more O
complex I-Treatment.Duration
and I-Treatment.Duration
longer I-Treatment.Duration
treatment I-Treatment.Duration
with I-Treatment
alternative I-Treatment
substances I-Treatment.Drug
. O

Intracranial I-Effect
haemorrhage I-Effect
from I-Effect
a I-Effect
meningioma I-Effect
in I-Adverse_event.Trigger
a I-Subject
patient I-Subject
receiving O
aspirin I-Treatment.Drug
prophylaxis O
: O
a O
case O
report O
. O

The O
objective O
of O
this O
report O
is O
to O
describe O
a O
case O
of O
fixed I-Effect
drug I-Effect
eruption I-Effect
that O
occurred I-Adverse_event.Trigger
during I-Treatment
omeprazole I-Treatment.Drug
treatment I-Treatment
. O

Case O
2 O
: O
A I-Subject
43 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
male I-Subject.Gender
alcoholic I-Treat_Disorder
remained O
completely I-Treatment
abstinent I-Treatment
with I-Treatment
cyanamide I-Treatment.Drug
treatment I-Treatment
for I-Treatment
5 I-Treatment.Duration
years I-Treatment.Duration
and O
complained I-Adverse_event.Trigger
of O
general I-Effect
fatigue I-Effect
. O

Delayed I-Effect
hypersensitivity I-Effect
to I-Adverse_event.Trigger
flurbiprofen I-Treatment.Drug
. O

Propafenone I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
ataxia I-Effect
: O
report O
of O
three I-Subject.Population
cases I-Subject
. O

Delavirdine I-Treatment.Drug
and I-Treatment
efavirenz I-Treatment.Drug
( I-Treatment
but I-Treatment
not I-Treatment
nevirapine I-Treatment
) I-Treatment
also O
were O
strong O
inhibitors O
of O
CYP3A O
, O
consistent I-Adverse_event.Trigger
with I-Adverse_event.Trigger
clinical I-Effect
hazards I-Effect
of O
initial O
cotreatment O
with O
either O
of O
these O
drugs O
and O
substrates O
of O
CYP3A. O

This O
is O
the O
first O
report O
of O
UFT I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
scleroderma I-Effect
- I-Effect
like I-Effect
reaction I-Effect
. O

Can O
roxithromycin I-Treatment.Combination.Drug
and I-Treatment
betamethasone I-Treatment.Combination.Drug
induce I-Adverse_event.Trigger
acute I-Effect
pancreatitis I-Effect
? O
A O
case O
report O
. O

Up I-Subject.Population
to I-Subject.Population
four I-Subject.Population
percent I-Subject.Population
of I-Subject
patients I-Subject
treated O
with O
imatinib I-Treatment.Drug
may O
develop I-Adverse_event.Trigger
hepatotoxicity I-Effect
, O
which O
usually O
resolves O
with O
discontinuation O
of O
the O
drug O
. O

Schneiderian I-Effect
first I-Effect
- I-Effect
rank I-Effect
symptoms I-Effect
associated I-Adverse_event.Trigger
with O
fluvoxamine I-Treatment.Drug
treatment O
: O
a O
case O
report O
. O

Peripheral I-Effect
and I-Effect
optic I-Effect
neuropathy I-Effect
was O
usually O
seen O
after I-Adverse_event.Trigger
several I-Treatment.Time_elapsed
months I-Treatment.Time_elapsed
of I-Treatment
linezolid I-Treatment.Drug
therapy I-Treatment
( I-Treatment
median I-Treatment
5 I-Treatment
mo I-Treatment
) I-Treatment
, O
lactic I-Effect
acidosis I-Effect
after I-Effect
several I-Effect
weeks I-Effect
( I-Effect
median I-Effect
6 I-Effect
wks I-Effect
) I-Effect
, I-Effect
and I-Effect
serotonin I-Effect
syndrome I-Effect
after I-Effect
several I-Effect
days I-Effect
( I-Effect
median I-Effect
4 I-Effect
days I-Effect
) I-Effect
. O

Muzolimine I-Treatment.Dosage
- O
induced I-Adverse_event.Trigger
severe O
neuromyeloencephalopathy I-Effect
: O
report O
of O
seven O
cases O
. O

We O
conclude O
peripheral I-Effect
neuropathy I-Effect
with I-Adverse_event.Trigger
5 I-Treatment.Drug
- I-Treatment.Drug
FU I-Treatment.Drug
is O
rare O
. O

Additionally O
, O
danazol I-Treatment.Drug
produces I-Adverse_event.Trigger
hepatocellular I-Effect
damage I-Effect
in O
approximately O
10 I-Subject.Population
% I-Subject.Population
of I-Subject
women I-Subject.Gender
. O

CONCLUSIONS O
: O
We O
report O
a O
typical I-Effect
symptoms I-Effect
of I-Effect
Charles I-Effect
- I-Effect
Bonnet I-Effect
syndrome I-Effect
( I-Effect
CBS I-Effect
) I-Effect
in O
patients I-Subject
with I-Subject
severe I-Subject
AMD I-Treat_Disorder
after I-Adverse_event.Trigger
intravitreal I-Treatment.Route
Avastin I-Treatment.Drug
- I-Treatment
injections I-Treatment.Route
. O

Proconvulsive I-Effect
tendency I-Effect
of O
imipenem I-Treatment.Combination.Drug
/ I-Treatment
cilastatin I-Treatment.Combination.Drug
is O
one O
of O
its O
well O
- O
known O
side I-Adverse_event.Trigger
effects I-Adverse_event.Trigger
. O

A O
49 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
man I-Subject.Gender
with I-Subject
Crohn I-Treat_Disorder
's I-Treat_Disorder
disease I-Treat_Disorder
treated O
with O
prednisone I-Treatment.Combination.Drug
and I-Treatment
mesalamine I-Treatment.Combination.Drug
( I-Treatment
5 I-Treatment
- I-Treatment
ASA I-Treatment
) I-Treatment
developed I-Adverse_event.Trigger
worsening I-Effect
respiratory I-Effect
distress I-Effect
and I-Effect
fever I-Effect
. I-Effect

OBJECTIVE O
: O
This I-Subject
case I-Subject
report O
outlines O
a I-Effect
significant I-Effect
type I-Effect
of I-Effect
morbidity I-Effect
due O
to O
continued O
use I-Adverse_event.Trigger
of O
gabapentin I-Treatment.Drug
during O
an O
episode O
of O
acute O
renal O
failure O
. O

Acute I-Effect
delirium I-Effect
resulting I-Adverse_event.Trigger
from O
levofloxacin I-Treatment.Drug
therapy O
is O
an O
exceedingly O
rare O
complication O
that O
has O
been O
thought O
to O
occur O
more O
commonly O
in O
elderly I-Subject.Age
patients I-Subject
. O

Selective O
estrogen O
receptor O
modulator O
raloxifene I-Treatment.Drug
- O
associated I-Adverse_event.Trigger
aggravation I-Effect
of I-Effect
nonalcoholic I-Effect
steatohepatitis I-Effect
. O

The I-Treatment.Time_elapsed
day I-Treatment.Time_elapsed
after I-Treatment.Time_elapsed
methotrexate I-Treatment.Drug
administration I-Treatment
, O
the O
patient O
complained I-Adverse_event.Trigger
of O
severe I-Effect
back I-Effect
pain I-Effect
and I-Effect
urinary I-Effect
retention I-Effect
. O

Pulmonary I-Effect
toxicity I-Effect
secondary I-Adverse_event.Trigger
to O
procarbazine I-Treatment.Drug
. O

In O
keeping O
with O
findings O
in O
the O
literature O
, O
the O
aortic I-Effect
wall I-Effect
in I-Effect
this I-Effect
case I-Effect
was I-Effect
damaged I-Effect
by O
secondary O
changes O
following I-Adverse_event.Trigger
irradiation I-Treatment
and I-Treatment
Bleomycin I-Treatment.Drug
treatment I-Treatment
. I-Treatment

It O
has O
been O
suggested O
that O
PPE I-Effect
caused I-Adverse_event.Trigger
by O
cytarabine I-Treatment.Drug
does O
not O
recur O
with O
subsequent O
cytarabine O
re O
- O
challenge O
. O

CONCLUSIONS O
: O
The O
value O
of O
multihormonal O
therapy O
in O
breast O
carcinoma O
is O
not O
established O
, O
and O
the O
addition I-Treatment
of I-Treatment
progestogens I-Treatment.Combination.Drug
to I-Treatment
tamoxifen I-Treatment.Combination.Drug
may I-Adverse_event.Trigger
not I-Adverse_event.Trigger
reduce I-Adverse_event.Trigger
of O
developing O
endometrial I-Effect
lesions I-Effect
, O
including O
carcinoma I-Effect
. O

Inappropriate I-Effect
antidiuretic I-Effect
hormone I-Effect
following I-Adverse_event.Trigger
adenine I-Treatment.Drug
arabinoside I-Treatment.Drug
administration O
. O

Ampicillin I-Treatment.Drug
- O
associated I-Adverse_event.Trigger
seizures I-Effect
. O

We O
describe O
a O
case O
of O
fibrosing I-Effect
alveolitis I-Effect
, O
diagnosed O
by O
lung O
biopsy O
, O
in O
a I-Subject
patient I-Subject
receiving I-Adverse_event.Trigger
amiodarone I-Treatment.Combination.Drug
which I-Treatment
responded I-Treatment
to I-Treatment
corticosteroid I-Treatment.Combination.Drug
therapy I-Treatment
. O

Furosemide I-Treatment.Drug
- O
associated I-Adverse_event.Trigger
fever I-Effect
. O

Thymic I-Effect
enlargement I-Effect
in O
a I-Subject
patient I-Subject
with I-Subject
juvenile I-Subject.Age
idiopathic I-Treat_Disorder
arthritis I-Treat_Disorder
during I-Adverse_event.Trigger
etanercept I-Treatment.Drug
therapy O
. O

Fatal O
methylene I-Treatment.Drug
blue I-Treatment.Drug
associated I-Adverse_event.Trigger
serotonin I-Effect
toxicity I-Effect
. O

Mannitol I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
ARF I-Effect
responds O
promptly O
to O
hemodialysis O
with O
rapid O
resolution O
of O
anuria I-Effect
and O
recovery O
of O
renal I-Effect
failure I-Effect
. O

We O
report O
a O
rare O
case O
of O
recurrent I-Effect
( I-Effect
stuttering I-Effect
) I-Effect
priapism I-Effect
in O
a I-Subject
patient I-Subject
with I-Subject
protein I-Treat_Disorder
C I-Treat_Disorder
deficiency I-Treat_Disorder
while I-Adverse_event.Trigger
maintained I-Treatment
on I-Treatment
Warfarin I-Treatment.Drug
therapy I-Treatment
. O

Angioedema I-Effect
and I-Effect
maculopapular I-Effect
eruptions I-Effect
associated I-Adverse_event.Trigger
with O
carbamazepine I-Treatment.Drug
administration I-Treatment
. I-Treatment

Mental I-Effect
nerve I-Effect
neuropathy I-Effect
as O
a O
result I-Adverse_event.Trigger
of O
hepatitis I-Treatment.Drug
B I-Treatment.Drug
vaccination I-Treatment.Drug
. I-Drug

We O
describe O
a I-Subject
premenopausal I-Subject.Age
woman I-Subject.Gender
who O
, O
while O
having O
tamoxifen I-Treatment.Drug
due O
to O
a O
diagnosis O
of O
in I-Treat_Disorder
situ I-Treat_Disorder
ductal I-Treat_Disorder
carcinoma I-Treat_Disorder
, O
developed I-Adverse_event.Trigger
endometriosis I-Effect
requiring O
surgery O
. O

Disseminated I-Effect
cellulitic I-Effect
cryptococcosis I-Effect
in I-Adverse_event.Trigger
the I-Adverse_event.Trigger
setting I-Adverse_event.Trigger
of I-Adverse_event.Trigger
prednisone I-Treatment.Drug
monotherapy I-Treatment
for O
pemphigus I-Treat_Disorder
vulgaris I-Treat_Disorder
. O

We O
describe O
a I-Subject
63 I-Subject.Age
year I-Subject.Age
old I-Subject.Age
woman I-Subject.Gender
with I-Subject
a I-Subject
suppurative I-Treat_Disorder
mediastinitis I-Treat_Disorder
, O
treated O
with O
continuous I-Treatment
PI I-Treatment.Drug
irrigation I-Treatment.Route
who O
developed I-Adverse_event.Trigger
an O
acute I-Effect
oliguric I-Effect
renal I-Effect
failure I-Effect
. O

A I-Subject
young I-Subject.Age
woman I-Subject.Gender
with I-Subject
epilepsy I-Treat_Disorder
had I-Adverse_event.Trigger
tonic I-Effect
- I-Effect
clonic I-Effect
seizures I-Effect
during O
antineoplastic I-Treatment
therapy I-Treatment
with I-Treatment
adriamycin I-Treatment.Combination.Drug
and I-Treatment
cisplatin I-Treatment.Combination.Drug
. I-Treatment

CONCLUSIONS O
: O
This I-Subject
patient I-Subject
's O
rhabdomyolysis I-Effect
was O
probably O
induced I-Adverse_event.Trigger
by O
sertraline I-Treatment.Drug
therapy O
. O

Nephrotic I-Effect
syndrome I-Effect
in O
a I-Subject
multiple I-Treat_Disorder
sclerosis I-Treat_Disorder
patient I-Subject
treated I-Adverse_event.Trigger
with O
interferon I-Treatment.Drug
beta I-Treatment.Drug
1a I-Treatment.Drug
. O

In O
our I-Subject
patient I-Subject
, O
DIAN I-Effect
possibly O
was O
related I-Adverse_event.Trigger
to I-Adverse_event.Trigger
cefuroxime I-Treatment.Drug
, O
but O
the O
patient O
did O
not O
experience O
associated O
allergic O
symptoms O
. O

We O
describe O
the O
case O
of O
a I-Subject
nonatopic I-Subject.Sub_Disorder
17 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
girl I-Subject.Gender
with I-Subject
bronchial I-Treat_Disorder
asthma I-Treat_Disorder
and I-Subject
aspirin I-Subject.Sub_Disorder
intolerance I-Subject.Sub_Disorder
who O
developed I-Adverse_event.Trigger
a I-Effect
dramatic I-Effect
anaphylactic I-Effect
reaction I-Effect
to O
oral I-Treatment.Route
prednisone I-Treatment.Drug
. O

CASE O
SUMMARY O
: O
A I-Subject
10 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
white I-Subject.Race
girl I-Subject.Gender
with I-Subject
bilateral I-Treat_Disorder
optic I-Treat_Disorder
glioma I-Treat_Disorder
developed I-Adverse_event.Trigger
a O
hypersensitivity I-Effect
reaction I-Effect
to O
carboplatin I-Treatment.Drug
after I-Treatment
nine I-Treatment.Duration
courses I-Treatment.Duration
. O

Liver I-Effect
function I-Effect
should I-Effect
be I-Effect
carefully I-Effect
monitored I-Effect
when I-Adverse_event.Trigger
rifampicin I-Treatment.Combination.Drug
and I-Treatment
lopinavir I-Treatment.Combination.Drug
/ I-Treatment.Combination.Drug
ritonavir I-Treatment.Combination.Drug
are I-Treatment
combined I-Treatment
in O
patients I-Subject
. O

We O
report O
three I-Subject.Population
patients I-Subject
, O
all O
of O
whom O
had O
preexisting I-Treat_Disorder
diabetic I-Treat_Disorder
dyslipidemia I-Treat_Disorder
, O
who O
showed O
a O
profound I-Effect
reduction I-Effect
in I-Effect
plasma I-Effect
HDL I-Effect
cholesterol I-Effect
and I-Effect
apolipoprotein I-Effect
AI I-Effect
levels I-Effect
soon I-Time_elapsed
after I-Time_elapsed
the O
initiation I-Potential_therapeutic_event.Trigger
of O
rosiglitazone I-Treatment.Drug
therapy I-Treatment
. O

This O
finding O
suggests O
that O
fluvoxamine I-Treatment.Drug
can O
precipitate I-Adverse_event.Trigger
Schneiderian I-Effect
first I-Effect
- I-Effect
rank I-Effect
symptoms I-Effect
in O
some I-Subject
susceptible I-Subject
patients I-Subject
. O

Warfarin I-Treatment.Drug
- O
associated I-Adverse_event.Trigger
thoracic I-Effect
aortic I-Effect
dissection I-Effect
in O
an I-Subject
elderly I-Subject.Age
woman I-Subject.Gender
. O

This O
is O
the O
first I-Subject
report I-Subject
of I-Subject
an I-Subject
adverse I-Subject
effect I-Subject
of I-Subject
fetal I-Effect
renal I-Effect
circulation I-Effect
by O
maternal I-Treatment.Route
ingestion I-Treatment.Route
of I-Treatment
nimesulide I-Treatment.Drug
. O

Diarrhea I-Effect
- I-Effect
associated I-Effect
over I-Effect
- I-Effect
anticoagulation I-Effect
in O
a O
patient I-Subject
taking O
warfarin I-Treatment.Drug
: O
therapeutic O
role O
of O
cholestyramine O
. O

A I-Subject
72 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
white I-Subject.Race
man I-Subject.Gender
suddenly O
developed I-Adverse_event.Trigger
combative I-Effect
behavior I-Effect
, I-Effect
refused I-Effect
to I-Effect
leave I-Effect
his I-Effect
room I-Effect
, I-Effect
stopped I-Effect
eating I-Effect
, I-Effect
and I-Effect
began I-Effect
falling I-Effect
to I-Effect
the I-Effect
floor I-Effect
6 I-Treatment.Time_elapsed
weeks I-Treatment.Time_elapsed
after I-Treatment
being I-Treatment
given I-Treatment
ticlopidine I-Treatment.Drug
. O

The O
case O
history O
confirms O
that O
gold I-Treatment.Drug
treatment O
, O
even O
in I-Subject
the I-Subject
same I-Subject
patient I-Subject
, I-Subject
can O
give I-Adverse_event.Trigger
rise I-Adverse_event.Trigger
to O
a O
wide I-Effect
range I-Effect
of I-Effect
skin I-Effect
disturbances I-Effect
, I-Effect
which I-Effect
in I-Effect
many I-Effect
cases I-Effect
do I-Effect
not I-Effect
break I-Effect
out I-Effect
until I-Effect
long I-Effect
after I-Effect
the I-Effect
drug I-Effect
has I-Effect
been I-Effect
withdrawn I-Effect
. O

Lithium I-Treatment.Drug
neurotoxicity I-Effect
should O
be O
considered I-Adverse_event.Trigger
in O
Creutzfeldt I-Treat_Disorder
- I-Treat_Disorder
Jakob I-Treat_Disorder
disease I-Treat_Disorder
differential O
diagnosis O
, O
serial O
electroencephalograms O
being O
the O
most O
valuable O
. O

The O
authors O
describe O
a O
case O
of O
neuroleptic I-Effect
malignant I-Effect
syndrome I-Effect
that O
occurred I-Adverse_event.Trigger
in O
a I-Subject
patient I-Subject
on O
amitriptyline I-Treatment.Combination.Drug
and I-Treatment
lithium I-Treatment.Combination.Drug
carbonate I-Treatment.Combination.Drug
. O

The O
findings O
were O
judged O
to O
be O
consistent O
with O
soft I-Effect
- I-Effect
tissue I-Effect
injury I-Effect
associated I-Adverse_event.Trigger
with O
intravenous I-Treatment.Route
administration I-Treatment.Route
of I-Treatment
phenytoin I-Treatment.Drug
, O
also O
termed O
purple O
glove O
syndrome O
. O

However O
, O
as O
illustrated O
by O
these O
and O
other O
cases O
reported O
to O
date O
, O
the O
onset O
of O
troglitazone I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
liver I-Effect
injury I-Effect
is I-Effect
insidious I-Effect
and I-Effect
temporally I-Effect
variable I-Effect
. O

Soon O
after O
its O
introduction O
in O
1952 O
, O
chlorpromazine I-Treatment.Drug
was O
noted O
to O
induce I-Adverse_event.Trigger
symptoms I-Effect
resembling I-Effect
Parkinson I-Effect
's I-Effect
disease I-Effect
. O

Erythromycin I-Treatment.Combination.Drug
is O
a O
macrolide O
antibiotic O
that O
may O
increase I-Effect
the I-Effect
risk I-Effect
of I-Effect
lovastatin I-Combination.Drug
- I-Effect
induced I-Effect
rhabdomyolysis I-Effect
. O

A I-Subject
23 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
white I-Subject.Race
male I-Subject.Gender
patient I-Subject
was O
originally O
admitted O
to O
receive I-Potential_therapeutic_event.Trigger
intravenous I-Treatment.Route
chemotherapy I-Treatment.Drug
for O
acute I-Treat_Disorder
myelogenous I-Treat_Disorder
leukemia I-Treat_Disorder
. O

We O
present O
two I-Subject.Population
children I-Subject.Age
with I-Subject
acute I-Treat_Disorder
lymphocytic I-Treat_Disorder
leukemia I-Treat_Disorder
who O
developed I-Adverse_event.Trigger
leukoencephalopathy I-Effect
following O
administration I-Treatment
of I-Treatment
a I-Treatment
combination I-Treatment
of I-Treatment
intravenous I-Treatment.Route
ara I-Treatment.Combination.Drug
= I-Treatment.Combination.Drug
C I-Treatment.Combination.Drug
and I-Treatment
methotrexate I-Treatment.Combination.Drug
during I-Treatment
the I-Treatment
consolidation I-Treatment
phase I-Treatment
of I-Treatment
chemotherapy I-Treatment
. O

Lethal O
anuria I-Effect
complicating I-Adverse_event.Trigger
high I-Treatment.Dosage
dose I-Treatment.Dosage
ifosfamide I-Treatment.Drug
chemotherapy I-Treatment.Route
in O
a I-Subject
breast I-Treat_Disorder
cancer I-Treat_Disorder
patient I-Subject
with I-Subject
an I-Subject.Sub_Disorder
impaired I-Subject.Sub_Disorder
renal I-Subject.Sub_Disorder
function I-Subject.Sub_Disorder
. O

CONCLUSIONS O
: O
Low I-Treatment.Dosage
dosages I-Treatment.Dosage
of I-Treatment
quinacrine I-Treatment.Drug
used I-Treatment
for I-Treatment
malaria I-Treatment.Treat_Disorder
prophylaxis I-Treatment.Treat_Disorder
can O
be O
associated I-Adverse_event.Trigger
with O
a O
delayed I-Time_elapsed
, O
severe O
maculopathy O
indistinguishable O
from O
chloroquine I-Effect
maculopathy I-Effect
in O
certain I-Subject
patients I-Subject
. I-Subject

CONCLUSIONS O
: O
Low I-Treatment.Dosage
dosages I-Treatment.Dosage
of I-Treatment
quinacrine I-Treatment.Drug
used I-Treatment
for I-Treatment
malaria I-Treatment.Treat_Disorder
prophylaxis I-Treatment.Treat_Disorder
can O
be O
associated I-Adverse_event.Trigger
with O
a I-Effect
delayed I-Time_elapsed
, I-Effect
severe I-Effect
maculopathy I-Effect
indistinguishable O
from O
chloroquine O
maculopathy O
in O
certain O
patients O
. O

When O
pilsicainide I-Treatment.Drug
is O
prescribed O
in O
patients I-Subject
with I-Subject
coronary I-Subject.Sub_Disorder
artery I-Subject.Sub_Disorder
disease I-Subject.Sub_Disorder
or I-Subject
renal I-Subject.Sub_Disorder
dysfunction I-Subject.Sub_Disorder
, I-Subject
close O
attention O
must O
be O
paid O
to O
avoid O
life I-Effect
- I-Effect
threatening I-Effect
arrhythmias I-Effect
due I-Adverse_event.Trigger
to O
high O
plasma O
concentrations O
of O
the O
drug O
. O

We O
describe O
a I-Subject
case I-Subject
of O
severe I-Effect
aplastic I-Effect
anemia I-Effect
( I-Effect
AA I-Effect
) I-Effect
that O
was O
probably O
induced I-Adverse_event.Trigger
by O
lenalidomide I-Treatment.Drug
. O

We O
present O
a O
case O
report O
of O
a I-Subject
patient I-Subject
with I-Subject
typhoid I-Treat_Disorder
fever I-Treat_Disorder
who O
experienced O
a O
hypersensitivity I-Effect
reaction I-Effect
subsequent I-Adverse_event.Trigger
to I-Adverse_event.Trigger
the I-Treatment
infusion I-Treatment.Route
of I-Treatment
chloramphenicol I-Treatment.Drug
sodium I-Treatment.Drug
succinate I-Treatment.Drug
. O

This O
confirmed O
the O
history O
of O
captopril I-Treatment.Drug
- O
related I-Adverse_event.Trigger
asthma I-Effect
. O

Four I-Subject.Population
cases I-Subject
of O
adverse I-Effect
experiences I-Effect
with I-Adverse_event.Trigger
clonidine I-Treatment.Drug
are O
described O
. O

OBJECTIVE O
: O
To O
report O
a O
case O
of O
reversible I-Effect
nonthrombocytopenic I-Effect
palpable I-Effect
purpura I-Effect
associated I-Adverse_event.Trigger
with O
metoclopramide I-Treatment.Drug
. O

Three I-Subject.Population
patients I-Subject
received I-Treatment
respectively I-Treatment
190 I-Treatment.Dosage
mg I-Treatment.Dosage
, I-Treatment
175 I-Treatment.Dosage
mg I-Treatment.Dosage
, I-Treatment
and I-Treatment
196 I-Treatment.Dosage
mg I-Treatment.Dosage
of I-Treatment
methotrexate I-Treatment.Drug
and O
developed I-Adverse_event.Trigger
bilateral I-Effect
pulmonary I-Effect
infiltrates I-Effect
without I-Effect
evidence I-Effect
of I-Effect
peripheral I-Effect
blood I-Effect
eosinophilia I-Effect
. O

Clinicians O
should O
be O
aware O
of O
the O
possibility O
that O
vinorelbine I-Treatment.Drug
may O
cause I-Adverse_event.Trigger
SIADH I-Effect
and I-Effect
possibly I-Effect
hypokalemia I-Effect
. O

We O
report O
a O
case O
of O
a I-Subject
34 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
man I-Subject.Gender
on I-Adverse_event.Trigger
carbamazepine I-Treatment.Combination.Drug
for O
complex I-Treat_Disorder
partial I-Treat_Disorder
seizures I-Treat_Disorder
who O
developed O
acute I-Effect
liver I-Effect
and I-Effect
renal I-Effect
failure I-Effect
on O
less I-Treatment.Dosage
than I-Treatment.Dosage
2.5 I-Treatment.Dosage
grams I-Treatment.Dosage
a I-Treatment.Freq
day I-Treatment.Freq
of I-Treatment
acetaminophen I-Treatment.Combination.Drug
. O

Fever I-Effect
and I-Effect
maculopapular I-Effect
rashes I-Effect
appeared I-Adverse_event.Trigger
at O
10 I-Time_elapsed
days I-Time_elapsed
after O
phenytoin I-Treatment.Drug
initiation O
, O
and O
then O
the O
drug O
was O
discontinued O
. O

We O
report O
AZA I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
drug I-Effect
eruption I-Effect
that O
developed O
in O
two I-Subject.Population
cases I-Subject
of I-Subject
systemic I-Treat_Disorder
scleroderma I-Treat_Disorder
with I-Treat_Disorder
polymyositis I-Treat_Disorder
. O

Safety I-Adverse_event.Trigger
aspects I-Adverse_event.Trigger
of O
a O
coumarin I-Treatment.Combination.Drug
- I-Treatment
troxerutin I-Treatment.Combination.Drug
combination I-Treatment
regarding O
liver I-Effect
function I-Effect
in O
a O
double O
- O
blind O
placebo O
- O
controlled O
study O
. O

Vogt I-Effect
- I-Effect
Koyanagi I-Effect
- I-Effect
Harada I-Effect
disease I-Effect
occurring I-Adverse_event.Trigger
during O
interferon I-Treatment.Drug
alpha I-Treatment.Drug
therapy O
for O
chronic I-Treat_Disorder
hepatitis I-Treat_Disorder
C. I-Treat_Disorder

Glucose I-Treatment.Combination.Drug
and I-Treatment
insulin I-Treatment.Combination.Drug
exert I-Adverse_event.Trigger
additive I-Effect
ocular I-Effect
and I-Effect
renal I-Effect
vasodilator I-Effect
effects I-Effect
on O
healthy I-Subject
humans I-Subject
. O

Two I-Subject.Population
patients I-Subject
with I-Subject
osteomyelitis I-Treat_Disorder
who O
developed I-Adverse_event.Trigger
reversible I-Effect
cholestatic I-Effect
jaundice I-Effect
during O
treatment O
with O
oxacillin I-Treatment.Drug
derivatives O
are O
described O
. O

DATA O
SYNTHESIS O
: O
A I-Subject
49 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
man I-Subject.Gender
developed I-Adverse_event.Trigger
symptoms O
of O
severe O
psychosis I-Effect
concomitant O
with O
ciprofloxacin I-Treatment.Drug
( O
250 I-Dosage
mg I-Dosage
bid I-Dosage
) O
treatment O
. O

Beneficial O
effect O
of O
low O
- O
dose O
mianserin O
on O
fluvoxamine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
akathisia I-Effect
in O
an O
obsessive I-Treat_Disorder
- I-Treat_Disorder
compulsive I-Treat_Disorder
patient I-Subject
. O

Beneficial I-Potential_therapeutic_event.Trigger
effect O
of O
low I-Treatment.Dosage
- I-Treatment.Dosage
dose I-Treatment.Dosage
mianserin I-Treatment.Drug
on O
fluvoxamine I-Treat_Disorder
- I-Treat_Disorder
induced I-Treat_Disorder
akathisia I-Treat_Disorder
in O
an O
obsessive I-Subject
- I-Subject
compulsive I-Subject
patient I-Subject
. O

Potential O
causes O
of O
methamphetamine I-Treatment.Drug
- O
related I-Adverse_event.Trigger
keratitis I-Effect
can O
be O
divided O
into O
four O
categories O
resulting O
from O
( O
a O
) O
direct O
pharmacologic O
and O
physical O
effects O
of O
methamphetamine O
; O
( O
b O
) O
the O
toxic O
effects O
of O
diluting O
or O
" O
cutting O
" O
agents O
such O
as O
lidocaine O
and O
quinine O
; O
( O
c O
) O
effects O
related O
to O
the O
route O
of O
drug O
administration O
( O
intravenous O
, O
inhalation O
, O
smoking O
) O
; O
and O
( O
d O
) O
manufacture O
- O
related O
effects O
of O
exposure O
to O
unintentional O
caustic O
contaminants O
in O
the O
final O
product O
. O

Pulmonary I-Effect
oedema I-Effect
after I-Adverse_event.Trigger
hexoprenaline I-Treatment.Drug
administration O
in O
preterm I-Treat_Disorder
labour I-Treat_Disorder
. O

Venlafaxine I-Treatment.Drug
- O
associated I-Adverse_event.Trigger
seizures I-Effect
at O
therapeutic O
doses O
have O
not O
been O
reported O
in O
the O
literature O
. O

Methotrexate I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
pneumonitis I-Effect
in O
patients I-Subject
with I-Subject
rheumatoid I-Treat_Disorder
arthritis I-Treat_Disorder
and I-Subject
psoriatic I-Treat_Disorder
arthritis I-Treat_Disorder
: O
report O
of O
five O
cases O
and O
review O
of O
the O
literature O
. O

She O
was O
receiving O
phenytoin O
sodium O
300 O
mg O
/ O
day O
; O
carbamazepine I-Treatment.Drug
200 I-Treatment.Dosage
mg I-Treatment.Dosage
four I-Treatment.Freq
times I-Treatment.Freq
daily I-Treatment.Freq
had O
been O
discontinued O
four O
days O
before O
admission O
because I-Adverse_event.Trigger
of O
leukopenia I-Effect
. O

Thoracoscopic O
biopsy O
to O
confirm O
metastasis O
revealed O
instead O
fibrotic I-Effect
lesions I-Effect
apparently O
attributable I-Adverse_event.Trigger
to O
bleomycin I-Treatment.Drug
or I-Treatment
cyclophosphamide I-Treatment.Drug
. O

We O
present O
a O
case O
of O
hemolytic I-Effect
- I-Effect
uremic I-Effect
syndrome I-Effect
that O
developed I-Adverse_event.Trigger
during I-Treatment
the I-Treatment
4th I-Treatment
cycle I-Treatment
of I-Treatment
combination I-Treatment
chemotherapy I-Treatment
with I-Treatment
oxaliplatin I-Treatment.Drug
, I-Treatment
5 I-Treatment
- I-Treatment
fluorouracil I-Treatment.Drug
and I-Treatment
leucovorin I-Treatment.Drug
. O

We O
report O
the O
case O
of O
a O
lung I-Treat_Disorder
cancer I-Treat_Disorder
patient I-Subject
with I-Subject
bronquiloalveolar I-Treat_Disorder
carcinoma I-Treat_Disorder
( I-Treat_Disorder
BAC I-Treat_Disorder
) I-Treat_Disorder
presenting O
with O
BOOP I-Effect
after I-Adverse_event.Trigger
chemotherapy I-Treatment.Route
with I-Treatment
docetaxel I-Treatment.Combination.Drug
and I-Treatment
gemcitabine I-Treatment.Combination.Drug
producing I-Effect
severe I-Effect
respiratory I-Effect
insufficiency I-Effect
, I-Effect
and I-Effect
simulating I-Effect
a I-Effect
progression I-Effect
of I-Effect
the I-Effect
tumor I-Effect
. O

Relapse I-Effect
in I-Effect
the I-Effect
external I-Effect
auditory I-Effect
canal I-Effect
of I-Effect
acute I-Effect
promyelocytic I-Effect
leukemia I-Effect
after I-Adverse_event.Trigger
treatment I-Treatment
with I-Treatment
all I-Treatment.Drug
- I-Treatment.Drug
trans I-Treatment.Drug
retinoic I-Treatment.Drug
acid I-Treatment.Drug
. O

Acute I-Effect
neutrophilic I-Effect
dermatosis I-Effect
induced I-Adverse_event.Trigger
by I-Adverse_event.Trigger
all I-Treatment.Drug
- I-Treatment.Drug
trans I-Treatment.Drug
- I-Treatment.Drug
retinoic I-Treatment.Drug
acid I-Treatment.Drug
treatment O
for O
acute I-Treat_Disorder
promyelocytic I-Treat_Disorder
leukemia I-Treat_Disorder
. O

Fluphenazine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
neuroleptic I-Effect
malignant I-Effect
syndrome I-Effect
in O
a I-Subject
schizophrenic I-Treat_Disorder
patient I-Subject
. O

Biopsy O
- O
proven O
acute I-Effect
interstitial I-Effect
nephritis I-Effect
associated I-Adverse_event.Trigger
with O
the O
tyrosine I-Treatment
kinase I-Treatment
inhibitor I-Treatment
sunitinib I-Treatment.Drug
: O
a O
class O
effect O
? O

We O
describe O
two I-Subject.Population
women I-Subject.Gender
who O
developed O
HUS I-Effect
after I-Adverse_event.Trigger
MMC I-Treatment.Drug
therapy O
and O
presented O
massive I-Effect
pulmonary I-Effect
bleeding I-Effect
. O

Alternating I-Effect
sinus I-Effect
rhythm I-Effect
and I-Effect
intermittent I-Effect
sinoatrial I-Effect
( I-Effect
S I-Effect
- I-Effect
A I-Effect
) I-Effect
block I-Effect
was O
observed O
in O
a I-Subject
57 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
woman I-Subject.Gender
, O
under O
treatment I-Adverse_event.Trigger
for O
angina I-Treat_Disorder
with O
80 I-Treatment.Dosage
mg I-Treatment.Dosage
propranolol I-Treatment.Drug
daily I-Treatment.Freq
. I-Treatment

These O
case O
reports O
provide O
evidence O
that O
5 I-Treatment.Drug
- I-Treatment.Drug
aminosalicylic I-Treatment.Drug
acid I-Treatment.Drug
may O
induce I-Adverse_event.Trigger
acute I-Effect
pancreatitis I-Effect
after O
long I-Duration
term I-Duration
treatment O
. O

During O
that O
time O
, O
he I-Subject.Gender
had O
also O
been O
taking I-Potential_therapeutic_event.Trigger
amphetamine I-Treatment.Drug
- I-Treatment.Drug
dextroamphetamine I-Treatment.Drug
( I-Treatment
Adderall I-Treatment
) I-Treatment
on O
work O
days O
for O
his O
ADHD I-Treat_Disorder
. O

Therefore O
, O
we O
diagnosed I-Adverse_event.Trigger
her I-Effect
eruption I-Effect
as I-Effect
contact I-Effect
dermatitis I-Effect
due O
to O
sodium I-Treatment.Drug
bisulfite I-Treatment.Drug
. O

Macular I-Effect
infarction I-Effect
after I-Adverse_event.Trigger
endophthalmitis I-Treatment.Treat_Disorder
treated I-Treatment
with I-Treatment
vitrectomy I-Treatment.Route
and I-Treatment.Route
intravitreal I-Treatment.Route
gentamicin I-Treatment.Drug
. O

Since O
tamoxifen I-Treatment.Drug
therapy I-Treatment
can O
induce I-Adverse_event.Trigger
endometrial I-Effect
disorders I-Effect
, O
surveillance O
schemes O
of O
women I-Subject.Gender
taking O
tamoxifen O
have O
been O
recommended O
. O

Warfarin I-Treatment.Drug
- O
associated I-Adverse_event.Trigger
bleeding I-Effect
complication I-Effect
saved I-Effect
life I-Effect
. O

METHODS O
/ O
RESULTS O
: O
This O
paper O
presents I-Adverse_event.Trigger
a O
new I-Subject
case I-Subject
of O
rifabutin I-Treatment.Drug
uveitis I-Effect
and O
a O
review O
of O
the O
various O
published O
reports O
to O
date O
. O

Acute I-Effect
abdomen I-Effect
due I-Effect
to I-Effect
endometriosis I-Effect
in O
a O
premenopausal O
woman O
taking I-Adverse_event.Trigger
tamoxifen I-Treatment.Drug
. O

DISCUSSION O
: O
Methotrexate I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
papular I-Effect
eruption I-Effect
is O
rarely O
reported O
shortly I-Time_elapsed
after I-Time_elapsed
beginning O
methotrexate O
therapy O
in O
patients I-Subject
with I-Subject
acute I-Subject.Sub_Disorder
exacerbation I-Subject.Sub_Disorder
of I-Subject.Sub_Disorder
collagen I-Subject.Sub_Disorder
vascular I-Subject.Sub_Disorder
diseases I-Subject.Sub_Disorder
. O

We O
describe O
3 I-Subject.Population
patients I-Subject
on O
concomitant I-Treatment
amiodarone I-Treatment.Combination.Drug
and I-Treatment
warfarin I-Treatment.Combination.Drug
who O
developed I-Adverse_event.Trigger
amiodarone I-Effect
- I-Effect
induced I-Effect
thyrotoxicosis I-Effect
heralded O
by O
a O
significant O
decrease O
in O
warfarin O
requirements O
. O

We O
describe O
3 O
patients O
on O
concomitant O
amiodarone O
and O
warfarin O
who O
developed O
amiodarone I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
thyrotoxicosis I-Effect
heralded O
by O
a O
significant O
decrease O
in O
warfarin O
requirements O
. O

The O
aim O
of O
this O
post O
- O
hoc O
analysis O
of O
data O
from O
a O
Phase O
III O
clinical O
trial O
( O
VISTA O
; O
NCT00298831 O
) O
was O
to O
investigate O
the O
impact O
of O
antibiotics O
on O
recovery O
from O
rocuronium I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
NMB I-Effect
after O
administration O
of O
sugammadex O
for O
reversal O
, O
and O
compared O
the O
neuromuscular O
recovery O
in O
patients O
who O
received O
antibiotics O
preoperatively O
with O
those O
who O
did O
not O
. O

The O
aim O
of O
this O
post O
- O
hoc O
analysis O
of O
data O
from O
a O
Phase O
III O
clinical O
trial O
( O
VISTA O
; O
NCT00298831 O
) O
was O
to O
investigate O
the O
impact O
of O
antibiotics I-Treatment.Drug
on O
recovery I-Potential_therapeutic_event.Trigger
from O
rocuronium I-Treat_Disorder
- I-Treat_Disorder
induced I-Treat_Disorder
NMB I-Treat_Disorder
after O
administration O
of O
sugammadex O
for O
reversal O
, O
and O
compared O
the O
neuromuscular O
recovery O
in O
patients O
who O
received O
antibiotics O
preoperatively O
with O
those O
who O
did O
not O
. O

All I-Subject
patients I-Subject
had O
taken O
phenytoin I-Treatment.Drug
for I-Treatment
variable I-Treatment
time I-Treatment
periods I-Treatment
( I-Treatment
range I-Treatment
16 I-Treatment.Duration
- I-Treatment.Duration
80 I-Treatment.Duration
days I-Treatment.Duration
; I-Treatment.Duration
mean I-Treatment
: I-Treatment
40 I-Treatment.Duration
) I-Treatment
and O
were O
on O
the O
medication O
when O
the O
skin I-Effect
lesions I-Effect
first O
appeared I-Adverse_event.Trigger
. O

One O
should O
therefore O
be O
aware O
of O
possible O
extrapyramidal I-Effect
side I-Effect
effects I-Effect
with I-Adverse_event.Trigger
olanzapine I-Treatment.Drug
that O
are O
reduced O
compared O
to O
classical O
neuroleptic O
drugs O
but O
not O
completely O
eliminated O
. O

A I-Subject
patient I-Subject
who O
had O
been O
treated O
with O
large O
doses O
of O
thyroid O
hormone O
for O
several O
years O
developed I-Adverse_event.Trigger
features O
of O
secondary I-Effect
hypothyroidism I-Effect
after O
thyroid I-Treatment.Drug
hormone I-Treatment.Drug
withdrawal I-Treatment
. O

This O
article O
discusses O
the O
possibility O
that O
simultaneous O
use O
of O
valproic I-Treatment.Combination.Drug
acid I-Treatment.Combination.Drug
, I-Treatment
lamotrigine I-Treatment.Combination.Drug
, I-Treatment
and I-Treatment
phenytoin I-Treatment.Combination.Drug
could O
give I-Adverse_event.Trigger
this O
combination O
of O
toxicities I-Effect
and O
that O
concurrent I-Effect
viral I-Effect
infection I-Effect
may O
increase O
this O
risk O
. O

A O
second O
patient O
with O
a O
similar O
glucose O
tolerance O
test O
result O
showed I-Adverse_event.Trigger
postprandial I-Effect
hyperglycemia I-Effect
when O
treated O
similarly O
with O
betamethasone I-Treatment.Drug
valerate I-Treatment.Drug
cream I-Treatment.Route
0.1 I-Treatment
% I-Treatment
. O

Phenytoin I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
hypersensitivity I-Effect
reactions I-Effect
. I-Effect

A I-Subject
54 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
man I-Subject.Gender
developed I-Adverse_event.Trigger
TEN I-Effect
4 I-Treatment.Time_elapsed
weeks I-Treatment.Time_elapsed
after I-Treatment
beginning I-Treatment
lamotrigine I-Treatment.Drug
for O
complex I-Treat_Disorder
partial I-Treat_Disorder
seizures I-Treat_Disorder
related I-Subject
to I-Subject
a I-Subject
glioblastoma I-Subject.Sub_Disorder
multiforme I-Subject.Sub_Disorder
brain I-Subject.Sub_Disorder
tumor I-Subject.Sub_Disorder
. O

The O
occurrence O
of O
acute I-Effect
hepatitis I-Effect
is O
best O
known O
for I-Adverse_event.Trigger
ketoconazole I-Treatment.Drug
. O

Optic I-Effect
neuropathy I-Effect
developed I-Adverse_event.Trigger
in O
a I-Subject
patient I-Subject
with I-Subject
rheumatoid I-Treat_Disorder
arthritis I-Treat_Disorder
who O
had O
been O
receiving O
D I-Treatment.Drug
- I-Treatment.Drug
penicillamine I-Treatment.Drug
for I-Treatment
about I-Treatment
1 I-Treatment.Duration
year I-Treatment.Duration
. O

Stupor I-Effect
and O
fast I-Effect
activity I-Effect
on I-Effect
electroencephalography I-Effect
in O
a I-Subject
child I-Subject.Age
treated O
with I-Adverse_event.Trigger
valproate I-Treatment.Drug
. O

During O
her O
third O
cycle O
, O
she I-Subject.Gender
again O
received O
cisplatin I-Treatment.Drug
100 I-Treatment.Dosage
mg I-Treatment.Dosage
/ I-Treatment.Dosage
m2 I-Treatment.Dosage
over I-Treatment
30 I-Treatment.Time_elapsed
minutes I-Treatment.Time_elapsed
and O
developed I-Adverse_event.Trigger
palmar I-Effect
pruritus I-Effect
, I-Effect
urticaria I-Effect
, I-Effect
and I-Effect
edema I-Effect
. O

The O
case O
of O
a I-Subject
patient I-Subject
with I-Subject
infectious I-Treat_Disorder
mononucleosis I-Treat_Disorder
treated O
with O
cephalexin I-Treatment.Drug
who O
later O
showed I-Adverse_event.Trigger
a O
rash I-Effect
is O
presented O
and O
the O
previous O
literature O
is O
reviewed O
. O

After I-Treatment
1 I-Treatment.Time_elapsed
week I-Treatment.Time_elapsed
of I-Treatment
nefazodone I-Treatment.Drug
therapy I-Treatment
the O
patient I-Subject
experienced I-Adverse_event.Trigger
headache I-Effect
, I-Effect
confusion I-Effect
, I-Effect
and I-Effect
" I-Effect
gray I-Effect
areas I-Effect
" I-Effect
in I-Effect
her I-Effect
vision I-Effect
, I-Effect
without I-Effect
abnormal I-Effect
ophthalmologic I-Effect
findings I-Effect
. O

Nitrofurantoin I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
pulmonary I-Effect
toxicity I-Effect
during O
pregnancy O
: O
a O
report O
of O
a O
case O
and O
review O
of O
the O
literature O
. O

Methylphenidate I-Treatment.Drug
- O
associated I-Adverse_event.Trigger
enuresis I-Effect
in O
attention O
deficit O
hyperactivity O
disorder O
. O

To O
our O
knowledge O
, O
this O
is O
the I-Subject
first I-Subject
case I-Subject
report O
that O
demonstrates O
the O
occurrence I-Adverse_event.Trigger
of O
fever I-Effect
with O
low I-Treatment.Dosage
- I-Treatment.Dosage
dose I-Treatment.Dosage
amifostine I-Treatment.Drug
therapy O
without O
the O
manifestation O
of O
accompanying O
rash O
or O
hypotension O
. O

Administration I-Treatment
of I-Treatment
excessive I-Treatment.Dosage
insulin I-Treatment.Drug
induced I-Adverse_event.Trigger
hypoglycemia I-Effect
within O
4 I-Duration
to I-Duration
8 I-Duration
hours I-Duration
, O
followed O
by O
rebound I-Effect
hyperglycemia I-Effect
. O

In O
both O
cases O
, O
symptoms I-Effect
of I-Effect
autonomic I-Effect
instability I-Effect
and I-Effect
severe I-Effect
agitation I-Effect
started I-Adverse_event.Trigger
within I-Treatment.Time_elapsed
hours I-Treatment.Time_elapsed
of I-Treatment.Time_elapsed
initiation I-Treatment.Time_elapsed
of I-Treatment
cyclobenzaprine I-Treatment.Drug
and O
fully O
resolved O
within O
3 O
days O
after O
discontinuing O
the O
proserotoninergic O
drugs O
. O

Secondary I-Effect
leukemia I-Effect
in I-Adverse_event.Trigger
a I-Subject
child I-Subject.Age
with I-Subject
neuroblastoma I-Treat_Disorder
while O
on O
oral I-Treatment.Route
etoposide I-Treatment.Drug
: O
what O
is O
the O
cause O
? O

Atorvastatin I-Treatment.Drug
induced I-Adverse_event.Trigger
multiple I-Effect
organ I-Effect
failure I-Effect
. O

While O
serotonin I-Effect
syndrome I-Effect
has O
become O
more O
frequent O
in O
an O
overdose O
situation O
and O
when O
an O
interacting O
drug O
is O
given O
, O
the O
toxicity I-Adverse_event.Trigger
of O
SSIRs I-Treatment.Drug
is O
less O
than O
that O
of O
most O
other O
psychiatric O
drugs O
. O

A I-Subject
73 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
woman I-Subject.Gender
with I-Subject
non I-Treat_Disorder
- I-Treat_Disorder
Hodgkin I-Treat_Disorder
's I-Treat_Disorder
lymphoma I-Treat_Disorder
had O
two I-Effect
episodes I-Effect
of I-Effect
severe I-Effect
, I-Effect
bilateral I-Effect
, I-Effect
sensori I-Effect
- I-Effect
neural I-Effect
hearing I-Effect
loss I-Effect
after I-Adverse_event.Trigger
vincristine I-Treatment.Drug
therapy I-Treatment
. O

Severe I-Effect
hemolytic I-Effect
uremic I-Effect
syndrome I-Effect
in I-Adverse_event.Trigger
an I-Subject
advanced I-Subject
ovarian I-Treat_Disorder
cancer I-Treat_Disorder
patient I-Subject
treated O
with O
carboplatin I-Treatment.Combination.Drug
and I-Treatment
gemcitabine I-Treatment.Combination.Drug
. O

Ulcerative I-Effect
proctitis I-Effect
in I-Effect
juvenile I-Effect
systemic I-Effect
lupus I-Effect
erythematosus I-Effect
after I-Adverse_event.Trigger
ibuprofen I-Treatment.Drug
treatment O
. O

Acute I-Effect
asthma I-Effect
associated I-Adverse_event.Trigger
with O
sustained I-Treatment.Drug
- I-Treatment.Drug
release I-Treatment.Drug
verapamil I-Treatment.Drug
. O

The O
renal I-Effect
insufficiency I-Effect
of O
three I-Subject.Population
patients I-Subject
and O
the O
timing O
of O
the O
seizures I-Effect
implicate I-Adverse_event.Trigger
accumulation I-Treatment
of I-Treatment
ofloxacin I-Treatment.Drug
as O
a O
contributing O
factor O
. O

Hemolytic I-Effect
uremic I-Effect
syndrome I-Effect
in I-Adverse_event.Trigger
a I-Subject
patient I-Subject
on O
cis I-Treatment.Drug
- I-Treatment.Drug
platinum I-Treatment.Drug
, I-Treatment
vinblastine I-Treatment.Drug
and I-Treatment
bleomycin I-Treatment.Drug
. O

A O
previous O
review O
described O
data O
on O
15 I-Subject.Population
patients I-Subject
who O
experienced O
acute I-Effect
hemoglobinemia I-Effect
or I-Effect
hemoglobinuria I-Effect
following I-Adverse_event.Trigger
anti I-Treatment.Drug
- I-Treatment.Drug
D I-Treatment.Drug
IGIV I-Treatment.Drug
administration I-Route
for O
ITP I-Treat_Disorder
or I-Treat_Disorder
secondary I-Treat_Disorder
thrombocytopenia I-Treat_Disorder
. O

Amiodarone I-Treatment.Drug
was I-Potential_therapeutic_event.Trigger
discontinued I-Potential_therapeutic_event.Trigger
, O
and O
thyrotoxicosis I-Effect
gradually I-Effect
abated I-Effect
. O

De I-Effect
novo I-Effect
absence I-Effect
status I-Effect
of I-Effect
late I-Effect
onset I-Effect
following I-Adverse_event.Trigger
withdrawal I-Treatment
of I-Treatment
lorazepam I-Treatment.Drug
: O
a O
case O
report O
. O

Tenofovir I-Treatment.Drug
- O
associated I-Adverse_event.Trigger
nephrotoxicity I-Effect
in O
two I-Subject.Population
HIV I-Treat_Disorder
- I-Treat_Disorder
infected I-Treat_Disorder
adolescent I-Subject.Age
males I-Subject.Gender
. O

Reports O
of O
colonic I-Effect
perforation I-Effect
as O
a O
result I-Adverse_event.Trigger
of O
the I-Route
administration I-Route
of O
calcium I-Treatment.Combination.Drug
polystyrene I-Treatment.Combination.Drug
sulfonate I-Treatment.Combination.Drug
and O
sorbitol I-Treatment.Combination.Drug
are O
rare O
. O

Improved O
awareness O
of O
and O
further O
investigation O
into O
the O
neurotoxic I-Effect
effects I-Effect
of I-Adverse_event.Trigger
ofloxacin I-Treatment.Drug
may O
enhance O
its O
safe O
use O
. O

Atypical I-Effect
neuroleptic I-Effect
malignant I-Effect
syndrome I-Effect
associated I-Adverse_event.Trigger
with O
olanzapine I-Treatment.Drug
. O

OBJECTIVE O
: O
The O
authors O
described O
a O
case O
of O
interferon I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
psychosis I-Effect
as O
a O
framework O
to O
review O
the O
literature O
and O
discuss O
the O
decision O
to O
pursue O
antiviral O
treatment O
in O
psychiatrically I-Subject.Sub_Disorder
ill I-Subject.Sub_Disorder
patients I-Subject
with I-Subject
hepatitis I-Treat_Disorder
C. I-Treat_Disorder

We O
believe O
that O
methotrexate I-Treatment.Drug
represents O
a O
relatively O
effective O
alternative O
to O
surgery O
in O
patients I-Subject
with I-Subject
early I-Treat_Disorder
unruptured I-Treat_Disorder
tubal I-Treat_Disorder
pregnancy I-Treat_Disorder
, O
but O
suggest O
that O
it O
be O
used O
with O
caution I-Adverse_event.Trigger
in O
view O
of O
possible O
systemic I-Effect
toxicity I-Effect
. O

After O
intravitreal I-Treatment.Route
injection I-Treatment.Route
of I-Treatment
triamcinolone I-Treatment.Drug
acetonide I-Treatment.Drug
, O
cataract I-Effect
may O
rapidly O
develop I-Adverse_event.Trigger
in O
eyes O
that O
have O
been O
intensively O
treated O
, O
topically O
and O
systemically O
, O
by O
corticosteroids O
for O
several O
years O
. O

Acute I-Effect
endophthalmitis I-Effect
following I-Adverse_event.Trigger
intravitreal I-Treatment.Route
bevacizumab I-Treatment.Drug
( I-Treatment
Avastin I-Treatment
) I-Treatment
injection I-Treatment.Route
. O

We O
report O
a O
case O
of O
bullous I-Effect
eruption I-Effect
, I-Effect
one I-Time_elapsed
month I-Time_elapsed
after I-Adverse_event.Trigger
starting I-Treatment
nicardipine I-Treatment.Combination.Drug
and I-Treatment
lercanidipine I-Treatment.Combination.Drug
. I-Treatment

Pulmonary I-Effect
fibrosis I-Effect
associated I-Adverse_event.Trigger
with O
nabumetone I-Treatment.Drug
. O

The O
ability O
of O
tumor I-Treatment.Drug
necrosis I-Treatment.Drug
factor I-Treatment.Drug
( I-Treatment.Drug
TNF) I-Treatment.Drug
- I-Treatment.Drug
alpha I-Treatment.Drug
inhibitors I-Treatment.Drug
to O
impair O
pivotal O
pro O
- O
inflammatory O
host O
defenses O
may O
facilitate O
the O
development I-Adverse_event.Trigger
of O
disseminated I-Effect
cryptococcosis I-Effect
. O

This O
was O
accepted O
as O
evidence O
for O
propranolol I-Treatment.Drug
being O
the O
cause I-Adverse_event.Trigger
of O
this O
conduction I-Effect
disorder I-Effect
. O

We O
report O
a O
third O
case O
of O
a O
6 I-Subject.Age
- I-Subject.Age
week I-Subject.Age
- I-Subject.Age
old I-Subject.Age
infant I-Subject.Age
with I-Subject
Escherichia I-Treat_Disorder
coli I-Treat_Disorder
sepsis I-Treat_Disorder
who O
received I-Treatment
ampicillin I-Treatment.Combination.Drug
and I-Treatment
other I-Treatment.Combination.Drug
antibiotics I-Treatment.Combination.Drug
and O
subsequently O
developed I-Adverse_event.Trigger
TEN I-Effect
. O

PURPOSE O
: O
To O
report O
a O
case I-Subject
of O
bilateral I-Effect
anterior I-Effect
uveitis I-Effect
associated I-Adverse_event.Trigger
with O
ovulation I-Treatment
induction I-Treatment
therapy I-Treatment
using I-Treatment
clomiphene I-Treatment.Drug
citrate I-Treatment.Drug
. O

A I-Subject
57 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
woman I-Subject.Gender
presented I-Adverse_event.Trigger
with O
a O
3 O
- O
week O
history O
of O
dysphagia I-Effect
for I-Effect
solids I-Effect
, O
6 I-Time_elapsed
months I-Time_elapsed
after O
starting O
treatment O
with O
nifedipine I-Treatment.Drug
. O

Although O
combinations I-Treatment
of I-Treatment
belladonna I-Treatment.Combination.Drug
, I-Treatment
ergotamine I-Treatment.Combination.Drug
, I-Treatment
and I-Treatment
phenobarbital I-Treatment.Combination.Drug
have O
been O
used O
for O
medical O
treatment O
of O
menopausal I-Treat_Disorder
symptoms I-Treat_Disorder
since O
the O
1960s O
, O
this O
is O
the O
first O
known O
case O
report O
of O
its O
association I-Adverse_event.Trigger
with O
anticonvulsant I-Effect
hypersensitivity I-Effect
syndrome I-Effect
. O

Rifampin I-Treatment.Drug
can O
be O
associated I-Adverse_event.Trigger
with O
severe O
adverse O
effects O
such O
as O
hepatitis I-Effect
, I-Effect
acute I-Effect
renal I-Effect
failure I-Effect
, I-Effect
hemolytic I-Effect
anemia I-Effect
, I-Effect
and I-Effect
thrombocytopenia I-Effect
. O

It O
is O
believed O
that O
this O
is O
the O
first O
reported O
case O
of O
reversible O
azathioprine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
cholestasis I-Effect
associated O
with O
histological O
evidence O
of O
bile O
duct O
injury O
. O

We O
present O
a O
fatal O
case O
of O
subacute O
methanol I-Treatment.Drug
toxicity O
with O
associated I-Adverse_event.Trigger
diffuse I-Effect
brain I-Effect
involvement I-Effect
, I-Effect
including I-Effect
bilateral I-Effect
putaminal I-Effect
necrosis I-Effect
and I-Effect
cerebral I-Effect
edema I-Effect
with I-Effect
ventricular I-Effect
compression I-Effect
. O

Patients I-Subject
with I-Subject
inoperable I-Treat_Disorder
or I-Subject
metastatic I-Treat_Disorder
colorectal I-Treat_Disorder
cancer I-Treat_Disorder
were O
randomized O
to O
receive I-Potential_therapeutic_event.Trigger
monthly I-Treatment.Freq
FU I-Treatment.Combination.Drug
400 I-Treatment.Dosage
mg I-Treatment.Dosage
/ I-Treatment.Dosage
m2/day I-Treatment.Dosage
plus I-Treatment
LV I-Treatment.Combination.Drug
20 I-Treatment.Dosage
mg I-Treatment.Dosage
/ I-Treatment.Dosage
m2/day I-Treatment.Dosage
as I-Treatment
intravenous I-Treatment.Route
push I-Treatment.Route
daily I-Treatment.Freq
for I-Treatment
five I-Treatment.Duration
days I-Treatment.Duration
, O
or O
FU O
alone O
. O

The O
present O
report O
suggests O
that O
clarithromycin I-Treatment.Drug
coadministration O
induces I-Adverse_event.Trigger
increased I-Effect
plasma I-Effect
carbamazepine I-Treatment
concentrations I-Effect
, O
which O
may O
result O
in O
carbamazepine I-Treatment
toxicity I-Effect
. I-Effect

In O
this O
case O
, O
interferon I-Treatment.Drug
alpha I-Treatment.Drug
induced I-Adverse_event.Trigger
polymyositis I-Effect
and I-Effect
cardiomyopathy I-Effect
is O
diagnosed O
in O
a I-Subject
33 I-Subject.Age
- I-Subject.Age
yr I-Subject.Age
- I-Subject.Age
old I-Subject.Age
male I-Subject.Gender
patient I-Subject
with I-Subject
history I-Treat_Disorder
of I-Treat_Disorder
chronic I-Treat_Disorder
hepatitis I-Treat_Disorder
B. I-Treat_Disorder

To O
describe O
the O
potential O
for O
interaction O
between O
opioids I-Treatment.Combination.Drug
and O
serotonergic I-Treatment.Combination.Drug
antidepressants I-Treatment.Combination.Drug
leading I-Adverse_event.Trigger
to O
the O
development O
of O
serotonin I-Effect
syndrome I-Effect
( O
SS O
) O
, O
mechanism O
of O
the O
interaction O
, O
and O
the O
spectrum O
of O
SS O
in O
elderly I-Subject.Age
residents I-Subject
of O
a O
long O
- O
term O
care O
facility O
. O

Erythema I-Effect
multiforme I-Effect
bullosum I-Effect
due I-Adverse_event.Trigger
to O
rifampicin I-Treatment.Drug
. O

We O
describe O
a I-Subject
patient I-Subject
with I-Subject
acute I-Treat_Disorder
leukemia I-Treat_Disorder
who O
developed I-Adverse_event.Trigger
Horner I-Effect
's I-Effect
syndrome I-Effect
and I-Effect
a I-Effect
severe I-Effect
demyelinating I-Effect
peripheral I-Effect
neuropathy I-Effect
leading I-Effect
to I-Effect
death I-Effect
after O
receiving O
high I-Treatment.Dosage
- I-Treatment.Dosage
dose I-Treatment.Dosage
cytosine I-Treatment.Drug
arabinoside I-Treatment.Drug
. I-Treatment

This O
profile O
should O
trigger I-Adverse_event.Trigger
a O
" O
red O
flag O
" O
as O
to O
the O
possibility O
of O
phenobarbital I-Treatment.Drug
behavioral I-Effect
side I-Effect
effects I-Effect
or I-Effect
exacerbation I-Effect
of I-Effect
preexisting I-Effect
maladaptive I-Effect
behaviors I-Effect
. O

Retinal I-Effect
abnormalities I-Effect
, I-Effect
including I-Effect
retinal I-Effect
hemorrhage I-Effect
and I-Effect
" I-Effect
cotton I-Effect
- I-Effect
wool I-Effect
" I-Effect
spots I-Effect
, O
often O
occur I-Adverse_event.Trigger
within O
the O
first O
8 I-Time_elapsed
weeks I-Time_elapsed
in O
the O
course O
of O
interferon I-Treatment.Drug
therapy O
in O
patients I-Subject
with I-Subject
chronic I-Treat_Disorder
hepatitis I-Treat_Disorder
C. I-Treat_Disorder

Rapamycin I-Treatment.Combination.Drug
/ I-Treatment
sirolimus I-Treatment.Combination.Drug
- O
induced I-Adverse_event.Trigger
pneumonitis I-Effect
has O
been O
described O
previously O
in O
renal O
transplant O
recipients O
, O
and O
this O
report O
describes O
a O
stable O
heart O
- O
lung O
transplant O
recipient O
who O
developed O
a O
pulmonary O
infiltrate O
that O
reversed O
after O
ceasing O
SR O
therapy O
. O

IFNalpha I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
recurrence I-Effect
of I-Effect
Graves I-Effect
' I-Effect
disease I-Effect
ten I-Treatment
years I-Treatment
after I-Treatment
thyroidectomy I-Treatment
in O
chronic I-Treat_Disorder
viral I-Treat_Disorder
hepatitis I-Treat_Disorder
C. I-Treat_Disorder

Risperidone I-Treatment.Drug
withdrawal O
- O
related I-Adverse_event.Trigger
respiratory I-Effect
dyskinesia I-Effect
: O
a O
case O
diagnosed O
by O
spirography O
and O
fibroscopy O
. O

Paralytic I-Effect
ileus I-Effect
in O
patients I-Subject
undergoing O
bortezomib I-Treatment.Drug
treatment I-Treatment
has O
been O
reported I-Adverse_event.Trigger
, O
although O
a O
definite O
attribution O
to O
bortezomib O
administration O
has O
not O
been O
established O
. O

Severe O
serotonin I-Effect
syndrome I-Effect
induced I-Adverse_event.Trigger
by I-Adverse_event.Trigger
mirtazapine I-Treatment.Drug
monotherapy I-Treatment
. O

Three I-Treatment.Time_elapsed
days I-Treatment.Time_elapsed
after I-Treatment
starting I-Treatment
fluconazole I-Treatment.Drug
, O
she O
developed I-Adverse_event.Trigger
polyuria I-Effect
and I-Effect
polydipsia I-Effect
and I-Effect
was I-Effect
found I-Effect
to I-Effect
have I-Effect
severe I-Effect
hyperglycemia I-Effect
, I-Effect
which I-Effect
led I-Effect
to I-Effect
the I-Effect
diagnosis I-Effect
of I-Effect
Cushing I-Effect
syndrome I-Effect
. O

Postoperative O
hypocalcemic I-Effect
tetany I-Effect
caused I-Adverse_event.Trigger
by O
fleet I-Treatment.Drug
phospho I-Treatment.Drug
- I-Treatment.Drug
soda I-Treatment.Drug
preparation O
in O
a O
patient I-Subject
taking O
alendronate I-Treatment.Drug
sodium I-Treatment.Drug
: O
report O
of O
a O
case O
. O

Observations O
in O
our O
patient O
suggest O
that O
the O
leukoencephalopathy I-Effect
that O
developed O
in O
previously O
reported O
patients I-Subject
who O
received O
5 O
- O
fluorouracil O
and O
levamisole O
may O
have O
been O
caused I-Adverse_event.Trigger
at O
least O
partly O
by O
levamisole I-Treatment.Drug
. O

We O
describe O
the O
clinical O
response O
, O
as O
determined O
by O
increases I-Effect
in I-Effect
total I-Effect
Hb I-Effect
and I-Effect
decreased I-Effect
transfusion I-Effect
needs I-Effect
, O
in I-Subject
five I-Subject.Population
patients I-Subject
with I-Subject
thalassemia I-Treat_Disorder
intermedia I-Treat_Disorder
treated I-Potential_therapeutic_event.Trigger
with O
HU I-Treatment.Combination.Drug
alone I-Treatment
or I-Treatment
in I-Treatment
combination I-Treatment
with I-Treatment
SPB I-Treatment.Combination.Drug
. O

According O
to O
the O
Naranjo O
et O
al O
. O
adverse O
- O
reaction O
probability O
scale O
, O
enoxaparin I-Treatment.Drug
was O
the O
probable O
cause I-Adverse_event.Trigger
of O
hepatotoxicity I-Effect
in O
this I-Subject
patient I-Subject
. O

This O
is O
the O
first O
reported O
case O
of O
hepatolithiasis I-Effect
during I-Adverse_event.Trigger
octreotide I-Treatment.Drug
therapy O
. O

Treatment O
of O
amiodarone I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
thyrotoxicosis I-Effect
( I-Effect
AIT I-Effect
) I-Effect
with O
thionamide O
, O
lithium O
or O
radioactive O
iodine O
is O
ineffective O
. O

Treatment I-Potential_therapeutic_event.Trigger
of O
amiodarone I-Treat_Disorder
- I-Treat_Disorder
induced I-Treat_Disorder
thyrotoxicosis I-Treat_Disorder
( I-Treat_Disorder
AIT I-Treat_Disorder
) I-Treat_Disorder
with O
thionamide I-Treatment
, I-Treatment
lithium I-Treatment
or I-Treatment
radioactive I-Treatment
iodine I-Treatment
is O
ineffective O
. O

Six I-Subject.Population
patients I-Subject
with I-Subject
no I-Subject
previous I-Subject
signs I-Subject
or I-Subject
symptoms I-Subject
suggestive I-Subject
of I-Subject
coronary I-Subject
artery I-Subject
disease I-Subject
developed I-Adverse_event.Trigger
acute I-Effect
coronary I-Effect
ischemia I-Effect
/ I-Effect
infarction I-Effect
shortly O
after O
cis I-Treatment.Drug
- I-Treatment.Drug
diamine I-Treatment.Drug
- I-Treatment.Drug
dichloroplatinum I-Treatment.Drug
II I-Treatment.Drug
( I-Treatment
cisplatin I-Treatment
) I-Treatment
-based I-Treatment
chemotherapy I-Treatment.Route
. O

RESULTS O
: O
Replacing I-Treatment
valproate I-Treatment
with I-Treatment
lamotrigine I-Treatment.Drug
resulted I-Adverse_event.Trigger
in O
a I-Effect
decrease I-Effect
in I-Effect
serum I-Effect
testosterone I-Effect
concentrations I-Effect
in O
all I-Subject
3 I-Subject.Population
women I-Subject.Gender
. O

A I-Subject
65 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
woman I-Subject.Gender
, I-Subject
in I-Subject
the I-Subject
intensive I-Subject
care I-Subject
unit I-Subject
because I-Subject
of I-Subject
septic I-Subject.Sub_Disorder
shock I-Subject.Sub_Disorder
and I-Subject
acute I-Subject.Sub_Disorder
renal I-Subject.Sub_Disorder
failure I-Subject.Sub_Disorder
, O
had O
a O
small I-Effect
- I-Effect
bowel I-Effect
obstruction I-Effect
due I-Adverse_event.Trigger
to O
Amphojel I-Treatment.Drug
concretions I-Effect
. O

After O
the O
first O
oral I-Treatment.Route
dose I-Treatment
of I-Treatment
propranolol I-Treatment.Drug
, O
syncope I-Effect
developed I-Adverse_event.Trigger
together O
with O
atrioventricular I-Effect
block I-Effect
. O

Sorafenib I-Treatment.Drug
induced I-Adverse_event.Trigger
tumor I-Effect
lysis I-Effect
syndrome I-Effect
in O
an I-Subject
advanced I-Subject
hepatocellular I-Treat_Disorder
carcinoma I-Treat_Disorder
patient I-Subject
. O

The I-Effect
symptoms I-Effect
did I-Effect
not I-Effect
recur I-Effect
during O
the I-Treatment
36 I-Treatment.Duration
months I-Treatment.Duration
of I-Treatment
itraconazole I-Treatment.Drug
treatment I-Treatment
after I-Treatment
discharge I-Treatment
, O
and O
it O
was O
concluded O
that O
ITCZ O
was O
effective I-Potential_therapeutic_event.Trigger
for O
A. I-Treat_Disorder
flavus I-Treat_Disorder
hypertrophic I-Treat_Disorder
pachymeningitis I-Treat_Disorder
. O

A O
prospective O
randomized O
clinical O
trial O
was O
implemented O
to O
assess O
whether O
the I-Treatment
concomitant I-Treatment
or I-Treatment
the I-Treatment
sequential I-Treatment
addition I-Treatment
of I-Treatment
tamoxifen I-Treatment.Drug
to I-Treatment
chemotherapy I-Treatment.Route
provides I-Potential_therapeutic_event.Trigger
improved I-Effect
clinical I-Effect
benefit I-Effect
in I-Effect
the I-Effect
adjuvant I-Effect
treatment I-Effect
of O
breast I-Treat_Disorder
cancer I-Treat_Disorder
in O
postmenopausal I-Subject.Sub_Disorder
patients I-Subject
. O

Increased I-Effect
libido I-Effect
in I-Adverse_event.Trigger
a I-Subject
woman I-Subject.Gender
treated O
with O
fluvoxamine I-Treatment.Drug
: O
a O
case O
report O
. O

In O
the O
following O
case O
report O
, O
a O
patient I-Subject
developed I-Adverse_event.Trigger
acute I-Effect
interstitial I-Effect
nephritis I-Effect
with I-Effect
renal I-Effect
failure I-Effect
and I-Effect
exfoliative I-Effect
dermatitis I-Effect
following O
ampicillin I-Treatment.Drug
therapy I-Treatment
. O

Severe I-Effect
symptoms I-Effect
associated I-Effect
with I-Effect
serotonin I-Drug
toxicity I-Effect
were O
shown O
to O
be O
uncommon O
in O
patients I-Subject
receiving I-Adverse_event.Trigger
linezolid I-Treatment.Combination.Drug
and I-Treatment
selected I-Treatment
serotonin I-Treatment.Combination.Drug
reuptake I-Treatment.Combination.Drug
inhibitors I-Treatment.Combination.Drug
. O

We O
describe O
the O
side I-Effect
effects I-Effect
of I-Adverse_event.Trigger
5 I-Treatment.Drug
- I-Treatment.Drug
FU I-Treatment.Drug
in O
a O
colon I-Treat_Disorder
cancer I-Treat_Disorder
patient I-Subject
who I-Subject
suffered I-Subject
severe I-Subject
mucositis I-Subject.Sub_Disorder
, I-Subject
desquamating I-Subject.Sub_Disorder
dermatitis I-Subject.Sub_Disorder
, I-Subject
prolonged I-Subject
myelosuppression I-Subject.Sub_Disorder
, I-Subject
and I-Subject
neurologic I-Subject.Sub_Disorder
toxicity I-Subject.Sub_Disorder
that I-Subject
required I-Subject
admission I-Subject
to I-Subject
the I-Subject
intensive I-Subject
care I-Subject
unit I-Subject
. O

There O
have O
been O
many O
reports O
of O
probable O
lithium I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
organic I-Effect
brain I-Effect
syndromes I-Effect
occurring O
when I-Treatment
serum I-Treatment
lithium I-Treatment
levels I-Treatment
are I-Treatment
within I-Treatment
or I-Treatment
close I-Treatment
to I-Treatment
the I-Treatment
therapeutic I-Treatment
range I-Treatment
. O

The O
patient I-Subject
was O
enrolled O
in O
a O
weight O
- O
loss O
clinic O
, O
and O
his O
diabetes O
medications O
were O
adjusted O
. O
Subsequently O
, O
olanzapine I-Treatment.Drug
was I-Treatment
discontinued I-Treatment
because I-Adverse_event.Trigger
of O
weight I-Effect
gain I-Effect
and I-Effect
uncontrolled I-Effect
diabetes I-Effect
. O

While O
most O
physicians O
are O
aware O
of O
heparin I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
thrombocytopenia I-Effect
and I-Effect
skin I-Effect
necrosis I-Effect
, O
the O
association O
of O
heparin O
and O
hyperkalemia O
is O
less O
well O
recognized O
. O

Gefitinib I-Treatment.Drug
( O
IRESSA I-Drug
, O
ZD1839 I-Drug
) O
, O
an O
epidermal I-Drug
growth I-Drug
factor I-Drug
receptor I-Drug
tyrosine I-Drug
kinase I-Drug
inhibitor I-Drug
, O
has O
been O
approved O
in O
several O
countries O
for O
the O
treatment I-Potential_therapeutic_event.Trigger
of O
advanced I-Treat_Disorder
non I-Treat_Disorder
- I-Treat_Disorder
small I-Treat_Disorder
- I-Treat_Disorder
cell I-Treat_Disorder
lung I-Treat_Disorder
cancer I-Treat_Disorder
. O

The O
case O
of O
a I-Subject
4 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
girl I-Subject.Gender
with O
valproate I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
stupor I-Effect
and I-Effect
electroencephalographic I-Effect
pattern I-Effect
of I-Effect
increased I-Effect
fast I-Effect
activity I-Effect
is O
reported O
. O

Prior O
to O
surgery O
, O
levodopa I-Effect
induced I-Effect
dyskinesia I-Effect
had O
improved I-Potential_therapeutic_event.Trigger
( O
< O
or O
= O
50 O
% O
) O
under O
treatment I-Treatment
with I-Treatment
amantadine I-Treatment.Drug
( I-Treatment
400 I-Treatment.Dosage
mg I-Treatment.Dosage
/ I-Treatment.Dosage
day I-Treatment.Dosage
, I-Treatment
po I-Treatment
) I-Treatment
in O
all I-Subject
three I-Subject.Population
patients I-Subject
. O

Foscarnet I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
severe O
hypomagnesemia I-Effect
and I-Effect
other I-Effect
electrolyte I-Effect
disorders I-Effect
. O

A O
case O
is O
reported O
of O
a O
child I-Subject.Age
with I-Subject
fatal I-Effect
pulmonary I-Effect
fibrosis I-Effect
following I-Adverse_event.Trigger
BCNU I-Treatment.Drug
therapy I-Treatment
. O

A I-Subject
64 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
man I-Subject.Gender
with I-Subject
schizophrenia I-Treat_Disorder
developed I-Adverse_event.Trigger
myoclonic I-Effect
jerks I-Effect
when O
given O
higher I-Treatment.Dosage
doses I-Treatment.Dosage
of I-Treatment
quetiapine I-Treatment.Drug
. O

The O
etiology O
of O
neurotoxicity I-Effect
in O
our O
two I-Subject.Population
patients I-Subject
remains O
unclear O
; O
however O
, O
as O
CAP O
is O
rapidly O
metabolized O
to O
5 O
- O
FU O
in O
patients O
with O
normal O
liver O
function O
, O
it O
is O
likely O
that O
5 I-Treatment.Drug
- I-Treatment.Drug
FU I-Treatment.Drug
or I-Treatment
its I-Treatment
active I-Treatment
metabolites I-Treatment
( I-Treatment
fluoro I-Treatment.Drug
- I-Treatment.Drug
beta I-Treatment.Drug
- I-Treatment.Drug
alanine I-Treatment.Drug
) I-Treatment
were O
contributing I-Adverse_event.Trigger
factors O
. O

CONCLUSIONS O
: O
Amantadine I-Treatment.Drug
can O
cause I-Adverse_event.Trigger
reversible I-Effect
corneal I-Effect
edema I-Effect
but O
can O
irreversibly O
reduce O
the O
density O
of O
endothelial O
cells O
. O

After O
gastric I-Effect
- I-Effect
outlet I-Effect
obstruction I-Effect
was O
recognized O
in O
several I-Subject
infants I-Subject.Age
who O
received I-Adverse_event.Trigger
prostaglandin I-Treatment.Drug
E1 I-Treatment.Drug
, O
we O
studied O
the O
association O
between O
the O
drug O
and O
this O
complication O
. O

A O
wide O
variety O
of O
adverse I-Effect
central I-Effect
nervous I-Effect
system I-Effect
effects I-Effect
have O
been O
reported O
in O
association I-Adverse_event.Trigger
with O
propafenone I-Treatment.Drug
; O
dizziness I-Effect
is O
the O
most O
common O
. O

Iatrogenic I-Effect
Cushing I-Effect
syndrome I-Effect
has O
been O
reported I-Adverse_event.Trigger
in O
patients I-Subject
with I-Subject
CF I-Subject.Sub_Disorder
treated O
concomitantly O
, O
and O
for O
extended O
duration O
, O
with O
inhaled I-Treatment.Route
corticosteroids I-Treatment.Combination.Drug
and I-Treatment
CYP3A4 I-Treatment.Combination.Drug
inhibitors I-Treatment.Combination.Drug
. O

Red I-Effect
blood I-Effect
cell I-Effect
anemia I-Effect
in O
a I-Subject
patient I-Subject
with I-Subject
pemphigus I-Treat_Disorder
vulgaris I-Treat_Disorder
induced I-Adverse_event.Trigger
by O
the O
use O
of O
mycophenolate I-Treatment.Combination.Drug
mofetil I-Treatment.Combination.Drug
and I-Treatment
prednisone I-Treatment.Combination.Drug
. O

Induction O
of O
systemic I-Effect
lupus I-Effect
erythematosus I-Effect
by I-Adverse_event.Trigger
interferon I-Treatment.Drug
- I-Treatment.Drug
gamma I-Treatment.Drug
in O
a I-Subject
patient I-Subject
with I-Subject
rheumatoid I-Treat_Disorder
arthritis I-Treat_Disorder
. I-Treat_Disorder

In O
this O
case O
, O
unlike O
those O
previously O
reported O
, O
hyponatremia I-Effect
recurred O
5 I-Time_elapsed
months I-Time_elapsed
after I-Adverse_event.Trigger
switching I-Treatment
from I-Treatment
citalopram I-Treatment.Drug
to I-Treatment
mirtazapine I-Treatment.Drug
, O
which O
is O
believed O
to O
be O
a O
safe O
antidepressant O
. O

This O
report O
describes O
a O
case O
of O
acute I-Effect
compromise I-Effect
of I-Effect
renal I-Effect
function I-Effect
associated I-Adverse_event.Trigger
with O
hypotension I-Effect
in O
a I-Subject
7 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
boy I-Subject.Gender
treated O
with O
the O
ACE I-Treatment
inhibitor I-Treatment
lisinopril I-Treatment.Combination.Drug
and I-Treatment
the I-Treatment
ARB I-Treatment
losartan I-Treatment.Combination.Drug
. O

We O
report O
a I-Subject
male I-Subject.Gender
patient I-Subject
with I-Subject
advanced I-Treat_Disorder
AIDS I-Treat_Disorder
who O
developed I-Adverse_event.Trigger
hypercalcemia I-Effect
2 I-Treatment.Time_elapsed
weeks I-Treatment.Time_elapsed
after I-Treatment
institution I-Treatment
of I-Treatment
rhGH I-Treatment.Drug
therapy I-Treatment
. O

RESULTS O
: O
Both I-Subject.Population
patients I-Subject
experienced O
a O
previously O
unreported O
side O
effect O
-- O
falling I-Effect
backward I-Effect
-- O
associated I-Adverse_event.Trigger
with O
bupropion I-Treatment.Drug
use O
. O

A O
second O
episode O
of O
jaundice I-Effect
followed I-Adverse_event.Trigger
the O
intravaginal I-Treatment.Route
administration I-Treatment
of I-Treatment
a I-Treatment
mixture I-Treatment
of I-Treatment
furazolidone I-Treatment.Combination.Drug
and I-Treatment
nifuroxime I-Treatment.Combination.Drug
. O

Clinicians O
should O
be O
aware O
that O
an I-Effect
erythematous I-Effect
and I-Effect
exfoliative I-Effect
rash I-Effect
may O
be O
induced I-Adverse_event.Trigger
by O
temozolomide I-Treatment.Drug
, O
and O
be O
familiar O
with O
the O
pharmacologic O
and O
supportive O
measures O
necessary O
for O
its O
treatment O
. O

Captopril I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
bone I-Effect
marrow I-Effect
suppression I-Effect
in O
two I-Subject.Population
cardiac I-Subject.Sub_Disorder
patients I-Subject
with I-Subject
trisomy I-Subject.Sub_Disorder
21 I-Subject.Sub_Disorder
. O

A I-Subject
65 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
woman I-Subject.Gender
with I-Subject
angina I-Treat_Disorder
pectoris I-Treat_Disorder
presented I-Adverse_event.Trigger
with O
syncope I-Effect
after O
sublingual I-Treatment.Route
ingestion I-Treatment.Route
of I-Treatment
isosorbide I-Treatment.Drug
dinitrate I-Treatment.Drug
( I-Treatment
5 I-Treatment.Dosage
mg I-Treatment.Dosage
) I-Treatment
. O

The O
authors O
present O
a O
case O
study O
of O
a I-Subject
mentally I-Subject
healthy I-Subject
man I-Subject.Gender
who O
repeatedly O
experienced I-Adverse_event.Trigger
short I-Effect
- I-Effect
lived I-Effect
, I-Effect
obsessional I-Effect
- I-Effect
like I-Effect
suicidal I-Effect
ideas I-Effect
and I-Effect
images I-Effect
after O
ingestion I-Treatment.Route
of I-Treatment
the I-Treatment
anti I-Treatment
- I-Treatment
fungal I-Treatment
drug I-Treatment
ketoconazole I-Treatment.Drug
. O

Flaccid I-Effect
quadriparesis I-Effect
was O
noted I-Adverse_event.Trigger
after O
discontinuation O
of O
vecuronium I-Treatment.Drug
. O

AIMS O
: O
The O
aim O
of O
this O
study O
was O
to O
report O
on O
the O
effectiveness O
and O
tumor I-Effect
side I-Effect
effects I-Effect
of O
topical I-Treatment.Route
interferon I-Treatment.Drug
( I-Treatment
INF I-Treatment
) I-Treatment
alpha I-Treatment.Drug
2 I-Treatment.Drug
- I-Treatment.Drug
beta I-Treatment.Drug
in O
a O
case O
of O
conjunctiva I-Treat_Disorder
- I-Treat_Disorder
cornea I-Treat_Disorder
intraepithelial I-Treat_Disorder
neoplasia I-Treat_Disorder
( I-Subject
CIN I-Subject
) I-Subject
of I-Subject
a I-Subject
patient I-Subject
that I-Subject
rejected I-Subject
any I-Subject
surgical I-Subject
procedure I-Subject
. O

Herein O
is O
reported O
an O
unusual O
case O
of O
coexistent O
warfarin I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
skin I-Effect
necrosis I-Effect
and O
heparin O
- O
induced O
thrombocytopenia O
following O
mitral O
valve O
replacement O
for O
thromboembolic O
phenomena O
associated O
with O
marantic O
endocarditis O
and O
bronchial O
adenocarcinoma O
. O

Herein O
is O
reported O
an O
unusual O
case O
of O
coexistent O
warfarin O
- O
induced O
skin O
necrosis O
and O
heparin I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
thrombocytopenia I-Effect
following O
mitral O
valve O
replacement O
for O
thromboembolic O
phenomena O
associated O
with O
marantic O
endocarditis O
and O
bronchial O
adenocarcinoma O
. O

We O
present O
a O
case O
of O
severe I-Effect
unilateral I-Effect
posterior I-Effect
scleritis I-Effect
associated I-Adverse_event.Trigger
with O
zoledronic I-Treatment.Drug
acid I-Treatment.Drug
administration O
that O
was O
recognized O
and O
treated O
in O
a O
timely O
manner O
. O

The O
patient O
's O
other O
comorbidities O
and O
medications O
have O
not O
been O
suggested O
as O
possible O
interactions O
with O
sertraline I-Treatment.Drug
that O
can O
cause I-Adverse_event.Trigger
rhabdomyolysis I-Effect
. O

L I-Treatment.Drug
- I-Treatment.Drug
asparaginase I-Treatment.Drug
- O
provoked I-Adverse_event.Trigger
seizures I-Effect
as I-Effect
singular I-Effect
expression I-Effect
of I-Effect
central I-Effect
nervous I-Effect
toxicity I-Effect
. O

Acute I-Effect
non I-Effect
- I-Effect
lymphocytic I-Effect
leukemia I-Effect
in O
patients I-Subject
with I-Subject
ovarian I-Treat_Disorder
carcinoma I-Treat_Disorder
following I-Adverse_event.Trigger
long I-Treatment
- I-Treatment
term I-Treatment
treatment I-Treatment
with I-Treatment
Treosulfan I-Treatment.Drug
(= I-Treatment
dihydroxybusulfan I-Treatment
) I-Treatment
. O

Children I-Subject.Age
treated O
with O
thalidomide I-Treatment.Drug
should O
undergo O
regular O
neurophysiologic O
studies O
in O
order O
to O
detect I-Adverse_event.Trigger
presymptomatic I-Effect
or I-Effect
progressive I-Effect
peripheral I-Effect
neuropathy I-Effect
. O

Nevirapine I-Treatment.Combination.Drug
is I-Treatment
a I-Treatment
non I-Treatment
- I-Treatment
nucleoside I-Treatment
reverse I-Treatment
transcriptase I-Treatment
inhibitor I-Treatment
widely I-Treatment
used I-Treatment
in I-Treatment
combination I-Treatment
with I-Treatment
other I-Treatment.Combination.Drug
antiretroviral I-Treatment.Combination.Drug
agents I-Treatment.Combination.Drug
for O
the O
treatment I-Potential_therapeutic_event.Trigger
of O
HIV I-Treat_Disorder
infection I-Treat_Disorder
. O

The O
case O
is O
presented O
of O
a I-Subject
72 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
man I-Subject.Gender
with I-Subject
hormone I-Treat_Disorder
- I-Treat_Disorder
refractory I-Treat_Disorder
prostate I-Treat_Disorder
cancer I-Treat_Disorder
and O
weekly I-Treatment.Freq
administration I-Treatment.Route
of I-Treatment
30 I-Treatment.Dosage
mg I-Treatment.Dosage
/ I-Treatment.Dosage
m2 I-Treatment.Dosage
docetaxel I-Treatment.Drug
who O
developed I-Adverse_event.Trigger
subacute I-Effect
interstitial I-Effect
pneumonitis I-Effect
- I-Effect
related I-Effect
pulmonary I-Effect
fibrosis I-Effect
after O
seven I-Treatment.Dosage
doses I-Treatment.Dosage
and I-Effect
died I-Effect
despite I-Treatment
mechanical I-Treatment
ventilation I-Treatment
and I-Treatment
high I-Treatment.Dosage
- I-Treatment.Dosage
dose I-Treatment.Dosage
corticosteroid I-Treatment.Drug
treatment I-Treatment
. O

In O
this O
case O
, O
it O
was O
suspected O
that O
a O
combination O
of O
cigarette O
smoking O
, O
pulmonary I-Subject.Sub_Disorder
fibrosis I-Subject.Sub_Disorder
, O
and O
low I-Treatment.Dosage
- I-Treatment.Dosage
dose I-Treatment.Dosage
methotrexate I-Treatment.Drug
therapy I-Treatment
might O
have O
promoted I-Adverse_event.Trigger
the I-Effect
development I-Effect
of I-Effect
lung I-Effect
cancer I-Effect
. O

Rapid O
onset I-Adverse_event.Trigger
of O
iatrogenic I-Effect
adrenal I-Effect
insufficiency I-Effect
in O
a I-Subject
patient I-Subject
with I-Subject
cystic I-Subject.Sub_Disorder
fibrosis I-Subject.Sub_Disorder
- I-Subject.Sub_Disorder
related I-Subject.Sub_Disorder
liver I-Subject.Sub_Disorder
disease I-Subject.Sub_Disorder
treated O
with O
inhaled I-Treatment.Combination.Drug
corticosteroids I-Treatment.Combination.Drug
and I-Treatment
a I-Treatment
moderate I-Treatment
CYP3A4 I-Treatment.Combination.Drug
inhibitor I-Treatment.Combination.Drug
. I-Combination.Drug

Heparin I-Treatment.Drug
- O
associated I-Adverse_event.Trigger
thrombocytopenia I-Effect
and I-Effect
thrombosis I-Effect
is O
a O
severe O
complication O
of O
systemic O
heparin I-Drug
therapy O
. O

The O
polycystic I-Effect
changes I-Effect
disappeared I-Effect
from I-Effect
the I-Effect
ovaries I-Effect
in O
2 I-Subject.Population
of I-Subject
the I-Subject
women I-Subject.Gender
after I-Treatment
valproate I-Treatment.Drug
therapy I-Treatment
was I-Treatment
discontinued I-Treatment
, O
and O
the O
2 O
women O
who O
had O
gained O
weight O
and O
developed O
amenorrhea O
while O
being O
treated O
with O
valproate O
lost I-Effect
weight I-Effect
and I-Effect
resumed I-Effect
menstruating I-Effect
after O
the O
change O
in O
medication O
. O

The O
polycystic O
changes O
disappeared O
from O
the O
ovaries O
in O
2 O
of O
the O
women O
after O
valproate O
therapy O
was O
discontinued O
, O
and O
the O
2 I-Subject.Population
women I-Subject.Gender
who O
had O
gained I-Effect
weight I-Effect
and I-Effect
developed I-Effect
amenorrhea I-Effect
while I-Adverse_event.Trigger
being O
treated O
with O
valproate I-Treatment.Drug
lost O
weight O
and O
resumed O
menstruating O
after O
the O
change O
in O
medication O
. O

The O
cause O
of O
his O
bleeding O
was O
a O
severe O
thrombocytopoaenia I-Effect
, O
induced I-Adverse_event.Trigger
by O
chronic I-Treatment
ingestion I-Treatment.Route
of I-Treatment
quinine I-Treatment.Drug
. O

The O
concomitant I-Treatment
use I-Treatment
of I-Treatment
antidepressant I-Treatment.Combination.Drug
drugs I-Treatment.Combination.Drug
associated I-Treatment
with I-Treatment
lithium I-Treatment.Combination.Drug
as I-Treatment
a I-Treatment
co I-Treatment
- I-Treatment
adjuvant I-Treatment
seems O
to O
increase I-Adverse_event.Trigger
the O
risk O
of O
this O
adverse I-Effect
reaction I-Effect
. O

Peripheral I-Effect
nervous I-Effect
system I-Effect
disturbances I-Effect
caused I-Adverse_event.Trigger
by O
cytosine I-Treatment.Drug
arabinoside I-Treatment.Drug
have O
rarely O
been O
reported O
. O

We O
report O
an O
unusually O
short O
lived O
and O
asymptomatic O
episode O
of O
severe O
cisplatin I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
renal I-Effect
tubular I-Effect
salt I-Effect
wasting I-Effect
in O
a I-Subject
fit I-Subject
41 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
patient I-Subject
with I-Subject
malignant I-Treat_Disorder
teratoma I-Treat_Disorder
. O

This I-Subject
case I-Subject
suggests O
that O
BH I-Treatment.Drug
- I-Treatment.Drug
AC I-Treatment.Drug
, I-Treatment
a I-Treatment
derivative I-Treatment
of I-Treatment
cytosine I-Treatment
arabinoside I-Treatment
( I-Treatment
1 I-Treatment
- I-Treatment
beta I-Treatment
- I-Treatment
D I-Treatment
- I-Treatment
arabinofuranosylcytosine I-Treatment
) I-Treatment
could O
be O
a O
cause I-Adverse_event.Trigger
of O
reversible I-Effect
encephalopathy I-Effect
syndrome I-Effect
. O

She O
was O
administered O
metoclopramide I-Treatment.Drug
because O
of O
nausea I-Treat_Disorder
and O
, O
within I-Time_elapsed
2 I-Time_elapsed
hours I-Time_elapsed
, O
developed I-Adverse_event.Trigger
agitation I-Effect
, I-Effect
dysarthria I-Effect
, I-Effect
diaphoresis I-Effect
, I-Effect
and I-Effect
a I-Effect
movement I-Effect
disorder I-Effect
. O

This O
article O
describes O
two I-Subject
cases I-Subject
of O
aplastic I-Effect
anemia I-Effect
, O
at O
least O
one O
of O
which O
was O
almost O
certainly O
induced I-Adverse_event.Trigger
by O
the O
use O
of O
methazolamide I-Treatment.Drug
, O
and O
one O
case O
of O
agranulocytosis O
related O
to O
the O
use O
of O
methazolamide O
. O

This O
article O
describes O
two O
cases O
of O
aplastic O
anemia O
, O
at O
least O
one O
of O
which O
was O
almost O
certainly O
induced O
by O
the O
use O
of O
methazolamide O
, O
and O
one O
case O
of O
agranulocytosis I-Effect
related I-Adverse_event.Trigger
to O
the O
use O
of O
methazolamide I-Treatment.Drug
. O

Amprenavir I-Treatment.Drug
is O
a O
human O
immunodeficiency O
virus O
- O
1 O
( O
HIV O
- O
1 O
) O
protease O
inhibitor O
intended O
to O
be O
used O
to O
treat I-Potential_therapeutic_event.Trigger
HIV I-Treat_Disorder
- I-Treat_Disorder
infected I-Treat_Disorder
children I-Subject.Age
. O

Methotrexate I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
papular I-Effect
eruption I-Effect
following O
treatment O
of O
psoriasis O
has O
not O
been O
previously O
reported O
. O

On O
day O
7 O
of O
linezolid I-Treatment.Drug
treatment O
, O
the I-Subject
patient I-Subject
developed I-Adverse_event.Trigger
severe O
pruritus I-Effect
, I-Effect
macular I-Effect
rash I-Effect
, I-Effect
facial I-Effect
edema I-Effect
, I-Effect
eosinophilia I-Effect
, I-Effect
marked I-Effect
increase I-Effect
in I-Effect
serum I-Effect
creatinine I-Effect
level I-Effect
, O
and O
mild O
hepatitis I-Effect
. O

We O
report O
a O
fatal O
case O
of O
acute I-Effect
interstitial I-Effect
pneumonitis I-Effect
in O
a I-Subject
patient I-Subject
treated I-Adverse_event.Trigger
with I-Adverse_event.Trigger
carmustine I-Treatment.Drug
( I-Treatment.Drug
BCNU I-Treatment.Drug
) I-Treatment.Drug
for I-Subject
a I-Treat_Disorder
brain I-Treat_Disorder
tumor I-Treat_Disorder
. O

The O
three I-Subject.Population
reported I-Subject
cases I-Subject
demonstrate O
that O
troglitazone I-Treatment.Drug
is O
an O
idiosyncratic O
hepatotoxin O
that O
can O
lead I-Adverse_event.Trigger
to O
irreversible I-Effect
liver I-Effect
injury I-Effect
. O

High I-Effect
- I-Effect
grade I-Effect
atrioventricular I-Effect
block I-Effect
during I-Adverse_event.Trigger
dipyridamole I-Treatment.Drug
stress I-Treatment
testing I-Treatment
. O

We O
describe O
a O
case O
of O
intraoperative I-Treatment.Route
gelatine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
anaphylaxis I-Effect
whose O
diagnosis O
was O
delayed O
as O
the O
use O
of O
gelatine O
during O
surgical O
procedures O
was O
omitted O
for O
two O
times O
in O
patient O
's O
medical O
records O
. O

The O
case O
of O
a I-Subject
29 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
man I-Subject.Gender
suffering I-Subject
from I-Subject
falciparum I-Treat_Disorder
malaria I-Treat_Disorder
disease I-Treat_Disorder
who O
got I-Adverse_event.Trigger
a O
reversible I-Effect
hearing I-Effect
loss I-Effect
from O
quinine I-Treatment.Drug
therapy O
is O
presented O
. O

The O
cases O
of O
two I-Subject.Population
asthmatic I-Treat_Disorder
patients I-Subject
who O
became O
hypokalemic I-Effect
after I-Adverse_event.Trigger
inhalation I-Treatment.Route
of I-Treatment
normal I-Treatment.Dosage
doses I-Treatment.Dosage
of I-Treatment
albuterol I-Treatment.Drug
are O
presented O
. O

This O
article O
presents O
a O
case O
of O
an I-Effect
atypical I-Effect
localized I-Effect
cutaneous I-Effect
eruption I-Effect
with I-Effect
an I-Effect
unusual I-Effect
course I-Effect
and I-Effect
protracted I-Effect
resolution I-Effect
time I-Effect
associated I-Adverse_event.Trigger
with I-Adverse_event.Trigger
sorafenib I-Treatment.Drug
therapy I-Treatment
. O

METHOD O
: O
We O
describe O
two I-Subject.Population
patients I-Subject
who O
presented I-Adverse_event.Trigger
with O
diabetic I-Effect
ketoacidosis I-Effect
after O
treatment O
with O
quetiapine I-Treatment.Drug
and I-Treatment
risperidone I-Treatment.Drug
, O
respectively O
. O

We O
suspect O
that O
nefazodone I-Treatment.Drug
inhibits I-Adverse_event.Trigger
metabolism I-Effect
of I-Effect
tacrolimus I-Effect
. O

Our O
review O
of O
194 I-Subject
RA I-Subject
patients I-Subject
and I-Subject
38 I-Subject
PsA I-Subject
patients I-Subject
receiving I-Subject
MTX I-Subject
has I-Subject
identified I-Subject
four I-Subject.Population
RA I-Treat_Disorder
patients I-Subject
and I-Subject
one I-Subject.Population
PsA I-Treat_Disorder
patient I-Subject
with O
MTX I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
pneumonitis I-Effect
, O
giving O
a O
prevalence O
of O
2.1 O
% O
and O
0.03 O
% O
, O
respectively O
. O

A O
case O
report O
of O
fatal O
dapsone I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
agranulocytosis I-Effect
in O
an I-Subject
Indian I-Subject.Race
mid I-Subject.Sub_Disorder
- I-Subject.Sub_Disorder
borderline I-Subject.Sub_Disorder
leprosy I-Subject.Sub_Disorder
patient I-Subject
. O

Autoimmune I-Effect
thyroid I-Effect
disease I-Effect
is O
a O
common O
side I-Adverse_event.Trigger
- I-Adverse_event.Trigger
effect I-Adverse_event.Trigger
of O
interferon I-Treatment.Drug
- I-Treatment.Drug
alpha I-Treatment.Drug
( I-Treatment
IFN I-Treatment
- I-Treatment
alpha I-Treatment
) I-Treatment
treatment O
of O
viral I-Treat_Disorder
hepatitis I-Treat_Disorder
C. I-Treat_Disorder

The O
side O
effects O
of O
MMF I-Treatment.Drug
, O
such O
as O
bone I-Effect
marrow I-Effect
toxicity I-Effect
, O
have O
been O
reported I-Adverse_event.Trigger
. O

He I-Subject.Gender
developed I-Adverse_event.Trigger
a O
late I-Effect
secondary I-Effect
infection I-Effect
in O
some O
sites O
treated O
with O
imiquimod I-Treatment.Drug
. O

We O
report O
the O
case O
of O
a I-Subject
51 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
man I-Subject.Gender
in O
whom O
IFN I-Treatment.Drug
- I-Treatment.Drug
alpha I-Treatment.Drug
treatment I-Treatment
was O
followed I-Adverse_event.Trigger
by O
recurrence I-Effect
of I-Effect
Graves I-Effect
' I-Effect
disease I-Effect
10 I-Treatment
years I-Treatment
after I-Treatment
thyroidectomy I-Treatment
was O
performed O
and O
the O
patient O
was O
declared O
cured O
. O

We O
report O
2 O
cases O
of O
maculopapular I-Effect
eruption I-Effect
and I-Effect
fever I-Effect
in O
patients I-Subject
infected I-Adverse_event.Trigger
with O
human I-Treat_Disorder
immunodeficiency I-Treat_Disorder
virus I-Treat_Disorder
( O
HIV O
) O
on O
the O
2nd I-Time_elapsed
day I-Time_elapsed
of I-Time_elapsed
first I-Time_elapsed
administration I-Time_elapsed
of O
ritonavir I-Treatment.Drug
, O
a O
protease O
inhibitor O
. O

We O
report O
the O
case O
of O
a I-Subject
woman I-Subject.Gender
who O
developed I-Adverse_event.Trigger
photo I-Effect
- I-Effect
onycholysis I-Effect
on I-Effect
multiple I-Effect
nails I-Effect
after I-Time_elapsed
uptake I-Treatment.Time_elapsed
of I-Treatment
olanzapine I-Treatment.Drug
. O

Cimetidine I-Treatment.Drug
is O
a O
rare O
cause I-Adverse_event.Trigger
of O
drug O
- O
induced O
fever I-Effect
. O

Reversible O
methotrexate I-Treatment.Drug
- O
associated I-Adverse_event.Trigger
lymphoproliferative I-Effect
disorder I-Effect
resembling O
advanced O
gastric O
cancer O
in O
a I-Subject
patient I-Subject
with I-Subject
rheumatoid I-Treat_Disorder
arthritis I-Treat_Disorder
. O

The O
field I-Effect
defects I-Effect
and I-Effect
some I-Effect
electrophysiological I-Effect
abnormalities I-Effect
persist I-Effect
when O
vigabatrin I-Treatment.Drug
therapy I-Treatment
is I-Treatment
withdrawn I-Treatment
. O

A I-Subject
possible I-Subject
case I-Subject
of O
carbamazepine I-Treatment.Drug
induced I-Adverse_event.Trigger
pancreatitis I-Effect
. O

Subsequent I-Adverse_event.Trigger
to O
the O
first O
dose O
of O
mirtazapine I-Treatment.Drug
the I-Subject
patient I-Subject
experienced O
seizures I-Effect
, I-Effect
bradycardia I-Effect
and I-Effect
prolonged I-Effect
QRS I-Effect
as I-Effect
well I-Effect
as I-Effect
QTc I-Effect
intervals I-Effect
on I-Effect
EKG I-Effect
. O

Stuttering I-Effect
priapism I-Effect
complicating O
warfarin I-Treatment.Drug
therapy O
in I-Adverse_event.Trigger
a I-Subject
patient I-Subject
with I-Subject
protein I-Treat_Disorder
C I-Treat_Disorder
deficiency I-Treat_Disorder
. O

She O
had O
been O
on O
a O
combined O
treatment I-Potential_therapeutic_event.Trigger
of O
steroid I-Treatment.Combination.Drug
and I-Treatment
lobenzarit I-Treatment.Combination.Drug
disodium I-Treatment.Combination.Drug
for I-Treatment
the I-Treatment
first I-Treatment
3 I-Treatment.Time_elapsed
years I-Treatment.Time_elapsed
, I-Treatment
and I-Treatment
then I-Treatment
continued I-Treatment
with I-Treatment
a I-Treatment
combined I-Treatment
treatment I-Treatment
of I-Treatment
steroid I-Treatment.Combination.Drug
and I-Treatment
bucillamine I-Treatment.Combination.Drug
for I-Treatment.Duration
the I-Treatment.Duration
following I-Treatment.Duration
years I-Treatment.Duration
until O
she O
was O
found O
to O
have O
pulmonary I-Effect
tuberculosis I-Effect
, O
at O
which O
time O
the O
steroid O
was O
suspended O
10 O
months O
before O
she O
visited O
the O
authors O
' O
clinic O
. O

We O
describe O
a I-Subject
rare I-Subject
case I-Subject
of O
severe O
drug O
- O
drug O
interaction O
between O
propafenone I-Treatment.Combination.Drug
and I-Treatment
mirtazapine I-Treatment.Combination.Drug
leading I-Adverse_event.Trigger
to O
propafenone I-Effect
toxicity I-Effect
. O

Because O
the O
combination O
of O
bleomycin I-Treatment.Combination.Drug
and O
vinca I-Treatment.Combination.Drug
alkaloids I-Treatment.Combination.Drug
is O
commonly O
used O
for O
the O
treatment O
of O
AIDS O
- O
related O
Kaposi O
's O
sarcoma O
, O
clinicians O
should O
be O
aware O
of O
the O
risk O
of O
provoking I-Adverse_event.Trigger
acral I-Effect
necrosis I-Effect
in O
patients O
who O
develop O
Raynaud I-Effect
's I-Effect
phenomenon I-Effect
under O
chemotherapy O
. O

The O
psychotic I-Treat_Disorder
behavior I-Treat_Disorder
resolved I-Potential_therapeutic_event.Trigger
completely O
soon I-Time_elapsed
after I-Time_elapsed
the O
discontinuation I-Treatment
of I-Treatment
levetiracetam I-Treatment.Drug
. O

Male I-Subject.Gender
volunteers I-Subject
( I-Subject
n=12 I-Subject.Population
) I-Subject
participated O
in O
a O
randomised O
, O
two O
- O
period O
, O
crossover O
trial O
evaluating O
the O
effect O
of O
multiple I-Treatment.Dosage
doses I-Treatment.Dosage
of I-Treatment.Dosage
600 I-Treatment.Dosage
mg I-Treatment.Dosage
rifampicin I-Treatment.Drug
once I-Treatment.Freq
daily I-Treatment.Freq
for I-Treatment
7 I-Treatment.Duration
days I-Treatment.Duration
on I-Adverse_event.Trigger
repaglinide I-Effect
metabolism I-Effect
. O

This O
report O
suggests O
that O
anemia I-Effect
can O
occur O
due I-Adverse_event.Trigger
to O
MMF I-Treatment.Combination.Drug
, O
in O
particular O
when O
it O
is O
given O
with O
prednisone I-Treatment.Combination.Drug
, O
a O
side O
effect O
well O
documented O
in O
the O
transplantation O
literature O
when O
the O
triple O
combination O
of O
MMF O
, O
cyclosporine O
and O
prednisone O
is O
used O
. O

Warfarin I-Treatment.Drug
was I-Treatment
initiated I-Treatment
for I-Treatment
deep I-Treatment.Treat_Disorder
vein I-Treatment.Treat_Disorder
thrombosis I-Treatment.Treat_Disorder
prophylaxis I-Potential_therapeutic_event.Trigger
due O
to O
the O
patient I-Subject
's I-Subject
inability I-Subject.Sub_Disorder
to I-Subject.Sub_Disorder
ambulate I-Subject.Sub_Disorder
. O

We O
report O
a O
case O
with O
chronic I-Treat_Disorder
hepatitis I-Treat_Disorder
C I-Treat_Disorder
( I-Treat_Disorder
CHC I-Treat_Disorder
) I-Treat_Disorder
who O
developed I-Adverse_event.Trigger
sarcoidosis I-Effect
after O
the O
treatment I-Treatment
by I-Treatment
interferon I-Treatment.Combination.Drug
alpha I-Treatment.Combination.Drug
and I-Treatment
ribavirin I-Treatment.Combination.Drug
. O

The O
relation O
between O
tacrolimus O
treatment O
and O
staining O
was O
suggested O
by O
the O
appearance I-Effect
of I-Effect
pigmentation I-Effect
during I-Adverse_event.Trigger
topical I-Treatment.Route
tacrolimus I-Treatment.Drug
treatment O
and O
its O
clinical O
disappearance O
when O
treatment O
was O
stopped O
. O

Though O
hypotension O
, O
dry O
mouth O
, O
and O
constipation O
are O
well O
- O
documented O
possible O
adverse O
effects O
, O
the O
possibility O
of O
clonidine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
bradycardia I-Effect
is O
less O
well O
recognized O
and O
is O
rare O
. O

Several O
hypersensitivity I-Effect
reactions I-Adverse_event.Trigger
to I-Adverse_event.Trigger
cloxacillin I-Treatment.Drug
have O
been O
reported O
, O
although O
IgE O
- O
mediated O
allergic O
reactions O
to O
the O
drug O
are O
rare O
and O
there O
is O
little O
information O
about O
possible O
tolerance O
to O
other O
semisynthetic O
penicillins O
or O
cephalosporins O
in O
patients O
with O
cloxacillin O
allergy O
. O

Brugada I-Effect
type I-Effect
electrocardiographic I-Effect
changes I-Effect
induced I-Adverse_event.Trigger
by O
concomitant I-Treatment
use I-Treatment
of I-Treatment
lithium I-Treatment.Combination.Drug
and I-Treatment
propafenone I-Treatment.Combination.Drug
in O
patient I-Subject
with I-Subject
Wolff I-Treat_Disorder
- I-Treat_Disorder
Parkinson I-Treat_Disorder
- I-Treat_Disorder
White I-Treat_Disorder
syndrome I-Treat_Disorder
. O

Docetaxel I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
Meibomian I-Effect
duct I-Effect
inflammation I-Effect
and I-Effect
blockage I-Effect
leading I-Effect
to I-Effect
chalazion I-Effect
formation I-Effect
. O

Allergic O
side O
effects O
of O
AZA O
are O
rare O
, O
and O
reported O
allergic I-Effect
skin I-Effect
eruptions I-Effect
from I-Adverse_event.Trigger
AZA I-Treatment.Drug
are O
very O
limited O
in O
Japan O
. O

Quetiapine O
and O
obsessive I-Effect
- I-Effect
compulsive I-Effect
symptoms I-Effect
( I-Effect
OCS I-Effect
) I-Effect
: O
case O
report O
and O
review O
of O
atypical O
antipsychotic I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
OCS I-Effect
. O

Outcome O
of O
pregnancy I-Treat_Disorder
in I-Subject
women I-Subject.Gender
treated I-Potential_therapeutic_event.Trigger
with O
all I-Treatment.Drug
- I-Treatment.Drug
trans I-Treatment.Drug
retinoic I-Treatment.Drug
acid I-Treatment.Drug
; O
a O
case O
report O
and O
review O
of O
literature O
. O

The O
potential O
development I-Adverse_event.Trigger
of O
SJS I-Effect
/ I-Effect
TEN I-Effect
, I-Effect
a I-Effect
severe I-Effect
life I-Effect
- I-Effect
threatening I-Effect
illness I-Effect
, O
emphasizes O
the O
need O
for O
judicious O
use O
of O
TMP O
- O
Sx O
and O
close O
monitoring O
and O
follow O
- O
up O
for O
patients I-Subject
who O
were O
given O
TMP I-Treatment.Combination.Drug
- I-Treatment
Sx I-Treatment.Combination.Drug
for O
SSTIs I-Treat_Disorder
. O

A O
case O
history O
of O
a I-Subject
15 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
boy I-Subject.Gender
who O
developed O
incapacitating I-Effect
tardive I-Effect
dyskinesia I-Effect
that O
resolved I-Potential_therapeutic_event.Trigger
during O
treatment O
with O
deanol I-Treatment.Drug
is O
presented O
. O

Drug I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
mammary I-Effect
hyperplasias I-Effect
have O
been O
reported O
as O
rare O
complications O
of O
D I-Treatment.Combination.Drug
- I-Treatment.Combination.Drug
penicillamine I-Treatment.Combination.Drug
and I-Treatment
Neothetazone I-Treatment.Combination.Drug
. O

The O
purpose O
of O
this O
report O
is O
to O
document O
a O
new O
case O
of O
in O
utero O
CP I-Treatment.Drug
exposure I-Adverse_event.Trigger
with O
multiple I-Effect
congenital I-Effect
anomalies I-Effect
and O
to O
establish O
an O
apparent O
CP I-Effect
embryopathy I-Effect
phenotype O
. O

AIM O
: O
The O
aim O
of O
this O
article O
is O
to O
present O
the O
clinical O
characteristics O
and O
management O
of O
an O
oral O
adverse I-Effect
effect I-Effect
stemming O
from I-Adverse_event.Trigger
the O
use O
of O
the O
antiretroviral I-Treatment
medication I-Treatment
Nevirapine I-Treatment.Drug
( I-Treatment
NVP I-Treatment
) I-Treatment
. O

A I-Subject
27 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
man I-Subject.Gender
who I-Subject
had I-Subject
a I-Subject
history I-Subject
of I-Subject
bronchial I-Subject.Sub_Disorder
asthma I-Subject.Sub_Disorder
, I-Subject
eosinophilic I-Subject.Sub_Disorder
enteritis I-Subject.Sub_Disorder
, I-Subject
and I-Subject
eosinophilic I-Subject.Sub_Disorder
pneumonia I-Subject.Sub_Disorder
presented O
with O
fever I-Effect
, I-Effect
skin I-Effect
eruptions I-Effect
, I-Effect
cervical I-Effect
lymphadenopathy I-Effect
, I-Effect
hepatosplenomegaly I-Effect
, I-Effect
atypical I-Effect
lymphocytosis I-Effect
, I-Effect
and I-Effect
eosinophilia I-Effect
two I-Time_elapsed
weeks I-Time_elapsed
after I-Time_elapsed
receiving I-Adverse_event.Trigger
trimethoprim I-Treatment.Combination.Drug
( I-Treatment
TMP) I-Treatment
- I-Treatment
sulfamethoxazole I-Treatment.Combination.Drug
( I-Treatment
SMX I-Treatment
) I-Treatment
treatment O
. O

Treatment I-Treatment
with I-Treatment
infliximab I-Treatment.Drug
is O
known O
to O
produce I-Adverse_event.Trigger
an O
increase I-Effect
of I-Effect
autoantibodies I-Effect
( I-Effect
antinuclear I-Effect
antibodies I-Effect
, I-Effect
anti I-Effect
- I-Effect
double I-Effect
- I-Effect
stranded I-Effect
DNA I-Effect
) I-Effect
, I-Effect
but I-Effect
not I-Effect
clinical I-Effect
disease I-Effect
. O

Serotonin I-Effect
syndrome I-Effect
, I-Effect
which O
occurs I-Adverse_event.Trigger
as O
a O
result O
of O
enhanced O
serotonin O
concentration O
in O
the O
central O
nervous O
system O
, O
is O
a O
well O
- O
known O
adverse O
effect O
of O
serotonin I-Treatment
- I-Treatment
active I-Treatment
medications I-Treatment
. O

Despite O
the O
risk O
of O
needle O
- O
track O
seeding O
, O
PEI I-Treatment.Drug
remains I-Potential_therapeutic_event.Trigger
useful O
in O
the O
treatment O
of O
HCC I-Treat_Disorder
. O

Trimethoprim I-Treatment.Combination.Drug
- I-Treatment
sulfamethoxazole I-Treatment.Combination.Drug
- O
induced I-Adverse_event.Trigger
hepatotoxicity I-Effect
in O
a I-Subject
pediatric I-Subject.Age
patient I-Subject
. O

Prolonged O
responses O
were O
achieved O
with O
low O
doses O
of O
HU I-Treatment.Drug
( I-Treatment
3 I-Treatment
- I-Treatment
10 I-Treatment
mg I-Treatment
/ I-Treatment
kg I-Treatment
/ I-Treatment
day I-Treatment
) I-Treatment
and I-Treatment
higher I-Treatment.Dosage
doses I-Treatment.Dosage
were O
associated I-Adverse_event.Trigger
with O
mild I-Effect
reversible I-Effect
hematologic I-Effect
or I-Effect
hepatic I-Effect
toxicity I-Effect
and I-Effect
no I-Effect
further I-Effect
increases I-Effect
in I-Effect
Hb I-Effect
. O

Prolonged I-Effect
responses I-Effect
were O
achieved I-Adverse_event.Trigger
with O
low I-Treatment.Dosage
doses I-Treatment.Dosage
of I-Treatment
HU I-Treatment.Drug
( O
3 O
- O
10 O
mg O
/ O
kg O
/ O
day O
) O
and O
higher O
doses O
were O
associated O
with O
mild O
reversible O
hematologic O
or O
hepatic O
toxicity O
and O
no O
further O
increases O
in O
Hb O
. O

Imidazoline I-Treatment.Drug
intoxication I-Effect
in O
children I-Subject.Age
. O

Concomitant O
administration O
of O
cytarabine I-Treatment.Drug
might O
have O
affected I-Adverse_event.Trigger
his O
liver I-Effect
function I-Effect
and O
there O
might O
have O
been O
interaction O
between O
the O
drugs O
. O

The O
probability O
of O
developing I-Adverse_event.Trigger
acute I-Effect
leukemia I-Effect
in O
this O
study O
was O
not O
significantly O
correlated O
to O
the I-Treatment
total I-Treatment
cumulative I-Treatment
dosage I-Treatment
of I-Treatment
Treosulfan I-Treatment.Drug
. O

Intraventricular I-Treatment.Route
vancomycin I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
cerebrospinal I-Effect
fluid I-Effect
eosinophilia I-Effect
: O
report O
of O
two I-Subject.Population
patients I-Subject
. I-Subject

This O
case O
supports O
the O
view O
that O
in I-Treat_Disorder
gold I-Drug
- I-Treat_Disorder
induced I-Treat_Disorder
pneumonitis I-Treat_Disorder
a I-Treatment
prolonged I-Treatment
treatment I-Treatment
with I-Treatment
corticosteroids I-Treatment.Drug
may O
be O
necessary O
, O
as I-Potential_therapeutic_event.Trigger
lung O
function O
continued O
to O
improve O
. O

Massive I-Effect
plasmocytosis I-Effect
due O
to O
methimazole I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
bone I-Effect
marrow I-Effect
toxicity I-Effect
. O

RESULTS O
: O
After I-Treatment
4 I-Treatment.Time_elapsed
- I-Treatment.Time_elapsed
to I-Treatment.Time_elapsed
14 I-Treatment.Time_elapsed
- I-Treatment.Time_elapsed
month I-Treatment.Time_elapsed
period I-Treatment
of I-Treatment
therapy I-Treatment
with I-Treatment
the I-Treatment
combination I-Treatment
of I-Treatment
indapamide I-Treatment.Combination.Drug
( I-Treatment
2.5 I-Treatment.Dosage
mg I-Treatment.Dosage
/ I-Treatment.Dosage
day I-Treatment.Dosage
) I-Treatment
and I-Treatment
fosinopril I-Treatment.Combination.Drug
( I-Treatment
10 I-Treatment.Dosage
mg I-Treatment.Dosage
/ I-Treatment.Dosage
day I-Treatment.Dosage
) I-Treatment
in O
three I-Subject.Population
patients I-Subject
and O
6 O
- O
month O
period O
of O
monotherapy O
with O
indapamide O
( O
2.5 O
mg O
/ O
day O
) O
in O
one O
patient O
, O
glucose I-Effect
levels I-Effect
of I-Effect
all I-Effect
patients I-Effect
increased I-Effect
and I-Effect
achieve I-Effect
criteria I-Effect
of I-Effect
diabetes I-Effect
diagnoses I-Effect
. O

RESULTS O
: O
After O
4 O
- O
to O
14 O
- O
month O
period O
of O
therapy O
with O
the O
combination O
of O
indapamide O
( O
2.5 O
mg O
/ O
day O
) O
and O
fosinopril O
( O
10 O
mg O
/ O
day O
) O
in O
three O
patients O
and O
6 I-Treatment.Duration
- I-Treatment.Duration
month I-Treatment.Duration
period I-Treatment
of I-Treatment
monotherapy I-Treatment
with I-Treatment
indapamide I-Treatment.Drug
( I-Treatment
2.5 I-Treatment.Dosage
mg I-Treatment.Dosage
/ I-Treatment.Dosage
day I-Treatment.Dosage
) I-Treatment
in O
one I-Subject.Population
patient I-Subject
, O
glucose I-Effect
levels I-Effect
of I-Effect
all I-Effect
patients I-Effect
increased I-Effect
and I-Effect
achieve I-Effect
criteria I-Effect
of I-Effect
diabetes I-Effect
diagnoses I-Effect
. O

A O
reversible I-Effect
toxic I-Effect
liver I-Effect
damage I-Effect
was O
observed O
in O
a I-Subject
non I-Subject.Sub_Disorder
- I-Subject.Sub_Disorder
alcoholic I-Subject.Sub_Disorder
woman I-Subject.Gender
treated O
with O
disulfiram I-Treatment.Drug
. O

A I-Subject
60 I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
woman I-Subject.Gender
with I-Subject
chronic I-Treat_Disorder
renal I-Treat_Disorder
failure I-Treat_Disorder
developed I-Adverse_event.Trigger
acute I-Effect
proximal I-Effect
muscle I-Effect
weakness I-Effect
after O
receiving O
a O
regular I-Treatment.Dosage
dosage I-Treatment.Dosage
of I-Treatment
colchicine I-Treatment.Drug
. O

The O
cause O
of O
these O
previously O
unreported O
side O
effects O
of O
niacin I-Treatment.Drug
therapy O
is O
uncertain O
but O
may O
be O
related I-Adverse_event.Trigger
to O
prostaglandin I-Effect
- I-Effect
mediated I-Effect
vasodilatation I-Effect
, I-Effect
hyperalgesia I-Effect
of I-Effect
sensory I-Effect
nerve I-Effect
receptors I-Effect
, I-Effect
and I-Effect
potentiation I-Effect
of I-Effect
inflammation I-Effect
in I-Effect
the I-Effect
gingiva I-Effect
with I-Effect
referral I-Effect
of I-Effect
pain I-Effect
to I-Effect
the I-Effect
teeth I-Effect
. O

Nocardia I-Effect
is O
an O
important O
opportunistic O
infectious I-Adverse_event.Trigger
agent I-Adverse_event.Trigger
in O
immunocompromised I-Subject.Sub_Disorder
hosts I-Subject
, O
i.e. O
in O
patients O
taking O
corticosteroids I-Treatment.Drug
. O

Hepatobiliary I-Effect
disorders I-Effect
associated I-Adverse_event.Trigger
with O
orally I-Treatment.Route
administered I-Treatment
terbinafine I-Treatment.Drug
have O
rarely O
been O
reported O
. O

We O
report O
a I-Subject
patient I-Subject
in O
whom O
the O
anti O
- O
depressant O
trazodone I-Treatment.Drug
hydrochloride I-Treatment.Drug
( I-Treatment
Molipaxin I-Treatment
, I-Treatment
Roussel I-Treatment
) I-Treatment
, O
a O
serotonin O
antagonist O
, O
provoked I-Adverse_event.Trigger
generalized I-Effect
pustular I-Effect
psoriasis I-Effect
( I-Effect
GPP I-Effect
) I-Effect
. O

Early I-Treatment
recognition I-Treatment
of I-Treatment
hereditary I-Treatment
motor I-Treatment
and I-Treatment
sensory I-Treatment
neuropathy I-Treatment
type I-Treatment
1 I-Treatment
can I-Potential_therapeutic_event.Trigger
avoid O
life O
- O
threatening O
vincristine O
neurotoxicity O
. O

Probable O
enoxaparin I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
hepatotoxicity I-Effect
. O

Interstitial I-Effect
pneumonitis I-Effect
associated I-Adverse_event.Trigger
with O
sirolimus I-Treatment.Drug
: O
a O
dilemma O
for O
lung O
transplantation O
. O

He I-Subject.Gender
had O
also O
developed I-Adverse_event.Trigger
elevated I-Effect
serum I-Effect
ammonia I-Effect
levels I-Effect
while O
on O
valproic I-Treatment.Drug
acid I-Treatment.Drug
. O

Cutaneous I-Effect
rashes I-Effect
and I-Effect
eruptions I-Effect
can O
be O
caused I-Adverse_event.Trigger
by O
many O
medications O
, O
including O
carbamazepine I-Treatment.Drug
. O

In O
this O
case O
, O
the I-Effect
increase I-Effect
in I-Effect
the I-Effect
INR I-Effect
value I-Effect
with I-Effect
associated I-Effect
bruising I-Effect
after I-Adverse_event.Trigger
the O
addition O
of O
amoxycillin I-Treatment.Drug
suggests O
a O
drug O
interaction O
between O
acenocoumarol I-Combination.Drug
and O
amoxycillin I-Combination.Drug
, O
other O
possible O
causes O
having O
been O
eliminated O
. O

Oncologists O
supervising O
future O
clinical O
trials O
for O
lung I-Treat_Disorder
cancer I-Treat_Disorder
should O
be O
alert O
to O
the O
fact O
that O
sorafenib I-Treatment.Drug
can O
potentially O
induce I-Adverse_event.Trigger
serious I-Effect
interstitial I-Effect
lung I-Effect
disease I-Effect
, O
although O
this O
might O
depend O
on O
racial O
differences O
. O

SUMMARY O
: O
A I-Subject
26 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
man I-Subject.Gender
with I-Subject
bipolar I-Subject.Sub_Disorder
disorder I-Subject.Sub_Disorder
, I-Subject
seizures I-Subject.Sub_Disorder
, I-Subject
and I-Subject
mild I-Subject.Sub_Disorder
mental I-Subject.Sub_Disorder
retardation I-Subject.Sub_Disorder
secondary I-Subject.Sub_Disorder
to I-Subject.Sub_Disorder
a I-Subject.Sub_Disorder
traumatic I-Subject.Sub_Disorder
brain I-Subject.Sub_Disorder
injury I-Subject.Sub_Disorder
began O
treatment I-Potential_therapeutic_event.Trigger
with O
carbamazepine I-Treatment.Drug
for O
aggression I-Treat_Disorder
and O
seizure I-Treat_Disorder
control O
. O

Serotonin I-Effect
toxicity I-Effect
precipitated I-Adverse_event.Trigger
by O
fentanyl I-Treatment.Combination.Drug
is O
unusual O
and O
has O
not O
previously O
been O
described O
in O
combination O
with O
SSRIs I-Combination.Drug
in O
the O
perioperative O
setting O
. O

It O
may O
cause I-Adverse_event.Trigger
a I-Effect
severe I-Effect
adverse I-Effect
drug I-Effect
reaction I-Effect
with O
multiorgan O
involvement O
known O
as O
dapsone I-Treatment.Drug
hypersensitivity I-Effect
syndrome I-Effect
. O

Visual I-Effect
system I-Effect
side I-Effect
effects I-Effect
caused I-Effect
by I-Effect
parasympathetic I-Effect
dysfunction I-Effect
after I-Adverse_event.Trigger
botulinum I-Treatment.Drug
toxin I-Treatment.Drug
type I-Treatment.Drug
B I-Treatment.Drug
injections I-Treatment.Route
. O

Renal I-Effect
failure I-Effect
associated I-Adverse_event.Trigger
with O
acetazolamide I-Treatment.Drug
therapy I-Treatment
for O
glaucoma I-Treat_Disorder
. O

Acute I-Effect
onset I-Effect
of I-Effect
nephrotic I-Effect
syndrome I-Effect
during I-Adverse_event.Trigger
interferon I-Treatment.Drug
- I-Treatment.Drug
alpha I-Treatment.Drug
retreatment I-Treatment
for O
chronic I-Treat_Disorder
active I-Treat_Disorder
hepatitis I-Treat_Disorder
C. I-Treat_Disorder

A I-Subject
16 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
boy I-Subject.Gender
developed O
fever I-Effect
, I-Effect
generalized I-Effect
rigidity I-Effect
, I-Effect
leukocytosis I-Effect
, I-Effect
and I-Effect
increased I-Effect
serum I-Effect
transaminase I-Effect
and I-Effect
creatine I-Effect
kinase I-Effect
levels I-Effect
while I-Adverse_event.Trigger
receiving O
treatment O
with O
olanzapine I-Treatment.Combination.Drug
and I-Treatment
lithium I-Treatment.Combination.Drug
. O

The O
hyperpigmentation I-Effect
was I-Effect
diffuse I-Effect
scattered I-Effect
, I-Effect
flagellate I-Effect
like I-Effect
and I-Effect
linear I-Effect
streaking I-Effect
which O
was O
thought O
to O
be O
mainly O
related O
to O
the O
skin O
toxicity I-Adverse_event.Trigger
of O
bleomycin I-Treatment.Drug
. O

Exacerbation O
of O
5 I-Treatment.Drug
- I-Treatment.Drug
FU I-Treatment.Drug
dermatologic I-Effect
toxicities I-Effect
in O
patients O
with O
preexisting O
conditions O
suggests O
the O
importance O
of O
aggressive O
ocular O
prophylaxis O
, O
using O
frequent O
ocular O
lubrication O
and O
topical O
steroid O
preparations O
with O
concurrent O
medical O
management O
of O
pre O
- O
existing O
dermatologic O
conditions O
. O

Bowel I-Effect
perforation I-Effect
associated I-Adverse_event.Trigger
with O
intraperitoneal I-Treatment.Route
chromic I-Treatment.Drug
phosphate I-Treatment.Drug
instillation I-Treatment.Route
. O

A I-Subject
62 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
woman I-Subject.Gender
who I-Subject
was I-Subject
being I-Subject
treated I-Subject
for I-Subject
squamous I-Treat_Disorder
cell I-Treat_Disorder
carcinoma I-Treat_Disorder
of I-Treat_Disorder
the I-Treat_Disorder
head I-Treat_Disorder
and I-Treat_Disorder
neck I-Treat_Disorder
developed I-Adverse_event.Trigger
a I-Effect
chemotherapy I-Effect
- I-Effect
related I-Effect
hemolytic I-Effect
- I-Effect
uremic I-Effect
syndrome I-Effect
during O
the I-Treatment
second I-Treatment.Dosage
cycle I-Treatment.Dosage
of I-Treatment
neoadjuvant I-Treatment
chemotherapy I-Treatment
consisting I-Treatment
of I-Treatment
cisplatin I-Treatment.Combination.Drug
, I-Treatment
bleomycin I-Treatment.Combination.Drug
, I-Treatment
and I-Treatment
methotrexate I-Treatment.Combination.Drug
. O

These O
data O
confirm O
the O
therapeutic I-Potential_therapeutic_event.Trigger
value I-Potential_therapeutic_event.Trigger
of O
arsenic I-Treatment
trioxide I-Treatment
in O
relapsed I-Treat_Disorder
/ I-Treat_Disorder
resistant I-Treat_Disorder
APL I-Treat_Disorder
. O

Avascular I-Effect
necrosis I-Effect
of I-Effect
the I-Effect
femoral I-Effect
head I-Effect
in I-Adverse_event.Trigger
patients I-Subject
with I-Subject
prostate I-Treat_Disorder
cancer I-Treat_Disorder
treated O
with O
cyproterone I-Treatment.Drug
acetate I-Treatment.Drug
and I-Treatment
radiotherapy I-Treatment
. O

Ectropion I-Effect
secondary I-Adverse_event.Trigger
to O
bolus I-Treatment.Route
injection I-Treatment.Route
of I-Treatment
5 I-Treatment.Drug
- I-Treatment.Drug
fluorouracil I-Treatment.Drug
. O

Metoclopramide I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
parkinsonism I-Effect
is O
not O
rare O
, O
and O
appropriate O
dose O
reduction O
in O
patients I-Subject
with I-Subject
renal I-Subject.Sub_Disorder
failure I-Subject.Sub_Disorder
will O
help O
reduce O
the O
incidence O
of O
this O
morbidity O
. O

Posterior I-Effect
reversible I-Effect
encephalopathy I-Effect
syndrome I-Effect
associated I-Adverse_event.Trigger
with O
methotrexate I-Treatment.Drug
neurotoxicity I-Treatment
: O
conventional O
magnetic O
resonance O
and O
diffusion O
- O
weighted O
imaging O
findings O
. O

A I-Subject
6 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
boy I-Subject.Gender
( I-Subject
weight I-Subject
: I-Subject
16 I-Subject
kg I-Subject
, I-Subject
at I-Subject
the I-Subject
start I-Subject
of I-Subject
treatment I-Subject
) I-Subject
began O
sodium I-Treatment.Drug
valproate I-Treatment.Drug
( I-Treatment
valproate I-Treatment
syrup I-Treatment
5 I-Treatment
% I-Treatment
) I-Treatment
treatment I-Potential_therapeutic_event.Trigger
for O
epilepsy I-Treat_Disorder
in O
February O
2012 O
. O

Pharmacokinetic O
determinants O
of O
6 I-Treatment.Drug
- I-Treatment.Drug
mercaptopurine I-Treatment.Drug
myelotoxicity I-Effect
and I-Effect
therapeutic I-Effect
failure I-Effect
in I-Adverse_event.Trigger
children I-Subject.Age
with I-Subject
acute I-Treat_Disorder
lymphoblastic I-Treat_Disorder
leukemia I-Treat_Disorder
. O

We O
report O
the O
case O
histories O
of O
identical I-Subject
twin I-Subject
brothers I-Subject.Gender
who O
developed O
concordant O
acute O
lymphoblastic O
leukemia O
at O
the O
age O
of O
4 O
years O
and O
who O
later O
developed I-Adverse_event.Trigger
leukoencephalopathy I-Effect
and I-Effect
hydrocephalus I-Effect
related O
to O
central O
nervous O
system O
prophylaxis O
by O
, O
in O
the O
first O
case O
intrathecally I-Treatment.Route
administered I-Treatment
methotrexate I-Treatment.Drug
and O
, O
in O
the O
second O
by O
intrathecally I-Treatment.Route
administered I-Treatment
methotrexate I-Treatment.Drug
and I-Treatment
cranial I-Treatment
irradiation I-Treatment
. O

Considering O
the O
increasing O
use O
of O
TMZ I-Treatment.Drug
, O
which O
is O
regarded O
as O
a O
drug O
with I-Adverse_event.Trigger
moderate I-Effect
toxicity I-Effect
, O
careful O
follow O
- O
up O
with O
routine O
blood O
testing O
is O
vital O
. O

While O
for O
ribavirin O
antidepressant O
effects O
are O
not O
known O
, O
we O
suppose O
that O
antidepressants I-Treatment.Drug
may O
prevent I-Potential_therapeutic_event.Trigger
changes I-Treat_Disorder
in I-Treat_Disorder
serotonergic I-Treat_Disorder
or I-Treat_Disorder
noradrenergic I-Treat_Disorder
neurotransmission I-Treat_Disorder
caused I-Treat_Disorder
by I-Treat_Disorder
IFN I-Treat_Disorder
- I-Treat_Disorder
alpha I-Treat_Disorder
. O

While O
for O
ribavirin O
antidepressant O
effects O
are O
not O
known O
, O
we O
suppose O
that O
antidepressants O
may O
prevent O
changes I-Effect
in I-Effect
serotonergic I-Effect
or I-Effect
noradrenergic I-Effect
neurotransmission I-Effect
caused I-Adverse_event.Trigger
by O
IFN I-Treatment.Drug
- I-Treatment.Drug
alpha I-Treatment.Drug
. O

To O
report O
a I-Subject
case I-Subject
of O
serotonin I-Effect
syndrome I-Effect
associated I-Adverse_event.Trigger
with O
interaction I-Treatment
between I-Treatment
fentanyl I-Treatment.Combination.Drug
and I-Treatment
citalopram I-Treatment.Combination.Drug
, O
as O
evidenced O
by O
medication O
history O
, O
clinical O
features O
and O
reversal O
following O
discontinuation O
of O
fentanyl O
. O

We O
report O
a O
case O
of O
ibuprofen I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
meningitis I-Effect
in O
an I-Subject
otherwise I-Subject
healthy I-Subject
individual I-Subject
. O

The O
reported O
cases O
of O
in I-Treatment
utero I-Treatment
exposure I-Treatment
to I-Treatment
cyclosposphamide I-Treatment.Drug
shared I-Adverse_event.Trigger
the O
following O
manifestations O
with O
our O
patient I-Subject
: O
growth I-Effect
deficiency I-Effect
, I-Effect
developmental I-Effect
delay I-Effect
, I-Effect
craniosynostosis I-Effect
, I-Effect
blepharophimosis I-Effect
, I-Effect
flat I-Effect
nasal I-Effect
bridge I-Effect
, I-Effect
abnormal I-Effect
ears I-Effect
, I-Effect
and I-Effect
distal I-Effect
limb I-Effect
defects I-Effect
including I-Effect
hypoplastic I-Effect
thumbs I-Effect
and I-Effect
oligodactyly I-Effect
. O

L I-Treatment.Drug
- I-Treatment.Drug
Thyroxine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
leukopenia I-Effect
in O
a I-Subject
patient I-Subject
with I-Subject
Hashimoto I-Treat_Disorder
's I-Treat_Disorder
disease I-Treat_Disorder
: O
involvement O
of O
suppressor O
- O
cytotoxic O
T O
cells O
. O

Carbamazepine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
systemic I-Effect
lupus I-Effect
erythematosus I-Effect
- I-Effect
like I-Effect
disease I-Effect
. O

CONCLUSIONS O
: O
This O
case O
describes O
the O
clinically O
significant O
increase I-Effect
of I-Effect
INR I-Effect
in I-Adverse_event.Trigger
an I-Subject
elderly I-Subject.Age
patient I-Subject
after O
adding O
a O
chemotherapy O
regimen O
of O
levamisole I-Treatment.Combination.Drug
and I-Treatment
5 I-Treatment.Combination.Drug
- I-Treatment.Combination.Drug
FU I-Treatment.Combination.Drug
to O
a O
previous O
regimen O
of O
warfarin I-Treatment.Combination.Drug
alone O
. O

These O
results O
suggest O
that O
the O
hepatoxicity I-Effect
of O
ethanol O
in O
alcoholic I-Treatment.Drug
beverages O
is O
enhanced I-Adverse_event.Trigger
by O
interaction O
with O
its O
congeners O
and O
acetaldehyde O
; O
they O
also O
suggest O
that O
alcoholic O
beverages O
are O
not O
equivalent O
in O
their O
potential O
to O
cause O
liver O
damage O
. O

The O
dermatology O
literature O
heretofore O
has O
not O
noted O
that O
anemia I-Effect
is I-Adverse_event.Trigger
a O
side O
effect O
of O
patients I-Subject
taking O
MMF I-Treatment
to O
treat O
pemphigus I-Treat_Disorder
. O

The O
9 O
other O
reported O
cases O
of O
D I-Treatment.Drug
- I-Treatment.Drug
penicillamine I-Treatment.Drug
induced I-Adverse_event.Trigger
rapidly I-Effect
progressive I-Effect
glomerulonephritis I-Effect
have O
been O
reviewed O
. O

We O
describe O
a I-Subject
heroin I-Treat_Disorder
abuser I-Treat_Disorder
in O
whom O
clinical O
and O
laboratory O
manifestations O
of O
acute I-Effect
hepatitis I-Effect
B I-Effect
and I-Effect
C I-Effect
appeared O
a O
few O
days O
after I-Adverse_event.Trigger
the O
insertion O
of O
a O
subcutaneous I-Treatment.Route
naltrexone I-Treatment.Drug
implant I-Treatment
. O

Ciprofloxacin I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
psychosis I-Effect
. O

Thalidomide I-Treatment.Drug
was O
withdrawn O
from O
world O
markets O
in O
1961 O
following I-Adverse_event.Trigger
recognition O
of O
its O
teratogenic I-Effect
effects I-Effect
. O

Weekly I-Treatment.Freq
AUC2 I-Treatment.Combination.Drug
carboplatin I-Treatment.Combination.Drug
in I-Potential_therapeutic_event.Trigger
acquired O
platinum I-Treat_Disorder
- I-Treat_Disorder
resistant I-Treat_Disorder
ovarian I-Treat_Disorder
cancer I-Treat_Disorder
with I-Treatment
or I-Treatment
without I-Treatment
oral I-Treatment.Route
phenoxodiol I-Treatment.Combination.Drug
, O
a O
sensitizer O
of O
platinum O
cytotoxicity O
: O
the O
phase O
III O
OVATURE O
multicenter O
randomized O
study O
. O

We O
suggest O
the O
use O
of O
esmolol I-Treatment.Drug
for O
treatment I-Potential_therapeutic_event.Trigger
of O
dysrhythmias I-Treat_Disorder
secondary O
to O
caffeine I-Drug
toxicity O
; O
to O
the O
best O
of O
our O
knowledge O
, O
the O
use O
of O
esmolol I-Drug
has O
not O
been O
reported O
for O
this O
purpose O
. O

To O
date O
, O
there O
have O
been O
few O
reports O
of O
visual I-Effect
disturbances I-Effect
associated I-Adverse_event.Trigger
with O
BTX I-Treatment.Drug
- I-Treatment.Drug
B I-Treatment.Drug
use O
. O

Gemcitabine O
is O
a O
known O
risk O
factor O
for O
hemolytic O
uremic O
syndrome O
( O
HUS O
) O
, O
which O
can O
often O
have O
a I-Treat_Disorder
rapidly I-Treat_Disorder
fatal I-Treat_Disorder
clinical O
course O
despite O
intervention I-Potential_therapeutic_event.Trigger
with I-Treatment
steroids I-Treatment.Drug
, I-Treatment
plasmapheresis I-Treatment.Drug
and I-Treatment
hemodialysis I-Treatment.Drug
. O

Gemcitabine I-Treatment.Drug
is O
a O
known O
risk I-Adverse_event.Trigger
factor O
for O
hemolytic I-Effect
uremic I-Effect
syndrome I-Effect
( O
HUS O
) O
, O
which O
can O
often O
have O
a O
rapidly O
fatal O
clinical O
course O
despite O
intervention O
with O
steroids O
, O
plasmapheresis O
and O
hemodialysis O
. O

Our O
objective O
is O
to O
present O
a O
retrospective O
analysis O
of O
the O
DWI O
findings O
in O
four I-Subject.Population
patients I-Subject
who O
suffered O
subacute I-Effect
neurotoxicity I-Effect
after I-Adverse_event.Trigger
intrathecal I-Treatment.Drug
MTX I-Treatment.Drug
. O

We O
report O
a O
case O
of O
ST I-Effect
elevation I-Effect
in I-Effect
right I-Effect
precordial I-Effect
leads I-Effect
compatible I-Effect
with I-Effect
type I-Effect
1 I-Effect
Brugada I-Effect
syndrome I-Effect
following I-Adverse_event.Trigger
administration I-Treatment
of I-Treatment
propafenone I-Treatment.Combination.Drug
in O
a I-Subject
patient I-Subject
with I-Subject
Wolff I-Treat_Disorder
- I-Treat_Disorder
Parkinson I-Treat_Disorder
- I-Treat_Disorder
White I-Treat_Disorder
syndrome I-Treat_Disorder
who O
was O
receiving I-Treatment
lithium I-Treatment.Combination.Drug
at I-Treatment
concentrations I-Treatment
within I-Treatment
therapeutic I-Treatment
levels I-Treatment
. O

The O
spectrum O
of O
cutaneous I-Effect
eruptions I-Effect
associated I-Adverse_event.Trigger
with O
dihydropyridines I-Treatment.Drug
is O
extensive O
, O
varying O
from O
exanthemas I-Effect
to O
severe O
adverse O
events O
. O

Polymyositis I-Effect
after I-Adverse_event.Trigger
propylthiouracil I-Treatment.Drug
treatment O
for O
hyperthyroidism I-Treat_Disorder
. O

Methamphetamine I-Treatment.Drug
's I-Treatment.Drug
extensive O
physiologic O
effects O
, O
inconsistent O
street O
purity O
, O
and O
multiple O
routes O
of O
administration O
offer I-Potential_therapeutic_event.Trigger
many O
possibilities O
for O
injury I-Treat_Disorder
to I-Treat_Disorder
the I-Treat_Disorder
cornea I-Treat_Disorder
. O

Since O
ethambutol I-Treatment.Drug
is O
actively O
excreted O
via O
the O
renal O
system O
, O
compromise O
of O
renal O
function O
such O
as O
due O
to O
renal O
tuberculosis O
may O
lead I-Adverse_event.Trigger
to O
serum I-Effect
concentration I-Effect
elevations I-Effect
of I-Effect
ethambutol I-Effect
sufficient I-Effect
to I-Effect
produce I-Effect
optic I-Effect
neuropathy I-Effect
. O

Renal I-Effect
failure I-Effect
appeared O
8 I-Time_elapsed
to I-Time_elapsed
17 I-Time_elapsed
days I-Time_elapsed
after O
beginning I-Adverse_event.Trigger
gentamicin I-Treatment.Drug
therapy I-Treatment
and O
was O
characterized O
by O
creatinine I-Effect
clearances I-Effect
4 I-Effect
to I-Effect
10 I-Effect
ml I-Effect
/ I-Effect
min I-Effect
, I-Effect
urine I-Effect
to I-Effect
plasma I-Effect
creatinine I-Effect
ratios I-Effect
less I-Effect
than I-Effect
20 I-Effect
, I-Effect
urinary I-Effect
sodium I-Effect
concentrations I-Effect
16 I-Effect
to I-Effect
60 I-Effect
mEq I-Effect
/ I-Effect
liter I-Effect
, I-Effect
proteinuria I-Effect
, I-Effect
and I-Effect
cylindruria I-Effect
. O

Seizures I-Effect
associated I-Adverse_event.Trigger
with O
ofloxacin I-Treatment.Drug
therapy O
. O

Cutaneous I-Effect
seeding I-Effect
after I-Adverse_event.Trigger
ultrasound I-Treatment
- I-Treatment
guided I-Treatment
percutaneous I-Treatment
ethanol I-Treatment.Drug
injection I-Treatment.Route
for O
treatment O
of O
hepatocellular I-Treat_Disorder
carcinoma I-Treat_Disorder
. O

Two I-Subject.Population
patients I-Subject
who O
developed O
decreased I-Effect
visual I-Effect
acuity I-Effect
after I-Adverse_event.Trigger
several O
months O
of O
ethambutol I-Treatment.Drug
treatment O
for O
Mycobacterium I-Treat_Disorder
avium I-Treat_Disorder
- I-Treat_Disorder
intracellulare I-Treat_Disorder
infection I-Treat_Disorder
had O
bitemporal I-Effect
visual I-Effect
field I-Effect
defects I-Effect
that O
suggested O
optic I-Effect
chiasm I-Effect
damage I-Effect
. O

CONCLUSIONS O
: O
Metoclopramide I-Treatment.Drug
may O
cause I-Adverse_event.Trigger
reversible I-Effect
nonthrombocytopenic I-Effect
vascular I-Effect
- I-Effect
type I-Effect
palpable I-Effect
purpura I-Effect
. O

CONCLUSIONS O
: O
Life O
- O
threatening O
adrenal O
suppression O
, O
requiring I-Potential_therapeutic_event.Trigger
hydrocortisone I-Treatment.Drug
supplementation I-Treatment
and I-Treatment
intensive I-Treatment
therapy I-Treatment
, O
was O
observed O
and O
successfully I-Effect
treated I-Effect
in O
a I-Subject
newborn I-Subject.Age
, I-Subject
whose I-Subject
mother I-Subject
had I-Subject
received I-Subject
high I-Subject
- I-Subject
dose I-Subject
methylprednisolone I-Subject
in I-Subject
late I-Subject
pregnancy I-Subject
. O

A O
case O
of O
extrapyramidal I-Effect
symptoms I-Effect
( I-Effect
EPS I-Effect
) I-Effect
following I-Adverse_event.Trigger
administration O
of O
aripiprazole I-Treatment.Drug
to O
a I-Subject
man I-Subject.Gender
with I-Subject
developmental I-Subject.Sub_Disorder
disabilities I-Subject.Sub_Disorder
who I-Subject
had I-Subject
never I-Subject
received I-Subject
antipsychotic I-Subject
medications I-Subject
and I-Subject
had I-Subject
no I-Subject
history I-Subject
of I-Subject
movement I-Subject
disorders I-Subject
is I-Subject
presented I-Subject
. O

Although O
high I-Treatment.Dosage
- I-Treatment.Dosage
dose I-Treatment.Dosage
methotrexate I-Treatment.Drug
has O
been O
shown O
to O
be O
useful O
in O
the O
treatment O
of O
primary I-Treat_Disorder
osteogenic I-Treat_Disorder
sarcoma I-Treat_Disorder
, O
the O
tumoricidal O
effects O
of O
therapy O
appear O
to O
have O
caused I-Adverse_event.Trigger
a I-Effect
fatal I-Effect
rise I-Effect
in I-Effect
intracranial I-Effect
pressure I-Effect
. O

This O
case O
had O
radiation O
fibrosis O
, O
so O
we O
suggest O
that O
radiation O
fibrosis O
may O
be O
another O
contributor O
of I-Adverse_event.Trigger
the O
occurrence I-Effect
of I-Effect
ILD I-Effect
in O
patients I-Subject
taking I-Treatment
erlotinib I-Treatment.Drug
. O

Since O
recent O
studies O
have O
reported O
no O
negative O
interactions O
with O
concurrent O
use O
, O
we O
here O
report O
three O
cases O
( O
one O
case O
of O
a O
prolonged O
seizure O
, O
a O
serotonin O
syndrome O
and O
a O
focal O
seizure O
) O
of O
severe O
lithium I-Treat_Disorder
- I-Treat_Disorder
induced I-Treat_Disorder
side I-Treat_Disorder
effects I-Treat_Disorder
while O
patients O
underwent I-Potential_therapeutic_event.Trigger
ECT I-Treatment.Drug
without I-Effect
complications I-Effect
and I-Effect
lithium I-Effect
serum I-Effect
levels I-Effect
were I-Effect
still I-Effect
subtherapeutic I-Effect
. O

Since O
recent O
studies O
have O
reported O
no O
negative O
interactions O
with O
concurrent O
use O
, O
we O
here O
report O
three O
cases O
( O
one O
case O
of O
a I-Effect
prolonged I-Effect
seizure I-Effect
, O
a O
serotonin O
syndrome O
and O
a O
focal O
seizure O
) O
of O
severe O
lithium I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
side O
effects O
while O
patients O
underwent O
ECT O
without O
complications O
and O
lithium O
serum O
levels O
were O
still O
subtherapeutic O
. O

Since O
recent O
studies O
have O
reported O
no O
negative O
interactions O
with O
concurrent O
use O
, O
we O
here O
report O
three O
cases O
( O
one O
case O
of O
a O
prolonged O
seizure O
, O
a I-Effect
serotonin I-Effect
syndrome I-Effect
and O
a O
focal O
seizure O
) O
of O
severe O
lithium I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
side O
effects O
while O
patients O
underwent O
ECT O
without O
complications O
and O
lithium O
serum O
levels O
were O
still O
subtherapeutic O
. O

Since O
recent O
studies O
have O
reported O
no O
negative O
interactions O
with O
concurrent O
use O
, O
we O
here O
report O
three O
cases O
( O
one O
case O
of O
a O
prolonged O
seizure O
, O
a O
serotonin O
syndrome O
and O
a I-Effect
focal I-Effect
seizure I-Effect
) O
of O
severe O
lithium I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
side O
effects O
while O
patients O
underwent O
ECT O
without O
complications O
and O
lithium O
serum O
levels O
were O
still O
subtherapeutic O
. O

Lithium I-Treatment.Drug
- O
associated I-Adverse_event.Trigger
transient I-Effect
thyrotoxicosis I-Effect
in O
4 I-Subject.Population
Chinese I-Subject.Race
women I-Subject.Gender
with I-Subject
autoimmune I-Subject.Sub_Disorder
thyroiditis I-Subject.Sub_Disorder
. O

A I-Subject
patient I-Subject
, O
while O
on I-Adverse_event.Trigger
intravenous I-Treatment.Route
ritodrine I-Treatment.Drug
therapy I-Treatment
for O
preterm O
labor O
, O
experienced O
an I-Effect
episode I-Effect
of I-Effect
acute I-Effect
chest I-Effect
pain I-Effect
. O

Subsequent O
in O
vivo O
/ O
vitro O
studies O
clearly O
demonstrated O
that O
the O
neurological I-Effect
effects I-Effect
were O
due I-Adverse_event.Trigger
to O
a O
synergistic O
action O
of O
desferrioxamine I-Treatment.Combination.Drug
and I-Treatment
prochlorperazine I-Treatment.Combination.Drug
, O
probably O
resulting O
in O
exceptional O
fluxes O
of O
intra O
/ O
extra O
cellular O
iron O
/ O
copper O
disturbing O
noradrenergic O
and O
serotonergic O
systems O
. O

Favorable O
outcome I-Potential_therapeutic_event.Trigger
of O
de O
novo O
hepatitis I-Treat_Disorder
B I-Treat_Disorder
infection I-Treat_Disorder
after I-Treatment
liver I-Treatment
transplantation I-Treatment
with I-Treatment
lamivudine I-Treatment.Combination.Drug
and I-Treatment
adefovir I-Treatment.Combination.Drug
therapy I-Treatment
. O

Pemphigus I-Effect
foliaceus I-Effect
was O
seen I-Adverse_event.Trigger
in O
a I-Subject
patient I-Subject
with I-Subject
pulmonary I-Treat_Disorder
tuberculosis I-Treat_Disorder
during O
rifampicin I-Treatment.Drug
therapy O
. O

CONCLUSIONS O
: O
Clinicians O
should O
be O
aware O
of O
a O
risk O
of O
serotonin I-Effect
syndrome I-Effect
with I-Effect
serious I-Effect
extrapyramidal I-Effect
reactions I-Effect
in O
patients I-Subject
receiving I-Adverse_event.Trigger
sertraline I-Treatment.Combination.Drug
or I-Treatment
venlafaxine I-Treatment.Combination.Drug
when I-Treatment
metoclopramide I-Treatment.Combination.Drug
is I-Treatment
coadministered I-Treatment
even I-Treatment
in I-Treatment
a I-Treatment
single I-Treatment.Dosage
, I-Treatment.Dosage
conventional I-Treatment.Dosage
dose I-Treatment.Dosage
. O

We O
report O
the O
case O
of O
a I-Subject
patient I-Subject
who O
developed O
polyserositis I-Effect
( I-Effect
pericardial I-Effect
effusion I-Effect
, I-Effect
pleural I-Effect
effusion I-Effect
, I-Effect
and I-Effect
pericarditis I-Effect
) I-Effect
after I-Adverse_event.Trigger
being O
started I-Treatment
on I-Treatment
clozapine I-Treatment.Drug
, O
and O
whose O
symptoms O
remitted O
upon O
discontinuation O
of O
clozapine O
. O

Three I-Time_elapsed
years I-Time_elapsed
later I-Time_elapsed
, O
treatment O
with O
ampicillin I-Treatment.Drug
caused I-Adverse_event.Trigger
another O
episode O
of O
cholestatic I-Effect
hepatitis I-Effect
with I-Effect
cholestasis I-Effect
and I-Effect
duct I-Effect
paucity I-Effect
on I-Effect
rebiopsy I-Effect
. O

METHODS O
: O
A I-Subject
patient I-Subject
who O
developed O
dramatic O
, O
permanent I-Effect
vision I-Effect
loss I-Effect
after I-Adverse_event.Trigger
a O
9 I-Treatment.Time_elapsed
- I-Treatment.Time_elapsed
month I-Treatment.Time_elapsed
course I-Treatment
of I-Treatment
treatment I-Treatment
with I-Treatment
ethambutol I-Treatment.Combination.Drug
and I-Treatment
isoniazid I-Treatment.Combination.Drug
for O
pulmonary I-Treat_Disorder
tuberculosis I-Treat_Disorder
is O
presented O
. O

The O
authors O
report O
a O
case O
of O
urinary I-Effect
incontinence I-Effect
( I-Effect
UI I-Effect
) I-Effect
that O
occurred I-Adverse_event.Trigger
in O
a I-Subject
woman I-Subject.Gender
after O
administration O
of O
venlafaxine I-Treatment.Drug
. O

The O
possibility O
can O
be O
raised O
that O
M I-Treatment.Drug
- I-Treatment.Drug
CSF I-Treatment.Drug
accelerated I-Adverse_event.Trigger
the O
underlying I-Effect
renal I-Effect
disease I-Effect
in I-Effect
this I-Effect
case I-Effect
through I-Effect
enhancing I-Effect
macrophage I-Effect
accumulation I-Effect
into I-Effect
the I-Effect
glomerulus I-Effect
, I-Effect
leading I-Effect
to I-Effect
the I-Effect
development I-Effect
of I-Effect
nephrotic I-Effect
syndrome I-Effect
. O

We O
describe O
two I-Subject.Population
ELBW I-Subject.Sub_Disorder
infants I-Subject.Age
affected I-Subject
by I-Subject
hyperkalaemia I-Treat_Disorder
, O
treated O
with O
Kayexalate I-Treatment.Drug
, O
who O
developed I-Adverse_event.Trigger
serious I-Effect
hypernatraemia I-Effect
, O
that O
has O
never O
been O
reported O
before O
in O
preterm O
infants O
. O

DISCUSSION O
: O
Electrolyte I-Effect
disorders I-Effect
associated I-Adverse_event.Trigger
with O
foscarnet I-Treatment.Drug
are O
reviewed O
. O

We O
report O
two I-Subject.Population
cases I-Subject
that O
developed I-Adverse_event.Trigger
acute I-Effect
myeloid I-Effect
leukaemia I-Effect
( I-Effect
AML I-Effect
) I-Effect
during O
tamoxifen I-Treatment.Drug
therapy I-Treatment
for I-Treatment
breast I-Treatment.Treat_Disorder
cancer I-Treatment.Treat_Disorder
. O

Our O
patient O
was O
a I-Subject
72 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
man I-Subject.Gender
with I-Subject
advanced I-Treat_Disorder
Parkinson I-Treat_Disorder
's I-Treat_Disorder
disease I-Treat_Disorder
( I-Treat_Disorder
PD I-Treat_Disorder
) I-Treat_Disorder
who O
received O
levodopa I-Treatment.Drug
and I-Treatment
anti I-Treatment.Drug
- I-Treatment.Drug
cholinergic I-Treatment.Drug
drugs I-Treatment.Drug
and O
whose O
head O
had O
become I-Adverse_event.Trigger
almost O
completely I-Effect
bald I-Effect
. O

The O
patient O
experienced I-Adverse_event.Trigger
hallucinations I-Effect
, I-Effect
agitation I-Effect
, I-Effect
vomiting I-Effect
, I-Effect
tachycardia I-Effect
and I-Effect
seizures I-Effect
after O
ingestion I-Treatment.Route
of I-Treatment
1050 I-Treatment.Dosage
( I-Treatment.Dosage
48 I-Treatment.Dosage
mg I-Treatment.Dosage
/ I-Treatment.Dosage
kg I-Treatment.Dosage
) I-Treatment.Dosage
of I-Treatment
extended I-Treatment
- I-Treatment
release I-Treatment
bupropion I-Treatment.Drug
. O

This O
case O
report O
describes O
a O
38 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
male I-Subject.Gender
in O
whom O
SIADH I-Effect
was O
strongly O
suspected I-Adverse_event.Trigger
secondary O
to O
Tegretol I-Treatment.Drug
therapy O
to O
control O
a I-Subject
seizure I-Treat_Disorder
disorder I-Subject
. O

However O
, O
cyclosporine I-Treatment.Drug
dependency I-Treatment
is O
associated I-Adverse_event.Trigger
with O
the O
risk O
of O
nephrotoxicity I-Effect
. O

The O
observations O
suggest O
that O
testicular I-Effect
swelling I-Effect
and I-Effect
pain I-Effect
are O
side I-Adverse_event.Trigger
effects I-Adverse_event.Trigger
of O
desipramine I-Treatment.Drug
. O

METHOD O
: O
We O
describe O
three O
case O
- O
reports O
concerning O
haematological I-Effect
adverse I-Effect
effects I-Effect
of O
quetiapine I-Treatment.Drug
. O

Typically O
, O
drug I-Effect
- I-Effect
induced I-Effect
neutropenia I-Effect
occurs I-Adverse_event.Trigger
in O
a I-Subject
patient I-Subject
receiving O
a I-Treatment
semisynthetic I-Treatment.Drug
penicillin I-Treatment.Drug
for I-Treatment
two I-Treatment.Duration
weeks I-Treatment.Duration
or I-Treatment
more I-Treatment
. O

Peripheral I-Effect
nerve I-Effect
dysfunction I-Effect
is O
a O
potentially O
serious O
complication O
of I-Adverse_event.Trigger
high I-Dosage
- I-Dosage
dose I-Dosage
cytosine I-Treatment.Drug
arabinoside I-Treatment.Drug
. O

Tumor I-Effect
- I-Effect
volume I-Effect
increase I-Effect
at O
beginning I-Time_elapsed
of O
primary I-Treatment
treatment I-Treatment
with I-Treatment
topical I-Treatment.Route
interferon I-Treatment.Drug
alpha I-Treatment.Drug
2 I-Treatment.Drug
- I-Treatment.Drug
beta I-Treatment.Drug
in O
a I-Subject
case I-Subject
of I-Subject
conjunctiva I-Treat_Disorder
- I-Treat_Disorder
cornea I-Treat_Disorder
intraepithelial I-Treat_Disorder
neoplasia I-Treat_Disorder
. O

L I-Treatment.Drug
- I-Treatment.Drug
asparaginase I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
posterior I-Effect
reversible I-Effect
encephalopathy I-Effect
syndrome I-Effect
during O
acute I-Treat_Disorder
lymphoblastic I-Treat_Disorder
leukemia I-Treat_Disorder
treatment O
in O
children I-Subject.Age
. O

On O
the O
other O
hand O
, O
MTX I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
pneumonitis I-Effect
seems O
to O
be O
very O
rare O
in O
psoriatic O
arthritis O
( O
PsA O
) O
. O

Ototoxicity I-Effect
as O
a O
result I-Adverse_event.Trigger
of O
cis I-Treatment.Drug
- I-Treatment.Drug
platinum I-Treatment.Drug
administration I-Treatment
is O
well O
documented O
. O

Massive I-Effect
subfascial I-Effect
hematoma I-Effect
after I-Adverse_event.Trigger
alteplase I-Treatment.Drug
therapy I-Treatment
for O
acute I-Treat_Disorder
myocardial I-Treat_Disorder
infarction I-Treat_Disorder
. O

We O
suggest O
that O
itraconazole I-Treatment.Drug
should O
be O
added O
to O
the O
list O
of O
drugs O
that O
may O
be O
responsible I-Adverse_event.Trigger
for O
a O
drug I-Effect
- I-Effect
induced I-Effect
vanishing I-Effect
bile I-Effect
duct I-Effect
syndrome I-Effect
. O

A I-Subject
67 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
man I-Subject.Gender
receiving O
a O
stable O
maintenance O
dosage O
of O
warfarin I-Treatment.Drug
experienced I-Adverse_event.Trigger
an O
increased I-Effect
international I-Effect
normalized I-Effect
ratio I-Effect
( I-Effect
INR I-Effect
) I-Effect
without O
bleeding O
when O
his O
atorvastatin O
therapy O
was O
switched O
to O
fluvastatin O
. O

A O
67 O
- O
year O
- O
old O
man O
receiving O
a O
stable O
maintenance O
dosage O
of O
warfarin O
experienced O
an O
increased O
international O
normalized O
ratio O
( O
INR O
) O
without O
bleeding I-Treat_Disorder
when O
his O
atorvastatin I-Treatment.Drug
therapy I-Treatment
was I-Treatment
switched I-Treatment
to I-Treatment
fluvastatin I-Treatment.Drug
. O

The O
cases O
of O
CBZ I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
SLE I-Effect
reported O
in O
the O
literature O
were O
reviewed O
. O

Ciprofloxacin I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
hemorrhagic I-Effect
vasculitis I-Effect
. O

INTERPRETATION O
: O
When O
high I-Treatment.Dosage
doses I-Treatment.Dosage
of I-Treatment
fluticasone I-Treatment.Drug
propionate I-Treatment.Drug
are O
used O
, O
growth I-Effect
may I-Effect
be I-Effect
retarded I-Effect
and I-Effect
adrenal I-Effect
suppression I-Effect
may O
occur I-Adverse_event.Trigger
. O

To O
our O
knowledge O
, O
this O
is O
the O
first O
report O
of O
significant O
hypotension I-Effect
associated I-Adverse_event.Trigger
with O
intravenous I-Treatment.Route
valproate I-Treatment.Drug
in O
the O
treatment O
of O
status I-Treat_Disorder
epilepticus I-Treat_Disorder
in O
the O
pediatric I-Subject.Age
population I-Subject
. O

While O
undergoing O
treatment O
with O
albendazole I-Treatment.Drug
, O
he I-Subject.Gender
developed I-Adverse_event.Trigger
worsening I-Effect
diarrhea I-Effect
with I-Effect
abdominal I-Effect
pain I-Effect
and I-Effect
fever I-Effect
. O

Linezolid I-Treatment.Drug
- O
associated I-Adverse_event.Trigger
peripheral I-Effect
and I-Effect
optic I-Effect
neuropathy I-Effect
, I-Effect
lactic I-Effect
acidosis I-Effect
, I-Effect
and I-Effect
serotonin I-Effect
syndrome I-Effect
. I-Effect

Bone I-Effect
marrow I-Effect
aplasia I-Effect
and I-Effect
severe I-Effect
skin I-Effect
rash I-Effect
after I-Adverse_event.Trigger
a I-Treatment
single I-Treatment.Dosage
low I-Treatment.Dosage
dose I-Treatment.Dosage
of I-Treatment
methotrexate I-Treatment.Drug
. O

A I-Subject
woman I-Subject.Gender
38 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
, I-Subject
suffering I-Subject
for I-Subject
about I-Subject
ten I-Subject
years I-Subject
from I-Subject
multiple I-Treat_Disorder
sclerosis I-Treat_Disorder
and O
treated O
with O
repeated I-Treatment.Freq
therapy I-Treatment
cycles I-Treatment
of I-Treatment
intrathecal I-Treatment.Route
Depo I-Treatment.Drug
- I-Treatment.Drug
Medrol I-Treatment.Drug
, O
developed I-Adverse_event.Trigger
a I-Effect
spastic I-Effect
paraparesis I-Effect
at I-Effect
the I-Effect
lower I-Effect
limbs I-Effect
. O

The O
efficacy O
of O
single I-Dosage
- I-Dosage
dose I-Dosage
disulfiram I-Drug
as O
an O
inhibitor O
of O
human O
P450 O
2E1 O
suggests O
that O
this O
modality O
for O
manipulating O
clinical O
P450 O
2E1 O
activity O
may O
provide O
a O
useful O
probe O
for O
delineating O
P450 O
2E1 O
participation O
in O
human O
drug O
biotransformation O
or O
for O
the O
treatment O
of O
poisoning I-Effect
by I-Adverse_event.Trigger
P450 I-Treatment.Drug
2E1 I-Treatment.Drug
- I-Treatment.Drug
activated I-Treatment.Drug
toxins I-Treatment.Drug
. O

To O
develop O
information O
on O
the O
relative O
rarity O
or O
frequency O
of O
neurologic O
worsening O
with O
the O
initiation O
of O
penicillamine O
therapy O
, O
we O
conducted O
a O
retrospective O
survey O
of O
25 I-Subject.Population
additional I-Subject
patients I-Subject
with I-Subject
Wilson I-Treat_Disorder
's I-Treat_Disorder
disease I-Treat_Disorder
who O
met O
the O
criteria O
of O
presenting I-Adverse_event.Trigger
with O
neurologic I-Effect
disease I-Effect
and O
having O
been O
treated O
with O
penicillamine I-Treatment.Drug
. O

The O
authors O
present O
a O
case O
of O
t I-Effect
- I-Effect
AML I-Effect
that O
developed O
in O
a I-Subject
child I-Subject.Age
with I-Subject
metastatic I-Treat_Disorder
neuroblastoma I-Treat_Disorder
18 I-Time_elapsed
months I-Time_elapsed
after I-Adverse_event.Trigger
he O
received O
oral I-Treatment.Route
etoposide I-Treatment.Drug
, O
given O
for O
palliation O
purpose O
. O

Mechanisms O
and O
triggering O
factors O
of O
hypoglycaemia I-Effect
induced I-Adverse_event.Trigger
by O
mefloquine I-Treatment.Combination.Drug
and I-Treatment
some I-Treatment
other I-Treatment
anti I-Treatment
- I-Treatment
malarial I-Treatment
quinine I-Treatment.Combination.Drug
analogues I-Treatment.Combination.Drug
are O
discussed O
. O

Only O
nondepolarizing I-Treatment.Drug
muscle I-Treatment.Drug
relaxants I-Treatment.Drug
should O
be O
used I-Potential_therapeutic_event.Trigger
in O
patients I-Subject
who I-Subject
are I-Subject
at I-Subject
risk I-Subject
for I-Subject
mucositis I-Subject.Sub_Disorder
. O

CONCLUSION O
: O
A O
possible O
pharmacokinetic O
interaction O
between O
Dantrolene I-Combination.Drug
and O
Oxybutynin I-Combination.Drug
should O
be O
borne O
in O
mind O
when O
considering O
Carbamazepine I-Treatment.Drug
medication I-Treatment
for O
a I-Subject
patient I-Subject
with O
a I-Treat_Disorder
spinal I-Treat_Disorder
cord I-Treat_Disorder
lesion I-Treat_Disorder
. O

We O
describe O
a I-Subject
15 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
female I-Subject.Gender
patient I-Subject
diagnosed I-Subject
with I-Subject
acute I-Treat_Disorder
lymphoblastic I-Treat_Disorder
leukemia I-Treat_Disorder
presenting I-Effect
with I-Effect
status I-Effect
epilepticus I-Effect
after I-Adverse_event.Trigger
receiving I-Treatment
intrathecal I-Treatment.Route
methotrexate I-Treatment.Drug
. O

Duodenal I-Effect
ulceration I-Effect
: O
a O
complication I-Adverse_event.Trigger
of O
tolazoline I-Treatment.Drug
therapy O
. O

Hepatic I-Effect
damage I-Effect
after I-Adverse_event.Trigger
danazol I-Treatment.Drug
treatment O
. O

Hepato I-Effect
- I-Effect
biliary I-Effect
abnormalities I-Effect
secondary I-Adverse_event.Trigger
to I-Adverse_event.Trigger
ceftriaxone I-Treatment.Drug
use I-Treatment
: O
a O
case O
report O
. O

Rhabdomyolysis I-Effect
with I-Adverse_event.Trigger
concurrent O
atorvastatin I-Treatment.Combination.Drug
and O
diltiazem I-Treatment.Combination.Drug
. O

Case O
report O
: O
mannitol I-Treatment.Drug
nephrotoxicity I-Effect
syndrome I-Adverse_event.Trigger
: O
role O
of O
hemodialysis O
and O
postulate O
of O
mechanisms O
. O

Uveitis I-Effect
during I-Adverse_event.Trigger
treatment O
of O
disseminated I-Treat_Disorder
Mycobacterium I-Treat_Disorder
avium I-Treat_Disorder
- I-Treat_Disorder
intracellulare I-Treat_Disorder
complex I-Treat_Disorder
infection I-Treat_Disorder
with O
the O
combination I-Treatment
of I-Treatment
rifabutin I-Treatment.Combination.Drug
, I-Treatment
clarithromycin I-Treatment.Combination.Drug
and I-Treatment
ethambutol I-Treatment.Combination.Drug
. O

The O
visual I-Effect
loss I-Effect
in O
this O
patient I-Subject
seems O
to O
result I-Adverse_event.Trigger
from O
phenol I-Treatment.Drug
neurotoxicity I-Effect
rather O
than O
mechanical O
compression O
of O
the O
intraorbital O
optic O
nerve O
. O

Polysomnographic O
and O
pharmacokinetic O
findings O
in O
levodopa I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
augmentation I-Effect
of I-Effect
restless I-Effect
legs I-Effect
syndrome I-Effect
. O

These I-Subject
cases I-Subject
highlight O
the O
occurrence O
of O
livedo I-Effect
reticularis I-Effect
as O
an O
uncommon O
side I-Adverse_event.Trigger
- I-Adverse_event.Trigger
effect I-Adverse_event.Trigger
of O
interferon I-Treatment.Drug
alpha I-Treatment.Drug
treatment O
. O

So O
far O
, O
few O
cases O
of O
pulmonary I-Effect
side I-Effect
effects I-Effect
caused I-Adverse_event.Trigger
by O
ticlopidine I-Treatment.Drug
have O
been O
reported O
. O

Abnormal I-Effect
dexamethasone I-Effect
suppression I-Effect
tests I-Effect
in O
a O
rifampicin I-Treatment.Drug
- O
treated O
patient I-Subject
with I-Subject
suspected I-Subject
Cushing I-Treat_Disorder
's I-Treat_Disorder
syndrome I-Treat_Disorder
. O

Gemcitabine I-Treatment.Drug
therapy O
has O
been O
associated I-Adverse_event.Trigger
with O
radiation I-Effect
recall I-Effect
reactions I-Effect
when O
used O
in O
the O
treatment O
of O
carcinoma I-Treat_Disorder
. O

Increased I-Effect
lash I-Effect
length I-Effect
, I-Effect
thickness I-Effect
, I-Effect
and I-Effect
pigmentation I-Effect
are I-Adverse_event.Trigger
well O
- O
documented O
side O
effects O
of O
prostaglandin I-Treatment.Drug
analog I-Treatment.Drug
glaucoma I-Treatment.Treat_Disorder
drops I-Treatment.Route
. O

Bullous I-Effect
Eruption I-Effect
Associated I-Adverse_event.Trigger
With O
Dihydropyridines I-Treatment.Drug
With O
Cross O
Reactivity O
. O

Ritonavir I-Treatment.Drug
acted I-Adverse_event.Trigger
as O
a O
CYP3A4 I-Effect
inhibitor I-Effect
, I-Effect
diminishing I-Effect
carbamazepine I-Effect
metabolism I-Effect
and I-Effect
provoking I-Effect
an I-Effect
increase I-Effect
in I-Effect
serum I-Effect
levels I-Effect
and I-Effect
clinical I-Effect
toxicity I-Effect
. O

Acute I-Effect
generalized I-Effect
exanthematous I-Effect
pustulosis I-Effect
induced I-Adverse_event.Trigger
by O
nimesulide I-Treatment.Drug
. O

Quinine I-Treatment.Drug
induced I-Adverse_event.Trigger
coagulopathy I-Effect
-- I-Effect
a I-Effect
near I-Effect
fatal I-Effect
experience I-Effect
. O

A I-Subject
58 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
man I-Subject.Gender
with I-Subject
rheumatoid I-Treat_Disorder
arthritis I-Treat_Disorder
developed I-Adverse_event.Trigger
lichen I-Effect
planus I-Effect
during I-Effect
treatment I-Treatment
with I-Treatment
gold I-Treatment.Drug
. O

Atenolol I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
pseudolymphoma I-Effect
. O

First O
case O
report O
of O
suspected O
onset O
of O
convulsive I-Effect
seizures I-Effect
due I-Adverse_event.Trigger
to O
co I-Treatment
- I-Treatment
administration I-Treatment
of I-Treatment
valproic I-Treatment.Combination.Drug
acid I-Treatment.Combination.Drug
and I-Treatment
tebipenem I-Treatment.Combination.Drug
. O

Fluoxetine I-Treatment.Drug
- O
related I-Adverse_event.Trigger
death I-Effect
in O
a O
child I-Subject.Age
with I-Subject
cytochrome I-Subject.Sub_Disorder
P I-Subject.Sub_Disorder
- I-Subject.Sub_Disorder
450 I-Subject.Sub_Disorder
2D6 I-Subject.Sub_Disorder
genetic I-Subject.Sub_Disorder
deficiency I-Subject.Sub_Disorder
. O

Aplastic I-Effect
anemia I-Effect
and I-Effect
agranulocytosis I-Effect
in I-Adverse_event.Trigger
patients I-Subject
using O
methazolamide I-Treatment.Drug
for O
glaucoma I-Treat_Disorder
. O

We O
report O
a I-Subject.Population
44 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
woman I-Subject.Gender
with O
t I-Effect
- I-Effect
MDS I-Effect
( I-Effect
refractory I-Effect
anemia I-Effect
with I-Effect
excess I-Effect
blasts I-Effect
) I-Effect
following I-Adverse_event.Trigger
treatment I-Treatment
of I-Treatment
recurrent I-Treatment.Treat_Disorder
anaplastic I-Treatment.Treat_Disorder
astrocytoma I-Treatment.Treat_Disorder
with I-Treatment
temozolomide I-Treatment.Drug
( I-Treatment
TMZ I-Treatment
) I-Treatment
. O

An I-Subject
infant I-Subject.Age
who O
developed O
pancreatitis I-Effect
during O
meglumine O
antimoniate O
treatment O
for O
visceral O
leishmaniasis O
and O
who O
was O
successfully O
treated I-Adverse_event.Trigger
with O
a I-Treatment
combination I-Treatment
of I-Treatment
allopurinol I-Treatment.Combination.Drug
and I-Treatment
ketoconazole I-Treatment.Combination.Drug
is O
reported O
. O

L O
- O
Carnitine O
supplementation O
has O
been O
recommended O
to O
prevent O
the O
fatal O
hepatotoxic I-Effect
effects I-Effect
associated I-Adverse_event.Trigger
with O
valproic I-Treatment.Drug
acid I-Treatment.Drug
. O

L I-Treatment.Drug
- I-Treatment.Drug
Carnitine I-Treatment.Drug
supplementation O
has O
been O
recommended I-Potential_therapeutic_event.Trigger
to O
prevent O
the O
fatal I-Treat_Disorder
hepatotoxic I-Treat_Disorder
effects I-Treat_Disorder
associated O
with O
valproic O
acid O
. O

The O
purpose O
of O
this O
study O
was O
to O
examine O
the O
incidence O
and O
cause O
of O
Clostridium I-Effect
difficile I-Effect
colitis I-Effect
occurring I-Adverse_event.Trigger
after O
cisplatin I-Treatment.Drug
- I-Treatment
based I-Treatment
combination I-Treatment
chemotherapy I-Treatment.Route
in O
ovarian I-Treat_Disorder
cancer I-Treat_Disorder
patients I-Subject
. O

Cerebral I-Effect
demyelinating I-Effect
disease I-Effect
developed O
in O
a I-Subject
patient I-Subject
during I-Adverse_event.Trigger
adjuvant I-Treatment
therapy I-Treatment
with I-Treatment
levamisole I-Treatment.Drug
for O
malignant I-Treat_Disorder
melanoma I-Treat_Disorder
. O

Amoxapine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
cognitive I-Effect
impairment I-Effect
in O
two I-Subject.Population
patients I-Subject
. O

Granisetron I-Treatment.Combination.Drug
hydrochloride I-Treatment.Combination.Drug
( I-Treatment
3 I-Treatment.Dosage
mg I-Treatment.Dosage
on I-Treatment.Freq
days I-Treatment.Freq
1 I-Treatment.Freq
, I-Treatment.Freq
8 I-Treatment.Freq
, I-Treatment.Freq
and I-Treatment.Freq
15 I-Treatment.Freq
) I-Treatment
and I-Treatment
dexamethasone I-Treatment.Combination.Drug
( I-Treatment
13.2 I-Treatment.Dosage
mg I-Treatment.Dosage
on I-Treatment.Freq
day I-Treatment.Freq
1 I-Treatment.Freq
and I-Treatment
6.6 I-Treatment.Dosage
mg I-Treatment.Dosage
on I-Treatment.Freq
days I-Treatment.Freq
2 I-Treatment.Freq
, I-Treatment.Freq
3 I-Treatment.Freq
, I-Treatment.Freq
8 I-Treatment.Freq
, I-Treatment.Freq
and I-Treatment.Freq
15 I-Treatment.Freq
) I-Treatment
were O
used I-Potential_therapeutic_event.Trigger
prior O
to O
irinotecan I-Treatment
administration O
in O
both I-Subject
patients I-Subject
. O

Visceral I-Effect
herpesvirus I-Effect
infections I-Effect
in I-Adverse_event.Trigger
leukemic I-Treat_Disorder
patients I-Subject
receiving O
cytarabine I-Treatment.Drug
. I-Drug

Although O
a O
few O
case O
reports O
link O
metronidazole I-Treatment.Drug
with O
the O
development I-Adverse_event.Trigger
of O
pseudomembranous I-Effect
colitis I-Effect
, O
albendazole O
has O
not O
been O
associated O
with O
the O
development O
of O
this O
condition O
. O

CONCLUSION O
: O
Oral I-Effect
mucositis I-Effect
is O
a O
frequent O
and O
potentially O
severe O
complication I-Adverse_event.Trigger
of O
cancer I-Treatment.Treat_Disorder
chemotherapy I-Treatment.Route
. O

One I-Subject
case I-Subject
of O
priapism I-Effect
occurred I-Adverse_event.Trigger
during I-Treatment
heparin I-Treatment.Drug
therapy I-Treatment
for O
a O
previous O
surgical I-Treat_Disorder
operation I-Treat_Disorder
to I-Treat_Disorder
the I-Treat_Disorder
knee I-Treat_Disorder
is O
reported O
. O

While O
both O
amiodarone I-Treatment.Combination.Drug
and I-Treatment
digoxin I-Treatment.Combination.Drug
can O
cause I-Adverse_event.Trigger
permanent I-Effect
visual I-Effect
changes I-Effect
, O
the O
ocular O
effects O
are O
often O
reversible O
. O

AIM O
: O
Report O
of O
a O
case O
of O
a I-Subject
woman I-Subject.Gender
patient I-Subject
who O
developed I-Adverse_event.Trigger
celiac I-Effect
disease I-Effect
after O
pegylated I-Treatment.Combination.Drug
interferon I-Treatment.Combination.Drug
alpha I-Treatment.Combination.Drug
- I-Treatment.Combination.Drug
2a I-Treatment.Combination.Drug
and I-Treatment
ribavirin I-Treatment.Combination.Drug
use I-Treatment
for I-Treatment
chronic I-Treatment.Treat_Disorder
hepatitis I-Treatment.Treat_Disorder
C. I-Treatment.Treat_Disorder

Differential O
diagnoses O
included O
ocular O
rosacea O
with O
cicatrizing O
conjunctivitis O
and O
5 I-Treatment.Drug
- I-Treatment.Drug
FU I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
ectropion I-Effect
. O

In I-Subject
rare I-Subject
cases I-Subject
mitomycin I-Treatment.Drug
C I-Treatment.Drug
( I-Treatment
MMC I-Treatment
) I-Treatment
may O
induce I-Adverse_event.Trigger
cancer I-Effect
- I-Effect
associated I-Effect
hemolytic I-Effect
uremic I-Effect
syndrome I-Effect
, O
which O
is O
characterized O
by O
hemolytic I-Effect
anemia I-Effect
, I-Effect
thrombocytopenia I-Effect
and I-Effect
progressive I-Effect
renal I-Effect
failure I-Effect
. O

Hemolytic I-Effect
uremic I-Effect
syndrome I-Effect
following I-Adverse_event.Trigger
the O
infusion O
of O
oxaliplatin I-Treatment.Drug
: O
case O
report O
. O

Tacrolimus I-Treatment.Drug
( I-Treatment
FK506) I-Treatment
- O
induced I-Adverse_event.Trigger
mutism I-Effect
after O
liver O
transplant O
. O

Though O
proteinuria I-Effect
and I-Effect
nephrotic I-Effect
syndrome I-Effect
is O
a O
rare O
adverse I-Adverse_event.Trigger
effect I-Adverse_event.Trigger
of O
IFN I-Treatment.Drug
- I-Treatment.Drug
beta I-Treatment.Drug
- I-Treatment.Drug
1b I-Treatment.Drug
therapy O
, O
physicians O
treating O
MS I-Treat_Disorder
patients I-Subject
with O
this O
agent O
should O
pay O
careful O
attention O
to O
new O
clinical O
symptoms O
and O
laboratory O
findings O
. O

It O
is O
suggested O
that O
the O
patient O
had O
sulfasalazine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
lupus I-Effect
, I-Effect
which I-Effect
manifested I-Effect
with I-Effect
serositis I-Effect
and I-Effect
pulmonary I-Effect
parenchymal I-Effect
involvement I-Effect
in I-Effect
the I-Effect
absence I-Effect
of I-Effect
joint I-Effect
symptoms I-Effect
. O

By O
means O
of O
the O
in O
vitro O
heparin O
- O
induced O
platelet O
activation O
( O
HIPA O
) O
assay O
it O
was O
shown O
that O
standard I-Treatment
heparin I-Treatment
and I-Treatment
the I-Treatment
LMW I-Treatment
heparins I-Treatment
Fragmin I-Treatment.Drug
and I-Treatment
Fraxiparin I-Treatment.Drug
( I-Treatment
Sanofi I-Treatment
Labaz I-Treatment
, I-Treatment
Munich I-Treatment
, I-Treatment
FRG I-Treatment
) I-Treatment
, I-Treatment
as I-Treatment
well I-Treatment
as I-Treatment
the I-Treatment
enoxaparine I-Treatment
Clexane I-Treatment.Drug
( I-Treatment
Nattermann I-Treatment
, I-Treatment
Cologne I-Treatment
, I-Treatment
FRG I-Treatment
) I-Treatment
, O
all O
induced I-Adverse_event.Trigger
platelet I-Effect
activation I-Effect
with O
the O
patient O
's O
serum O
. O

DISCUSSION O
: O
This I-Subject
case I-Subject
shows O
that O
switching O
to O
zidovudine I-Treatment.Drug
potentially O
can O
lead I-Adverse_event.Trigger
to O
a O
hyperlactatemia I-Effect
relapse I-Effect
. O

Acute I-Effect
leukaemia I-Effect
during I-Adverse_event.Trigger
tamoxifen I-Treatment.Drug
therapy I-Treatment
. O

Heparin I-Treatment.Drug
- O
associated I-Adverse_event.Trigger
thrombocytopenia I-Effect
: O
successful O
therapy O
with O
the O
heparinoid O
Org O
10172 O
in O
a I-Subject
patient I-Subject
showing O
cross O
- O
reaction O
to O
LMW O
heparins O
. O

A I-Subject
patient I-Subject
presented I-Adverse_event.Trigger
with O
a O
painful I-Effect
, I-Effect
oedematous I-Effect
, I-Effect
cyanosed I-Effect
hand I-Effect
having O
injected I-Treatment.Route
a I-Treatment
solution I-Treatment
of I-Treatment
diamorphine I-Treatment.Combination.Drug
and I-Treatment
methylphenidate I-Treatment.Combination.Drug
into I-Treatment.Route
his I-Treatment.Route
radial I-Treatment.Route
artery I-Treatment.Route
. O

We O
conclude O
that O
vincristine I-Treatment.Combination.Drug
and I-Treatment
actinomycin I-Treatment.Combination.Drug
D I-Treatment.Combination.Drug
were O
the O
cause I-Adverse_event.Trigger
of O
this O
rare O
from O
of O
hepatotoxicity I-Effect
and O
that O
chemotherapy O
for O
the O
underlying O
malignant O
disease O
could O
be O
given O
safely O
after O
clinical O
recovery O
. O

Pure I-Effect
red I-Effect
cell I-Effect
aplasia I-Effect
associated I-Adverse_event.Trigger
with O
fenoprofen I-Treatment.Drug
. O

A I-Subject
56 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
white I-Subject.Race
woman I-Subject.Gender
with I-Subject
a I-Subject
diagnosis I-Subject
of I-Subject
reactive I-Treat_Disorder
depression I-Treat_Disorder
developed O
severe I-Effect
UI I-Effect
after I-Adverse_event.Trigger
a O
30 I-Treatment.Time_elapsed
days I-Treatment.Time_elapsed
' I-Treatment
treatment I-Treatment
with I-Treatment
venlafaxine I-Treatment.Drug
75 I-Treatment.Dosage
mg I-Treatment.Dosage
/ I-Treatment.Dosage
day I-Treatment.Dosage
. I-Treatment

PATIENTS O
: O
Three I-Subject.Population
patients I-Subject
developed I-Adverse_event.Trigger
a O
reproductive I-Effect
endocrine I-Effect
disorder I-Effect
during O
treatment O
with O
valproate I-Treatment.Drug
. O

OBJECTIVE O
: O
To O
report O
a O
case O
of O
marked I-Effect
elevation I-Effect
of I-Effect
serum I-Effect
creatine I-Effect
kinase I-Effect
( O
CK O
) O
associated I-Adverse_event.Trigger
with O
olanzapine I-Treatment.Drug
therapy O
. O

Severe I-Effect
C. I-Effect
difficile I-Effect
colitis I-Effect
occurred I-Adverse_event.Trigger
in O
2 I-Subject.Population
patients I-Subject
( I-Subject.Population
6.1 I-Subject.Population
% I-Subject.Population
) I-Subject.Population
after O
receiving O
cisplatin I-Treatment.Drug
- I-Treatment
based I-Treatment
combination I-Treatment
chemotherapy I-Treatment.Route
for O
ovarian I-Treat_Disorder
malignancies I-Treat_Disorder
. O

A I-Subject
56 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
woman I-Subject.Gender
with I-Subject
scleroderma I-Treat_Disorder
developed I-Adverse_event.Trigger
rapidly I-Effect
progressive I-Effect
glomerulonephritis I-Effect
with I-Effect
epithelial I-Effect
crescents I-Effect
associated I-Effect
with I-Effect
hemoptysis I-Effect
after O
27 I-Treatment.Time_elapsed
months I-Treatment.Time_elapsed
of I-Treatment
D I-Treatment.Drug
- I-Treatment.Drug
penicillamine I-Treatment.Drug
therapy I-Treatment
and I-Treatment
a I-Treatment
cumulative I-Treatment
dose I-Treatment
of I-Treatment
1,200 I-Treatment.Dosage
g. I-Treatment.Dosage

High I-Treatment.Dosage
- I-Treatment.Dosage
dose I-Treatment.Dosage
phosphate I-Treatment.Drug
treatment O
leads I-Adverse_event.Trigger
to O
hypokalemia I-Effect
in O
hypophosphatemic I-Treat_Disorder
osteomalacia I-Treat_Disorder
. O

We O
report O
a I-Subject
patient I-Subject
who O
developed O
heparin I-Treatment.Drug
associated I-Effect
thrombocytopenia I-Effect
during I-Adverse_event.Trigger
continuous I-Treatment
arteriovenous I-Treatment
haemofiltration I-Treatment
and O
discuss O
its O
implications O
and O
alternative O
anticoagulant O
treatment O
. O

We O
describe O
a O
detailed O
case O
of O
fulminant I-Effect
hepatitis I-Effect
induced I-Adverse_event.Trigger
by O
nevirapine I-Treatment.Drug
( O
Viramune O
) O
and O
treated O
by O
liver O
transplantation O
. O

The O
literature O
is O
also O
reviewed O
for O
ARF I-Effect
associated I-Adverse_event.Trigger
with O
mannitol I-Treatment.Drug
infusion I-Treatment.Route
in O
patients I-Subject
who O
received O
dialysis O
and O
those O
who O
did O
not O
receive O
dialysis O
; O
and O
the O
possible O
mechanism(s O
) O
of O
mannitol O
nephrotoxicity O
are O
discussed O
. O

In O
this O
case O
report O
, O
we O
present O
clinical O
and O
laboratory O
findings O
of O
a I-Subject.Population
case I-Subject
with I-Subject
chronic I-Treat_Disorder
hepatitis I-Treat_Disorder
B I-Treat_Disorder
that O
developed O
acute I-Effect
dystonia I-Effect
soon O
after I-Adverse_event.Trigger
the I-Treatment
first I-Treatment.Dosage
dose I-Treatment.Dosage
of I-Treatment
pegylated I-Treatment.Drug
interferon I-Treatment.Drug
alpha I-Treatment.Drug
. I-Treatment

Trichiasis I-Effect
associated I-Adverse_event.Trigger
with O
prostaglandin I-Treatment.Drug
analog I-Treatment.Drug
use O
. O

The O
possible O
development I-Adverse_event.Trigger
of O
a O
drug I-Effect
- I-Effect
induced I-Effect
vasculitis I-Effect
or I-Effect
lupus I-Effect
- I-Effect
like I-Effect
syndrome I-Effect
should O
be O
added O
to O
the O
list O
of O
rare O
toxic O
effects O
of O
vancomycin I-Treatment.Drug
. O

Healthcare O
professionals O
should O
be O
aware O
of O
the O
possible O
development I-Adverse_event.Trigger
of O
serotonin I-Effect
syndrome I-Effect
as O
a O
complication O
of O
initiation O
of O
fentanyl I-Treatment.Combination.Drug
and I-Treatment
other I-Treatment
phenylpiperidine I-Treatment.Combination.Drug
opioids I-Treatment.Combination.Drug
in O
patients I-Subject
treated I-Treatment
with I-Treatment
SSRIs I-Treatment.Combination.Drug
. O

Acute I-Effect
myocardial I-Effect
ischemia I-Effect
following I-Adverse_event.Trigger
accidental I-Treatment
intravenous I-Treatment.Route
administration I-Treatment.Route
of I-Treatment
epinephrine I-Treatment.Drug
in I-Treatment
high I-Treatment.Dosage
concentration I-Treatment.Dosage
. O

Bromide I-Effect
intoxication I-Effect
secondary I-Adverse_event.Trigger
to O
pyridostigmine I-Treatment.Drug
bromide I-Treatment.Drug
therapy O
. O

We O
have O
recently O
encountered O
a O
patient I-Subject
with I-Subject
acquired I-Treat_Disorder
haemophilia I-Treat_Disorder
who I-Subject
developed I-Subject
a I-Subject
thrombotic I-Effect
left I-Effect
middle I-Effect
cerebral I-Effect
artery I-Effect
distribution I-Effect
stroke I-Effect
while O
being O
treated I-Adverse_event.Trigger
with O
pFVIII I-Treatment.Drug
. O

We O
present O
a O
case O
of O
serotonin I-Effect
syndrome I-Effect
, O
which O
was O
precipitated I-Adverse_event.Trigger
by O
this O
medicine O
in O
a I-Subject
patient I-Subject
who O
had O
been O
predisposed O
by O
long I-Treatment.Time_elapsed
- I-Treatment.Time_elapsed
term I-Treatment.Time_elapsed
treatment I-Treatment
with I-Treatment
sertraline I-Treatment.Drug
, O
a O
selective O
serotonin O
reuptake O
inhibitor O
. O

Of O
the O
15 I-Subject.Population
patients I-Subject
treated O
with O
tizanidine I-Treatment.Combination.Drug
and I-Treatment
mexiletine I-Treatment.Combination.Drug
, O
4 I-Subject
suffered O
tizanidine I-Drug
- O
induced I-Adverse_event.Trigger
adverse O
effects O
such O
as O
drowsiness I-Effect
and I-Effect
dry I-Effect
mouth I-Effect
in O
the O
retrospective O
survey O
. O

Type I-Effect
I I-Effect
second I-Effect
- I-Effect
degree I-Effect
AV I-Effect
block I-Effect
( I-Effect
Mobitz I-Effect
type I-Effect
I I-Effect
, I-Effect
Wenckebach I-Effect
AV I-Effect
block I-Effect
) I-Effect
during I-Adverse_event.Trigger
ritodrine I-Treatment.Drug
therapy O
for O
preterm I-Treat_Disorder
labor I-Treat_Disorder
. O

After O
other O
potential O
causes O
of O
liver O
toxicity O
were O
excluded O
, O
TMP I-Treatment.Combination.Drug
- I-Treatment
SMX I-Treatment.Combination.Drug
was O
determined I-Adverse_event.Trigger
to O
be O
the O
cause O
of O
his O
acute I-Effect
liver I-Effect
toxicity I-Effect
. O

One I-Subject.Population
of I-Subject
the I-Subject
patients I-Subject
had I-Adverse_event.Trigger
a O
dexamethasone I-Treatment.Drug
dependent O
brain I-Treat_Disorder
metastatic I-Treat_Disorder
condition I-Treat_Disorder
. O

Biomicroscopy I-Treatment.Drug
revealed I-Adverse_event.Trigger
amiodarone I-Effect
corneal I-Effect
deposits I-Effect
. O

This O
case O
and O
a O
review O
of O
the O
literature O
show O
the O
severe O
and O
unpredictable I-Adverse_event.Trigger
nature O
of O
ethambutol I-Treatment.Drug
toxicity O
and O
its O
potential O
for O
irreversible I-Effect
vision I-Effect
loss I-Effect
despite O
careful O
ophthalmologic O
monitoring O
. O

Recently O
, O
some O
studies O
have O
also O
reported O
association I-Adverse_event.Trigger
between O
patients I-Subject
with I-Subject
juvenile I-Treat_Disorder
rheumatoid I-Treat_Disorder
arthritis I-Treat_Disorder
( I-Subject
JRA I-Subject
) O
treated O
with O
Methotrexate I-Treatment.Drug
( I-Treatment
MTX I-Treatment
) I-Treatment
and O
malignant I-Effect
lymphoma I-Effect
developing O
. O

The I-Subject
two I-Subject.Population
middle I-Subject.Age
aged I-Subject.Age
women I-Subject.Gender
presented I-Adverse_event.Trigger
with O
respiratory I-Effect
symptoms I-Effect
after O
prolonged I-Treatment.Freq
treatment I-Treatment.Freq
with I-Treatment
nitrofurantoin I-Treatment.Drug
. O

OBJECTIVE O
: O
1 O
) O
To O
describe O
a I-Subject
patient I-Subject
with I-Subject
rheumatoid I-Subject.Sub_Disorder
arthritis I-Subject.Sub_Disorder
receiving O
adalimumab I-Treatment.Drug
who O
developed I-Adverse_event.Trigger
fever I-Effect
, I-Effect
pancytopenia I-Effect
, I-Effect
splenomegaly I-Effect
, I-Effect
and I-Effect
extreme I-Effect
hyperferritinemia I-Effect
. O

Visual I-Effect
hallucinations I-Effect
associated I-Adverse_event.Trigger
with I-Adverse_event.Trigger
zonisamide I-Treatment.Drug
. O

Milk I-Effect
- I-Effect
alkali I-Effect
syndrome I-Effect
induced I-Adverse_event.Trigger
by O
1,25(OH)2D I-Treatment.Drug
in O
a I-Subject
patient I-Subject
with I-Subject
hypoparathyroidism I-Treat_Disorder
. I-Subject

We O
report O
the O
case O
of O
a I-Subject
female I-Subject.Gender
acromegalic I-Subject.Sub_Disorder
patient I-Subject
in O
whom O
multiple O
hepatic I-Effect
adenomas I-Effect
appeared I-Adverse_event.Trigger
soon O
after O
danazol I-Treatment.Drug
treatment I-Treatment
for O
uterine I-Treat_Disorder
fibromatosis I-Treat_Disorder
. I-Treat_Disorder

Carbamazepine I-Combination.Drug
toxicity I-Effect
induced I-Adverse_event.Trigger
by O
clarithromycin I-Treatment.Combination.Drug
coadministration O
in O
psychiatric I-Subject.Sub_Disorder
patients I-Subject
. O

Thrombolytic O
therapy O
with O
tissue I-Treatment.Drug
plasminogen I-Treatment.Drug
activator I-Treatment.Drug
( O
tPA O
) O
for O
acute I-Treat_Disorder
myocardial I-Treat_Disorder
infarction I-Treat_Disorder
may O
result I-Adverse_event.Trigger
in O
major O
bleeding O
complications O
such O
as O
gastrointestinal I-Effect
or I-Effect
intracranial I-Effect
bleeding I-Effect
. O

CONCLUSION O
: O
The O
hemolytic I-Effect
- I-Effect
uremic I-Effect
syndrome I-Effect
may O
be O
a O
rare O
complication I-Adverse_event.Trigger
of O
oxaliplatin I-Treatment.Drug
- I-Treatment
based I-Treatment
chemotherapy I-Treatment.Route
. O

However O
, O
recurrent O
staphylococcus I-Effect
aureus I-Effect
sepsis I-Effect
developed I-Adverse_event.Trigger
during O
CyA I-Treatment.Drug
therapy I-Treatment
. O

Nabumetone I-Treatment.Drug
- O
associated I-Adverse_event.Trigger
interstitial I-Effect
nephritis I-Effect
. O

A O
short O
review O
on O
imatinib I-Treatment.Drug
- O
related I-Adverse_event.Trigger
hepatotoxicity I-Effect
is O
also O
presented O
. O

Fatal I-Effect
interstitial I-Effect
pneumonitis I-Effect
associated I-Adverse_event.Trigger
with O
docetaxel I-Treatment.Drug
administration O
in O
a I-Subject
patient I-Subject
with I-Subject
hormone I-Treat_Disorder
- I-Treat_Disorder
refractory I-Treat_Disorder
prostate I-Treat_Disorder
cancer I-Treat_Disorder
. O

BACKGROUND O
: O
Etanercept I-Treatment.Drug
is O
a I-Treatment
tumor I-Treatment
necrosis I-Treatment
factor I-Treatment
( I-Treatment
TNF I-Treatment
) I-Treatment
inhibitor I-Treatment
that O
has O
been O
licensed I-Potential_therapeutic_event.Trigger
in O
the O
United O
States O
for O
the O
treatment O
of O
adult I-Treat_Disorder
and I-Treat_Disorder
juvenile I-Treat_Disorder
rheumatoid I-Treat_Disorder
arthritis I-Treat_Disorder
as I-Subject
well I-Subject
as I-Subject
psoriatic I-Treat_Disorder
arthritis I-Treat_Disorder
. O

Reye I-Effect
- I-Effect
like I-Effect
syndrome I-Effect
following I-Adverse_event.Trigger
treatment O
with O
the O
pantothenic O
acid O
antagonist O
, O
calcium I-Treatment.Drug
hopantenate I-Treatment.Drug
. O

Sudden I-Effect
death I-Effect
in O
an I-Subject
infant I-Subject.Age
from O
methemoglobinemia I-Effect
after I-Adverse_event.Trigger
administration O
of O
" O
sweet I-Treatment.Drug
spirits I-Treatment.Drug
of I-Treatment.Drug
nitre I-Treatment.Drug
" O
. O

FINDINGS O
: O
Six I-Subject.Population
children I-Subject.Age
with I-Subject
growth I-Treat_Disorder
retardation I-Treat_Disorder
noted O
after O
treatment O
with O
high I-Treatment.Dosage
- I-Treatment.Dosage
dose I-Treatment.Dosage
fluticasone I-Treatment.Drug
propionate I-Treatment.Drug
were O
found O
to O
have I-Adverse_event.Trigger
adrenal I-Effect
suppression I-Effect
. O

Methotrexate I-Treatment.Drug
- O
associated I-Adverse_event.Trigger
nephropathy I-Effect
is O
a O
rare O
complication O
in O
pediatric O
oncology O
, O
and O
a O
review O
of O
the O
literature O
suggests O
that O
exposure O
to O
nephrotoxic O
agents O
may O
be O
a O
significant O
but O
perhaps O
underrecognized O
risk O
factor O
for O
its O
development O
. O

Four I-Subject.Population
cases I-Subject
of O
oesophageal I-Effect
damage I-Effect
associated I-Adverse_event.Trigger
with O
ingestion I-Treatment.Route
of I-Treatment
the I-Treatment
urinary I-Treatment
anti I-Treatment
- I-Treatment
spasmodic I-Treatment
agent I-Treatment
emepronium I-Treatment.Drug
bromide I-Treatment.Drug
are O
described O
. O

A I-Subject
66 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
Japanese I-Subject.Race
woman I-Subject.Gender
with I-Subject
severe I-Treat_Disorder
scleroderma I-Treat_Disorder
developed I-Adverse_event.Trigger
anemia I-Effect
and I-Effect
thrombocytopenia I-Effect
due O
to O
D I-Treatment.Drug
- I-Treatment.Drug
penicillamine I-Treatment.Drug
( I-Treatment
D I-Treatment
- I-Treatment
Pen I-Treatment
) I-Treatment
treatment I-Treatment
, O
although O
the O
leukopenia O
was O
not O
markedly O
severe O
. O

Corticosteroid I-Treatment.Drug
injections I-Treatment.Route
are O
commonly O
used O
as O
effective O
treatments I-Potential_therapeutic_event.Trigger
for O
a O
variety O
of O
pain I-Treat_Disorder
disorders I-Treat_Disorder
. O

We O
present O
two O
cases O
of O
anaphylaxis I-Treat_Disorder
under I-Treat_Disorder
anaesthesia I-Treat_Disorder
where O
return I-Effect
of I-Effect
spontaneous I-Effect
circulation I-Effect
was O
refractory O
to O
epinephrine I-Treatment.Combination.Drug
, O
but O
occurred I-Potential_therapeutic_event.Trigger
following O
the O
administration I-Treatment
of I-Treatment
the I-Treatment
alpha I-Treatment
- I-Treatment
agonist I-Treatment
metaraminol I-Treatment.Combination.Drug
. O

A I-Subject
51 I-Subject.Age
- I-Subject.Age
yr I-Subject.Age
- I-Subject.Age
old I-Subject.Age
nonsmoking I-Subject
male I-Subject.Gender
patient I-Subject
without I-Subject
any I-Subject
history I-Subject
of I-Subject
previous I-Subject
allergies I-Subject
, I-Subject
asthma I-Subject
, I-Subject
hay I-Subject
fever I-Subject
, I-Subject
or I-Subject
urticaria I-Subject
developed I-Adverse_event.Trigger
attacks I-Effect
of I-Effect
asthma I-Effect
when O
captopril I-Treatment.Combination.Drug
was I-Treatment
added I-Treatment
to I-Treatment
the I-Treatment
nadolol I-Treatment.Combination.Drug
and I-Treatment
dyazide I-Treatment.Combination.Drug
treatment O
for O
his O
high I-Treat_Disorder
blood I-Treat_Disorder
pressure I-Treat_Disorder
. O

After I-Treatment
ticlopidine I-Treatment.Drug
was I-Treatment
discontinued I-Treatment
, O
the O
patient O
was O
rechallenged I-Treatment
with I-Treatment
the I-Treatment
same I-Treatment
dose I-Treatment
of I-Treatment
phenytoin I-Treatment.Drug
without O
symptoms O
of O
toxicity I-Effect
. O

Rhabdomyolysis I-Effect
due I-Adverse_event.Trigger
to O
an O
uncommon O
interaction I-Treatment
of I-Treatment
ciprofloxacin I-Treatment.Combination.Drug
with I-Treatment
simvastatin I-Treatment.Combination.Drug
. O

After O
receiving O
3 O
doses O
of O
ifosfamide I-Treatment.Combination.Drug
/ I-Treatment
mesna I-Treatment.Combination.Drug
, O
she I-Subject.Gender
was O
found I-Potential_therapeutic_event.Trigger
to O
be O
unresponsive I-Effect
. O

Symptomatic I-Effect
hypoglycemia I-Effect
secondary I-Adverse_event.Trigger
to I-Adverse_event.Trigger
a O
glipizide I-Treatment.Combination.Drug
- I-Treatment
trimethoprim I-Treatment.Combination.Drug
/ I-Treatment
sulfamethoxazole I-Treatment.Combination.Drug
drug I-Treatment
interaction I-Treatment
. O

A I-Subject
51 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
man I-Subject.Gender
developed I-Adverse_event.Trigger
type I-Effect
1 I-Effect
diabetes I-Effect
mellitus I-Effect
following O
24 I-Treatment.Time_elapsed
weeks I-Treatment.Time_elapsed
of I-Treatment
treatment I-Treatment
with I-Treatment
recombinant I-Treatment.Combination.Drug
alpha I-Treatment.Combination.Drug
- I-Treatment.Combination.Drug
2b I-Treatment.Combination.Drug
peginterferon I-Treatment.Combination.Drug
plus I-Treatment
ribavirin I-Treatment.Combination.Drug
for O
chronic I-Treat_Disorder
hepatitis I-Treat_Disorder
C. I-Treat_Disorder

A O
noninvasive O
method O
in O
the O
differential O
diagnosis O
of O
vecuronium I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
and O
magnesium O
- O
induced O
protracted I-Effect
neuromuscular I-Effect
block I-Effect
in O
a O
severely I-Subject.Sub_Disorder
preeclamptic I-Subject.Sub_Disorder
patient I-Subject
. O

A O
noninvasive O
method O
in O
the O
differential O
diagnosis O
of O
vecuronium O
- O
induced O
and O
magnesium I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
protracted I-Effect
neuromuscular I-Effect
block I-Effect
in O
a O
severely I-Subject.Sub_Disorder
preeclamptic I-Subject.Sub_Disorder
patient I-Subject
. O

Paroxysmal I-Effect
supraventricular I-Effect
tachycardia I-Effect
during I-Adverse_event.Trigger
treatment O
with O
cisplatin I-Treatment.Combination.Drug
and I-Treatment
etoposide I-Treatment.Combination.Drug
combination I-Treatment
. O

Conversely O
, O
diffuse I-Effect
interstitial I-Effect
pulmonary I-Effect
fibrosis I-Effect
should O
be O
considered O
in O
the O
differential O
diagnosis O
of O
patients I-Subject
receiving O
methotrexate I-Treatment.Drug
who O
develop I-Adverse_event.Trigger
bilateral I-Effect
pulmonary I-Effect
infiltrates I-Effect
seen O
on O
chest O
roentgenograms O
. O

An I-Subject
83 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
man I-Subject.Gender
receiving I-Treatment
glipizide I-Treatment.Combination.Drug
10 I-Treatment.Dosage
mg I-Treatment.Dosage
bid O
developed I-Adverse_event.Trigger
symptomatic I-Effect
hypoglycemia I-Effect
within O
three I-Treatment.Time_elapsed
days I-Treatment.Time_elapsed
of I-Treatment
adding I-Treatment
trimethoprim I-Treatment.Combination.Drug
/ I-Treatment
sulfamethoxazole I-Treatment.Combination.Drug
( I-Treatment
TMP I-Treatment
/ I-Treatment
SMX I-Treatment
) I-Treatment
to O
his O
regimen O
. O

In O
this O
case O
senna I-Treatment.Drug
was O
likely O
the O
cause I-Adverse_event.Trigger
of O
a I-Effect
subacute I-Effect
cholestatic I-Effect
hepatitis I-Effect
exemplifying O
again O
the O
potential O
role O
of O
herbal I-Effect
related I-Effect
liver I-Effect
injury I-Effect
. O

Early O
peritoneal O
dialysis O
has O
not O
previously O
been O
reported O
for O
lisinopril I-Treatment.Drug
induced I-Adverse_event.Trigger
multiorgan I-Effect
failure I-Effect
. O

Various O
case O
reports O
concerning O
dapsone I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
agranulocytosis I-Effect
are O
reviewed O
. O

We O
report O
the O
first O
case O
of O
a I-Subject
54 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
Turkish I-Subject.Race
woman I-Subject.Gender
who O
presented O
with O
ceftriaxone I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
FDE I-Effect
. O

In O
all O
cases O
, O
seizures I-Effect
were O
controlled I-Potential_therapeutic_event.Trigger
by O
withdrawal I-Treatment
of I-Treatment
phenytoin I-Treatment.Drug
and I-Treatment
reduction I-Treatment
of I-Treatment
drug I-Treatment
levels I-Treatment
. O

This O
case O
describes O
fulminant I-Effect
hepatic I-Effect
failure I-Effect
in I-Adverse_event.Trigger
a I-Subject
patient I-Subject
taking O
disulfiram I-Treatment.Drug
with O
no O
previous O
liver O
disease O
and O
report O
of O
being O
compliant O
with O
alcohol O
abstinence O
. O

Fungal I-Treat_Disorder
infection I-Treat_Disorder
is O
a O
significant O
comorbidity O
in O
patients I-Subject
with I-Subject
diabetes I-Subject.Sub_Disorder
mellitus I-Subject.Sub_Disorder
, O
and O
ketoconazole I-Treatment.Drug
, O
an O
antifungal O
agent O
, O
causes I-Adverse_event.Trigger
a I-Effect
number I-Effect
of I-Effect
drug I-Effect
interactions I-Effect
with I-Effect
coadministered I-Effect
drugs I-Effect
. O

Dorzolamide I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
choroidal I-Effect
detachment I-Effect
in O
a I-Subject
surgically I-Subject
untreated I-Subject
eye I-Subject
. O

Idiosyncratic O
factors O
involving O
vasopressin I-Treatment.Drug
receptor O
affinity O
and O
distribution O
, O
vasopressin O
- O
associated O
vasodilation O
in O
some O
vascular O
beds O
, O
and O
the O
effect O
of O
vasopressin O
on O
the O
renin O
- O
angiotensin O
system O
may O
further O
contribute I-Adverse_event.Trigger
to O
impaired I-Effect
tissue I-Effect
perfusion I-Effect
. O

Rapid O
resolution I-Potential_therapeutic_event.Trigger
of O
topiramate I-Treat_Disorder
- I-Treat_Disorder
induced I-Treat_Disorder
angle I-Treat_Disorder
- I-Treat_Disorder
closure I-Treat_Disorder
glaucoma I-Treat_Disorder
with O
methylprednisolone I-Treatment.Combination.Drug
and I-Treatment
mannitol I-Treatment.Combination.Drug
. O

Rapid O
resolution O
of O
topiramate I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
angle I-Effect
- I-Effect
closure I-Effect
glaucoma I-Effect
with O
methylprednisolone O
and O
mannitol O
. O

A I-Subject
66 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
mand I-Subject.Gender
suffering I-Subject
from I-Subject
severe I-Subject
coronary I-Subject.Sub_Disorder
heart I-Subject.Sub_Disorder
disease I-Subject.Sub_Disorder
took I-Adverse_event.Trigger
digoxin I-Treatment.Drug
with O
suicidal O
intent O
an O
was O
treated O
for O
the O
ensuing O
complete I-Effect
atrioventricular I-Effect
block I-Effect
with O
digoxin O
- O
specific O
antibody O
fragments O
. O

A I-Subject
patient I-Subject
with I-Subject
generalized I-Subject
MG I-Subject
was O
effectively O
managed O
with O
MM I-Treatment
but O
developed I-Adverse_event.Trigger
CNS I-Effect
lymphoma I-Effect
after O
3 I-Duration
years I-Duration
of O
treatment O
. O

A O
patient O
with O
generalized I-Treat_Disorder
MG I-Treat_Disorder
was O
effectively O
managed I-Potential_therapeutic_event.Trigger
with O
MM I-Treatment.Drug
but O
developed O
CNS O
lymphoma O
after O
3 O
years O
of O
treatment O
. O

Epoprostenol I-Treatment.Drug
may O
be O
associated I-Adverse_event.Trigger
rarely O
with O
severe I-Effect
erythroderma I-Effect
. I-Effect

We O
report O
the O
case O
of O
a I-Subject
patient I-Subject
with O
increased I-Effect
cerebral I-Effect
cortical I-Effect
excitability I-Effect
following I-Adverse_event.Trigger
intoxication O
with O
flupirtine I-Treatment.Drug
, O
a O
centrally O
acting O
analgesic O
and O
antispastic O
drug O
. O

This O
case O
represents O
the O
third O
example O
of O
erythroid I-Effect
aplasia I-Effect
associated I-Adverse_event.Trigger
with O
an O
anti O
- O
inflammatory O
agent O
and O
the O
first O
instance O
due O
to O
fenoprofen I-Treatment.Drug
. O

Lichenoid I-Effect
drug I-Effect
eruption I-Effect
to O
salsalate I-Treatment.Drug
. O

Two I-Subject.Population
pediatric I-Subject.Age
oncology I-Subject
patients I-Subject
with I-Subject
Ewing I-Treat_Disorder
's I-Treat_Disorder
sarcoma I-Treat_Disorder
and I-Subject
one I-Subject.Population
with I-Subject
mixed I-Treat_Disorder
germ I-Treat_Disorder
cell I-Treat_Disorder
tumor I-Treat_Disorder
were O
treated I-Potential_therapeutic_event.Trigger
with I-Potential_therapeutic_event.Trigger
drug I-Treatment
regimens I-Treatment
that I-Treatment
included I-Treatment
bleomycin I-Treatment.Drug
or I-Treatment
cyclophosphamide I-Treatment.Drug
. O

Although O
retinoic I-Treatment.Drug
acid I-Treatment.Drug
is O
well O
tolerated O
by O
the O
majority O
of O
patients O
with O
this O
disease O
, O
a O
potentially O
fatal I-Effect
complication I-Effect
of O
this O
kind O
of O
treatment O
has O
been O
reported O
: O
" O
the O
retinoic O
acid O
syndrome O
" O
. O

Three O
of O
38 I-Subject.Population
children I-Subject.Age
given O
high I-Treatment.Dosage
- I-Treatment.Dosage
dose I-Treatment.Dosage
cytosine I-Treatment.Drug
arabinoside I-Treatment.Drug
therapy O
developed I-Adverse_event.Trigger
a O
previously O
undescribed O
complication I-Effect
. O

A O
case O
of O
aseptic I-Effect
pleuropericarditis I-Effect
in I-Adverse_event.Trigger
a I-Subject
patient I-Subject
with I-Subject
chronic I-Treat_Disorder
plaque I-Treat_Disorder
psoriasis I-Treat_Disorder
under O
methotrexate I-Treatment.Drug
therapy I-Treatment
. O

Linezolid I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
dyserythropoiesis I-Effect
: O
chloramphenicol O
toxicity O
revisited O
. O

CONCLUSION O
: O
The O
present O
findings O
suggest O
that O
fluvoxamine I-Treatment.Drug
can O
cause I-Adverse_event.Trigger
increased I-Effect
libido I-Effect
in O
some I-Subject
patients I-Subject
. O

A O
unique O
case O
of O
a I-Effect
transient I-Effect
, I-Effect
nonpigmenting I-Effect
fixed I-Effect
drug I-Effect
eruption I-Effect
caused I-Adverse_event.Trigger
by O
the O
radiopaque O
contrast O
medium O
iothalamate I-Treatment.Drug
is O
reported O
. O

Mucosal I-Effect
pigmentation I-Effect
after O
oral I-Treat_Disorder
lichen I-Treat_Disorder
planus I-Treat_Disorder
treatment I-Adverse_event.Trigger
with O
topical I-Treatment.Route
tacrolimus I-Treatment.Drug
. O

We O
now O
report O
the O
first O
known O
cancer I-Treat_Disorder
patient I-Subject
who O
developed I-Adverse_event.Trigger
life I-Effect
- I-Effect
threatening I-Effect
complications I-Effect
after O
treatment O
with O
topical I-Treatment.Route
5 I-Treatment.Drug
- I-Treatment.Drug
FU I-Treatment.Drug
and O
was O
shown O
subsequently O
to O
have I-Effect
profound I-Effect
DPD I-Effect
deficiency I-Effect
. O

When O
the O
acute I-Effect
manic I-Effect
state I-Effect
is I-Effect
characterized I-Effect
by I-Effect
marked I-Effect
psychotic I-Effect
symptoms I-Effect
and I-Effect
intense I-Effect
anxiety I-Effect
, O
it O
may O
be O
associated I-Adverse_event.Trigger
with I-Adverse_event.Trigger
increased O
vulnerability O
to O
the O
development O
of O
severe O
lithium I-Treatment.Drug
neurotoxicity O
. O

Clinicians O
who O
manage O
cachectic I-Treat_Disorder
patients I-Subject
, O
particularly O
those O
with I-Subject
protracted I-Treat_Disorder
diarrhoea I-Treat_Disorder
and/or O
receiving O
anti I-Treatment
- I-Treatment
malarial I-Treatment
drugs I-Treatment
including I-Treatment
mefloquine I-Treatment.Drug
, O
should O
be O
aware O
of O
the O
risk I-Adverse_event.Trigger
of O
severe I-Effect
hypoglycaemia I-Effect
. O

Arrhythmias I-Effect
and I-Effect
cardiac I-Effect
arrest I-Effect
have O
been O
reported O
during I-Adverse_event.Trigger
amphotericin I-Treatment.Drug
B I-Treatment.Drug
administration I-Treatment
but O
no O
effective O
technique O
has O
been O
described O
to O
prevent O
them O
. O

Based O
upon O
the O
literature O
review O
, O
the I-Effect
hypotension I-Effect
in O
this I-Subject
patient I-Subject
was O
possibly O
due I-Adverse_event.Trigger
to O
the I-Treatment
interaction I-Treatment
between I-Treatment
tizanidine I-Treatment.Combination.Drug
and I-Treatment
lisinopril I-Treatment.Combination.Drug
. O

Baclofen I-Treatment.Drug
withdrawal I-Treatment
: O
a O
cause I-Adverse_event.Trigger
of O
prolonged I-Effect
fever I-Effect
in O
the O
intensive O
care O
unit O
. O

Interstitial I-Effect
pneumonitis I-Effect
and I-Effect
alveolar I-Effect
hemorrhage I-Effect
complicating I-Adverse_event.Trigger
use O
of O
rituximab I-Treatment.Drug
: O
case O
report O
and O
review O
of O
the O
literature O
. O

We O
introduce O
a O
case O
of O
a I-Subject
sixty I-Subject.Age
years I-Subject.Age
old I-Subject.Age
woman I-Subject.Gender
with O
several I-Effect
previous I-Effect
episodes I-Effect
of I-Effect
rhinitis I-Effect
, I-Effect
conjunctivitis I-Effect
and I-Effect
perspiration I-Effect
immediately I-Effect
after I-Adverse_event.Trigger
the O
administration O
of O
salmon I-Treatment.Drug
calcitonin I-Treatment.Drug
with I-Treatment
nasal I-Treatment.Route
spray I-Treatment.Route
or I-Treatment
intramuscular I-Treatment.Route
administration I-Treatment
( I-Treatment
Calsynar I-Treatment
) I-Treatment
. O

In O
this O
article O
, O
we O
describe O
another O
case O
of O
subcutaneous I-Effect
changes I-Effect
following I-Adverse_event.Trigger
repeated I-Treatment
glatiramer I-Treatment.Drug
acetate I-Treatment.Drug
injection I-Treatment.Route
, O
presented I-Effect
as I-Effect
localized I-Effect
panniculitis I-Effect
in I-Effect
the I-Effect
area I-Effect
around I-Effect
the I-Effect
injection I-Effect
sites I-Effect
, O
in O
a I-Subject
46 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
female I-Subject.Gender
patient I-Subject
who O
was O
treated O
with O
glatiramer O
acetate O
for O
18 O
months O
. O

In O
this O
article O
, O
we O
describe O
another O
case O
of O
subcutaneous O
changes O
following O
repeated O
glatiramer O
acetate O
injection O
, O
presented O
as O
localized O
panniculitis O
in O
the O
area O
around O
the O
injection O
sites O
, O
in O
a I-Subject
46 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
female I-Subject.Gender
patient I-Subject
who O
was O
treated I-Potential_therapeutic_event.Trigger
with O
glatiramer I-Treatment.Drug
acetate I-Treatment.Drug
for I-Treatment
18 I-Treatment.Time_elapsed
months I-Treatment.Time_elapsed
. I-Time_elapsed

Eighty I-Subject.Population
- I-Subject.Population
two I-Subject.Population
patients I-Subject
with I-Subject
various I-Subject.Sub_Disorder
malignancies I-Subject.Sub_Disorder
who O
received I-Potential_therapeutic_event.Trigger
imipenem I-Treatment.Combination.Drug
/ I-Treatment
cilastatin I-Treatment.Combination.Drug
143 I-Treatment
times I-Treatment
for I-Treatment
neutropenic I-Treatment.Treat_Disorder
fever I-Treatment.Treat_Disorder
between O
March O
1994 O
and O
October O
1999 O
in O
Department O
of O
Pediatric O
Oncology O
, O
Gazi O
University O
, O
were O
identified O
. O

The O
present O
report O
first O
highlights O
the O
potentially I-Effect
life I-Effect
- I-Effect
threatening I-Effect
side I-Effect
effects I-Effect
associated I-Adverse_event.Trigger
with I-Adverse_event.Trigger
over O
- O
the O
- O
counter O
NSAIDs I-Treatment.Combination.Drug
during O
DDAVP I-Combination.Drug
replacement O
therapy O
for O
central O
DI O
. O

Case O
report O
: O
lack O
of O
control O
of O
diabetes I-Effect
and O
weight I-Effect
gain I-Effect
in O
a I-Subject
patient I-Subject
on O
initiation I-Adverse_event.Trigger
and I-Adverse_event.Trigger
rechallenge I-Adverse_event.Trigger
of O
therapy O
with O
olanzapine I-Treatment.Drug
. O

Intravenous O
azithromycin I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
ototoxicity I-Effect
. O

Orally I-Treatment.Route
delivered I-Treatment
PXD I-Treatment.Combination.Drug
showed O
no O
evidence O
of O
clinical I-Potential_therapeutic_event.Trigger
activity I-Potential_therapeutic_event.Trigger
, O
when O
combined O
with O
weekly I-Treatment.Freq
AUC2 I-Treatment.Combination.Drug
- I-Treatment.Combination.Drug
carboplatin I-Treatment.Combination.Drug
in O
PROC I-Treat_Disorder
. O

We O
report O
such O
a I-Subject.Population
series I-Subject.Population
of I-Subject
patients I-Subject
who O
had O
transient I-Effect
asymptomatic I-Effect
bradycardia I-Effect
after I-Adverse_event.Trigger
being O
treated O
with O
continuous I-Treatment.Freq
infusion I-Treatment.Route
5 I-Treatment.Drug
- I-Treatment.Drug
FU I-Treatment.Drug
. O

Consolidation I-Treatment
therapy I-Treatment
with I-Treatment
bortezomib I-Treatment.Combination.Drug
/ I-Treatment
lenalidomide/ I-Treatment.Combination.Drug
dexamethasone I-Treatment.Combination.Drug
versus I-Treatment
bortezomib I-Treatment.Combination.Drug
/ I-Treatment
dexamethasone I-Treatment.Combination.Drug
after I-Treatment
a I-Treatment
dexamethasone I-Treatment
- I-Treatment
based I-Treatment
induction I-Treatment
regimen I-Treatment
in I-Potential_therapeutic_event.Trigger
patients I-Subject
with I-Subject
multiple I-Treat_Disorder
myeloma I-Treat_Disorder
: O
a O
randomized O
phase O
III O
trial O
. O

Based O
on O
prior O
data O
suggesting O
that O
scheduling O
alterations O
of O
platinum O
would O
increase O
activity O
, O
the O
aim O
of O
the O
present O
study O
was O
to O
assess I-Potential_therapeutic_event.Trigger
the O
potential I-Effect
therapeutic I-Effect
benefit I-Effect
of O
phenoxodiol I-Treatment.Combination.Drug
( I-Treatment
PXD I-Treatment
) I-Treatment
, I-Treatment
a I-Treatment
novel I-Treatment
biomodulator I-Treatment
shown I-Treatment
to I-Treatment
have I-Treatment
chemoresistance I-Treatment
reversing I-Treatment
potential I-Treatment
, I-Treatment
when I-Treatment
combined I-Treatment
with I-Treatment
weekly I-Treatment.Freq
AUC2 I-Treatment
- I-Treatment
carboplatin I-Treatment.Combination.Drug
in O
PROC I-Treat_Disorder
patients I-Subject
. O

We O
also O
describe O
a O
new O
, O
noninvasive O
method O
to O
assess O
magnesium I-Combination.Drug
- O
induced I-Adverse_event.Trigger
neuromuscular I-Effect
block I-Effect
when O
curariform I-Treatment.Combination.Drug
muscle I-Treatment.Combination.Drug
relaxant I-Treatment.Combination.Drug
was I-Treatment
given I-Treatment
simultaneously I-Treatment
. O

Our O
series O
of O
3 I-Subject.Population
patients I-Subject
supports I-Adverse_event.Trigger
a O
causal O
connection O
between O
bleomycin I-Treatment.Drug
and O
scleroderma I-Effect
. O

In O
this O
paper O
, O
we O
report O
a I-Subject
patient I-Subject
with O
primary O
anti I-Treat_Disorder
- I-Treat_Disorder
phospholipid I-Treat_Disorder
syndrome I-Treat_Disorder
treated O
by O
corticosteroid I-Treatment.Drug
, O
who O
developed I-Adverse_event.Trigger
disseminated I-Effect
nocardiosis I-Effect
. O

Eye I-Effect
movement I-Effect
disorders I-Effect
in O
bone I-Subject.Sub_Disorder
marrow I-Subject.Sub_Disorder
transplant I-Subject.Sub_Disorder
patients I-Subject
on I-Adverse_event.Trigger
cyclosporin I-Treatment.Combination.Drug
and I-Treatment
ganciclovir I-Treatment.Combination.Drug
. O

Prolonged I-Effect
severe I-Effect
cholestasis I-Effect
induced I-Adverse_event.Trigger
by O
oxacillin I-Treatment.Drug
derivatives I-Treatment
. O

Cisplatin I-Treatment.Drug
was O
the O
common O
drug O
in O
the I-Subject
cases I-Subject
presented O
and O
therefore O
could O
be O
related I-Adverse_event.Trigger
to O
the O
INR I-Effect
elevations I-Effect
. O

5 I-Treatment.Drug
- I-Treatment.Drug
Fluorouracil I-Treatment.Drug
cardiotoxicity I-Effect
complicating I-Adverse_event.Trigger
treatment O
of O
stage O
IIB O
cervical I-Treat_Disorder
cancer I-Treat_Disorder
-- O
case O
report O
. O

RESULTS O
: O
A O
clinical O
diagnosis O
of O
fixed I-Effect
drug I-Effect
eruption I-Effect
owing I-Adverse_event.Trigger
to O
use O
of O
the O
PDE5 I-Treatment
inhibitor I-Treatment
tadalafil I-Treatment.Drug
( I-Treatment
Cialis I-Treatment
) I-Treatment
was O
made O
. O

Pancytopenia I-Effect
associated I-Adverse_event.Trigger
with O
5 I-Treatment.Drug
- I-Treatment.Drug
aminosalicylic I-Treatment.Drug
acid I-Treatment.Drug
use O
in O
a I-Subject
patient I-Subject
with I-Subject
Crohn I-Treat_Disorder
's I-Treat_Disorder
disease I-Treat_Disorder
. O

Fludarabine I-Effect
induced I-Effect
lung I-Effect
toxicity I-Effect
must O
be O
considered O
in O
all I-Subject
patients I-Subject
who I-Subject
develop I-Subject
unexplained I-Subject
lung I-Subject.Sub_Disorder
disease I-Subject.Sub_Disorder
while O
receiving I-Adverse_event.Trigger
fludarabine I-Treatment.Drug
. O

Although O
other O
nitrites O
induce O
methemoglobinemia O
, O
exposure O
to O
methyl I-Treatment.Drug
nitrite I-Treatment.Drug
during O
phenylpropanolamine O
production O
appears O
to O
be O
a O
new O
cause I-Adverse_event.Trigger
of O
occupational I-Effect
methemoglobinemia I-Effect
. O

We O
report O
four I-Subject.Population
cases I-Subject
of O
sensorimotor I-Effect
axonal I-Effect
neuropathy I-Effect
in O
children I-Subject
aged I-Subject
10 I-Subject.Age
- I-Subject.Age
15 I-Subject.Age
years I-Subject.Age
, O
treated I-Adverse_event.Trigger
with O
thalidomide I-Treatment.Drug
for O
myxopapillary I-Treat_Disorder
ependymoma I-Treat_Disorder
, I-Subject
Crohn I-Treat_Disorder
's I-Treat_Disorder
disease I-Treat_Disorder
and I-Subject
recurrent I-Treat_Disorder
giant I-Treat_Disorder
aphthous I-Treat_Disorder
ulceration I-Treat_Disorder
. O

The I-Subject
patient I-Subject
died I-Effect
of I-Effect
respiratory I-Effect
failure I-Effect
after I-Time_elapsed
8 I-Treatment.Time_elapsed
days I-Treatment.Time_elapsed
of I-Treatment
steroid I-Treatment.Drug
infusion I-Treatment.Route
and I-Treatment
erlotinib I-Treatment.Drug
discontinuation I-Treatment
. I-Treatment

Hypo I-Effect
- I-Effect
oestrogenic I-Effect
and I-Effect
anabolic I-Effect
/ I-Effect
androgenic I-Effect
side I-Adverse_event.Trigger
- I-Adverse_event.Trigger
effects I-Adverse_event.Trigger
of O
danazol I-Treatment.Drug
are O
well O
known O
by O
the O
gynaecologist O
and O
some O
of O
them O
are O
present O
in O
> O
50 O
% O
of O
patients O
being O
treated O
for O
endometriosis I-Treat_Disorder
. O

We O
believe O
that O
this O
is O
the O
first O
description O
of O
acute I-Effect
hepatitis I-Effect
caused O
by O
an O
idiosyncratic I-Adverse_event.Trigger
adverse I-Adverse_event.Trigger
reaction I-Adverse_event.Trigger
to O
gliclazide I-Treatment.Drug
or O
to O
one O
of O
its O
metabolites O
. O

In O
view O
of O
our O
experience O
in O
the O
present O
case O
, O
it O
should O
be O
stressed O
that O
close O
monitoring O
of O
coagulation O
capacity O
is O
necessary O
in O
critically O
ill O
patients O
in O
order O
to O
avoid O
fatal O
haemorrhage I-Effect
after I-Adverse_event.Trigger
initiating I-Treatment
warfarin I-Treatment.Drug
therapy I-Treatment
regardless I-Treatment
of I-Treatment
the I-Treatment
dosage I-Treatment
. O

We O
report O
a I-Subject
patient I-Subject
who O
developed O
acute I-Effect
pancreatitis I-Effect
during I-Adverse_event.Trigger
amiodarone I-Treatment.Drug
therapy O
. O

We O
report O
a O
76 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
man I-Subject.Gender
who O
developed I-Adverse_event.Trigger
an O
acute I-Effect
blistering I-Effect
eruption I-Effect
following O
high I-Treatment.Dosage
- I-Treatment.Dosage
dose I-Treatment.Dosage
penicillin I-Treatment.Drug
treatment I-Treatment
for O
pneumococcal I-Treat_Disorder
septicaemia I-Treat_Disorder
. O

OBJECTIVE O
: O
To O
report O
a O
case O
of O
colchicine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
myopathy I-Effect
in O
a I-Subject
teenager I-Subject.Age
with I-Subject
familial I-Treat_Disorder
Mediterranean I-Treat_Disorder
fever I-Treat_Disorder
( I-Subject
FMF I-Subject
) I-Subject
. O

We O
believe O
that O
mucositis I-Subject.Sub_Disorder
was O
a O
contributing O
factor O
to O
this O
case O
of O
fatal I-Effect
hyperkalemia I-Effect
after I-Adverse_event.Trigger
administration O
of O
succinylcholine I-Treatment.Drug
, O
with O
a O
mechanism O
similar O
to O
that O
reported O
with O
thermal O
injury O
. O

Our O
experience O
supports O
hemodialysis I-Treatment.Drug
for I-Potential_therapeutic_event.Trigger
ESRF I-Subject.Sub_Disorder
patients I-Subject
with I-Subject
atenolol I-Treat_Disorder
toxicity I-Treat_Disorder
. O

Epirubicin I-Treatment.Combination.Drug
- I-Treatment.Combination.Drug
cyclophosphamide I-Treatment.Combination.Drug
adjuvant I-Treatment
chemotherapy I-Treatment
plus I-Treatment
tamoxifen I-Treatment.Combination.Drug
administered I-Treatment
concurrently I-Treatment
versus O
sequentially O
: O
randomized O
phase O
III O
trial O
in O
postmenopausal I-Subject
node I-Treat_Disorder
- I-Treat_Disorder
positive I-Treat_Disorder
breast I-Treat_Disorder
cancer I-Treat_Disorder
patients I-Subject
. O

Rupture I-Effect
of I-Effect
a I-Effect
cerebral I-Effect
aneurysm I-Effect
associated I-Adverse_event.Trigger
with O
nifedipine I-Treatment.Drug
treatment O
. O

An O
immediate I-Effect
hemolytic I-Effect
reaction I-Effect
induced I-Adverse_event.Trigger
by O
repeated I-Treatment.Freq
administration I-Treatment
of I-Treatment
oxaliplatin I-Treatment.Drug
. O

Patient I-Subject
B I-Subject
developed I-Adverse_event.Trigger
perioral I-Effect
and I-Effect
upper I-Effect
extremity I-Effect
paresthesias I-Effect
during O
the I-Treatment.Freq
fourth I-Treatment.Freq
cycle I-Treatment.Freq
of I-Treatment
CAP I-Treatment.Drug
alone I-Treatment
( I-Treatment
2500 I-Treatment.Dosage
mg I-Treatment.Dosage
/ I-Treatment.Dosage
m2 I-Treatment.Dosage
) I-Treatment
. O

We O
describe O
four I-Subject.Population
patients I-Subject
who O
had O
seizures I-Effect
while O
receiving I-Adverse_event.Trigger
ofloxacin I-Treatment.Drug
; O
no O
other O
causes O
were O
evident O
. O

The O
case O
history O
and O
toxicological O
findings O
of O
an I-Subject
infant I-Effect
fatality I-Effect
involving I-Adverse_event.Trigger
pseudoephedrine I-Treatment.Drug
, I-Treatment
brompheniramine I-Treatment.Drug
, I-Treatment
and I-Treatment
dextromethorphan I-Treatment.Drug
are O
presented O
. O

A O
drug I-Effect
interaction I-Effect
between I-Adverse_event.Trigger
zafirlukast I-Treatment.Combination.Drug
and I-Treatment
theophylline I-Treatment.Combination.Drug
. O

Dipyrone I-Treatment.Drug
, I-Treatment
also I-Treatment
known I-Treatment
as I-Treatment
metamizole I-Treatment
, O
is O
an O
analgesic O
and O
antipyretic O
drug O
that O
was O
banned O
by O
the O
United O
States O
Food O
and O
Drug O
Administration O
because O
of O
its O
association I-Adverse_event.Trigger
with O
agranulocytosis I-Effect
. O

A I-Subject
fatal I-Subject
case I-Subject
of O
pancytopenia I-Effect
due I-Adverse_event.Trigger
to O
levomepromazine I-Treatment.Drug
. O

Reversible I-Effect
heart I-Effect
failure I-Effect
in I-Adverse_event.Trigger
a I-Subject
patient I-Subject
receiving O
etanercept I-Treatment.Drug
for O
ankylosing I-Treat_Disorder
spondylitis I-Treat_Disorder
. O

The O
most O
likely O
cause I-Adverse_event.Trigger
of O
liver I-Effect
failure I-Effect
in O
this O
patient O
was O
, O
therefore O
, O
clarithromycin I-Treatment.Drug
, O
which O
undergoes O
hepatic O
metabolism O
and O
has O
been O
reported O
to O
cause O
fulminant O
hepatic O
failure O
. O

Localized I-Effect
panniculitis I-Effect
and I-Effect
subsequent I-Effect
lipoatrophy I-Effect
with I-Adverse_event.Trigger
subcutaneous I-Treatment
glatiramer I-Treatment.Drug
acetate I-Treatment.Drug
( I-Treatment.Drug
Copaxone I-Treatment.Drug
) I-Treatment.Drug
injection I-Treatment.Route
for O
the O
treatment O
of O
multiple I-Treat_Disorder
sclerosis I-Treat_Disorder
. O

glycopyrrolate I-Treatment.Drug
( I-Treatment
5.0 I-Treatment.Dosage
microg I-Treatment.Dosage
/ I-Treatment.Dosage
kg I-Treatment.Dosage
) I-Treatment
not O
only O
resulting I-Adverse_event.Trigger
in O
resolution I-Effect
of I-Effect
bradycardia I-Effect
but O
also O
resulting O
in O
an I-Effect
exaggerated I-Effect
increase I-Effect
of I-Effect
arterial I-Effect
blood I-Effect
pressure I-Effect
. O

This O
case O
underscores O
problems O
in O
clinical O
management O
with O
sulfadiazine I-Treatment.Drug
hypersensitivity I-Effect
, O
potential O
immunosuppression O
from O
corticosteroids O
and O
selection O
of O
medications O
for O
recurrences O
of O
toxoplasmic O
chorioretinitis O
. O

This O
case O
underscores O
problems O
in O
clinical O
management O
with O
sulfadiazine O
hypersensitivity O
, O
potential O
immunosuppression I-Effect
from I-Adverse_event.Trigger
corticosteroids I-Treatment.Drug
and O
selection O
of O
medications O
for O
recurrences O
of O
toxoplasmic O
chorioretinitis O
. O

CONCLUSION O
: O
The O
results O
suggest O
that O
olanzapine I-Treatment.Drug
may O
be O
useful O
in O
treating I-Potential_therapeutic_event.Trigger
patients I-Subject
with I-Subject
clozapine I-Subject
- I-Subject
induced I-Subject
granulocytopenia I-Subject
without I-Effect
the I-Effect
risk I-Effect
of I-Effect
recurrence I-Effect
of I-Effect
hematologic I-Effect
side I-Effect
effects I-Effect
. O

CONCLUSION O
: O
The O
results O
suggest O
that O
olanzapine O
may O
be O
useful O
in O
treating O
patients O
with O
clozapine I-Treatment.Drug
- I-Treat_Disorder
induced I-Treat_Disorder
granulocytopenia I-Treat_Disorder
without O
the O
risk O
of O
recurrence O
of O
hematologic O
side O
effects O
. O

CONCLUSION O
: O
Patients I-Subject
with I-Subject
insulin I-Subject.Sub_Disorder
allergy I-Subject.Sub_Disorder
may O
not O
have O
complete O
resolution I-Potential_therapeutic_event.Trigger
of O
their O
symptoms O
after O
standard I-Treatment
desensitization I-Treatment
, O
particularly O
those O
patients O
with O
concomitant I-Subject
protamine I-Subject.Sub_Disorder
allergy I-Subject.Sub_Disorder
. O

To O
our O
knowledge O
, O
the O
syndrome O
of O
fever I-Effect
, I-Effect
pulmonary I-Effect
infiltrates I-Effect
, I-Effect
and I-Effect
pleural I-Effect
effusion I-Effect
following I-Adverse_event.Trigger
use O
of O
acyclovir I-Treatment.Drug
has O
not O
been O
previously O
reported O
. O

We O
are O
concerned O
that O
the O
macular I-Effect
lesion I-Effect
was O
a O
retinal O
toxic O
effect O
of I-Adverse_event.Trigger
gentamicin I-Treatment.Drug
because O
of O
the O
recent O
description O
of O
similar O
lesions O
occurring O
after O
the O
inadvertent O
intraocular O
injection O
of O
massive O
doses O
of O
this O
drug O
. O

Acute I-Effect
myocardial I-Effect
infarction I-Effect
during I-Adverse_event.Trigger
high I-Treatment.Dosage
- I-Treatment.Dosage
dose I-Treatment.Dosage
methylprednisolone I-Treatment.Drug
therapy I-Treatment
for O
Graves I-Treat_Disorder
' I-Treat_Disorder
ophthalmopathy I-Treat_Disorder
. O

With O
itraconazole I-Treatment.Drug
, O
hepatotoxic I-Effect
reactions O
have O
only O
very O
rarely O
been O
reported I-Adverse_event.Trigger
, O
and O
histologic O
data O
are O
lacking O
. O

We O
describe O
in O
detail O
the O
first O
U.S. O
case O
report O
, O
of O
a I-Subject
4(1/2) I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
boy I-Subject.Gender
who O
experienced O
angioedema I-Effect
during O
treatment I-Adverse_event.Trigger
with O
oxcarbazepine I-Treatment.Drug
. O

Caution I-Effect
should O
be O
used I-Adverse_event.Trigger
when O
coadministering I-Treatment
enfuvirtide I-Treatment.Combination.Drug
and I-Treatment
niacin I-Treatment.Combination.Drug
to O
HIV I-Treat_Disorder
- I-Subject
infected I-Subject
patients I-Subject
. O

Several I-Subject.Population
case I-Subject
reports I-Adverse_event.Trigger
of O
aplastic I-Effect
anemia I-Effect
with O
use O
of O
acetazolamide I-Treatment.Drug
, O
and O
two O
cases O
with O
use O
of O
methazolamide O
, O
have O
appeared O
in O
the O
literature O
. O

SSRIs I-Treatment.Combination.Drug
and I-Treatment
fentanyl I-Treatment.Combination.Drug
are I-Treatment
commonly I-Treatment
co I-Treatment
- I-Treatment
administered I-Treatment
, O
especially O
in I-Potential_therapeutic_event.Trigger
the O
setting O
of O
chronic I-Treat_Disorder
or I-Treat_Disorder
malignant I-Treat_Disorder
pain I-Treat_Disorder
, O
as O
underlying I-Treat_Disorder
depression I-Treat_Disorder
may O
contribute O
to O
the O
pathogenesis O
of O
pain O
. O

In O
this O
report O
we O
present O
four I-Subject.Population
patients I-Subject
treated O
with O
a O
combination O
of O
different O
psychotropic O
drugs O
, O
in O
whom O
asterixis I-Effect
was O
triggered I-Adverse_event.Trigger
either O
by O
adding O
carbamazepine I-Treatment.Drug
( O
CBZ O
) O
to O
a O
treatment O
regimen O
, O
or O
by O
increasing O
its O
dosage O
. O

Squamous I-Effect
- I-Effect
cell I-Effect
carcinoma I-Effect
arising I-Effect
in O
a O
basal O
- O
cell O
epithelioma O
treated I-Adverse_event.Trigger
with O
5 I-Treatment.Drug
- I-Treatment.Drug
fluorouracil I-Treatment.Drug
. O

The I-Subject
case I-Subject
of I-Subject
a I-Subject
bipolar I-Treat_Disorder
patient I-Subject
who O
developed O
thyrotoxicosis I-Effect
with I-Effect
severe I-Effect
exophthalmos I-Effect
while O
on I-Adverse_event.Trigger
lithium I-Treatment.Drug
therapy O
is O
described O
. O

The I-Subject
patient I-Subject
received O
only O
the O
ophthalmic I-Treatment.Route
sulfonamide I-Treatment.Drug
, I-Treatment
and I-Treatment
it I-Treatment
was I-Treatment
used I-Treatment
for I-Treatment
one I-Treatment.Duration
day I-Treatment.Duration
, O
but O
he I-Subject.Gender
developed I-Adverse_event.Trigger
Stevens I-Effect
- I-Effect
Johnson I-Effect
syndrome I-Effect
. O

Papillary I-Effect
necrosis I-Effect
associated I-Adverse_event.Trigger
with O
the O
HIV I-Treat_Disorder
protease O
inhibitor O
indinavir I-Treatment.Drug
. O

A O
case O
is O
reported O
of O
a I-Subject
40 I-Subject.Age
year I-Subject.Age
old I-Subject.Age
woman I-Subject.Gender
treated O
with O
intraventricular I-Treatment.Route
IL I-Treatment.Drug
- I-Treatment.Drug
2 I-Treatment.Drug
for O
leptomeningeal I-Treat_Disorder
disease I-Treat_Disorder
who O
developed I-Adverse_event.Trigger
progressive I-Effect
cognitive I-Effect
dysfunction I-Effect
. O

We O
document O
the O
abrupt O
development I-Adverse_event.Trigger
of O
an O
extensive I-Effect
choroidal I-Effect
detachment I-Effect
after O
initiation O
of O
dorzolamide I-Treatment.Drug
therapy I-Treatment
in O
a O
surgically I-Treat_Disorder
untreated I-Treat_Disorder
eye I-Treat_Disorder
with I-Treat_Disorder
primary I-Treat_Disorder
open I-Treat_Disorder
- I-Treat_Disorder
angle I-Treat_Disorder
glaucoma I-Treat_Disorder
. O

Serotonin I-Treatment.Drug
toxicity I-Effect
as O
a O
consequence I-Adverse_event.Trigger
of O
linezolid I-Treatment.Drug
use I-Treatment
in I-Treatment
revision I-Treatment
hip I-Treatment
arthroplasty I-Treatment
. O

Gallstones I-Effect
and I-Effect
bile I-Effect
sludge I-Effect
are O
common O
side I-Adverse_event.Trigger
effects I-Adverse_event.Trigger
of I-Adverse_event.Trigger
octreotide I-Treatment.Drug
therapy I-Treatment
but O
rarely O
become O
symptomatic O
or O
require O
treatment O
. O

The O
authors O
' O
results O
suggest O
that O
L I-Treatment.Drug
- I-Treatment.Drug
dopa I-Treatment.Drug
may O
cause I-Adverse_event.Trigger
daytime I-Effect
somnolence I-Effect
in O
some I-Subject
patients I-Subject
with I-Subject
Parkinson I-Treat_Disorder
's I-Treat_Disorder
disease I-Treat_Disorder
. O

Seventy I-Subject.Population
- I-Subject.Population
four I-Subject.Population
per I-Subject.Population
cent I-Subject.Population
of I-Subject
patients I-Subject
with I-Subject
epileptogenic I-Treat_Disorder
disorders I-Subject
seen O
at O
the O
Emergency O
Unit O
at O
Groote O
Schuur O
Hospital O
were O
on O
phenytoin I-Treatment.Drug
and O
11.6 I-Subject.Population
% I-Subject.Population
of I-Subject
these I-Subject
had I-Adverse_event.Trigger
blood I-Effect
levels I-Effect
in I-Effect
the I-Effect
toxic I-Effect
range I-Effect
. O

Based O
on O
the O
history O
and O
clinical O
features O
, O
a O
diagnosis O
of O
insulin I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
lipohypertrophy I-Effect
was O
made O
. O

An O
unusual O
presentation O
of O
spontaneous I-Effect
sub I-Effect
- I-Effect
conjunctival I-Effect
haematoma I-Effect
in I-Adverse_event.Trigger
a I-Subject
patient I-Subject
receiving O
warfarin I-Treatment.Drug
. O

He O
developed I-Adverse_event.Trigger
congestive I-Effect
heart I-Effect
failure I-Effect
5 I-Treatment.Time_elapsed
days I-Treatment.Time_elapsed
after I-Treatment
administration I-Treatment
of I-Treatment
cyclophosphamide I-Treatment.Drug
. O

Fulminant I-Effect
liver I-Effect
failure I-Effect
associated I-Adverse_event.Trigger
with O
clarithromycin I-Treatment.Drug
. O

Nifedipine I-Treatment.Drug
may O
induce I-Adverse_event.Trigger
, I-Adverse_event.Trigger
or I-Adverse_event.Trigger
aggravate I-Adverse_event.Trigger
, O
pre O
- O
existing O
, O
gastro I-Effect
- I-Effect
oesophageal I-Effect
reflux I-Effect
. O

Rifampin I-Treatment.Drug
- O
associated I-Adverse_event.Trigger
thrombocytopenia I-Effect
secondary I-Effect
to I-Effect
poor I-Effect
compliance I-Effect
. O

CONCLUSIONS O
: O
There O
was O
a O
temporal O
relationship I-Adverse_event.Trigger
between O
the O
onset I-Effect
of I-Effect
nonconvulsive I-Effect
status I-Effect
epilepticus I-Effect
and O
initiation I-Treatment
of I-Treatment
ifosfamide I-Treatment.Drug
infusion I-Treatment.Route
. O

Gemcitabine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
pericardial I-Effect
effusion I-Effect
and I-Effect
tamponade I-Effect
after O
unblocked I-Treat_Disorder
cardiac I-Treat_Disorder
irradiation I-Treat_Disorder
. O

Although O
useful O
in O
the O
management O
of O
chronic I-Treat_Disorder
alcoholism I-Treat_Disorder
, O
disulfiram I-Treatment.Drug
is O
being O
increasingly O
associated I-Adverse_event.Trigger
with O
a I-Effect
wide I-Effect
spectrum I-Effect
of I-Effect
side I-Effect
effects I-Effect
and I-Effect
untoward I-Effect
medical I-Effect
sequelae I-Effect
, I-Effect
which I-Effect
now I-Effect
include I-Effect
catatonia I-Effect
. O

DISCUSSION O
: O
The O
Naranjo O
probability O
scale O
indicated O
a O
probable O
relationship I-Adverse_event.Trigger
between O
sertraline I-Treatment.Drug
treatment O
and O
the O
onset O
of O
rhabdomyolysis I-Effect
. O

Severe O
Raynaud I-Effect
's I-Effect
phenomenon I-Effect
with I-Adverse_event.Trigger
yohimbine I-Treatment.Drug
therapy O
for O
erectile I-Treat_Disorder
dysfunction I-Treat_Disorder
. O

Possible O
theophylline I-Effect
toxicity I-Effect
during I-Adverse_event.Trigger
anesthesia I-Treatment.Drug
. O

Calcification I-Effect
and I-Effect
ossification I-Effect
of I-Effect
the I-Effect
spinal I-Effect
arachnoid I-Effect
after I-Adverse_event.Trigger
intrathecal I-Treatment.Route
administration I-Treatment
of I-Treatment
Depo I-Treatment.Drug
- I-Treatment.Drug
Medrol I-Treatment.Drug
. O

Circulating O
anticoagulant O
in O
the O
procainamide I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
lupus I-Effect
syndrome I-Effect
. O

This O
report O
describes O
a I-Subject
case I-Subject
of O
bilateral I-Effect
ptosis I-Effect
induced I-Adverse_event.Trigger
by O
chloroquine I-Treatment.Drug
. O

When O
the O
data O
of O
the O
57 I-Subject.Population
patients I-Subject
are O
evaluated O
, O
a O
reversible O
direct O
cytotoxic I-Effect
effect I-Effect
of O
ticlopidine I-Treatment.Drug
on O
the O
pluripotent O
/ O
bipotent O
hematopoietic O
progenitor O
stem O
cell O
is O
proposed I-Adverse_event.Trigger
. O

We O
report O
a I-Subject
child I-Subject.Age
with I-Subject
yolk I-Treat_Disorder
sac I-Treat_Disorder
tumor I-Treat_Disorder
who O
developed O
localized I-Effect
pigmentation I-Effect
after I-Adverse_event.Trigger
the I-Treatment.Duration
first I-Treatment.Duration
course I-Treatment.Duration
of I-Treatment
chemotherapy I-Treatment
regimen I-Treatment
that I-Treatment
included I-Treatment
cisplatin I-Treatment.Combination.Drug
, I-Treatment
etoposide I-Treatment.Combination.Drug
and I-Treatment
bleomycin I-Treatment.Combination.Drug
. O

Except O
hypothyroidism I-Effect
after I-Adverse_event.Trigger
radioiodine I-Treatment.Drug
treatment I-Treatment
( I-Treatment
euthyroid I-Treatment
under I-Treatment
substitutional I-Treatment
therapy I-Treatment
) I-Treatment
, O
she I-Subject.Gender
suffered O
from O
no O
other O
diseases O
. O

Late I-Effect
lethal I-Effect
hepatitis I-Effect
B I-Effect
virus I-Effect
reactivation I-Effect
after I-Adverse_event.Trigger
rituximab I-Treatment.Drug
treatment O
of O
low I-Treat_Disorder
- I-Treat_Disorder
grade I-Treat_Disorder
cutaneous I-Treat_Disorder
B I-Treat_Disorder
- I-Treat_Disorder
cell I-Treat_Disorder
lymphoma I-Treat_Disorder
. O

Despite O
the O
low I-Treatment.Dosage
dosage I-Treatment.Dosage
of I-Treatment
warfarin I-Treatment.Drug
, O
international I-Effect
normalized I-Effect
ratio I-Effect
( I-Effect
INR I-Effect
) I-Effect
was I-Effect
markedly I-Effect
elevated I-Effect
from O
1.15 I-Dosage
to O
11.28 I-Dosage
for O
only O
4 I-Duration
days I-Duration
, O
and O
bleeding I-Effect
symptoms I-Effect
concurrently O
developed I-Adverse_event.Trigger
. O

The O
possible O
role I-Adverse_event.Trigger
of O
interferon I-Treatment.Drug
beta I-Treatment.Drug
in O
the O
pathogenesis O
of O
sarcoidosis I-Effect
in O
this I-Subject
patient I-Subject
is O
discussed O
. O

We O
hypothesize O
that O
a O
pharmacodynamic O
or O
pharmacokinetic O
drug O
interaction O
between O
venlafaxine I-Treatment.Combination.Drug
and I-Treatment
trimipramine I-Treatment.Combination.Drug
involving O
the O
CYP2D6 O
isoenzyme O
may O
have O
played O
a O
role O
in O
inducing I-Adverse_event.Trigger
the O
seizures I-Effect
. O

A O
case O
is O
described O
of O
severe I-Effect
splenic I-Effect
hemorrhage I-Effect
and I-Effect
rupture I-Effect
which O
developed I-Adverse_event.Trigger
3 I-Treatment.Time_elapsed
h I-Treatment.Time_elapsed
after I-Treatment
completion I-Treatment
of I-Treatment
tPA I-Treatment.Drug
infusion I-Treatment.Route
for O
suspected I-Treat_Disorder
acute I-Treat_Disorder
myocardial I-Treat_Disorder
infarction I-Treat_Disorder
. O

Three O
weeks O
later O
, O
the O
decerebrate I-Treat_Disorder
rigidity I-Treat_Disorder
and I-Treat_Disorder
high I-Treat_Disorder
BP I-Treat_Disorder
remained O
, O
and O
tizanidine I-Treatment.Drug
was O
initiated I-Potential_therapeutic_event.Trigger
to O
see O
whether O
the O
decrease O
in O
muscle O
tone O
could O
facilitate O
hypertension I-Effect
control I-Effect
and I-Effect
motor I-Effect
recovery I-Effect
. O

CONCLUSIONS O
: O
The O
administration O
of O
prostaglandin I-Treatment.Drug
E1 I-Treatment.Drug
to O
neonates I-Subject.Age
can O
cause I-Adverse_event.Trigger
gastric I-Effect
- I-Effect
outlet I-Effect
obstruction I-Effect
due I-Effect
to I-Effect
antral I-Effect
hyperplasia I-Effect
. O

During I-Time_elapsed
and I-Time_elapsed
after I-Time_elapsed
IFN I-Treatment.Drug
therapy I-Treatment.Drug
we O
should O
consider O
the O
possibility O
of O
occurrence I-Adverse_event.Trigger
of O
IDDM I-Effect
as I-Effect
well I-Effect
as I-Effect
other I-Effect
autoimmune I-Effect
diseases I-Effect
and O
observe O
the O
clinical O
course O
carefully O
. O

In O
two I-Subject.Population
of I-Subject
these I-Subject
cases I-Subject
akathisia I-Effect
resolved I-Adverse_event.Trigger
after O
withdrawal I-Treatment
of I-Treatment
olanzapine I-Treatment.Drug
and I-Treatment
substitution I-Treatment
by I-Treatment
a I-Treatment
classical I-Treatment
or O
an O
atypical O
neuroleptic I-Treatment.Drug
agent I-Treatment.Drug
, O
respectively O
. O

In O
two O
of O
these O
cases O
akathisia I-Effect
resolved I-Adverse_event.Trigger
after O
withdrawal I-Treatment
of I-Treatment
olanzapine I-Treatment
and I-Treatment
substitution I-Treatment
by I-Treatment
a O
classical O
or O
an I-Treatment
atypical I-Treatment
neuroleptic I-Treatment
agent I-Treatment
, O
respectively O
. O

Captopril I-Treatment.Drug
- O
related I-Adverse_event.Trigger
( O
and O
-induced O
? O
) O
asthma I-Effect
. O

These O
findings O
suggest O
that O
clozapine I-Treat_Disorder
- I-Treat_Disorder
induced I-Treat_Disorder
seizures I-Treat_Disorder
can O
be O
successfully O
treated I-Potential_therapeutic_event.Trigger
, O
that O
gradual I-Treatment
dose I-Treatment
titration I-Treatment
can O
reduce O
the I-Effect
likelihood I-Effect
of I-Effect
further I-Effect
episodes I-Effect
of I-Effect
seizures I-Effect
and O
that O
concomitant I-Treatment
use I-Treatment
of I-Treatment
a I-Treatment
suitable I-Treatment
mood I-Treatment
stabilizer I-Treatment
/ I-Treatment
anti I-Treatment
- I-Treatment
epileptic I-Treatment
medication I-Treatment
can O
improve I-Effect
the I-Effect
outcome I-Effect
of I-Effect
treatment I-Effect
- I-Effect
resistant I-Effect
schizophrenia I-Effect
. O

These O
findings O
suggest O
that O
clozapine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
seizures I-Effect
can O
be O
successfully O
treated O
, O
that O
gradual O
dose O
titration O
can O
reduce O
the O
likelihood O
of O
further O
episodes O
of O
seizures O
and O
that O
concomitant O
use O
of O
a O
suitable O
mood O
stabilizer O
/ O
anti O
- O
epileptic O
medication O
can O
improve O
the O
outcome O
of O
treatment O
- O
resistant O
schizophrenia O
. O

According O
to O
the O
Naranjo O
probability O
scale O
, O
the O
papular I-Effect
eruption I-Effect
was O
probably O
caused I-Adverse_event.Trigger
by O
methotrexate I-Treatment.Drug
. O

The O
patient O
's O
defects O
may O
be O
due I-Adverse_event.Trigger
to O
methimazole I-Treatment.Drug
teratogenicity I-Effect
or O
could O
represent O
a O
previously O
undescribed O
syndrome O
affecting O
ectodermal O
structures O
. O

CONCLUSIONS O
: O
Itraconazole I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
liver I-Effect
injury I-Effect
presents I-Effect
with I-Effect
a I-Effect
cholestatic I-Effect
pattern I-Effect
of I-Effect
injury I-Effect
with I-Effect
damage I-Effect
to I-Effect
the I-Effect
interlobular I-Effect
bile I-Effect
ducts I-Effect
, I-Effect
possibly I-Effect
leading I-Effect
to I-Effect
ductopenia I-Effect
. O

Rhabdomyolysis I-Effect
resulting I-Adverse_event.Trigger
from O
the O
drug O
interaction O
between O
diltiazem I-Treatment.Combination.Drug
and I-Treatment
other I-Treatment
HMG I-Treatment.Combination.Drug
- I-Treatment.Combination.Drug
CoA I-Treatment.Combination.Drug
reductase I-Treatment.Combination.Drug
inhibitors I-Treatment.Combination.Drug
has O
been O
described O
in O
the O
literature O
. O

Acute O
angioedema I-Effect
response I-Adverse_event.Trigger
to O
topical O
5 I-Treatment.Drug
- I-Treatment.Drug
fluorouracil I-Treatment.Drug
therapy O
. O

Hypersensitivity I-Effect
reactions I-Effect
due I-Adverse_event.Trigger
to O
chloramphenicol I-Treatment.Drug
are O
rarely O
reported O
in O
the O
literature O
. O

Diagnosis O
of O
sclerosing I-Effect
glomerulonephritis I-Effect
occurred O
in O
this O
patient I-Subject
during I-Adverse_event.Trigger
anastrozole I-Treatment.Drug
use O
, O
suggesting O
a O
newly O
defined O
side O
effect O
of O
anastrozole O
. O

A I-Subject
patient I-Subject
with I-Subject
coccidioidal I-Treat_Disorder
meningitis I-Treat_Disorder
was O
treated I-Adverse_event.Trigger
with I-Adverse_event.Trigger
intrathecally I-Treatment.Route
administered I-Treatment
amphotericin I-Treatment.Drug
B I-Treatment.Drug
, O
and O
an I-Effect
acute I-Effect
toxic I-Effect
delirium I-Effect
with I-Effect
EEG I-Effect
abnormalities I-Effect
developed O
. O

This O
case O
raises O
important O
questions O
about O
non I-Effect
- I-Effect
ketotic I-Effect
, I-Effect
hyperosmolar I-Effect
diabetic I-Effect
coma I-Effect
with O
antipsychotics I-Treatment.Drug
, O
the O
possible O
association I-Adverse_event.Trigger
between O
hyperglycaemia I-Effect
and I-Effect
hyperthermia I-Effect
, O
and O
the O
direction O
of O
causality O
in O
this O
, O
the O
recognition O
of O
either O
syndrome O
when O
they O
co O
- O
exist O
and O
management O
issues O
in O
such O
patients O
. O

CONCLUSIONS O
: O
Reversible I-Effect
lupus I-Effect
- I-Effect
like I-Effect
syndrome I-Effect
appears O
to O
be O
a O
rare O
but O
significant O
side I-Adverse_event.Trigger
effect I-Adverse_event.Trigger
of O
5 I-Treatment.Drug
- I-Treatment.Drug
ASA I-Treatment.Drug
compounds O
. O

A I-Subject
patient I-Subject
with I-Subject
chronic I-Treat_Disorder
myeloid I-Treat_Disorder
leukaemia I-Treat_Disorder
treated O
with O
busulphan I-Treatment.Drug
for I-Treatment
4 I-Treatment.Duration
- I-Treatment.Duration
5 I-Treatment.Duration
years I-Treatment.Duration
, O
developed I-Adverse_event.Trigger
signs O
of O
busulphan I-Effect
toxicity I-Effect
and I-Effect
portal I-Effect
hypertension I-Effect
with I-Effect
ascites I-Effect
, I-Effect
oesophageal I-Effect
varices I-Effect
and I-Effect
jaundice I-Effect
. O

Several O
cases O
of O
lithium I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
Creutzfeldt I-Effect
- I-Effect
Jakob I-Effect
syndrome I-Effect
have O
been O
reported O
to O
date O
; O
all O
of O
them O
were O
elderly I-Subject.Age
patients I-Subject
and O
a O
half O
had O
" I-Treatment
therapeutic I-Treatment
" I-Treatment
lithium I-Treatment.Drug
serum I-Treatment
levels I-Treatment
. O

There O
is O
, O
however O
, O
currently O
no O
data O
on O
the O
effect O
of O
combined I-Subject
hyperglycaemia I-Combination.Drug
and I-Subject
hyperinsulinaemia I-Combination.Drug
on O
the O
renal I-Effect
and I-Effect
ocular I-Effect
blood I-Effect
flow I-Effect
seen O
in O
diabetic I-Treat_Disorder
patients I-Subject
on I-Adverse_event.Trigger
insulin I-Treatment
therapy I-Treatment
. O

Pemphigus I-Effect
vulgaris I-Effect
precipitated I-Adverse_event.Trigger
by O
glibenclamide I-Treatment.Drug
therapy O
. O

Methimazole I-Treatment.Drug
- O
associated I-Adverse_event.Trigger
cholestatic I-Effect
liver I-Effect
injury I-Effect
: O
case O
report O
and O
brief O
literature O
review O
. O

The O
most O
likely O
cause O
of O
such O
hyponatremic I-Effect
episode I-Effect
is I-Adverse_event.Trigger
vinblastine I-Treatment.Drug
. O

Anti O
- O
tuberculous O
drugs O
had O
been O
stopped O
on O
the O
2nd O
day O
of O
therapy O
due O
to O
development O
of O
optic I-Effect
neuritis I-Effect
secondary I-Effect
to I-Adverse_event.Trigger
ethambutol I-Treatment.Drug
administration O
at O
another O
hospital O
. O

Based O
on O
this O
experience O
, O
we O
suggest O
that O
low I-Treatment.Dosage
- I-Treatment.Dosage
dose I-Treatment.Dosage
ketamine I-Treatment.Combination.Drug
added I-Treatment
to I-Treatment
propofol I-Treatment.Combination.Drug
may O
be O
associated O
with O
prevention I-Potential_therapeutic_event.Trigger
of O
EA I-Treat_Disorder
in O
children I-Subject.Age
with I-Subject
a I-Subject
history I-Subject
of I-Subject
EA I-Subject.Sub_Disorder
with I-Subject.Sub_Disorder
propofol I-Subject.Sub_Disorder
TIVA I-Subject.Sub_Disorder
. O

Tetany I-Effect
in I-Adverse_event.Trigger
a I-Subject
child I-Subject.Age
with I-Subject
AIDS I-Subject.Sub_Disorder
receiving O
intravenous I-Treatment.Route
tobramycin I-Treatment.Drug
. O

Sideroblastic I-Effect
anemia I-Effect
due I-Adverse_event.Trigger
to O
linezolid I-Treatment.Drug
in O
a O
patient I-Subject
with I-Subject
a I-Subject
left I-Treat_Disorder
ventricular I-Treat_Disorder
assist I-Treat_Disorder
device I-Treat_Disorder
. O

Oral I-Treatment.Route
dapsone I-Treatment.Drug
has O
been O
available O
for O
over O
60 O
years O
and O
has O
been O
used O
to O
treat O
severe O
acne O
vulgaris O
; O
however O
, O
the O
oral O
formulation O
is O
known O
to O
cause I-Adverse_event.Trigger
dose I-Effect
- I-Effect
dependent I-Effect
haematological I-Effect
reactions I-Effect
and O
is O
currently O
indicated O
only O
for O
diseases O
such O
as O
dermatitis I-Treat_Disorder
herpetiformis I-Treat_Disorder
and O
Hansen I-Treat_Disorder
's I-Treat_Disorder
disease I-Treat_Disorder
. O

Enalapril I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
anemia I-Effect
in O
two I-Subject
kidney I-Treat_Disorder
transplant I-Treat_Disorder
recipients I-Subject
. O

PURPOSE O
: O
To O
report O
two O
cases O
in O
which O
topical I-Treatment.Route
brimonidine I-Treatment.Drug
resulted I-Adverse_event.Trigger
in O
apparent I-Effect
central I-Effect
nervous I-Effect
system I-Effect
depression I-Effect
and I-Effect
unresponsiveness I-Effect
in O
an I-Subject
infant I-Subject.Age
. O

BACKGROUND O
: O
Interferon I-Treatment.Drug
beta I-Treatment.Drug
has O
become O
standard I-Potential_therapeutic_event.Trigger
therapy I-Potential_therapeutic_event.Trigger
for O
reducing O
relapse O
frequency O
in O
relapsing I-Treat_Disorder
/ I-Treat_Disorder
remitting I-Treat_Disorder
Multiple I-Treat_Disorder
Sclerosis I-Treat_Disorder
( O
RRMS O
) O
. O

In O
this O
article O
lithium O
is O
not O
discussed O
, O
although O
there O
are O
a O
number O
of O
concerns O
about O
lithium O
's O
potential O
teratogenicity O
, O
and O
it O
has O
been O
implicated I-Adverse_event.Trigger
in O
Epstein I-Effect
's I-Effect
anomaly I-Effect
, O
a O
congenital O
heart O
defect O
among O
infants O
born O
to O
women O
taking O
lithium I-Treatment.Drug
; O
as O
with O
other O
medications O
, O
however O
, O
the O
data O
have O
specific O
limitations O
. O

The O
risk O
of O
gastrointestinal I-Effect
bleeding I-Effect
during I-Adverse_event.Trigger
the O
treatment O
with O
antiagregants I-Treatment.Combination.Drug
and I-Treatment
anticoagulants I-Treatment.Combination.Drug
, O
the O
risk O
of O
bradycardia O
in O
beta O
- O
blockade O
, O
possible O
interactions O
with O
other O
medications O
lowering O
the O
heart O
rate O
are O
discussed O
. O

The O
risk O
of O
gastrointestinal O
bleeding O
during O
the O
treatment O
with O
antiagregants O
and O
anticoagulants O
, O
the O
risk O
of O
bradycardia I-Effect
in I-Adverse_event.Trigger
beta I-Treatment.Drug
- I-Treatment.Drug
blockade I-Treatment.Drug
, O
possible O
interactions O
with O
other O
medications O
lowering O
the O
heart O
rate O
are O
discussed O
. O

Hepatotoxicity I-Effect
of O
paracetamol I-Treatment.Combination.Drug
enhanced I-Adverse_event.Trigger
by O
ingestion I-Treatment.Route
of I-Treatment
alcohol I-Treatment.Combination.Drug
: O
report O
of O
two I-Subject.Population
cases I-Subject
. I-Subject

Cancer I-Treat_Disorder
patients I-Subject
who O
are O
receiving I-Treatment
5 I-Treatment.Drug
- I-Treatment.Drug
FU I-Treatment.Drug
treatment O
and O
are I-Subject
DPD I-Subject.Sub_Disorder
deficient I-Subject.Sub_Disorder
can O
develop I-Adverse_event.Trigger
severe I-Effect
side I-Effect
effects I-Effect
. O

A I-Subject
patient I-Subject
is O
described O
who O
developed I-Adverse_event.Trigger
a O
poorly I-Effect
differentiated I-Effect
sarcoma I-Effect
after O
cyclophosphamide I-Treatment.Drug
was O
used O
to O
treat O
his I-Subject.Gender
rheumatoid I-Treat_Disorder
arthritis I-Treat_Disorder
. O

Photo I-Effect
- I-Effect
onycholysis I-Effect
caused I-Adverse_event.Trigger
by O
olanzapine I-Treatment.Drug
and I-Treatment
aripiprazole I-Treatment.Drug
. O

We O
observed O
5 O
reactions O
in O
3 I-Subject.Population
patients I-Subject
that O
appear O
to O
be O
related O
to O
a O
high I-Treatment.Dosage
dose I-Treatment.Dosage
- I-Treatment
infusion I-Treatment
time I-Treatment
ratio I-Treatment
, O
indicating O
that O
dose O
and O
rate O
of O
infusion O
may O
be O
important O
factors O
in O
precipitating I-Adverse_event.Trigger
anaphylactoid I-Effect
reactions I-Effect
with O
cisplatin I-Treatment.Drug
. O

CONCLUSION O
: O
Fixed I-Effect
drug I-Effect
eruption I-Effect
is O
associated I-Adverse_event.Trigger
with O
many O
drugs O
but O
this O
is O
the O
first O
such O
report O
with O
omeprazole I-Treatment.Drug
. O

One O
type O
of O
SMON I-Effect
is O
associated O
with O
acrodermatitis I-Effect
enteropathica I-Effect
which O
has O
a O
very O
high O
frequency O
of O
occurrence O
in O
association I-Adverse_event.Trigger
with O
administration O
of O
clioquinol I-Treatment.Drug
. O

We O
report O
a I-Subject
case I-Subject
of O
amiodarone I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
thyrotoxicosis I-Effect
of O
protracted O
duration O
, O
unresponsive O
to O
conventional O
thionamide O
therapy O
, O
with O
therapy O
limited O
by O
severe O
adverse O
drug O
reactions O
. O

The O
addition O
of O
ciprofloxacin I-Treatment.Combination.Drug
to O
chronic I-Treatment.Combination.Drug
simvastatin I-Treatment.Combination.Drug
therapy O
led I-Adverse_event.Trigger
to O
the O
development O
of O
rhabdomyolysis I-Effect
. O

Nephropathy I-Effect
caused I-Adverse_event.Trigger
by O
methicillin I-Treatment.Drug
therapy I-Treatment
for I-Treatment
staphylococcal I-Treatment.Treat_Disorder
septicemia I-Treatment.Treat_Disorder
. O

Four I-Subject.Population
patients I-Subject
in O
whom O
pulmonary I-Effect
oedema I-Effect
developed I-Adverse_event.Trigger
during O
tocolysis I-Treatment
with I-Treatment
hexoprenaline I-Treatment.Drug
are O
described O
and O
the O
aetiological O
factors O
and O
pathogenesis O
of O
this O
potentially O
lethal O
complication O
discussed O
. O

A O
case O
of O
skeletal I-Effect
fluorosis I-Effect
induced I-Adverse_event.Trigger
by O
prolonged O
treatment O
with O
niflumic I-Treatment.Combination.Drug
acid I-Treatment.Combination.Drug
, O
a O
fast O
- O
acting O
non O
- O
steroid O
antiinflammatory O
agent O
, O
is O
reported O
in O
a I-Subject
35 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
woman I-Subject.Gender
suffering I-Subject
from I-Subject
rheumatoid I-Treat_Disorder
arthritis I-Treat_Disorder
and O
treated O
, O
in I-Treatment
addition I-Treatment
, I-Treatment
with I-Treatment
corticosteroids I-Treatment.Combination.Drug
. O

A I-Subject
65 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
man I-Subject.Gender
on O
warfarin I-Treatment.Drug
therapy I-Treatment
with I-Adverse_event.Trigger
a I-Effect
sudden I-Effect
spontaneous I-Effect
onset I-Effect
of I-Effect
sub I-Effect
- I-Effect
conjunctival I-Effect
haematoma I-Effect
associated I-Effect
with I-Effect
bloody I-Effect
tears I-Effect
was O
assessed O
in O
the O
clinic O
following O
a O
referral O
from O
an O
optometrist O
. O

This O
case O
report O
describes O
the O
development I-Adverse_event.Trigger
of O
asymptomatic I-Effect
visual I-Effect
field I-Effect
defects I-Effect
( O
VFDs O
) O
in O
a O
psychiatric O
patient I-Subject
with O
bipolar I-Treat_Disorder
disorder I-Treat_Disorder
receiving O
adjunctive O
tiagabine I-Treatment.Drug
treatment O
. O

Cardiorespiratory I-Effect
toxicity I-Effect
due I-Adverse_event.Trigger
to I-Adverse_event.Trigger
miconazole I-Treatment.Drug
. O

Lovastatin I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
rhabdomyolysis I-Effect
possibly O
associated O
with O
clarithromycin I-Treatment.Combination.Drug
and O
azithromycin I-Treatment.Combination.Drug
. O

For O
prevention O
of O
CYP2E1 O
- O
mediated O
bioactivation O
, O
depending O
on O
protoxicant I-Drug
disposition O
, O
a I-Treatment.Dosage
second I-Treatment.Dosage
DSF I-Treatment.Drug
dose I-Treatment.Dosage
might O
be O
necessary O
to I-Potential_therapeutic_event.Trigger
completely O
prevent O
toxicity O
. O

We O
describe O
a I-Subject
patient I-Subject
with I-Subject
rheumatoid I-Treat_Disorder
arthritis I-Treat_Disorder
treated I-Adverse_event.Trigger
with I-Adverse_event.Trigger
gold I-Treatment.Drug
salts I-Treatment.Drug
, O
who O
developed O
bilateral I-Effect
interstitial I-Effect
pulmonary I-Effect
abnormalities I-Effect
and O
showed O
a O
dramatic O
response O
on O
corticosteroid I-Drug
therapy O
. O

Pneumonitis I-Effect
is O
emerging O
as O
one O
of O
the O
most O
unpredictable O
and O
potentially O
serious O
, O
adverse O
effects O
of O
treatment O
with I-Adverse_event.Trigger
MTX I-Treatment.Drug
. O

A O
chronic O
reaction O
associated O
with O
long I-Treatment.Dosage
- I-Treatment.Dosage
term I-Treatment.Dosage
treatment I-Treatment.Dosage
with I-Treatment
nitrofurantoin I-Treatment.Drug
has O
also O
been O
reported O
and O
causes I-Adverse_event.Trigger
irreversible I-Effect
pulmonary I-Effect
fibrosis I-Effect
. O

Nitrofurantoin I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
acute I-Effect
liver I-Effect
damage I-Effect
in O
pregnancy I-Subject
. O

A I-Subject
58 I-Subject.Age
- I-Subject.Age
yr I-Subject.Age
- I-Subject.Age
old I-Subject.Age
male I-Subject.Gender
patient I-Subject
with I-Subject
essential I-Treat_Disorder
thrombocythaemia I-Treat_Disorder
( I-Treat_Disorder
ET I-Treat_Disorder
) I-Treat_Disorder
developed I-Adverse_event.Trigger
chronic I-Effect
myeloid I-Effect
leukaemia I-Effect
( I-Effect
CML I-Effect
) I-Effect
after O
continuous I-Treatment
uneventful I-Treatment
treatment I-Treatment
with I-Treatment
hydroxyurea I-Treatment.Drug
for I-Treatment
18 I-Treatment.Duration
yr I-Treatment.Duration
. O

A I-Subject
64 I-Subject.Age
year I-Subject.Age
old I-Subject.Age
man I-Subject.Gender
with I-Subject
recurrent I-Treat_Disorder
metastatic I-Treat_Disorder
squamous I-Treat_Disorder
cell I-Treat_Disorder
carcinoma I-Treat_Disorder
of I-Treat_Disorder
the I-Treat_Disorder
head I-Treat_Disorder
and I-Treat_Disorder
neck I-Treat_Disorder
developed I-Adverse_event.Trigger
severe O
skin I-Effect
rash I-Effect
and I-Effect
bone I-Effect
marrow I-Effect
aplasia I-Effect
4 I-Time_elapsed
and I-Time_elapsed
7 I-Time_elapsed
days I-Time_elapsed
, O
respectively O
, O
following O
a I-Treatment.Freq
single I-Treatment.Freq
dose I-Treatment.Freq
of I-Treatment
40 I-Treatment.Dosage
mg I-Treatment.Dosage
/ I-Treatment.Dosage
m2 I-Treatment.Dosage
methotrexate I-Treatment.Drug
( I-Treatment
MTX I-Treatment
) I-Treatment
. O

We O
present O
four I-Subject.Population
cases I-Subject
in O
which O
the O
use O
of O
heparin I-Treatment.Drug
was O
associated I-Adverse_event.Trigger
with O
hyperkalemia I-Effect
and O
discuss O
the O
pathophysiology O
. O

Three O
cycles O
of O
chemotherapy I-Treatment.Drug
had O
been O
administered O
without O
complications O
when O
, O
at I-Treatment
the I-Treatment
beginning I-Treatment
of I-Treatment
the I-Treatment
fourth I-Treatment.Duration
cycle I-Treatment.Duration
, O
the I-Subject
patient I-Subject
developed I-Adverse_event.Trigger
clinical O
and O
laboratory O
abnormalities O
consistent O
with O
the O
development O
of O
the O
hemolytic I-Effect
- I-Effect
uremic I-Effect
syndrome I-Effect
. I-Effect

Keratitis I-Effect
in I-Adverse_event.Trigger
methamphetamine I-Treatment.Drug
abusers I-Treatment
. O

A O
rechallenge O
, O
performed O
in O
both I-Subject
patients I-Subject
, O
confirmed O
the O
diagnosis O
of O
mesalamine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
pancreatitis I-Effect
. O

Central I-Effect
nervous I-Effect
system I-Effect
toxicity I-Effect
associated I-Adverse_event.Trigger
with O
meperidine I-Treatment.Drug
use O
in O
hepatic I-Treat_Disorder
disease I-Treat_Disorder
. O

To O
our O
knowledge O
, O
this O
case O
is O
the O
first O
published O
report O
of O
levofloxacin I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
TEN I-Effect
. O

On O
the O
second O
day O
of O
hospitalization O
, O
it O
was O
noted O
that O
the O
patient I-Subject
's O
dyspnea I-Effect
and I-Effect
sinus I-Effect
bradycardia I-Effect
could O
be O
related I-Adverse_event.Trigger
to O
a I-Treatment
recent I-Treatment
increase I-Treatment
in I-Treatment
his I-Treatment
timolol I-Treatment.Drug
dosage I-Treatment
. O

Three I-Treatment.Duration
months I-Treatment.Duration
following I-Treatment
splenectomy I-Treatment.Combination.Drug
, O
multiple I-Effect
abscesses I-Effect
occurred I-Effect
in I-Effect
the I-Effect
muscles I-Effect
of I-Effect
both I-Effect
thighs I-Effect
while I-Adverse_event.Trigger
the I-Subject
patient I-Subject
was O
receiving O
the O
third I-Treatment.Dosage
course I-Treatment.Dosage
of I-Treatment
the I-Treatment
CHOP I-Treatment.Combination.Drug
regimen I-Treatment
. O

Methylene I-Treatment.Drug
blue I-Treatment.Drug
is O
used O
in O
a O
variety O
of O
surgical O
settings O
as O
well O
as O
for O
treatment I-Potential_therapeutic_event.Trigger
of O
various O
types O
of O
hypotensive I-Treat_Disorder
shock I-Treat_Disorder
and O
methemoglobinaemia I-Treat_Disorder
. O

Methanol I-Treatment.Drug
toxicity I-Treatment
can O
cause I-Adverse_event.Trigger
severe O
central I-Effect
nervous I-Effect
system I-Effect
insult I-Effect
in O
which O
a O
characteristic O
pattern O
of O
bilateral O
putaminal O
injury O
is O
noted O
on O
brain O
imaging O
studies O
. O

We O
believe O
that O
these O
skin I-Effect
eruptions I-Effect
belong O
to O
a O
spectrum O
of O
neutrophilic O
dermatoses O
that O
can O
be O
induced I-Adverse_event.Trigger
or O
aggravated O
by O
G I-Treatment.Drug
- I-Treatment.Drug
CSF I-Treatment.Drug
therapy O
. O

Although O
adverse O
reactions O
to O
protamine O
are O
reported O
infrequently O
and O
are O
usually O
mild O
, O
we O
recently O
observed O
the O
first O
fatal I-Effect
case I-Effect
of I-Effect
type I-Effect
I I-Effect
anaphylaxis I-Effect
resulting I-Adverse_event.Trigger
from O
protamine I-Treatment.Drug
. O

We O
have O
reported O
six I-Subject.Population
cases I-Subject
of O
metoclopramide I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
parkinsonism I-Effect
seen O
in O
consultation O
over O
a O
two O
- O
year O
period O
. O

Neutrophilic I-Effect
eccrine I-Effect
hidradenitis I-Effect
mimicking O
cutaneous O
vasculitis O
in O
a I-Subject
lupus I-Treat_Disorder
patient I-Subject
: O
a O
complication I-Adverse_event.Trigger
of O
cyclophosphamide I-Treatment.Drug
. O

Gliclazide I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
acute I-Effect
hepatitis I-Effect
. O

A I-Subject
16 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
white I-Subject.Race
male I-Subject.Gender
with I-Subject
acute I-Subject.Sub_Disorder
biphenotypic I-Subject.Sub_Disorder
leukemia I-Subject.Sub_Disorder
developed I-Adverse_event.Trigger
evidence O
of O
the O
eosinophilia I-Effect
myalgia I-Effect
syndrome I-Effect
associated O
with O
total I-Treatment
parenteral I-Treatment.Route
nutritional I-Treatment
support I-Treatment
with I-Treatment
solutions I-Treatment
containing I-Treatment
tryptophan I-Treatment.Drug
, I-Treatment
which I-Treatment
were I-Treatment
given I-Treatment
during I-Treatment
his I-Treatment
initial I-Treatment
induction I-Treatment
chemotherapy I-Treatment
and I-Treatment
also I-Treatment
after I-Treatment
autologous I-Treatment
marrow I-Treatment
transplantation I-Treatment
. O

Subacute I-Effect
cholestatic I-Effect
hepatitis I-Effect
likely O
related I-Adverse_event.Trigger
to I-Adverse_event.Trigger
the O
use I-Treatment
of I-Treatment
senna I-Treatment.Drug
for O
chronic I-Treat_Disorder
constipation I-Treat_Disorder
. I-Treat_Disorder

Palmar I-Effect
- I-Effect
plantar I-Effect
erythrodysaesthesia I-Effect
( I-Effect
PPE I-Effect
) I-Effect
is O
an I-Effect
uncommon I-Effect
cutaneous I-Effect
complication I-Effect
of O
cytotoxic I-Treatment.Drug
chemotherapy I-Treatment.Route
which O
generally O
presents O
as O
a I-Effect
painful I-Effect
erythema I-Effect
involving I-Effect
the I-Effect
palms I-Effect
and I-Effect
soles I-Effect
. O

We O
report O
a O
case O
of O
an I-Subject
11 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
boy I-Subject.Gender
who O
experienced I-Adverse_event.Trigger
an I-Effect
anaphylactic I-Effect
reaction I-Effect
after I-Treatment
administration I-Treatment
of I-Treatment
bacitracin I-Treatment.Drug
ointment I-Treatment
. O

The I-Subject
patient I-Subject
was O
found I-Adverse_event.Trigger
to O
have O
no I-Effect
motile I-Effect
sperm I-Effect
with I-Effect
a I-Effect
normal I-Effect
sperm I-Effect
count I-Effect
, O
while O
taking O
a O
dose O
of O
400 I-Treatment.Dosage
mg I-Treatment.Dosage
/ I-Treatment.Dosage
day I-Treatment.Dosage
of I-Treatment
carbamazepine I-Treatment.Drug
. O

A I-Effect
fatal I-Effect
pancytopenia I-Effect
occurred I-Adverse_event.Trigger
in O
a I-Subject
patient I-Subject
with I-Subject
an I-Subject
history I-Subject
of I-Subject
depression I-Subject.Sub_Disorder
with I-Subject
hypomanic I-Subject.Sub_Disorder
rebounds I-Subject.Sub_Disorder
, O
admitted O
for O
a I-Treat_Disorder
manic I-Treat_Disorder
episode I-Treat_Disorder
and O
treated I-Treatment
with I-Treatment
levomepromazine I-Treatment.Combination.Drug
, I-Treatment
diazepam I-Treatment.Combination.Drug
and I-Treatment
lithium I-Treatment.Combination.Drug
carbonate I-Treatment.Combination.Drug
. O

Oxatomide I-Treatment.Drug
is O
an O
antiallergic O
drug O
used I-Potential_therapeutic_event.Trigger
for O
the O
treatment O
of O
diseases I-Treat_Disorder
mediated I-Treat_Disorder
by I-Treat_Disorder
type I-Treat_Disorder
I I-Treat_Disorder
allergy I-Treat_Disorder
. O

Toxic I-Effect
hepatitis I-Effect
induced I-Adverse_event.Trigger
by O
disulfiram I-Treatment.Drug
in O
a I-Subject
non I-Subject
- I-Subject
alcoholic I-Subject
. O

Accordingly O
, O
camptocormia I-Effect
is O
a O
dose O
- O
dependent O
side O
effect I-Adverse_event.Trigger
of O
valproate I-Treatment.Drug
. O

The O
uncomplicated O
long I-Treatment.Duration
- I-Treatment.Duration
term I-Treatment.Duration
use I-Treatment
of I-Treatment
adequately I-Treatment.Dosage
- I-Treatment.Dosage
dosed I-Treatment.Dosage
AZA I-Treatment.Drug
and I-Treatment
stable I-Treatment
non I-Treatment
- I-Treatment
toxic I-Treatment
metabolite I-Treatment
levels I-Treatment
could I-Treatment
not I-Treatment
acknowledge I-Treatment
TPMT I-Treatment
deficiency I-Treatment
as O
a O
primary O
cause I-Adverse_event.Trigger
of O
the O
leukopenia I-Effect
. O

CASE O
SUMMARY O
: O
A O
65 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
patient I-Subject
chronically I-Treatment.Duration
treated I-Treatment
with I-Treatment
the I-Treatment
selective I-Treatment
serotonin I-Treatment
reuptake I-Treatment
inhibitor I-Treatment
( I-Treatment
SSRI I-Treatment
) I-Treatment
citalopram I-Treatment.Combination.Drug
developed I-Adverse_event.Trigger
confusion I-Effect
, I-Effect
agitation I-Effect
, I-Effect
tachycardia I-Effect
, I-Effect
tremors I-Effect
, I-Effect
myoclonic I-Effect
jerks I-Effect
and I-Effect
unsteady I-Effect
gait I-Effect
, I-Effect
consistent I-Effect
with I-Effect
serotonin I-Effect
syndrome I-Effect
, O
following I-Treatment
initiation I-Treatment
of I-Treatment
fentanyl I-Treatment.Combination.Drug
, O
and O
all O
symptoms O
and O
signs O
resolved O
following O
discontinuation O
of O
fentanyl O
. O

Such O
a O
case O
induced O
by O
hypothyroidism I-Effect
complicating I-Adverse_event.Trigger
long I-Treatment.Duration
- I-Treatment.Duration
term I-Treatment.Duration
therapy I-Treatment
with I-Treatment
amiodarone I-Treatment.Drug
in O
a I-Subject
45 I-Subject.Age
year I-Subject.Age
old I-Subject.Age
woman I-Subject.Gender
with I-Subject
pre I-Treat_Disorder
- I-Treat_Disorder
excitation I-Treat_Disorder
is O
presented O
. O

The O
diagnosis O
was O
based O
on O
the O
rapid I-Effect
onset I-Effect
of I-Effect
renal I-Effect
failure I-Effect
, I-Effect
presence I-Effect
of I-Effect
eosinophilia I-Effect
, I-Effect
skin I-Effect
rash I-Effect
, I-Effect
and I-Effect
characteristic I-Effect
renal I-Effect
biopsy I-Effect
finding O
, O
following I-Adverse_event.Trigger
the O
administration O
of O
ampicillin I-Treatment.Drug
. O

46 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
woman I-Subject.Gender
developed I-Adverse_event.Trigger
painful I-Effect
ulcers I-Effect
over I-Effect
her I-Effect
lower I-Effect
abdomen I-Effect
in I-Effect
the I-Effect
form I-Effect
of I-Effect
reticulate I-Effect
erythema I-Effect
after O
injecting I-Treatment.Route
interferon I-Treatment.Drug
beta I-Treatment.Drug
- I-Treatment.Drug
1b I-Treatment.Drug
subcutaneously I-Treatment
for O
multiple I-Treat_Disorder
sclerosis I-Treat_Disorder
. O

Lupus I-Effect
- I-Effect
like I-Effect
syndrome I-Effect
caused I-Adverse_event.Trigger
by O
5 I-Treatment.Drug
- I-Treatment.Drug
aminosalicylic I-Treatment.Drug
acid I-Treatment.Drug
in O
patients I-Subject
with I-Subject
inflammatory I-Treat_Disorder
bowel I-Treat_Disorder
disease I-Treat_Disorder
. O

Fatal O
acute I-Effect
tubular I-Effect
necrosis I-Effect
occurred I-Adverse_event.Trigger
in O
1 I-Subject.Population
patient I-Subject
in O
whom O
intravesical I-Treatment.Route
formalin I-Treatment.Drug
was O
used O
to O
control O
massive I-Treat_Disorder
persistent I-Treat_Disorder
hemorrhage I-Treat_Disorder
from I-Treat_Disorder
radiation I-Treat_Disorder
cystitis I-Treat_Disorder
. O

The O
hypercalcemia I-Treat_Disorder
responded I-Potential_therapeutic_event.Trigger
to O
discontinuation I-Treatment
of I-Treatment
rhGH I-Treatment.Drug
and I-Treatment
a I-Treatment
single I-Treatment
dose I-Treatment
of I-Treatment
intravenous I-Treatment.Route
pamidronate I-Treatment.Drug
disodium I-Treatment.Drug
and O
has I-Effect
not I-Effect
recurred I-Effect
in I-Effect
8 I-Effect
months I-Effect
of I-Effect
follow I-Effect
- I-Effect
up I-Effect
. O

The O
administration O
of O
" I-Treatment
sweet I-Treatment.Drug
spirits I-Treatment.Drug
of I-Treatment.Drug
nitre I-Treatment.Drug
" I-Treatment
( I-Treatment
4 I-Treatment
% I-Treatment
ethyl I-Treatment
nitrite I-Treatment
CH3CH2ONO I-Treatment
in I-Treatment
70 I-Treatment
% I-Treatment
ethyl I-Treatment
alcohol I-Treatment
) I-Treatment
was O
followed I-Adverse_event.Trigger
by O
acute I-Effect
methemoglobinemia I-Effect
and I-Effect
severe I-Effect
anoxic I-Effect
metabolic I-Effect
acidosis I-Effect
in O
infant I-Subject.Age
twins I-Subject
, O
Methylene O
blue O
administration O
reversed O
methemoglobinemia O
in O
both O
, O
but O
one O
twin O
died O
from O
the O
consequences O
of O
hypoxemia O
. O

The O
administration O
of O
" O
sweet O
spirits O
of O
nitre O
" O
( O
4 O
% O
ethyl O
nitrite O
CH3CH2ONO O
in O
70 O
% O
ethyl O
alcohol O
) O
was O
followed O
by O
acute O
methemoglobinemia O
and O
severe O
anoxic O
metabolic O
acidosis O
in O
infant I-Subject.Age
twins I-Subject
, O
Methylene I-Treatment.Drug
blue I-Treatment.Drug
administration O
reversed I-Potential_therapeutic_event.Trigger
methemoglobinemia I-Treat_Disorder
in O
both O
, O
but O
one O
twin O
died O
from O
the O
consequences O
of O
hypoxemia O
. O

The O
administration O
of O
" I-Treatment
sweet I-Treatment.Drug
spirits I-Treatment.Drug
of I-Treatment.Drug
nitre I-Treatment.Drug
" I-Treatment
( I-Treatment
4 I-Treatment
% I-Treatment
ethyl I-Treatment
nitrite I-Treatment
CH3CH2ONO I-Treatment
in I-Treatment
70 I-Treatment
% I-Treatment
ethyl I-Treatment
alcohol I-Treatment
) I-Treatment
was O
followed O
by O
acute O
methemoglobinemia O
and O
severe O
anoxic O
metabolic O
acidosis O
in O
infant O
twins O
, O
Methylene O
blue O
administration O
reversed O
methemoglobinemia O
in O
both O
, O
but O
one I-Subject
twin I-Subject
died I-Effect
from I-Effect
the I-Effect
consequences I-Effect
of I-Effect
hypoxemia I-Effect
. O

The O
authors O
describe O
three I-Subject.Population
families I-Subject
in O
whom O
the O
occurrence O
of O
FVS I-Effect
in O
all I-Subject
the I-Subject
siblings I-Subject
strongly O
suggests O
hereditary O
susceptibility I-Adverse_event.Trigger
to O
valproic I-Treatment.Drug
acid I-Treatment.Drug
- I-Treatment
induced I-Treatment
adverse O
outcome O
. O

We O
hypothesize O
that O
capecitabine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
headache I-Effect
is O
vascular O
in O
nature O
. O

A I-Effect
lupus I-Effect
- I-Effect
like I-Effect
syndrome I-Effect
associated I-Adverse_event.Trigger
with O
infliximab I-Treatment.Drug
therapy O
. O

A O
case O
report O
of O
a I-Subject
patient I-Subject
with I-Subject
probable I-Treat_Disorder
cisplatin I-Treat_Disorder
and O
bleomycin I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
TMA I-Effect
is O
presented O
. O

In O
some O
cases O
this O
seems O
to O
happen O
because O
spironolactone I-Treatment.Drug
causes I-Adverse_event.Trigger
diarrhoea I-Effect
. O

Painful I-Effect
neutrophilic I-Effect
skin I-Effect
lesions I-Effect
were O
observed I-Adverse_event.Trigger
in O
two I-Subject.Population
children I-Subject.Age
receiving O
granulocyte I-Treatment.Drug
colony I-Treatment.Drug
- I-Treatment.Drug
stimulating I-Treatment.Drug
factor I-Treatment.Drug
( I-Treatment
G I-Treatment
- I-Treatment
CSF I-Treatment
) I-Treatment
for O
treatment O
of O
idiopathic I-Treat_Disorder
neutropenia I-Treat_Disorder
. O

Apparent I-Effect
central I-Effect
nervous I-Effect
system I-Effect
depression I-Effect
in O
infants I-Subject.Age
after I-Adverse_event.Trigger
the O
use O
of O
topical I-Treatment.Route
brimonidine I-Treatment.Drug
. O

To O
our O
knowledge O
, O
this O
is O
the O
first O
report O
of O
insulin I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
lipohypertrophy I-Effect
with O
detailed O
histological O
examinations O
. O

Tigecycline I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
acute I-Effect
pancreatitis I-Effect
: O
case O
report O
and O
literature O
review O
. O

Polymyositis I-Effect
is O
a O
rare O
complication I-Adverse_event.Trigger
of I-Adverse_event.Trigger
interferon I-Treatment.Drug
alpha I-Treatment.Drug
treatment I-Treatment
as O
a O
result O
of O
immune O
- O
modulating O
role O
of O
the O
drug O
itself O
. O

Sodium I-Treatment.Combination.Drug
thiosulfate I-Treatment.Combination.Drug
is I-Treatment
a I-Treatment
neutralizing I-Treatment
agent I-Treatment
for I-Treatment
cisplatin I-Treatment.Combination.Drug
that O
protects I-Effect
against I-Effect
renal I-Treat_Disorder
damage I-Treat_Disorder
. O

Anaphylactic I-Effect
reaction I-Adverse_event.Trigger
to O
bacitracin I-Treatment.Drug
ointment I-Treatment
. O

Severe I-Effect
bleomycin I-Treatment.Drug
lung I-Effect
toxicity I-Effect
: O
reversal O
with O
high O
dose O
corticosteroids O
. O

CONCLUSIONS O
: O
Although O
mirtazapine I-Treatment.Drug
offers O
clinicians O
a O
combination O
of O
strong O
efficacy O
and O
good O
safety O
, O
we O
suggest O
bearing I-Adverse_event.Trigger
SS I-Effect
in O
mind O
when O
prescribing O
this O
drug O
, O
especially O
in O
frail I-Subject
, I-Subject
elderly I-Subject.Age
patients I-Subject
with I-Subject
underlying I-Subject.Sub_Disorder
chronic I-Subject.Sub_Disorder
conditions I-Subject.Sub_Disorder
. O

Five O
cases O
of O
clindamycin I-Treatment.Drug
- O
associated I-Adverse_event.Trigger
pseudomembranous I-Effect
colitis I-Effect
in O
leukaemic I-Subject.Sub_Disorder
patients I-Subject
are O
reported O
. O

Three O
days O
after O
receiving O
intravitreal I-Treatment.Route
injection I-Treatment.Route
of I-Treatment
bevacizumab I-Treatment.Drug
( I-Treatment
1.25 I-Treatment.Dosage
mg I-Treatment.Dosage
in I-Treatment.Dosage
0.1 I-Treatment.Dosage
ml I-Treatment.Dosage
) I-Treatment
, I-Treatment
he I-Subject.Gender
developed I-Adverse_event.Trigger
acute I-Effect
vision I-Effect
loss I-Effect
and I-Effect
change I-Effect
of I-Effect
consciousness I-Effect
. O

The O
proposed O
cause O
of O
the O
nausea I-Effect
and I-Effect
anorexia I-Effect
was I-Effect
digoxin I-Combination.Drug
toxicity I-Effect
secondary I-Adverse_event.Trigger
to O
a O
drug O
- O
drug O
interaction O
with O
ciprofloxacin I-Treatment.Combination.Drug
. O

Mitomycin I-Treatment.Drug
C I-Treatment.Drug
( I-Treatment
MMC I-Treatment
) I-Treatment
is O
an O
alkylating O
agent O
that O
has O
been O
recently O
associated I-Adverse_event.Trigger
with O
the I-Effect
hemolytic I-Effect
- I-Effect
uremic I-Effect
syndrome I-Effect
( I-Effect
HUS I-Effect
) I-Effect
. O

Muscle O
biopsy O
revealed O
variation I-Effect
in I-Effect
muscle I-Effect
fiber I-Effect
size I-Effect
and I-Effect
few I-Effect
vacuolated I-Effect
fibers I-Effect
which O
were O
features O
of O
colchicine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
myopathy I-Effect
. O

We O
describe O
a I-Subject
patient I-Subject
who O
developed O
NEH I-Effect
on O
three O
separate O
occasions O
provoked I-Adverse_event.Trigger
by O
two O
different O
chemotherapeutic O
agents O
-- O
cytarabine I-Treatment.Combination.Drug
and I-Treatment
mitoxantrone I-Treatment.Combination.Drug
. O

Orofacial I-Effect
dyskinesia I-Effect
appeared I-Adverse_event.Trigger
5 I-Treatment.Time_elapsed
hours I-Treatment.Time_elapsed
after I-Treatment.Time_elapsed
methylphenidate I-Treatment.Drug
administration O
, O
persisted O
for O
10 O
hours O
, O
and O
had O
completely O
resolved O
within O
2 O
days O
. O

Present O
results O
suggested O
that O
coadministration I-Treatment
of I-Treatment
mexiletine I-Treatment.Combination.Drug
increased I-Treatment
blood I-Treatment
tizanidine I-Treatment.Combination.Drug
concentrations I-Treatment
and O
enhanced I-Potential_therapeutic_event.Trigger
tizanidine I-Effect
pharmacodynamics I-Effect
in I-Effect
terms I-Effect
of I-Effect
reduction I-Effect
in I-Effect
blood I-Effect
pressure I-Effect
and I-Effect
adverse I-Effect
symptoms I-Effect
. O

Bilateral I-Effect
acoustic I-Effect
( I-Effect
VIII I-Effect
) I-Effect
nerve I-Effect
palsy I-Effect
in O
this I-Subject
patient I-Subject
was O
most I-Adverse_event.Trigger
likely I-Adverse_event.Trigger
a O
manifestation O
of O
vincristine I-Treatment.Drug
neurotoxicity I-Effect
. O

Acute I-Effect
leukopenia I-Effect
associated I-Adverse_event.Trigger
with O
silver I-Treatment.Drug
sulfadiazine I-Treatment.Drug
therapy O
. O

We O
describe O
two I-Subject.Population
cases I-Subject
of I-Subject
PSVT I-Treat_Disorder
that O
changed I-Adverse_event.Trigger
to O
non I-Effect
- I-Effect
sustained I-Effect
polymorphic I-Effect
ventricular I-Effect
tachycardia I-Effect
after O
administration I-Treatment
of I-Treatment
verapamil I-Treatment.Drug
. I-Treatment

We O
described O
the O
occurrence O
of O
L I-Treatment.Drug
- I-Treatment.Drug
dopa I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
myoclonus I-Effect
and I-Effect
seizures I-Effect
in O
a O
case I-Subject
of I-Subject
parkinsonism I-Treat_Disorder
with O
its O
SEPs O
findings O
. O

Retrospectively O
, O
bucillamine I-Treatment.Drug
was O
believed O
to O
be O
the O
cause I-Adverse_event.Trigger
of I-Adverse_event.Trigger
the O
giant I-Effect
hypertrophy I-Effect
because O
of O
its O
structural O
similarity O
to O
D I-Drug
- I-Drug
penicillamine I-Drug
, O
which O
was O
the O
subject O
of O
an O
abundance O
of O
reports O
of O
mammary O
hyperplasia O
. O

We O
speculate O
that O
platelet O
activation O
induced O
by O
pFVIII I-Treatment.Drug
may O
have O
contributed I-Adverse_event.Trigger
to O
thrombosis I-Effect
and O
suggest O
that O
pFVIII O
be O
used O
with O
caution O
in O
elderly O
patients O
with O
pre O
- O
existing O
cardiovascular I-Treat_Disorder
risk O
factors O
. O

Restoration I-Effect
of I-Effect
vancomycin I-Drug
susceptibility I-Effect
in I-Effect
Enterococcus I-Effect
faecalis I-Effect
by I-Potential_therapeutic_event.Trigger
antiresistance I-Treatment
determinant I-Treatment
gene I-Treatment
transfer I-Treatment
. O

Dental I-Effect
and I-Effect
gingival I-Effect
pain I-Effect
as O
side I-Adverse_event.Trigger
effects I-Adverse_event.Trigger
of O
niacin I-Treatment.Drug
therapy O
. O

We O
describe O
a O
case O
of O
significant I-Effect
elevation I-Effect
of I-Effect
serum I-Effect
transaminases I-Effect
in O
a I-Subject
patient I-Subject
treated O
with O
6 I-Treatment.Drug
- I-Treatment.Drug
TG I-Treatment.Drug
for O
a O
flare O
of O
Crohn I-Treat_Disorder
's I-Treat_Disorder
disease I-Treat_Disorder
. O

A I-Subject
patient I-Subject
developed I-Adverse_event.Trigger
transient I-Effect
, I-Effect
acute I-Effect
myopia I-Effect
while O
on O
isotretinoin I-Treatment.Drug
( I-Treatment
Accutane I-Treatment
) I-Treatment
therapy O
for O
acne I-Treat_Disorder
. O

CONCLUSIONS O
: O
The O
pathogenesis O
of O
methotrexate I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
papular I-Effect
eruption I-Effect
in O
collagen I-Treat_Disorder
vascular I-Treat_Disorder
diseases I-Treat_Disorder
may O
suggest O
cutaneous O
small O
- O
vessel O
vasculitis O
. O

Aminophylline I-Effect
hypersensitivity I-Effect
apparently O
due I-Adverse_event.Trigger
to O
ethylenediamine I-Treatment.Drug
. O

The O
main O
clinical O
features O
of O
this I-Subject
58 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
female I-Subject.Gender
patient O
were O
laboratory O
evidence O
of O
leucopenia I-Effect
and I-Effect
cholestasis I-Effect
, I-Effect
and I-Effect
biopsy I-Effect
features I-Effect
of I-Effect
fatty I-Effect
liver I-Effect
parenchyma I-Effect
degeneration I-Effect
with I-Effect
granulocytic I-Effect
portal I-Effect
infiltration I-Effect
and I-Effect
bile I-Effect
stasis I-Effect
, O
demonstrated I-Adverse_event.Trigger
20 I-Time_elapsed
days I-Time_elapsed
after I-Time_elapsed
the O
initiation O
of O
antithyroid I-Treatment
therapy I-Treatment
with I-Treatment
20 I-Treatment.Dosage
mg I-Treatment.Dosage
methimazole I-Treatment.Drug
daily I-Treatment.Freq
. O

In O
one I-Subject.Population
patient I-Subject
the I-Subject
vasculitis I-Treat_Disorder
resolved I-Potential_therapeutic_event.Trigger
after O
termination I-Treatment
of I-Treatment
the I-Treatment
ciprofloxacin I-Treatment.Drug
therapy I-Treatment
; O
in O
the O
other O
patient O
the O
ciprofloxacin O
- O
induced O
hemorrhagic O
vasculitis O
was O
superimposed O
on O
a O
severe O
forefoot O
infection O
, O
leading O
to O
progressive O
gangrene O
and O
a O
below O
- O
knee O
amputation O
. O

In O
one O
patient O
the O
vasculitis O
resolved O
after O
termination O
of O
the O
ciprofloxacin O
therapy O
; O
in O
the O
other O
patient I-Subject
the O
ciprofloxacin I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
hemorrhagic I-Effect
vasculitis I-Effect
was I-Effect
superimposed I-Effect
on I-Effect
a I-Effect
severe I-Effect
forefoot I-Effect
infection I-Effect
, I-Effect
leading I-Effect
to I-Effect
progressive I-Effect
gangrene I-Effect
and I-Effect
a I-Effect
below I-Effect
- I-Effect
knee I-Effect
amputation I-Effect
. O

Excluding O
other O
causes O
, O
Pentasa I-Treatment.Drug
- O
associated I-Adverse_event.Trigger
pancytopenia I-Effect
was O
considered O
. O

RESULTS O
: O
A I-Effect
patient I-Effect
developed I-Adverse_event.Trigger
a O
bilaterally I-Effect
symmetric I-Effect
bull's I-Effect
- I-Effect
eye I-Effect
maculopathy I-Effect
45 I-Treatment.Time_elapsed
years I-Treatment.Time_elapsed
after I-Treatment.Time_elapsed
taking I-Treatment
quinacrine I-Treatment.Drug
for I-Treatment
18 I-Treatment.Time_elapsed
months I-Treatment.Time_elapsed
as O
prophylaxis O
against O
malaria I-Treat_Disorder
. O

Possible O
digoxin I-Treatment.Combination.Drug
toxicity I-Effect
associated I-Adverse_event.Trigger
with O
concomitant O
ciprofloxacin I-Treatment.Combination.Drug
therapy O
. O

The O
exophthalmos I-Treat_Disorder
improved I-Potential_therapeutic_event.Trigger
dramatically O
within I-Treatment.Time_elapsed
72 I-Treatment.Time_elapsed
hours I-Treatment.Time_elapsed
of I-Treatment
the I-Treatment
withdrawal I-Treatment
of I-Treatment
lithium I-Treatment.Drug
. O

We O
report O
two I-Subject.Population
cases I-Subject
of I-Subject
neutropenia I-Effect
following I-Adverse_event.Trigger
captopril I-Treatment.Drug
use I-Treatment
in O
cardiac I-Subject.Sub_Disorder
patients I-Subject
with I-Subject
trisomy I-Subject.Sub_Disorder
21 I-Subject.Sub_Disorder
. O

We O
report O
a O
case O
of O
hyponatremia I-Effect
associated I-Effect
with I-Effect
a I-Effect
grand I-Effect
mal I-Effect
seizure I-Effect
in O
a I-Subject
28 I-Subject.Age
month I-Subject.Age
- I-Subject.Age
old I-Subject.Age
child I-Subject.Age
after I-Adverse_event.Trigger
intra I-Treatment.Route
- I-Treatment.Route
nasal I-Treatment.Route
desmopressin I-Treatment.Drug
administration I-Treatment
for O
high I-Treat_Disorder
fluid I-Treat_Disorder
intake I-Treat_Disorder
with I-Treat_Disorder
nocturnal I-Treat_Disorder
enuresis I-Treat_Disorder
. O

He I-Subject.Gender
developed I-Adverse_event.Trigger
fever I-Effect
, I-Effect
nausea I-Effect
, I-Effect
diarrhea I-Effect
, I-Effect
and I-Effect
malaise I-Effect
and O
stopped O
taking O
on O
the O
third I-Time_elapsed
day I-Time_elapsed
after O
commencing O
Pentasa I-Treatment.Drug
. O

Livedo I-Effect
reticularis I-Effect
associated I-Adverse_event.Trigger
with O
interferon I-Treatment.Drug
alpha I-Treatment.Drug
therapy I-Treatment
in O
two I-Subject.Population
melanoma I-Treat_Disorder
patients I-Subject
. O

A I-Subject
60 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
woman I-Subject.Gender
with I-Subject
diabetes I-Treat_Disorder
mellitus I-Treat_Disorder
( I-Treat_Disorder
type I-Treat_Disorder
2 I-Treat_Disorder
) I-Treat_Disorder
developed I-Adverse_event.Trigger
an I-Effect
acute I-Effect
icteric I-Effect
hepatitis I-Effect
- I-Effect
like I-Effect
illness I-Effect
6 I-Treatment.Time_elapsed
weeks I-Treatment.Time_elapsed
after I-Treatment
the I-Treatment
initiation I-Treatment
of I-Treatment
gliclazide I-Treatment.Drug
therapy I-Treatment
. O

Thus O
cabergoline I-Treatment.Drug
may O
cause I-Adverse_event.Trigger
similar O
pleuropulmonary I-Effect
abnormalities I-Effect
to O
bromocriptine I-Treatment.Drug
. O

Although O
the O
existence O
of O
an O
acute O
pericarditis O
or O
an O
acute O
myocarditis O
as O
possible O
causes O
of O
the O
ST O
elevation O
can O
not O
be O
fully O
ruled O
out O
, O
the O
sudden O
onset O
, O
prominent O
magnitude O
, O
and O
brief O
duration O
of O
the O
ST O
elevation O
are O
perhaps O
more O
indicative O
of O
an O
acute O
ischemic O
event O
, O
possibly O
related O
to O
a O
transient I-Effect
coronary I-Effect
vasoconstriction I-Effect
induced I-Adverse_event.Trigger
by O
the O
dopamine I-Treatment.Drug
infusion O
. O

Acute I-Effect
sensorineural I-Effect
hearing I-Effect
loss I-Effect
following I-Adverse_event.Trigger
intravenous I-Treatment.Route
ketoralac I-Treatment.Drug
administration O
. O

Trimethoprim I-Treatment.Drug
- I-Treatment.Drug
sulfamethoxazole I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
hypersensitivity I-Effect
syndrome I-Effect
associated I-Effect
with I-Effect
reactivation I-Effect
of I-Effect
human I-Effect
herpesvirus I-Effect
- I-Effect
6 I-Effect
. O

A I-Subject
patient I-Subject
is O
described O
who O
developed I-Adverse_event.Trigger
a O
rapid O
onset O
of O
pulmonary I-Effect
fibrosis I-Effect
following O
treatment O
with O
a O
new O
non O
- O
steroidal O
anti O
- O
inflammatory O
drug O
, O
nabumetone I-Treatment.Drug
. O

To O
report O
a O
case I-Adverse_event.Trigger
of O
increased I-Effect
international I-Effect
normalized I-Effect
ratio I-Effect
( I-Effect
INR I-Effect
) I-Effect
in O
a I-Subject
geriatric I-Subject.Age
patient I-Subject
receiving O
warfarin I-Treatment.Combination.Drug
and I-Treatment
ropinirole I-Treatment.Combination.Drug
. O

There O
is O
documentation O
of O
ocular I-Effect
toxicity I-Effect
with I-Adverse_event.Trigger
ethambutol I-Treatment.Drug
when O
administered O
at O
dosages O
generally O
pronounced O
as O
being O
safe O
. O

k I-Treat_Disorder
bipolar I-Treat_Disorder
manic I-Treat_Disorder
- I-Treat_Disorder
depressive I-Treat_Disorder
patient I-Subject
, O
developed I-Adverse_event.Trigger
while O
on O
lithium I-Treatment.Drug
prophylaxis O
, O
akathisia I-Effect
at I-Treatment
therapeutic I-Treatment
serum I-Treatment
lithium I-Treatment
levels I-Treatment
and O
subsequently O
bucco I-Effect
- I-Effect
linguo I-Effect
- I-Effect
masticatory I-Effect
dyskinesia I-Effect
. O

We O
describe O
a I-Subject
patient I-Subject
who O
had O
a O
systemic I-Effect
allergic I-Effect
contact I-Effect
dermatitis I-Effect
to I-Effect
8 I-Effect
- I-Effect
MOP I-Effect
develop I-Adverse_event.Trigger
during O
her O
second O
course O
of O
PUVA I-Treatment.Drug
treatment O
for O
psoriasis I-Treat_Disorder
. O

Seizures I-Treat_Disorder
were O
treated I-Potential_therapeutic_event.Trigger
with O
diazepam I-Treatment.Drug
. O

Paradoxical I-Effect
seizures I-Effect
in O
phenytoin I-Treatment.Drug
toxicity I-Treatment
. O

CASE O
SUMMARY O
: O
Two I-Subject.Population
children I-Subject.Age
with I-Subject
attention I-Treat_Disorder
deficit I-Treat_Disorder
disorder I-Treat_Disorder
treated O
with O
methylphenidate I-Treatment.Drug
as I-Treatment
a I-Treatment
simple I-Treatment
drug I-Treatment
developed I-Adverse_event.Trigger
fixed I-Effect
drug I-Effect
eruption I-Effect
of I-Effect
the I-Effect
scrotum I-Effect
. O

While O
the O
patient O
was O
receiving O
both O
drugs O
, O
platelet O
aggregation O
studies O
revealed I-Adverse_event.Trigger
less I-Effect
platelet I-Effect
inhibition I-Effect
than I-Effect
would I-Effect
be I-Effect
expected I-Effect
in O
a I-Subject
patient I-Subject
not O
taking I-Treatment
a I-Treatment
concomitant I-Treatment
inducer I-Treatment.Combination.Drug
of I-Treatment.Combination.Drug
ticagrelor I-Treatment.Combination.Drug
metabolism I-Treatment.Combination.Drug
. I-Treatment

Metformin I-Treatment.Drug
- O
associated I-Adverse_event.Trigger
lactic I-Effect
acidosis I-Effect
precipitated O
by O
diarrhea O
. O

To O
date O
, O
only O
1 I-Subject.Population
death I-Effect
attributable I-Adverse_event.Trigger
to O
risperidone I-Treatment.Drug
overdose I-Treatment.Dosage
has O
been O
reported O
. O

Systemic I-Effect
allergic I-Effect
contact I-Effect
dermatitis I-Effect
to I-Adverse_event.Trigger
8 I-Treatment.Drug
- I-Treatment.Drug
methoxypsoralen I-Treatment.Drug
( I-Treatment
8 I-Treatment
- I-Treatment
MOP I-Treatment
) I-Treatment
. O

A O
case O
of O
a I-Subject
21 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
woman I-Subject.Gender
who O
had O
developed O
mild I-Effect
hepatotoxicity I-Effect
while O
receiving I-Adverse_event.Trigger
choline I-Treatment.Drug
magnesium I-Treatment.Drug
trisalicylate I-Treatment.Drug
therapy O
is O
described O
. O

Early O
ritonavir I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
maculopapular I-Effect
eruption I-Effect
. O

In O
our I-Subject
patient I-Subject
, O
an O
objective O
causality O
scale O
showed O
that O
therapeutic I-Treatment.Dosage
doses I-Treatment.Dosage
of I-Treatment
colchicine I-Treatment.Drug
for I-Treatment
FMF I-Treatment.Treat_Disorder
were O
the O
definite O
cause I-Adverse_event.Trigger
of O
myopathy I-Effect
, O
even O
though O
his I-Subject.Gender
renal I-Subject
and I-Subject
hepatic I-Subject
function I-Subject
were I-Subject
normal I-Subject
. O

Thrombocytosis I-Effect
induced I-Adverse_event.Trigger
by O
enoxaparin I-Treatment.Drug
has O
been O
reported O
as O
a O
rare O
adverse O
effect O
of O
this O
medication O
in O
adults O
. O

A I-Subject
woman I-Subject.Gender
with I-Subject
a I-Subject
20 I-Subject
- I-Subject
year I-Subject
history I-Subject
of I-Subject
acral I-Treat_Disorder
pustular I-Treat_Disorder
psoriasis I-Treat_Disorder
of I-Treat_Disorder
Hallopeau I-Treat_Disorder
and I-Treat_Disorder
recurrent I-Treat_Disorder
pustular I-Treat_Disorder
lesions I-Treat_Disorder
of I-Treat_Disorder
the I-Treat_Disorder
forearms I-Treat_Disorder
and I-Treat_Disorder
lower I-Treat_Disorder
legs I-Treat_Disorder
, O
developed I-Adverse_event.Trigger
a I-Effect
B I-Effect
- I-Effect
cell I-Effect
lymphoma I-Effect
of I-Effect
the I-Effect
lip I-Effect
following I-Duration
4 I-Treatment.Duration
1/2 I-Treatment.Duration
years I-Treatment.Duration
of I-Treatment
treatment I-Treatment
with I-Treatment
razoxane I-Treatment.Drug
. O

The O
evidence O
of O
high O
plasmatic O
levels O
of O
CBZ I-Drug
and O
the O
absence O
of O
other O
aetiologic O
factors O
lead O
the O
authors O
to O
conclude O
that O
the O
overdose I-Treatment
of I-Treatment
CBZ I-Treatment
could O
have O
represented O
the O
precipitating I-Adverse_event.Trigger
of O
the O
episode O
of O
acute I-Effect
pancreatitis I-Effect
. O

In O
this O
report O
, O
we O
describe O
a O
fatal O
gemcitabine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
pulmonary I-Effect
toxicity I-Effect
in O
a I-Subject
patient I-Subject
with I-Subject
gallbladder I-Treat_Disorder
metastatic I-Treat_Disorder
adenocarcinoma I-Treat_Disorder
. O

Progressive I-Effect
interstitial I-Effect
fibrosis I-Effect
with I-Effect
roentgenographic I-Effect
honeycombing I-Effect
developed I-Adverse_event.Trigger
in O
the O
case O
of O
a I-Subject
psoriatic I-Treat_Disorder
patient I-Subject
who O
had O
been O
on O
a I-Treatment
regimen I-Treatment
of I-Treatment
methotrexate I-Treatment.Drug
for I-Treatment
18 I-Treatment.Duration
years I-Treatment.Duration
. O

In O
this O
report O
, O
one I-Subject.Population
patient I-Subject
who O
developed I-Adverse_event.Trigger
gangrene I-Effect
after O
bleomycin I-Treatment.Combination.Drug
and I-Treatment
vincristine I-Treatment.Combination.Drug
/ I-Treatment
vinblastine I-Treatment.Combination.Drug
chemotherapy O
for O
AIDS O
- O
related O
Kaposi O
's O
sarcoma O
and O
another O
HIV O
- O
infected O
patient O
who O
exhibited O
symptoms O
of O
severe O
Raynaud O
's O
phenomenon O
related O
to O
the O
same O
regimen O
are O
presented O
. O

These O
multiple O
overlapping O
factors O
probably O
lead I-Adverse_event.Trigger
to O
rhabdomyolysis I-Effect
in O
a O
minority O
of O
patients I-Subject
receiving O
vasopressin I-Treatment.Drug
infusion I-Route
. O

Due O
to O
the O
increasing O
use O
of O
TMP I-Treatment.Drug
- I-Treatment.Drug
SMX I-Treatment.Drug
in O
children I-Subject.Age
, O
clinicians O
should O
be O
aware O
of O
this O
potentially O
life I-Effect
- I-Effect
threatening I-Effect
, I-Effect
immunemediated I-Effect
hypersensitivity I-Effect
reaction I-Adverse_event.Trigger
. O

Given O
that O
discontinuation O
of O
nitrofurantoin O
and O
introduction O
of O
methylprednisolon O
therapy O
significantly O
lowered O
liver O
enzyme O
levels O
, O
restoring O
most O
of O
them O
to O
normal O
, O
we O
concluded O
that O
this O
was O
probably O
the O
case O
of O
toxic I-Effect
liver I-Effect
damage I-Effect
caused I-Adverse_event.Trigger
by O
nitrofurantoin I-Treatment.Drug
. O

Slow I-Subject.Sub_Disorder
acetylators I-Subject.Sub_Disorder
, O
who O
comprise O
roughly O
50 O
% O
of O
the O
South O
African O
population O
, O
are O
likely O
to O
develop I-Adverse_event.Trigger
clinical I-Effect
and I-Effect
biochemical I-Effect
features I-Effect
of I-Effect
phenytoin I-Treatment.Combination.Drug
toxicity I-Effect
when O
this O
drug O
is O
given O
together I-Treatment
with I-Treatment
antituberculosis I-Treatment.Combination.Drug
therapy O
. O

Therefore O
there O
is O
the O
potential I-Adverse_event.Trigger
for O
significant I-Effect
concentration I-Effect
- I-Effect
related I-Effect
adverse I-Effect
effects I-Effect
when O
phenytoin I-Treatment.Combination.Drug
is O
coadministered O
with O
other I-Treatment.Combination.Drug
CYP2C9 I-Treatment.Combination.Drug
substrates I-Treatment.Combination.Drug
. O

Putaminal I-Effect
infarct I-Effect
in I-Effect
methanol I-Treatment.Drug
intoxication I-Effect
: O
case O
report O
and O
role O
of O
brain O
imaging O
studies O
. O

Progressive I-Effect
interstitial I-Effect
lung I-Effect
disease I-Effect
from I-Adverse_event.Trigger
prolonged I-Treatment.Duration
methotrexate I-Treatment.Drug
therapy I-Treatment
. O

The O
case O
reported O
here O
is O
of O
a I-Subject
child I-Subject.Age
given O
a I-Treatment
large I-Treatment
dose I-Treatment
of I-Treatment
intravenous I-Treatment
iron I-Treatment.Drug
sucrose I-Treatment.Drug
( O
16 I-Dosage
mg I-Dosage
/ I-Dosage
kg I-Dosage
) O
over O
3 I-Duration
hours I-Duration
, O
who O
subsequently O
developed I-Adverse_event.Trigger
features O
of O
systemic I-Effect
iron I-Effect
toxicity I-Effect
. O

We O
report O
a I-Subject
patient I-Subject
with I-Subject
advanced I-Treat_Disorder
colonic I-Treat_Disorder
carcinoma I-Treat_Disorder
who I-Subject
was I-Subject
treated I-Subject
with I-Subject
concomitant I-Drug
chemoirradiation I-Drug
with I-Subject
oxaliplatin I-Drug
and O
developed I-Adverse_event.Trigger
a I-Effect
peculiar I-Effect
dermnatitis I-Effect
in I-Effect
the I-Effect
irradiated I-Effect
field I-Effect
after O
being O
exposed I-Treatment
to I-Treatment
subsequent I-Treatment
chemotherapy I-Treatment
with I-Treatment
oxaliplatin I-Treatment.Drug
. O

Recombinant I-Treatment.Drug
human I-Treatment.Drug
interferon I-Treatment.Drug
- I-Treatment.Drug
alpha I-Treatment.Drug
has O
been O
used O
in O
the O
treatment O
of O
several O
cancers I-Treat_Disorder
, O
but O
there O
have O
been O
several O
reports O
that O
it O
may O
exacerbate I-Effect
psoriasis I-Effect
or O
trigger I-Adverse_event.Trigger
off O
its O
onset O
. O

This O
is O
the O
first O
case O
of O
HBV I-Effect
reactivation I-Effect
occurring I-Adverse_event.Trigger
during O
the I-Treatment
year I-Treatment.Time_elapsed
following I-Treatment.Time_elapsed
rituximab I-Treatment.Drug
monotherapy I-Treatment
in I-Treatment
the I-Treatment
absence I-Treatment
of I-Treatment
any I-Treatment
other I-Treatment
immunosuppressive I-Treatment
factor I-Treatment
. O

Systemic I-Effect
lupus I-Effect
erythematosus I-Effect
during I-Adverse_event.Trigger
penicillamine I-Treatment.Drug
therapy I-Treatment
for O
rheumatoid I-Treat_Disorder
arthritis I-Treat_Disorder
. I-Treat_Disorder

In O
the O
absence O
of O
mucositis O
or O
diarrhea O
, O
severe O
dermatologic I-Effect
toxicity I-Effect
following I-Adverse_event.Trigger
a I-Treatment
single I-Treatment.Dosage
low I-Treatment.Dosage
dose I-Treatment.Dosage
of I-Treatment
the I-Treatment
drug I-Treatment
suggests O
an I-Effect
' I-Effect
allergic I-Effect
' I-Effect
or I-Effect
acute I-Effect
hypersensitivity I-Effect
reaction I-Effect
to O
MTX I-Treatment.Drug
in O
this I-Subject
patient I-Subject
. O

Erosion I-Effect
of I-Effect
psoriatic I-Effect
plaques I-Effect
after I-Adverse_event.Trigger
chronic O
methotrexate I-Treatment.Drug
administration O
. O

Cardiac I-Effect
decompensation I-Effect
following I-Adverse_event.Trigger
verapamil I-Treatment.Drug
therapy I-Treatment
in O
infants I-Subject.Age
with I-Subject
supraventricular I-Treat_Disorder
tachycardia I-Treat_Disorder
. O

We O
report O
two O
cases O
of O
tenofovir I-Treatment.Drug
( I-Treatment
TDF) I-Treatment
- O
associated I-Adverse_event.Trigger
nephrotoxicity I-Effect
in O
perinatally I-Subject
HIV I-Treat_Disorder
- I-Subject
infected I-Subject
adolescents I-Subject.Age
. O

RESULTS O
: O
Including O
our O
own O
patient O
, O
a O
total O
of O
26 O
cases O
of O
gemcitabine I-Treatment.Drug
- O
associated I-Adverse_event.Trigger
HUS I-Effect
were O
identified O
. O

Even O
though O
only O
a O
few O
cases O
of O
this O
adverse O
event O
have O
been O
reported O
in O
the O
literature O
, O
severe O
docetaxel I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
pulmonary I-Effect
toxicity I-Effect
needs O
to O
be O
considered O
in O
the O
differential O
diagnosis O
when O
such O
patients O
present O
with O
respiratory I-Effect
symptoms I-Effect
. O

In O
this O
article O
, O
the O
authors O
report O
a I-Subject
7 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
male I-Subject.Gender
patient I-Subject
who O
presented O
with O
orofacial I-Effect
and I-Effect
limb I-Effect
dyskinesia I-Effect
after I-Adverse_event.Trigger
his O
first I-Treatment.Time_elapsed
dose I-Treatment.Time_elapsed
of I-Treatment
methylphenidate I-Treatment.Drug
treatment O
for O
a O
diagnosis O
of O
attention I-Treat_Disorder
- I-Treat_Disorder
deficit I-Treat_Disorder
/ I-Treat_Disorder
hyperactivity I-Treat_Disorder
disorder I-Treat_Disorder
; O
he O
was O
also O
receiving O
sodium O
valproate O
treatment O
for O
epilepsy O
. O

In O
this O
article O
, O
the O
authors O
report O
a I-Subject
7 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
male I-Subject.Gender
patient I-Subject
who O
presented O
with O
orofacial O
and O
limb O
dyskinesia O
after O
his O
first O
dose O
of O
methylphenidate O
treatment O
for O
a O
diagnosis O
of O
attention O
- O
deficit O
/ O
hyperactivity O
disorder O
; O
he O
was O
also O
receiving I-Potential_therapeutic_event.Trigger
sodium I-Treatment.Drug
valproate I-Treatment.Drug
treatment O
for O
epilepsy I-Treat_Disorder
. O

The O
first O
case O
concerns O
a O
70 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
man I-Subject.Gender
who O
developed I-Adverse_event.Trigger
severe I-Effect
aplastic I-Effect
anemia I-Effect
7 I-Treatment.Time_elapsed
weeks I-Treatment.Time_elapsed
after I-Treatment
treatment I-Treatment
with I-Treatment
500 I-Treatment.Dosage
mg I-Treatment.Dosage
of I-Treatment
ticlopidine I-Treatment.Drug
daily I-Treatment.Freq
. O

CASE O
REPORT O
: O
A I-Subject
six I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
boy I-Subject.Gender
with I-Subject
transfusion I-Treat_Disorder
- I-Treat_Disorder
dependent I-Treat_Disorder
beta I-Treat_Disorder
- I-Treat_Disorder
thalassaemia I-Treat_Disorder
developed I-Adverse_event.Trigger
a I-Effect
unilateral I-Effect
hearing I-Effect
loss I-Effect
shortly I-Time_elapsed
after I-Time_elapsed
commencing I-Treatment
desferrioxamine I-Treatment.Drug
therapy I-Treatment
. O

Syncope I-Effect
in O
a I-Subject
65 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
woman I-Subject.Gender
after I-Adverse_event.Trigger
nitrate I-Treatment.Drug
ingestion I-Treatment.Route
. O

Both O
the O
longitudinal I-Effect
melanonychia I-Effect
and I-Effect
the I-Effect
multiple I-Effect
skin I-Effect
cancers I-Effect
first O
appeared I-Adverse_event.Trigger
after O
approximately I-Treatment
6 I-Treatment.Duration
months I-Treatment.Duration
of I-Treatment
hydroxyurea I-Treatment.Drug
treatment I-Treatment
. O

Multifocal I-Effect
inflammatory I-Effect
leukoencephalopathy I-Effect
associated I-Adverse_event.Trigger
with I-Adverse_event.Trigger
levamisole I-Treatment.Drug
therapy I-Treatment
. O

The O
observation O
of O
cutaneous I-Effect
vasculitis I-Effect
during I-Adverse_event.Trigger
administration O
of O
propylthiouracil I-Treatment.Drug
suggested O
that O
clinical O
awareness O
of O
this O
complication O
should O
be O
of O
considerable O
importance O
. O

Physicians O
should O
be O
aware O
of O
the O
potential O
for O
developing O
a O
gemcitabine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
radiation I-Effect
recall I-Effect
reaction I-Effect
resulting I-Effect
in I-Effect
hemodynamically I-Effect
significant I-Effect
pericardial I-Effect
effusion I-Effect
. O

OBJECTIVE O
: O
To O
describe O
a O
case O
of O
cefazolin I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
leukopenia I-Effect
in O
a I-Subject
critically I-Subject.Sub_Disorder
ill I-Subject.Sub_Disorder
patient I-Subject
who O
developed O
this O
adverse O
reaction O
upon O
rechallenge O
with O
cefoxitin O
. O

The I-Subject
second I-Subject
patient I-Subject
suffered I-Subject
from I-Subject
high I-Treat_Disorder
blood I-Treat_Disorder
pressure I-Treat_Disorder
, O
which O
was O
controlled I-Potential_therapeutic_event.Trigger
with O
beta I-Treatment.Drug
- I-Treatment.Drug
blocker I-Treatment.Drug
drugs I-Treatment.Drug
. O

The I-Subject
female I-Subject.Gender
patient I-Subject
received O
clozapine I-Treatment.Drug
in I-Treatment
a I-Treatment
daily I-Treatment.Freq
dose I-Treatment
of I-Treatment
400 I-Treatment.Dosage
mg I-Treatment.Dosage
, O
which O
induced I-Adverse_event.Trigger
agranulocytosis I-Effect
after I-Treatment
2 I-Treatment.Duration
months I-Treatment.Duration
. O

We O
report O
a I-Subject
case I-Subject
of O
interstitial I-Effect
pulmonary I-Effect
disease I-Effect
that O
occurred O
together O
with O
lymphocytic I-Effect
colitis I-Effect
during I-Adverse_event.Trigger
treatment O
with O
ticlopidine I-Treatment.Drug
. O

Increased I-Effect
ocular I-Effect
pressure I-Effect
in I-Adverse_event.Trigger
two I-Subject.Population
patients I-Subject
with I-Subject
narrow I-Subject.Sub_Disorder
angle I-Subject.Sub_Disorder
glaucoma I-Subject.Sub_Disorder
treated O
with O
venlafaxine I-Treatment.Drug
. O

Although O
they O
had O
complex O
medical O
problems O
, O
the O
high O
serum O
concentrations O
of O
ampicillin O
at O
the O
time O
of O
seizures O
without O
their O
recurrence O
after O
discontinuing O
the O
antibiotic O
suggest O
that O
the O
seizures I-Effect
were O
related I-Adverse_event.Trigger
to O
the O
ampicillin I-Treatment.Drug
therapy I-Treatment
. O

Glaucoma I-Effect
secondary I-Adverse_event.Trigger
to O
epithelial O
downgrowth O
and O
5 I-Treatment.Drug
- I-Treatment.Drug
fluorouracil I-Treatment.Drug
. O

Of O
particular O
interest O
in O
this I-Subject
patient I-Subject
is O
the O
fluctuation I-Effect
of I-Effect
the I-Effect
QT I-Effect
interval I-Effect
at I-Adverse_event.Trigger
a I-Treatment.Dosage
stable I-Treatment.Dosage
dose I-Treatment.Dosage
of I-Treatment
methadone I-Treatment.Drug
, O
suggesting O
that O
a O
single O
normal O
electrocardiogram O
( O
ECG O
) O
does O
not O
guarantee O
that O
the O
patient O
is O
not O
at O
risk O
of O
ventricular O
arrhythmias O
. O

This O
is O
the O
first O
report O
of O
acute I-Effect
kidney I-Effect
injury I-Effect
due I-Effect
to I-Effect
zonisamide I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
DRESS I-Effect
/ I-Effect
DIHS I-Effect
. O

Although O
both O
the O
spontaneous O
occurrence O
of O
SLE O
and O
the O
psychosis O
as O
a O
sign O
of O
CNS O
involvement O
of O
SLE O
can O
not O
be O
excluded O
, O
SLE I-Effect
could O
be O
considered I-Adverse_event.Trigger
as O
an O
adverse O
effect O
of O
carbamazepine I-Treatment.Drug
. O

BACKGROUND O
: O
Cyanamide I-Treatment.Drug
, O
an O
aversive O
agent O
widely O
used O
in O
Japan O
, O
is O
known O
to O
induce I-Adverse_event.Trigger
various I-Effect
degrees I-Effect
of I-Effect
hepatic I-Effect
lesion I-Effect
with I-Effect
ground I-Effect
- I-Effect
glass I-Effect
inclusion I-Effect
bodies I-Effect
. O

Oxcarbazepine I-Treatment.Drug
- O
associated I-Adverse_event.Trigger
angioedema I-Effect
manifested I-Effect
by I-Effect
swelling I-Effect
of I-Effect
the I-Effect
face I-Effect
, I-Effect
eyes I-Effect
, I-Effect
lips I-Effect
, I-Effect
or I-Effect
tongue I-Effect
or I-Effect
difficulty I-Effect
swallowing I-Effect
or I-Effect
breathing I-Effect
( I-Effect
or I-Effect
both I-Effect
) I-Effect
is O
a O
rare O
but O
potentially O
life O
- O
threatening O
reaction O
for O
which O
early O
recognition O
and O
management O
are O
vital O
. O

The O
combination I-Treatment
therapy I-Treatment
of I-Treatment
interferon I-Treatment.Combination.Drug
alpha I-Treatment.Combination.Drug
and I-Treatment
ribavirin I-Treatment.Combination.Drug
was O
given I-Potential_therapeutic_event.Trigger
to O
a I-Subject
50 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
female I-Subject.Gender
with I-Subject
CHC I-Treat_Disorder
who I-Subject
had I-Subject
not I-Subject
responded I-Subject
to I-Subject
a I-Subject
previous I-Subject
treatment I-Subject
by I-Subject
interferon I-Subject
alpha I-Subject
. O

Peripheral I-Effect
neuropathy I-Effect
associated I-Adverse_event.Trigger
with O
capecitabine I-Treatment.Drug
. I-Treatment

DESIGN O
: O
We O
reviewed O
the O
medical I-Subject
records I-Subject
of I-Subject
four I-Subject.Population
patients I-Subject
, O
who O
were O
seen O
by O
us O
between O
July O
2000 O
and O
February O
2004 O
for O
sudden O
onset O
of O
a I-Effect
central I-Effect
neurological I-Effect
syndrome I-Effect
within I-Time_elapsed
days I-Time_elapsed
of O
intrathecal I-Adverse_event.Trigger
MTX I-Treatment.Drug
. O

Prothipendylhydrochloride I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
priapism I-Effect
: O
case O
report O
. O

Interstitial I-Effect
pneumonia I-Effect
probably O
associated I-Adverse_event.Trigger
with O
sorafenib I-Treatment.Drug
treatment I-Treatment
: I-Treatment
An O
alert O
of O
an O
adverse O
event O
. O

He O
had O
hypokalemia I-Effect
( I-Effect
K I-Effect
2.3 I-Effect
mmol I-Effect
/ I-Effect
L I-Effect
) I-Effect
induced I-Adverse_event.Trigger
by O
licorice I-Treatment.Combination.Drug
and I-Treatment
also I-Treatment
had I-Treatment
received I-Treatment
disopyramide I-Treatment.Combination.Drug
for I-Treatment
arrhythmia I-Treatment.Treat_Disorder
, I-Treatment
bicalutamide I-Treatment.Combination.Drug
for I-Treatment
prostate I-Treatment.Treat_Disorder
cancer I-Treatment.Treat_Disorder
, I-Treatment
and I-Treatment
silodosin I-Treatment.Combination.Drug
for I-Treatment
prostate I-Treatment.Treat_Disorder
hypertrophy I-Treatment.Treat_Disorder
. O

Use O
of O
the O
Naranjo O
adverse O
drug O
reaction O
probability O
scale O
indicated O
a O
probable O
relationship O
( O
score O
of O
5 O
) O
between O
the O
patient I-Subject
's I-Subject
development I-Adverse_event.Trigger
of O
hepatotoxicity I-Effect
and O
the O
TMP I-Treatment.Drug
- I-Treatment.Drug
SMX I-Treatment.Drug
therapy I-Treatment
. O

Since O
its O
introduction O
in O
2012 O
, O
vismodegib I-Treatment.Drug
has O
been O
implicated I-Adverse_event.Trigger
as O
a O
possible O
factor O
in O
seven I-Subject.Population
reports I-Subject
of I-Subject
patient I-Subject
deaths I-Effect
. O

Acceleration I-Effect
of I-Effect
ventricular I-Effect
response I-Effect
to O
atrial I-Treat_Disorder
flutter I-Treat_Disorder
after I-Adverse_event.Trigger
intravenous I-Treatment.Route
adenosine I-Treatment.Drug
. I-Treatment

Possible O
induction I-Adverse_event.Trigger
of O
diabetes I-Effect
by O
treatment O
of O
hypertension I-Treat_Disorder
with O
indapamide I-Treatment.Drug
( O
with O
four O
case O
reports O
) O
. O

Physicians O
should O
be O
aware O
of O
the O
potential O
for O
the O
development I-Adverse_event.Trigger
of O
RS I-Effect
among O
children I-Subject.Age
who O
are O
receiving O
long I-Treatment
- I-Treatment
term I-Treatment
aspirin I-Treatment.Drug
therapy I-Treatment
for O
the O
treatment O
of O
systemic I-Treat_Disorder
inflammatory I-Treat_Disorder
illnesses I-Treat_Disorder
. O

While O
a O
lower O
systemic O
steroid O
dosage O
may O
have O
been O
the O
provoking O
factor O
, O
we O
feel O
that O
an O
adverse I-Effect
reaction I-Effect
to I-Adverse_event.Trigger
oleic I-Treatment.Drug
acid I-Treatment.Drug
, O
a O
dispersing O
agent O
in O
the O
aerosol O
freon O
vehicle O
, O
is O
a O
strong O
possibility O
. O

Baclofen I-Effect
withdrawal I-Effect
syndrome I-Effect
resulting I-Adverse_event.Trigger
from O
underdosing I-Treatment
of I-Treatment
oral I-Treatment.Route
baclofen I-Treatment.Drug
should O
be O
considered O
as O
a O
potential O
source O
of O
prolonged I-Effect
fever I-Effect
in I-Effect
the I-Effect
intensive I-Effect
care I-Effect
unit I-Effect
. O

We O
present O
a I-Subject
case I-Subject
of O
sotalol I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
bradycardia I-Effect
reversed O
by O
glucagon O
. O

Hyperammonemia I-Effect
has O
been O
described O
as O
a O
complication I-Adverse_event.Trigger
of O
valproic I-Treatment.Drug
acid I-Treatment.Drug
therapy I-Treatment
but O
may O
often O
be O
overlooked O
as O
a O
cause O
of O
lethargy O
in O
the O
postictal O
patient O
who O
presents O
to O
the O
emergency O
department O
. O

Methylene I-Treatment.Drug
blue I-Treatment.Drug
has O
been O
found O
to O
be O
a O
potent O
inhibitor O
of O
monoamine O
oxidase O
( O
MAO O
) O
, O
and O
several I-Subject
cases I-Subject
of O
serotonin I-Effect
toxicity I-Effect
have O
been O
reported O
recently O
following I-Adverse_event.Trigger
its O
administration O
. O

She O
had O
just O
finished O
a I-Treatment
3 I-Treatment.Duration
- I-Treatment.Duration
week I-Treatment.Duration
course I-Treatment.Duration
of I-Treatment
intravenous I-Treatment.Route
tobramycin I-Treatment.Drug
for O
bronchiectasis I-Treat_Disorder
and O
had I-Adverse_event.Trigger
an O
elevated I-Effect
serum I-Effect
tobramycin I-Effect
trough I-Effect
level I-Effect
1 I-Effect
week I-Effect
before I-Effect
the I-Effect
onset I-Effect
of I-Effect
tetany I-Effect
. O

In O
a O
postural O
challenge O
test O
after I-Adverse_event.Trigger
administration I-Treatment
of I-Treatment
isosorbide I-Treatment.Drug
dinitrate I-Treatment.Drug
( I-Treatment
5 I-Treatment.Dosage
mg I-Treatment.Dosage
) I-Treatment
, O
blood I-Effect
pressure I-Effect
decreased I-Effect
from O
120/67 O
to O
65/35 O
mmHg O
, O
followed O
by O
syncope I-Effect
with O
a I-Effect
sudden I-Effect
decrease I-Effect
in I-Effect
pulse I-Effect
rate I-Effect
from O
85 O
to O
60 O
beats O
/ O
min O
. O

The O
condition I-Effect
improved I-Effect
slowly O
after O
stopping I-Adverse_event.Trigger
medication O
and O
systemic O
steroids I-Treatment.Drug
. O

Acetaminophen I-Treatment.Drug
is O
a O
widely O
used O
analgesic O
that O
can O
cause I-Adverse_event.Trigger
acute I-Effect
liver I-Effect
failure I-Effect
when O
consumed O
above O
a O
maximum O
daily O
dose O
. O

Patients I-Subject
treated O
with O
5 I-Treatment.Drug
- I-Treatment.Drug
ASA I-Treatment.Drug
compounds I-Treatment
who I-Subject
experience I-Subject
acute I-Subject
inflammatory I-Subject
symptoms I-Subject
or I-Subject
clinical I-Subject
deterioration I-Subject
not I-Subject
related I-Subject
to I-Subject
their I-Subject
gastrointestinal I-Treat_Disorder
disease I-Treat_Disorder
should O
be O
screened O
to O
rule O
out O
a O
lupus I-Effect
- I-Effect
like I-Effect
reaction I-Effect
. O

Successful O
treatment I-Potential_therapeutic_event.Trigger
with O
arsenic I-Treatment.Drug
trioxide I-Treatment.Drug
of O
a I-Subject
patient I-Subject
with I-Subject
ATRA I-Treat_Disorder
- I-Treat_Disorder
resistant I-Treat_Disorder
relapse I-Treat_Disorder
of I-Treat_Disorder
acute I-Treat_Disorder
promyelocytic I-Treat_Disorder
leukemia I-Treat_Disorder
. O

Drug I-Effect
rash I-Effect
with I-Effect
eosinophilia I-Effect
and I-Effect
systemic I-Effect
symptoms I-Effect
after I-Adverse_event.Trigger
chlorambucil I-Treatment.Drug
treatment O
in O
chronic I-Treat_Disorder
lymphocytic I-Treat_Disorder
leukaemia I-Treat_Disorder
. O

She I-Subject.Gender
manifested I-Adverse_event.Trigger
all I-Effect
the I-Effect
clinical I-Effect
symptoms I-Effect
and I-Effect
signs I-Effect
of I-Effect
caffeine I-Treatment.Drug
toxicity I-Effect
. I-Effect

Quinine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
hearing I-Effect
loss I-Effect
. O

Ezetimibe I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
acute I-Effect
pancreatitis I-Effect
. O

We O
report O
a I-Subject
case I-Subject
of O
drug O
- O
induced I-Adverse_event.Trigger
pemphigus I-Effect
caused O
by O
an O
angiotensin O
- O
converting O
enzyme O
inhibitor O
, O
captopril I-Treatment.Drug
. O

We O
conclude O
that O
low I-Treatment.Dosage
- I-Treatment.Dosage
dose I-Treatment.Dosage
HU I-Treatment.Drug
therapy I-Treatment
in I-Subject
patients I-Subject
with I-Subject
thalassemia I-Treat_Disorder
intermedia I-Treat_Disorder
may O
increase I-Effect
total I-Effect
Hb I-Effect
levels I-Effect
sufficiently O
to O
eliminate O
the O
need O
for O
transfusions O
. O

There O
is O
the O
risk O
of O
convulsions I-Effect
occurring I-Adverse_event.Trigger
in O
susceptible I-Subject
patients I-Subject
following O
the I-Treatment
use I-Treatment
of I-Treatment
the I-Treatment
new I-Treatment
anaesthetic I-Treatment.Drug
agents I-Treatment
which I-Treatment
are I-Treatment
capable I-Treatment
of I-Treatment
inducing I-Treatment
CNS I-Treatment
excitability I-Treatment
. O

A I-Subject
patient I-Subject
with I-Subject
psoriasis I-Treat_Disorder
is I-Subject
described I-Subject
who I-Subject
had I-Subject
an I-Subject.Sub_Disorder
abnormal I-Subject.Sub_Disorder
response I-Subject.Sub_Disorder
to I-Subject.Sub_Disorder
the I-Subject.Sub_Disorder
glucose I-Subject.Sub_Disorder
tolerance I-Subject.Sub_Disorder
test I-Subject.Sub_Disorder
without I-Subject.Sub_Disorder
other I-Subject.Sub_Disorder
evidence I-Subject.Sub_Disorder
of I-Subject.Sub_Disorder
diabetes I-Subject.Sub_Disorder
and O
then O
developed I-Adverse_event.Trigger
postprandial I-Effect
hyperglycemia I-Effect
and I-Effect
glycosuria I-Effect
during O
a I-Treatment
period I-Treatment
of I-Treatment
topical I-Treatment
administration I-Treatment
of I-Treatment
a I-Treatment
corticosteroid I-Treatment
cream I-Treatment
, I-Treatment
halcinonide I-Treatment.Drug
cream I-Treatment.Route
0.1 I-Treatment
% I-Treatment
, I-Treatment
under I-Treatment
occlusion I-Treatment
. O

Although O
there O
is O
one O
case O
report O
of O
cholesterol I-Effect
crystal I-Effect
embolization I-Effect
following I-Adverse_event.Trigger
t I-Treatment.Drug
- I-Treatment.Drug
PA I-Treatment.Drug
therapy O
with I-Effect
only I-Effect
extrarenal I-Effect
manifestations I-Effect
( O
N O
Engl O
J O
Med O
321:1270 O
, O
1989 O
) O
, O
this O
is O
the O
first O
reported O
case O
of O
atheroembolic O
acute O
renal O
failure O
following O
t O
- O
PA O
therapy O
. O

Although O
there O
is O
one O
case O
report O
of O
cholesterol O
crystal O
embolization O
following O
t O
- O
PA O
therapy O
with O
only O
extrarenal O
manifestations O
( O
N O
Engl O
J O
Med O
321:1270 O
, O
1989 O
) O
, O
this O
is O
the O
first O
reported O
case O
of O
atheroembolic I-Effect
acute I-Effect
renal I-Effect
failure I-Effect
following I-Adverse_event.Trigger
t I-Treatment.Drug
- I-Treatment.Drug
PA I-Treatment.Drug
therapy I-Treatment
. O

A I-Subject
young I-Subject.Age
woman I-Subject.Gender
developed I-Adverse_event.Trigger
galactorrhea I-Effect
during I-Treatment
treatment I-Treatment
with I-Treatment
a I-Treatment
new I-Treatment
dibenzoxazepine I-Treatment
antidepressant I-Treatment
, I-Treatment
amoxapine I-Treatment.Drug
. O

After O
ruling O
out O
a O
hydrotelluric O
source O
of O
fluorine O
, O
the I-Subject
patient I-Subject
's I-Subject
fluorosis I-Effect
was O
linked I-Adverse_event.Trigger
to I-Adverse_event.Trigger
chronic I-Treatment.Duration
use I-Treatment
of I-Treatment
niflumic I-Treatment.Drug
acid I-Treatment.Drug
, O
following O
the O
publication O
in O
1978 O
of O
the O
2 O
previously O
reported O
cases O
affected O
by O
this O
drug O
. O

The O
hospital O
course O
of O
the O
acute O
renal O
failure O
is O
presented O
with O
a O
review O
of O
the O
literature O
on O
cases O
of O
acute I-Effect
renal I-Effect
failure I-Effect
after I-Adverse_event.Trigger
IVIG I-Treatment.Drug
. O

We O
report O
3 I-Subject.Population
cases I-Subject
of I-Subject
children I-Subject.Age
with I-Subject
acute I-Treat_Disorder
lymphoblastic I-Treat_Disorder
leukemia I-Treat_Disorder
who O
developed O
seizures I-Effect
and I-Effect
altered I-Effect
sensorium I-Effect
after I-Adverse_event.Trigger
L I-Treatment.Drug
- I-Treatment.Drug
asparaginase I-Treatment.Drug
therapy O
. O

Caution O
with O
use O
of O
cimetidine O
in O
tolazoline I-Treatment.Drug
induced I-Adverse_event.Trigger
upper I-Effect
gastrointestinal I-Effect
bleeding I-Effect
. O

Other O
thiazolidinediones I-Treatment.Drug
currently O
in O
clinical O
trials O
may O
be O
able O
to O
provide I-Potential_therapeutic_event.Trigger
the O
therapeutic O
benefits O
of O
troglitazone O
without O
significant O
hepatotoxicity O
. O

OBJECTIVE O
: O
To O
report O
a I-Effect
case I-Effect
of I-Effect
neuroleptic I-Effect
malignant I-Effect
syndrome I-Effect
( I-Effect
NMS I-Effect
) I-Effect
associated I-Adverse_event.Trigger
with O
fluphenazine I-Treatment.Drug
in O
a O
schizophrenic I-Treat_Disorder
patient I-Subject
and O
review O
the O
literature O
related O
to O
this O
condition O
. O

CONCLUSIONS O
: O
Because O
of O
its O
structural O
similarity O
to O
the O
other O
vinca O
alkaloids O
, O
vinorelbine I-Treatment.Drug
is O
believed O
to O
be O
responsible I-Adverse_event.Trigger
for O
SIADH I-Effect
in O
our O
patient O
. O

Abnormal I-Effect
retinal I-Effect
function I-Effect
associated I-Adverse_event.Trigger
with O
isotretinoin I-Treatment.Drug
therapy O
for O
acne I-Treat_Disorder
. O

To O
our O
knowledge O
, O
this O
is O
the O
first I-Subject.Population
reported I-Subject
case I-Subject
of O
bromide I-Effect
intoxication I-Effect
due I-Adverse_event.Trigger
to O
pyridostigmine I-Treatment.Drug
bromide I-Treatment.Drug
administration O
. O

In O
deciding O
if O
tamoxifen I-Drug
therapy O
is O
warranted O
, O
all O
potentially I-Effect
life I-Effect
- I-Effect
threatening I-Effect
adverse I-Effect
events I-Effect
associated I-Adverse_event.Trigger
with I-Adverse_event.Trigger
tamoxifen I-Treatment.Drug
should O
be O
considered O
, O
including I-Effect
endometrial I-Effect
adenocarcinoma I-Effect
or I-Effect
uterine I-Effect
sarcoma I-Effect
. O

We O
report O
the O
case O
of O
a I-Subject
patient I-Subject
with I-Subject
chronic I-Treat_Disorder
lymphocytic I-Treat_Disorder
leukemia I-Treat_Disorder
( I-Subject
CLL I-Subject
) I-Subject
who O
developed O
fatal I-Effect
intravascular I-Effect
autoimmune I-Effect
hemolytic I-Effect
anemia I-Effect
( I-Effect
AIHA I-Effect
) I-Effect
after I-Adverse_event.Trigger
fludarabine I-Treatment.Drug
treatment I-Treatment
. O

A I-Subject
59 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
woman I-Subject.Gender
with I-Subject
myasthenia I-Treat_Disorder
gravis I-Treat_Disorder
who O
received O
a I-Treatment.Dosage
large I-Treatment.Dosage
dose I-Treatment.Dosage
of I-Treatment
pyridostigmine I-Treatment.Drug
bromide I-Treatment.Drug
developed I-Adverse_event.Trigger
postoperative I-Effect
psychosis I-Effect
and I-Effect
was I-Effect
diagnosed I-Effect
as I-Effect
having I-Effect
bromide I-Effect
intoxication I-Effect
. I-Effect

This O
is O
a O
report O
of O
a I-Subject
renal I-Subject.Sub_Disorder
transplant I-Subject.Sub_Disorder
patient I-Subject
with I-Subject
Pneumocystis I-Treat_Disorder
pneumonia I-Treat_Disorder
who O
developed I-Adverse_event.Trigger
chemical I-Effect
cellulitis I-Effect
and I-Effect
ulceration I-Effect
following O
the O
extravasation O
of O
intravenous I-Treatment.Route
pentamidine I-Treatment.Drug
into I-Treatment
the I-Treatment
soft I-Treatment
tissues I-Treatment
of I-Treatment
the I-Treatment
left I-Treatment
hand I-Treatment
and I-Treatment
forearm I-Treatment
. O

Attempts O
were O
made O
to O
stop O
and O
then O
restart O
the O
theophylline I-Treatment.Drug
therapy I-Treatment
at O
progressively O
lower O
doses O
; O
however O
, O
with O
each O
attempt O
, O
the O
patient I-Subject
's O
reaction I-Effect
to I-Effect
the I-Effect
drug I-Effect
became I-Effect
more I-Effect
toxic I-Effect
, O
with O
serum O
theophylline O
levels O
ranging O
between O
99.9 I-Dosage
and I-Dosage
149.9 I-Dosage
micromol I-Dosage
/ I-Dosage
L I-Dosage
( O
18 I-Dosage
and I-Dosage
27 I-Dosage
microg I-Dosage
/ I-Dosage
mL I-Dosage
) O
. O

Dyspnea I-Effect
, I-Effect
hypoxemia I-Effect
, I-Effect
and I-Effect
pleuritic I-Effect
chest I-Effect
pain I-Effect
occurred I-Adverse_event.Trigger
within O
24 I-Time_elapsed
hours I-Time_elapsed
of O
rituximab I-Treatment.Drug
administration I-Treatment
, O
and O
there O
was O
no O
other O
apparent O
explanation O
. O

Dermatitis I-Treat_Disorder
to I-Potential_therapeutic_event.Trigger
captopril I-Treatment.Drug
. O

Histological O
examination O
of O
the O
dacryolith I-Effect
suggested O
its O
derivation O
from I-Adverse_event.Trigger
breakdown I-Treatment
products I-Treatment
of I-Treatment
adrenaline I-Treatment.Drug
. O

Two I-Subject.Population
patients I-Subject
developed I-Adverse_event.Trigger
diabetic I-Effect
coma I-Effect
when O
taking O
a I-Treatment
combination I-Treatment
of I-Treatment
a I-Treatment
thiazide I-Treatment.Combination.Drug
diuretic I-Treatment
and I-Treatment
propranolol I-Treatment.Combination.Drug
. O

Platinum I-Treat_Disorder
- I-Treat_Disorder
resistant I-Treat_Disorder
ovarian I-Treat_Disorder
cancer I-Treat_Disorder
( I-Treat_Disorder
PROC I-Treat_Disorder
) I-Treat_Disorder
constitutes O
a O
therapeutic O
dilemma O
with O
limited I-Effect
efficacy I-Effect
from I-Potential_therapeutic_event.Trigger
traditional I-Treatment.Drug
cytotoxic I-Treatment.Drug
agents I-Treatment.Drug
. O

A I-Subject
patient I-Subject
suffering O
from O
heparin O
- O
associated O
thrombocytopenia I-Effect
( I-Effect
HAT I-Effect
) I-Effect
, I-Effect
recurrent I-Effect
arteriothromboses I-Effect
, I-Effect
and I-Effect
acute I-Effect
renal I-Effect
failure I-Effect
after I-Adverse_event.Trigger
treatment O
with O
standard I-Treatment
heparin I-Treatment.Drug
is O
described O
. O

Despite O
minimal O
short O
- O
term O
side O
effects O
and O
apparent O
efficacy O
, O
chronic O
treatment O
of O
MG I-Treatment.Treat_Disorder
with I-Treatment
MM I-Treatment.Drug
may O
be O
associated I-Adverse_event.Trigger
with O
increased I-Effect
risk I-Effect
of I-Effect
lymphoproliferative I-Effect
disorders O
. O

We O
report O
the O
case O
of O
a I-Subject
patient I-Subject
with I-Subject
multiple I-Treat_Disorder
myeloma I-Treat_Disorder
who O
developed I-Adverse_event.Trigger
acute I-Effect
life I-Effect
- I-Effect
threatening I-Effect
water I-Effect
intoxication I-Effect
following O
treatment O
with O
oral I-Treatment.Route
indomethacin I-Treatment.Combination.Drug
and I-Treatment
low I-Treatment.Dosage
dose I-Treatment.Dosage
intravenous I-Treatment.Route
cyclophosphamide I-Treatment.Combination.Drug
. O

Multifocal O
electroretinographic O
abnormalities O
in O
ethambutol I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
visual I-Effect
loss I-Effect
. O

She I-Subject.Gender
was O
on O
etanercept I-Treatment.Combination.Drug
and I-Treatment
methotrexate I-Treatment.Combination.Drug
for I-Potential_therapeutic_event.Trigger
rheumatoid I-Treat_Disorder
arthritis I-Treat_Disorder
. O

Central O
nervous O
system O
effects O
secondary I-Treatment
to I-Treatment
ciprofloxacin I-Treatment.Drug
treatment I-Treatment
are O
uncommon O
and O
usually O
consist I-Adverse_event.Trigger
only O
of O
minor I-Effect
dizziness I-Effect
or I-Effect
mild I-Effect
headache I-Effect
, I-Effect
although I-Effect
rare I-Effect
occurrences I-Effect
of I-Effect
seizures I-Effect
and I-Effect
hallucinations I-Effect
have O
been O
reported O
. O

We O
present O
a O
case O
of O
a I-Subject
20 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
woman I-Subject.Gender
who O
ingested I-Adverse_event.Trigger
900 I-Treatment.Dosage
mg I-Treatment.Dosage
of I-Treatment
glyburide I-Treatment.Drug
causing O
refractory I-Effect
hypoglycemia I-Effect
resistant O
to O
treatment O
with O
intravenous O
dextrose O
, O
glucagon O
, O
and O
diazoxide O
. O

Etoposide I-Treatment.Drug
- O
related I-Adverse_event.Trigger
myocardial I-Effect
infarction I-Effect
. O

Contrary O
to O
previous O
recommendations O
, O
our O
experience O
cautions O
against O
the O
further O
use O
of O
high I-Treatment.Dosage
- I-Treatment.Dosage
dose I-Treatment.Dosage
cytarabine I-Treatment.Drug
in O
patients O
who O
develop O
PPE I-Effect
, O
and O
is O
a O
timely O
reminder O
of O
the O
potential O
toxicity I-Adverse_event.Trigger
of O
this O
agent O
, O
which O
is O
now O
increasingly O
being O
used O
as O
first O
- O
line O
treatment O
in O
the O
management O
of O
haematologic I-Treat_Disorder
malignancies I-Treat_Disorder
. O

She O
had O
been O
on O
Copaxone I-Treatment.Drug
20 I-Treatment.Dosage
mg I-Treatment.Dosage
/ I-Treatment.Dosage
day I-Treatment.Dosage
treatment I-Treatment
for I-Treatment
2 I-Treatment.Duration
years I-Treatment.Duration
when O
she I-Subject.Gender
first O
exhibited I-Adverse_event.Trigger
gastrointestinal I-Effect
symptoms I-Effect
. O

The O
authors O
present O
an O
elderly I-Subject.Age
patient I-Subject
with I-Subject
mixed I-Treat_Disorder
dementia I-Treat_Disorder
who O
developed I-Adverse_event.Trigger
TD I-Effect
at I-Effect
multiple I-Effect
sites I-Effect
, I-Effect
( I-Effect
including I-Effect
respiratory I-Effect
dyskinesia I-Effect
[ I-Effect
RD I-Effect
] I-Effect
, I-Effect
limb I-Effect
dyskinesia I-Effect
, I-Effect
and I-Effect
orofacial I-Effect
dyskinesia I-Effect
) I-Effect
following O
abrupt I-Treatment
withdrawal I-Treatment
of I-Treatment
risperidone I-Treatment.Drug
therapy I-Treatment
. O

Interferon I-Treatment.Drug
- O
based O
treatments O
have O
the O
potential O
to O
decrease O
the O
burden O
of O
disease O
, O
but O
are O
complicated I-Adverse_event.Trigger
by O
side O
effects O
, O
including O
neuropsychiatric I-Effect
symptoms I-Effect
. O

Long O
- O
term O
efficacy I-Potential_therapeutic_event.Trigger
of O
adding I-Treatment
fenofibric I-Treatment.Combination.Drug
acid I-Treatment.Combination.Drug
to I-Treatment
moderate I-Treatment.Dosage
- I-Treatment.Dosage
dose I-Treatment.Dosage
statin I-Treatment.Combination.Drug
therapy I-Treatment
in O
patients I-Subject
with I-Subject
persistent I-Treat_Disorder
elevated I-Treat_Disorder
triglycerides I-Treat_Disorder
. O

Type I-Effect
1 I-Effect
diabetes I-Effect
mellitus I-Effect
provoked I-Adverse_event.Trigger
by O
peginterferon I-Treatment.Combination.Drug
alpha I-Treatment.Combination.Drug
- I-Treatment.Combination.Drug
2b I-Treatment.Combination.Drug
plus I-Treatment
ribavirin I-Treatment.Combination.Drug
treatment I-Treatment
for O
chronic I-Treat_Disorder
hepatitis I-Treat_Disorder
C. I-Treat_Disorder

A I-Subject
61 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
man I-Subject.Gender
with I-Subject
early I-Subject.Sub_Disorder
diffuse I-Subject.Sub_Disorder
cutaneous I-Subject.Sub_Disorder
scleroderma I-Subject.Sub_Disorder
with I-Subject.Sub_Disorder
myositis I-Subject.Sub_Disorder
and I-Subject
progressive I-Subject.Sub_Disorder
interstitial I-Subject.Sub_Disorder
pneumonia I-Subject.Sub_Disorder
developed O
generalized I-Effect
erythema I-Effect
with I-Effect
high I-Effect
fever I-Effect
3 I-Time_elapsed
weeks I-Time_elapsed
after I-Time_elapsed
taking I-Adverse_event.Trigger
sulfamethoxazole I-Treatment.Combination.Drug
/ I-Treatment
trimethoprim I-Treatment.Combination.Drug
. O

Serotonin I-Effect
toxicity I-Effect
caused I-Adverse_event.Trigger
by O
an I-Treatment
interaction I-Treatment
between I-Treatment
fentanyl I-Treatment.Combination.Drug
and I-Treatment
paroxetine I-Treatment.Combination.Drug
. O

The O
sub I-Effect
- I-Effect
conjunctival I-Effect
haematoma I-Effect
in O
a O
patient O
receiving I-Adverse_event.Trigger
warfarin I-Treatment.Drug
can O
pose O
a O
significant O
management O
challenge O
. O

Toxic I-Effect
optic I-Effect
neuropathy I-Effect
associated I-Adverse_event.Trigger
with O
ethambutol I-Treatment.Drug
: O
implications O
for O
current O
therapy O
. O

The O
site O
of O
thrombosis O
and O
the O
chronological O
relationship O
with O
the O
IIR O
implicates O
a O
hypersensitivity O
to O
infliximab I-Treatment.Drug
in O
the O
causation I-Adverse_event.Trigger
of O
the O
venous I-Effect
thrombosis I-Effect
in O
this O
case O
. O

One I-Treatment.Time_elapsed
week I-Treatment.Time_elapsed
after I-Treatment
the I-Treatment
initial I-Treatment
- I-Treatment
dose I-Treatment
of I-Treatment
adalimumab I-Treatment.Drug
( I-Treatment
160 I-Treatment.Dosage
mg I-Treatment.Dosage
) I-Treatment
, O
which O
was O
initiated O
due O
to O
an I-Subject
acute I-Subject
exacerbation I-Subject
of I-Subject
Crohn I-Treat_Disorder
's I-Treat_Disorder
disease I-Treat_Disorder
, I-Subject
the I-Subject
patient I-Subject
developed I-Adverse_event.Trigger
a O
fulminant I-Effect
cardiomyopathy I-Effect
. O

RESULTS O
: O
Ethambutol I-Treatment.Combination.Drug
, O
and O
to O
a O
lesser O
extent O
isoniazid I-Treatment.Combination.Drug
, O
are O
both O
implicated O
in O
the O
development I-Adverse_event.Trigger
of O
visually I-Effect
related I-Effect
side I-Effect
effects I-Effect
. O

We O
report O
a O
case O
of O
an O
inadvertent I-Effect
increase I-Effect
in I-Effect
the I-Effect
international I-Effect
normalized I-Effect
ratio I-Effect
( I-Effect
INR I-Effect
) I-Effect
after I-Adverse_event.Trigger
the O
addition I-Treatment
of I-Treatment
bismuth I-Treatment.Combination.Drug
subsalicylate I-Treatment.Combination.Drug
for O
the O
treatment O
of O
diarrhea I-Treat_Disorder
in O
an I-Subject
enterally I-Subject
fed I-Subject
patient I-Subject
receiving O
warfarin I-Treatment.Combination.Drug
therapy I-Treatment
. O

Oral I-Route
triazolam I-Treatment.Drug
is O
potentially O
hazardous I-Effect
to I-Adverse_event.Trigger
patients I-Subject
receiving O
systemic O
antimycotics O
ketoconazole I-Drug
or O
itraconazole I-Drug
. O

LFT O
elevation O
is O
transient O
and O
the I-Adverse_event.Trigger
low I-Adverse_event.Trigger
risk I-Adverse_event.Trigger
of O
the O
SB I-Treatment.Drug
- I-Treatment.Drug
LOT I-Treatment.Drug
therapy O
to O
increase I-Treat_Disorder
LFT I-Treat_Disorder
value I-Treat_Disorder
can O
be O
limited O
when O
risk O
factors O
are O
considered O
. O

Nineteen I-Subject.Population
cases I-Subject
of O
unusual I-Effect
enhanced I-Effect
vincristine I-Effect
neurotoxicity I-Effect
related I-Adverse_event.Trigger
to O
itraconazole I-Treatment.Drug
have O
been O
reported O
in O
children I-Subject.Age
. O

Extended I-Treatment.Drug
- I-Treatment.Drug
release I-Treatment.Drug
tolterodine I-Treatment.Drug
4 I-Treatment.Dosage
mg I-Treatment.Dosage
/ I-Treatment.Dosage
day I-Treatment.Dosage
was O
then O
prescribed I-Potential_therapeutic_event.Trigger
to O
manage O
overactive I-Treat_Disorder
bladder I-Treat_Disorder
. O

Although O
it O
is O
difficult O
to O
be O
certain O
of O
the O
direct O
link O
of O
amiodarone I-Drug
on O
the O
basis O
of O
a I-Subject
single I-Subject.Population
case I-Subject
, O
it O
is O
reasonable O
to O
presume O
that O
this O
histopathology O
is O
associated O
with O
amiodarone I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
hypothyroidism I-Effect
and O
that O
involution O
changes O
represent O
the O
hypofunctional O
status O
of O
this O
drug O
- O
induced O
disorder O
. O

The O
present O
report O
describes O
the I-Subject
first I-Subject
case I-Subject
of O
acute I-Effect
pancreatitis I-Effect
associated I-Adverse_event.Trigger
with O
danazol I-Treatment.Drug
treatment I-Treatment
of I-Treatment
endometriosis I-Treatment.Treat_Disorder
. O

Awareness O
of O
this O
route O
of O
intoxication O
might O
be O
important O
in O
patients O
in O
whom O
neurologic I-Effect
or I-Effect
psychiatric I-Effect
symptoms I-Effect
develop I-Adverse_event.Trigger
while O
large I-Treatment.Dosage
amounts I-Treatment.Dosage
of I-Treatment
lidocaine I-Treatment.Drug
cream I-Treatment.Route
are I-Treatment
being I-Treatment
used I-Treatment
. O

Cephalosporin I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
leukopenia I-Effect
following O
rechallenge O
with O
cefoxitin I-Treatment.Drug
. O

Thrombotic I-Effect
thrombocytopenic I-Effect
purpura I-Effect
induced I-Adverse_event.Trigger
by O
trimethoprim I-Treatment.Drug
- I-Treatment.Drug
sulfamethoxazole I-Treatment.Drug
in O
a I-Subject
Jehovah I-Subject
's I-Subject
Witness I-Subject
. O

This O
eruption I-Effect
appears O
to O
be O
a O
distinct I-Effect
cutaneous I-Effect
toxicity I-Effect
of I-Adverse_event.Trigger
PLD I-Treatment.Drug
. O

Granulocytopenia I-Effect
and I-Effect
agranulocytosis I-Effect
are O
considered O
among I-Adverse_event.Trigger
the O
most O
dangerous O
adverse O
effects O
of O
clozapine I-Treatment.Drug
. O

RESULTS O
: O
We O
recently O
experienced O
a O
case O
of O
fatal O
erlotinib I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
ILD I-Effect
, O
diagnosed O
based O
on O
clinical O
and O
radiologic O
findings O
, O
which O
occurred O
in O
a I-Subject
patient I-Subject
with I-Subject
radiation I-Subject.Sub_Disorder
fibrosis I-Subject.Sub_Disorder
. O

Unusual I-Effect
hypersensitivity I-Effect
to I-Adverse_event.Trigger
warfarin I-Treatment.Drug
in O
a I-Subject
critically I-Subject.Sub_Disorder
ill I-Subject.Sub_Disorder
patient I-Subject
. O

Flumazenil O
reversal O
of O
benzodiazepine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
sedation I-Effect
for O
a I-Subject
patient I-Subject
with I-Subject
severe I-Subject.Sub_Disorder
pre I-Subject.Sub_Disorder
- I-Subject.Sub_Disorder
ECT I-Subject.Sub_Disorder
anxiety I-Subject.Sub_Disorder
. O

Flumazenil I-Treatment.Drug
reversal I-Potential_therapeutic_event.Trigger
of O
benzodiazepine I-Treat_Disorder
- I-Treat_Disorder
induced I-Treat_Disorder
sedation I-Treat_Disorder
for O
a I-Subject
patient I-Subject
with I-Subject
severe I-Subject.Sub_Disorder
pre I-Subject.Sub_Disorder
- I-Subject.Sub_Disorder
ECT I-Subject.Sub_Disorder
anxiety I-Subject.Sub_Disorder
. O

We O
report O
a O
case O
of O
seizure I-Effect
associated I-Adverse_event.Trigger
with O
L I-Treatment.Drug
- I-Treatment.Drug
asparaginase I-Treatment.Drug
therapy I-Treatment
but O
no O
evidence O
of O
hemorrhagic O
or O
thrombotic O
cerebrovascular O
events O
. O

Here O
we O
describe O
a I-Subject
patient I-Subject
with I-Subject
Crohn I-Treat_Disorder
's I-Treat_Disorder
disease I-Treat_Disorder
who O
developed I-Adverse_event.Trigger
a O
severe I-Effect
infliximab I-Effect
infusion I-Effect
reaction I-Effect
( I-Effect
IIR I-Effect
) I-Effect
, I-Effect
complicated I-Effect
1 I-Effect
day I-Effect
later I-Effect
by I-Effect
severe I-Effect
swelling I-Effect
of I-Effect
the I-Effect
forearm I-Effect
and I-Effect
hand I-Effect
ipsilateral I-Effect
to O
the O
site O
of O
infliximab I-Treatment.Drug
infusion I-Treatment.Route
. O

She O
died I-Effect
within I-Effect
six I-Effect
weeks I-Effect
of I-Effect
developing I-Effect
congestive I-Effect
heart I-Effect
failure I-Effect
coupled I-Effect
with I-Effect
liver I-Effect
failure I-Effect
due O
to O
haemosiderosis I-Treat_Disorder
despite I-Potential_therapeutic_event.Trigger
regular I-Treatment
use I-Treatment
of I-Treatment
desferrioxamine I-Treatment.Drug
. O

A I-Subject
56 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
Caucasian I-Subject.Race
man I-Subject.Gender
who O
received O
concomitant I-Treatment
chemotherapy I-Treatment.Combination.Drug
and I-Treatment
radiation I-Treatment.Combination.Drug
for I-Treatment
head I-Treatment.Treat_Disorder
and I-Treatment.Treat_Disorder
neck I-Treatment.Treat_Disorder
cancer I-Treatment.Treat_Disorder
developed I-Adverse_event.Trigger
fever I-Effect
concurrent I-Treatment
with I-Treatment
the I-Treatment
administration I-Treatment
of I-Treatment
amifostine I-Treatment.Combination.Drug
. O

In O
this O
study O
, O
we O
report O
on O
three I-Subject.Population
individual I-Subject
patients I-Subject
who O
received O
BTX I-Treatment.Drug
- I-Treatment.Drug
B I-Treatment.Drug
and O
who O
subsequently O
developed I-Adverse_event.Trigger
parasympathetic I-Effect
dysfunction I-Effect
of I-Effect
the I-Effect
visual I-Effect
system I-Effect
after O
injections O
of O
BTX I-Treatment.Drug
- I-Treatment.Drug
B I-Treatment.Drug
at O
remote O
sites O
. O

Minocycline I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
autoimmune I-Effect
hepatitis I-Effect
is O
usually O
identical O
to O
sporadic I-Treat_Disorder
autoimmune I-Treat_Disorder
hepatitis I-Treat_Disorder
. O

BACKGROUND O
: O
Reproductive I-Effect
endocrine I-Effect
disorders I-Effect
characterized I-Effect
by I-Effect
menstrual I-Effect
disorders I-Effect
, I-Effect
polycystic I-Effect
ovaries I-Effect
, I-Effect
and I-Effect
hyperandrogenism I-Effect
seem O
to O
be O
common O
among O
women I-Subject.Gender
treated I-Adverse_event.Trigger
with O
sodium I-Treatment.Drug
valproate I-Treatment.Drug
for I-Treatment
epilepsy I-Treatment.Treat_Disorder
. O

Two I-Subject.Population
cases I-Subject
of I-Subject
lepromatous I-Treat_Disorder
leprosy I-Treat_Disorder
with I-Treat_Disorder
erythema I-Treat_Disorder
nodosum I-Treat_Disorder
leprosum I-Treat_Disorder
who O
were O
on O
high I-Treatment.Dosage
doses I-Treatment.Dosage
of I-Treatment
clofazimine I-Treatment.Drug
, O
showed I-Adverse_event.Trigger
discoloration I-Effect
of I-Effect
nail I-Effect
plate I-Effect
, I-Effect
subungual I-Effect
hyperkeratosis I-Effect
and I-Effect
onycholysis I-Effect
. O

Doxycycline I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
photo I-Effect
- I-Effect
onycholysis I-Effect
. O

Case O
report O
: O
acute I-Effect
renal I-Effect
failure I-Effect
after I-Adverse_event.Trigger
administering I-Treatment
intravenous I-Treatment.Route
immunoglobulin I-Treatment.Drug
. O

Sweet I-Effect
's I-Effect
syndrome I-Effect
associated I-Adverse_event.Trigger
with O
sargramostim I-Treatment.Drug
( I-Treatment
granulocyte I-Treatment
- I-Treatment
macrophage I-Treatment
colony I-Treatment
stimulating I-Treatment
factor I-Treatment
) I-Treatment
treatment I-Treatment
. O

This O
is O
a O
rare O
case O
of O
ARDS I-Effect
associated I-Adverse_event.Trigger
with O
lithium I-Treatment.Drug
intoxication O
. O

Intravenous I-Treatment
haloperidol I-Treatment
is O
generally O
well O
tolerated O
, O
but O
multiform I-Effect
ventricular I-Effect
tachycardia I-Effect
has O
been O
reported I-Adverse_event.Trigger
. O

To O
report O
a O
case O
of O
rhabdomyolysis I-Effect
and I-Effect
acute I-Effect
hepatitis I-Effect
associated I-Adverse_event.Trigger
with O
the O
coadministration I-Treatment
of I-Treatment
atorvastatin I-Treatment.Combination.Drug
and I-Treatment
diltiazem I-Treatment.Combination.Drug
. O

Ten I-Treatment.Time_elapsed
hours I-Treatment.Time_elapsed
after I-Treatment
the I-Treatment
second I-Treatment.Time_elapsed
methotrexate I-Treatment.Drug
injection I-Treatment.Route
, O
the I-Subject
patient I-Subject
experienced I-Adverse_event.Trigger
a O
diffuse I-Effect
pruritic I-Effect
papular I-Effect
eruption I-Effect
located I-Effect
mainly I-Effect
on I-Effect
the I-Effect
limbs I-Effect
. O

Flecainide I-Treatment.Drug
and I-Treatment
pharmacologically I-Treatment
similar I-Treatment
agents I-Treatment
that I-Treatment
interact I-Treatment
with I-Treatment
sodium I-Treatment
channels I-Treatment
may O
cause I-Adverse_event.Trigger
delirium I-Effect
in O
susceptible I-Subject
patients I-Subject
. O

An I-Subject
elderly I-Subject.Age
man I-Subject.Gender
with O
procainamide I-Treatment.Drug
hydrochloride I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
lupus I-Effect
syndrome O
had O
a O
circulating O
anticoagulant O
against O
factor O
XI O
and O
a O
biologic O
false O
- O
positive O
( O
BFP O
) O
test O
result O
for O
syphilis O
. O

In O
one I-Subject.Population
patient I-Subject
, O
treatment O
with O
DCA I-Treatment.Drug
was O
associated I-Adverse_event.Trigger
with O
a O
decrease I-Effect
in I-Effect
blood I-Effect
lactate I-Effect
levels I-Effect
from O
11.2 O
mM O
before O
treatment O
to O
0.8 O
mM O
16 I-Time_elapsed
h I-Time_elapsed
later I-Time_elapsed
. O

We O
report O
a O
case O
of O
noncardiogenic I-Effect
pulmonary I-Effect
edema I-Effect
developed I-Adverse_event.Trigger
after O
therapeutic O
trial O
of O
EO I-Treatment.Drug
as O
sclerosing O
agent O
for O
esophageal I-Treat_Disorder
varix I-Treat_Disorder
. O

That O
review O
suggested O
that O
patients I-Subject
receiving I-Treatment
anti I-Treatment.Drug
- I-Treatment.Drug
D I-Treatment.Drug
IGIV I-Treatment.Drug
be O
monitored O
for O
those O
and O
other O
potential O
complications I-Adverse_event.Trigger
of O
hemoglobinemia I-Effect
, I-Effect
particularly I-Effect
disseminated I-Effect
intravascular I-Effect
coagulation I-Effect
( I-Effect
DIC I-Effect
) I-Effect
. O

Seizures I-Effect
associated I-Adverse_event.Trigger
with O
therapeutic I-Treatment.Dosage
doses I-Treatment.Dosage
of I-Treatment
venlafaxine I-Treatment.Combination.Drug
and I-Treatment
trimipramine I-Treatment.Combination.Drug
. O

BACKGROUND O
: O
The O
risk O
/ O
benefit O
ratio O
of O
warfarin I-Treatment.Drug
therapy I-Treatment
changes O
in O
the O
over I-Subject.Age
75s I-Subject.Age
, O
when O
haemorrhagic I-Effect
side I-Effect
- I-Effect
effects I-Effect
become I-Adverse_event.Trigger
more O
common O
. O

Norethisterone I-Treatment.Drug
in O
these O
69 I-Subject.Population
pregnancies I-Subject
accounted I-Adverse_event.Trigger
for O
33.3 O
% O
( O
5 O
of O
15 O
) O
cases O
of O
clitoral I-Effect
hypertrophy I-Effect
diagnosed O
in O
100,756 O
consecutive O
births O
. O

Interstitial I-Effect
fibrosis I-Effect
of I-Effect
the I-Effect
lung I-Effect
is O
a O
potential O
complication I-Adverse_event.Trigger
of O
methotrexate I-Treatment.Drug
therapy O
for O
psoriasis I-Treat_Disorder
. O

This O
is O
the O
first O
reported O
fatality O
due O
to O
this O
drug O
interaction O
and O
only O
the O
second O
case O
of O
serotonin I-Effect
syndrome I-Effect
reported I-Adverse_event.Trigger
with O
oxcarbazepine I-Treatment.Drug
. O

Purple I-Effect
glove I-Effect
syndrome I-Effect
, O
named O
for O
its O
distinctive O
purple I-Effect
discoloration I-Effect
and I-Effect
swelling I-Effect
of I-Effect
the I-Effect
hands I-Effect
in I-Effect
the I-Effect
distribution I-Effect
of I-Effect
a I-Effect
glove I-Effect
, O
is O
an O
uncommon O
complication I-Adverse_event.Trigger
of O
intravenous I-Treatment.Route
phenytoin I-Treatment.Drug
administration I-Treatment
through I-Treatment
small I-Treatment
dorsal I-Treatment
veins I-Treatment
of I-Treatment
the I-Treatment
hands I-Treatment
. O

Possible O
linkage I-Adverse_event.Trigger
of O
amprenavir I-Treatment.Drug
with O
intracranial I-Effect
bleeding I-Effect
in O
an I-Subject
HIV I-Treat_Disorder
- I-Subject
infected I-Subject
hemophiliac I-Subject
. O

Inadvertent I-Treatment
subsequent I-Treatment
rechallenge I-Treatment
with I-Treatment
celiprolol I-Treatment.Drug
led I-Adverse_event.Trigger
to I-Adverse_event.Trigger
recurrence I-Effect
of I-Effect
the I-Effect
pneumonitis I-Effect
, O
10 I-Treatment.Time_elapsed
weeks I-Treatment.Time_elapsed
after I-Treatment
drug I-Treatment
readministration I-Treatment
. O

Flecainide I-Treatment.Drug
had O
been O
started O
2 O
weeks O
prior O
for I-Potential_therapeutic_event.Trigger
atrial I-Treat_Disorder
fibrillation I-Treat_Disorder
. O

In O
the O
absence O
of O
evidence O
of O
a O
potential O
role O
for O
concomitant O
medication O
i.e. O
hydroxychloroquine O
sulfate O
to O
play O
a O
role O
in O
the O
clinical O
, O
biochemical O
and O
morphological O
picture O
, O
an I-Treatment
interaction I-Treatment
between I-Treatment
the I-Treatment
herbal I-Treatment.Combination.Drug
preparation I-Treatment.Combination.Drug
and I-Treatment
tibolone I-Treatment.Combination.Drug
was O
suspected I-Adverse_event.Trigger
as O
the O
likely O
cause O
of O
liver I-Effect
damage I-Effect
. O

Its O
overall O
toxicity O
is O
considerably O
less O
compared O
to O
standard O
induction O
chemotherapy O
; O
however O
, O
it O
is O
associated O
with O
a O
high O
incidence O
of O
a O
potentially O
fatal O
symptom I-Effect
complex I-Effect
referred I-Effect
to I-Effect
as I-Effect
" I-Effect
retinoic I-Effect
acid I-Effect
syndrome I-Effect
. I-Effect
" I-Effect
This O
report O
describes O
a I-Subject
patient I-Subject
with I-Subject
APL I-Treat_Disorder
who O
developed I-Adverse_event.Trigger
the O
syndrome O
a I-Treatment.Time_elapsed
few I-Treatment.Time_elapsed
weeks I-Treatment.Time_elapsed
after I-Treatment
initiating I-Treatment
induction I-Treatment
therapy I-Treatment
with I-Treatment
ATRA I-Treatment.Drug
despite I-Treatment
being I-Treatment
treated I-Treatment
for I-Treatment
hyperleukocytosis I-Treatment
. O

During I-Treatment
intravenous I-Treatment.Route
treatment I-Treatment
with I-Treatment
terlipressin I-Treatment.Drug
for I-Treatment
recurrent I-Treatment.Treat_Disorder
gastrointestinal I-Treatment.Treat_Disorder
( I-Treatment
GI I-Treatment
) I-Treatment
bleeding I-Treatment
, O
a I-Subject
50 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
male I-Subject.Gender
with I-Subject
no I-Subject
history I-Subject
of I-Subject
heart I-Subject
disease I-Subject
developed I-Adverse_event.Trigger
a I-Effect
newly I-Effect
prolonged I-Effect
QT I-Effect
interval I-Effect
and I-Effect
torsade I-Effect
de I-Effect
pointes I-Effect
. O

It O
is O
concluded O
that O
chloral I-Treatment.Combination.Drug
hydrate I-Treatment.Combination.Drug
and I-Treatment
methaqualone I-Treatment.Combination.Drug
may O
be O
administered O
safely O
without O
additional O
caution I-Adverse_event.Trigger
in O
prothrombin O
test O
monitoring O
during I-Treatment
oral I-Treatment.Route
anticoagulant I-Treatment.Combination.Drug
therapy I-Treatment
. O

Amiodarone I-Treatment.Drug
hydrochloride I-Treatment.Drug
, O
a O
new O
antiarrhythmic O
agent O
, O
has O
been O
associated I-Adverse_event.Trigger
with O
pulmonary I-Effect
toxicity I-Effect
characterized I-Effect
by I-Effect
cough I-Effect
, I-Effect
dyspnea I-Effect
and I-Effect
diffuse I-Effect
pulmonary I-Effect
infiltrates I-Effect
. O

Although O
major I-Adverse_event.Trigger
hazards I-Adverse_event.Trigger
of O
treatment O
of O
hypophosphatemic I-Treatment.Treat_Disorder
osteomalacia I-Treatment.Treat_Disorder
with I-Treatment
phosphate I-Treatment.Combination.Drug
and I-Treatment
calcitriol I-Treatment.Combination.Drug
are O
secondary I-Effect
hyperparathyroidism I-Effect
and I-Effect
vitamin I-Effect
D I-Effect
intoxication I-Effect
, I-Effect
potassium I-Effect
loss I-Effect
also O
should O
be O
kept O
in O
mind O
. O

He O
had O
priapism I-Effect
following I-Adverse_event.Trigger
the O
use O
of O
olanzapine I-Treatment.Drug
. O

CONCLUSION O
: O
Our O
case O
shows O
a O
fatal O
side I-Effect
effect I-Effect
of I-Adverse_event.Trigger
erlotinib I-Treatment.Drug
. O

Data O
have O
been O
published O
regarding O
the O
possibility O
that O
tamoxifen I-Treatment.Drug
may O
be O
responsible I-Adverse_event.Trigger
for O
the O
subsequent I-Effect
development I-Effect
of I-Effect
carcinoma I-Effect
of I-Effect
the I-Effect
corpus I-Effect
uteri I-Effect
in O
these I-Subject
patients I-Subject
. O

Corticosteroids I-Treatment.Drug
may O
be I-Potential_therapeutic_event.Trigger
useful I-Potential_therapeutic_event.Trigger
for O
therapy O
of O
some O
features O
of O
this O
syndrome O
, O
such O
as O
thrombocytopenia I-Treat_Disorder
. O

Eosinophilic I-Effect
cystitis I-Effect
after I-Adverse_event.Trigger
bladder I-Treatment.Route
instillation I-Treatment.Route
with I-Treatment
dimethyl I-Treatment.Drug
sulfoxide I-Treatment.Drug
. O

Beginning O
ductopenia I-Effect
was O
present O
in O
two I-Subject
, O
suggesting O
that O
itraconazole I-Treatment.Drug
might O
be O
responsible I-Adverse_event.Trigger
for O
the O
occurrence O
of O
prolonged I-Treat_Disorder
drug I-Treat_Disorder
- I-Treat_Disorder
induced I-Treat_Disorder
cholangiopathy I-Treat_Disorder
. O

A I-Effect
15 I-Effect
- I-Effect
kg I-Effect
weight I-Effect
gain I-Effect
developed I-Adverse_event.Trigger
in O
a I-Subject
patient I-Subject
during O
the I-Time_elapsed
third I-Time_elapsed
week I-Time_elapsed
of O
ibuprofen I-Treatment.Drug
therapy O
. O

Cefoxitin I-Treatment.Drug
- O
associated I-Adverse_event.Trigger
renal I-Effect
failure I-Effect
. O

The O
rash I-Effect
seen I-Adverse_event.Trigger
in O
this O
patient I-Subject
, O
who O
was O
treated O
with O
cephalexin I-Treatment.Drug
, O
may O
be O
similar O
to O
the O
rash O
seen O
with O
ampicillin O
treatment O
of O
patients O
with O
infectious O
mononucleosis O
. O

The O
rash O
seen O
in O
this O
patient O
, O
who O
was O
treated O
with O
cephalexin O
, O
may O
be O
similar O
to O
the O
rash O
seen I-Adverse_event.Trigger
with O
ampicillin I-Treatment.Drug
treatment I-Treatment
of O
patients I-Subject
with O
infectious I-Effect
mononucleosis I-Effect
. O

Two I-Subject.Population
of I-Subject
our I-Subject
patients I-Subject
developed I-Adverse_event.Trigger
TD I-Effect
after O
23 I-Time_elapsed
months I-Time_elapsed
and O
34 I-Time_elapsed
months I-Time_elapsed
of O
ziprasidone I-Treatment.Drug
monotherapy O
, O
respectively O
. O

We O
describe O
two I-Subject.Population
dark I-Subject.Race
- I-Subject.Race
skinned I-Subject.Race
patients I-Subject
who O
developed O
hyperpigmented I-Effect
skin I-Effect
and I-Effect
tongue I-Effect
lesions I-Effect
during I-Adverse_event.Trigger
combination I-Treatment
therapy I-Treatment
with I-Treatment
IFN I-Treatment.Combination.Drug
and I-Treatment
ribavirin I-Treatment.Combination.Drug
. I-Treatment

Attenuation I-Effect
of I-Effect
asparaginase I-Effect
- I-Effect
induced I-Effect
hyperglycemia I-Effect
after I-Potential_therapeutic_event.Trigger
substitution I-Treatment
of I-Treatment
the I-Treatment
Erwinia I-Treatment.Drug
carotovora I-Treatment.Drug
for I-Treatment
the I-Treatment
Escherichia I-Treatment.Drug
coli I-Treatment.Drug
enzyme I-Treatment.Drug
preparation I-Treatment.Drug
. O

It O
remains O
to O
be O
seen O
whether O
the O
hepatotoxicity I-Effect
associated I-Adverse_event.Trigger
with O
troglitazone I-Treatment.Drug
is O
a O
drug O
- O
class O
effect O
or O
specific O
to O
troglitazone O
. O

Ampicillin I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
interstitial I-Effect
nephritis I-Effect
with I-Effect
generalised I-Effect
exfoliative I-Effect
dermatitis I-Effect
. O

High I-Treatment.Dosage
- I-Treatment.Dosage
dose I-Treatment.Dosage
intravenous I-Treatment.Route
mannitol I-Treatment.Drug
infusion I-Treatment.Route
in O
various O
clinical O
settings O
may O
result I-Adverse_event.Trigger
in O
acute I-Effect
renal I-Effect
failure I-Effect
( O
ARF O
) O
. O

A I-Subject
7 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
boy I-Subject.Gender
developed I-Subject
a I-Subject.Sub_Disorder
severe I-Subject.Sub_Disorder
unilateral I-Subject.Sub_Disorder
grand I-Subject.Sub_Disorder
mal I-Subject.Sub_Disorder
seizure I-Subject.Sub_Disorder
at I-Treatment
the I-Treatment
age I-Treatment
of I-Treatment
5 I-Treatment
years I-Treatment
( I-Treatment
phenobarbitone I-Treatment.Combination.Drug
therapy I-Treatment
) I-Treatment
; I-Treatment
1.5 I-Treatment.Time_elapsed
years I-Treatment.Time_elapsed
later I-Treatment.Time_elapsed
valproate I-Treatment.Combination.Drug
( I-Treatment
2 I-Treatment
- I-Treatment
propylpentanoic I-Treatment
acid I-Treatment
, I-Treatment
VPA I-Treatment
) I-Treatment
was I-Treatment
added I-Treatment
to I-Treatment
the I-Treatment
therapy I-Treatment
. I-Treatment

We O
report O
the O
first O
case O
of O
rhabdomyolysis I-Effect
related I-Adverse_event.Trigger
to I-Adverse_event.Trigger
the O
administration I-Treatment
of I-Treatment
clarithromycin I-Treatment.Drug
without I-Treatment
concurrent I-Treatment
use I-Treatment
of I-Treatment
other I-Treatment
medications I-Treatment
. O

The O
authors O
report O
a I-Subject
further I-Subject
case I-Subject
of O
methimazole I-Treatment.Drug
- O
associated I-Adverse_event.Trigger
liver I-Effect
damage I-Effect
and O
present O
a O
brief O
review O
of O
eleven I-Subject.Population
previous I-Subject
cases I-Subject
found O
in O
the O
literature O
. O

A I-Subject
67 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
patient I-Subject
, I-Subject
with I-Subject
primary I-Treat_Disorder
polymyositis I-Treat_Disorder
and I-Subject
without I-Subject
previous I-Subject
evidence I-Subject
of I-Subject
liver I-Subject
disease I-Subject
, O
developed I-Adverse_event.Trigger
clinical O
and O
biochemical O
features O
of O
severe O
cholestasis I-Effect
3 I-Treatment.Time_elapsed
months I-Treatment.Time_elapsed
after I-Treatment
initiation I-Treatment
of I-Treatment
azathioprine I-Treatment.Drug
therapy O
. O

Hypersensitivity I-Effect
reaction I-Effect
following I-Adverse_event.Trigger
chloramphenicol I-Treatment.Drug
administration O
in O
a I-Subject
patient I-Subject
with I-Subject
typhoid I-Treat_Disorder
fever I-Treat_Disorder
. O

Allergic O
and O
irritant O
contact I-Effect
dermatitis I-Effect
to I-Adverse_event.Trigger
calcipotriol I-Treatment.Drug
. O

A I-Subject
23 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
woman I-Subject.Gender
with I-Subject
systemic I-Treat_Disorder
lupus I-Treat_Disorder
erythematosus I-Treat_Disorder
had I-Adverse_event.Trigger
a O
severe O
hypersensitivity I-Effect
reaction I-Effect
to O
the O
drug O
ibuprofen I-Treatment.Drug
. O

We O
present O
the O
first O
case I-Adverse_event.Trigger
of O
WES I-Effect
in O
an I-Subject
infant I-Subject.Age
born I-Subject
to I-Subject
a I-Subject
mother I-Subject
taking O
haloperidol I-Treatment.Drug
during O
her O
pregnancy O
. O

Despite O
treatment O
with O
levofloxacin I-Treatment.Drug
, I-Treatment
acyclovir I-Treatment.Drug
, I-Treatment
and I-Treatment
voriconazole I-Treatment.Drug
, O
the O
patient I-Subject
developed I-Adverse_event.Trigger
high I-Effect
fevers I-Effect
. O

The I-Subject
5 I-Subject.Population
patients I-Subject
had I-Subject
severe I-Subject
renovascular I-Subject.Sub_Disorder
disease I-Subject.Sub_Disorder
which O
might O
thus O
represent O
a O
significant O
risk O
factor O
in O
the O
development O
of O
captopril I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
acute I-Effect
renal I-Effect
failure I-Effect
. O

METHODS O
: O
Growth I-Effect
retardation I-Effect
was O
observed O
in O
six I-Subject.Population
severely I-Treat_Disorder
asthmatic I-Treat_Disorder
children I-Subject.Age
after I-Adverse_event.Trigger
introduction I-Treatment
of I-Treatment
high I-Treatment.Dosage
- I-Treatment.Dosage
dose I-Treatment.Dosage
fluticasone I-Treatment.Drug
propionate I-Treatment.Drug
treatment I-Treatment
( I-Treatment
dry I-Treatment.Route
powder I-Treatment.Route
) I-Treatment
. O

The O
toxic I-Effect
effects I-Effect
of I-Adverse_event.Trigger
methotrexate I-Treatment.Drug
included O
elevated I-Effect
liver I-Effect
transaminases I-Effect
( I-Effect
3/4 I-Effect
) I-Effect
, I-Effect
nausea I-Effect
( I-Effect
2/4 I-Effect
) I-Effect
, I-Effect
abdominal I-Effect
pain I-Effect
( I-Effect
2/4 I-Effect
) I-Effect
, I-Effect
bone I-Effect
pain I-Effect
( I-Effect
2/4 I-Effect
) I-Effect
, I-Effect
mild I-Effect
neutropenia I-Effect
( I-Effect
1/4 I-Effect
) I-Effect
, I-Effect
and I-Effect
mild I-Effect
pruritus I-Effect
( I-Effect
1/4 I-Effect
) I-Effect
. O

CONCLUSION O
: O
Zidovudine I-Treatment.Drug
is O
well O
a O
known O
cause I-Adverse_event.Trigger
of O
anaemia I-Effect
and O
thus O
should O
be O
used O
with O
caution O
in O
the O
initiation O
of O
antiretroviral O
therapy O
. O

A I-Subject
60 I-Subject.Age
- I-Subject.Age
yr I-Subject.Age
- I-Subject.Age
old I-Subject.Age
woman I-Subject.Gender
, O
established I-Potential_therapeutic_event.Trigger
on O
paroxetine I-Treatment.Drug
for O
depression I-Treat_Disorder
, O
underwent I-Treatment
excision I-Treatment
of I-Treatment
a I-Treatment
chest I-Treatment
wall I-Treatment
myxofibrosarcoma I-Treatment.Treat_Disorder
and I-Treatment
chest I-Treatment
wall I-Treatment
reconstruction I-Treatment
. O

Papilloedema I-Effect
and I-Effect
hepatic I-Effect
dysfunction I-Effect
apparently O
induced I-Adverse_event.Trigger
by O
perhexiline I-Treatment.Drug
maleate I-Treatment.Drug
( I-Treatment
Pexid I-Treatment
) I-Treatment
. O

The O
volatile I-Treatment.Route
anesthetic I-Treatment
halothane I-Treatment.Drug
undergoes O
substantial O
biotransformation O
generating O
metabolites O
that O
mediate I-Adverse_event.Trigger
hepatotoxicity I-Effect
. O

Case O
4 O
: O
A O
61 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
male I-Subject.Gender
alcoholic I-Treat_Disorder
who I-Subject
remained I-Subject
completely I-Subject
abstinent I-Subject
while O
taking I-Adverse_event.Trigger
cyanamide I-Treatment.Drug
for I-Treatment
3 I-Treatment.Duration
years I-Treatment.Duration
showed O
slight O
elevation I-Effect
of I-Effect
serum I-Effect
transaminases I-Effect
. O

These O
observations O
indicate O
that O
submassive I-Effect
hepatic I-Effect
necrosis I-Effect
may O
result I-Adverse_event.Trigger
from O
treatment O
with O
propylthiouracil I-Treatment.Drug
and O
are O
consistent O
with O
the O
notion O
that O
sensitization O
mechanisms O
may O
be O
responsible O
for O
the O
hepatic O
injury O
induced O
by O
this O
drug O
. O

Two I-Subject.Population
children I-Subject.Age
with I-Subject
rheumatic I-Treat_Disorder
fever I-Treat_Disorder
developed I-Adverse_event.Trigger
anicteric I-Effect
hepatitis I-Effect
while O
on O
high I-Treatment.Dosage
- I-Treatment.Dosage
dose I-Treatment.Dosage
aspirin I-Treatment.Drug
therapy O
. O

The O
authors O
describe O
valproate I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
hyperammonemia I-Effect
and I-Effect
mental I-Effect
status I-Effect
changes I-Effect
in O
an I-Subject
88 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
man I-Subject.Gender
, O
the O
first O
known O
reported O
case O
in O
an O
elderly O
patient O
. O

The O
mechanism O
of O
the O
decrease I-Effect
in I-Effect
plasma I-Effect
potassium I-Effect
induced I-Adverse_event.Trigger
by O
phosphate I-Treatment.Drug
treatment I-Treatment
was O
investigated O
in O
a I-Subject
24 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
hypertensive I-Subject.Sub_Disorder
patient I-Subject
with I-Subject
hypophosphatemic I-Treat_Disorder
osteomalacia I-Treat_Disorder
, I-Subject
who I-Subject
was I-Subject
the I-Subject
youngest I-Subject
of I-Subject
four I-Subject
patients I-Subject
, I-Subject
belonging I-Subject
to I-Subject
a I-Subject
23 I-Subject
number I-Subject
kindred I-Subject
of I-Subject
five I-Subject
generations I-Subject
. O

In O
the O
two I-Subject.Population
cases I-Subject
, O
a O
combination O
of O
iloprost I-Treatment.Combination.Drug
, I-Treatment
a I-Treatment
stable I-Treatment
prostacyclin I-Treatment
analogue I-Treatment
( I-Treatment
1 I-Treatment.Dosage
to I-Treatment.Dosage
2 I-Treatment.Dosage
ng I-Treatment.Dosage
/ I-Treatment.Dosage
kg I-Treatment.Dosage
/ I-Treatment.Dosage
mn I-Treatment.Dosage
) I-Treatment
with I-Treatment
aspirin I-Treatment.Combination.Drug
and I-Treatment
dipyridamole I-Treatment.Combination.Drug
was O
shown O
to O
inhibit I-Potential_therapeutic_event.Trigger
ex I-Potential_therapeutic_event.Trigger
vivo I-Potential_therapeutic_event.Trigger
the O
heparin I-Treat_Disorder
- I-Treat_Disorder
induced I-Treat_Disorder
platelet I-Treat_Disorder
aggregation I-Treat_Disorder
. O

In O
the O
two O
cases O
, O
a O
combination O
of O
iloprost O
, O
a O
stable O
prostacyclin O
analogue O
( O
1 O
to O
2 O
ng O
/ O
kg O
/ O
mn O
) O
with O
aspirin O
and O
dipyridamole O
was O
shown O
to O
inhibit O
ex O
vivo O
the O
heparin I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
platelet I-Effect
aggregation I-Effect
. O

Adrenaline I-Treatment.Drug
dacryolith I-Effect
: O
detection O
by O
ultrasound O
examination O
of O
the O
nasolacrimal I-Route
duct I-Route
. O

Ten O
days O
after O
itraconazole I-Treatment.Drug
was O
started O
, O
he O
developed I-Adverse_event.Trigger
paralytic I-Effect
ileus I-Effect
, I-Effect
neurogenic I-Effect
bladder I-Effect
, I-Effect
mild I-Effect
left I-Effect
ptosis I-Effect
, I-Effect
and I-Effect
absence I-Effect
of I-Effect
deep I-Effect
reflexes I-Effect
, I-Effect
with I-Effect
severe I-Effect
paralysis I-Effect
of I-Effect
the I-Effect
lower I-Effect
extremities I-Effect
and I-Effect
mild I-Effect
weakness I-Effect
of I-Effect
the I-Effect
upper I-Effect
extremities I-Effect
. O

OBJECTIVE O
: O
The O
aim O
of O
this O
paper O
is O
to O
describe O
a I-Subject
case I-Subject
of O
increased I-Effect
libido I-Effect
during I-Adverse_event.Trigger
fluvoxamine I-Treatment.Drug
therapy I-Treatment
. I-Treatment

An I-Subject
8 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
child I-Subject.Age
with O
familial I-Treat_Disorder
Mediterranean I-Treat_Disorder
fever I-Treat_Disorder
exhibited I-Adverse_event.Trigger
signs O
of O
colchicine I-Drug
intoxication I-Effect
while O
receiving O
prophylactic I-Treatment.Dosage
doses I-Treatment.Dosage
of I-Treatment
the I-Treatment
drug I-Treatment
. O

Furthermore O
, O
the I-Treatment
warfarin I-Treatment.Drug
dose I-Treatment
was I-Treatment
again I-Treatment
increased I-Treatment
after I-Treatment
discontinuation I-Treatment
of I-Treatment
ropinirole I-Treatment
due I-Potential_therapeutic_event.Trigger
to I-Potential_therapeutic_event.Trigger
common O
gastrointestinal I-Treat_Disorder
adverse I-Treat_Disorder
effects I-Treat_Disorder
. O

Serotonin I-Effect
syndrome I-Effect
following I-Adverse_event.Trigger
metaxalone I-Treatment.Combination.Drug
overdose I-Treatment.Dosage
and O
therapeutic O
use O
of O
a O
selective I-Combination.Drug
serotonin I-Combination.Drug
reuptake I-Combination.Drug
inhibitor I-Combination.Drug
. O

The O
aim O
of O
this O
report O
is O
to O
describe O
the O
clinical O
and O
electroencephalographic O
findings O
seen O
in O
an I-Subject
elderly I-Subject.Age
woman I-Subject.Gender
without O
previous O
history O
of O
seizures O
who O
developed O
a O
nonconvulsive I-Effect
generalized I-Effect
status I-Effect
epilepticus I-Effect
following I-Adverse_event.Trigger
acute I-Treatment
withdrawal I-Treatment
of I-Treatment
lorazepam I-Treatment.Drug
. O

We O
describe O
a I-Subject
patient I-Subject
with I-Subject
androgen I-Treat_Disorder
- I-Treat_Disorder
independent I-Treat_Disorder
prostate I-Treat_Disorder
cancer I-Treat_Disorder
in O
whom O
PSA I-Effect
continued I-Effect
to I-Effect
decrease I-Effect
for I-Effect
a I-Effect
period I-Effect
of I-Effect
15 I-Effect
months I-Effect
after I-Adverse_event.Trigger
flutamide I-Treatment.Drug
withdrawal I-Treatment
. O

Acute I-Effect
renal I-Effect
failure I-Effect
following I-Adverse_event.Trigger
intravenous I-Treatment.Route
immunoglobulin I-Treatment.Drug
therapy I-Treatment
in O
a I-Subject
HIV I-Subject.Sub_Disorder
- I-Subject
infected I-Subject
patient I-Subject
. O

After O
a I-Treatment
total I-Treatment
of I-Treatment
four I-Treatment.Dosage
doses I-Treatment.Dosage
of I-Treatment
linezolid I-Treatment.Drug
, O
the I-Subject
patient I-Subject
reported I-Adverse_event.Trigger
further I-Effect
discomfort I-Effect
. O

Although O
moderate O
myelosuppression O
is O
not O
uncommonly O
seen O
in O
patients O
treated O
with O
lenalidomide I-Treatment.Drug
, O
aplastic I-Effect
anemia I-Effect
has O
not O
previously O
been O
reported O
to O
be O
associated I-Adverse_event.Trigger
with O
this O
agent O
. O

This O
paper O
contributed O
to O
the O
identification O
of O
possible O
reactions I-Effect
in I-Effect
the I-Effect
oral I-Effect
cavity I-Effect
due I-Adverse_event.Trigger
to O
antiretroviral I-Treatment.Drug
medication I-Treatment.Drug
. O

Persistent I-Effect
light I-Effect
reactivity I-Effect
from I-Adverse_event.Trigger
systemic I-Treatment
quinine I-Treatment.Drug
. O

Based O
on O
the O
clinical O
status O
of O
the I-Subject
patient I-Subject
, O
it O
was O
suspected O
that O
several O
conditions O
contributed O
to O
the O
abnormal I-Effect
hypersensitivity I-Effect
to I-Adverse_event.Trigger
warfarin I-Treatment.Drug
. O

Treatment O
of O
APL O
in O
pregnancy O
is O
controversial O
as O
the O
use O
of O
ATRA O
has O
been O
questioned O
due I-Adverse_event.Trigger
to O
the O
teratogenic I-Effect
effect I-Effect
of O
retinoids I-Treatment.Drug
. O

Diazepam I-Treatment.Drug
use O
by O
pregnant O
women O
can O
be O
associated I-Adverse_event.Trigger
with O
a O
later I-Effect
presentation I-Effect
of I-Effect
withdrawal I-Effect
symptoms I-Effect
in I-Effect
the I-Effect
neonate I-Effect
than O
that O
induced O
by O
the O
use O
of O
other O
drugs O
. O

A I-Subject
65 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
patient I-Subject
chronically I-Treatment.Time_elapsed
treated I-Treatment
with I-Treatment
the I-Treatment
selective I-Treatment
serotonin I-Treatment
reuptake I-Treatment
inhibitor I-Treatment
( I-Treatment
SSRI I-Treatment
) I-Treatment
citalopram I-Treatment.Combination.Drug
developed I-Adverse_event.Trigger
confusion I-Effect
, I-Effect
agitation I-Effect
, I-Effect
tachycardia I-Effect
, I-Effect
tremors I-Effect
, I-Effect
myoclonic I-Effect
jerks I-Effect
and I-Effect
unsteady I-Effect
gait I-Effect
, I-Effect
consistent I-Effect
with I-Effect
serotonin I-Effect
syndrome I-Effect
, O
following I-Treatment
initiation I-Treatment
of I-Treatment
fentanyl I-Treatment.Combination.Drug
, O
and O
all O
symptoms O
and O
signs O
resolved O
following O
discontinuation O
of O
fentanyl O
. O

This O
case O
highlights O
rapid I-Effect
onset I-Effect
of I-Effect
adrenal I-Effect
insufficiency I-Effect
in O
a I-Subject
patient I-Subject
with I-Subject
CF I-Treat_Disorder
- I-Treat_Disorder
related I-Treat_Disorder
liver I-Treat_Disorder
disease I-Treat_Disorder
treated O
briefly I-Treatment
with I-Treatment
a I-Treatment
moderate I-Treatment
CYP3A4 I-Treatment.Drug
inhibitor I-Treatment.Drug
. O

The O
biochemistry O
of O
paracetamol O
hepatotoxicity O
is O
outlined O
and O
the O
increased O
susceptibility O
of O
alcoholic I-Subject
patients I-Subject
to O
the O
hepatotoxic I-Effect
effects I-Effect
of O
paracetamol I-Treatment.Drug
is O
remarked I-Adverse_event.Trigger
upon O
. O

The O
newborn I-Subject.Age
manifested I-Adverse_event.Trigger
a O
four I-Effect
day I-Effect
course I-Effect
of I-Effect
lethargy I-Effect
with I-Effect
unexplained I-Effect
high I-Effect
lithium I-Treatment.Drug
levels I-Effect
in O
the O
adult O
toxic O
range O
. O

The O
occurrence O
of O
severe I-Effect
AIHA I-Effect
in O
CLL I-Treat_Disorder
patients I-Subject
treated I-Adverse_event.Trigger
with O
fludarabine I-Treatment.Drug
has O
been O
reported O
by O
several O
authors O
. O

Corneal I-Effect
endothelial I-Effect
dysfunction I-Effect
associated I-Adverse_event.Trigger
with O
amantadine I-Treatment.Drug
toxicity O
. O

We O
describe O
the O
development I-Adverse_event.Trigger
of O
cutaneous I-Effect
scleroderma I-Effect
in O
3 I-Subject.Population
patients I-Subject
coincident O
with O
the I-Treatment
use I-Treatment
of I-Treatment
bleomycin I-Treatment.Drug
in I-Treatment
low I-Treatment
cumulative I-Treatment
doses I-Treatment
of I-Treatment
less I-Treatment.Dosage
than I-Treatment.Dosage
100 I-Treatment.Dosage
U. I-Treatment.Dosage

This O
case O
suggests O
that O
sarcoidosis O
and O
pravastatin I-Treatment.Drug
, O
two O
entities O
not O
frequently O
associated O
with O
myotonia O
, O
may O
interact I-Adverse_event.Trigger
in O
a O
synergistic O
manner O
to O
produce O
severe I-Effect
clinical I-Effect
myotonia I-Effect
in O
humans I-Subject
. I-Subject

Disopyramide I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
heart I-Effect
block I-Effect
. O

Telescoped I-Effect
digits I-Effect
of I-Effect
the I-Effect
hands I-Effect
and I-Effect
feet I-Effect
developed I-Adverse_event.Trigger
in O
a I-Subject
69 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
male I-Subject.Gender
with I-Subject
severe I-Treat_Disorder
chronic I-Treat_Disorder
tophaceous I-Treat_Disorder
gout I-Treat_Disorder
during O
allopurinol I-Treatment.Drug
treatment I-Treatment
. O

CONCLUSIONS O
: O
Jet I-Treatment.Route
- I-Treatment.Route
injection I-Treatment.Route
devices I-Treatment
might O
constitute O
a O
helpful O
method O
to O
treat I-Potential_therapeutic_event.Trigger
those O
patients I-Subject
affected O
by O
severe O
human O
insulin I-Treat_Disorder
- I-Treat_Disorder
induced I-Treat_Disorder
lipoatrophy I-Treat_Disorder
. O

CONCLUSIONS O
: O
Jet O
- O
injection O
devices O
might O
constitute O
a O
helpful O
method O
to O
treat O
those O
patients O
affected O
by O
severe O
human O
insulin I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
lipoatrophy I-Effect
. O

We O
describe O
a I-Subject
relatively I-Subject
healthy I-Subject
, I-Subject
9 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
boy I-Subject.Gender
who O
developed O
a O
CA I-Treat_Disorder
- I-Treat_Disorder
MRSA I-Treat_Disorder
skin I-Treat_Disorder
and I-Treat_Disorder
soft I-Treat_Disorder
tissue I-Treat_Disorder
infection I-Treat_Disorder
and O
was O
treated I-Potential_therapeutic_event.Trigger
with O
TMP I-Treatment.Drug
- I-Treatment.Drug
SMX I-Treatment.Drug
. O

Recurrent I-Effect
septicemia I-Effect
with I-Effect
lethal I-Effect
outcome I-Effect
during O
and O
after I-Adverse_event.Trigger
cyclosporine I-Treatment.Drug
therapy O
in O
severe I-Treat_Disorder
ulcerative I-Treat_Disorder
colitis I-Treat_Disorder
. O

Amifostine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
fever I-Effect
: O
case O
report O
and O
review O
of O
the O
literature O
. O

We O
report O
a I-Subject
patient I-Subject
who O
developed I-Adverse_event.Trigger
spontaneous I-Effect
splenic I-Effect
infarction I-Effect
after O
the O
use O
of O
sumatriptan I-Treatment.Drug
for O
the O
treatment O
of O
migraine I-Treat_Disorder
headache I-Treat_Disorder
. O

Hepatotoxicity I-Effect
associated I-Adverse_event.Trigger
with O
6 I-Treatment.Drug
- I-Treatment.Drug
thioguanine I-Treatment.Drug
therapy O
for O
Crohn I-Treat_Disorder
's I-Treat_Disorder
disease I-Treat_Disorder
. O

Neuropathy I-Effect
is O
a O
significant O
side I-Adverse_event.Trigger
effect I-Adverse_event.Trigger
of O
thalidomide I-Treatment.Drug
therapy O
, O
which O
may O
limit O
its O
clinical O
use O
. O

A O
possible O
mechanism I-Adverse_event.Trigger
for O
focal I-Effect
neurological I-Effect
deficit I-Effect
in O
brain I-Treat_Disorder
- I-Treat_Disorder
damaged I-Treat_Disorder
patients I-Subject
on O
phenytoin I-Treatment.Drug
therapy I-Treatment
is O
discussed O
. O

Pulmonary I-Effect
toxicity I-Effect
with I-Adverse_event.Trigger
mefloquine I-Treatment.Drug
. O

Ciprofloxacin I-Treatment.Drug
is O
one O
drug O
that O
has O
been O
reported O
to O
cause I-Adverse_event.Trigger
interstitial I-Effect
nephritis I-Effect
. O

Acute I-Effect
renal I-Effect
failure I-Effect
during I-Adverse_event.Trigger
lisinopril I-Treatment.Combination.Drug
and I-Treatment
losartan I-Treatment.Combination.Drug
therapy O
for O
proteinuria I-Treat_Disorder
. O

We O
present O
the O
first O
case O
of O
a I-Subject
patient I-Subject
with O
priapism I-Effect
after I-Adverse_event.Trigger
oral I-Treatment.Route
intake I-Treatment
of I-Treatment
the I-Treatment
phenothiazine I-Treatment
prothipendylhydrochloride I-Treatment.Drug
. O

However O
, O
because I-Adverse_event.Trigger
diphenhydramine I-Treatment.Drug
also I-Effect
exhibits I-Effect
type I-Effect
IA I-Effect
sodium I-Effect
channel I-Effect
blockade I-Effect
, I-Effect
cardiac I-Effect
toxicity I-Effect
is O
also O
possible O
. O

Ticlopidine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
interstitial I-Effect
pulmonary I-Effect
disease I-Effect
: O
a O
case O
report O
. O

Linezolid I-Treatment.Drug
is O
a O
popular O
choice O
of O
antibiotic O
, O
especially O
for O
the O
treatment I-Potential_therapeutic_event.Trigger
of O
orthopedic I-Treat_Disorder
- I-Treat_Disorder
related I-Treat_Disorder
MRSA I-Treat_Disorder
infections I-Treat_Disorder
. O

We O
present O
a O
case O
of O
photo I-Effect
- I-Effect
onycholysis I-Effect
in O
a I-Subject
patient I-Subject
treated I-Adverse_event.Trigger
with O
doxycycline I-Treatment.Drug
for O
acne I-Treat_Disorder
vulgaris I-Treat_Disorder
. O

Anticonvulsant I-Effect
hypersensitivity I-Effect
syndrome I-Effect
associated I-Adverse_event.Trigger
with O
Bellamine I-Treatment.Drug
S I-Treatment.Drug
, I-Treatment
a I-Treatment
therapy I-Treatment
for I-Treatment
menopausal I-Treatment.Treat_Disorder
symptoms I-Treatment.Treat_Disorder
. I-Treat_Disorder

CASE O
SUMMARY O
: O
A I-Subject
66 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
white I-Subject.Race
woman I-Subject.Gender
with I-Subject
a I-Subject
10 I-Subject
- I-Subject
year I-Subject
history I-Subject
of I-Subject
hypertension I-Treat_Disorder
and I-Subject
bronchial I-Subject.Sub_Disorder
asthma I-Subject.Sub_Disorder
was O
switched I-Treatment
from I-Treatment
immediate I-Treatment.Drug
- I-Treatment.Drug
release I-Treatment.Drug
verapamil I-Treatment.Drug
hydrocloride I-Treatment.Drug
40 I-Treatment.Dosage
mg I-Treatment.Dosage
tid I-Treatment.Dosage
to I-Treatment
sustained I-Treatment.Drug
- I-Treatment.Drug
release I-Treatment.Drug
verapamil I-Treatment.Drug
240 I-Treatment.Dosage
mg I-Treatment.Dosage
/ I-Treatment.Dosage
d I-Treatment.Dosage
po I-Treatment.Route
for O
better O
hypertension I-Treat_Disorder
control I-Potential_therapeutic_event.Trigger
. O

Due I-Adverse_event.Trigger
to O
the O
severity O
of O
the O
rash I-Effect
, O
temozolomide I-Treatment.Drug
was O
permanently O
discontinued O
. O

Ovarian I-Effect
endometrioid I-Effect
carcinoma I-Effect
and I-Effect
endometriosis I-Effect
developing O
in O
a I-Subject
postmenopausal I-Subject.Sub_Disorder
breast I-Treat_Disorder
cancer I-Treat_Disorder
patient I-Subject
during I-Adverse_event.Trigger
tamoxifen I-Treatment.Drug
therapy I-Treatment
: O
a O
case O
report O
and O
review O
of O
the O
literature O
. O

CONCLUSION O
: O
The I-Treatment
new I-Treatment
quinolone I-Treatment
derivatives I-Treatment
( I-Treatment
levofloxacin I-Treatment.Drug
, I-Treatment
sparfloxacin I-Treatment.Drug
, I-Treatment
grepafloxacin I-Treatment.Drug
, I-Treatment
trovafloxacin I-Treatment.Drug
, I-Treatment
gatifloxacin I-Treatment.Drug
and I-Treatment
moxifloxacin I-Treatment.Drug
) I-Treatment
, I-Treatment
also I-Treatment
called I-Treatment
gyrase I-Treatment
inhibitors I-Treatment
, O
are O
known O
for O
their O
potential O
to O
cause I-Adverse_event.Trigger
central I-Effect
nervous I-Effect
system I-Effect
- I-Effect
related I-Effect
adverse I-Effect
effects I-Effect
, I-Effect
including I-Effect
headache I-Effect
, I-Effect
dizziness I-Effect
and I-Effect
insomnia I-Effect
. O

Terlipressin I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
ventricular I-Effect
arrhythmia I-Effect
. O

CASE O
REPORT O
: O
We O
report O
a O
case O
of O
acute I-Effect
severe I-Effect
hepatitis I-Effect
resulting I-Adverse_event.Trigger
from O
erlotinib I-Treatment.Drug
monotherapy I-Treatment
in O
a I-Subject
patient I-Subject
with I-Subject
locally I-Treat_Disorder
advanced I-Treat_Disorder
pancreatic I-Treat_Disorder
cancer I-Treat_Disorder
. O

We O
highlight O
two I-Subject.Population
instances I-Subject
of O
systemic I-Effect
allergic I-Effect
reaction I-Effect
, O
and O
discuss O
the O
potential I-Effect
side I-Effect
effects I-Effect
of I-Adverse_event.Trigger
local O
aprotinin I-Treatment.Drug
injections I-Route
in O
the O
orthopaedic O
setting O
as O
well O
as O
the O
evidence O
base O
for O
its O
use O
. O

Acute I-Effect
pancreatitis I-Effect
associated I-Adverse_event.Trigger
with O
danazol I-Treatment.Drug
treatment I-Treatment
for O
endometriosis I-Treat_Disorder
. O

CASE O
REPORT O
: O
We O
report O
the O
case O
of O
a I-Subject
58 I-Subject.Age
year I-Subject.Age
old I-Subject.Age
patient I-Subject
who O
, O
after I-Treatment
2 I-Treatment.Time_elapsed
days I-Treatment.Time_elapsed
of I-Treatment
treatment I-Treatment
with I-Treatment
roxithromycin I-Treatment.Combination.Drug
and O
betamethasone I-Treatment.Combination.Drug
, O
manifested I-Adverse_event.Trigger
acute I-Effect
pancreatitis I-Effect
. O

It O
should O
be O
recognized O
that O
ibuprofen I-Treatment.Drug
may O
be O
associated I-Adverse_event.Trigger
with O
salt I-Effect
and I-Effect
water I-Effect
retention I-Effect
in O
the O
same O
fashion O
as O
previously O
described O
with O
phenylbutazone I-Drug
and O
indomethacin I-Drug
. O

Gastric I-Effect
tumor I-Effect
, I-Effect
endometrial I-Effect
carcinoma I-Effect
and I-Effect
cervical I-Effect
adenocarcinoma I-Effect
in I-Effect
situ I-Effect
were O
detected I-Adverse_event.Trigger
after O
treatment O
with O
tamoxifen I-Treatment.Drug
for O
breast I-Treat_Disorder
cancer I-Treat_Disorder
. O

This O
therapy O
was O
also O
complicated O
by O
Warfarin I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
skin I-Effect
necrosis I-Effect
. O

Immobilization O
, O
while O
Paget O
's O
bone O
disease O
was O
present O
, O
and O
perhaps O
enhanced O
activation O
of O
dihydrotachysterol I-Treatment.Drug
by O
rifampicin O
, O
could O
have O
led I-Adverse_event.Trigger
to O
increased I-Effect
calcium I-Effect
- I-Effect
release I-Effect
into O
the O
circulation O
. O

Failure O
of O
plasmapheresis I-Treatment
, I-Treatment
corticosteroids I-Treatment.Drug
and I-Treatment
thionamides I-Treatment.Drug
to O
ameliorate I-Potential_therapeutic_event.Trigger
a O
case O
of O
protracted O
amiodarone I-Treat_Disorder
- I-Treat_Disorder
induced I-Treat_Disorder
thyroiditis I-Treat_Disorder
. O

Failure O
of O
plasmapheresis O
, O
corticosteroids O
and O
thionamides O
to O
ameliorate O
a O
case O
of O
protracted O
amiodarone I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
thyroiditis I-Effect
. O

Although O
neurotoxicity I-Effect
is O
a O
frequent O
complication I-Adverse_event.Trigger
of O
methotrexate I-Treatment.Drug
therapy I-Treatment
, O
fatal O
acute O
neurotoxicity O
is O
extremely O
uncommon O
, O
especially O
in O
adults O
. O

Intravenous I-Treatment.Route
sodium I-Treatment.Drug
bicarbonate I-Treatment.Drug
appears O
to O
be O
indicated O
prophylactically O
in O
combating I-Potential_therapeutic_event.Trigger
the O
associated O
metabolic I-Treat_Disorder
acidosis I-Treat_Disorder
due I-Treat_Disorder
to I-Treat_Disorder
absorbed I-Treat_Disorder
formic I-Treat_Disorder
acid I-Treat_Disorder
. O

Intravenous O
sodium O
bicarbonate O
appears O
to O
be O
indicated O
prophylactically O
in O
combating O
the O
associated O
metabolic I-Effect
acidosis I-Effect
due I-Adverse_event.Trigger
to O
absorbed I-Treatment
formic I-Treatment.Drug
acid I-Treatment.Drug
. O

Allopurinol I-Treatment.Drug
- O
associated I-Adverse_event.Trigger
hand I-Effect
and I-Effect
foot I-Effect
deformities I-Effect
in O
chronic I-Treat_Disorder
tophaceous I-Treat_Disorder
gout I-Treat_Disorder
. O

The O
intramuscular O
challenge O
test O
with O
25 I-Treatment.Dosage
UI I-Treatment.Dosage
of I-Treatment
Miacalcic I-Treatment.Drug
was O
positive O
with O
an O
immediate I-Treatment.Time_elapsed
anaphylactic I-Effect
reaction I-Effect
. O

There O
are O
several I-Subject.Population
documented I-Subject
case I-Subject
reports I-Adverse_event.Trigger
of O
serotonin I-Combination.Drug
toxicity I-Effect
when O
used O
with O
selective I-Treatment.Combination.Drug
serotonin I-Treatment.Combination.Drug
reuptake I-Treatment.Combination.Drug
inhibitors I-Treatment.Combination.Drug
. O

A O
literature O
review O
revealed O
83 I-Subject.Population
other I-Subject
reported I-Subject
cases I-Subject
of O
rifampicin I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
renal I-Effect
insufficiency I-Effect
. O

Complete O
regression I-Potential_therapeutic_event.Trigger
of O
iatrogenic O
Kaposi I-Treat_Disorder
's I-Treat_Disorder
sarcoma I-Treat_Disorder
due O
to O
corticosteroid I-Treatment.Drug
treatment O
in O
a I-Subject
patient I-Subject
with I-Subject
tubercular I-Subject.Sub_Disorder
pericarditis I-Subject.Sub_Disorder
. O

DIAGNOSIS O
: O
Severe O
temozolomide I-Treatment.Combination.Drug
- O
induced I-Adverse_event.Trigger
immunosuppression I-Effect
, O
exacerbated I-Treatment
by I-Treatment
corticosteroids I-Treatment.Combination.Drug
, O
with O
profound O
T I-Effect
- I-Effect
cell I-Effect
lymphocytopenia I-Effect
and O
simultaneous O
opportunistic O
infections O
with O
Pneumocystis I-Effect
jiroveci I-Effect
pneumonia I-Effect
, O
brain I-Effect
abscess I-Effect
with I-Effect
Listeria I-Effect
monocytogenes I-Effect
, O
and O
cutaneous I-Effect
Kaposi I-Effect
's I-Effect
sarcoma I-Effect
. O

The O
use O
of O
cyclosporin I-Treatment.Drug
has O
been O
associated O
with O
the O
development I-Adverse_event.Trigger
of O
cholelithiasis I-Effect
in O
transplant I-Subject.Sub_Disorder
recipients I-Subject
. O

Rifampicin I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
adrenal I-Effect
insufficiency I-Effect
in O
the O
acquired O
immunodeficiency O
syndrome O
: O
difficulties O
in O
diagnosis O
and O
treatment O
. O

Bisphosphonate I-Treatment.Drug
- O
related I-Adverse_event.Trigger
osteonecrosis I-Effect
of I-Effect
the I-Effect
skull I-Effect
base I-Effect
. O

Angioedema I-Effect
and I-Effect
dysphagia I-Effect
caused O
by O
contact I-Effect
allergy I-Effect
to O
inhaled I-Adverse_event.Trigger
budesonide I-Treatment.Drug
. O

Emergence I-Effect
of I-Effect
Philadelphia I-Effect
positive I-Effect
chronic I-Effect
myeloid I-Effect
leukaemia I-Effect
during O
treatment I-Adverse_event.Trigger
with O
hydroxyurea I-Treatment.Drug
for O
Philadelphia I-Treat_Disorder
negative I-Treat_Disorder
essential I-Treat_Disorder
thrombocythaemia I-Treat_Disorder
. O

Ciprofloxacin I-Treatment.Drug
greatly O
increases I-Potential_therapeutic_event.Trigger
concentrations I-Effect
and I-Effect
hypotensive I-Effect
effect I-Effect
of I-Effect
tizanidine I-Drug
by O
inhibiting O
its O
cytochrome O
P450 O
1A2 O
- O
mediated O
presystemic O
metabolism O
. O

2 I-Treatment.Drug
- I-Treatment.Drug
CdA I-Treatment.Drug
induces I-Potential_therapeutic_event.Trigger
lymphocytopenia I-Effect
, O
which O
may O
explain O
the O
improvement O
in O
this O
patient I-Subject
's I-Subject
psoriasis I-Treat_Disorder
. O

There O
is O
a O
dose O
- O
effect O
relationship I-Adverse_event.Trigger
between O
doxorubicin I-Treatment.Drug
and O
the O
incidence O
of O
symptomatic I-Effect
cardiac I-Effect
failure I-Effect
. O

These O
are O
the O
first O
reported O
patients O
to O
show O
mfERG O
abnormalities O
that O
correspond O
to O
bitemporal O
visual O
field O
defects O
and O
add O
to O
the O
growing O
evidence I-Adverse_event.Trigger
that O
ethambutol I-Treatment.Drug
damages I-Effect
the I-Effect
retina I-Effect
. O

Two I-Treatment.Time_elapsed
days I-Treatment.Time_elapsed
after I-Treatment
administration I-Treatment
of I-Treatment
Kalimate I-Treatment.Drug
enema I-Treatment.Route
, O
he I-Subject.Gender
had O
profuse I-Effect
hematochezia I-Effect
, O
and O
a O
sigmoidoscopy O
showed O
diffuse I-Effect
colonic I-Effect
mucosal I-Effect
necrosis I-Effect
in I-Effect
the I-Effect
rectum I-Effect
and O
sigmoid O
colon O
. O

Conventional O
and O
diffusion O
- O
weighted O
MRI O
findings O
of O
methotrexate I-Treatment.Drug
related I-Adverse_event.Trigger
sub I-Effect
- I-Effect
acute I-Effect
neurotoxicity I-Effect
. O

Scleromyxedema I-Effect
in O
a I-Subject
patient I-Subject
with I-Subject
multiple I-Treat_Disorder
sclerosis I-Treat_Disorder
and I-Subject
monoclonal I-Subject.Sub_Disorder
gammopathy I-Subject.Sub_Disorder
on I-Adverse_event.Trigger
interferon I-Treatment.Drug
beta I-Treatment.Drug
- I-Treatment.Drug
1a I-Treatment.Drug
. O

The O
literature O
search O
revealed O
22 I-Subject.Population
cases I-Subject
of O
hypersensitivity I-Effect
reaction I-Effect
to I-Adverse_event.Trigger
cyclosporine I-Treatment.Drug
. O

The O
presence O
of O
a I-Effect
lymphocyte I-Effect
alveolitis I-Effect
with I-Effect
a I-Effect
predominance I-Effect
of I-Effect
CD4 I-Effect
+ I-Effect
T I-Effect
cells I-Effect
in O
3 I-Subject.Population
RA I-Treat_Disorder
patients I-Subject
and O
CD8 I-Effect
+ I-Effect
T I-Effect
cells I-Effect
with I-Effect
a I-Effect
concomitant I-Effect
increase I-Effect
in I-Effect
neutrophils I-Effect
in O
another O
case O
suggests O
that O
immunologically O
mediated O
reactions O
may O
be O
one O
damage O
mechanism O
in O
MTX I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
pneumonitis I-Effect
. O

The O
authors O
report O
two O
cases O
of O
delayed I-Effect
elimination I-Effect
of I-Adverse_event.Trigger
methotrexate I-Treatment.Drug
in O
patients I-Subject
receiving I-Subject
ciprofloxacin I-Subject
, O
with O
severe O
toxicity O
. O

Severe I-Effect
acute I-Effect
encephalopathy I-Effect
following I-Adverse_event.Trigger
inadvertent O
intrathecal I-Treatment.Route
doxorubicin I-Treatment.Drug
administration I-Treatment
. O

Porcine I-Treatment.Drug
factor I-Treatment.Drug
VIII I-Treatment.Drug
( I-Treatment
pFVIII I-Treatment
) I-Treatment
, O
which O
is O
used O
to O
control O
bleeding I-Treat_Disorder
in O
patients I-Subject
with I-Subject
congenital I-Treat_Disorder
or I-Treat_Disorder
acquired I-Treat_Disorder
haemophilia I-Treat_Disorder
who I-Subject
have I-Subject
high I-Treat_Disorder
- I-Treat_Disorder
titre I-Treat_Disorder
neutralizing I-Treat_Disorder
antibodies I-Treat_Disorder
to I-Treat_Disorder
human I-Treat_Disorder
FVIII I-Treat_Disorder
, O
is O
not O
known O
to O
increase I-Adverse_event.Trigger
the O
risk I-Effect
of I-Effect
arterial I-Effect
or I-Effect
venous I-Effect
thrombosis I-Effect
. I-Effect

In O
all I-Subject
the I-Subject
patients I-Subject
, O
pellagra I-Effect
symptoms I-Effect
appeared I-Adverse_event.Trigger
during O
isoniazid I-Treatment.Drug
therapy I-Treatment
. O

Fatal O
gemcitabine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
pulmonary I-Effect
toxicity I-Effect
in O
metastatic I-Treat_Disorder
gallbladder I-Treat_Disorder
adenocarcinoma I-Treat_Disorder
. O

Olanzapine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
hyperglycaemic I-Effect
coma I-Effect
and I-Effect
neuroleptic I-Effect
malignant I-Effect
syndrome I-Effect
: O
case O
report O
and O
review O
of O
literature O
. O

Neurologic I-Effect
symptoms I-Effect
resolved I-Effect
after I-Potential_therapeutic_event.Trigger
stopping I-Treatment
CAP I-Treatment.Drug
for I-Treatment
4 I-Treatment.Time_elapsed
weeks I-Treatment.Time_elapsed
in O
Patient O
A O
, O
with O
no O
recurrence O
after O
reinitiating O
CAP O
alone O
at O
2000 O
mg O
/ O
m2 O
. O

OBJECTIVE O
: O
To O
report O
a I-Subject
case I-Subject
of O
serotonin I-Effect
syndrome I-Effect
associated O
with O
interaction I-Adverse_event.Trigger
between O
fentanyl I-Treatment.Combination.Drug
and I-Treatment
citalopram I-Treatment.Combination.Drug
, O
as O
evidenced O
by O
medication O
history O
, O
clinical O
features O
and O
reversal O
following O
discontinuation O
of O
fentanyl O
. O

We O
report O
( O
to O
our O
knowledge O
, O
for O
the O
first O
time O
in O
a O
child O
) O
the O
emergence I-Adverse_event.Trigger
of O
psychosis I-Effect
in O
a I-Subject
12 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
old I-Subject.Age
white I-Subject.Race
girl I-Subject.Gender
with O
an O
increased I-Treatment
efavirenz I-Treatment.Drug
concentration I-Treatment
and O
heterozygous I-Subject
gene I-Subject
polymorphism I-Subject
of I-Subject
the I-Subject
CYP2B6 I-Subject
- I-Subject
G516T. I-Subject

Severe I-Effect
erythroderma I-Effect
as O
a O
complication I-Adverse_event.Trigger
of O
continuous I-Treatment.Freq
epoprostenol I-Treatment.Drug
therapy O
. O

FDE I-Effect
from I-Adverse_event.Trigger
cephalosporins I-Treatment.Drug
has O
been O
rarely O
reported O
, O
and O
to O
the O
best O
of O
our O
knowledge O
there O
is O
no O
published O
report O
of O
ceftriaxone O
- O
induced O
FDE O
in O
the O
literature O
. O

FDE O
from O
cephalosporins O
has O
been O
rarely O
reported O
, O
and O
to O
the O
best O
of O
our O
knowledge O
there O
is O
no O
published O
report O
of O
ceftriaxone I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
FDE I-Effect
in O
the O
literature O
. O

CASE O
SUMMARY O
: O
A I-Subject
58 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
white I-Subject.Race
woman I-Subject.Gender
developed I-Adverse_event.Trigger
fulminant I-Effect
liver I-Effect
failure I-Effect
while O
being O
treated O
with O
the O
macrolide I-Treatment
antibiotic I-Treatment
clarithromycin I-Treatment.Drug
for I-Treatment
pneumonia I-Treatment.Treat_Disorder
. O

CONCLUSIONS O
: O
Marked I-Effect
elevation I-Effect
of I-Effect
serum I-Effect
CK I-Effect
may O
be O
a O
possible O
complication I-Adverse_event.Trigger
of O
olanzapine I-Treatment.Drug
therapy I-Treatment
. O

OBJECTIVE O
: O
To O
describe O
a O
case O
of O
severe O
skin I-Effect
necrosis I-Effect
resulting I-Adverse_event.Trigger
from O
peripheral I-Treatment.Route
intravenous I-Treatment.Route
administration I-Treatment.Route
of I-Treatment
low I-Treatment.Dosage
- I-Treatment.Dosage
dose I-Treatment.Dosage
vasopressin I-Treatment.Drug
in O
a I-Subject
patient I-Subject
with I-Subject
catecholamine I-Treat_Disorder
- I-Treat_Disorder
resistant I-Treat_Disorder
septic I-Treat_Disorder
shock I-Treat_Disorder
. O

Although O
the O
essential O
cause O
of O
PV I-Effect
is O
unclear O
, O
its O
onset O
has O
occasionally O
been O
associated I-Adverse_event.Trigger
with O
drug O
therapy O
, O
in O
particular O
penicillamine I-Treatment.Drug
. O

Recurrent I-Effect
hypotension I-Effect
immediately I-Effect
after I-Effect
seizures I-Effect
in I-Adverse_event.Trigger
nortriptyline I-Treatment.Drug
overdose I-Treatment.Dosage
. O

We O
report O
a I-Subject
patient I-Subject
with O
recurrent I-Effect
, I-Effect
increasingly I-Effect
severe I-Effect
episodes I-Effect
of I-Effect
PPE I-Effect
, I-Effect
ultimately I-Effect
complicated I-Effect
by I-Effect
a I-Effect
severe I-Effect
bullous I-Effect
eruption I-Effect
, O
following I-Adverse_event.Trigger
successive O
cycles I-Treatment
of I-Treatment
high I-Treatment.Dosage
- I-Treatment.Dosage
dose I-Treatment.Dosage
cytarabine I-Treatment.Drug
for I-Treatment
the I-Treatment
treatment I-Treatment
of I-Treatment
acute I-Treatment.Treat_Disorder
lymphoblastic I-Treatment.Treat_Disorder
leukaemia I-Treatment.Treat_Disorder
. O

Intravenous I-Treatment.Route
diazepam I-Treatment.Drug
exacerbated I-Adverse_event.Trigger
the O
seizures I-Effect
. O

After O
nine O
previous O
uncomplicated O
cycles O
she I-Subject.Gender
developed I-Adverse_event.Trigger
severe I-Effect
anaphylaxis I-Effect
to O
cisplatin I-Treatment.Drug
. O

Cefuroxime I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
acute I-Effect
renal I-Effect
failure I-Effect
. O

We O
describe O
the O
clinical O
and O
liver O
biopsy O
morphologic O
features O
for O
4 I-Subject.Population
patients I-Subject
with O
minocycline I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
autoimmune I-Effect
hepatitis I-Effect
( O
group O
1 O
) O
. O

Intravitreal I-Treatment.Route
triamcinolone I-Treatment.Drug
acetonide I-Treatment.Drug
for I-Potential_therapeutic_event.Trigger
persisting I-Treat_Disorder
cystoid I-Treat_Disorder
macular I-Treat_Disorder
edema I-Treat_Disorder
after O
penetrating O
keratoplasty O
. O

Intravitreal O
triamcinolone O
acetonide O
for O
persisting I-Effect
cystoid I-Effect
macular I-Effect
edema I-Effect
after I-Adverse_event.Trigger
penetrating I-Treatment
keratoplasty I-Treatment
. O

We O
report O
a O
case O
of O
a I-Subject
29 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
liver I-Subject.Sub_Disorder
transplant I-Subject.Sub_Disorder
patient I-Subject
who O
suffered O
liver I-Effect
injury I-Effect
most O
likely O
induced I-Adverse_event.Trigger
by O
drug I-Treatment
interaction I-Treatment
between I-Treatment
capecitabine I-Treatment.Combination.Drug
and I-Treatment
warfarin I-Treatment.Combination.Drug
. O

DISCUSSION O
: O
Patients I-Subject
with I-Subject
5 I-Treatment.Drug
- I-Treatment.Drug
FU I-Treatment.Drug
- I-Subject
induced I-Subject
ectropion I-Effect
experience O
tender I-Effect
, I-Effect
red I-Effect
, I-Effect
scaled I-Effect
lids I-Effect
, O
making O
contact O
lens O
wear O
difficult O
. O

Restless I-Effect
legs I-Effect
syndrome I-Effect
may O
thus O
be O
an O
adverse I-Adverse_event.Trigger
effect I-Adverse_event.Trigger
of O
IFN I-Treatment.Drug
alpha I-Treatment.Drug
treatment I-Treatment
. I-Treatment

Treatment O
of O
chronic I-Treat_Disorder
hepatitis I-Treat_Disorder
C I-Treat_Disorder
with O
interferon I-Treatment.Drug
alpha I-Treatment.Drug
( I-Treatment
IFN I-Treatment
- I-Treatment
alpha I-Treatment
) I-Treatment
is O
relatively O
contraindicated I-Adverse_event.Trigger
in O
patients I-Subject
with I-Subject
psychiatric I-Subject.Sub_Disorder
disorders I-Subject.Sub_Disorder
because O
of O
possible I-Effect
severe I-Effect
psychiatric I-Effect
side I-Effect
effects I-Effect
. O

METHODS O
: O
We O
report O
a I-Subject
patient I-Subject
who O
had O
an O
anaphylactic I-Effect
reaction I-Effect
during I-Adverse_event.Trigger
the O
intravenous I-Treatment.Route
infusion I-Treatment.Route
of I-Treatment
cyclosporine I-Treatment.Drug
. O

Gabapentin I-Treatment.Drug
toxicity I-Adverse_event.Trigger
in O
renal I-Effect
failure I-Effect
: O
the O
importance O
of O
dose O
adjustment O
. O

We O
describe O
a O
case O
of O
a I-Subject
man I-Subject.Gender
treated O
with O
an O
EGFR I-Treatment.Drug
- I-Treatment.Drug
inhibitor I-Treatment.Drug
( I-Treatment
erlotinib I-Treatment
) I-Treatment
for O
a O
cell I-Treat_Disorder
lung I-Treat_Disorder
cancer I-Treat_Disorder
who O
developed I-Adverse_event.Trigger
skin I-Effect
manifestations I-Effect
localized I-Effect
in I-Effect
an I-Effect
uncommon I-Effect
area I-Effect
and I-Effect
with I-Effect
an I-Effect
atypical I-Effect
evolution I-Effect
. O

We O
describe O
a O
case O
of O
clozapine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
seizures I-Effect
in O
a I-Subject
patient I-Subject
with I-Subject
treatment I-Treat_Disorder
- I-Treat_Disorder
resistant I-Treat_Disorder
schizophrenia I-Treat_Disorder
. O

Two I-Subject.Population
fatal I-Subject
cases I-Subject
of O
poisoning I-Effect
by I-Adverse_event.Trigger
paracetamol I-Treatment.Drug
are O
described O
. O

The O
neurotoxicity I-Effect
seen O
with O
HDARAC I-Treatment.Drug
is O
dose O
- O
related I-Adverse_event.Trigger
and O
has O
occurred O
in O
up O
to O
60 I-Subject.Population
percent I-Subject.Population
of I-Subject
treated I-Subject
patients I-Subject
. O

The O
HIV I-Treatment
protease I-Treatment
inhibitor I-Treatment
indinavir I-Treatment.Drug
may O
cause I-Adverse_event.Trigger
nephrolithiasis I-Effect
and I-Effect
interstitial I-Effect
nephritis I-Effect
. O

BACKGROUND O
: O
Colchicine I-Treatment.Drug
has O
a O
known O
adverse I-Adverse_event.Trigger
effect I-Adverse_event.Trigger
on O
wound I-Effect
healing I-Effect
through O
its O
inhibitory O
effect O
on O
tubulin O
- O
dependent O
cell O
functions O
and O
through O
collagenase O
activation O
. O

Pneumocystis I-Effect
carinii I-Effect
pneumonia I-Effect
as O
a O
complication I-Adverse_event.Trigger
of O
methotrexate I-Treatment.Drug
treatment O
of O
asthma I-Treat_Disorder
. O

2 I-Treatment.Drug
- I-Treatment.Drug
CdA I-Treatment.Drug
typically O
causes I-Adverse_event.Trigger
a I-Effect
long I-Effect
- I-Effect
lasting I-Effect
state I-Effect
of I-Effect
immunodeficiency I-Effect
and O
the O
profound O
influence O
of O
this O
drug O
on O
the O
immune O
system O
has O
raised O
questions O
concerning O
the O
emergence I-Effect
of I-Effect
secondary I-Effect
neoplasms I-Effect
after I-Effect
its I-Effect
use I-Effect
. O

CONCLUSIONS O
: O
Topiramate I-Treatment.Drug
may O
be O
associated O
with O
ciliochoroidal O
effusion O
with O
forward O
displacement O
of O
the O
lens O
- O
iris O
diaphragm O
and O
anterior O
chamber O
shallowing O
, O
resulting I-Adverse_event.Trigger
in O
acute I-Effect
myopia I-Effect
and I-Effect
angle I-Effect
- I-Effect
closure I-Effect
glaucoma I-Effect
. O

Increased O
awareness O
is O
needed O
on O
the O
possible O
occurrence I-Adverse_event.Trigger
of O
LPD I-Effect
resembling O
gastric O
cancer O
in O
rheumatoid I-Treat_Disorder
arthritis I-Treat_Disorder
patients I-Subject
treated O
with O
MTX I-Treatment.Drug
. O

A O
dapsone I-Treatment.Drug
hypersensitivity I-Effect
syndrome I-Effect
, I-Effect
consisting I-Effect
of I-Effect
fever I-Effect
, I-Effect
headache I-Effect
, I-Effect
nausea I-Effect
, I-Effect
vomiting I-Effect
, I-Effect
lymphadenopathy I-Effect
, I-Effect
hepatitis I-Effect
, I-Effect
hemolysis I-Effect
, I-Effect
leukopenia I-Effect
, I-Effect
and I-Effect
mononucleosis I-Effect
, O
has O
been O
described O
in O
patients I-Subject
treated I-Adverse_event.Trigger
with O
the O
drug O
for O
leprosy I-Treat_Disorder
. O

CONCLUSIONS O
: O
Intravitreal I-Treatment.Route
injection I-Treatment.Route
of I-Treatment
triamcinolone I-Treatment.Drug
acetonide I-Treatment.Drug
may O
be O
an O
additional O
tool O
in O
the O
treatment I-Potential_therapeutic_event.Trigger
of O
therapy I-Treat_Disorder
- I-Treat_Disorder
resistant I-Treat_Disorder
cystoid I-Treat_Disorder
macular I-Treat_Disorder
edema I-Treat_Disorder
after O
penetrating O
keratoplasty O
. O

Since O
its O
FDA O
approval O
in O
2002 O
, O
there O
are O
no O
known O
citations O
of O
ezetimibe I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
pancreatitis I-Effect
. O

Acute I-Effect
acoustic I-Effect
nerve I-Effect
palsy I-Effect
associated I-Adverse_event.Trigger
with O
vincristine I-Treatment.Drug
therapy I-Treatment
. O

Review O
of O
all O
reported O
cases O
of O
the O
use O
of O
ATRA I-Treatment.Drug
in I-Subject
pregnancy I-Subject.Sub_Disorder
revealed I-Adverse_event.Trigger
no O
serious O
adverse I-Effect
outcomes I-Effect
or I-Effect
congenital I-Effect
anomalies I-Effect
although O
only O
very O
few O
cases O
had O
exposure O
in O
the O
first O
trimester O
. O

The O
first O
patient O
was O
a I-Subject
57 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
man I-Subject.Gender
with I-Subject
HIV I-Treat_Disorder
and I-Subject
bipolar I-Treat_Disorder
disease I-Treat_Disorder
who O
developed I-Adverse_event.Trigger
rapid I-Effect
and I-Effect
severe I-Effect
weight I-Effect
gain I-Effect
when O
quetiapine I-Treatment.Combination.Drug
was I-Treatment
added I-Treatment
to I-Treatment
a I-Treatment
stable I-Treatment
atazanavir I-Treatment.Combination.Drug
- I-Treatment
ritonavir I-Treatment.Combination.Drug
- I-Treatment
based I-Treatment
antiretroviral I-Treatment
regimen I-Treatment
. O

A I-Subject
43 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
woman I-Subject.Gender
with I-Subject
multiple I-Treat_Disorder
sclerosis I-Treat_Disorder
( I-Subject
MS I-Subject
) I-Subject
had I-Adverse_event.Trigger
nephrotic I-Effect
syndrome I-Effect
21 I-Treatment.Time_elapsed
months I-Treatment.Time_elapsed
after I-Treatment
starting I-Treatment
treatment I-Treatment
with I-Treatment
interferon I-Treatment.Drug
( I-Treatment.Drug
IFN) I-Treatment.Drug
- I-Treatment.Drug
beta I-Treatment.Drug
- I-Treatment.Drug
1b I-Treatment.Drug
( I-Treatment
subcutaneous I-Treatment
administration I-Treatment
) I-Treatment
. O

RESULTS O
: O
An I-Subject
81 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
man I-Subject.Gender
with I-Subject
a I-Subject
history I-Subject
of I-Subject
neoplasies I-Treat_Disorder
of I-Treat_Disorder
the I-Treat_Disorder
colon I-Treat_Disorder
and I-Treat_Disorder
prostate I-Treat_Disorder
and O
anticoagulant I-Treatment.Drug
treatment O
was O
referred I-Adverse_event.Trigger
for O
treatment O
of O
an I-Effect
ocular I-Effect
surface I-Effect
neoplasia I-Effect
on I-Effect
his I-Effect
left I-Effect
eye I-Effect
. O

CONCLUSION O
: O
The O
present O
findings O
suggest O
that O
: O
( O
i O
) O
amantadine I-Treatment.Drug
probably O
exerts I-Potential_therapeutic_event.Trigger
its O
anti I-Effect
- I-Effect
dyskinetic I-Effect
effect I-Effect
by O
acting O
on O
the O
" O
indirect O
" O
pathway O
; O
( O
ii O
) O
the O
pathophysiological O
mechanisms O
of O
subthalamotomy O
induced O
dyskinesias O
may O
differ O
from O
those O
involved O
in O
L O
- O
dopa O
induced O
dyskinesias O
; O
( O
iii O
) O
dyskinesias O
induced O
by O
STN O
surgery O
resolve O
spontaneously O
as O
compensatory O
mechanisms O
develop O
. O

We O
report O
a O
case O
of O
a I-Subject
previously I-Subject
healthy I-Subject
, I-Subject
postmenopausal I-Subject
woman I-Subject.Gender
who O
developed I-Adverse_event.Trigger
anticonvulsant I-Effect
hypersensitivity I-Effect
syndrome I-Effect
while O
taking O
Bellamine I-Treatment.Drug
S I-Treatment.Drug
( I-Treatment
belladonna I-Treatment.Drug
alkaloids I-Treatment.Drug
; I-Treatment
ergotamine I-Treatment.Drug
; I-Treatment
phenobarbital I-Treatment.Drug
) I-Treatment
for O
hot I-Treat_Disorder
flashes I-Treat_Disorder
. O

Skin I-Effect
rash I-Effect
began O
after O
2 I-Time_elapsed
weeks I-Time_elapsed
of O
treatment O
, O
and O
signs O
of O
hepatocellular I-Effect
failure I-Effect
developed I-Adverse_event.Trigger
3 I-Time_elapsed
weeks I-Time_elapsed
after O
phenobarbital I-Treatment.Drug
had O
been O
started O
. O

Ceftriaxone O
was O
approved O
in O
1997 O
for O
the O
treatment O
of O
otitis I-Treat_Disorder
media I-Treat_Disorder
despite O
previous O
studies O
that O
documented O
an O
association I-Adverse_event.Trigger
of I-Adverse_event.Trigger
ceftriaxone I-Treatment.Drug
with O
elevated I-Effect
hepato I-Effect
- I-Effect
biliary I-Effect
enzymes I-Effect
and I-Effect
transient I-Effect
biliary I-Effect
stasis I-Effect
. O

A I-Subject
rare I-Subject
case I-Subject
of I-Subject
advanced I-Treat_Disorder
ovarian I-Treat_Disorder
carcinoma I-Treat_Disorder
who O
developed I-Adverse_event.Trigger
difficulty I-Effect
walking I-Effect
25 I-Treatment.Time_elapsed
days I-Treatment.Time_elapsed
after I-Treatment
treatment I-Treatment
with I-Treatment
weekly I-Treatment.Freq
paclitaxel I-Treatment.Drug
. O

We O
report O
a O
case O
of O
cough I-Effect
following I-Adverse_event.Trigger
the I-Treatment
administration I-Treatment
of I-Treatment
quinapril I-Treatment.Drug
, O
with O
complete O
resolution O
after O
changing O
to O
the O
alternative O
ACE O
inhibitor O
fosinopril O
in O
a O
patient I-Subject
with I-Subject
essential I-Subject
hypertension I-Treat_Disorder
. O

Liver I-Effect
disease I-Effect
induced I-Adverse_event.Trigger
by I-Adverse_event.Trigger
perhexiline I-Treatment.Drug
maleate I-Treatment.Drug
. O

OBJECTIVE O
: O
To O
report O
the O
occurrence O
of O
anaphylactoid I-Effect
reactions I-Effect
to I-Adverse_event.Trigger
intraperitoneal I-Treatment.Route
cisplatin I-Treatment.Drug
in O
3 I-Subject.Population
patients I-Subject
. I-Subject

In O
a O
female I-Subject.Gender
with I-Subject
acute I-Treat_Disorder
lymphoblastic I-Treat_Disorder
leukemia I-Treat_Disorder
, O
inadvertent I-Treatment
doxorubicin I-Treatment.Drug
administration I-Treatment
intrathecally I-Treatment.Route
caused I-Adverse_event.Trigger
severe I-Effect
, I-Effect
life I-Effect
- I-Effect
threatening I-Effect
, I-Effect
acute I-Effect
encephalopathy I-Effect
with I-Effect
high I-Effect
- I-Effect
pressure I-Effect
hydrocephalus I-Effect
. O

These O
skin I-Effect
lesions I-Effect
may O
be O
induced I-Adverse_event.Trigger
or O
worsened O
during O
antiviral I-Treatment
therapy I-Treatment
with I-Treatment
interferon I-Treatment.Drug
- I-Treatment.Drug
alpha I-Treatment.Drug
( I-Treatment.Drug
IFN I-Treatment.Drug
) I-Treatment.Drug
. I-Drug

Clinicians O
should O
be O
aware O
of O
the O
proepileptogenic O
effect O
of O
venlafaxine I-Treatment.Combination.Drug
and I-Treatment
trimipramine I-Treatment.Combination.Drug
at I-Treatment
therapeutic I-Treatment.Dosage
doses I-Treatment.Dosage
and O
that O
this O
combination O
may O
eventually I-Adverse_event.Trigger
increase I-Effect
the I-Effect
risk I-Effect
of I-Effect
seizures I-Effect
. O

We O
report O
the I-Subject
case I-Subject
of I-Subject
a I-Subject
43 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
man I-Subject.Gender
with I-Subject
ITP I-Treat_Disorder
refractory I-Subject.Sub_Disorder
to I-Subject.Sub_Disorder
steroids I-Subject.Sub_Disorder
and I-Subject.Sub_Disorder
intravenous I-Subject.Sub_Disorder
immunoglobulin I-Subject.Sub_Disorder
who O
developed I-Adverse_event.Trigger
acute I-Effect
respiratory I-Effect
distress I-Effect
syndrome I-Effect
( I-Effect
ARDS I-Effect
) I-Effect
after O
a O
single I-Treatment
infusion I-Treatment.Route
of I-Treatment
rituximab I-Treatment.Drug
. O

She O
had O
been O
prescribed I-Treatment
two I-Treatment
mood I-Treatment.Drug
stabilizers I-Treatment.Drug
and O
suffered I-Adverse_event.Trigger
from I-Adverse_event.Trigger
anticholinergic I-Effect
adverse I-Effect
effects I-Effect
and I-Effect
the I-Effect
movement I-Effect
disorder I-Effect
tardive I-Effect
dyskinesia I-Effect
( I-Effect
TD I-Effect
) I-Effect
. O

CASE O
REPORT O
: O
We O
describe O
here O
a I-Subject
case I-Subject
of I-Subject
a I-Subject
60 I-Subject.Age
year I-Subject.Age
old I-Subject.Age
female I-Subject.Gender
that O
experienced O
a O
relapse I-Effect
of I-Effect
symptomatic I-Effect
hyperlactatemia I-Effect
after I-Adverse_event.Trigger
being O
switched I-Treatment
from I-Treatment
stavudine I-Treatment.Drug
to I-Treatment
zidovudine I-Treatment.Drug
and O
how O
the O
case O
was O
managed O
at O
the O
Infectious O
Diseases O
Institute O
, O
Kampala O
, O
Uganda O
. O

This O
report O
describes O
two I-Subject.Population
patients I-Subject
who O
developed I-Adverse_event.Trigger
acute I-Effect
myelocytic I-Effect
leukemia I-Effect
only O
after O
exposure I-Treatment
to I-Treatment
cyclophosphamide I-Treatment.Combination.Drug
, I-Treatment
methotrexate I-Treatment.Combination.Drug
, I-Treatment
and I-Treatment
5 I-Treatment.Combination.Drug
- I-Treatment.Combination.Drug
fluorouracil I-Treatment.Combination.Drug
adjuvant I-Treatment
therapy I-Treatment
. O

Reversible I-Effect
corneal I-Effect
keratinization I-Effect
following I-Adverse_event.Trigger
trabeculectomy O
and O
treatment O
with O
5 I-Treatment.Drug
- I-Treatment.Drug
fluorouracil I-Treatment.Drug
. I-Drug

CASE O
: O
We O
report O
a O
case O
of O
a O
woman I-Subject.Gender
with O
severe I-Effect
human I-Effect
insulin I-Effect
- I-Effect
induced I-Effect
lipoatrophy I-Effect
who O
has O
been O
treated I-Adverse_event.Trigger
exclusively O
with O
recombinant I-Treatment.Drug
DNA I-Treatment.Drug
human I-Treatment.Drug
insulin I-Treatment.Drug
since O
the O
onset O
of O
IDDM O
. O

METHOD O
: O
Case O
analysis O
of O
a I-Treatment
poly I-Treatment
- I-Treatment
drug I-Treatment
overdose I-Treatment.Dosage
( I-Treatment
venlafaxine I-Treatment.Drug
, I-Treatment
topiramate I-Treatment.Drug
, I-Treatment
divalproex I-Treatment.Drug
sodium I-Treatment.Drug
, I-Treatment
risperidone I-Treatment.Drug
, I-Treatment
and I-Treatment
carbamazepine I-Treatment.Drug
) I-Treatment
presenting I-Adverse_event.Trigger
with O
mixed I-Effect
SS I-Effect
/ I-Effect
NMS I-Effect
features I-Effect
and O
whose O
clinical O
management O
suggests O
a O
practical O
algorithm O
for O
treatment O
of O
undifferentiated O
SS O
/ O
NMS O
in O
critical O
care O
settings O
. O

Hyperpigmentation I-Effect
is O
one O
of O
the O
cutaneous O
side O
effects O
of I-Adverse_event.Trigger
chemotherapautic I-Treatment.Drug
agents I-Treatment.Drug
, O
but O
it O
is O
usually O
accepted O
as O
a O
cosmetic O
problem O
. O

Pancreatitis O
is O
a O
very O
rare O
adverse O
effect O
associated O
with O
the O
use O
of O
amiodarone O
, O
and O
only O
four I-Subject.Population
cases I-Subject
of O
amiodarone I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
pancreatitis I-Effect
have O
been O
reported O
in O
literature O
. O

The O
latter O
form O
( O
Macrodantin I-Treatment.Drug
) O
is O
reported O
to O
engender O
less I-Effect
gastrointestinal I-Effect
intolerance I-Effect
but O
it O
can O
produce O
the O
same O
adverse I-Adverse_event.Trigger
effects I-Adverse_event.Trigger
as O
the O
conventional O
form O
-- O
liver I-Effect
damage I-Effect
, I-Effect
acute I-Effect
and I-Effect
chronic I-Effect
pulmonary I-Effect
reactions I-Effect
, I-Effect
peripheral I-Effect
neuropathy I-Effect
, I-Effect
blood I-Effect
dyscrasias I-Effect
and I-Effect
allergic I-Effect
reactions I-Effect
-- O
and O
does O
so O
just O
as O
rapidly O
and O
floridly O
; O
one I-Subject.Population
such I-Subject
case I-Subject
is O
reported O
here O
. O

CASE O
REPORT O
: O
A I-Subject
29 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
black I-Subject.Race
man I-Subject.Gender
, I-Subject
HIV I-Treat_Disorder
- I-Subject
infected I-Subject
since I-Subject
1996 I-Subject
, O
began I-Potential_therapeutic_event.Trigger
highly I-Treatment
active I-Treatment
antiretroviral I-Treatment
therapy I-Treatment
( I-Treatment
HAART I-Treatment
) I-Treatment
with I-Treatment
zidovudine I-Treatment.Combination.Drug
, I-Treatment
lamivudine I-Treatment.Combination.Drug
, I-Treatment
and I-Treatment
indinavir I-Treatment.Combination.Drug
. O

METHOD O
: O
The O
authors O
followed O
a I-Subject
patient I-Subject
with I-Subject
chronic I-Treat_Disorder
HCV I-Treat_Disorder
who O
received O
interferon I-Treatment.Combination.Drug
and I-Treatment
ribavirin I-Treatment.Combination.Drug
and O
who O
developed I-Adverse_event.Trigger
hallucinations I-Effect
ultimately O
requiring O
psychiatric O
hospitalization O
. O

This O
case O
of O
linezolid I-Treatment.Drug
- O
associated I-Adverse_event.Trigger
acute I-Effect
interstitial I-Effect
nephritis I-Effect
within I-Effect
the I-Effect
context I-Effect
of I-Effect
a I-Effect
drug I-Effect
rash I-Effect
with I-Effect
eosinophilia I-Effect
and I-Effect
systemic I-Effect
symptoms I-Effect
( I-Effect
DRESS I-Effect
) I-Effect
syndrome I-Effect
in O
a O
patient O
treated O
with O
linezolid O
raises O
concerns O
about O
the O
presumed O
renal O
safety O
of O
this O
drug O
. O

Easily O
reversible O
hypoxemia I-Effect
and I-Effect
hypotension I-Effect
induced I-Adverse_event.Trigger
by O
nimodipine I-Treatment.Drug
. O

Adverse O
effects O
of O
amiodarone I-Treatment.Drug
including I-Adverse_event.Trigger
pulmonary I-Effect
toxicity I-Effect
, I-Effect
hepatotoxicity I-Effect
, I-Effect
aggravation I-Effect
of I-Effect
arrhythmia I-Effect
, I-Effect
and I-Effect
thyroid I-Effect
diseases I-Effect
are O
well O
understood O
. O

Chronic I-Effect
photosensitivity I-Effect
associated I-Adverse_event.Trigger
with O
hydrochlorothiazide I-Treatment.Drug
ingestion I-Treatment.Route
occurred O
in O
four I-Subject.Population
patients I-Subject
. O

Chlorambucil I-Treatment.Drug
central I-Effect
nervous I-Effect
toxicity I-Effect
: O
a O
significant O
side I-Adverse_event.Trigger
effect I-Adverse_event.Trigger
of O
chlorambucil O
therapy O
in O
childhood I-Treat_Disorder
nephrotic I-Treat_Disorder
syndrome I-Treat_Disorder
. O

The O
mechanism O
of O
action O
of O
this O
centrally I-Treatment.Drug
acting I-Treatment.Drug
muscle I-Treatment.Drug
relaxant I-Treatment.Drug
is O
unknown O
; O
however O
, O
the O
observation O
of O
serotonin I-Effect
syndrome I-Effect
in I-Adverse_event.Trigger
patients I-Subject
with O
metaxalone I-Treatment.Drug
overdose I-Treatment.Dosage
suggests O
a O
role O
in O
the O
serotonergic O
pathway O
. O

In O
general O
, O
angiotensin I-Treatment.Drug
converting I-Treatment.Drug
enzyme I-Treatment.Drug
( I-Treatment.Drug
ACE I-Treatment.Drug
) I-Treatment.Drug
inhibitors I-Treatment.Drug
should O
be O
discontinued O
in O
pregnancy I-Subject.Sub_Disorder
, O
as O
they O
can O
induce I-Adverse_event.Trigger
an O
ACE I-Effect
fetopathy I-Effect
. O

Of I-Subject
371 I-Subject.Population
patients I-Subject
treated I-Treatment
with I-Treatment
8MOP I-Treatment.Drug
, O
three I-Subject.Population
( I-Subject.Population
0.8 I-Subject.Population
% I-Subject.Population
) I-Subject.Population
developed I-Adverse_event.Trigger
an O
acute I-Effect
dermatitis I-Effect
in O
the O
PUVA O
- O
treated O
areas O
. O

There O
is O
a O
putative O
role O
of O
liothyronine I-Treatment.Drug
administration O
in O
precipitating I-Adverse_event.Trigger
or I-Adverse_event.Trigger
activating I-Adverse_event.Trigger
hyperthyroidism I-Effect
. O

Neutropenic I-Effect
colitis I-Effect
during I-Adverse_event.Trigger
standard I-Treatment.Dosage
dose I-Treatment.Dosage
combination I-Treatment
chemotherapy I-Treatment
with I-Treatment
nedaplatin I-Treatment.Combination.Drug
and I-Treatment
irinotecan I-Treatment.Combination.Drug
for I-Treatment
testicular I-Treatment.Treat_Disorder
cancer I-Treatment.Treat_Disorder
. O

Brain I-Treat_Disorder
metastases I-Treat_Disorder
are O
a O
frequent O
finding O
in O
patients I-Subject
with I-Subject
advanced I-Subject.Sub_Disorder
non I-Subject.Sub_Disorder
- I-Subject.Sub_Disorder
small I-Subject.Sub_Disorder
cell I-Subject.Sub_Disorder
lung I-Subject.Sub_Disorder
cancer I-Subject.Sub_Disorder
and O
concomitant I-Treatment
administration I-Treatment
of I-Treatment
antiepileptic I-Treatment.Combination.Drug
and I-Treatment
chemotherapeutic I-Treatment.Combination.Drug
drugs I-Treatment
or I-Treatment
epidermal I-Treatment.Drug
growth I-Treatment.Drug
factor I-Treatment.Drug
receptor I-Treatment.Drug
( I-Treatment.Drug
EGFR I-Treatment.Drug
) I-Treatment.Drug
inhibitor I-Treatment.Drug
is O
necessary I-Potential_therapeutic_event.Trigger
in O
many O
cases O
. O

A I-Subject
female I-Subject.Gender
patient I-Subject
with I-Subject
HER2 I-Treat_Disorder
positive I-Treat_Disorder
, I-Treat_Disorder
metastatic I-Treat_Disorder
breast I-Treat_Disorder
cancer I-Treat_Disorder
presented I-Adverse_event.Trigger
with O
pulmonary I-Effect
infiltrates I-Effect
, I-Effect
and I-Effect
a I-Effect
plural I-Effect
effusion I-Effect
dyspnoea I-Effect
after O
several I-Time_elapsed
months I-Time_elapsed
of O
trastuzumab I-Treatment.Drug
treatment O
. O

Thrombocytosis I-Effect
under I-Adverse_event.Trigger
ciprofloxacin I-Treatment.Combination.Drug
and I-Treatment
tazobactam I-Treatment.Combination.Drug
/ I-Treatment
piperacillin I-Treatment.Combination.Drug
. O

Quinine I-Treatment.Drug
and I-Treatment
its I-Treatment
isomer I-Treatment
quinidine I-Treatment
are O
well O
- O
known O
causes I-Adverse_event.Trigger
of O
iatrogenic I-Effect
hypoglycaemia I-Effect
, I-Effect
due I-Effect
to I-Effect
excessive I-Effect
insulin I-Effect
secretion I-Effect
. O

Therefore O
, O
it O
is O
reasonable O
to O
conclude O
that O
: O
1 O
) O
2 I-Treatment.Drug
- I-Treatment.Drug
CdA I-Treatment.Drug
can O
induce I-Potential_therapeutic_event.Trigger
durable I-Effect
complete I-Effect
remission I-Effect
in O
MCD I-Treat_Disorder
patients O
but O
unfortunately O
it O
can O
not O
cure O
the O
disease O
; O
2 O
) O
the O
possibility O
that O
2 O
- O
CdA O
may O
accelerate O
the O
transformation O
of O
MCD O
to O
NHL O
can O
not O
be O
ruled O
out O
. O

Therefore O
, O
it O
is O
reasonable O
to O
conclude O
that O
: O
1 O
) O
2 O
- O
CdA O
can O
induce O
durable O
complete O
remission O
in O
MCD O
patients O
but O
unfortunately O
it O
can O
not O
cure O
the O
disease O
; O
2 O
) O
the O
possibility O
that O
2 I-Treatment.Drug
- I-Treatment.Drug
CdA I-Treatment.Drug
may O
accelerate I-Adverse_event.Trigger
the I-Effect
transformation I-Effect
of I-Effect
MCD I-Effect
to I-Effect
NHL I-Effect
can O
not O
be O
ruled O
out O
. O

Hyperammonemia I-Effect
secondary O
to O
valproic I-Treatment.Drug
acid I-Treatment.Drug
as O
a O
cause I-Adverse_event.Trigger
of O
lethargy O
in O
a I-Subject
postictal I-Subject
patient I-Subject
. O

OBJECTIVE O
: O
To O
report O
on O
the O
possible O
development O
of O
serotonin I-Effect
syndrome I-Effect
in O
a O
patient I-Subject
receiving I-Adverse_event.Trigger
clomipramine I-Treatment.Combination.Drug
after O
clozapine I-Combination.Drug
was O
withdrawn O
from O
the O
treatment O
regimen O
. O

Fatal I-Effect
ventricular I-Effect
fibrillation I-Effect
after I-Adverse_event.Trigger
treatment O
with O
digoxin I-Treatment.Drug
in O
a I-Subject
27 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
man I-Subject.Gender
with I-Subject
mitral I-Treat_Disorder
leaflet I-Treat_Disorder
prolapse I-Treat_Disorder
syndrome I-Treat_Disorder
. O

Clostridium I-Effect
difficile I-Effect
colitis I-Effect
associated I-Adverse_event.Trigger
with O
cisplatin I-Treatment.Drug
- I-Treatment
based I-Treatment
chemotherapy I-Treatment.Route
in O
ovarian I-Treat_Disorder
cancer I-Treat_Disorder
patients I-Subject
. I-Subject

Lithium I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
Creutzfeldt I-Effect
- I-Effect
Jakob I-Effect
syndrome I-Effect
. O

It O
is O
concluded O
that O
simultaneous I-Treatment
administration I-Treatment
of I-Treatment
ciprofloxacin I-Treatment.Combination.Drug
and I-Treatment
tazobactam I-Treatment.Combination.Drug
/ I-Treatment.Combination.Drug
piperacillin I-Treatment.Combination.Drug
may O
cause I-Adverse_event.Trigger
marked I-Effect
thrombocytosis I-Effect
. O

Alone I-Treatment
or I-Treatment
in I-Treatment
combination I-Treatment
with I-Treatment
corticosteroids I-Treatment.Combination.Drug
, I-Treatment
cyclosporine I-Treatment.Combination.Drug
is I-Potential_therapeutic_event.Trigger
an O
effective O
drug O
of O
choice O
for O
the O
resistant I-Subject
patients I-Subject
. O

Bull's I-Effect
- I-Effect
eye I-Effect
maculopathy I-Effect
associated I-Adverse_event.Trigger
with O
quinacrine I-Treatment.Drug
therapy O
for O
malaria I-Treat_Disorder
. O

Physicians O
should O
be O
aware O
that O
indinavir I-Treatment.Drug
nephrolithiasis I-Treatment
may O
cause I-Adverse_event.Trigger
papillary I-Effect
necrosis I-Effect
. O

Following O
the O
institution O
of O
intravenous O
therapy O
with O
acyclovir I-Treatment.Drug
, O
the I-Subject
patient I-Subject
developed I-Adverse_event.Trigger
fever I-Effect
, I-Effect
hemoptysis I-Effect
, I-Effect
and I-Effect
a I-Effect
pleural I-Effect
friction I-Effect
rub I-Effect
. O

Due I-Adverse_event.Trigger
to I-Adverse_event.Trigger
discomfort I-Effect
, I-Effect
diplopia I-Effect
and I-Effect
lagophthalmos I-Effect
, I-Effect
the I-Effect
haematoma I-Effect
necessitated O
suspension O
of O
warfarin I-Treatment.Drug
therapy I-Treatment
and I-Treatment
a I-Treatment
surgical I-Treatment
evacuation I-Treatment
. O

Acute I-Effect
dystonia I-Effect
with I-Effect
thalamic I-Effect
and I-Effect
brainstem I-Effect
lesions I-Effect
after I-Adverse_event.Trigger
initial O
penicillamine I-Treatment.Drug
treatment O
in O
Wilson I-Treat_Disorder
's I-Treat_Disorder
disease I-Treat_Disorder
. O

Fatal I-Effect
agranulocytosis I-Effect
in O
an O
Indian I-Race
male I-Gender
receiving I-Adverse_event.Trigger
100 I-Treatment.Dosage
mg I-Treatment.Dosage
of I-Treatment
dapsone I-Treatment.Drug
daily I-Treatment.Freq
, O
hospitalized O
for O
mid I-Treat_Disorder
- I-Treat_Disorder
borderline I-Treat_Disorder
leprosy I-Treat_Disorder
in I-Treat_Disorder
type I-Treat_Disorder
I I-Treat_Disorder
reaction I-Treat_Disorder
with I-Treat_Disorder
triple I-Treat_Disorder
nerve I-Treat_Disorder
paralysis I-Treat_Disorder
is O
reported O
. O

The O
authors O
presented O
a O
case O
of O
pulmonary I-Effect
hypertension I-Effect
during I-Adverse_event.Trigger
lithium I-Treatment.Drug
therapy I-Treatment
, O
while O
she I-Subject.Gender
has O
been O
on O
lithium O
for O
6 I-Duration
years I-Duration
. O

BACKGROUND O
: O
Oxaliplatin I-Treatment.Drug
is I-Treatment
a I-Treatment
platinum I-Treatment.Drug
derivative I-Treatment.Drug
, O
which O
is O
used O
in O
the O
treatment I-Potential_therapeutic_event.Trigger
of O
colorectal I-Treat_Disorder
cancer I-Treat_Disorder
. O

After O
having O
received I-Treatment
gemcitabine I-Treatment.Drug
on I-Treatment
day I-Treatment
1 I-Treatment
of I-Treatment
the I-Treatment
second I-Treatment
course I-Treatment
, O
the I-Subject
patient I-Subject
developed I-Adverse_event.Trigger
dry I-Effect
cough I-Effect
, I-Effect
subfebrile I-Effect
temperatures I-Effect
and I-Effect
dyspnea I-Effect
within I-Time_elapsed
48 I-Time_elapsed
h. I-Time_elapsed

As O
linezolid I-Treatment.Drug
has O
been O
shown O
to O
have I-Adverse_event.Trigger
hematologic I-Effect
side I-Effect
effects I-Effect
, O
blood O
count O
monitoring O
is O
recommended O
in O
patients O
receiving O
this O
drug O
for O
long I-Duration
- I-Duration
term I-Duration
therapy O
. O

The O
role O
of O
Adriamycin I-Treatment.Drug
in O
the O
production I-Adverse_event.Trigger
of O
cardiotoxicity I-Effect
is O
reviewed O
. O

He O
began O
taking I-Potential_therapeutic_event.Trigger
propafenone I-Treatment.Drug
only O
6 O
days O
prior O
to O
admission O
because O
of O
uncontrolled O
atrial I-Treat_Disorder
fibrillation I-Treat_Disorder
and O
symptoms O
of O
fatigue I-Treat_Disorder
. O

A I-Subject
53 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
man I-Subject.Gender
developed I-Adverse_event.Trigger
NMS I-Effect
without I-Effect
rigidity I-Effect
while O
taking O
olanzapine I-Treatment.Drug
. O

We O
report O
on O
a I-Subject
14 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
boy I-Subject.Gender
with I-Subject
severe I-Subject
haemophilia I-Treat_Disorder
A I-Treat_Disorder
who O
developed I-Adverse_event.Trigger
a I-Effect
portal I-Effect
vein I-Effect
thrombosis I-Effect
during O
continuous I-Treatment.Freq
infusion I-Treatment.Route
of I-Treatment
F I-Treatment.Drug
VIII I-Treatment.Drug
. O

Suxamethonium I-Effect
apnoea I-Effect
terminated I-Potential_therapeutic_event.Trigger
with O
commercial I-Treatment.Drug
serumcholinesterase I-Treatment.Drug
. O

Fatal O
multiple I-Effect
drug I-Effect
intoxication I-Effect
following I-Adverse_event.Trigger
acute I-Treatment
sertraline I-Treatment.Drug
use I-Treatment
. O

OBSERVATIONS O
: O
We O
observed I-Adverse_event.Trigger
aggravation I-Effect
and I-Effect
spreading I-Effect
of I-Effect
a I-Effect
psoriatic I-Effect
plaque I-Effect
when O
treated O
topically I-Route
with O
the I-Treatment
toll I-Treatment
- I-Treatment
like I-Treatment
receptor I-Treatment
( I-Treatment
TLR I-Treatment
) I-Treatment
7 I-Treatment
agonist I-Treatment
imiquimod I-Treatment.Drug
. O

Hypercalcemia I-Effect
in O
an I-Subject
AIDS I-Treat_Disorder
patient I-Subject
treated O
with I-Adverse_event.Trigger
growth I-Treatment.Drug
hormone I-Treatment.Drug
. O

Significant O
drug O
interaction O
: O
phenytoin I-Effect
toxicity I-Effect
due I-Adverse_event.Trigger
to O
erlotinib I-Treatment.Drug
. O

A I-Effect
pharmacokinetic I-Effect
interaction I-Effect
between O
the I-Treatment
selective I-Treatment
serotonin I-Treatment
reuptake I-Treatment
inhibitor I-Treatment
citalopram I-Treatment.Combination.Drug
and I-Treatment
a I-Treatment
tricyclic I-Treatment
antidepressant I-Treatment
, I-Treatment
clomipramine I-Treatment.Combination.Drug
, O
was O
noted O
in O
a I-Subject
patient I-Subject
treated I-Subject
for I-Subject
major I-Subject
depression I-Treat_Disorder
and I-Subject
obsessive I-Treat_Disorder
- I-Treat_Disorder
compulsive I-Treat_Disorder
disorder I-Treat_Disorder
. O

They O
continued O
to O
rise O
for O
five O
more O
days O
before O
salicylate I-Treatment.Drug
hepatotoxicity I-Effect
was O
suspected I-Adverse_event.Trigger
. O

The O
occurrence O
of O
neuromuscular I-Effect
blockade I-Effect
and O
the O
resulting O
potentiation I-Effect
of I-Effect
muscle I-Effect
relaxants I-Effect
during I-Adverse_event.Trigger
magnesium I-Treatment.Drug
sulfate I-Treatment.Drug
( I-Drug
MgSO4 I-Drug
) I-Drug
administration O
is O
well O
known O
. O

Based O
on O
these O
findings O
, O
the O
patient O
was O
diagnosed O
with O
diabetes I-Treat_Disorder
insipidus I-Treat_Disorder
secondary I-Treat_Disorder
to I-Treat_Disorder
lithium I-Treat_Disorder
therapy I-Treat_Disorder
and O
was O
treated I-Potential_therapeutic_event.Trigger
successfully I-Effect
with O
amiloride I-Treatment.Drug
. O

Based O
on O
these O
findings O
, O
the O
patient O
was O
diagnosed I-Adverse_event.Trigger
with O
diabetes I-Effect
insipidus I-Effect
secondary O
to O
lithium I-Treatment.Drug
therapy O
and O
was O
treated O
successfully O
with O
amiloride O
. O

Gabapentin I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
mood I-Effect
changes I-Effect
with I-Effect
hypomanic I-Effect
features I-Effect
in O
adults I-Subject.Age
. O

Drug I-Effect
induced I-Effect
polymyositis I-Effect
secondary I-Adverse_event.Trigger
to I-Adverse_event.Trigger
leuprolide I-Treatment.Drug
acetate I-Treatment.Drug
( I-Treatment.Drug
Lupron I-Treatment.Drug
) I-Treatment.Drug
therapy I-Treatment
for O
prostate I-Treat_Disorder
carcinoma I-Treat_Disorder
. O

Incomplete I-Effect
posterior I-Effect
hyaloid I-Effect
detachment I-Effect
after I-Adverse_event.Trigger
intravitreal I-Treatment.Route
pegaptanib I-Treatment.Drug
injection I-Treatment.Route
in I-Treatment
diabetic I-Treatment.Treat_Disorder
macular I-Treatment.Treat_Disorder
edema I-Treatment.Treat_Disorder
. O

This O
paper O
reports O
a I-Adverse_event.Trigger
case I-Adverse_event.Trigger
of I-Adverse_event.Trigger
fatal O
perhexiline I-Treatment.Drug
maleate I-Treatment.Drug
liver I-Effect
injury I-Effect
. O

During O
the O
second O
hospitalization O
it O
is O
possible O
that O
antipsychotic I-Treatment.Combination.Drug
treatment I-Treatment
combined I-Treatment
with I-Treatment
an I-Treatment
antidepressant I-Treatment.Combination.Drug
caused I-Adverse_event.Trigger
akathisia I-Effect
or O
there O
were O
symptoms O
of O
agitated O
depression O
and O
akathisia O
present O
at O
the O
same O
time O
, O
which O
is O
very O
difficult O
to O
determine O
in O
everyday O
clinical O
practice O
. O

OBJECTIVES O
: O
To O
describe O
the O
presentation O
and O
treatment O
of O
acute O
isoniazid I-Treatment.Drug
( I-Treatment
INH I-Treatment
) I-Treatment
neurotoxicity I-Effect
appearing O
at O
an O
inner O
- O
city O
municipal O
hospital O
. O

Clozapine I-Treatment.Drug
, O
an O
atypical O
antipsychotic O
, O
can O
be I-Adverse_event.Trigger
toxic I-Effect
at O
doses I-Treatment
4 I-Treatment.Dosage
times I-Treatment.Dosage
a I-Treatment.Dosage
moderate I-Treatment.Dosage
dose I-Treatment.Dosage
. O

This O
article O
presents O
a I-Subject
3(1/2) I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
child I-Subject.Age
on O
valproic I-Treatment.Combination.Drug
acid I-Treatment.Combination.Drug
, I-Treatment
lamotrigine I-Treatment.Combination.Drug
, I-Treatment
and I-Treatment
phenytoin I-Treatment.Combination.Drug
who O
developed I-Adverse_event.Trigger
simultaneous I-Effect
hepatotoxicity I-Effect
and I-Effect
bone I-Effect
marrow I-Effect
toxicity I-Effect
during O
a O
parainfluenza O
virus O
type O
3 O
infection O
. O

Reversible I-Effect
cholestasis I-Effect
with I-Effect
bile I-Effect
duct I-Effect
injury I-Effect
following I-Adverse_event.Trigger
azathioprine I-Treatment.Drug
therapy O
. O

The O
authors O
report O
five O
cases O
of O
tremor I-Effect
related I-Adverse_event.Trigger
to O
itraconazole I-Treatment.Drug
therapy I-Treatment
, I-Treatment
which O
occurred O
within I-Time_elapsed
1 I-Time_elapsed
- I-Time_elapsed
12 I-Time_elapsed
months I-Time_elapsed
of O
initiating O
treatment O
and O
resolved O
gradually O
following O
itraconazole O
withdrawal O
. O

OBJECTIVE O
: O
To O
report O
a I-Subject
case I-Subject
of I-Subject
phenolphthalein I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
toxic I-Effect
epidermal I-Effect
necrolysis I-Effect
( I-Effect
TEN I-Effect
) I-Effect
in O
a I-Subject
patient I-Subject
maintained I-Treatment
on I-Treatment
several I-Treatment
other I-Treatment
medications I-Treatment
more I-Treatment
commonly I-Treatment
known I-Treatment
to I-Treatment
be I-Treatment
associated I-Treatment
with I-Treatment
TEN I-Treatment
. O

Clinical I-Effect
symptoms I-Effect
and I-Effect
leukopenia I-Effect
normalized I-Effect
after O
discontinuation I-Treatment
of I-Treatment
CBZ I-Treatment.Combination.Drug
and I-Treatment
administration I-Treatment
of I-Treatment
prednisolone I-Treatment.Combination.Drug
at I-Treatment
40 I-Treatment.Dosage
mg I-Treatment.Dosage
. O

A I-Subject
patient I-Subject
with I-Subject
alcoholic I-Subject.Sub_Disorder
cerebellar I-Subject.Sub_Disorder
degeneration I-Subject.Sub_Disorder
had O
periodic I-Effect
alternating I-Effect
nystagmus I-Effect
during I-Adverse_event.Trigger
a O
period O
of O
phenytoin I-Treatment.Drug
intoxication O
. O

Extensive I-Effect
forearm I-Effect
deep I-Effect
venous I-Effect
thrombosis I-Effect
following I-Adverse_event.Trigger
a O
severe O
infliximab I-Treatment.Drug
infusion I-Effect
reaction I-Effect
. O

Severe I-Effect
acidosis I-Effect
from I-Adverse_event.Trigger
acetazolamide I-Treatment.Drug
in O
a I-Subject
diabetic I-Subject.Sub_Disorder
patient I-Subject
. O

CONCLUSIONS O
: O
Clinicians O
should O
be O
aware O
that O
Crohn I-Effect
's I-Effect
disease I-Effect
is O
a O
potential O
novel O
adverse O
drug O
effect I-Adverse_event.Trigger
of O
Copaxone I-Treatment.Drug
. O

ADR O
induced O
by O
drug O
treatment O
can O
be O
a O
side O
effect O
of O
treatment O
with O
antipsychotic O
drugs O
and O
other O
drugs O
; O
however O
, O
there O
have O
been O
no O
reports O
of O
lamivudine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
ADR I-Effect
in O
the O
English O
literature O
. O

CONCLUSIONS O
: O
The O
piloerection I-Effect
observed I-Adverse_event.Trigger
after O
the O
replacement O
of O
fluvoxamine O
with O
milnacipran I-Treatment.Drug
in O
this I-Subject
patient I-Subject
appears O
to O
have O
been O
due O
to O
an O
increase O
in O
the O
alpha(1) O
- O
adrenoceptor O
occupancy O
by O
endogenous O
norepinephrine O
induced O
by O
milnacipran O
. O

CONCLUSIONS O
: O
The O
piloerection O
observed O
after O
the O
replacement O
of O
fluvoxamine O
with O
milnacipran O
in O
this O
patient O
appears O
to O
have O
been O
due O
to O
an I-Effect
increase I-Effect
in I-Effect
the I-Effect
alpha(1) I-Effect
- I-Effect
adrenoceptor I-Effect
occupancy I-Effect
by I-Effect
endogenous I-Effect
norepinephrine I-Effect
induced I-Adverse_event.Trigger
by O
milnacipran I-Treatment.Drug
. O

Serotonin I-Effect
syndrome I-Effect
from I-Adverse_event.Trigger
the O
interaction I-Treatment
of I-Treatment
cyclobenzaprine I-Treatment.Drug
with I-Treatment
other I-Treatment
serotoninergic I-Treatment.Drug
drugs I-Treatment.Drug
. O

However O
, O
a O
recent O
post O
- O
marketing O
survey O
in O
Japan O
revealed O
that O
interstitial I-Effect
pneumonia I-Effect
occurred I-Adverse_event.Trigger
in O
4 I-Subject.Population
among I-Subject.Population
approximately I-Subject.Population
2 I-Subject.Population
000 I-Subject.Population
Japanese I-Subject.Race
patients I-Subject
treated O
with O
sorafenib I-Treatment.Drug
. O

The I-Subject
other I-Subject
patient I-Subject
developed I-Adverse_event.Trigger
transient I-Effect
intraoperative I-Effect
hypertension I-Effect
immediately I-Effect
after O
inadvertent I-Treatment
submucosal I-Treatment
injection I-Treatment.Route
of I-Treatment
concentrated I-Treatment
epinephrine I-Treatment.Drug
. O

This O
experience O
supports O
the O
hypothesis O
that O
heparin I-Treatment.Combination.Drug
can O
be O
readministered I-Potential_therapeutic_event.Trigger
early O
to O
patients O
with O
heparin I-Treat_Disorder
- I-Treat_Disorder
associated I-Treat_Disorder
thrombocytopenia I-Treat_Disorder
and O
thrombosis O
, O
provided O
antiplatelet I-Treatment.Combination.Drug
therapy I-Treatment
is I-Treatment
given I-Treatment
. O

This O
experience O
supports O
the O
hypothesis O
that O
heparin O
can O
be O
readministered O
early O
to O
patients O
with O
heparin I-Treatment.Drug
- O
associated I-Adverse_event.Trigger
thrombocytopenia I-Effect
and I-Effect
thrombosis I-Effect
, O
provided O
antiplatelet O
therapy O
is O
given O
. O

Pneumonitis I-Effect
with I-Effect
pleural I-Effect
and I-Effect
pericardial I-Effect
effusion I-Effect
and I-Effect
neuropathy I-Effect
during I-Adverse_event.Trigger
amiodarone I-Treatment.Drug
therapy I-Treatment
. O

We O
report O
a I-Subject
case I-Subject
of O
interstitial I-Effect
pneumonitis I-Effect
induced I-Adverse_event.Trigger
by O
bicalutamide I-Treatment.Combination.Drug
and/or I-Treatment
leuprorelin I-Treatment.Combination.Drug
acetate I-Treatment.Combination.Drug
given I-Treatment
as I-Treatment
therapy I-Treatment
for I-Treatment
prostate I-Treatment.Treat_Disorder
cancer I-Treatment.Treat_Disorder
, O
in O
which O
the O
pneumonitis O
was O
successfully O
managed O
by O
steroid O
treatment O
. O

For O
those O
patients I-Subject
with I-Subject
a I-Subject.Sub_Disorder
history I-Subject.Sub_Disorder
of I-Subject.Sub_Disorder
NMS I-Subject.Sub_Disorder
, O
or O
even O
of O
isolated I-Effect
serum I-Effect
CK I-Effect
elevation I-Effect
during I-Adverse_event.Trigger
antipsychotic I-Treatment
therapy I-Treatment
, O
follow O
- O
up O
should O
be O
stricter O
. O

Children I-Subject.Age
with I-Subject
acute I-Treat_Disorder
lymphoblastic I-Treat_Disorder
leukemia I-Treat_Disorder
( I-Treat_Disorder
ALL I-Treat_Disorder
) I-Treat_Disorder
, O
treated O
with O
L I-Treatment.Drug
- I-Treatment.Drug
asparaginase I-Treatment.Drug
are O
at O
risk I-Adverse_event.Trigger
for O
cerebral I-Effect
thrombosis I-Effect
or I-Effect
hemorrhage I-Effect
because O
of O
coagulation I-Effect
protein I-Effect
deficiencies I-Effect
. O

Two I-Subject.Population
of I-Subject.Population
the I-Subject.Population
five I-Subject.Population
patients I-Subject
who I-Subject
worsened I-Subject.Sub_Disorder
motorically I-Subject.Sub_Disorder
also O
developed I-Adverse_event.Trigger
encephalopathy I-Effect
during O
risperidone I-Treatment.Drug
treatment I-Treatment
; O
the O
encephalopathy O
resolved O
when O
the O
patients O
were O
switched O
to O
clozapine O
treatment O
. O

Two I-Subject.Population
of I-Subject.Population
the I-Subject.Population
five I-Subject.Population
patients I-Subject
who I-Subject
worsened I-Subject.Sub_Disorder
motorically I-Subject.Sub_Disorder
also O
developed O
encephalopathy O
during O
risperidone O
treatment O
; O
the O
encephalopathy I-Treat_Disorder
resolved I-Potential_therapeutic_event.Trigger
when O
the O
patients O
were O
switched I-Treatment
to I-Treatment
clozapine I-Treatment.Drug
treatment I-Treatment
. O

The O
effectiveness O
of O
sugammadex I-Treatment.Drug
in O
reversing I-Potential_therapeutic_event.Trigger
rocuronium I-Treat_Disorder
- I-Treat_Disorder
induced I-Treat_Disorder
neuromuscular I-Treat_Disorder
blockade I-Treat_Disorder
( I-Treat_Disorder
NMB I-Treat_Disorder
) I-Treat_Disorder
in I-Treatment
the I-Treatment
presence I-Treatment
of I-Treatment
drugs I-Treatment
that I-Treatment
may I-Treatment
potentiate I-Treatment
NMB I-Treatment
remains O
to O
be O
fully O
established O
. O

The O
effectiveness O
of O
sugammadex O
in O
reversing O
rocuronium I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
neuromuscular I-Effect
blockade I-Effect
( I-Effect
NMB I-Effect
) I-Effect
in O
the O
presence O
of O
drugs O
that O
may O
potentiate O
NMB O
remains O
to O
be O
fully O
established O
. O

Dexamethasone O
treatment O
of O
amiodarone I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
thyrotoxicosis I-Effect
( I-Effect
AIT I-Effect
) I-Effect
with O
or O
without O
persistent O
administration O
of O
the O
drug O
. O

Acyclovir I-Treatment.Drug
neurotoxicity I-Effect
: O
clinical O
experience I-Adverse_event.Trigger
and O
review O
of O
the O
literature O
. O

Inadvertent I-Effect
exaggerated I-Effect
anticoagulation I-Effect
following I-Adverse_event.Trigger
use O
of O
bismuth I-Treatment.Drug
subsalicylate I-Treatment.Drug
in O
an I-Subject
enterally I-Subject
fed I-Subject
patient I-Subject
receiving O
warfarin I-Treatment.Drug
therapy I-Treatment
. O

We O
report O
the O
specifics O
of O
12 I-Subject.Population
cases I-Subject
of O
severe O
hypertension I-Effect
after I-Adverse_event.Trigger
the O
intraoperative I-Treatment
use I-Treatment
of I-Treatment
topical I-Treatment.Route
phenylephrine I-Treatment.Combination.Drug
, I-Treatment
submucosal I-Treatment.Route
epinephrine I-Treatment.Combination.Drug
, I-Treatment
or I-Treatment
both I-Treatment
. O

The O
patient I-Subject
experienced I-Adverse_event.Trigger
muscle I-Effect
twitches I-Effect
, I-Effect
tremulousness I-Effect
, I-Effect
and I-Effect
anxiety I-Effect
on I-Time_elapsed
day I-Time_elapsed
17 I-Time_elapsed
of O
foscarnet I-Treatment.Drug
therapy I-Treatment
. O

A O
case O
of O
timolol I-Treatment.Drug
- O
associated I-Adverse_event.Trigger
heart I-Effect
failure I-Effect
in O
a I-Subject
73 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
old I-Subject.Age
white I-Subject.Race
man I-Subject.Gender
is O
reported O
. O

In O
December O
, O
he I-Subject.Gender
was O
prescribed O
160 I-Treatment.Dosage
mg I-Treatment.Dosage
/ I-Treatment.Dosage
day I-Treatment.Dosage
tebipenem I-Treatment.Drug
pivoxil I-Treatment.Drug
by O
an O
otolaryngologist O
for I-Potential_therapeutic_event.Trigger
inflammation I-Treat_Disorder
of I-Treat_Disorder
the I-Treat_Disorder
tympanic I-Treat_Disorder
membrane I-Treat_Disorder
. O

A I-Subject
65 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
female I-Subject.Gender
patient I-Subject
presented I-Adverse_event.Trigger
with O
jaundice I-Effect
followed I-Effect
2 I-Effect
days I-Effect
later I-Effect
by I-Effect
severe I-Effect
dyspnea I-Effect
and I-Effect
tachypnea I-Effect
which I-Effect
worsened I-Effect
when I-Effect
patient I-Effect
was I-Effect
lying I-Effect
flat I-Effect
, O
1 I-Treatment.Time_elapsed
week I-Treatment.Time_elapsed
after I-Treatment.Time_elapsed
the I-Treatment
fourth I-Treatment.Dosage
dose I-Treatment.Dosage
of I-Treatment
adalimumab I-Treatment.Drug
. O

Renal I-Effect
failure I-Effect
is O
a O
rare O
complication O
associated I-Adverse_event.Trigger
with O
the O
use O
of O
rifampicin I-Treatment.Drug
for O
the O
treatment O
of O
tuberculosis I-Treat_Disorder
, O
usually O
occurring O
well O
into O
the O
course O
of O
therapy O
. O

An I-Subject
autopsy I-Subject
case I-Subject
of O
multiple I-Treatment
psychotropic I-Treatment.Drug
drug I-Treatment
poisoning I-Effect
. O

Severe O
heparin I-Treatment.Drug
associated I-Adverse_event.Trigger
thrombocytopenia I-Effect
is O
a O
rare O
complication O
of O
heparin O
therapy O
. O

Six I-Subject.Population
patients I-Subject
at O
steady O
state O
in O
treatment I-Potential_therapeutic_event.Trigger
with O
indinavir I-Treatment.Drug
participated O
in O
the O
study O
. O

RESULTS O
: O
A I-Subject
52 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
woman I-Subject.Gender
with I-Subject
Parkinson I-Treat_Disorder
disease I-Treat_Disorder
who O
had O
taken I-Treatment
amantadine I-Treatment.Drug
for I-Treatment
6 I-Treatment.Duration
years I-Treatment.Duration
had I-Adverse_event.Trigger
bilateral I-Effect
corneal I-Effect
edema I-Effect
for I-Effect
2 I-Effect
months I-Effect
at I-Effect
baseline I-Effect
. O

We O
report O
a O
case O
of O
a I-Subject
patient I-Subject
with I-Subject
pulmonary I-Treat_Disorder
hypertension I-Treat_Disorder
and I-Subject
undifferentiated I-Treat_Disorder
connective I-Treat_Disorder
tissue I-Treat_Disorder
disease I-Treat_Disorder
who O
, O
after I-Time_elapsed
2 I-Treatment.Time_elapsed
months I-Treatment.Time_elapsed
of I-Treatment
treatment I-Treatment
with I-Treatment
epoprostenol I-Treatment.Drug
, O
presented I-Adverse_event.Trigger
with O
rapidly I-Effect
progressive I-Effect
erythema I-Effect
, I-Effect
scaling I-Effect
, I-Effect
nausea I-Effect
and I-Effect
vomiting I-Effect
, I-Effect
and I-Effect
fever I-Effect
. O

Neuroleptic I-Effect
malignant I-Effect
syndrome I-Effect
in O
an O
adolescent I-Subject
receiving I-Adverse_event.Trigger
olanzapine I-Treatment.Combination.Drug
- I-Treatment
lithium I-Treatment.Combination.Drug
combination I-Treatment
therapy I-Treatment
. O

A O
lethal O
complication I-Effect
of O
peripheral I-Treatment.Route
vein I-Treatment.Route
vasopressin I-Treatment.Drug
infusion I-Treatment
. O

Cutaneous I-Effect
eruptions I-Effect
occur I-Adverse_event.Trigger
in O
3 O
% O
of O
individuals O
administered O
carbamazepine I-Treatment.Drug
. O

A I-Subject
27 I-Subject.Age
year I-Subject.Age
old I-Subject.Age
female I-Subject.Gender
with I-Subject
a I-Subject
complex I-Subject
history I-Subject
of I-Subject
congenital I-Subject.Sub_Disorder
heart I-Subject.Sub_Disorder
disease I-Subject.Sub_Disorder
, I-Subject
cardiac I-Subject.Sub_Disorder
surgery I-Subject.Sub_Disorder
, I-Subject
heart I-Subject.Sub_Disorder
failure I-Subject.Sub_Disorder
, I-Subject
and I-Subject
arrhythmias I-Subject.Sub_Disorder
was O
admitted O
for O
a I-Treat_Disorder
Pseudomonas I-Treat_Disorder
aeruginosa I-Treat_Disorder
sternal I-Treat_Disorder
wound I-Treat_Disorder
infection I-Treat_Disorder
and O
treated I-Potential_therapeutic_event.Trigger
with O
intravenous I-Treatment.Route
antibiotics I-Treatment.Drug
. O

Hyperkalaemia I-Effect
with I-Effect
renal I-Effect
tubular I-Effect
dysfunction I-Effect
by O
oral I-Treatment.Route
therapy I-Treatment
of I-Treatment
sulfamethoxazole I-Treatment.Drug
- I-Treatment.Drug
trimethoprim I-Treatment.Drug
( I-Treatment
co I-Treatment
- I-Treatment
trimoxazole I-Treatment
) I-Treatment
is O
described I-Adverse_event.Trigger
in O
2 I-Subject.Population
elderly I-Subject.Age
Japanese I-Subject.Race
patients I-Subject
with I-Subject
lymphoid I-Subject.Sub_Disorder
malignancy I-Subject.Sub_Disorder
, O
who O
developed O
Pneumocystis I-Treat_Disorder
carinii I-Treat_Disorder
pneumonia I-Treat_Disorder
and O
improved O
. O

This O
is O
the O
first O
report O
on O
the O
histopathological O
findings O
of O
thyroid O
tissue O
from O
a O
patient O
with O
amiodarone I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
hypothyroidism I-Effect
. O

Acute I-Effect
pulmonary I-Effect
reactions I-Effect
to O
nitrofurantoin I-Treatment.Drug
are I-Adverse_event.Trigger
an O
uncommon O
side O
effect O
of O
therapy O
and O
can I-Effect
cause I-Effect
minor I-Effect
or I-Effect
life I-Effect
- I-Effect
threatening I-Effect
pulmonary I-Effect
dysfunction I-Effect
. O

High I-Treatment.Dosage
- I-Treatment.Dosage
dose I-Treatment.Dosage
cytosine I-Treatment.Drug
arabinoside I-Treatment.Drug
may O
benefit I-Potential_therapeutic_event.Trigger
patients I-Subject
with I-Subject
refractory I-Treat_Disorder
acute I-Treat_Disorder
leukemia I-Treat_Disorder
. O

Life O
- O
threatening O
hyponatremia I-Effect
caused I-Adverse_event.Trigger
by O
vinblastine I-Treatment.Drug
. O

We O
report O
a I-Subject
myeloma I-Treat_Disorder
patient I-Subject
who O
developed I-Adverse_event.Trigger
severe O
paralytic I-Effect
ileus I-Effect
during O
bortezomib I-Treatment.Drug
therapy I-Treatment
, O
which O
presented I-Effect
in I-Effect
the I-Effect
context I-Effect
of I-Effect
progressive I-Effect
constipation I-Effect
without I-Effect
other I-Effect
known I-Effect
causes I-Effect
and I-Effect
which I-Effect
regressed I-Effect
promptly I-Effect
with I-Effect
medical I-Effect
management I-Effect
after I-Effect
drug I-Effect
cessation I-Effect
, O
suggesting O
a O
direct O
causal O
relationship O
. O

Here O
, O
we O
report O
on O
the O
drug O
safety O
of O
coumarin I-Treatment.Drug
with O
special O
respect I-Adverse_event.Trigger
to O
liver I-Effect
reaction I-Effect
. O

However O
, O
EO I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
noncardiogenic I-Effect
pulmonary I-Effect
edema I-Effect
has O
not O
been O
reported O
in O
human I-Subject
. O

Since I-Adverse_event.Trigger
the I-Effect
thrombocyte I-Effect
count I-Effect
started I-Effect
to I-Effect
increase I-Effect
immediately I-Effect
after I-Effect
initiation I-Effect
and I-Effect
dropped I-Effect
immediately I-Effect
after O
discontinuation I-Treatment.Dosage
of I-Treatment
ciprofloxacin I-Treatment.Combination.Drug
and I-Treatment
tazobactam I-Treatment.Combination.Drug
/ I-Treatment.Combination.Drug
piperacillin I-Treatment.Combination.Drug
and O
all O
other O
drugs O
were O
discontinued O
already O
before O
or O
were O
started O
after O
the O
nadir O
of O
the O
thrombocyte O
count O
, O
these O
two O
antibiotics O
were O
regarded O
causative O
. O

However O
, O
in O
1993 O
, O
a O
clinical O
study O
involving O
400 I-Subject.Population
patients I-Subject
on I-Subject
the I-Subject
Thai I-Subject
- I-Subject
Burmese I-Subject
border I-Subject
revealed O
cardiac I-Effect
effects I-Effect
of O
antimalarial I-Combination.Drug
treatment I-Combination.Drug
with O
halofantrine I-Treatment.Combination.Drug
, O
including O
one O
sudden I-Effect
death I-Effect
after O
the O
treatment O
. O

Tetracycline I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
benign I-Effect
intracranial I-Effect
hypertension I-Effect
. O

Only O
one I-Subject.Population
case I-Subject
of O
a O
generalized I-Effect
maculopapular I-Effect
rash I-Effect
with I-Adverse_event.Trigger
enoxaparin I-Treatment.Drug
has O
been O
reported O
in O
Europe O
. O

After I-Potential_therapeutic_event.Trigger
3 I-Treatment.Time_elapsed
- I-Treatment.Time_elapsed
to I-Treatment.Time_elapsed
13 I-Treatment.Time_elapsed
- I-Treatment.Time_elapsed
month I-Treatment.Time_elapsed
period I-Treatment
of I-Treatment
therapy I-Treatment
without I-Treatment
indapamide I-Treatment.Drug
, O
glucose I-Effect
levels I-Effect
of I-Effect
all I-Effect
patients I-Effect
decreased I-Effect
and I-Effect
diabetes I-Effect
disappeared I-Effect
. O

The O
favourable O
outcome O
in O
these O
two I-Subject.Population
patients I-Subject
contrasts O
with O
the O
fatal O
outcome O
of O
the O
two O
other O
reported O
cases O
of O
nitrofurantoin I-Treatment.Drug
induced I-Adverse_event.Trigger
BOOP I-Effect
. O

Skin I-Effect
necrosis I-Effect
after O
extravasation I-Adverse_event.Trigger
of O
low O
- O
dose O
vasopressin I-Treatment.Drug
administered O
for O
septic I-Treat_Disorder
shock I-Treat_Disorder
. O

The I-Subject
patient I-Subject
was O
previously I-Treatment
on I-Treatment
phenytoin I-Treatment.Drug
and O
was O
initiated I-Treatment
on I-Treatment
ticagrelor I-Treatment.Drug
for I-Potential_therapeutic_event.Trigger
antiplatelet I-Treat_Disorder
therapy I-Treat_Disorder
following I-Treatment
stent I-Treatment
placement I-Treatment
. O

Clonidine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
bradycardia I-Effect
in O
patients I-Subject
with I-Subject
spinal I-Treat_Disorder
cord I-Treat_Disorder
injury I-Treat_Disorder
. O

MI I-Effect
related I-Adverse_event.Trigger
to O
the O
use O
of O
activated I-Treatment.Drug
and I-Treatment
non I-Treatment.Drug
- I-Treatment.Drug
activated I-Treatment.Drug
PCCs I-Treatment.Drug
predominantly O
affects O
young I-Subject.Age
patients I-Subject
who I-Subject
often I-Subject
have I-Subject
no I-Subject
preceding I-Subject
history I-Subject
of I-Subject
, I-Subject
or I-Subject
risk I-Subject
factors I-Subject
for I-Subject
, I-Subject
MI I-Subject
and O
tends O
to O
be O
associated O
with O
large I-Treatment.Dosage
cumulative I-Treatment.Dosage
doses I-Treatment.Dosage
of I-Treatment
concentrate I-Treatment
. O

To O
our O
knowledge O
, O
we O
describe O
the O
first O
reported O
case O
of O
isolated I-Effect
paresthesia I-Effect
and I-Effect
peripheral I-Effect
neuropathy I-Effect
, O
without O
systemic O
involvement O
, O
secondary I-Adverse_event.Trigger
to O
sulindac I-Treatment.Drug
administration I-Treatment
. O

To O
report O
a I-Subject
probable I-Subject
case I-Subject
of O
ticlopidine I-Treatment.Combination.Drug
- O
induced I-Adverse_event.Trigger
phenytoin I-Treatment.Combination.Drug
toxicity I-Effect
. O

Two I-Subject.Population
patients I-Subject
are O
described O
in O
whom O
subtle I-Effect
cognitive I-Effect
impairments I-Effect
are O
associated I-Adverse_event.Trigger
with O
therapeutic I-Treatment.Dosage
doses I-Treatment.Dosage
of I-Treatment
amoxapine I-Treatment.Drug
. O

Itraconazole I-Treatment.Drug
is O
particularly O
attractive O
in O
fungal I-Treat_Disorder
prophylaxis I-Potential_therapeutic_event.Trigger
for O
cancer I-Subject.Sub_Disorder
patients I-Subject
due O
to O
its O
broad O
spectrum O
, O
including O
Candida O
and O
Aspergillus O
. O

The O
authors O
think O
that O
although O
lamivudine I-Treatment.Drug
is O
widely O
used O
and O
well O
tolerated O
, O
it O
can O
cause I-Adverse_event.Trigger
ADRs I-Effect
, O
which O
are O
reversible O
after O
drug O
withdrawal O
. O

Psoriasis I-Effect
induced I-Adverse_event.Trigger
by O
interferon I-Treatment.Drug
- I-Treatment.Drug
alpha I-Treatment.Drug
. O

We O
report O
the I-Subject
first I-Subject
case I-Subject
of O
IHA I-Effect
associated I-Adverse_event.Trigger
with O
cefuroxime I-Treatment.Drug
administration O
. O

We O
report O
a I-Subject
16 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
male I-Subject.Gender
who O
developed O
nephrotic I-Effect
syndrome I-Effect
related I-Effect
to I-Effect
membranous I-Effect
glomerulopathy I-Effect
with I-Effect
clinical I-Effect
and I-Effect
serological I-Effect
evidence I-Effect
of I-Effect
systemic I-Effect
lupus I-Effect
erythematosus I-Effect
after I-Adverse_event.Trigger
treatment I-Treatment
with I-Treatment
griseofulvin I-Treatment.Drug
. O

CONCLUSION O
: O
In I-Adverse_event.Trigger
some I-Subject
abstainers I-Subject
who O
take I-Treatment
cyanamide I-Treatment.Drug
for I-Treatment
several I-Treatment.Freq
years I-Treatment.Freq
, O
thin I-Effect
septum I-Effect
- I-Effect
like I-Effect
liver I-Effect
fibrosis I-Effect
progresses I-Effect
along I-Effect
with I-Effect
the I-Effect
emergence I-Effect
of I-Effect
ground I-Effect
- I-Effect
glass I-Effect
hepatocytes I-Effect
. O

Metabolic I-Effect
acidosis I-Effect
induced I-Adverse_event.Trigger
by O
acetazolamide I-Treatment.Drug
. O

In O
this O
paper O
we O
report O
a O
case O
of O
nimodipine I-Treatment.Drug
overdosage I-Treatment.Dosage
resulting I-Adverse_event.Trigger
in O
prolonged I-Effect
hypotension I-Effect
and I-Effect
hypoxemia I-Effect
, O
which O
was O
successfully O
treated O
with O
calcium O
gluconate O
. O

In O
this O
paper O
we O
report O
a O
case O
of O
nimodipine O
overdosage O
resulting O
in O
prolonged I-Treat_Disorder
hypotension I-Treat_Disorder
and I-Treat_Disorder
hypoxemia I-Treat_Disorder
, O
which O
was O
successfully O
treated I-Potential_therapeutic_event.Trigger
with O
calcium I-Treatment.Drug
gluconate I-Treatment.Drug
. O

Valproic I-Treatment.Combination.Drug
acid I-Treatment.Combination.Drug
also I-Treatment
displaces I-Treatment
warfarin I-Treatment.Combination.Drug
from I-Treatment
the I-Treatment
protein I-Treatment
binding I-Treatment
sites I-Treatment
resulting I-Adverse_event.Trigger
in O
significant I-Effect
INR I-Effect
changes I-Effect
but O
this O
type O
of O
drug O
interaction O
is O
less O
well O
known O
. O

Therapy I-Treatment
with I-Treatment
IFN I-Treatment.Drug
- I-Treatment.Drug
alpha I-Treatment.Drug
may O
be O
associated I-Adverse_event.Trigger
with I-Adverse_event.Trigger
a O
number O
of O
neuropsychiatric I-Effect
symptoms I-Effect
, I-Effect
such I-Effect
as I-Effect
Parkinsonism I-Effect
, I-Effect
akathisia I-Effect
, I-Effect
seizure I-Effect
, I-Effect
and I-Effect
depressive I-Effect
disorders I-Effect
. O

DISCUSSION O
: O
The O
main O
adverse O
effects I-Adverse_event.Trigger
of O
leflunomide I-Treatment.Drug
consist O
of O
diarrhea I-Effect
, I-Effect
nausea I-Effect
, I-Effect
liver I-Effect
enzyme I-Effect
elevation I-Effect
, I-Effect
hypertension I-Effect
, I-Effect
alopecia I-Effect
, I-Effect
and I-Effect
allergic I-Effect
skin I-Effect
reactions I-Effect
. O

In O
a O
single O
practice O
during O
the O
21 O
years O
1971 O
- O
1991 O
, O
the O
incidence I-Adverse_event.Trigger
of O
gestational I-Effect
diabetes I-Effect
in O
pregnancies I-Subject
in O
which O
norethisterone I-Treatment.Drug
was O
prescribed O
was O
32.4 O
% O
( O
22 O
of O
69 O
) O
in O
comparison O
with O
7.1 O
% O
in O
pregnancies O
in O
which O
the O
women O
did O
not O
take O
norethisterone O
( O
137 O
of O
1,684 O
) O
( O
p O
< O
0.001 O
) O
. O

The O
development I-Adverse_event.Trigger
of O
systemic I-Effect
lupus I-Effect
erythematosus I-Effect
( O
SLE O
) O
after I-Treatment.Time_elapsed
38 I-Treatment.Time_elapsed
months I-Treatment.Time_elapsed
of O
therapy O
with O
recombinant I-Treatment.Drug
human I-Treatment.Drug
interferon I-Treatment.Drug
gamma I-Treatment.Drug
( O
rIFN O
- O
gamma O
) O
was O
observed O
in O
a I-Subject
patient I-Subject
with I-Subject
rheumatoid I-Treat_Disorder
arthritis I-Treat_Disorder
. I-Treat_Disorder

To O
the O
best O
of O
our O
knowledge O
no O
comparable O
case O
and O
no O
discussion O
of O
possible O
complications I-Adverse_event.Trigger
of O
aspirin I-Treatment.Drug
prophylaxis I-Treatment
in O
patients I-Subject
with I-Subject
brain I-Subject.Sub_Disorder
tumours I-Subject.Sub_Disorder
have O
been O
published O
. O

CASE O
REPORT O
: O
We O
present O
a O
case O
of O
a O
28 I-Subject.Age
- I-Subject.Age
yr I-Subject.Age
- I-Subject.Age
old I-Subject.Age
male I-Subject.Gender
who O
developed I-Adverse_event.Trigger
a O
severe O
case O
of O
nephrotic I-Effect
syndrome I-Effect
while O
being O
treated O
for O
relapsing I-Treat_Disorder
/ I-Treat_Disorder
remitting I-Treat_Disorder
Multiple I-Treat_Disorder
Sclerosis I-Treat_Disorder
( I-Subject
RRMS I-Subject
) I-Subject
with O
weekly I-Treatment.Freq
injections I-Treatment.Route
of I-Treatment
interferon I-Treatment.Drug
beta I-Treatment.Drug
1a I-Treatment.Drug
. O

This O
is O
the O
third O
report O
of O
reversible I-Effect
hepatic I-Effect
decompensation I-Effect
associated I-Adverse_event.Trigger
with O
prolonged O
MTX I-Treatment.Drug
therapy O
in O
patients I-Subject
with I-Subject
rheumatoid I-Treat_Disorder
arthritis I-Treat_Disorder
. O

CONCLUSIONS O
: O
Acute I-Effect
severe I-Effect
hepatitis I-Effect
though O
rare O
is O
occasionally O
observed I-Adverse_event.Trigger
with O
EGFR I-Treatment
inhibitors I-Treatment
gefitinib I-Treatment.Drug
or I-Treatment
erlotinib I-Treatment.Drug
. O

Propafenone I-Treatment.Drug
is O
an O
established O
class O
IC O
antiarrhythmic O
drug O
commonly O
used O
in O
the O
treatment I-Potential_therapeutic_event.Trigger
of O
atrial I-Treat_Disorder
fibrillation I-Treat_Disorder
. O

Reversible I-Effect
nonthrombocytopenic I-Effect
palpable I-Effect
purpura I-Effect
associated I-Adverse_event.Trigger
with O
metoclopramide I-Treatment.Drug
. O

Physicians O
who O
use O
sulfasalazine I-Treatment.Drug
to O
treat O
patients O
with O
inflammatory I-Treat_Disorder
bowel I-Treat_Disorder
disease I-Treat_Disorder
should O
be O
aware O
of O
the O
signs O
of O
sulfasalazine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
lupus I-Effect
syndrome I-Effect
. O

Transient I-Effect
hemiparesis I-Effect
caused I-Adverse_event.Trigger
by O
phenytoin I-Treatment.Drug
toxicity I-Treatment
. O

Sensorineural I-Effect
hearing I-Effect
loss I-Effect
due I-Adverse_event.Trigger
to O
quinine I-Treatment.Drug
therapy O
for O
malaria I-Treat_Disorder
has O
frequently O
been O
mentioned O
in O
the O
literature O
but O
has O
not O
been O
a O
subject O
of O
research O
during O
the O
last O
decades O
. O

We O
report O
a I-Subject
78 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
man I-Subject.Gender
who O
had O
acute I-Effect
unilateral I-Effect
total I-Effect
visual I-Effect
loss I-Effect
after I-Adverse_event.Trigger
retrogasserian I-Treatment
phenol I-Treatment.Drug
injection I-Treatment.Route
for O
the O
treatment O
of O
trigeminal I-Treat_Disorder
neuralgia I-Treat_Disorder
. O

Four I-Time_elapsed
months I-Time_elapsed
after I-Subject
receiving I-Subject
an I-Subject
orthotopic I-Subject
liver I-Subject
transplant I-Subject
, I-Subject
a I-Subject.Age
51 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
man I-Subject
was O
admitted O
for O
progressive I-Effect
liver I-Effect
failure I-Effect
and I-Effect
severe I-Effect
hepatocellular I-Effect
necrosis I-Effect
thought O
to O
be O
due I-Adverse_event.Trigger
to I-Adverse_event.Trigger
tacrolimus I-Treatment.Drug
. O

Patients I-Subject
receiving O
neutral I-Treatment.Drug
protamine I-Treatment.Drug
Hagedorn I-Treatment.Drug
( I-Treatment.Drug
NPH I-Treatment.Drug
) I-Treatment.Drug
insulin I-Treatment.Drug
are O
at O
increased O
risk O
for O
the O
development I-Adverse_event.Trigger
of O
protamine I-Effect
hypersensitivity I-Effect
. O

The I-Subject
second I-Subject
patient I-Subject
, O
who O
developed I-Adverse_event.Trigger
cholestasis I-Effect
after O
receiving O
trimethoprim I-Treatment.Drug
- I-Treatment.Drug
sulfamethoxazole I-Treatment.Drug
, O
had O
marked O
duct I-Effect
paucity I-Effect
in O
the O
liver O
biopsy O
. O

We O
describe O
a I-Subject
patient I-Subject
who O
became I-Adverse_event.Trigger
hypothyroid I-Effect
while O
taking O
ferrous I-Treatment.Drug
sulfate I-Treatment.Drug
. O

Allergy I-Effect
to I-Adverse_event.Trigger
cloxacillin I-Treatment.Drug
with O
normal O
tolerance O
to O
amoxicillin I-Drug
and O
cefuroxime I-Drug
. O

Triazolam I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
nocturnal I-Effect
bingeing I-Effect
with I-Effect
amnesia I-Effect
. O

Ticlopidine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
aplastic I-Effect
anemia I-Effect
( I-Effect
TIAA I-Effect
) I-Effect
is O
considered O
very O
uncommon O
. O

One I-Subject.Population
case I-Subject
report O
describes O
an O
interaction O
between O
simvastatin I-Treatment.Combination.Drug
and I-Treatment
the I-Treatment
anticoagulant I-Treatment.Combination.Drug
acenocoumarol I-Treatment.Combination.Drug
, O
which O
resulted I-Adverse_event.Trigger
in O
an O
elevated I-Effect
INR I-Effect
. O

A I-Subject
35 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
woman I-Subject.Gender
presented O
with O
neurotoxicity I-Effect
correlated I-Adverse_event.Trigger
to O
an I-Treatment
i.v I-Treatment.Route
. I-Treatment.Route
regimen I-Treatment
of I-Treatment
5 I-Treatment.Drug
- I-Treatment.Drug
fluorouracil I-Treatment.Drug
as O
episodes O
of O
acute I-Effect
confusional I-Effect
state I-Effect
and I-Effect
abnormalities I-Effect
of I-Effect
symmetrically I-Effect
restricted I-Effect
diffusion I-Effect
in I-Effect
the I-Effect
periventricular I-Effect
white I-Effect
matter I-Effect
and I-Effect
corpus I-Effect
callosum I-Effect
. O

Ampicillin I-Treatment.Drug
may O
aggravate I-Adverse_event.Trigger
clinical O
and O
experimental O
myasthenia I-Effect
gravis I-Effect
. O

In O
the O
present O
paper O
, O
we O
discuss O
the O
first O
Japanese I-Subject.Race
vivax I-Treat_Disorder
malaria I-Treat_Disorder
patient I-Subject
whose O
QT I-Effect
interval I-Effect
was I-Effect
prolonged I-Effect
after I-Adverse_event.Trigger
treatment O
with O
halofantrine I-Treatment.Drug
. O

The O
Center O
for O
Disease O
Control O
has O
received O
numerous O
reports O
of O
an O
eosinophilia I-Effect
- I-Effect
myalgia I-Effect
syndrome I-Effect
related I-Adverse_event.Trigger
to O
products I-Treatment
containing I-Treatment
L I-Treatment.Drug
- I-Treatment.Drug
tryptophan I-Treatment.Drug
. O

Disopyramide I-Treatment.Drug
( I-Treatment
Norpace) I-Treatment
- O
induced I-Adverse_event.Trigger
hypoglycemia I-Effect
. O

A O
case O
report O
of O
the O
hypersensitivity I-Effect
syndrome I-Effect
occurring O
in O
a I-Subject
patient I-Subject
being O
treated I-Adverse_event.Trigger
with O
dapsone I-Treatment.Drug
for O
a O
brown I-Treat_Disorder
recluse I-Treat_Disorder
spider I-Treat_Disorder
bite I-Treat_Disorder
is O
presented O
. O

AIMS O
: O
To O
present O
a O
case O
of O
piloerection I-Effect
after I-Adverse_event.Trigger
replacing O
fluvoxamine I-Treatment.Drug
maleate I-Treatment.Drug
with O
milnacipran I-Drug
hydrochloride I-Drug
, O
and O
to O
analyse O
this O
effect O
based O
on O
receptor O
occupancy O
theory O
. O

Serotonin I-Effect
syndrome I-Effect
after I-Adverse_event.Trigger
concomitant O
linezolid I-Treatment.Combination.Drug
and I-Treatment
meperidine I-Treatment.Combination.Drug
therapy O
has O
not O
been O
described O
. O

She I-Subject.Gender
presented I-Adverse_event.Trigger
to O
clinic O
with O
nausea I-Effect
and I-Effect
anorexia I-Effect
within I-Time_elapsed
a I-Time_elapsed
few I-Time_elapsed
days I-Time_elapsed
of O
addition I-Treatment
of I-Treatment
ciprofloxacin I-Treatment.Combination.Drug
to I-Treatment
her I-Treatment
current I-Treatment
regimen I-Treatment
of I-Treatment
medications I-Treatment
, I-Treatment
which I-Treatment
included I-Treatment
digoxin I-Treatment.Combination.Drug
. O

Disulfiram I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
fulminant I-Effect
hepatic I-Effect
failure I-Effect
in O
an I-Subject
active I-Subject
duty I-Subject
soldier I-Subject
. O

BACKGROUND O
: O
We O
report O
six I-Subject.Population
cases I-Subject
of O
psychosis I-Treat_Disorder
in O
patients I-Subject
with I-Subject
akinetic I-Subject.Sub_Disorder
- I-Subject.Sub_Disorder
rigid I-Subject.Sub_Disorder
syndromes I-Subject.Sub_Disorder
who O
were O
treated I-Potential_therapeutic_event.Trigger
with O
risperidone I-Treatment.Drug
. O

Colonic I-Effect
necrosis I-Effect
is O
known O
as O
a O
rare O
complication O
following I-Adverse_event.Trigger
the O
administration O
of O
Kayexalate I-Treatment.Combination.Drug
( I-Treatment
sodium I-Treatment
polystryrene I-Treatment
sulfonate I-Treatment
) I-Treatment
in I-Treatment
sorbitol I-Treatment.Combination.Drug
. O

Anaphylaxis I-Effect
to O
cisplatin I-Treatment.Drug
is O
an O
infrequent O
life O
- O
threatening O
complication O
which O
may O
occur I-Adverse_event.Trigger
even O
in O
patients I-Subject
who O
have O
received O
prior O
treatment O
with O
cisplatin O
. O

Piloerection I-Effect
induced I-Adverse_event.Trigger
by O
replacing I-Treatment
fluvoxamine I-Treatment.Drug
with I-Treatment
milnacipran I-Treatment.Drug
. O

Ethambutol I-Treatment.Drug
is O
an O
antimicrobial O
agent O
used O
frequently O
to O
treat I-Potential_therapeutic_event.Trigger
tuberculosis I-Treat_Disorder
. O

The O
purpose O
of O
this O
review O
is O
to O
increase O
awareness O
among O
physicians O
and O
other O
health O
care O
professionals O
that O
DIC I-Effect
may O
be O
a O
rare O
but O
potentially O
severe O
complication I-Adverse_event.Trigger
of O
anti I-Treatment.Drug
- I-Treatment.Drug
D I-Treatment.Drug
IGIV I-Treatment.Drug
treatment O
. O

Four I-Subject.Population
Chinese I-Subject.Race
female I-Subject.Gender
patients I-Subject
who I-Subject
suffered I-Subject
from I-Subject
manic I-Treat_Disorder
- I-Treat_Disorder
depressive I-Treat_Disorder
disorder I-Treat_Disorder
and I-Subject
underlying I-Subject.Sub_Disorder
autoimmune I-Subject.Sub_Disorder
thyroiditis I-Subject.Sub_Disorder
developed O
transient I-Effect
episodes I-Effect
of I-Effect
thyrotoxicosis I-Effect
during I-Adverse_event.Trigger
maintenance I-Treatment
lithium I-Treatment.Drug
therapy I-Treatment
. O

Neurointensive O
care O
management O
of O
raised I-Effect
intracranial I-Effect
pressure I-Effect
caused I-Adverse_event.Trigger
by O
severe O
valproic I-Treatment.Drug
acid I-Treatment.Drug
intoxication O
. O

Primary I-Effect
ovarian I-Effect
large I-Effect
B I-Effect
- I-Effect
cell I-Effect
lymphoma I-Effect
in I-Adverse_event.Trigger
patient I-Subject
with I-Subject
juvenile I-Treat_Disorder
rheumatoid I-Treat_Disorder
arthritis I-Treat_Disorder
treated O
with O
low I-Treatment.Dosage
dose I-Treatment.Dosage
Methotrexate I-Treatment.Drug
. O

Asterixis I-Effect
induced I-Adverse_event.Trigger
by O
carbamazepine I-Treatment.Drug
therapy O
. O

Ifosfamide I-Treatment.Drug
is O
a O
known O
nephrotoxic O
drug O
with I-Adverse_event.Trigger
demonstrated O
tubulopathies I-Effect
. O

A I-Subject
case I-Subject
of O
noncardiogenic I-Effect
pulmonary I-Effect
edema I-Effect
by I-Adverse_event.Trigger
ethanolamine I-Treatment.Drug
oleate I-Treatment.Drug
. O

A I-Subject
boy I-Subject.Gender
with I-Subject
chronic I-Treat_Disorder
neutropenia I-Treat_Disorder
and I-Treat_Disorder
recurrent I-Treat_Disorder
inflammatory I-Treat_Disorder
skin I-Treat_Disorder
lesions I-Treat_Disorder
developed I-Adverse_event.Trigger
multiple I-Effect
erythematous I-Effect
nodules I-Effect
following O
administration O
of O
G I-Treatment.Drug
- I-Treatment.Drug
CSF I-Treatment.Drug
. O

Fulminant I-Effect
hepatitis I-Effect
and O
lymphocyte I-Effect
sensitization I-Effect
due I-Adverse_event.Trigger
to O
propylthiouracil I-Treatment.Drug
. O

We O
report O
on O
three I-Subject.Population
patients I-Subject
with I-Subject
acute I-Treat_Disorder
schizophrenia I-Treat_Disorder
, O
who O
developed O
severe O
akathisia I-Effect
during O
treatment O
with I-Adverse_event.Trigger
olanzapine I-Treatment.Drug
( I-Treatment
20 I-Treatment.Dosage
- I-Treatment.Dosage
25 I-Treatment.Dosage
mg I-Treatment.Dosage
/ I-Treatment.Dosage
d I-Treatment.Dosage
) I-Treatment
. O

AIMS O
/ O
HYPOTHESIS O
: O
There O
is O
evidence O
that O
insulin I-Treatment.Combination.Drug
and I-Treatment
glucose I-Treatment.Combination.Drug
cause I-Adverse_event.Trigger
renal I-Effect
and I-Effect
ocular I-Effect
vasodilation I-Effect
. O

A O
cause O
- O
effect O
relationship I-Adverse_event.Trigger
to I-Adverse_event.Trigger
capecitabine I-Treatment.Drug
was O
suggested O
due O
to O
resolution O
of O
headache I-Effect
with O
capecitabine O
withdrawal O
and O
reappearance O
with O
capecitabine O
rechallenge O
. O

This O
is O
a O
report O
of O
a I-Subject
case I-Subject
of O
anuric I-Effect
ARF I-Effect
after I-Adverse_event.Trigger
high I-Treatment.Dosage
- I-Treatment.Dosage
dose I-Treatment.Dosage
mannitol I-Treatment.Drug
infusion I-Treatment.Route
for O
treatment O
of O
narrow I-Treat_Disorder
- I-Treat_Disorder
angle I-Treat_Disorder
glaucoma I-Treat_Disorder
that O
readily O
responded O
to O
acute O
hemodialysis O
. O

She I-Subject.Gender
was O
treated I-Potential_therapeutic_event.Trigger
with O
sorafenib I-Treatment.Drug
at I-Treatment
400 I-Treatment.Dosage
mg I-Treatment.Dosage
daily I-Treatment.Freq
. O

The O
clinical O
course O
suggested O
that O
recombinant I-Treatment.Combination.Drug
alpha I-Treatment.Combination.Drug
- I-Treatment.Combination.Drug
2b I-Treatment.Combination.Drug
peginterferon I-Treatment.Combination.Drug
plus I-Treatment
ribavirin I-Treatment.Combination.Drug
provoked I-Adverse_event.Trigger
type I-Effect
1 I-Effect
diabetes I-Effect
mellitus I-Effect
, O
therefore O
, O
in O
patients O
who O
are O
candidates O
for O
interferon O
therapy O
the O
presence O
of O
pancreatic O
autoantibodies O
and O
the O
fasting O
plasma O
glucose O
level O
should O
be O
investigated O
before O
and O
during O
treatment O
. O

Rhabdomyolysis I-Effect
following I-Adverse_event.Trigger
clarithromycin I-Treatment.Drug
monotherapy I-Treatment
. O

In O
addition O
to O
its O
known O
effect I-Adverse_event.Trigger
on I-Adverse_event.Trigger
gallbladder I-Effect
stasis I-Effect
, O
octreotide I-Treatment.Drug
alters I-Effect
bile I-Effect
acid I-Effect
composition I-Effect
and I-Effect
may I-Effect
thus I-Effect
hasten I-Effect
intrahepatic I-Effect
sludge I-Effect
and I-Effect
stone I-Effect
formation I-Effect
. O

A O
17 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
boy I-Subject.Gender
with I-Subject
acute I-Treat_Disorder
lymphoblastic I-Treat_Disorder
leukemia I-Treat_Disorder
developed I-Adverse_event.Trigger
acute I-Effect
renal I-Effect
failure I-Effect
within I-Time_elapsed
48 I-Time_elapsed
h I-Time_elapsed
of O
an O
intravenous I-Treatment.Route
high I-Treatment
- I-Treatment
dose I-Treatment
methotrexate I-Treatment.Drug
( I-Treatment
5 I-Treatment.Dosage
g I-Treatment.Dosage
/ I-Treatment.Dosage
m2 I-Treatment.Dosage
) I-Treatment
infusion I-Treatment
. O

Splenic I-Effect
hemorrhage I-Effect
: O
a O
complication I-Adverse_event.Trigger
of I-Adverse_event.Trigger
tissue I-Treatment.Drug
plasminogen I-Treatment.Drug
activator I-Treatment.Drug
treatment I-Treatment
. O

CONCLUSIONS O
: O
Cefazolin I-Treatment.Drug
was O
a O
probable O
cause I-Adverse_event.Trigger
of O
this O
patient I-Subject
's O
leukopenia I-Effect
. O

Paradoxical I-Effect
cerebral I-Effect
cortical I-Effect
hyperexcitability I-Effect
following I-Adverse_event.Trigger
flupirtine I-Treatment.Drug
overdose I-Treatment.Dosage
. O

Autopsy O
evidence O
of O
herpesvirus I-Effect
infection I-Effect
was O
found I-Adverse_event.Trigger
in O
visceral O
organs O
of O
four I-Subject.Population
leukemic I-Treat_Disorder
patients I-Subject
who O
had O
received O
large I-Treatment
doses I-Treatment
of I-Treatment
cytarabine I-Treatment.Drug
( I-Drug
cytosine I-Drug
arabinoside I-Drug
; I-Drug
Ara I-Drug
- I-Drug
C I-Drug
) I-Drug
shortly O
before O
their O
death O
. O

Heparin I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
hyperkalemia I-Effect
. O

Although O
myelosuppression I-Effect
is O
mild O
, O
immunosuppression I-Effect
and I-Effect
superinfection I-Effect
are O
potential O
hazards I-Adverse_event.Trigger
of O
treatment O
with O
DCF I-Treatment.Drug
. O

The O
photosensitivity I-Effect
is I-Effect
still I-Effect
present I-Effect
3 I-Effect
years I-Effect
after I-Adverse_event.Trigger
the O
withdrawal I-Treatment
of I-Treatment
quinine I-Treatment.Drug
. O

Interference I-Effect
with I-Effect
the I-Effect
cortisol I-Effect
axis I-Effect
by I-Adverse_event.Trigger
the O
microtubule O
antagonist O
, O
CPH82 I-Treatment.Drug
. O

Physicians O
should O
be O
aware O
of O
the O
possible O
association O
between O
the O
use O
of O
alteplase I-Treatment.Drug
and O
the O
development I-Adverse_event.Trigger
of O
subfascial I-Effect
hemorrhage I-Effect
. O

The O
clinical O
findings O
and O
laboratory O
studies O
suggested O
an I-Effect
autoimmune I-Effect
cell I-Effect
- I-Effect
mediated I-Effect
hypersensitivity I-Effect
reaction I-Effect
triggered I-Adverse_event.Trigger
by O
phenobarbital I-Treatment.Drug
. O

Anaphylactic I-Effect
reaction I-Effect
to I-Adverse_event.Trigger
oral I-Treatment.Route
prednisone I-Treatment.Drug
: O
a I-Subject
case I-Subject
report O
and O
review O
of O
the O
literature O
. O

Prolonged I-Effect
prostate I-Effect
- I-Effect
specific I-Effect
antigen I-Effect
response I-Effect
in I-Adverse_event.Trigger
flutamide I-Treatment.Drug
withdrawal O
syndrome O
despite O
disease O
progression O
. O

None O
of O
them O
had O
a O
history O
of O
cardiac O
disease O
, O
and O
with O
the O
possible O
exception O
of O
one O
case O
of O
cardiac I-Effect
arrest I-Effect
, O
where O
the I-Subject
patient I-Subject
received I-Adverse_event.Trigger
doxorubicin I-Treatment.Drug
, O
no O
predisposing O
factors O
could O
be O
found O
. O

We O
report O
a I-Subject
case I-Subject
of O
IDDM I-Effect
which O
occurred I-Adverse_event.Trigger
during O
interferon I-Treatment.Drug
therapy I-Treatment
for O
chronic I-Treat_Disorder
hepatitis I-Treat_Disorder
. I-Treat_Disorder

Though O
physicians O
treating O
large O
populations O
of O
patients I-Subject
with I-Subject
HIV I-Treat_Disorder
are O
well O
aware O
of O
this O
complication O
, O
only O
one O
other O
report O
of O
nevirapine I-Treatment.Drug
- O
associated I-Adverse_event.Trigger
SJS I-Effect
has O
been O
documented O
in O
the O
dermatology O
literature O
. O

We O
report O
a O
case O
of O
baclofen I-Effect
withdrawal I-Effect
syndrome I-Effect
resulting I-Adverse_event.Trigger
from O
oral I-Treatment.Route
baclofen I-Treatment.Drug
underdosing I-Treatment.Dosage
. O

A I-Subject
35 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
nephrotic I-Treat_Disorder
man I-Subject.Gender
developed O
acute I-Effect
renal I-Effect
failure I-Effect
with I-Effect
serum I-Effect
creatinine I-Effect
to I-Effect
1543 I-Effect
micromol I-Effect
/ I-Effect
l I-Effect
after I-Adverse_event.Trigger
a I-Treatment.Duration
month I-Treatment.Duration
of I-Treatment
therapy I-Treatment
with I-Treatment
enalapril I-Treatment.Drug
. O

Comparable O
adverse O
effects O
, O
such O
as O
disorientation I-Effect
and I-Effect
temporary I-Effect
amnesia I-Effect
, O
have O
been I-Adverse_event.Trigger
reported I-Adverse_event.Trigger
in O
patients I-Subject
in O
the O
analogous O
agent O
, O
propranolol I-Treatment.Drug
. O

This O
is O
an O
image O
and O
brief O
case O
report O
of O
a I-Subject
13 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
boy I-Subject.Gender
who O
presented O
with O
severe I-Effect
rash I-Effect
and I-Effect
systemic I-Effect
symptoms I-Effect
after I-Adverse_event.Trigger
starting O
oxcarbazepine I-Treatment.Drug
. O

Renal I-Effect
damage I-Effect
associated I-Adverse_event.Trigger
with O
long O
term O
use O
of O
lithium I-Treatment.Drug
carbonate I-Treatment.Drug
. I-Drug

Triamcinolone I-Treatment.Combination.Drug
acetonide I-Treatment.Combination.Drug
induced I-Adverse_event.Trigger
secondary I-Effect
adrenal I-Effect
insufficiency I-Effect
related O
to O
impaired O
CYP3A4 O
metabolism O
by O
coadministration I-Treatment
of I-Treatment
nefazodone I-Treatment.Combination.Drug
. O

Hepatocellular I-Effect
damage I-Effect
following I-Adverse_event.Trigger
therapeutic O
intravenous I-Treatment.Route
iron I-Treatment.Drug
sucrose I-Treatment.Drug
infusion I-Treatment.Route
in O
a I-Subject
child I-Subject.Age
. O

We O
report O
a I-Subject
43 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
woman I-Subject.Gender
who O
developed I-Adverse_event.Trigger
sore I-Effect
throat I-Effect
, I-Effect
swelling I-Effect
of I-Effect
the I-Effect
lips I-Effect
and I-Effect
oral I-Effect
cavity I-Effect
and I-Effect
dysphagia I-Effect
, O
2 I-Treatment.Time_elapsed
weeks I-Treatment.Time_elapsed
after I-Treatment.Time_elapsed
the I-Treatment
use I-Treatment
of I-Treatment
budesonide I-Treatment.Drug
spray I-Treatment.Route
( I-Treatment
Budefat I-Treatment.Drug
) I-Treatment
for O
treatment O
of O
bronchial I-Treat_Disorder
asthma I-Treat_Disorder
. I-Treat_Disorder

Among O
the O
risk O
factors O
studied O
, O
two O
appear I-Adverse_event.Trigger
to I-Adverse_event.Trigger
increase I-Effect
the I-Effect
risk I-Effect
of I-Effect
ARE I-Effect
: O
the O
prescription I-Treatment
of I-Treatment
thiabendazole I-Treatment.Drug
to O
treat O
strongyloidiasis I-Treat_Disorder
during I-Treatment
the I-Treatment
melarsoprol I-Treatment.Drug
cure I-Treatment
and O
the O
bad O
general O
clinical O
conditions O
of O
patients O
. O

Review O
of O
this O
and O
previously O
reported O
cases O
indicates O
the O
need O
for O
early O
diagnosis O
of O
amiodarone O
pneumonitis I-Treat_Disorder
, O
immediate I-Treatment
withdrawal I-Treatment
of I-Treatment
amiodarone I-Treatment.Drug
, I-Treatment
and I-Treatment
prompt I-Treatment
but I-Treatment
continued I-Treatment
steroid I-Treatment.Drug
therapy I-Treatment
to O
ensure O
full O
recovery I-Potential_therapeutic_event.Trigger
. O

Review O
of O
this O
and O
previously O
reported O
cases O
indicates O
the O
need O
for O
early O
diagnosis O
of I-Adverse_event.Trigger
amiodarone I-Treatment.Drug
pneumonitis I-Effect
, O
immediate O
withdrawal O
of O
amiodarone O
, O
and O
prompt O
but O
continued O
steroid O
therapy O
to O
ensure O
full O
recovery O
. O

A O
second O
possibility O
is O
an O
interaction I-Treatment
between I-Treatment
clarithromycin I-Treatment.Combination.Drug
and I-Treatment
isradipine I-Treatment.Combination.Drug
, O
potentially O
increasing I-Adverse_event.Trigger
the O
hepatic I-Effect
toxicity I-Effect
of O
isradipine O
. O

We O
report O
two I-Subject.Population
cases I-Subject
of O
cerebrospinal I-Effect
fluid I-Effect
eosinophilia I-Effect
( I-Effect
CSFE I-Effect
) I-Effect
secondary I-Adverse_event.Trigger
to O
the O
intraventricular I-Treatment.Route
administration I-Treatment
of I-Treatment
vancomycin I-Treatment.Drug
. O

We O
describe O
two I-Subject.Population
patients I-Subject
who O
experienced I-Adverse_event.Trigger
serious I-Effect
quetiapine I-Effect
adverse I-Effect
effects I-Effect
potentially O
mediated O
through O
an O
interaction O
with O
ritonavir I-Treatment.Combination.Drug
- I-Treatment
boosted I-Treatment
atazanavir I-Treatment.Combination.Drug
. O

The O
patient I-Subject
was O
diagnosed O
with O
carbamazepine I-Effect
toxicity I-Effect
related I-Adverse_event.Trigger
to O
the O
introduction O
of O
ritonavir I-Treatment.Drug
. O

Caution O
should O
be O
exercised O
, O
especially O
in O
patients I-Subject
who O
are O
given O
voriconazole I-Combination.Drug
or O
fluconazole I-Combination.Drug
during O
long O
- O
lasting O
fentanyl I-Treatment
treatment O
, O
because O
insidiously O
elevated O
fentanyl I-Drug
concentration O
may O
lead I-Adverse_event.Trigger
to O
respiratory I-Effect
depression I-Effect
. O

This O
review O
presents O
the O
first O
case O
series O
of O
DIC I-Effect
associated I-Effect
with I-Effect
acute I-Effect
hemoglobinemia I-Effect
or I-Effect
hemoglobinuria I-Effect
following I-Adverse_event.Trigger
anti I-Treatment.Drug
- I-Treatment.Drug
D I-Treatment.Drug
IGIV I-Treatment.Route
administration I-Treatment.Route
for O
ITP I-Treat_Disorder
. O

Risperidone I-Treatment.Drug
is O
a O
frequently O
used O
member O
of O
a O
new O
class O
of O
atypical O
antipsychotics O
- O
the O
serotonin O
- O
dopamine O
antagonists O
( O
SDAs) O
- O
due O
to O
its O
comparatively O
high O
efficacy O
and O
low O
D2/5HT2 O
binding O
ratio O
, O
which O
results I-Adverse_event.Trigger
in O
a O
low O
incidence O
of O
extrapyramidal O
side O
effects O
including O
tardive I-Effect
dyskinesia I-Effect
( O
TD O
) O
. O

A I-Subject
5 I-Subject.Age
- I-Subject.Age
month I-Subject.Age
- I-Subject.Age
old I-Subject.Age
infant I-Subject.Age
became I-Adverse_event.Trigger
lethargic I-Effect
and I-Effect
poorly I-Effect
responsive I-Effect
after O
receiving I-Treatment
1 I-Treatment.Dosage
drop I-Treatment.Dosage
of I-Treatment
brimonidine I-Treatment.Drug
in I-Treatment.Route
each I-Treatment.Route
eye I-Treatment.Route
. O

The O
authors O
report O
2 I-Subject.Population
cases I-Subject
of O
renal I-Effect
damage I-Effect
associated I-Adverse_event.Trigger
with O
lithium I-Treatment.Drug
carbonate I-Treatment.Drug
treatment I-Treatment
. O

It O
was O
hypothesized O
that O
valproic I-Treatment.Combination.Drug
acid I-Treatment.Combination.Drug
may I-Treatment
interfere I-Treatment
with I-Treatment
glucuronidation I-Treatment
of I-Treatment
lamotrigine I-Treatment.Combination.Drug
, O
leading I-Adverse_event.Trigger
to O
increased I-Effect
serum I-Effect
lamotrigine I-Effect
levels I-Effect
, I-Effect
or I-Effect
perhaps I-Effect
alter I-Effect
the I-Effect
drug I-Effect
's I-Effect
metabolism I-Effect
, I-Effect
resulting I-Effect
in I-Effect
accumulation I-Effect
of I-Effect
a I-Effect
toxic I-Effect
intermediate I-Effect
metabolite I-Effect
. O

Portal I-Effect
vein I-Effect
thrombosis I-Effect
in O
a I-Subject
patient I-Subject
with I-Subject
severe I-Subject
haemophilia I-Subject.Sub_Disorder
A I-Subject.Sub_Disorder
and I-Subject.Sub_Disorder
F I-Subject.Sub_Disorder
V I-Subject.Sub_Disorder
G1691A I-Subject.Sub_Disorder
mutation I-Subject.Sub_Disorder
during I-Adverse_event.Trigger
continuous I-Treatment.Route
infusion I-Treatment.Route
of I-Treatment
F I-Treatment.Drug
VIII I-Treatment.Drug
after O
intramural I-Treat_Disorder
jejunal I-Treat_Disorder
bleeding I-Treat_Disorder
-- O
successful O
thrombolysis O
under O
heparin O
therapy O
. O

Portal I-Treat_Disorder
vein I-Treat_Disorder
thrombosis I-Treat_Disorder
in O
a O
patient O
with O
severe O
haemophilia O
A O
and O
F O
V O
G1691A O
mutation O
during O
continuous O
infusion O
of O
F O
VIII O
after O
intramural O
jejunal O
bleeding O
-- O
successful I-Effect
thrombolysis I-Effect
under O
heparin I-Treatment.Drug
therapy I-Potential_therapeutic_event.Trigger
. O

A I-Subject
healthy I-Subject
, I-Subject
30 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
man I-Subject.Gender
, O
exposed I-Adverse_event.Trigger
to O
sulindac I-Treatment.Drug
on O
two O
separate O
occasions O
, O
had O
an O
incapacitating I-Effect
isolated I-Effect
idential I-Effect
sensory I-Effect
neuropathy I-Effect
. O

Clofibrate I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
myopathy I-Effect
in O
patients I-Subject
with I-Subject
diabetes I-Treat_Disorder
insipidus I-Treat_Disorder
. O

This O
is O
the I-Subject
first I-Subject
histologically I-Subject
confirmed I-Subject
case I-Subject
of O
NASH I-Effect
that O
was O
aggravated I-Adverse_event.Trigger
by O
raloxifene I-Treatment.Drug
. O

To O
date O
, O
eight O
cases O
of O
TEN I-Effect
and O
one O
of O
SJS I-Effect
related I-Adverse_event.Trigger
to O
lamotrigine I-Treatment.Drug
administration O
have O
been O
reported O
in O
the O
literature O
. O

ARA I-Treatment.Drug
- I-Treatment.Drug
C I-Treatment.Drug
is O
frequently O
associated I-Adverse_event.Trigger
with O
dermatologic I-Effect
toxicity I-Effect
, O
but O
this O
is O
only O
the O
second O
case O
of O
toxic O
epidermal O
necrolysis O
described O
in O
connection O
with O
this O
drug O
. O

Hyperglycemia I-Effect
and I-Effect
diabetic I-Effect
coma I-Effect
: O
possible O
relationship O
to I-Adverse_event.Trigger
diuretic O
- O
propranolol I-Treatment.Drug
therapy O
. O

Potential O
mechanisms O
involved O
in O
the O
occurrence I-Adverse_event.Trigger
of O
ischemic I-Effect
colitis I-Effect
in O
patients I-Subject
receiving O
tegaserod I-Treatment.Drug
are O
also O
discussed O
. O

Anaphylaxis I-Effect
to I-Adverse_event.Trigger
intravenous I-Treatment.Route
cyclosporine I-Treatment.Drug
and O
tolerance O
to O
oral O
cyclosporine O
: O
case I-Subject
report O
and O
review O
. O

CASE O
REPORT O
: O
A I-Subject
woman I-Subject.Gender
of I-Subject
80 I-Subject.Age
years I-Subject.Age
, O
on I-Treatment
long I-Treatment.Duration
- I-Treatment.Duration
term I-Treatment.Duration
warfarin I-Treatment.Drug
therapy O
presented I-Adverse_event.Trigger
with O
an O
acute I-Effect
dissecting I-Effect
thoracic I-Effect
aortic I-Effect
aneurysm I-Effect
; O
on O
investigation O
the O
only O
precipitating O
factor O
found O
was O
an O
international O
normalised O
ratio O
of O
4.8 O
. O

A I-Subject
patient I-Subject
with I-Subject
an I-Subject
allergy I-Subject.Sub_Disorder
to I-Subject.Sub_Disorder
a I-Subject.Sub_Disorder
macrolide I-Subject.Sub_Disorder
antibiotic I-Subject.Sub_Disorder
was O
given I-Treatment
tacrolimus I-Treatment.Drug
and O
developed I-Adverse_event.Trigger
a O
sudden I-Effect
cutaneous I-Effect
reaction I-Effect
. O

This O
case O
suggests O
the O
importance O
of O
careful O
observation O
for O
extramedullary I-Effect
relapse I-Effect
in O
patients I-Subject
who O
are O
treated I-Adverse_event.Trigger
with O
ATRA I-Treatment.Drug
. O

Olanzapine I-Treatment.Drug
- O
associated I-Adverse_event.Trigger
neuroleptic I-Effect
malignant I-Effect
syndrome I-Effect
. O

Acute I-Effect
dystonia I-Effect
induced I-Adverse_event.Trigger
by O
lamivudine I-Treatment.Drug
. O

We O
report O
in O
detail O
an O
unusual O
adverse O
reaction O
to O
infliximab I-Treatment.Drug
therapy O
, O
a O
drug O
- O
induced I-Adverse_event.Trigger
lupus I-Effect
- I-Effect
like I-Effect
clinical I-Effect
syndrome I-Effect
. O

RESULTS O
: O
Quetiapine I-Treatment.Drug
was O
associated I-Adverse_event.Trigger
with O
leucopenia I-Effect
in O
two I-Subject.Population
patients I-Subject
and O
clinically O
apparent O
agranulocytosis O
in O
one O
patient O
. O

RESULTS O
: O
Quetiapine I-Treatment.Drug
was O
associated I-Adverse_event.Trigger
with O
leucopenia O
in O
two O
patients O
and O
clinically I-Effect
apparent I-Effect
agranulocytosis I-Effect
in O
one I-Subject.Population
patient I-Subject
. O

Oral I-Treatment.Route
intake I-Treatment.Route
and I-Treatment
acarbose I-Treatment.Drug
were O
withheld O
and O
the I-Effect
ileus I-Effect
spontaneously I-Effect
resolved I-Effect
after I-Adverse_event.Trigger
2 O
days O
. O

No O
explanation O
for O
this O
delay O
was O
found O
, O
other O
than O
the O
possibility O
that O
magnesium I-Treatment.Drug
sulfate I-Treatment.Drug
treatment O
impeded I-Adverse_event.Trigger
lactogenesis I-Effect
. O

Although O
its O
side O
effects O
are O
few O
, O
tamoxifen I-Treatment.Drug
increases I-Adverse_event.Trigger
the O
incidence I-Effect
of I-Effect
proliferative I-Effect
lesions I-Effect
of I-Effect
the I-Effect
endometrium I-Effect
, O
which O
theoretically O
should O
be O
preventable O
with O
progestational O
agents O
. O

Three I-Subject.Population
senile I-Subject.Age
patients I-Subject
developed I-Adverse_event.Trigger
fatal O
acute O
encephalopathy I-Effect
while O
receiving O
calcium I-Treatment.Drug
hopantenate I-Treatment.Drug
. O

Renal I-Effect
injury I-Effect
due I-Adverse_event.Trigger
to O
anastrozole I-Treatment.Drug
has O
not O
been O
published O
in O
the O
English O
literature O
. O

Facial I-Effect
, I-Effect
tongue I-Effect
, I-Effect
and I-Effect
arm I-Effect
movements I-Effect
were O
first O
reported O
approximately O
five I-Time_elapsed
weeks I-Time_elapsed
after I-Adverse_event.Trigger
the O
initiation I-Treatment
of I-Treatment
aripiprazole I-Treatment.Drug
. O

Restless I-Effect
legs I-Effect
syndrome I-Effect
due I-Adverse_event.Trigger
to O
interferon I-Treatment.Drug
- I-Treatment.Drug
alpha I-Treatment.Drug
. O

HUS I-Effect
has O
been O
reported I-Adverse_event.Trigger
after O
several I-Treatment
anticancer I-Treatment
chemotherapies I-Treatment
and I-Treatment
most I-Treatment
often I-Treatment
after I-Treatment
mitomycin I-Treatment.Drug
C I-Treatment.Drug
- I-Treatment
based I-Treatment
chemotherapy I-Treatment
regimens I-Treatment
. O

Although O
the O
association I-Adverse_event.Trigger
between O
SJS I-Effect
/ I-Effect
TEN I-Effect
and O
the O
sulfonamide I-Treatment.Drug
class I-Treatment.Drug
of I-Treatment.Drug
antibiotics I-Treatment.Drug
is O
well O
established O
, O
the O
increasing O
prevalence O
of O
CA I-Subject.Sub_Disorder
- I-Subject.Sub_Disorder
MRSA I-Subject.Sub_Disorder
has O
left O
practitioners O
with O
limited O
regimens O
to O
effectively O
treat O
skin I-Treat_Disorder
and I-Treat_Disorder
soft I-Treat_Disorder
tissue I-Treat_Disorder
infections I-Treat_Disorder
( I-Treat_Disorder
SSTIs I-Treat_Disorder
) I-Treat_Disorder
in O
the O
outpatient O
setting O
. O

Acute I-Effect
non I-Effect
- I-Effect
lymphocytic I-Effect
leukemia I-Effect
occurred I-Adverse_event.Trigger
in O
eight I-Subject.Population
women I-Subject.Gender
following O
long O
- O
term O
treatment O
with O
Treosulfan I-Treatment.Drug
(= I-Treatment
dihydroxybusulfan I-Treatment.Drug
) I-Treatment
for O
ovarian I-Treat_Disorder
carcinoma I-Treat_Disorder
. O

Elderly I-Subject.Age
patients I-Subject
for O
whom O
nitrate I-Treatment.Drug
has O
been O
prescribed O
should O
be O
warned O
of O
the O
occurrence I-Adverse_event.Trigger
of O
hypotension I-Effect
, O
leading O
to O
unconsciousness I-Effect
. O

A O
patient O
receiving O
vancomycin I-Treatment.Drug
for O
a O
serious I-Treat_Disorder
staphylococcal I-Treat_Disorder
infection I-Treat_Disorder
had I-Adverse_event.Trigger
a I-Effect
lupus I-Effect
- I-Effect
like I-Effect
syndrome I-Effect
characterized I-Effect
by I-Effect
a I-Effect
malar I-Effect
rash I-Effect
, I-Effect
pain I-Effect
and I-Effect
erythema I-Effect
of I-Effect
the I-Effect
cartilage I-Effect
of I-Effect
both I-Effect
ears I-Effect
, I-Effect
and I-Effect
tender I-Effect
erythematous I-Effect
and I-Effect
hemorrhagic I-Effect
lesions I-Effect
of I-Effect
the I-Effect
finger I-Effect
tips I-Effect
. O

Seven I-Subject.Population
patients I-Subject
with I-Subject
hematologic I-Subject.Sub_Disorder
malignancies I-Subject.Sub_Disorder
who O
were O
treated O
with O
miconazole I-Treatment.Drug
for O
either O
suspected O
or O
proven O
fungal I-Treat_Disorder
infections I-Treat_Disorder
developed I-Adverse_event.Trigger
eight I-Effect
episodes I-Effect
of I-Effect
major I-Effect
adverse I-Effect
cardiorespiratory I-Effect
and I-Effect
anaphylactic I-Effect
reactions I-Effect
. O

We O
report O
the O
first O
case O
, O
to O
our O
knowledge O
, O
of O
rituximab I-Treatment.Drug
- O
related I-Adverse_event.Trigger
autoimmune I-Effect
hemolytic I-Effect
anemia I-Effect
. O

Anaphylactoid I-Effect
reactions I-Effect
with I-Adverse_event.Trigger
intraperitoneal I-Treatment.Route
cisplatin I-Treatment.Drug
. O

Tremor I-Effect
: O
a O
newly O
described O
adverse O
event O
with I-Adverse_event.Trigger
long I-Treatment.Duration
- I-Treatment.Duration
term I-Treatment.Duration
itraconazole I-Treatment.Drug
therapy I-Treatment
. O

Treatment O
- O
related O
myelodysplastic I-Effect
syndrome I-Effect
after I-Adverse_event.Trigger
temozolomide I-Treatment.Drug
for O
recurrent I-Treat_Disorder
high I-Treat_Disorder
- I-Treat_Disorder
grade I-Treat_Disorder
glioma I-Treat_Disorder
. O

It O
occasionally O
accompanies O
the O
heparin I-Treatment.Drug
- O
associated I-Adverse_event.Trigger
thrombocytopenia I-Effect
and I-Effect
thrombosis I-Effect
syndrome I-Effect
. O

We O
report O
an I-Subject
unusual I-Subject
case I-Subject
of O
massive I-Treatment.Dosage
fluoxetine I-Treatment.Drug
ingestion I-Treatment.Route
resulting I-Adverse_event.Trigger
in I-Adverse_event.Trigger
neurological I-Effect
and I-Effect
cardiovascular I-Effect
toxicity I-Effect
resulting I-Effect
in I-Effect
death I-Effect
. O

Although O
dyspnea O
associated O
with O
verapamil O
administration O
has O
been O
reported O
, O
this O
is O
the O
first O
report O
of O
an I-Subject
elderly I-Subject.Age
asymptomatic I-Subject.Sub_Disorder
asthmatic I-Subject.Sub_Disorder
patient I-Subject
with I-Subject
hypertension I-Treat_Disorder
who O
developed I-Adverse_event.Trigger
an I-Effect
acute I-Effect
asthma I-Effect
attack I-Effect
following O
sustained I-Treatment.Drug
- I-Treatment.Drug
release I-Treatment.Drug
verapamil I-Treatment.Drug
administration I-Treatment
. O

The I-Treat_Disorder
bleeding I-Treat_Disorder
resolved I-Potential_therapeutic_event.Trigger
on O
discontinuation I-Treatment
of I-Treatment
APV I-Treatment.Drug
. O

We O
describe O
a O
case O
of O
infection I-Effect
with I-Effect
Mycobacterium I-Effect
abscessus I-Effect
in O
a I-Subject
67 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
woman I-Subject.Gender
receiving I-Adverse_event.Trigger
infliximab I-Treatment.Drug
as I-Treatment
a I-Treatment
component I-Treatment
of I-Treatment
her I-Treatment
therapy I-Treatment
for O
RA I-Treat_Disorder
. O

Renal I-Effect
toxicities I-Effect
have O
been O
reported I-Adverse_event.Trigger
in O
less I-Subject.Population
than I-Subject.Population
one I-Subject.Population
percent I-Subject.Population
of I-Subject
the I-Subject
patients I-Subject
receiving O
ciprofloxacin I-Treatment.Drug
therapy I-Treatment
. I-Treatment

Taxane I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
glaucoma I-Effect
. O

Ciprofloxacin I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
toxic I-Effect
epidermal I-Effect
necrolysis I-Effect
in O
a I-Subject
patient I-Subject
with I-Subject
systemic I-Treat_Disorder
lupus I-Treat_Disorder
erythematosus I-Treat_Disorder
. I-Subject

Hypotension I-Effect
due I-Adverse_event.Trigger
to I-Adverse_event.Trigger
interaction I-Treatment
between I-Treatment
lisinopril I-Treatment.Combination.Drug
and I-Treatment
tizanidine I-Treatment.Combination.Drug
. O

Development O
of O
an O
extensive I-Effect
skin I-Effect
rash I-Effect
following I-Adverse_event.Trigger
a O
single O
dose O
of O
MTX I-Treatment.Drug
may O
be O
an O
early O
warning O
sign O
for O
life O
- O
threatening O
bone O
marrow O
aplasia O
. O

Anaphylactoid I-Effect
reaction I-Effect
to I-Adverse_event.Trigger
50 I-Treatment
% I-Treatment
solution I-Treatment
of I-Treatment
dextrose I-Treatment.Drug
. O

Hypokalemia I-Effect
after I-Adverse_event.Trigger
normal I-Treatment.Dosage
doses I-Treatment.Dosage
of I-Treatment
neubulized I-Treatment
albuterol I-Treatment.Drug
( I-Treatment
salbutamol I-Treatment.Drug
) I-Treatment
. O

Although O
praziquantel I-Treatment.Drug
administration O
may O
have O
been O
effective O
in O
killing O
the O
parasite I-Treat_Disorder
in I-Subject
both I-Subject.Population
patients I-Subject
, O
we O
are O
concerned O
about O
the O
production I-Adverse_event.Trigger
of O
marked I-Effect
inflammation I-Effect
as O
a O
result O
of O
treatment O
. O

We O
describe O
a I-Subject
patient I-Subject
who O
developed I-Adverse_event.Trigger
granulocytopenia I-Effect
and I-Effect
fever I-Effect
after O
taking I-Treatment
dipyrone I-Treatment.Drug
and O
discuss O
the O
available O
literature O
. O

Spectral O
- O
domain O
optical O
coherence O
tomography O
and O
adaptive O
optics O
may O
detect O
hydroxychloroquine I-Treatment.Drug
retinal O
toxicity O
before I-Adverse_event.Trigger
symptomatic I-Effect
vision I-Effect
loss I-Effect
. O

A I-Subject
64 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
man I-Subject.Gender
presented O
with O
proteinuria I-Effect
during I-Adverse_event.Trigger
postoperative I-Treatment
interferon I-Treatment.Drug
( I-Treatment.Drug
IFN) I-Treatment.Drug
- I-Treatment.Drug
beta I-Treatment.Drug
therapy I-Treatment
against O
malignant I-Treat_Disorder
melanoma I-Treat_Disorder
. O

Ethambutol I-Treatment.Drug
toxicity I-Adverse_event.Trigger
manifesting O
as O
acute I-Effect
onset I-Effect
psychosis I-Effect
. O

Cholesterol I-Effect
crystal I-Effect
embolization I-Effect
- I-Effect
associated I-Effect
renal I-Effect
failure I-Effect
after I-Adverse_event.Trigger
therapy I-Treatment
with I-Treatment
recombinant I-Treatment
tissue I-Treatment
- I-Treatment
type I-Treatment
plasminogen I-Treatment.Drug
activator I-Treatment.Drug
. O

METHODS O
: O
A I-Subject
76 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
woman I-Subject.Gender
with I-Subject
primary I-Subject
open I-Treat_Disorder
- I-Treat_Disorder
angle I-Treat_Disorder
glaucoma I-Treat_Disorder
and I-Subject
no I-Subject
history I-Subject
of I-Subject
ocular I-Subject
surgery I-Subject
developed I-Adverse_event.Trigger
a O
choroidal I-Effect
detachment I-Effect
12 I-Treatment.Time_elapsed
hours I-Treatment.Time_elapsed
after I-Treatment
initiation I-Treatment
of I-Treatment
therapy I-Treatment
with I-Treatment
dorzolamide I-Treatment.Drug
eye I-Treatment.Route
drops I-Treatment.Route
. O

Life O
- O
threatening O
hyperkalemia I-Effect
induced I-Adverse_event.Trigger
by O
arginine I-Treatment.Drug
. O

We O
report O
on O
three I-Subject.Population
patients I-Subject
who O
developed I-Adverse_event.Trigger
acute I-Effect
liver I-Effect
damage I-Effect
during O
therapy O
with O
itraconazole I-Treatment.Drug
, O
and O
in O
whom O
liver O
biopsy O
specimens O
were O
obtained O
. O

METHODS O
: O
A I-Subject
68 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
man I-Subject.Gender
developed I-Adverse_event.Trigger
intense I-Effect
conjunctival I-Effect
hyperemia I-Effect
and I-Effect
cystoid I-Effect
macula I-Effect
edema I-Effect
after O
switching O
from O
latanoprost O
to O
bimatoprost I-Treatment.Drug
9 O
months O
after O
cataract I-Treat_Disorder
surgery I-Treat_Disorder
in O
an O
eye O
at O
low O
- O
risk O
for O
this O
cystoid O
macular O
edema O
. O

Tacrolimus I-Treatment.Drug
( I-Treatment
FK506 I-Treatment
) I-Treatment
, I-Treatment
an I-Treatment
immunosuppressant I-Treatment
, O
has O
been O
associated I-Adverse_event.Trigger
with I-Adverse_event.Trigger
mutism I-Effect
in O
adults I-Subject.Age
after I-Subject
liver I-Subject.Sub_Disorder
transplant I-Subject.Sub_Disorder
. I-Sub_Disorder

Gemcitabine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
pulmonary I-Effect
toxicity I-Effect
is O
usually O
a O
dramatic O
condition O
. O

However O
, O
the O
amount O
of O
prednisone I-Treatment.Drug
required O
to I-Treatment
maintain I-Treatment
normotension I-Treatment
resulted I-Adverse_event.Trigger
in I-Adverse_event.Trigger
Cushingoid I-Effect
features I-Effect
and O
has O
been O
discontinued O
. O

We O
present O
the O
case O
of O
a I-Subject
woman I-Subject.Gender
undergoing O
treatment I-Potential_therapeutic_event.Trigger
with O
acenocoumarol I-Treatment.Drug
for O
deep I-Treat_Disorder
vein I-Treat_Disorder
thrombosis I-Treat_Disorder
, O
who O
maintained O
an O
international O
normalized O
ratio O
( O
INR O
) O
of O
between O
2.5 O
and O
4 O
for O
2 O
months O
. O

Development I-Effect
of I-Effect
tics I-Effect
in O
a I-Subject
thirteen I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
male I-Subject.Gender
following I-Adverse_event.Trigger
atomoxetine I-Treatment.Drug
use O
. O

OBJECTIVE O
: O
To O
report O
a O
case O
of O
chronic I-Effect
, I-Effect
nonproductive I-Effect
cough I-Effect
secondary I-Effect
to I-Effect
the I-Effect
angiotensin I-Effect
- I-Effect
converting I-Effect
enzyme I-Effect
( I-Effect
ACE I-Effect
) I-Effect
inhibitor I-Effect
quinapril I-Effect
, O
with O
complete O
resolution I-Potential_therapeutic_event.Trigger
after O
switching I-Treatment
to I-Treatment
another I-Treatment
ACE I-Treatment
inhibitor I-Treatment
, I-Treatment
fosinopril I-Treatment.Drug
. O

Cholelithiasis I-Effect
and I-Effect
thrombosis I-Effect
of I-Effect
the I-Effect
central I-Effect
retinal I-Effect
vein I-Effect
in I-Adverse_event.Trigger
a I-Subject
renal I-Subject.Sub_Disorder
transplant I-Subject.Sub_Disorder
recipient I-Subject
treated O
with O
cyclosporin I-Treatment.Drug
. O

We O
report O
a O
case O
of O
hepatolithiasis I-Effect
( I-Effect
intrahepatic I-Effect
stone I-Effect
) I-Effect
complicated I-Effect
by I-Effect
gram I-Effect
- I-Effect
negative I-Effect
sepsis I-Effect
in I-Adverse_event.Trigger
a I-Subject
37 I-Subject.Age
year I-Subject.Age
old I-Subject.Age
male I-Subject.Gender
with I-Subject
acromegaly I-Treat_Disorder
being O
treated O
with O
octreotide I-Treatment.Drug
. O

Proliferation I-Effect
of I-Effect
abnormal I-Effect
bone I-Effect
marrow I-Effect
histiocytes I-Effect
, O
an O
undesired I-Adverse_event.Trigger
effect I-Adverse_event.Trigger
of O
granulocyte I-Treatment.Drug
macrophage I-Treatment.Drug
- I-Treatment.Drug
colony I-Treatment.Drug
- I-Treatment.Drug
stimulating I-Treatment.Drug
factor I-Treatment.Drug
therapy O
in O
a I-Subject
patient I-Subject
with I-Subject
Hurler I-Treat_Disorder
's I-Treat_Disorder
syndrome I-Treat_Disorder
undergoing O
bone O
marrow O
transplantation O
. O

We O
report O
4 O
patients O
, O
2 O
on O
methylphenidate O
and O
2 I-Subject
on O
dextroamphetamine I-Treatment.Drug
who O
presented I-Adverse_event.Trigger
with O
acral I-Effect
cyanosis I-Effect
, I-Effect
livedo I-Effect
reticularis I-Effect
, I-Effect
or I-Effect
Raynaud I-Effect
phenomenon I-Effect
. O

We O
report O
4 I-Subject
patients I-Subject
, I-Subject
2 I-Subject
on I-Subject
methylphenidate I-Treatment.Drug
and O
2 O
on O
dextroamphetamine O
who O
presented I-Adverse_event.Trigger
with O
acral I-Effect
cyanosis I-Effect
, I-Effect
livedo I-Effect
reticularis I-Effect
, I-Effect
or I-Effect
Raynaud I-Effect
phenomenon I-Effect
. O

Described O
here O
are O
2 I-Subject.Population
patients I-Subject
who O
developed O
thrombotic I-Effect
microangiopathy I-Effect
of I-Effect
the I-Effect
kidneys I-Effect
after O
receiving I-Adverse_event.Trigger
high I-Dosage
cumulative I-Dosage
doses I-Dosage
of O
the O
new O
anticancer O
drug O
gemcitabine I-Treatment.Drug
. O

CONCLUSIONS O
: O
An O
objective O
causality O
assessment O
revealed O
that O
fluphenazine I-Treatment.Drug
was O
the O
probable O
cause I-Adverse_event.Trigger
of O
NMS I-Effect
in O
this O
patient I-Subject
. O

Like O
other O
atypical O
neuroleptics O
olanzapine I-Treatment.Drug
is O
considered O
to O
show I-Adverse_event.Trigger
a O
reduced I-Effect
prevalence I-Effect
of I-Effect
extrapyramidal I-Effect
side I-Effect
effects I-Effect
when O
compared O
to O
classical O
neuroleptic I-Drug
drugs I-Drug
. I-Drug

Based O
on O
our O
experience O
and O
on O
previously O
published O
data O
, O
serum O
ammonia O
levels O
appear O
to O
be O
indicated O
in O
all I-Subject
ED I-Treat_Disorder
patients I-Subject
on O
valproic I-Treatment.Drug
acid I-Treatment.Drug
therapy I-Treatment
who O
present I-Adverse_event.Trigger
with O
altered I-Effect
mental I-Effect
status I-Effect
. O

Rapamycin I-Treatment.Drug
/ I-Treatment.Drug
sirolimus I-Treatment.Drug
( I-Treatment
SR I-Treatment
) I-Treatment
, I-Treatment
trade I-Treatment
named I-Treatment
Rapammune I-Treatment
( I-Treatment
Wyeth I-Treatment
- I-Treatment
Ayerst I-Treatment
, I-Treatment
Sydney I-Treatment
, I-Treatment
Australia I-Treatment
) I-Treatment
, O
is O
a O
potent O
immunosuppressive O
drug O
associated I-Adverse_event.Trigger
with O
myelosuppression I-Effect
, I-Effect
hypertension I-Effect
, I-Effect
hyperlipidemia I-Effect
, I-Effect
and I-Effect
infection I-Effect
. O

Enoxaparin I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
generalized I-Effect
exanthem I-Effect
. O

Our O
cases O
constitute O
the O
most O
severe O
cases O
of I-Adverse_event.Trigger
benzarone I-Treatment.Drug
hepatotoxicity I-Effect
reported O
so O
far O
, O
and O
comprise O
the O
first O
cases O
of O
( I-Effect
sub)fulminant I-Effect
hepatitis I-Effect
and I-Effect
cirrhosis I-Effect
related O
to O
benzarone I-Drug
. O

Within I-Treatment
3 I-Treatment.Duration
days I-Treatment.Duration
after I-Treatment
starting I-Treatment
bismuth I-Treatment.Drug
subsalicylate I-Treatment.Drug
therapy I-Treatment
, O
the I-Subject
patient I-Subject
's O
INR I-Effect
increased I-Effect
from I-Effect
2.56 I-Effect
to I-Effect
3.54 I-Effect
and I-Effect
minor I-Effect
bleeding I-Effect
was I-Effect
noted I-Effect
from I-Effect
the I-Effect
patient I-Effect
's I-Effect
tracheostomy I-Effect
site I-Effect
. O

After I-Treatment
three I-Treatment.Duration
weeks I-Treatment.Duration
of I-Treatment
carbamazepine I-Treatment.Drug
therapy I-Treatment
, O
the O
patient I-Subject
arrived O
at O
the O
emergency O
department O
( O
ED O
) O
with O
severe I-Effect
agitation I-Effect
and I-Effect
aggressive I-Effect
behavior I-Effect
. O

OBJECTIVE O
: O
To O
report O
a O
case O
of O
ciprofloxacin I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
psychosis I-Effect
and O
to O
discuss O
occurrence O
rates O
, O
risk O
factors O
, O
possible O
etiologies O
, O
preventive O
measures O
, O
and O
treatment O
courses O
for O
this O
adverse O
reaction O
. O

A I-Subject
77 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
man I-Subject.Gender
developed I-Adverse_event.Trigger
ankle I-Effect
, I-Effect
hand I-Effect
, I-Effect
and I-Effect
facial I-Effect
swelling I-Effect
2 I-Treatment.Time_elapsed
weeks I-Treatment.Time_elapsed
after I-Treatment
starting I-Treatment
rosiglitazone I-Treatment.Drug
. O

Although O
rare O
, O
massive I-Effect
pulmonary I-Effect
embolus I-Effect
must O
be O
considered O
to O
be O
a O
major O
risk I-Adverse_event.Trigger
of O
thrombolytic I-Treatment.Drug
therapy O
for O
deep O
venous O
thrombosis O
. O

We O
report O
a O
case O
of O
hypoglycaemia I-Effect
after I-Adverse_event.Trigger
mefloquine I-Treatment.Drug
therapy I-Treatment
( I-Treatment
1,500 I-Treatment.Dosage
mg I-Treatment.Dosage
over I-Treatment
two I-Treatment
days I-Treatment
) I-Treatment
for O
severe I-Treat_Disorder
gastrointestinal I-Treat_Disorder
cryptosporidiasis I-Treat_Disorder
in O
a I-Subject
cachectic I-Subject.Sub_Disorder
AIDS I-Subject.Sub_Disorder
patient I-Subject
with I-Subject
protracted I-Subject.Sub_Disorder
diarrhoea I-Subject.Sub_Disorder
. O

OBJECTIVE O
: O
To O
describe O
onset O
of O
syndrome I-Effect
of I-Effect
inappropriate I-Effect
antidiuretic I-Effect
hormone I-Effect
( I-Effect
SIADH I-Effect
) I-Effect
associated I-Adverse_event.Trigger
with I-Adverse_event.Trigger
vinorelbine I-Treatment.Drug
therapy O
for O
advanced I-Treat_Disorder
breast I-Treat_Disorder
cancer I-Treat_Disorder
. O

The O
thiazolidinediones I-Treatment
( O
rosiglitazone O
and O
pioglitazone O
) O
, O
a O
new O
class O
of O
oral O
antidiabetic O
agents O
, O
are O
" O
insulin O
sensitizers O
" O
and O
exert I-Potential_therapeutic_event.Trigger
direct O
effects O
on O
the O
mechanisms O
of O
insulin I-Treat_Disorder
resistance I-Treat_Disorder
. O

The O
exacerbation I-Effect
of I-Effect
psoriasis I-Effect
was O
accompanied O
by O
a I-Effect
massive I-Effect
induction I-Effect
of I-Effect
lesional I-Effect
type I-Effect
I I-Effect
interferon I-Effect
activity I-Effect
, O
detected I-Adverse_event.Trigger
by O
MxA O
expression O
after O
imiquimod I-Treatment.Drug
therapy O
. O

Two I-Subject.Population
patients I-Subject
treated O
with O
alprazolam I-Treatment.Drug
had O
histories O
suggestive O
of O
a I-Sub_Disorder
bipolar I-Sub_Disorder
disorder I-Sub_Disorder
and O
developed I-Adverse_event.Trigger
lithium I-Effect
- I-Effect
responsive I-Effect
manic I-Effect
episodes I-Effect
. O

Cerebrovascular I-Effect
complications I-Effect
of O
L I-Treatment.Drug
- I-Treatment.Drug
asparaginase I-Treatment.Drug
therapy O
in O
children I-Subject.Age
with I-Subject
leukemia I-Treat_Disorder
: O
aphasia I-Effect
and I-Effect
other I-Effect
neuropsychological I-Effect
deficits I-Effect
. O

We O
report O
two I-Subject.Population
patients I-Subject
who O
developed O
intense I-Effect
livedo I-Effect
reticularis I-Effect
clearly O
related I-Adverse_event.Trigger
to O
the O
administration O
of O
interferon I-Treatment.Drug
alpha I-Treatment.Drug
2b I-Treatment.Drug
as I-Treatment
an I-Treatment
adjuvant I-Treatment
therapy I-Treatment
for I-Treatment
melanoma I-Treatment.Treat_Disorder
. O

A O
case O
of O
SIADH I-Effect
associated I-Adverse_event.Trigger
with O
desipramine I-Treatment.Drug
treatment I-Treatment
in O
an I-Subject
elderly I-Subject.Age
depressed I-Treat_Disorder
woman I-Subject.Gender
is O
described O
. O

Niflumic I-Treatment.Drug
acid I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
skeletal I-Effect
fluorosis I-Effect
: O
iatrogenic O
disease O
or O
therapeutic O
perspective O
for O
osteoporosis O
? O

Both I-Subject
patients I-Subject
developed I-Adverse_event.Trigger
severe I-Effect
complications I-Effect
when O
treated O
with O
aminoglutethimide I-Treatment.Drug
as O
a O
cancer I-Treat_Disorder
hormonal O
therapy O
. O

An I-Subject
11 I-Subject.Age
- I-Subject.Age
day I-Subject.Age
- I-Subject.Age
old I-Subject.Age
infant I-Subject.Age
became I-Adverse_event.Trigger
lethargic I-Effect
and I-Effect
apneic I-Effect
after O
a I-Treatment
single I-Treatment.Dosage
drop I-Treatment.Dosage
of I-Treatment
brimonidine I-Treatment.Drug
. O

Investigations O
suggested O
that O
the O
dextrose I-Treatment.Drug
, O
rather O
than O
any O
additives O
, O
was O
responsible I-Adverse_event.Trigger
for O
the I-Effect
reaction I-Effect
. O

Since O
renal I-Treat_Disorder
insufficiency I-Treat_Disorder
was O
induced O
by O
AMPH O
and O
the O
other O
antifungal O
drugs O
were O
ineffective O
, O
daily I-Treatment.Freq
administration I-Treatment.Freq
of I-Treatment
200 I-Treatment.Dosage
mg I-Treatment.Dosage
of I-Treatment
ITCZ I-Treatment.Drug
was O
initiated I-Potential_therapeutic_event.Trigger
, O
and O
the I-Effect
inflammatory I-Effect
signs I-Effect
and I-Effect
symptoms I-Effect
gradually I-Effect
subsided I-Effect
. I-Effect

Since O
renal I-Effect
insufficiency I-Effect
was O
induced I-Adverse_event.Trigger
by O
AMPH I-Treatment.Drug
and O
the O
other O
antifungal O
drugs O
were O
ineffective O
, O
daily O
administration O
of O
200 O
mg O
of O
ITCZ O
was O
initiated O
, O
and O
the O
inflammatory O
signs O
and O
symptoms O
gradually O
subsided O
. O

Correction O
of O
serum O
electrolyte O
imbalance O
prevents O
cardiac I-Effect
arrhythmia I-Effect
during I-Adverse_event.Trigger
amphotericin I-Treatment.Drug
B I-Treatment.Drug
administration I-Treatment
. O

Acute I-Effect
myopathy I-Effect
with I-Effect
selective I-Effect
degeneration I-Effect
of I-Effect
myosin I-Effect
filaments I-Effect
following I-Adverse_event.Trigger
status O
asthmaticus I-Treat_Disorder
treated O
with O
methylprednisolone I-Treatment.Combination.Drug
and O
vecuronium I-Treatment.Combination.Drug
. O

Presented O
is O
a O
case O
of O
acute I-Effect
renal I-Effect
failure I-Effect
induced I-Adverse_event.Trigger
by O
acetazolamide I-Treatment.Drug
therapy I-Treatment
for I-Treatment
glaucoma I-Treatment.Treat_Disorder
. O

Cyanamide I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
liver I-Effect
dysfunction I-Effect
after O
abstinence I-Subject
in I-Subject
alcoholics I-Subject
: O
a O
long O
- O
term O
follow O
- O
up O
study O
on O
four O
cases O
. O

Fewer O
subjects O
reported O
adverse O
events O
following O
treatment O
with O
desipramine I-Drug
alone O
than O
when O
receiving O
desipramine I-Combination.Drug
with O
cinacalcet I-Combination.Drug
( O
33 O
versus O
86 O
% O
) O
, O
the O
most O
frequent O
of O
which O
( O
nausea I-Effect
and I-Effect
headache I-Effect
) O
have O
been O
reported I-Adverse_event.Trigger
for O
patients I-Subject
treated O
with O
either O
desipramine I-Treatment.Drug
or I-Treatment
cinacalcet I-Treatment.Drug
. O

Three I-Subject.Population
patients I-Subject
developed O
proteinuria I-Effect
following I-Adverse_event.Trigger
gold I-Treatment.Drug
therapy O
for O
rheumatoid I-Treat_Disorder
arthritis I-Treat_Disorder
. O

The O
authors O
report O
a I-Subject
case I-Subject
of I-Subject
a I-Subject
patient I-Subject
who O
received O
alteplase I-Treatment.Drug
for O
acute I-Treat_Disorder
myocardial I-Treat_Disorder
infarction I-Treat_Disorder
and O
developed I-Adverse_event.Trigger
spontaneous I-Effect
subfascial I-Effect
hematoma I-Effect
without I-Effect
any I-Effect
evidence I-Effect
of I-Effect
direct I-Effect
trauma I-Effect
. O

Ticlopidine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
marrow I-Effect
aplasia I-Effect
treated O
with O
cyclosporine O
. O

Dural I-Effect
sinus I-Effect
thrombosis I-Effect
developed I-Adverse_event.Trigger
in O
two I-Subject.Population
children I-Subject.Age
with I-Subject
acute I-Treat_Disorder
lymphoblastic I-Treat_Disorder
leukemia I-Treat_Disorder
during O
induction I-Treatment
treatment I-Treatment
with I-Treatment
vincristine I-Treatment.Combination.Drug
sulfate I-Treatment.Combination.Drug
, I-Treatment
prednisone I-Treatment.Combination.Drug
, I-Treatment
and I-Treatment
asparaginase I-Treatment.Combination.Drug
. O

Zolpidem I-Treatment.Drug
( I-Treatment
Ambien I-Treatment
) I-Treatment
, O
a O
relatively O
new O
nonbenzodiazepine O
sedative O
- O
hypnotic O
, O
was O
involved I-Adverse_event.Trigger
in O
the O
death I-Effect
of O
a I-Subject
39 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
obese I-Subject.Sub_Disorder
male I-Subject.Gender
who O
was O
being O
treated O
for O
depression I-Treat_Disorder
and I-Treat_Disorder
insomnia I-Treat_Disorder
. O

A O
MEDLINE O
search O
identified O
all O
the O
reported O
cases O
of O
hypersensitivity I-Effect
reactions I-Effect
to O
cyclosporine I-Treatment.Drug
. O

METHODS O
: O
A I-Subject
79 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
woman I-Subject.Gender
being O
treated O
with O
imiquimod I-Treatment.Drug
5 I-Treatment.Freq
days I-Treatment.Freq
per I-Treatment.Freq
week I-Treatment.Freq
for O
a O
nodular I-Treat_Disorder
basal I-Treat_Disorder
cell I-Treat_Disorder
developed I-Adverse_event.Trigger
a O
verrucous I-Effect
plaque I-Effect
over O
the O
treatment O
area O
after I-Treatment
7 I-Treatment.Time_elapsed
weeks I-Treatment.Time_elapsed
of O
therapy O
. O

Oxcarbazepine I-Treatment.Drug
, O
a O
metabolite O
of O
carbamazepine O
, O
is O
used I-Potential_therapeutic_event.Trigger
as O
an O
antiepileptic I-Effect
, I-Effect
analgesic I-Effect
for O
neuropathic I-Treat_Disorder
pain I-Treat_Disorder
and O
in O
the O
treatment O
of O
affective I-Treat_Disorder
disorders I-Treat_Disorder
. O

PATIENT O
AND O
METHOD O
: O
A I-Subject
34 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
woman I-Subject.Gender
with I-Subject
chronic I-Treat_Disorder
hepatitis I-Treat_Disorder
C I-Treat_Disorder
, I-Subject
genotype I-Subject.Sub_Disorder
3 I-Subject.Sub_Disorder
, O
receiving O
pegylated I-Treatment.Combination.Drug
interferon I-Treatment.Combination.Drug
alpha I-Treatment.Combination.Drug
- I-Treatment.Combination.Drug
2a I-Treatment.Combination.Drug
and I-Treatment
ribavirin I-Treatment.Combination.Drug
for I-Treatment
6 I-Treatment.Duration
months I-Treatment.Duration
, O
developed I-Adverse_event.Trigger
progressive I-Effect
malaise I-Effect
and I-Effect
anemia I-Effect
6 I-Time_elapsed
months I-Time_elapsed
after O
the O
end O
of O
treatment O
. O

We O
report O
on O
three O
cases O
wherein O
treatment I-Treatment
of I-Treatment
dexmedetomidine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
bradycardia I-Effect
with I-Effect
i.v I-Effect
. O

Esmolol I-Treatment.Drug
, I-Treatment
an I-Treatment
ultrashort I-Treatment
- I-Treatment
acting I-Treatment
beta I-Treatment
1 I-Treatment
- I-Treatment
selective I-Treatment
antagonist I-Treatment
, O
controlled I-Potential_therapeutic_event.Trigger
her I-Subject
multiple I-Treat_Disorder
dysrhythmias I-Treat_Disorder
and I-Treat_Disorder
symptoms I-Treat_Disorder
of I-Treat_Disorder
sympathetic I-Treat_Disorder
nervous I-Treat_Disorder
system I-Treat_Disorder
hyperstimulation I-Treat_Disorder
. O

( O
Case O
1 O
) O
A I-Subject
29 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
woman I-Subject.Gender
with O
overdose I-Dosage
of O
metaxalone I-Treatment.Drug
presented I-Adverse_event.Trigger
to O
the O
emergency O
department O
with O
altered I-Effect
mental I-Effect
status I-Effect
, I-Effect
seizure I-Effect
- I-Effect
like I-Effect
activity I-Effect
, I-Effect
hyperthermia I-Effect
, I-Effect
rigidity I-Effect
in I-Effect
the I-Effect
lower I-Effect
extremities I-Effect
, I-Effect
myoclonus I-Effect
, I-Effect
and I-Effect
hyperreflexia I-Effect
. O

Warfarin I-Treatment.Combination.Drug
and O
boceprevir I-Treatment.Combination.Drug
interaction O
causing I-Adverse_event.Trigger
subtherapeutic I-Effect
international I-Effect
normalized I-Effect
ratio I-Effect
: O
a O
case O
report O
. O

A O
brief O
review O
of O
reported O
cases O
of I-Adverse_event.Trigger
chloramphenicol I-Treatment.Drug
hypersensitivity I-Effect
in O
the O
English O
- O
language O
literature O
, O
as O
well O
as O
possible O
alternative O
explanations O
in O
this O
case O
, O
are O
provided O
. O

Possible O
recurrence O
of O
amiodarone I-Drug
pulmonary I-Effect
toxicity I-Effect
following I-Adverse_event.Trigger
corticosteroid I-Treatment.Drug
therapy O
. O

In O
the O
present O
study O
, O
arsenic I-Treatment.Drug
trioxide I-Treatment.Drug
was O
given I-Potential_therapeutic_event.Trigger
intravenously O
for O
42 I-Duration
days I-Duration
to O
a O
56 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
female I-Subject.Gender
patient I-Subject
suffering O
from O
chemotherapy I-Treat_Disorder
/ I-Treat_Disorder
ATRA I-Treat_Disorder
- I-Treat_Disorder
resistant I-Treat_Disorder
APL I-Treat_Disorder
, O
with O
43 O
% O
APL O
blasts O
in O
the O
bone O
marrow O
and O
elevated O
D O
- O
dimers O
. O

We O
assume O
that O
rIFN I-Treatment.Drug
- I-Treatment.Drug
gamma I-Treatment.Drug
induced I-Adverse_event.Trigger
the I-Effect
de I-Effect
novo I-Effect
development I-Effect
of I-Effect
SLE I-Effect
in O
our I-Subject
patient I-Subject
. O

Interstitial I-Effect
pneumopathy I-Effect
and I-Adverse_event.Trigger
low I-Treatment.Dosage
- I-Treatment.Dosage
dosage I-Treatment.Dosage
amiodarone I-Treatment.Drug
. O

CONCLUSIONS O
: O
These O
results O
suggest O
that O
clozapine I-Treatment.Drug
may O
cause I-Adverse_event.Trigger
TD I-Effect
; O
however O
, O
the O
prevalence O
is O
low O
and O
the O
severity O
is O
relatively O
mild O
, O
with O
no O
or O
mild O
self O
- O
reported O
discomfort O
. O

Hepatotoxicity I-Treat_Disorder
resolved O
once O
erlotinib I-Treatment.Drug
was O
discontinued I-Potential_therapeutic_event.Trigger
and O
serum O
transaminases O
returned O
to O
baseline O
normal O
values O
. O

CONCLUSIONS O
: O
Sustained I-Treatment
- I-Treatment
release I-Treatment
verapamil I-Treatment.Drug
is O
thought O
to O
be O
the O
cause I-Adverse_event.Trigger
of O
the O
asthma I-Effect
attack I-Effect
in O
this O
patient O
because O
she O
was O
not O
taking O
any O
other O
preparations O
; O
the O
symptoms O
started O
with O
the O
administration O
of O
sustained O
- O
release O
verapamil O
and O
were O
relieved O
after O
its O
discontinuation O
. O

A O
patient O
developed I-Adverse_event.Trigger
cholestatic I-Effect
hepatitis I-Effect
while O
being O
treated O
with O
nitrofurantoin I-Treatment.Drug
. O

Severe O
apnea I-Effect
in I-Adverse_event.Trigger
an I-Subject
infant I-Subject.Age
exposed O
to O
lamotrigine I-Treatment.Drug
in O
breast I-Route
milk I-Route
. O

Pneumonitis I-Effect
, I-Effect
bilateral I-Effect
pleural I-Effect
effusions I-Effect
, I-Effect
echocardiographic I-Effect
evidence I-Effect
of I-Effect
cardiac I-Effect
tamponade I-Effect
, I-Effect
and I-Effect
positive I-Effect
autoantibodies I-Effect
developed I-Adverse_event.Trigger
in O
a I-Subject
43 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
man I-Subject.Gender
, O
who O
was O
receiving O
long I-Treatment
- I-Treatment
term I-Treatment
sulfasalazine I-Treatment.Drug
therapy O
for O
chronic I-Treat_Disorder
ulcerative I-Treat_Disorder
colitis I-Treat_Disorder
. O

Bone I-Effect
formation I-Effect
induced I-Potential_therapeutic_event.Trigger
in O
an I-Subject
infant I-Subject.Age
by O
systemic I-Treatment.Route
prostaglandin I-Treatment.Drug
- I-Treatment.Drug
E2 I-Treatment.Drug
administration I-Treatment.Route
. O

A I-Treatment
high I-Treatment.Dosage
dose I-Treatment.Dosage
of I-Treatment
cotrimoxazole I-Treatment.Drug
induced O
hyperkalaemia O
with O
the O
elevation O
of O
serum O
creatinine O
and O
blood O
urea O
, O
and O
increased O
urinary O
N O
- O
acetyl O
glucosaminase O
after I-Treatment
several I-Treatment.Time_elapsed
days I-Treatment.Time_elapsed
of I-Treatment
the I-Treatment
drug I-Treatment
administration I-Treatment
in O
these O
patients O
; O
one I-Subject.Population
patient I-Subject
became I-Adverse_event.Trigger
unconscious I-Effect
. O

A I-Treatment
high I-Treatment.Dosage
dose I-Treatment.Dosage
of I-Treatment
cotrimoxazole I-Treatment.Drug
induced I-Adverse_event.Trigger
hyperkalaemia I-Effect
with I-Effect
the I-Effect
elevation I-Effect
of I-Effect
serum I-Effect
creatinine I-Effect
and I-Effect
blood I-Effect
urea I-Effect
, I-Effect
and I-Effect
increased I-Effect
urinary I-Effect
N I-Effect
- I-Effect
acetyl I-Effect
glucosaminase I-Effect
after I-Treatment
several I-Treatment.Time_elapsed
days I-Treatment.Time_elapsed
of I-Treatment
the I-Treatment
drug I-Treatment
administration I-Treatment
in O
these I-Subject
patients I-Subject
; O
one O
patient O
became O
unconscious O
. O

Angioedema I-Effect
, O
a O
rare O
side O
effect O
of I-Adverse_event.Trigger
carbamazepine I-Treatment.Drug
, O
involves I-Effect
vascular I-Effect
leakage I-Effect
in I-Effect
dermis I-Effect
and I-Effect
subcutis I-Effect
mediated I-Effect
by I-Effect
immunoglobulin I-Effect
E I-Effect
and/or I-Effect
bradykinins I-Effect
. O

A O
diagnosis O
of O
trastuzumab I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
pneumonitis I-Effect
was O
made O
. O

We O
present O
a O
case O
of O
HUS I-Effect
in O
an O
advanced I-Treat_Disorder
ovarian I-Treat_Disorder
cancer I-Treat_Disorder
patient O
treated I-Adverse_event.Trigger
with O
carboplatin I-Treatment.Combination.Drug
and I-Treatment
gemcitabine I-Treatment.Combination.Drug
, O
and O
described O
its O
favorable O
outcome O
after O
chemotherapy O
interruption O
and O
supportive O
care O
with O
a O
1 O
year O
follow O
- O
up O
. O

We O
present O
a O
case O
of O
HUS I-Treat_Disorder
in O
an I-Subject
advanced I-Subject
ovarian I-Subject
cancer I-Subject
patient I-Subject
treated O
with O
carboplatin O
and O
gemcitabine O
, O
and O
described O
its O
favorable I-Effect
outcome I-Effect
after I-Potential_therapeutic_event.Trigger
chemotherapy I-Treatment
interruption I-Treatment
and I-Treatment
supportive I-Treatment
care I-Treatment
with I-Treatment
a I-Treatment
1 I-Treatment
year I-Treatment
follow I-Treatment
- I-Treatment
up I-Treatment
. O

Several I-Effect
such I-Effect
HBV I-Effect
reactivations I-Effect
were O
reported O
after I-Adverse_event.Trigger
combined I-Treatment
rituximab I-Treatment.Drug
and I-Treatment
multiagent I-Treatment
chemotherapy I-Treatment.Route
for O
B I-Treat_Disorder
- I-Treat_Disorder
cell I-Treat_Disorder
lymphomas I-Treat_Disorder
. O

Thus O
, O
the O
eosinophilia I-Effect
myalgia I-Effect
syndrome I-Effect
can O
be O
associated I-Adverse_event.Trigger
with O
parenteral I-Treatment.Route
tryptophan I-Treatment.Drug
administration O
. O

Generalized I-Effect
pustular I-Effect
psoriasis I-Effect
precipitated I-Adverse_event.Trigger
by O
trazodone I-Treatment.Drug
in O
the O
treatment O
of O
depression I-Treat_Disorder
. O

We O
report O
a O
case O
of O
Sweet I-Effect
's I-Effect
syndrome I-Effect
in O
association I-Adverse_event.Trigger
with O
sargramostim I-Treatment.Drug
treatment I-Treatment
following I-Treatment
chemotherapy I-Treatment.Route
for O
acute I-Treat_Disorder
myelogenous I-Treat_Disorder
leukemia I-Treat_Disorder
. O

This O
regimen O
could O
prove O
useful O
for O
other O
patients I-Subject
who O
develop I-Adverse_event.Trigger
hypersensitivity I-Effect
reactions I-Effect
to O
carboplatin I-Treatment.Drug
and O
allow O
therapy O
to O
continue O
. O

We O
present O
a I-Subject
neonate I-Subject.Age
with I-Subject
a I-Subject
seizure I-Treat_Disorder
disorder I-Treat_Disorder
who O
acutely O
developed I-Adverse_event.Trigger
pupillary I-Effect
mydriasis I-Effect
secondary O
to O
lidocaine I-Treatment.Drug
overdose I-Treatment.Dosage
. O

Based O
on O
the O
Naranjo O
algorithm O
, O
the O
adverse O
reaction O
observed O
was O
probably O
related I-Adverse_event.Trigger
to O
the O
hydroxyurea I-Drug
treatment O
( O
score O
= O
6 O
) O
; O
however O
, O
the O
hydroxyurea I-Treatment.Drug
chemotherapy I-Treatment.Route
could O
not O
be O
discontinued O
because O
of O
the O
myeloproliferative I-Effect
disorder I-Effect
. O

Extrapyramidal I-Effect
side I-Effect
effects I-Effect
induced I-Adverse_event.Trigger
by I-Adverse_event.Trigger
some I-Treatment
selective I-Treatment
serotonin I-Treatment.Drug
reuptake I-Treatment.Drug
inhibitors I-Treatment.Drug
( I-Treatment
SSRIs I-Treatment
) I-Treatment
, I-Treatment
i.e. I-Treatment
fluoxetine I-Treatment.Drug
and I-Treatment
sertraline I-Treatment.Drug
, O
have O
been O
previously O
reported O
in O
patients I-Subject
with I-Subject
depression I-Treat_Disorder
and I-Subject
obsessive I-Treat_Disorder
- I-Treat_Disorder
compulsive I-Treat_Disorder
disorder I-Treat_Disorder
( I-Treat_Disorder
OCD I-Treat_Disorder
) I-Treat_Disorder
. O

Ten I-Treatment.Time_elapsed
- I-Treatment.Time_elapsed
17 I-Treatment.Time_elapsed
days I-Treatment.Time_elapsed
after I-Treatment
receiving I-Treatment
chemotherapy I-Treatment.Route
, O
five I-Subject.Population
patients I-Subject
( I-Subject
4 I-Subject.Gender
males I-Subject.Gender
and I-Subject.Gender
1 I-Subject.Gender
female I-Subject.Gender
) I-Subject
with I-Subject
acute I-Treat_Disorder
lymphoblastic I-Treat_Disorder
leukemia I-Treat_Disorder
developed I-Adverse_event.Trigger
incapacitating I-Effect
myalgias I-Effect
in I-Effect
neck I-Effect
, I-Effect
thighs I-Effect
and I-Effect
arms I-Effect
. O

We O
report O
a O
case O
of O
a O
potential O
drug O
- O
drug O
interaction O
in O
a I-Subject
woman I-Subject.Gender
treated I-Potential_therapeutic_event.Trigger
by O
a I-Treatment
first I-Treatment
injection I-Treatment.Route
of I-Treatment
high I-Treatment.Dosage
- I-Treatment.Dosage
dose I-Treatment.Dosage
methotrexate I-Treatment.Drug
for O
a I-Treat_Disorder
T I-Treat_Disorder
- I-Treat_Disorder
lymphoblastic I-Treat_Disorder
lymphoma I-Treat_Disorder
. O

We O
conclude O
that O
myocardial I-Effect
infarction I-Effect
may O
develop I-Adverse_event.Trigger
in O
patients I-Subject
treated O
with O
high I-Treatment.Dosage
- I-Treatment.Dosage
dose I-Treatment.Dosage
glucocorticoids I-Treatment.Drug
for O
Graves I-Treat_Disorder
' I-Treat_Disorder
ophthalmopathy I-Treat_Disorder
, O
and O
increased I-Effect
blood I-Effect
pressure I-Effect
may O
herald O
this O
complication O
. O

A O
40 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
man I-Subject.Gender
with I-Subject
relapsing I-Treat_Disorder
- I-Treat_Disorder
remitting I-Treat_Disorder
multiple I-Treat_Disorder
sclerosis I-Treat_Disorder
( I-Treat_Disorder
MS I-Treat_Disorder
) I-Treat_Disorder
developed I-Adverse_event.Trigger
primary I-Effect
central I-Effect
nervous I-Effect
system I-Effect
lymphoma I-Effect
( I-Effect
PCNSL I-Effect
) I-Effect
after O
having O
received O
21 I-Treatment.Dosage
doses I-Treatment.Dosage
of I-Treatment
natalizumab I-Treatment.Drug
monotherapy I-Treatment
. O

Serotonin I-Effect
syndrome I-Effect
caused I-Adverse_event.Trigger
by O
selective I-Treatment.Combination.Drug
serotonin I-Treatment.Combination.Drug
reuptake I-Treatment.Combination.Drug
- I-Treatment.Combination.Drug
inhibitors I-Treatment.Combination.Drug
- I-Treatment
metoclopramide I-Treatment.Combination.Drug
interaction I-Treatment
. O

This O
is O
the O
first I-Subject
reported I-Subject
case I-Subject
of O
suspected O
DIAN I-Effect
due I-Adverse_event.Trigger
to I-Adverse_event.Trigger
cefuroxime I-Treatment.Drug
. O

We O
report O
a I-Subject
cae I-Subject
of O
paranoid I-Effect
psychosis I-Effect
following I-Adverse_event.Trigger
use O
of O
a O
decongestant I-Treatment
containing I-Treatment
PPA I-Treatment.Drug
and O
summarize O
the O
case O
report O
literature O
of O
psychiatric O
adverse O
effects O
to O
PPA O
in O
which O
doses O
were O
known O
and O
stated O
to O
be O
within O
recommended O
guidelines O
. O

Liver I-Effect
transplantation I-Effect
for I-Effect
fulminant I-Effect
hepatitis I-Effect
related I-Adverse_event.Trigger
to O
nevirapine I-Treatment.Drug
therapy I-Treatment
. O

OBJECTIVE O
: O
To O
report O
a O
case O
of O
fatal O
hyperkalemia I-Effect
owing I-Adverse_event.Trigger
to O
succinylcholine I-Treatment.Drug
administration I-Treatment
in O
a I-Subject
patient I-Subject
with I-Subject
mucositis I-Treat_Disorder
secondary I-Subject
to I-Subject
chemotherapy I-Subject
. O

OBJECTIVE O
: O
To O
report O
a O
case O
of O
fatal O
hyperkalemia O
owing O
to O
succinylcholine O
administration O
in O
a I-Subject
patient I-Subject
with O
mucositis I-Effect
secondary I-Adverse_event.Trigger
to O
chemotherapy I-Treatment.Drug
. O

We O
describe O
a I-Subject
case I-Subject
of O
prolonged I-Treatment
terbinafine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
cholestatic I-Effect
liver I-Effect
disease I-Effect
. O

We O
describe O
a O
case O
of O
interstitial I-Effect
hypoxaemiant I-Effect
pneumonitis I-Effect
probably O
related I-Adverse_event.Trigger
to O
flecainide I-Treatment.Drug
in O
a I-Subject
patient I-Subject
with I-Subject
the I-Subject
LEOPARD I-Treat_Disorder
syndrome I-Treat_Disorder
, O
a O
rare O
congenital O
disorder O
. O

This I-Subject
case I-Subject
showed O
sequential O
manifestation O
from O
transient O
thyrotoxicosis O
to O
the O
appearance O
of O
TSH O
- O
receptor O
autoantibodies O
, O
and O
then O
the O
occurrence I-Adverse_event.Trigger
of O
Graves I-Effect
' I-Effect
hyperthyroidism I-Effect
during O
IFN I-Treatment.Drug
therapy I-Treatment
. O

Halothane I-Treat_Disorder
hepatitis I-Treat_Disorder
and O
prompt O
resolution I-Potential_therapeutic_event.Trigger
with O
methionine I-Treatment.Drug
therapy O
: O
case I-Subject
report O
. O

This O
report O
describes O
an O
unexpected O
drug O
- O
induced O
hepatitis I-Effect
in O
a I-Subject
previously I-Subject
healthy I-Subject
young I-Subject.Gender
woman I-Subject.Gender
exposed I-Adverse_event.Trigger
to O
2 I-Treatment.Dosage
doses I-Treatment.Dosage
of I-Treatment
amodiaquine I-Treatment.Combination.Drug
and I-Treatment
artesunate I-Treatment.Combination.Drug
. O

It O
was O
restarted O
6 O
weeks O
later O
, O
and O
10 I-Treatment.Time_elapsed
weeks I-Treatment.Time_elapsed
after I-Treatment.Time_elapsed
that O
, O
the I-Subject
patient I-Subject
presented I-Adverse_event.Trigger
with O
fulminant I-Effect
hepatic I-Effect
failure I-Effect
, O
which O
resolved O
rapidly O
after O
cessation O
of O
nicotinic I-Treatment.Drug
acid I-Treatment.Drug
therapy O
. O

We O
describe O
a I-Subject
patient I-Subject
with I-Subject
the I-Subject
antiphospholipid I-Treat_Disorder
syndrome I-Treat_Disorder
who O
had O
skin I-Effect
necrosis I-Effect
develop I-Adverse_event.Trigger
from O
low I-Treatment.Drug
- I-Treatment.Drug
molecular I-Treatment.Drug
weight I-Treatment.Drug
heparin I-Treatment.Drug
therapy I-Treatment
at I-Treatment
sites I-Treatment
distant I-Treatment
from I-Treatment
injection I-Treatment.Route
sites I-Treatment
. O

While O
CYP O
form O
induction I-Adverse_event.Trigger
by O
Pyrethrins I-Treatment.Combination.Drug
, I-Treatment
Phenobarbital I-Treatment.Combination.Drug
and I-Treatment
related I-Treatment.Combination.Drug
compounds I-Treatment.Combination.Drug
can O
be O
associated O
with O
liver I-Effect
and I-Effect
thyroid I-Effect
gland I-Effect
tumour I-Effect
formation I-Effect
in I-Effect
rodents I-Effect
, O
epidemiological O
data O
for O
Phenobarbital O
suggests O
that O
such O
effects O
do O
not O
occur O
in O
humans O
. O

Disulfiram I-Treatment.Drug
encephalopathy I-Effect
as O
a O
cause I-Adverse_event.Trigger
of O
the O
catatonia I-Effect
syndrome I-Effect
. O

Little O
has O
been O
studied O
of O
the O
adverse I-Effect
effects I-Effect
of I-Effect
the I-Effect
exposure I-Effect
of I-Effect
the I-Effect
liver I-Effect
to O
the O
interaction I-Adverse_event.Trigger
of O
ethanol I-Treatment.Combination.Drug
with I-Treatment
its I-Treatment
congeners I-Treatment
and I-Treatment
acetaldehyde I-Treatment.Combination.Drug
, O
coexisting O
in O
the O
contents O
of O
alcoholic O
beverages O
. O

Fatal O
serotonin I-Effect
syndrome I-Effect
precipitated I-Adverse_event.Trigger
by O
oxcarbazepine I-Treatment.Drug
in O
a I-Subject
patient I-Subject
using O
an O
selective O
serotonin O
reuptake O
inhibitor O
. O

This O
eruption I-Effect
emerged I-Adverse_event.Trigger
after I-Treatment
1 I-Treatment.Time_elapsed
month I-Treatment.Time_elapsed
of I-Treatment
therapy I-Treatment
with I-Treatment
salsalate I-Treatment.Drug
, O
persisted O
for O
as O
long O
as O
salsalate O
was O
administered O
, O
and O
cleared O
within O
3 O
weeks O
of O
discontinuing O
the O
medication O
. O

A O
case O
report O
is O
presented O
concerning O
the O
administration O
of O
ketanserin O
in O
the O
treatment O
of O
pulmonary I-Effect
vasoconstriction I-Effect
and I-Effect
right I-Effect
ventricular I-Effect
failure I-Effect
following I-Adverse_event.Trigger
the O
infusion I-Treatment.Route
of I-Treatment
protamine I-Treatment.Drug
in O
a I-Subject
patient I-Subject
undergoing I-Treatment
coronary I-Treatment
artery I-Treatment
bypass I-Treatment
surgery I-Treatment
and I-Treatment
mitral I-Treatment
valve I-Treatment
replacement I-Treatment
. O

When O
cyanamide I-Treatment.Drug
- I-Subject
treated I-Subject
alcoholics I-Treat_Disorder
relapse O
into O
drinking O
, O
more O
severe O
inflammation I-Effect
develops I-Adverse_event.Trigger
in O
the O
liver O
. O

Acute I-Effect
renal I-Effect
failure I-Effect
should O
be O
recognized O
as O
a O
potential O
complication I-Adverse_event.Trigger
of O
suramin I-Treatment.Drug
treatment I-Treatment
. O

After I-Adverse_event.Trigger
induction I-Treatment
of I-Treatment
general I-Treatment.Combination.Drug
anesthesia I-Treatment.Combination.Drug
and I-Treatment
administration I-Treatment
of I-Treatment
a I-Treatment
standard I-Treatment
dose I-Treatment
of I-Treatment
intravenous I-Treatment.Route
esmolol I-Treatment.Combination.Drug
hydrochloride I-Treatment.Combination.Drug
, O
her I-Subject.Gender
cardiac O
rhythm O
progressed O
to O
asystole I-Effect
. O

Exacerbation I-Effect
of I-Effect
schizophrenia I-Effect
associated I-Adverse_event.Trigger
with O
amantadine I-Treatment.Drug
. O

Priapism I-Effect
as O
a O
complication I-Adverse_event.Trigger
of O
heparin I-Treatment.Drug
therapy O
. O

Torsades I-Effect
de I-Effect
pointes I-Effect
occurring O
in O
association I-Adverse_event.Trigger
with O
terfenadine I-Treatment.Drug
use O
. O

Protamine I-Effect
allergy I-Effect
as O
a O
complication I-Adverse_event.Trigger
of O
insulin I-Treatment.Drug
hypersensitivity I-Effect
: O
A O
case O
report O
. O

We O
report O
a O
case O
of O
recurrent I-Effect
torsades I-Effect
de I-Effect
pointes I-Effect
following O
treatment I-Adverse_event.Trigger
with I-Adverse_event.Trigger
pentavalent I-Treatment.Combination.Drug
antimonial I-Treatment.Combination.Drug
drugs I-Treatment.Combination.Drug
and I-Treatment
amiodarone I-Treatment.Combination.Drug
. O

This O
case O
presentation O
is O
of O
a I-Subject
patient I-Subject
who O
had O
the O
clinical I-Effect
appearance I-Effect
of I-Effect
epiglottitis I-Effect
, O
but O
actually I-Effect
had I-Effect
an I-Effect
oro I-Effect
- I-Effect
pharyngeal I-Effect
dystonic I-Effect
reaction I-Effect
to O
prochlorperazine I-Treatment.Drug
. O

Localized I-Effect
dyskeratotic I-Effect
plaque I-Effect
with I-Effect
milia I-Effect
associated I-Adverse_event.Trigger
with O
sorafenib I-Treatment.Drug
. O

The O
authors O
describe O
a O
case O
of O
the O
catatonia I-Effect
syndrome I-Effect
associated I-Adverse_event.Trigger
with O
disulfiram I-Treatment.Drug
therapy I-Treatment
. O

Most O
of O
the O
clinical O
data O
on O
the O
safety O
profile O
of O
desmopressin I-Treatment.Drug
( I-Treatment
DDAVP I-Treatment
) I-Treatment
, O
which O
is O
an O
effective O
treatment I-Potential_therapeutic_event.Trigger
for O
both I-Subject
polyuric I-Treat_Disorder
conditions I-Treat_Disorder
and I-Subject
bleeding I-Treat_Disorder
disorders I-Treat_Disorder
, O
originate O
from O
studies O
on O
the O
tailoring O
of O
drug O
treatment O
, O
whereas O
few O
reports O
exist O
describing O
severe O
side O
effects O
secondary O
to O
drug O
- O
drug O
interaction O
. O

Propafenone I-Treatment.Drug
's O
distribution O
, O
clearance O
, O
and O
structural O
similarity O
to O
propranolol I-Drug
contribute I-Potential_therapeutic_event.Trigger
to O
its O
central I-Effect
nervous I-Effect
system I-Effect
effects I-Effect
. O

Risk O
of O
severe O
serotonin I-Effect
toxicity I-Effect
following I-Adverse_event.Trigger
co I-Treatment
- I-Treatment
administration I-Treatment
of I-Treatment
methylene I-Treatment.Combination.Drug
blue I-Treatment.Combination.Drug
and I-Treatment
serotonin I-Treatment.Combination.Drug
reuptake I-Treatment.Combination.Drug
inhibitors I-Treatment.Combination.Drug
: O
an O
update O
on O
a O
case O
report O
of O
post I-Effect
- I-Effect
operative I-Effect
delirium I-Effect
. O

Cyclophosphamide I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
cardiotoxicity I-Effect
occurred O
, O
even O
though O
the I-Subject
patient I-Subject
had I-Subject
both I-Subject
shown I-Subject
normal I-Subject
cardiac I-Subject
function I-Subject
before O
high I-Treatment
- I-Treatment
dose I-Treatment
chemotherapy I-Treatment
and I-Treatment
had I-Treatment
received I-Treatment
a I-Treatment
lower I-Treatment.Dosage
dose I-Treatment.Dosage
of I-Treatment
cyclophosphamide I-Treatment
. O

A I-Subject
64 I-Subject.Age
year I-Subject.Age
old I-Subject.Age
woman I-Subject.Gender
with I-Subject
previous I-Subject
history I-Subject
of I-Subject
coronary I-Treat_Disorder
stenting I-Treat_Disorder
five I-Treatment.Time_elapsed
days I-Treatment.Time_elapsed
before I-Treatment
was O
admitted O
in O
our O
institution O
for O
intracranial I-Effect
bleeding I-Effect
while O
receiving I-Adverse_event.Trigger
aspirin I-Treatment.Combination.Drug
and I-Treatment
clopidogrel I-Treatment.Combination.Drug
. O

METHODS O
: O
A O
case O
is O
presented O
of O
a I-Subject
45 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
woman I-Subject.Gender
on O
prolonged I-Treatment.Duration
gemcitabine I-Treatment.Drug
treatment I-Treatment
for O
ovarian I-Treat_Disorder
cancer I-Treat_Disorder
who O
developed I-Adverse_event.Trigger
HUS I-Effect
and O
recovered O
after O
drug O
discontinuation O
. O

A O
more O
serious O
development I-Effect
of I-Effect
adrenal I-Effect
insufficiency I-Effect
may O
occur O
upon O
the O
improper O
replacement I-Adverse_event.Trigger
of O
systemic I-Treatment
steroids I-Treatment.Drug
. O

We O
describe O
a I-Subject
case I-Subject
of O
pneumonitis I-Effect
following I-Adverse_event.Trigger
local I-Treatment
administration I-Treatment
of I-Treatment
methotrexate I-Treatment.Drug
for O
nonsurgical O
termination O
of O
an O
ectopic I-Treat_Disorder
pregnancy I-Treat_Disorder
. O

There O
is O
currently O
no O
consensus O
on O
the O
best O
treatment O
for O
unresectable O
hyaline O
- O
vascular O
variant O
or O
for O
multicentric O
Castleman O
's O
disease O
( O
MCD O
) O
, O
because O
none O
of O
the O
reported O
regimens O
have O
consistently O
produced O
complete O
response O
or O
durable O
remission O
in O
the O
majority O
of O
patients O
In O
the O
present O
study O
, O
we O
report O
on O
the O
use I-Potential_therapeutic_event.Trigger
of O
2 I-Treatment.Drug
- I-Treatment.Drug
CdA I-Treatment.Drug
( I-Treatment
2 I-Treatment
- I-Treatment
chloro I-Treatment
- I-Treatment
deoxyadenosine I-Treatment
) I-Treatment
in O
three O
patients O
, O
two I-Subject.Population
of O
them O
with O
MCD I-Treat_Disorder
and O
one O
with O
unresectable I-Treat_Disorder
hyaline I-Treat_Disorder
- I-Treat_Disorder
vascular I-Treat_Disorder
type I-Treat_Disorder
disease I-Treat_Disorder
. O

There O
is O
currently O
no O
consensus O
on O
the O
best O
treatment O
for O
unresectable O
hyaline O
- O
vascular O
variant O
or O
for O
multicentric O
Castleman O
's O
disease O
( O
MCD O
) O
, O
because O
none O
of O
the O
reported O
regimens O
have O
consistently O
produced O
complete O
response O
or O
durable O
remission O
in O
the O
majority O
of O
patients O
In O
the O
present O
study O
, O
we O
report O
on O
the O
use I-Potential_therapeutic_event.Trigger
of O
2 O
- O
CdA O
( O
2 O
- O
chloro O
- O
deoxyadenosine O
) O
in O
three O
patients O
, O
two O
of O
them O
with O
MCD O
and O
one I-Subject.Population
with O
unresectable O
hyaline O
- O
vascular O
type O
disease O
. O

Carbamazepine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
hyperammonemia I-Effect
. O

Case O
3 O
: O
A I-Subject
29 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
female I-Subject.Gender
alcoholic I-Treat_Disorder
complained I-Adverse_event.Trigger
of O
general I-Effect
fatigue I-Effect
and I-Effect
a I-Effect
slight I-Effect
fever I-Effect
after I-Treatment
1.5 I-Treatment.Duration
years I-Treatment.Duration
of I-Treatment
abstinence I-Treatment
with I-Treatment
cyanamide I-Treatment.Drug
treatment O
. O

Caution O
is O
, O
therefore O
, O
needed O
to O
prevent O
undesired O
accumulation O
of O
TCA I-Treatment.Drug
that O
may O
lead I-Adverse_event.Trigger
to I-Adverse_event.Trigger
protracted I-Effect
Cushing I-Effect
's I-Effect
syndrome I-Effect
. O

Unusual I-Effect
pigmentary I-Effect
changes I-Effect
associated I-Adverse_event.Trigger
with O
5 I-Treatment.Drug
- I-Treatment.Drug
fluorouracil I-Treatment.Drug
therapy O
. O

Syndrome I-Effect
of I-Effect
inappropriate I-Effect
antidiuretic I-Effect
hormone I-Effect
associated I-Adverse_event.Trigger
with O
vinorelbine I-Treatment.Drug
therapy O
. O

The O
study O
showed O
a O
high O
incidence O
of O
adverse I-Effect
events I-Effect
when I-Adverse_event.Trigger
a O
higher I-Treatment.Dosage
than I-Treatment.Dosage
standard I-Treatment.Dosage
dose I-Treatment.Dosage
of I-Treatment
the I-Treatment
new I-Treatment
lopinavir I-Treatment.Combination.Drug
/ I-Treatment
ritonavir I-Treatment.Combination.Drug
tablets I-Treatment
was I-Treatment
combined I-Treatment
with I-Treatment
rifampicin I-Treatment.Combination.Drug
. O

Onset I-Adverse_event.Trigger
of O
male I-Subject.Gender
gynaecomastia I-Effect
in O
a I-Subject
patient I-Subject
treated O
with O
sunitinib I-Treatment.Drug
for I-Treatment
metastatic I-Treatment.Treat_Disorder
renal I-Treatment.Treat_Disorder
cell I-Treatment.Treat_Disorder
carcinoma I-Treatment.Treat_Disorder
. O

Systemic I-Effect
disease I-Effect
, I-Effect
most I-Effect
commonly I-Effect
renal I-Effect
dysfunction I-Effect
, O
preceded I-Adverse_event.Trigger
all O
30 I-Subject.Population
reported I-Subject
cases I-Subject
of O
acyclovir I-Treatment.Drug
neurotoxicity I-Effect
. O

Rifampicin I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
renal I-Effect
failure I-Effect
. O

A I-Subject.Population
case I-Subject
of I-Subject
high I-Treat_Disorder
- I-Treat_Disorder
grade I-Treat_Disorder
endometrial I-Treat_Disorder
stromal I-Treat_Disorder
sarcoma I-Treat_Disorder
, I-Treat_Disorder
confined I-Treat_Disorder
into I-Treat_Disorder
an I-Treat_Disorder
intrauterine I-Treat_Disorder
polypoid I-Treat_Disorder
growth I-Treat_Disorder
, I-Subject
in I-Subject
a I-Subject
woman I-Subject.Gender
with I-Subject
a I-Subject
history I-Subject
of I-Subject
breast I-Subject.Sub_Disorder
cancer I-Subject.Sub_Disorder
who O
was O
treated I-Potential_therapeutic_event.Trigger
with O
adjuvant I-Treatment
tamoxifen I-Treatment.Drug
. O

After I-Adverse_event.Trigger
therapy I-Treatment
for I-Treatment
diabetic I-Treatment.Treat_Disorder
coma I-Treatment.Treat_Disorder
with I-Treatment
insulin I-Treatment.Combination.Drug
( I-Treatment
containing I-Treatment
the I-Treatment
preservative I-Treatment.Combination.Drug
cresol I-Treatment.Combination.Drug
) I-Treatment
and I-Treatment
electrolyte I-Treatment.Combination.Drug
solutions I-Treatment.Combination.Drug
was O
started O
, O
the I-Subject
patient I-Subject
complained O
of O
increasing I-Effect
myalgia I-Effect
, I-Effect
developed I-Effect
a I-Effect
high I-Effect
fever I-Effect
and I-Effect
respiratory I-Effect
and I-Effect
metabolic I-Effect
acidosis I-Effect
and I-Effect
lost I-Effect
consciousness I-Effect
. O

A I-Subject
case I-Subject
of O
severe I-Effect
aplastic I-Effect
anemia I-Effect
secondary I-Adverse_event.Trigger
to O
treatment O
with O
lenalidomide I-Treatment.Drug
for I-Treatment
multiple I-Treatment.Treat_Disorder
myeloma I-Treatment.Treat_Disorder
. O

Seven I-Treatment.Time_elapsed
weeks I-Treatment.Time_elapsed
after I-Treatment
the I-Treatment
initiation I-Treatment
of I-Treatment
inhaled I-Treatment.Route
fluticasone I-Treatment.Drug
, O
she O
developed I-Adverse_event.Trigger
vaginal I-Effect
candidiasis I-Effect
and O
was O
prescribed O
fluconazole O
100 O
mg O
/ O
day O
, O
a O
CYP3A4 O
inhibitor O
. O

Seven O
weeks O
after O
the O
initiation O
of O
inhaled O
fluticasone O
, O
she O
developed O
vaginal I-Treat_Disorder
candidiasis I-Treat_Disorder
and O
was O
prescribed I-Potential_therapeutic_event.Trigger
fluconazole I-Treatment.Drug
100 I-Treatment.Dosage
mg I-Treatment.Dosage
/ I-Treatment.Dosage
day I-Treatment.Dosage
, I-Treatment
a I-Treatment
CYP3A4 I-Treatment
inhibitor I-Treatment
. O

The I-Treatment
introduction I-Treatment
of I-Treatment
para I-Treatment.Drug
- I-Treatment.Drug
aminosalicylic I-Treatment.Drug
acid I-Treatment.Drug
( I-Treatment
PAS I-Treatment
) I-Treatment
led I-Adverse_event.Trigger
to I-Adverse_event.Trigger
hypoglycaemic I-Effect
coma I-Effect
. O

The O
risk O
of O
developing O
sAML I-Effect
is O
estimated O
to O
be O
between O
1 O
% O
and O
5 O
% O
, O
2 I-Treatment.Time_elapsed
- I-Treatment.Time_elapsed
20 I-Treatment.Time_elapsed
years I-Treatment.Time_elapsed
after I-Treatment
exposure I-Treatment
to I-Treatment
etoposide I-Treatment.Drug
but O
may O
also O
be O
related O
to O
cumulative O
drug O
doses O
, O
treatment O
schedules O
, O
host O
factors O
and O
co O
- O
administration O
of O
other O
antineoplastic O
agents O
. O

An I-Effect
infant I-Effect
girl I-Effect
with I-Effect
choanal I-Effect
atresia I-Effect
, I-Effect
athelia I-Effect
, I-Effect
minor I-Effect
anomalies I-Effect
, I-Effect
and I-Effect
mild I-Effect
to I-Effect
moderate I-Effect
mental I-Effect
retardation I-Effect
was O
born O
to O
a I-Subject
woman I-Subject.Gender
treated O
for O
hyperthyroidism I-Treat_Disorder
throughout O
pregnancy O
with I-Adverse_event.Trigger
methimazole I-Treatment.Combination.Drug
and I-Treatment
propranolol I-Treatment.Combination.Drug
. O

Ethambutol I-Treatment.Drug
is O
frequently O
used I-Potential_therapeutic_event.Trigger
in O
the O
treatment O
of O
tuberculosis I-Treat_Disorder
, O
and O
, O
although O
optic O
neuropathies O
have O
been O
reported O
with O
the O
use O
of O
ethambutol O
, O
this O
adverse O
side O
effect O
has O
been O
considered O
to O
be O
rare O
and O
generally O
reversible O
with O
discontinuation O
of O
the O
medication O
. O

Skin O
manifestations O
of O
a O
case O
of O
phenylbutazone I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
serum I-Effect
sickness I-Effect
- I-Effect
like I-Effect
reactions I-Effect
. O

Development I-Adverse_event.Trigger
of O
Crohn I-Effect
's I-Effect
disease I-Effect
in O
a I-Subject
patient I-Subject
with I-Subject
multiple I-Treat_Disorder
sclerosis I-Treat_Disorder
treated O
with O
copaxone I-Treatment.Drug
. O

Aliskiren I-Treatment.Drug
- O
associated I-Adverse_event.Trigger
acute I-Effect
renal I-Effect
failure I-Effect
with O
hyperkalemia O
. O

Fever I-Effect
caused I-Adverse_event.Trigger
by O
the O
use O
of O
furosemide I-Treatment.Drug
was O
proved O
; O
the O
fever O
resolved O
after O
discontinuation O
of O
this O
medication O
and O
recurred O
after O
its O
reintroduction O
. O

The O
use O
of O
methotrexate I-Drug
( I-Drug
MTX I-Drug
) I-Drug
has O
been O
contraindicated O
for O
treatment O
of O
severe O
psoriasis O
in O
HIV O
infection O
on O
the O
basis O
of O
six O
previously O
reported O
cases O
in O
which O
MTX I-Treatment.Drug
appeared O
to O
potentiate O
opportunistic O
infections O
and O
accelerate I-Adverse_event.Trigger
HIV I-Effect
disease I-Effect
. O

Pharmacokinetics O
of O
dapsone I-Treatment.Drug
gel I-Treatment
, I-Treatment
5 I-Treatment
% I-Treatment
for O
the O
treatment I-Potential_therapeutic_event.Trigger
of O
acne I-Treat_Disorder
vulgaris I-Treat_Disorder
. O

To O
our O
knowledge O
, O
these O
cases O
represent O
the O
first O
reports O
of O
TDF I-Treatment.Drug
- O
associated I-Adverse_event.Trigger
irreversible I-Effect
renal I-Effect
failure I-Effect
and I-Effect
rickets I-Effect
in O
pediatric I-Subject.Age
patients I-Subject
. O

In O
particular O
, O
this O
adverse I-Effect
effect I-Effect
has O
never O
been O
described I-Adverse_event.Trigger
with O
mefloquine I-Treatment.Drug
( I-Treatment
Lariam I-Treatment
) I-Treatment
. O

A O
potential O
role O
for O
renal O
and O
hepatic O
impairment O
in O
the O
observed O
protracted O
course O
of O
amiodarone I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
thyrotoxicosis I-Effect
is O
suggested O
. O

The I-Subject
patient I-Subject
completed O
a O
10 I-Duration
- I-Duration
month I-Duration
follow O
- O
up O
, O
maintaining O
a O
complete O
resolution O
of O
the O
treated O
skin I-Treat_Disorder
lesions I-Treat_Disorder
; O
however O
, O
the O
development O
of O
a I-Effect
painful I-Effect
hand I-Effect
ulcer I-Effect
, O
possibly O
associated I-Adverse_event.Trigger
with O
the O
hydroxyurea I-Treatment.Drug
, O
and O
new I-Effect
skin I-Effect
cancers I-Effect
were O
observed O
at O
the O
last O
follow O
- O
up O
visit O
. O

Potential O
aripiprazole I-Treatment.Drug
- O
mediated I-Adverse_event.Trigger
extrapyramidal I-Effect
symptoms I-Effect
in O
an I-Subject
adult I-Subject.Age
with I-Subject
developmental I-Treat_Disorder
disabilities I-Treat_Disorder
. O

We O
describe O
a I-Subject
patient I-Subject
with I-Subject
extranodal I-Treat_Disorder
non I-Treat_Disorder
- I-Treat_Disorder
Hodgkin I-Treat_Disorder
lymphoma I-Treat_Disorder
who O
developed O
systemic I-Effect
candidiasis I-Effect
after O
treatment I-Adverse_event.Trigger
with O
a I-Treatment
cyclophosphamide I-Treatment.Drug
- I-Treatment.Drug
based I-Treatment.Drug
chemotherapy I-Treatment.Drug
regimen I-Treatment
. I-Treatment

We O
describe O
the O
first O
case O
of O
de I-Effect
novo I-Effect
asthma I-Effect
following O
treatment I-Adverse_event.Trigger
with I-Adverse_event.Trigger
the I-Treatment
angiotensin I-Treatment
converting I-Treatment
enzyme I-Treatment
( I-Treatment
ACE I-Treatment
) I-Treatment
inhibitor I-Treatment
captopril I-Treatment.Drug
. O

A I-Subject
53 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
male I-Subject.Gender
, I-Subject
without I-Subject
any I-Subject
prior I-Subject
history I-Subject
of I-Subject
psychosis I-Subject
, O
developed I-Adverse_event.Trigger
schizophrenia I-Effect
4 I-Treatment.Time_elapsed
days I-Treatment.Time_elapsed
after I-Treatment.Time_elapsed
starting I-Treatment
low I-Treatment.Dosage
- I-Treatment.Dosage
dose I-Treatment.Dosage
bromocriptine I-Treatment.Drug
therapy I-Treatment
for O
a O
macroprolactinoma I-Treat_Disorder
. O

Six I-Treatment.Time_elapsed
days I-Treatment.Time_elapsed
after I-Adverse_event.Trigger
taking O
erlotinib I-Treatment.Drug
, O
a O
chest O
radiograph O
showed O
rapid I-Effect
progression I-Effect
of I-Effect
reticular I-Effect
infiltration I-Effect
in I-Effect
both I-Effect
lung I-Effect
fields I-Effect
. O

Because O
of O
suspected O
drug O
- O
induced O
seizures I-Effect
, O
both O
antidepressants I-Treatment.Drug
were O
stopped I-Adverse_event.Trigger
. O

Based O
on O
the O
Naranjo O
probability O
scale O
, O
serotonin I-Effect
syndrome I-Effect
was O
a O
probable O
adverse O
reaction O
associated I-Adverse_event.Trigger
with O
co I-Treatment
- I-Treatment
administration I-Treatment
of I-Treatment
citalopram I-Treatment.Combination.Drug
and I-Treatment
fentanyl I-Treatment.Combination.Drug
. O

We O
report O
a O
case O
of O
a O
patient I-Subject
with I-Subject
rheumatoid I-Treat_Disorder
arthritis I-Treat_Disorder
treated O
with O
low I-Treatment
- I-Treatment
dose I-Treatment
methotrexate I-Treatment.Drug
( I-Treatment
15 I-Treatment.Dosage
mg I-Treatment.Dosage
/ I-Treatment.Dosage
week I-Treatment.Dosage
) I-Treatment
who O
developed I-Adverse_event.Trigger
infection I-Effect
with I-Effect
both I-Effect
M. I-Effect
tuberculosis I-Effect
and I-Effect
M. I-Effect
chelonae I-Effect
after O
the O
revision O
of O
a O
prosthetic O
hip O
. O

Thrombotic I-Effect
microangiopathy I-Effect
with I-Effect
renal I-Effect
failure I-Effect
in O
two I-Subject.Population
patients I-Subject
undergoing I-Adverse_event.Trigger
gemcitabine I-Treatment.Drug
chemotherapy I-Treatment.Route
. O

Despite O
the O
known O
pulmonary I-Effect
side I-Effect
effects I-Effect
of I-Adverse_event.Trigger
nitrofurantoin I-Treatment.Drug
, O
there O
is O
no O
report O
of O
this O
toxicity O
occurring O
in O
pregnant O
patients O
. O

However O
, O
several O
case O
reports O
have O
suggested O
that O
clozapine I-Treatment.Drug
could O
also O
cause I-Adverse_event.Trigger
TD I-Effect
. O

A O
case O
is O
presented O
in O
which O
a O
68 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
man I-Subject.Gender
became O
delirious I-Effect
after I-Adverse_event.Trigger
being O
withdrawn I-Treatment
from I-Treatment
a I-Treatment
low I-Treatment.Dosage
dosage I-Treatment.Dosage
of I-Treatment
alprazolam I-Treatment.Drug
. O

However O
, O
re O
- O
initiation O
of O
sunitinib I-Treatment.Drug
treatment O
was O
followed I-Adverse_event.Trigger
by O
bilateral I-Effect
breast I-Effect
enlargement I-Effect
again O
. O

BACKGROUND O
: O
Hydroxyurea I-Treatment.Drug
is I-Treatment
a I-Treatment
cytostatic I-Treatment
agent I-Treatment
used O
to O
treat O
myeloproliferative I-Treat_Disorder
disorders I-Treat_Disorder
and O
long O
- O
term O
treatment O
is O
associated I-Adverse_event.Trigger
with O
mucocutaneous I-Effect
adverse I-Effect
events I-Effect
and I-Effect
nail I-Effect
hyperpigmentation I-Effect
. O

Captopril I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
acute I-Effect
reversible I-Effect
renal I-Effect
failure I-Effect
. O

Hence O
, O
hyperthyroidism I-Effect
induced I-Adverse_event.Trigger
by O
IFN I-Treatment.Drug
- I-Treatment.Drug
alpha I-Treatment.Drug
could O
correspond O
to O
the O
first O
phase O
of O
silent O
thyroiditis O
, O
to O
Graves O
' O
disease O
or O
to O
the O
succession O
of O
both O
. O

The O
epivodes O
of O
NMS I-Effect
occured I-Adverse_event.Trigger
under O
treatment O
with O
clozapine I-Treatment.Combination.Drug
, I-Treatment
risperidone I-Treatment.Combination.Drug
, I-Treatment
and I-Treatment
amisulpride I-Treatment.Combination.Drug
. O

During I-Adverse_event.Trigger
the I-Treatment.Duration
first I-Treatment.Duration
days I-Treatment.Duration
of I-Treatment
arsenic I-Treatment.Drug
trioxide I-Treatment.Drug
treatment I-Treatment
a I-Effect
rapid I-Effect
decrease I-Effect
in I-Effect
the I-Effect
D I-Effect
- I-Effect
dimers I-Effect
was I-Effect
seen I-Effect
( I-Effect
normal I-Effect
values I-Effect
reached I-Effect
until I-Effect
day I-Effect
7 I-Effect
) I-Effect
, I-Effect
together I-Effect
with I-Effect
a I-Effect
slight I-Effect
decrease I-Effect
in I-Effect
peripheral I-Effect
blood I-Effect
leukocytes I-Effect
. O

In O
contrast O
to O
chronic O
or O
subacute O
thyroiditis O
, O
Graves I-Subject.Sub_Disorder
' I-Subject.Sub_Disorder
disease I-Subject.Sub_Disorder
rarely O
complicates O
IFN I-Treatment.Drug
- I-Treatment.Drug
alpha I-Treatment.Drug
therapy O
for I-Potential_therapeutic_event.Trigger
chronic I-Treat_Disorder
viral I-Treat_Disorder
C I-Treat_Disorder
hepatitis I-Treat_Disorder
. O

We O
postulate O
that O
gastritis I-Effect
caused I-Adverse_event.Trigger
by O
dexamethasone I-Treatment.Drug
, O
mucositis O
caused O
by O
doxorubicin O
, O
and O
the O
unique O
anatomic O
nature O
of O
a O
Meckel O
diverticulum O
may O
have O
contributed O
to O
this O
extremely O
unlikely O
and O
previously O
unreported O
event O
. O

We O
postulate O
that O
gastritis O
caused O
by O
dexamethasone O
, O
mucositis I-Effect
caused I-Adverse_event.Trigger
by O
doxorubicin I-Treatment.Drug
, O
and O
the O
unique O
anatomic O
nature O
of O
a O
Meckel O
diverticulum O
may O
have O
contributed O
to O
this O
extremely O
unlikely O
and O
previously O
unreported O
event O
. O

Mesalamine I-Treatment.Drug
may O
cause I-Adverse_event.Trigger
hypersensitivity I-Effect
pneumonitis I-Effect
in O
patients I-Subject
with I-Subject
Crohn I-Treat_Disorder
's I-Treat_Disorder
disease I-Treat_Disorder
. O

We O
present O
a O
case O
in O
which O
dipyridamole I-Treat_Disorder
induced I-Treat_Disorder
high I-Treat_Disorder
- I-Treat_Disorder
grade I-Treat_Disorder
atrioventricular I-Treat_Disorder
( I-Treat_Disorder
AV I-Treat_Disorder
) I-Treat_Disorder
block I-Treat_Disorder
that O
responded I-Potential_therapeutic_event.Trigger
promptly O
to O
intravenous I-Treatment.Drug
aminophylline I-Treatment.Drug
but I-Treatment
not I-Treatment
to I-Treatment
atropine I-Treatment.Drug
. O

We O
present O
a O
case O
in O
which O
dipyridamole I-Treatment.Drug
induced I-Adverse_event.Trigger
high I-Effect
- I-Effect
grade I-Effect
atrioventricular I-Effect
( I-Effect
AV I-Effect
) I-Effect
block I-Effect
that O
responded O
promptly O
to O
intravenous O
aminophylline O
but O
not O
to O
atropine O
. O

This O
paper O
reports O
an I-Subject
autopsy I-Subject
case I-Subject
of I-Subject
a I-Subject
78 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
male I-Subject.Gender
with O
multiple I-Effect
nodules I-Effect
in I-Effect
the I-Effect
liver I-Effect
developed I-Adverse_event.Trigger
after O
long O
- O
termed O
administration O
of O
phosphate I-Treatment.Drug
diethylstilbestrol I-Treatment.Drug
( I-Treatment
PDES I-Treatment
) I-Treatment
for O
prostatic I-Treat_Disorder
cancer I-Treat_Disorder
. O

Fracture I-Effect
of I-Effect
the I-Effect
femoral I-Effect
neck I-Effect
occurred I-Adverse_event.Trigger
in O
one I-Subject.Population
patient I-Subject
during O
PSL I-Treatment.Drug
therapy I-Treatment
, O
although O
the O
relationship O
between O
the O
fracture O
and O
PSL O
therapy O
was O
uncertain O
. O

This O
panic I-Treat_Disorder
anxiety I-Treat_Disorder
was O
not O
relieved O
by O
taking O
etizolam I-Treatment.Combination.Drug
and I-Treatment
flunitrazepam I-Treatment.Combination.Drug
again O
, O
but O
subsided I-Potential_therapeutic_event.Trigger
rapidly O
by O
the O
re O
- O
administration O
of O
mianserin I-Treatment.Combination.Drug
30 I-Treatment.Dosage
mg I-Treatment.Dosage
/ I-Treatment.Dosage
day I-Treatment.Dosage
, O
and O
because I-Effect
of I-Effect
that I-Effect
the I-Effect
depressive I-Treat_Disorder
symptom I-Treat_Disorder
also I-Effect
disappeared I-Effect
. O

When O
co I-Treatment.Drug
- I-Treatment.Drug
trimoxazole I-Treatment.Drug
was O
stopped I-Potential_therapeutic_event.Trigger
the O
red I-Effect
cell I-Effect
aplasia I-Effect
resolved I-Effect
. O

Interaction I-Treatment
of I-Treatment
sildenafil I-Treatment.Combination.Drug
and I-Treatment
indinavir I-Treatment.Combination.Drug
when O
co I-Potential_therapeutic_event.Trigger
- I-Potential_therapeutic_event.Trigger
administered I-Potential_therapeutic_event.Trigger
to O
HIV I-Treat_Disorder
- I-Treat_Disorder
positive I-Treat_Disorder
patients I-Subject
. O

Cerebral I-Effect
and I-Effect
ocular I-Effect
toxicity I-Effect
induced I-Adverse_event.Trigger
by O
desferrioxamine I-Treatment.Drug
. O

A I-Subject
patient I-Subject
developed O
papilloedema I-Effect
and I-Effect
hepatic I-Effect
dysfunction I-Effect
while I-Adverse_event.Trigger
being O
treated O
with O
perhexiline I-Treatment.Drug
maleate I-Treatment.Drug
. O

We O
describe O
a I-Subject
case I-Subject
of O
subcutaneous I-Effect
metastasis I-Effect
along O
the O
needle O
track O
after I-Adverse_event.Trigger
percutaneous I-Treatment
ethanol I-Treatment.Drug
injection I-Treatment.Route
( I-Treatment
PEI I-Treatment
) I-Treatment
for O
treatment O
of O
hepatocellular I-Treat_Disorder
carcinoma I-Treat_Disorder
. O

He O
developed I-Adverse_event.Trigger
episodic I-Effect
movements I-Effect
possibly I-Effect
consistent I-Effect
with I-Effect
EPS I-Effect
secondary I-Treatment
to I-Treatment
aripiprazole I-Treatment.Drug
usage I-Treatment
. O

Recently O
, O
it O
has O
been O
reported O
that O
terfenadine I-Treatment.Combination.Drug
and I-Treatment
astemizole I-Treatment.Combination.Drug
, O
which O
have O
antiallergic O
actions O
similar O
to O
those O
of O
oxatomide O
, O
show I-Adverse_event.Trigger
side I-Effect
effects I-Effect
on I-Effect
the I-Effect
cardiovascular I-Effect
system I-Effect
, I-Effect
such I-Effect
as I-Effect
QT I-Effect
prolongation I-Effect
, I-Effect
ventricular I-Effect
arrhythmia I-Effect
and I-Effect
cardiac I-Effect
arrest I-Effect
. O

We O
reported O
3 I-Subject.Population
patients I-Subject
who O
developed O
acute I-Effect
generalized I-Effect
dystonia I-Effect
and I-Effect
akinetic I-Effect
rigid I-Effect
syndrome I-Effect
following I-Adverse_event.Trigger
an O
initial O
therapy O
with O
d I-Treatment.Drug
- I-Treatment.Drug
penicillamine I-Treatment.Drug
125 I-Treatment.Dosage
- I-Treatment.Dosage
500 I-Treatment.Dosage
mg I-Treatment.Dosage
daily I-Treatment.Dosage
. O

Priapism I-Effect
associated I-Adverse_event.Trigger
with O
olanzapine I-Treatment.Drug
. O

Thus O
, O
an O
immunological O
mechanism O
might O
be O
involved O
in O
the O
mechanism O
of O
pirmenol I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
QT I-Effect
prolongation I-Effect
and I-Effect
T I-Effect
wave I-Effect
inversion I-Effect
on O
the O
electrocardiogram O
. O

Five I-Treatment.Time_elapsed
months I-Treatment.Time_elapsed
after I-Treatment
initiating I-Treatment
mirtazapine I-Treatment.Drug
therapy O
, O
she I-Subject.Gender
developed I-Adverse_event.Trigger
symptomatic I-Effect
hyponatremia I-Effect
. O

Intravenous I-Treatment.Route
verapamil I-Treatment.Drug
therapy O
in O
babies I-Subject.Age
may O
cause I-Adverse_event.Trigger
apnea I-Effect
, I-Effect
hypotension I-Effect
, I-Effect
and I-Effect
bradycardia I-Effect
; O
continued O
episodes O
of O
atrial O
flutter O
in O
a O
child O
may O
cause O
sudden O
death O
; O
quinidine O
may O
be O
related O
to O
the O
death O
; O
children O
with O
" O
familial O
seizure O
disorders O
" O
may O
in O
fact O
have O
the O
long O
QT O
interval O
syndrome O
. O

Intravenous O
verapamil O
therapy O
in O
babies O
may O
cause O
apnea O
, O
hypotension O
, O
and O
bradycardia O
; O
continued O
episodes O
of O
atrial O
flutter O
in O
a O
child O
may O
cause O
sudden O
death O
; O
quinidine I-Treatment.Drug
may O
be O
related I-Adverse_event.Trigger
to O
the O
death I-Effect
; O
children O
with O
" O
familial O
seizure O
disorders O
" O
may O
in O
fact O
have O
the O
long O
QT O
interval O
syndrome O
. O

The I-Effect
renal I-Effect
biopsy I-Effect
showed I-Effect
focal I-Effect
segmental I-Effect
glomerulosclerosis I-Effect
, O
which O
has O
only O
been O
previously O
reported I-Adverse_event.Trigger
in O
two I-Subject.Population
cases I-Subject
of O
CML I-Treat_Disorder
treated O
with O
IFNalpha I-Treatment.Drug
. O

Sulindac I-Treatment.Drug
( I-Treatment
Clinoril I-Treatment
) I-Treatment
, O
a O
nonsteroidal O
anti O
- O
inflammatory O
agent O
, O
has O
few O
reported I-Adverse_event.Trigger
neurologic I-Effect
toxic I-Effect
effects I-Effect
, O
all O
of O
which O
have O
been O
associated O
with O
systemic O
disease O
. O

The O
second O
patient O
was O
a I-Subject
32 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
woman I-Subject.Gender
with I-Subject
HIV I-Treat_Disorder
, I-Subject
anxiety I-Treat_Disorder
disorder I-Treat_Disorder
, I-Subject
and I-Subject
a I-Subject
history I-Subject
of I-Subject
intravenous I-Subject.Sub_Disorder
drug I-Subject.Sub_Disorder
abuse I-Subject.Sub_Disorder
who O
developed I-Adverse_event.Trigger
increased I-Effect
sedation I-Effect
and I-Effect
mental I-Effect
confusion I-Effect
when O
an O
atazanavir I-Treatment.Combination.Drug
- I-Treatment
ritonavir I-Treatment.Combination.Drug
- I-Treatment
based I-Treatment
antiretroviral I-Treatment
regimen I-Treatment
was I-Treatment
added I-Treatment
to I-Treatment
her I-Treatment
stable I-Treatment
antianxiety I-Treatment
drug I-Treatment
regimen I-Treatment
, I-Treatment
which I-Treatment
included I-Treatment
quetiapine I-Treatment.Combination.Drug
. O

Fulminant I-Effect
hepatitis I-Effect
associated I-Adverse_event.Trigger
with O
disulfiram I-Treatment.Drug
. O

Anhedonic I-Effect
ejaculation I-Effect
with I-Adverse_event.Trigger
desipramine I-Treatment.Drug
. O

Serotonin I-Effect
syndrome I-Effect
induced I-Adverse_event.Trigger
by O
transitioning O
from O
phenelzine I-Treatment.Drug
to I-Treatment
venlafaxine I-Treatment.Drug
: O
four I-Subject
patient I-Subject
reports O
. O

Lower I-Effect
extremity I-Effect
arterial I-Effect
thrombosis I-Effect
following I-Adverse_event.Trigger
sonographically O
guided O
thrombin I-Treatment.Drug
injection I-Treatment.Route
of I-Treatment
a I-Treatment
femoral I-Treatment.Treat_Disorder
pseudoaneurysm I-Treatment.Treat_Disorder
. O

A O
severe O
form O
of O
exophthalmos I-Effect
resulting I-Adverse_event.Trigger
from O
lithium I-Treatment.Drug
therapy O
has O
not O
been O
described O
in O
the O
literature O
. O

No O
cases O
of O
renal O
acidosis O
, O
and O
only O
one O
case O
of O
nephrogenic I-Effect
diabetes I-Effect
insipidus I-Effect
, O
has O
been O
previously O
reported I-Adverse_event.Trigger
as O
a O
complication O
of O
foscarnet I-Treatment.Drug
treatment I-Treatment
. O

Cough I-Effect
induced O
by O
quinapril I-Drug
with O
resolution I-Potential_therapeutic_event.Trigger
after O
changing O
to O
fosinopril I-Treatment.Drug
. O

INTRODUCTION O
: O
Although O
gefitinib I-Treatment.Drug
used O
for O
the O
treatment O
of O
non I-Treat_Disorder
- I-Treat_Disorder
small I-Treat_Disorder
- I-Treat_Disorder
cell I-Treat_Disorder
lung I-Treat_Disorder
cancer I-Treat_Disorder
is O
a O
well O
- O
known O
cause I-Adverse_event.Trigger
of O
interstitial I-Effect
lung I-Effect
disease I-Effect
( I-Effect
ILD I-Effect
) I-Effect
, O
few O
case O
reports O
on O
erlotinib O
- O
induced O
ILD O
have O
been O
issued O
. O

INTRODUCTION O
: O
Although O
gefitinib O
used O
for O
the O
treatment O
of O
non O
- O
small O
- O
cell O
lung O
cancer O
is O
a O
well O
- O
known O
cause O
of O
interstitial O
lung O
disease O
( O
ILD O
) O
, O
few O
case O
reports O
on O
erlotinib I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
ILD I-Effect
have O
been O
issued O
. O

We O
report O
a O
case O
in O
which O
a I-Treatment
potential I-Treatment
drug I-Treatment
interaction I-Treatment
resulted I-Adverse_event.Trigger
in I-Adverse_event.Trigger
elevated I-Effect
phenytoin I-Effect
levels I-Effect
after O
initiation I-Treatment
of I-Treatment
erlotinib I-Treatment.Combination.Drug
therapy I-Treatment
in O
a I-Subject
patient I-Subject
who O
was O
receiving I-Treatment
phenytoin I-Treatment.Combination.Drug
. O

Anastrozole I-Treatment.Drug
- O
associated I-Adverse_event.Trigger
sclerosing I-Effect
glomerulonephritis I-Effect
in O
a I-Subject
patient I-Subject
with I-Subject
breast I-Treat_Disorder
cancer I-Treat_Disorder
. I-Subject

BACKGROUND O
: O
Gemcitabine O
has O
mild O
renal I-Effect
toxicity I-Effect
, O
but O
cases I-Subject
of O
gemcitabine I-Treatment.Drug
- O
associated I-Adverse_event.Trigger
hemolytic I-Effect
- I-Effect
uremic I-Effect
syndrome I-Effect
( I-Effect
HUS I-Effect
) I-Effect
have O
been O
reported O
. O

Recurrent O
palmar I-Effect
- I-Effect
plantar I-Effect
erythrodysaesthesia I-Effect
following O
high I-Treatment.Dosage
- I-Treatment.Dosage
dose I-Treatment.Dosage
cytarabine I-Treatment.Drug
treatment I-Potential_therapeutic_event.Trigger
for O
acute I-Treat_Disorder
lymphoblastic I-Treat_Disorder
leukemia I-Treat_Disorder
. O

CONCLUSIONS O
: O
Peripheral I-Treatment.Route
administration I-Treatment.Route
of I-Treatment
low I-Treatment.Dosage
- I-Treatment.Dosage
dose I-Treatment.Dosage
vasopressin I-Treatment.Drug
for O
septic I-Treat_Disorder
shock I-Treat_Disorder
should O
be O
discouraged O
because O
of O
the O
risk I-Adverse_event.Trigger
of O
ischemic I-Effect
skin I-Effect
complications I-Effect
. O

Many O
types O
of O
medicaments O
can O
cause O
akathisia I-Effect
as O
an O
adverse I-Adverse_event.Trigger
event I-Adverse_event.Trigger
of O
their O
use O
and O
they O
include O
: O
antipsychotics I-Treatment.Combination.Drug
, I-Treatment
antidepressants I-Treatment.Combination.Drug
, I-Treatment
antiemetics I-Treatment.Combination.Drug
, I-Treatment
antihistamines I-Treatment.Combination.Drug
, I-Treatment
and I-Treatment
psychoactive I-Treatment.Combination.Drug
substances I-Treatment.Combination.Drug
. I-Combination.Drug

We O
report O
the O
case O
of O
a I-Subject
60 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
woman I-Subject.Gender
who O
developed I-Adverse_event.Trigger
erythema I-Effect
and O
erosions I-Effect
in I-Effect
the I-Effect
axilla I-Effect
and I-Effect
groin I-Effect
while O
on O
PLD I-Treatment.Drug
for O
breast I-Treat_Disorder
cancer I-Treat_Disorder
. O

Serotonin I-Effect
syndrome I-Effect
has O
been O
reported I-Adverse_event.Trigger
with I-Adverse_event.Trigger
administration I-Treatment
of I-Treatment
linezolid I-Treatment.Combination.Drug
and I-Treatment
serotonin I-Treatment.Combination.Drug
reuptake I-Treatment.Combination.Drug
inhibitors I-Treatment.Combination.Drug
. O

We O
suggest O
that O
the O
treatment O
of O
hypoglycaemia I-Treat_Disorder
with O
50 I-Treatment.Route
% I-Treatment.Route
solution I-Treatment.Route
of I-Treatment
dextrose I-Treatment.Drug
is O
associated I-Adverse_event.Trigger
with O
a I-Effect
significant I-Effect
risk I-Effect
factor I-Effect
in O
those O
diabetic I-Subject.Sub_Disorder
individuals I-Subject
who I-Subject
are I-Subject
either I-Subject
allergic I-Subject
or I-Subject
are I-Subject
receiving I-Subject
beta I-Subject
- I-Subject
adrenoreceptor I-Subject
blocking I-Subject
drugs I-Subject
. O

A O
case O
of O
phenobarbital I-Treatment.Combination.Drug
exacerbation I-Effect
of I-Effect
a I-Effect
preexisting I-Effect
maladaptive I-Effect
behavior I-Effect
partially I-Treatment
suppressed I-Treatment
by I-Treatment
chlorpromazine I-Treatment.Combination.Drug
and O
misinterpreted O
as O
chlorpromazine O
efficacy O
. O

Colchicine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
myopathy I-Effect
in O
a I-Subject
teenager I-Subject.Age
with I-Subject
familial I-Subject
Mediterranean I-Treat_Disorder
fever I-Treat_Disorder
. O

Levofloxacin I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
delirium I-Effect
with I-Effect
psychotic I-Effect
features I-Effect
. O

Methemoglobinemia I-Effect
: O
an O
occupational O
hazard O
of O
phenylpropanolamine I-Treatment.Drug
production I-Adverse_event.Trigger
. O

Destructive I-Effect
thyrotoxicosis I-Effect
appeared O
4 I-Time_elapsed
- I-Time_elapsed
6 I-Time_elapsed
months I-Time_elapsed
after I-Adverse_event.Trigger
starting O
IFN I-Treatment.Drug
- I-Treatment.Drug
alpha I-Treatment.Drug
, O
followed O
by O
Graves I-Effect
' I-Effect
hyperthyroidism I-Effect
within O
8 O
to O
11 O
months O
. O

CASE O
SUMMARIES O
: O
In O
each O
case O
, O
the O
patients I-Subject
were O
treated O
over O
5 I-Treatment.Duration
years I-Treatment.Duration
with I-Treatment
lovastatin I-Treatment.Combination.Drug
and O
developed I-Adverse_event.Trigger
rhabdomyolysis I-Effect
that O
coincided O
with O
the O
completion O
of O
a O
prescribed O
regimen O
of O
a I-Treatment
newer I-Treatment
macrolide I-Treatment.Combination.Drug
antibiotic I-Treatment.Combination.Drug
. O

Thrombotic I-Effect
stroke I-Effect
associated I-Adverse_event.Trigger
with O
the O
use O
of O
porcine I-Treatment.Drug
factor I-Treatment.Drug
VIII I-Treatment.Drug
in O
a O
patient I-Subject
with I-Subject
acquired I-Treat_Disorder
haemophilia I-Treat_Disorder
. O

PURPOSE O
: O
The I-Treatment
intravitreal I-Treatment.Route
application I-Treatment
of I-Treatment
triamcinolone I-Treatment.Drug
acetonide I-Treatment.Drug
as O
treatment I-Potential_therapeutic_event.Trigger
of O
long O
- O
standing O
, O
therapy O
- O
resistant O
cystoid I-Treat_Disorder
macular I-Treat_Disorder
edema I-Treat_Disorder
after O
penetrating O
keratoplasty O
is O
reported O
. O

Patients I-Subject
receiving O
ciprofloxacin I-Treatment.Combination.Drug
and I-Treatment
digoxin I-Treatment.Combination.Drug
should O
be O
monitored O
closely O
for O
the I-Adverse_event.Trigger
risk I-Adverse_event.Trigger
of O
digoxin I-Effect
toxicity I-Effect
. O

To O
our O
knowledge O
this O
is O
the O
first O
report O
of O
pancytopenia I-Effect
due I-Adverse_event.Trigger
to O
MMI I-Treatment.Drug
, O
where O
the O
usual O
hypoplasia O
found O
is O
replaced O
by O
massive O
plasmocytosis O
. O

The O
following O
is O
a O
report O
of O
2 O
cases O
of O
rifampicin I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
renal I-Effect
insufficiency I-Effect
. O

Fatal I-Effect
eosinophilia I-Effect
myalgia I-Effect
syndrome I-Effect
in O
a O
marrow I-Subject
transplant I-Subject
patient I-Subject
attributed I-Adverse_event.Trigger
to O
total I-Treatment
parenteral I-Treatment.Route
nutrition I-Treatment
with I-Treatment
a I-Treatment
solution I-Treatment
containing I-Treatment
tryptophan I-Treatment.Drug
. O

We O
describe O
a O
43 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
man I-Subject.Gender
who O
developed I-Adverse_event.Trigger
signs O
and O
symptoms O
of O
bilateral I-Effect
optic I-Effect
neuropathy I-Effect
during O
treatment O
with O
ethambutol I-Treatment.Drug
. O

The I-Subject
patient I-Subject
described I-Subject
in I-Subject
this I-Subject
paper I-Subject
was I-Subject
a I-Subject
78 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
diabetic I-Treat_Disorder
man I-Subject.Gender
who O
developed O
oral I-Effect
lesions I-Effect
of I-Effect
PV I-Effect
following I-Adverse_event.Trigger
institution I-Treatment
of I-Treatment
glibenclamide I-Treatment.Drug
therapy O
. O

Since O
elevated O
cortisol O
levels O
in O
Cushing O
's O
disease O
poses O
a O
threat O
for O
pancreatitis O
, O
there O
is O
a O
possibility O
that O
patients I-Subject
with I-Subject
Cushing I-Treat_Disorder
's I-Treat_Disorder
disease I-Treat_Disorder
might O
be O
more O
prone O
to O
acute I-Effect
pancreatitis I-Effect
following I-Adverse_event.Trigger
propofol I-Treatment.Drug
administration O
. O

Ticlopidine I-Treatment.Drug
is I-Treatment
an I-Treatment
oral I-Treatment.Route
antiplatelet I-Treatment
agent I-Treatment
frequently O
utilized O
in O
the O
treatment O
of O
cerebrovascular I-Treat_Disorder
disease I-Treat_Disorder
and O
is O
rarely O
associated I-Adverse_event.Trigger
with O
severe I-Effect
bone I-Effect
marrow I-Effect
suppression I-Effect
, I-Effect
typically I-Effect
aplastic I-Effect
anemia I-Effect
. O

Moxifloxacin I-Treatment.Drug
and I-Treatment
lomefloxacin I-Treatment.Drug
are O
fluoroquinolone I-Treatment.Drug
antibiotics I-Treatment.Drug
used O
in O
treating I-Potential_therapeutic_event.Trigger
urinary I-Treat_Disorder
and I-Treat_Disorder
respiratory I-Treat_Disorder
tract I-Treat_Disorder
infections I-Treat_Disorder
. O

To O
our O
knowledge O
, O
this O
case O
report O
represents O
only O
the O
third O
description O
of O
laxative I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
TEN I-Effect
. O

Prompted O
by O
the O
advent O
of O
potentially O
life I-Effect
- I-Effect
threatening I-Effect
neuromuscular I-Effect
symptoms I-Effect
following I-Adverse_event.Trigger
initiation O
of O
linezolid I-Treatment.Combination.Drug
therapy O
in O
two I-Subject.Population
patients I-Subject
receiving O
treatment O
with I-Treatment
a I-Treatment
serotonin I-Treatment.Combination.Drug
reuptake I-Treatment.Combination.Drug
inhibitor I-Treatment.Combination.Drug
antidepressant I-Treatment.Combination.Drug
, O
an O
evaluation O
was O
conducted O
to O
determine O
the O
incidence O
and O
characteristics O
of O
symptomatic O
serotonin O
toxicity O
among O
hospitalized O
patients O
receiving O
combined O
treatment O
with O
these O
medications O
. O

Celiac I-Effect
disease I-Effect
onset I-Adverse_event.Trigger
after O
pegylated I-Treatment.Combination.Drug
interferon I-Treatment.Combination.Drug
and I-Treatment
ribavirin I-Treatment.Combination.Drug
treatment I-Treatment.Combination.Drug
of I-Treatment
chronic I-Treatment.Treat_Disorder
hepatitis I-Treatment.Treat_Disorder
C. I-Treatment.Treat_Disorder

Hyperkalaemia I-Effect
with I-Effect
renal I-Effect
tubular I-Effect
dysfunction I-Effect
by I-Adverse_event.Trigger
sulfamethoxazole I-Treatment.Drug
- I-Treatment.Drug
trimethoprim I-Treatment.Drug
for I-Treatment
Pneumocystis I-Treatment.Treat_Disorder
carinii I-Treatment.Treat_Disorder
pneumonia I-Treatment.Treat_Disorder
in O
patients I-Subject
with I-Subject
lymphoid I-Subject.Sub_Disorder
malignancy I-Subject.Sub_Disorder
. O

Following O
7 I-Treatment.Time_elapsed
days I-Treatment.Time_elapsed
of I-Treatment
tigecycline I-Treatment.Drug
she I-Subject
developed I-Adverse_event.Trigger
severe O
abdominal I-Effect
pain I-Effect
and I-Effect
elevated I-Effect
pancreatic I-Effect
enzymes I-Effect
suggesting O
acute O
pancreatitis O
. O

To O
treat O
hepatitis I-Treat_Disorder
B I-Treat_Disorder
, O
interferon I-Treatment.Drug
alpha I-Treatment.Drug
was O
administered O
until O
the O
proximal I-Effect
muscle I-Effect
weakness I-Effect
developed I-Adverse_event.Trigger
. O

We O
report O
a I-Subject
case I-Subject
of O
the O
serotonin I-Effect
syndrome I-Effect
during I-Adverse_event.Trigger
treatment O
with O
lithium I-Treatment.Combination.Drug
and I-Treatment
venlafaxine I-Treatment.Combination.Drug
, O
an O
antidepressant O
with O
a O
dual O
selective O
re O
- O
uptake O
inhibition O
mechanism O
, O
and O
review O
the O
literature O
for O
similar O
cases O
. O

Supratherapeutic I-Treatment
flecainide I-Treatment.Drug
plasma I-Treatment
concentrations I-Treatment
may O
cause I-Adverse_event.Trigger
delirium I-Effect
. O

At O
the O
end O
of O
his O
fifth I-Treatment.Freq
cycle I-Treatment.Freq
of I-Treatment
sunitinib I-Treatment.Drug
therapy I-Treatment
, O
the I-Subject
patient I-Subject
complained O
of O
the O
development I-Adverse_event.Trigger
of O
abnormally I-Effect
large I-Effect
mammary I-Effect
glands I-Effect
associated I-Effect
with I-Effect
pain I-Effect
and I-Effect
peri I-Effect
- I-Effect
areolar I-Effect
erythema I-Effect
. O

This O
is O
a O
case O
report O
of O
possible O
association I-Adverse_event.Trigger
of O
methylphenidate I-Treatment.Drug
and O
enuresis I-Effect
in O
an I-Subject
11 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
boy I-Subject.Gender
with I-Subject
attention I-Treat_Disorder
deficit I-Treat_Disorder
hyperactivity I-Treat_Disorder
disorder I-Treat_Disorder
. O

This O
report O
describes O
a O
case O
of O
neuroleptic I-Effect
malignant I-Effect
syndrome I-Effect
due I-Adverse_event.Trigger
to I-Adverse_event.Trigger
risperidone I-Treatment.Drug
in O
a I-Subject
child I-Subject.Age
with I-Subject
Joubert I-Treat_Disorder
syndrome I-Treat_Disorder
. O

A I-Subject
47 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
HIV I-Treat_Disorder
- I-Treat_Disorder
infected I-Treat_Disorder
man I-Subject.Gender
with I-Subject
dilated I-Subject.Sub_Disorder
cardiomyopathy I-Subject.Sub_Disorder
and I-Subject
prolonged I-Subject.Sub_Disorder
QT I-Subject.Sub_Disorder
syndrome I-Subject.Sub_Disorder
with I-Subject
an I-Subject
automatic I-Subject
implantable I-Subject
cardiovascular I-Subject
defibrillator I-Subject
device I-Subject
was O
prescribed O
subcutaneous I-Treatment.Route
enfuvirtide I-Treatment.Combination.Drug
90 I-Treatment.Dosage
mg I-Treatment.Dosage
twice I-Treatment.Freq
daily I-Treatment.Freq
as I-Treatment
part I-Treatment
of I-Treatment
his I-Treatment
antiretroviral I-Treatment
regimen I-Treatment
and I-Treatment
oral I-Treatment.Route
extended I-Treatment
- I-Treatment
release I-Treatment
niacin I-Treatment.Combination.Drug
500 I-Treatment.Dosage
mg I-Treatment.Dosage
/ I-Treatment
day I-Treatment.Freq
for I-Treatment
a I-Treatment
high I-Treatment
- I-Treatment
density I-Treatment
lipoprotein I-Treatment
level I-Treatment
of I-Treatment
8 I-Treatment
mg I-Treatment
/ I-Treatment
dL. I-Treatment
After O
1 I-Time_elapsed
week I-Time_elapsed
of O
concomitant O
therapy O
, O
the O
patient O
began O
experiencing I-Adverse_event.Trigger
extreme I-Effect
redness I-Effect
, I-Effect
edema I-Effect
, I-Effect
and I-Effect
swelling I-Effect
at I-Effect
the I-Effect
injection I-Effect
site I-Effect
that I-Effect
corresponded I-Effect
with I-Effect
the I-Effect
flushing I-Effect
sensation I-Effect
due I-Effect
to I-Effect
niacin I-Effect
. O

Acute O
INH O
neurotoxicity O
was O
not O
suspected O
on O
the O
first O
admission O
; O
however O
, O
when O
readmitted O
4 O
weeks O
later O
with O
another O
seizure I-Effect
, O
the O
diagnosis I-Adverse_event.Trigger
of O
acute I-Effect
INH I-Treatment.Drug
neurotoxicity I-Effect
was O
made O
. O

Levofloxacin I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
toxic I-Effect
epidermal I-Effect
necrolysis I-Effect
in O
an I-Subject
elderly I-Subject.Age
patient I-Subject
. I-Subject

The O
incidence O
of O
5 I-Treatment.Drug
- I-Treatment.Drug
fluorouracil I-Treatment.Drug
( I-Drug
5 I-Drug
- I-Drug
FU) I-Drug
- O
related I-Adverse_event.Trigger
cardiotoxicity I-Effect
seems O
to O
be O
dosage I-Treatment
and O
schedule I-Treatment
dependent O
. O

Torsades I-Effect
de I-Effect
Pointes I-Effect
induced I-Adverse_event.Trigger
by O
a I-Treatment
combination I-Treatment
of I-Treatment
garenoxacin I-Treatment.Combination.Drug
and I-Treatment
disopyramide I-Treatment.Combination.Drug
and I-Treatment
other I-Treatment
cytochrome I-Treatment.Combination.Drug
P450 I-Treatment.Combination.Drug
, I-Treatment.Combination.Drug
family I-Treatment.Combination.Drug
3 I-Treatment.Combination.Drug
, I-Treatment.Combination.Drug
subfamily I-Treatment.Combination.Drug
A I-Treatment.Combination.Drug
polypeptide I-Treatment.Combination.Drug
- I-Treatment.Combination.Drug
4 I-Treatment.Combination.Drug
- I-Treatment.Combination.Drug
influencing I-Treatment.Combination.Drug
drugs I-Treatment.Combination.Drug
during O
hypokalemia O
due O
to O
licorice O
. O

Ataxia I-Effect
caused I-Adverse_event.Trigger
by O
propafenone I-Treatment.Drug
has O
been O
reported O
to O
the O
pharmaceutical O
companies O
and O
drug O
monitoring O
agencies O
, O
but O
has O
not O
been O
well O
described O
or O
emphasized O
in O
the O
medical O
literature O
. O

The I-Subject
first I-Subject
patient I-Subject
developed I-Adverse_event.Trigger
mild I-Effect
nitritoid I-Effect
symptoms I-Effect
and I-Effect
pain I-Effect
in I-Effect
a I-Effect
band I-Effect
- I-Effect
like I-Effect
distribution I-Effect
, O
corresponding O
to O
T10 O
- O
T12 O
dermatomes O
, O
shortly O
after O
gold I-Treatment.Drug
sodium I-Treatment.Drug
thiomalate I-Treatment.Drug
( I-Treatment
GSTM I-Treatment
) I-Treatment
injection I-Treatment.Route
. O

A O
case O
is O
reported O
of O
an I-Subject
elderly I-Subject.Age
woman I-Subject.Gender
who O
developed I-Adverse_event.Trigger
febrile I-Effect
agranulocytosis I-Effect
several I-Treatment.Time_elapsed
weeks I-Treatment.Time_elapsed
after I-Treatment
commencing I-Treatment
ticlopidine I-Treatment.Drug
but O
who O
had O
a O
favorable O
outcome O
after O
cessation O
of O
that O
drug O
and O
treatment O
with O
filgastrim O
. O

A O
case O
is O
reported O
of O
an I-Subject
elderly I-Subject.Age
woman I-Subject.Gender
who O
developed O
febrile I-Treat_Disorder
agranulocytosis I-Treat_Disorder
several O
weeks O
after O
commencing O
ticlopidine O
but O
who O
had O
a I-Effect
favorable I-Effect
outcome I-Effect
after I-Potential_therapeutic_event.Trigger
cessation I-Treatment
of I-Treatment
that I-Treatment
drug I-Treatment
and I-Treatment
treatment I-Treatment
with I-Treatment
filgastrim I-Treatment.Drug
. O

Two I-Subject.Population
65 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
white I-Subject.Race
men I-Subject.Gender
with I-Subject
coronary I-Subject.Sub_Disorder
heart I-Subject.Sub_Disorder
disease I-Subject.Sub_Disorder
, O
given O
niacin I-Treatment.Drug
therapy I-Treatment
for I-Treatment
dyslipidemia I-Treatment.Treat_Disorder
for I-Treatment
5 I-Treatment.Duration
months I-Treatment.Duration
, O
developed I-Adverse_event.Trigger
intense I-Effect
dental I-Effect
and I-Effect
gingival I-Effect
pain I-Effect
that O
was O
associated O
with O
increases I-Treatment.Dosage
in I-Treatment.Dosage
dose I-Treatment.Dosage
and O
that O
was O
relieved O
with O
discontinuance O
of O
niacin O
treatment O
. O

Two I-Subject.Population
patients I-Subject
are O
described O
who O
developed O
testicular I-Effect
swelling I-Effect
and I-Effect
pain I-Effect
during I-Adverse_event.Trigger
treatment O
with O
desipramine I-Treatment.Drug
. O

Metabolic O
balance O
studies O
and O
rechallenge O
with O
hydrochlorothiazide I-Drug
were O
undertaken O
to O
investigate O
the O
mechanism O
of O
the O
thiazide I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
hyponatremia I-Effect
. O

Paradoxical I-Effect
pulmonary I-Effect
vasoconstriction I-Effect
induced I-Adverse_event.Trigger
by O
nitroglycerin I-Treatment.Drug
in O
idiopathic I-Treat_Disorder
pulmonary I-Treat_Disorder
hypertension I-Treat_Disorder
. O

Although O
visual O
hallucinations O
have O
not O
been O
reported O
as O
an O
adverse O
effect O
of O
this O
agent O
, O
we O
describe O
three O
patients O
who O
experienced O
complex I-Effect
visual I-Effect
hallucinations I-Effect
and I-Effect
altered I-Effect
mental I-Effect
status I-Effect
after I-Adverse_event.Trigger
zonisamide I-Treatment.Drug
treatment O
was O
begun O
or O
its O
dosage O
increased O
. O

Clinical O
profile O
of O
oxcarbazepine I-Treatment.Drug
- O
related I-Adverse_event.Trigger
angioneurotic I-Effect
edema I-Effect
: O
case I-Subject
report O
and O
review O
. O

Extra O
caution O
should O
be O
taken O
in O
using O
octreotide I-Treatment.Drug
or I-Treatment
its I-Treatment
long I-Treatment.Drug
- I-Treatment.Drug
acting I-Treatment.Drug
analog I-Treatment.Drug
in O
patients I-Subject
otherwise O
predisposed I-Adverse_event.Trigger
to O
intrahepatic I-Effect
bile I-Effect
stasis I-Effect
. O

BACKGROUND O
: O
Fluoxetine I-Treatment.Drug
, O
a O
highly O
specific O
serotonin O
reuptake O
inhibitor O
, O
has O
been O
reported O
to O
cause I-Adverse_event.Trigger
sexual I-Effect
dysfunction I-Effect
in O
a O
minority I-Subject
of I-Subject
patients I-Subject
. O

We O
report O
a I-Subject
45 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
Chinese I-Subject.Race
man I-Subject.Gender
with I-Subject
CML I-Treat_Disorder
and I-Treat_Disorder
chronic I-Treat_Disorder
hepatitis I-Treat_Disorder
B I-Treat_Disorder
virus I-Subject
infection I-Subject
, O
on I-Treatment
imatinib I-Treatment.Drug
treatment I-Treatment
, O
presenting I-Adverse_event.Trigger
with O
herpetic I-Effect
rash I-Effect
and I-Effect
acute I-Effect
liver I-Effect
failure I-Effect
. O

One I-Subject.Population
patient I-Subject
had O
severe O
temporary I-Effect
weakness I-Effect
after I-Adverse_event.Trigger
an I-Treatment
ampicillin I-Treatment.Drug
sodium I-Treatment.Drug
challenge I-Treatment
. O

Acute I-Effect
myeloid I-Effect
leukemia I-Effect
and I-Effect
lung I-Effect
cancer I-Effect
occurring I-Adverse_event.Trigger
in O
a I-Subject
chronic I-Treat_Disorder
lymphocytic I-Treat_Disorder
leukemia I-Treat_Disorder
patient I-Subject
treated O
with O
fludarabine I-Treatment.Drug
and I-Treatment
autologous I-Treatment
peripheral I-Treatment
blood I-Treatment
stem I-Treatment
- I-Treatment
cell I-Treatment
transplantation I-Treatment
. O

Despite O
a O
very O
low O
complication O
rate O
, O
several O
severe O
arterial I-Effect
thrombotic I-Effect
events O
have O
been O
reported O
following I-Adverse_event.Trigger
thrombin I-Treatment.Drug
injection I-Treatment.Route
of O
pseudoaneurysms I-Treat_Disorder
. O

The O
results O
clearly O
demonstrate O
that O
CPH82 I-Treatment.Drug
was O
associated I-Adverse_event.Trigger
with O
suppression I-Effect
of I-Effect
the I-Effect
endogeneous I-Effect
production I-Effect
of I-Effect
ACTH I-Effect
and I-Effect
cortisol I-Effect
with I-Effect
a I-Effect
concomitant I-Effect
paradoxical I-Effect
picture I-Effect
of I-Effect
clinical I-Effect
hypercortisolism I-Effect
. O

Exposure O
of O
the O
fetus I-Subject.Age
to O
indomethacin I-Treatment.Drug
by O
administration O
of O
the O
drug O
to O
the O
mother O
may O
cause O
many O
side I-Adverse_event.Trigger
effects I-Adverse_event.Trigger
, O
including O
premature I-Effect
closure I-Effect
of I-Effect
the I-Effect
ductus I-Effect
arteriosus I-Effect
. O

She I-Subject.Gender
was O
diagnosed O
with O
Epstein I-Effect
- I-Effect
Barr I-Effect
virus I-Effect
- I-Effect
associated I-Effect
polymorphic I-Effect
lymphoproliferative I-Effect
disorder I-Effect
( I-Effect
LPD I-Effect
) I-Effect
due I-Adverse_event.Trigger
to O
immunodeficiency I-Treatment
caused I-Treatment
by I-Treatment
MTX I-Treatment.Drug
administration I-Treatment
. O

Pulmonary I-Effect
hypertension I-Effect
during I-Adverse_event.Trigger
lithium I-Treatment.Drug
therapy I-Treatment
: O
clinical O
case O
study O
. O

CONCLUSIONS O
: O
Clinicians O
should O
be O
aware O
of O
this O
adverse I-Adverse_event.Trigger
reaction I-Adverse_event.Trigger
when O
facing O
similar O
complex O
neurologic I-Effect
symptoms I-Effect
in O
patients I-Subject
who O
are O
receiving O
the O
antibiotic O
treatment O
described O
here O
, O
especially O
vancomycin I-Treatment.Drug
. O

Corneal I-Effect
edema I-Effect
recurred O
when I-Adverse_event.Trigger
the I-Treatment
administration I-Treatment
of I-Treatment
amantadine I-Treatment.Drug
was I-Treatment
resumed I-Treatment
. O

Vitamin I-Treatment.Drug
K1 I-Treatment.Drug
caused I-Adverse_event.Trigger
skin I-Effect
rash I-Effect
possibly O
because O
of O
the O
distribution O
and O
metabolism O
characteristic O
of O
the O
drug O
in O
this O
patient O
. O

Initial O
treatment O
with O
heparin O
was O
substituted O
with O
thrombolysis I-Treatment.Drug
, O
which O
resulted I-Adverse_event.Trigger
in O
clinical O
improvement O
and O
dissolution O
of O
right O
heart O
thrombus O
but O
was O
followed O
by O
fatal I-Effect
intracerebral I-Effect
haemorrhage I-Effect
. O

The O
most O
commonly O
recognized O
toxic O
effect I-Adverse_event.Trigger
of O
ethambutol I-Treatment.Drug
is O
optic I-Effect
neuropathy I-Effect
, O
which O
generally O
is O
considered O
uncommon O
and O
reversible O
in O
medical O
literature O
. O

A O
case O
of O
congestive I-Effect
heart I-Effect
failure I-Effect
in I-Adverse_event.Trigger
a I-Subject
child I-Subject.Age
with I-Subject
Wilms I-Treat_Disorder
' I-Treat_Disorder
tumor I-Treat_Disorder
treated O
Adriamycin I-Treatment.Drug
is O
presented O
and O
discussed O
. O

BACKGROUND O
: O
Hypersensitivity I-Effect
reactions I-Effect
to I-Adverse_event.Trigger
cyclosporine I-Treatment.Drug
are O
rare O
. O

This O
is O
the O
first I-Subject
case I-Subject
of O
TMP I-Treatment.Combination.Drug
- I-Treatment
SMX I-Treatment.Combination.Drug
- O
induced I-Adverse_event.Trigger
hypersensitivity I-Effect
syndrome I-Effect
associated O
with O
the O
reactivation I-Effect
of I-Effect
a I-Effect
latent I-Effect
viral I-Effect
infection I-Effect
. O

In O
addition O
, O
single I-Treatment
- I-Treatment
agent I-Treatment
weekly I-Treatment.Freq
AUC2 I-Treatment.Drug
- I-Treatment.Drug
carboplatin I-Treatment.Drug
appeared O
to O
be O
inactive I-Potential_therapeutic_event.Trigger
by O
response O
criteria O
in O
a I-Subject
homogenously I-Subject
defined I-Subject
population I-Subject
of I-Subject
PROC I-Treat_Disorder
. O

CONCLUSIONS O
: O
Intrathecal I-Treatment.Route
baclofen I-Treatment.Drug
can O
impair I-Effect
sexual I-Effect
function I-Effect
and I-Effect
ejaculation I-Effect
in O
some I-Subject
patients I-Subject
. O

A I-Subject
case I-Subject
of O
clozapine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
tonic I-Effect
- I-Effect
clonic I-Effect
seizures I-Effect
managed O
with O
valproate O
: O
implications O
for O
clinical O
care O
. O

A I-Subject
case I-Subject
of O
clozapine I-Treat_Disorder
- I-Treat_Disorder
induced I-Treat_Disorder
tonic I-Treat_Disorder
- I-Treat_Disorder
clonic I-Treat_Disorder
seizures I-Treat_Disorder
managed I-Potential_therapeutic_event.Trigger
with O
valproate I-Treatment.Drug
: O
implications O
for O
clinical O
care O
. O

Serum O
sickness O
consists O
of O
a O
systemic O
reaction O
resulting O
from O
the O
formation O
of O
soluble O
circulating O
immunocomplexes O
after O
the O
introduction O
of O
a O
foreign O
substance O
into O
the O
body O
We O
studied O
a I-Subject
38 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
woman I-Subject.Gender
diagnosed I-Subject
with I-Subject
anxiety I-Treat_Disorder
, I-Treat_Disorder
depression I-Treat_Disorder
and I-Treat_Disorder
right I-Treat_Disorder
sacroileitis I-Treat_Disorder
who O
was O
treated I-Potential_therapeutic_event.Trigger
with O
phenylbutazone I-Treatment.Combination.Drug
, I-Treatment
ranitidine I-Treatment.Combination.Drug
, I-Treatment
clomipramine I-Treatment.Combination.Drug
and I-Treatment
levomepromazine I-Treatment.Combination.Drug
. O

The O
symptomatology I-Adverse_event.Trigger
of O
18 I-Subject.Population
other I-Subject
paediatric I-Subject.Age
cases I-Subject
of O
naphthylimidazoline I-Treatment.Drug
exposure I-Effect
reported O
to O
the O
Belgian O
National O
Poison O
Centre O
, O
is O
also O
discussed O
. O

Anterior I-Effect
spinal I-Effect
artery I-Effect
syndrome I-Effect
-- O
a O
complication I-Adverse_event.Trigger
of O
cervical I-Treatment
intrathecal I-Treatment
phenol I-Treatment.Drug
injection I-Treatment.Route
. O

Phenytoin O
was O
discontinued O
after O
admission O
; O
however O
, O
phenytoin I-Treatment.Drug
1 I-Treatment.Dosage
g I-Treatment.Dosage
i.v I-Treatment.Route
. I-Treatment.Route
was O
given O
for O
a I-Treat_Disorder
tonic I-Treat_Disorder
- I-Treat_Disorder
clonic I-Treat_Disorder
seizure I-Treat_Disorder
two O
days O
after O
admission O
, O
after O
which O
swelling I-Effect
of I-Effect
the I-Effect
face I-Effect
and I-Effect
legs I-Effect
and I-Effect
pruritus I-Effect
developed I-Adverse_event.Trigger
. O

To O
our O
knowledge O
this O
is O
the O
first O
report O
that O
demonstrates O
histological I-Effect
abnormalities I-Effect
of I-Effect
the I-Effect
glomerulus I-Effect
associated I-Adverse_event.Trigger
with O
postoperative I-Treatment
IFN I-Treatment.Drug
- I-Treatment.Drug
beta I-Treatment.Drug
therapy I-Treatment
for O
the O
malignant I-Treat_Disorder
melanoma I-Treat_Disorder
. O

Protease I-Treatment.Drug
inhibitor I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
carbamazepine I-Effect
toxicity I-Effect
. O

This O
report O
details O
a O
case O
of O
bilateral I-Effect
avascular I-Effect
necrosis I-Effect
of I-Effect
the I-Effect
femoral I-Effect
heads I-Effect
in O
a I-Subject
patient I-Subject
receiving I-Adverse_event.Trigger
' I-Treatment.Dosage
standard I-Treatment.Dosage
' I-Treatment.Dosage
doses I-Treatment.Dosage
of I-Treatment
dexamethasone I-Treatment.Drug
as O
part O
of O
the O
antiemetic O
regimen O
used O
in O
cisplatin O
- O
based O
combination O
chemotherapy O
. O

He I-Subject.Gender
recovered I-Potential_therapeutic_event.Trigger
successfully O
after O
treatment O
with O
very I-Treatment.Dosage
high I-Treatment.Dosage
doses I-Treatment.Dosage
of I-Treatment
corticosteroids I-Treatment.Combination.Drug
and I-Treatment
azathioprine I-Treatment.Combination.Drug
. O

Marked I-Effect
hyperkalemia I-Effect
was O
observed I-Adverse_event.Trigger
during I-Treatment
and I-Treatment
immediately I-Treatment.Time_elapsed
after I-Treatment
an I-Treatment
infusion I-Treatment.Route
of I-Treatment
arginine I-Treatment.Drug
monohydrochloride I-Treatment.Drug
in O
two I-Subject.Population
patients I-Subject
with I-Subject
severe I-Subject
hepatic I-Treat_Disorder
disease I-Treat_Disorder
and I-Subject
moderate I-Subject.Sub_Disorder
renal I-Subject.Sub_Disorder
insufficiency I-Subject.Sub_Disorder
. O

Finally O
, O
reserpine I-Treatment.Combination.Drug
toxicity I-Effect
, I-Effect
in I-Effect
particular I-Effect
central I-Effect
nervous I-Effect
system I-Effect
( I-Effect
CNS I-Effect
) I-Effect
disturbances I-Effect
, O
was O
reported I-Adverse_event.Trigger
more O
frequently O
in O
patients O
also I-Treatment
receiving I-Treatment
barbiturates I-Treatment.Combination.Drug
, I-Treatment
suggesting O
additive I-Effect
CNS I-Effect
effects I-Effect
. O

Patients O
receiving O
amifostine I-Treatment.Drug
who O
develop I-Adverse_event.Trigger
only O
fever I-Effect
should O
be O
evaluated O
for O
an O
adverse O
drug O
reaction O
, O
as O
well O
as O
for O
sepsis I-Effect
and I-Effect
fevers I-Effect
of I-Effect
neutropenia I-Effect
, O
and O
it O
may O
be O
necessary O
to O
discontinue O
the O
drug O
. O

Clinical O
signs O
of O
hypermagnesemia I-Effect
are O
an O
uncommon O
complication I-Adverse_event.Trigger
following O
oral I-Treatment.Route
administration I-Treatment
of I-Treatment
magnesium I-Treatment.Drug
sulfate I-Treatment.Drug
. O

Markedly I-Effect
increased I-Effect
pigmementation I-Effect
of I-Effect
skin I-Effect
immediately I-Effect
overlying I-Effect
veins I-Effect
used O
for O
multiple I-Treatment
5 I-Treatment.Drug
- I-Treatment.Drug
fluorouracil I-Treatment.Drug
infusions I-Treatment.Route
was O
noted I-Adverse_event.Trigger
. O

Severe I-Effect
hepatitis I-Effect
caused I-Adverse_event.Trigger
by O
cyproterone I-Treatment.Drug
acetate I-Treatment.Drug
. O

Erythema I-Effect
multiforme I-Effect
associated I-Adverse_event.Trigger
with O
phenytoin I-Treatment.Drug
and I-Treatment
cranial I-Treatment
radiation I-Treatment
therapy I-Treatment
: O
a O
report O
of O
three I-Subject.Population
patients I-Subject
and O
review O
of O
the O
literature O
. O

Chloroquine I-Treatment.Drug
has O
been O
used O
for O
many O
decades O
in O
the O
prophylaxis I-Effect
and I-Effect
treatment I-Effect
of I-Potential_therapeutic_event.Trigger
malaria I-Treat_Disorder
. O

Before O
ICU O
admission O
, O
the I-Subject
patient I-Subject
had I-Subject
suffered I-Subject
from I-Subject
painful I-Subject
mucositis I-Subject.Sub_Disorder
causing O
severe I-Effect
dysphagia I-Effect
and I-Effect
bleeding I-Effect
, O
which O
was O
thought O
to O
be O
the O
result I-Adverse_event.Trigger
of O
chemotherapy I-Treatment.Route
. O

We O
report O
the O
case O
of O
a I-Subject
patient I-Subject
with I-Subject
the I-Subject
acquired I-Treat_Disorder
immunodeficiency I-Treat_Disorder
syndrome I-Treat_Disorder
treated O
with O
rifampicin I-Treatment.Drug
who O
had O
a O
' O
normal O
' O
screening O
test O
for O
adrenal O
insufficiency O
, O
yet O
had I-Adverse_event.Trigger
clinical O
evidence O
of O
adrenal I-Effect
failure I-Effect
. O

We O
postulate O
that O
cyclosporin I-Treatment.Combination.Drug
, O
possibly O
together I-Treatment
with I-Treatment
ganciclovir I-Treatment.Combination.Drug
, O
can O
produce I-Adverse_event.Trigger
transient I-Effect
brain I-Effect
stem I-Effect
or I-Effect
neuromuscular I-Effect
dysfunction I-Effect
with I-Effect
eye I-Effect
movement I-Effect
abnormality I-Effect
in O
occasional I-Subject
patients I-Subject
. O

Three I-Subject.Population
patients I-Subject
, O
in O
whom O
tumour I-Treat_Disorder
overkill O
by O
cytotoxic I-Treatment.Combination.Drug
treatment I-Treatment
, I-Treatment
including I-Treatment
high I-Treatment.Dosage
dose I-Treatment.Dosage
methotrexate I-Treatment.Combination.Drug
with I-Treatment
folinic I-Treatment.Combination.Drug
acid I-Treatment.Combination.Drug
rescue I-Treatment.Combination.Drug
, O
resulted I-Adverse_event.Trigger
in O
the O
' I-Effect
phosphate I-Effect
shower I-Effect
syndrome I-Effect
' I-Effect
( I-Effect
hyper I-Effect
- I-Effect
uricaemia I-Effect
, I-Effect
hyperkalaemia I-Effect
and I-Effect
hyperphosphataemia I-Effect
with I-Effect
hypocalcaemia I-Effect
and I-Effect
tetany I-Effect
, I-Effect
with I-Effect
metabolic I-Effect
acidosis I-Effect
and I-Effect
acute I-Effect
renal I-Effect
impairment I-Effect
) I-Effect
are O
described O
. O

Methylene I-Treatment.Drug
blue I-Treatment.Drug
- O
associated I-Adverse_event.Trigger
serotonin I-Effect
toxicity I-Effect
has O
been O
described O
before O
but O
usually O
as O
mild O
toxicity O
. O

The O
second O
was O
an O
82 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
man I-Subject.Gender
receiving I-Treatment
ticlopidine I-Treatment.Drug
for I-Treatment
2 I-Treatment.Duration
years I-Treatment.Duration
when O
, O
during O
a O
febrile O
episode O
, O
he O
was O
found I-Adverse_event.Trigger
neutropenic I-Effect
with I-Effect
marrow I-Effect
aplasia I-Effect
. I-Effect

INTRODUCTION O
: O
In O
resource O
limited O
settings O
patients I-Subject
on I-Subject
antiretroviral I-Subject
treatment I-Subject
who O
develop O
stavudine I-Treatment.Drug
induced I-Adverse_event.Trigger
hyperlactatemia I-Effect
are O
often O
switched O
to O
zidovudine O
on O
the O
basis O
of O
published O
studies O
that O
demonstrate O
that O
this O
agent O
can O
be O
a O
safe O
alternative O
. O

INTRODUCTION O
: O
In O
resource O
limited O
settings O
patients I-Subject
on I-Subject
antiretroviral I-Subject
treatment I-Subject
who O
develop O
stavudine I-Treat_Disorder
induced I-Treat_Disorder
hyperlactatemia I-Treat_Disorder
are O
often O
switched I-Potential_therapeutic_event.Trigger
to O
zidovudine I-Treatment.Drug
on O
the O
basis O
of O
published O
studies O
that O
demonstrate O
that O
this O
agent O
can O
be O
a O
safe O
alternative O
. O

We O
report O
a O
case O
of O
pediatric I-Subject.Age
bupropion I-Treatment.Drug
ingestion I-Treatment.Route
resulting I-Adverse_event.Trigger
in O
multiple I-Effect
seizures I-Effect
. O

The O
co I-Treatment
- I-Treatment
administration I-Treatment
of I-Treatment
SSRIs I-Treatment.Combination.Drug
and I-Treatment
fentanyl I-Treatment.Combination.Drug
may O
precipitate I-Adverse_event.Trigger
serotonin I-Effect
toxicity I-Effect
. O

Three I-Treatment.Time_elapsed
days I-Treatment.Time_elapsed
after I-Treatment
intravitreal I-Treatment.Route
injection I-Treatment.Route
of I-Treatment
bevacizumab I-Treatment.Drug
, O
acute I-Effect
ocular I-Effect
ischemic I-Effect
syndrome I-Effect
occurred I-Adverse_event.Trigger
. O

After I-Adverse_event.Trigger
addition O
of O
lopinavir I-Treatment.Combination.Drug
/ I-Treatment
ritonavir I-Treatment.Combination.Drug
, O
eight I-Subject.Population
volunteers I-Subject
suffered O
from O
both O
nausea I-Effect
and I-Effect
vomiting I-Effect
, O
one O
from O
nausea O
only O
, O
and O
one O
from O
vomiting O
only O
. O

After I-Adverse_event.Trigger
addition O
of O
lopinavir I-Treatment.Drug
/ I-Treatment
ritonavir I-Treatment.Drug
, O
eight O
volunteers O
suffered O
from O
both O
nausea O
and O
vomiting O
, O
one O
from O
nausea O
only O
, O
and O
one I-Subject.Population
from O
vomiting I-Effect
only O
. O

After I-Adverse_event.Trigger
addition O
of O
lopinavir I-Treatment.Drug
/ I-Treatment
ritonavir I-Treatment.Drug
, O
eight O
volunteers O
suffered O
from O
both O
nausea O
and O
vomiting O
, O
one I-Subject.Population
from O
nausea I-Effect
only O
, O
and O
one O
from O
vomiting O
only O
. O

Calcipotriol I-Treatment.Drug
( O
Daivonex O
R O
; O
Leo O
Pharmaceuticals O
, O
Zurich O
, O
Switzerland O
) O
may O
cause I-Adverse_event.Trigger
irritation I-Effect
of I-Effect
the I-Effect
skin I-Effect
, O
whereas O
allergic O
reactions O
are O
less O
common O
. O

After O
discontinuation I-Treatment
of I-Treatment
danazol I-Treatment.Drug
the O
diabetes I-Treat_Disorder
completely O
resolved I-Potential_therapeutic_event.Trigger
. O

We O
describe O
the O
development I-Adverse_event.Trigger
of O
ischemic I-Effect
colitis I-Effect
in O
a O
woman I-Subject.Gender
who O
was O
treated O
with O
tegaserod I-Treatment.Drug
and O
review O
the O
relationship O
among O
ischemic O
colitis O
, O
tegaserod O
use O
, O
and O
irritable O
bowel O
syndrome O
. O

We O
presented O
the O
case O
of O
a I-Subject
patient I-Subject
who O
developed O
a O
cutaneous I-Effect
reaction I-Effect
induced I-Adverse_event.Trigger
by O
captopril I-Treatment.Drug
with O
positive O
patch O
test O
. O

Three I-Subject.Population
of I-Subject
these I-Subject
patients I-Subject
had O
convulsions I-Effect
attributed I-Adverse_event.Trigger
to O
imipenem I-Treatment.Combination.Drug
/ I-Treatment
cilastatin I-Treatment.Combination.Drug
; O
3.6 O
% O
of O
the O
patients O
had O
seizure O
, O
or O
2 O
% O
of O
imipenem O
/ O
cilastatin O
administrations O
was O
followed O
by O
a O
seizure O
attack O
. O

Three O
of O
these O
patients O
had O
convulsions O
attributed O
to O
imipenem O
/ O
cilastatin O
; O
3.6 O
% O
of O
the O
patients O
had O
seizure O
, O
or O
2 I-Subject.Population
% I-Subject.Population
of O
imipenem I-Treatment.Combination.Drug
/ I-Treatment
cilastatin I-Treatment.Combination.Drug
administrations O
was O
followed I-Adverse_event.Trigger
by O
a O
seizure I-Effect
attack O
. O

This O
latest O
( O
third O
) O
report O
suggests O
that O
the O
safety O
profile O
should O
be O
reexamined O
and O
at O
least O
raises I-Adverse_event.Trigger
the O
question O
of O
potential I-Effect
renal I-Effect
toxicity I-Effect
of O
interferons I-Treatment.Drug
in O
MS. I-Treat_Disorder

Co I-Treatment.Drug
- I-Treatment.Drug
trimoxazole I-Treatment.Drug
red I-Effect
cell I-Effect
aplasia I-Effect
in I-Adverse_event.Trigger
leukaemia I-Treat_Disorder
. O

Interferon I-Treatment.Drug
- I-Treatment.Drug
alpha I-Treatment.Drug
( I-Treatment.Drug
IFN I-Treatment.Drug
- I-Treatment.Drug
alpha I-Treatment.Drug
) I-Treatment.Drug
may O
precipitate O
or O
exacerbate O
the O
occurrence I-Adverse_event.Trigger
of O
MPGN I-Effect
. O

Toxic I-Effect
epidermal I-Effect
necrolysis I-Effect
after I-Adverse_event.Trigger
the O
use O
of O
high I-Treatment
- I-Treatment
dose I-Treatment
cytosine I-Treatment.Drug
arabinoside I-Treatment.Drug
. O

We O
describe O
3 I-Subject.Population
elderly I-Subject.Age
patients I-Subject
with O
moderate I-Effect
to I-Effect
severe I-Effect
ataxia I-Effect
that O
occurred I-Adverse_event.Trigger
while O
they O
were O
taking I-Treatment
propafenone I-Treatment.Drug
. O

Gestational I-Effect
diabetes I-Effect
was O
no O
less O
severe O
( O
degree O
of O
hyperglycaemia O
, O
need O
for O
insulin O
therapy O
) O
when O
associated I-Adverse_event.Trigger
with O
norethisterone I-Treatment.Drug
. O

However O
, O
follow O
- O
up O
revealed O
that O
gestational O
diabetes O
when O
associated O
with O
norethisterone I-Treatment.Drug
had O
a O
lesser O
risk O
of O
emerging I-Adverse_event.Trigger
diabetes I-Effect
mellitus I-Effect
and I-Effect
impaired I-Effect
glucose I-Effect
tolerance I-Effect
. O

Because O
the O
cerebellar I-Effect
toxicity I-Effect
may O
be O
worsened O
by O
continuation O
of O
therapy O
after O
initial O
onset O
of O
symptoms O
, O
prompt O
termination O
of I-Adverse_event.Trigger
HDARAC I-Treatment.Drug
is O
recommended O
. O

We O
describe O
a O
case O
of O
ulcerative I-Effect
proctitis I-Effect
after I-Adverse_event.Trigger
ibuprofen I-Treatment.Drug
treatment I-Treatment
in O
a I-Subject
girl I-Subject.Gender
with I-Subject
juvenile I-Treat_Disorder
systemic I-Treat_Disorder
lupus I-Treat_Disorder
erythematosus I-Treat_Disorder
. O

Clinicians O
should O
include O
phenolphthalein I-Treatment.Drug
in O
their O
list O
of O
possible O
causes O
of O
drug O
- O
induced I-Adverse_event.Trigger
TEN I-Effect
. O

Methotrexate I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
diffuse I-Effect
interstitial I-Effect
pulmonary I-Effect
fibrosis I-Effect
. O

Abdominal I-Effect
wall I-Effect
ulceration I-Effect
and I-Effect
mucinosis I-Effect
secondary I-Adverse_event.Trigger
to O
recombinant I-Treatment.Drug
human I-Treatment.Drug
interferon I-Treatment.Drug
- I-Treatment.Drug
beta I-Treatment.Drug
- I-Treatment.Drug
1b I-Treatment.Drug
. O

Asthenozoospermia I-Effect
: O
possible O
association I-Adverse_event.Trigger
with O
long I-Treatment.Duration
- I-Treatment.Duration
term I-Treatment.Duration
exposure I-Treatment
to I-Treatment
an I-Treatment
anti I-Treatment
- I-Treatment
epileptic I-Treatment
drug I-Treatment
of I-Treatment
carbamazepine I-Treatment.Drug
. O

Psoriasis I-Effect
triggered I-Adverse_event.Trigger
by O
toll O
- O
like O
receptor O
7 O
agonist O
imiquimod I-Treatment.Drug
in O
the O
presence O
of O
dermal I-Treat_Disorder
plasmacytoid I-Treat_Disorder
dendritic I-Treat_Disorder
cell I-Treat_Disorder
precursors I-Treat_Disorder
. O

A I-Subject
52 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
Black I-Subject.Race
woman I-Subject.Gender
on O
phenytoin I-Treatment.Drug
therapy O
for O
post I-Treat_Disorder
- I-Treat_Disorder
traumatic I-Treat_Disorder
epilepsy I-Treat_Disorder
developed I-Adverse_event.Trigger
transient I-Effect
hemiparesis I-Effect
contralateral I-Effect
to I-Effect
the I-Effect
injury I-Effect
. O

Use O
of O
the O
Naranjo O
probability O
scale O
determined O
the O
association O
between O
cephalosporin I-Treatment.Drug
use I-Adverse_event.Trigger
and O
leukopenia I-Effect
to O
be O
probable O
. O

Sister O
chromatid O
exchanges O
( O
SCEs O
) O
, O
a O
sensitive O
measure O
of O
chromosome I-Effect
damage I-Effect
, O
were O
counted O
in O
peripheral O
- O
blood O
lymphocytes O
from O
10 I-Subject.Population
patients I-Subject
with I-Subject
Behcet I-Treat_Disorder
's I-Treat_Disorder
syndrome I-Treat_Disorder
receiving I-Adverse_event.Trigger
chlorambucil I-Treatment.Drug
. O

Sarcoma I-Effect
complicating I-Adverse_event.Trigger
therapy O
with O
cyclophosphamide I-Treatment.Drug
. O

Clozapine I-Treatment.Drug
induced I-Adverse_event.Trigger
polyserositis I-Effect
. O

Fatal O
interstitial I-Effect
lung I-Effect
disease I-Effect
after I-Adverse_event.Trigger
erlotinib I-Treatment.Drug
administration O
in O
a I-Subject
patient I-Subject
with I-Subject
radiation I-Subject.Sub_Disorder
fibrosis I-Subject.Sub_Disorder
. O

The O
pharmaceutical O
company O
producing O
Halfan I-Treatment.Drug
has O
reported I-Adverse_event.Trigger
8 I-Effect
cardiac I-Effect
arrests I-Effect
, O
leading O
to O
6 I-Effect
deaths I-Effect
, O
when I-Treatment
a I-Treatment.Dosage
higher I-Treatment.Dosage
dose I-Treatment.Dosage
than I-Treatment.Dosage
recommended I-Treatment.Dosage
was I-Treatment
used I-Treatment
, O
there O
was O
recent O
or O
concomitant O
treatment O
with O
mefloquine I-Drug
, O
there O
was O
pre O
- O
existing O
prolongation O
of O
the O
QT O
interval O
or O
the O
patient O
had O
a O
thiamine O
deficiency O
. O

CONCLUSIONS O
: O
Fixed I-Effect
drug I-Effect
rash I-Effect
induced I-Adverse_event.Trigger
by O
methylphenidate I-Treatment.Drug
is O
a O
possible O
but O
rare O
phenomenon O
. O

Special O
care O
should O
be O
taken O
when O
pulmonary I-Effect
symptoms I-Effect
appear I-Adverse_event.Trigger
in O
association O
with O
ticlopidine I-Treatment.Drug
treatment I-Treatment
. O

CONCLUSION O
: O
Although O
a O
definite O
association O
has O
not O
been O
proven O
, O
clinicians O
should O
be O
aware O
of O
the O
possibility O
of O
agranulocytosis I-Effect
while O
using I-Adverse_event.Trigger
quetiapine I-Treatment.Drug
. O

Acute I-Effect
renal I-Effect
failure I-Effect
is O
a O
rare O
complication I-Adverse_event.Trigger
following O
the O
administration O
of O
intravenous I-Treatment.Route
immunoglobulin I-Treatment.Drug
( I-Treatment
IVIG I-Treatment
) I-Treatment
. O

We O
report O
four O
patients O
, O
three O
of O
whom O
first O
developed O
psoriasis O
and O
one I-Subject.Population
who O
had I-Effect
an I-Effect
aggravation I-Effect
of I-Effect
the I-Effect
condition I-Effect
during O
treatment O
with I-Adverse_event.Trigger
interferon I-Treatment.Drug
- I-Treatment.Drug
alpha I-Treatment.Drug
. O

We O
report O
four O
patients O
, O
three I-Subject.Population
of O
whom O
first O
developed I-Adverse_event.Trigger
psoriasis I-Effect
and O
one O
who O
had O
an O
aggravation O
of O
the O
condition O
during O
treatment O
with O
interferon I-Treatment.Drug
- I-Treatment.Drug
alpha I-Treatment.Drug
. O

Reactivation I-Effect
of I-Effect
cytomegalovirus I-Effect
probably O
followed I-Adverse_event.Trigger
the O
treatment O
of O
Wegener I-Treat_Disorder
's I-Treat_Disorder
granulomatosis I-Treat_Disorder
with O
corticosteroids I-Treatment.Combination.Drug
and I-Treatment
azathioprine I-Treatment.Combination.Drug
. O

We O
present O
a O
case O
of O
respiratory I-Effect
failure I-Effect
occurring I-Adverse_event.Trigger
in O
a I-Subject
woman I-Subject.Gender
at I-Subject
16 I-Subject.Sub_Disorder
weeks I-Subject.Sub_Disorder
' I-Subject.Sub_Disorder
gestation I-Subject.Sub_Disorder
who O
was O
being I-Treatment
treated I-Treatment
with I-Treatment
nitrofurantoin I-Treatment.Drug
for I-Treatment
a I-Treatment
urinary I-Treatment.Treat_Disorder
tract I-Treatment.Treat_Disorder
infection I-Treatment.Treat_Disorder
. O

We O
describe O
a I-Subject
case I-Subject
of I-Subject
EGE I-Subject.Sub_Disorder
manifested I-Adverse_event.Trigger
as O
an O
allergy I-Effect
to O
gemfibrozil I-Treatment.Drug
. O

RESULTS O
: O
At O
our O
institution O
, O
no O
children I-Subject.Age
appeared I-Adverse_event.Trigger
with I-Adverse_event.Trigger
acute O
INH I-Treatment.Drug
neurotoxicity I-Effect
in O
the O
period O
1985 O
through O
1990 O
, O
whereas O
seven O
patients O
were O
treated O
from O
1991 O
through O
1993 O
. O

Two I-Subject.Population
patients I-Subject
on O
long I-Treatment
- I-Treatment
term I-Treatment
lithium I-Treatment.Drug
therapy I-Treatment
developed I-Adverse_event.Trigger
the O
nephrotic I-Effect
syndrome I-Effect
. O

Acute I-Effect
psychosis I-Effect
associated I-Adverse_event.Trigger
with O
levetiracetam I-Treatment.Drug
. O

Hypoglycemia I-Effect
induced I-Adverse_event.Trigger
by O
long I-Treatment.Drug
- I-Treatment.Drug
acting I-Treatment.Drug
somatostatin I-Treatment.Drug
analogues I-Treatment.Drug
in O
a I-Subject
patient I-Subject
with I-Subject
nonfunctional I-Treat_Disorder
neuroendocrine I-Treat_Disorder
tumor I-Treat_Disorder
. O

CASE O
REPORT O
: O
We O
report O
a I-Subject
patient I-Subject
who O
developed I-Effect
a I-Effect
DAT I-Effect
- I-Effect
positive I-Effect
hemolytic I-Effect
episode I-Effect
after I-Adverse_event.Trigger
a I-Treatment.Combination.Drug
red I-Treatment.Combination.Drug
cell I-Treatment.Combination.Drug
( I-Treatment
RBC I-Treatment
) I-Treatment
transfusion I-Treatment.Route
was I-Treatment
delivered I-Treatment
during I-Treatment
the I-Treatment
infusion I-Treatment.Route
of I-Treatment
her I-Treatment
17th I-Treatment.Duration
cycle I-Treatment.Duration
of I-Treatment
oxaliplatin I-Treatment.Combination.Drug
. O

Regression I-Potential_therapeutic_event.Trigger
of O
thyrotoxic I-Treat_Disorder
ophthalmopathy I-Treat_Disorder
following O
lithium I-Treatment.Drug
withdrawal I-Treatment
. O

Mechanism O
of O
topiramate I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
acute I-Effect
- I-Effect
onset I-Effect
myopia I-Effect
and I-Effect
angle I-Effect
closure I-Effect
glaucoma I-Effect
. O

The O
clinical O
symptoms O
of O
gastric I-Effect
mucosa I-Effect
foveolar I-Effect
hyperplasia I-Effect
due I-Adverse_event.Trigger
to O
long I-Treatment.Duration
- I-Treatment.Duration
term I-Treatment.Duration
PGE1 I-Treatment.Drug
therapy I-Treatment
simulate I-Effect
hypertrophic I-Effect
pyloric I-Effect
stenosis I-Effect
. O

Aggressive O
management O
of O
doxorubicin I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
cardiomyopathy I-Effect
associated O
with O
' I-Treatment.Dosage
low I-Treatment.Dosage
' I-Treatment.Dosage
doses I-Treatment.Dosage
of O
doxorubicin O
. O

Generalized I-Effect
argyria I-Effect
after I-Adverse_event.Trigger
habitual I-Treatment
use I-Treatment
of I-Treatment
AgNO3 I-Treatment.Drug
. O

The O
authors O
report O
the O
first O
case O
of O
bucillamine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
giant I-Effect
mammary I-Effect
hyperplasia I-Effect
. O

Hydroxyurea I-Treatment.Combination.Drug
( I-Treatment
HU I-Treatment
) I-Treatment
and I-Treatment
sodium I-Treatment.Combination.Drug
phenylbutyrate I-Treatment.Combination.Drug
( I-Treatment
SPB I-Treatment
) I-Treatment
have O
been O
shown O
to O
increase I-Adverse_event.Trigger
fetal O
hemoglobin I-Effect
( I-Effect
Hb I-Effect
F I-Effect
) I-Effect
levels I-Effect
in O
patients I-Subject
with I-Subject
thalassemia I-Treat_Disorder
intermedia I-Treat_Disorder
. O

We O
report O
a I-Subject
case I-Subject
of O
biopsy O
proven O
myositis I-Effect
whose O
symptoms I-Adverse_event.Trigger
began I-Adverse_event.Trigger
within I-Treatment
10 I-Treatment.Time_elapsed
days I-Treatment.Time_elapsed
of I-Treatment
receiving I-Treatment
leuprolide I-Treatment.Drug
acetate I-Treatment.Drug
therapy I-Treatment
for O
prostate I-Treat_Disorder
cancer I-Treat_Disorder
. O

Venlafaxine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
urinary I-Effect
incontinence I-Effect
resolved O
after O
switching O
to O
sertraline O
. O

Venlafaxine I-Treat_Disorder
- I-Treat_Disorder
induced I-Treat_Disorder
urinary I-Treat_Disorder
incontinence I-Treat_Disorder
resolved I-Potential_therapeutic_event.Trigger
after O
switching O
to O
sertraline I-Treatment.Drug
. O

We O
report O
two O
cases O
of O
severe O
serotonin I-Effect
syndrome I-Effect
induced I-Adverse_event.Trigger
by O
the O
administration O
of O
cyclobenzaprine I-Treatment.Combination.Drug
in O
postoperative I-Subject.Sub_Disorder
patients I-Subject
already O
receiving O
another O
proserotoninergic O
drug O
( O
phenelzine I-Treatment.Combination.Drug
in O
one O
case O
and O
duloxetine O
in O
the O
other O
) O
. O

We O
report O
two O
cases O
of O
severe O
serotonin I-Effect
syndrome I-Effect
induced I-Adverse_event.Trigger
by O
the O
administration O
of O
cyclobenzaprine I-Treatment.Combination.Drug
in O
postoperative I-Subject.Sub_Disorder
patients I-Subject
already O
receiving O
another O
proserotoninergic O
drug O
( O
phenelzine O
in O
one O
case O
and O
duloxetine I-Treatment.Combination.Drug
in O
the O
other O
) O
. O

OBJECTIVE O
: O
To O
report O
2 I-Subject.Population
cases I-Subject
of O
serotonin I-Effect
syndrome I-Effect
with I-Effect
serious I-Effect
extrapyramidal I-Effect
movement I-Effect
disorders I-Effect
occurring I-Adverse_event.Trigger
when O
metoclopramide I-Treatment.Combination.Drug
was I-Treatment
coadministered I-Treatment
with I-Treatment
sertraline I-Treatment.Combination.Drug
or I-Treatment
venlafaxine I-Treatment.Combination.Drug
. O

We O
report O
a I-Subject
31 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
women I-Subject.Gender
with I-Subject
recurrent I-Treat_Disorder
Hodgkin I-Treat_Disorder
's I-Treat_Disorder
lymphoma I-Treat_Disorder
and I-Subject
unrecognized I-Subject.Sub_Disorder
HMSN I-Subject.Sub_Disorder
- I-Subject.Sub_Disorder
1 I-Subject.Sub_Disorder
who O
developed I-Adverse_event.Trigger
severe I-Effect
motor I-Effect
neuropathy I-Effect
3 I-Treatment.Time_elapsed
weeks I-Treatment.Time_elapsed
after I-Treatment
the I-Treatment
first I-Treatment
cycle I-Treatment
of I-Treatment
treatment I-Treatment
including I-Treatment
2 I-Treatment.Dosage
mg I-Treatment.Dosage
of I-Treatment
vincristine I-Treatment.Drug
. O

When O
the I-Subject
patient I-Subject
was O
treated I-Adverse_event.Trigger
again O
with O
fludarabine I-Treatment.Drug
nine I-Time_elapsed
months I-Time_elapsed
later I-Time_elapsed
, O
the I-Effect
DAT I-Effect
became I-Effect
positive I-Effect
with I-Effect
anti I-Effect
- I-Effect
IgG I-Effect
and I-Effect
anti I-Effect
- I-Effect
C3d I-Effect
antiglobulins I-Effect
after O
the O
second I-Treatment
course I-Treatment
of I-Treatment
treatment I-Treatment
. O

This O
case O
report O
describes O
a O
patient I-Subject
who O
was O
previously O
prescribed O
alendronate I-Treatment.Combination.Drug
( I-Treatment
Fosamax I-Treatment
) I-Treatment
and O
presented I-Adverse_event.Trigger
with O
postoperative I-Effect
hypophosphatemia I-Effect
and I-Effect
hypocalcemic I-Effect
tetany I-Effect
after I-Treatment
bowel I-Treatment
preparation I-Treatment
with I-Treatment
Fleet I-Treatment.Combination.Drug
Phospho I-Treatment.Combination.Drug
- I-Treatment.Combination.Drug
Soda I-Treatment.Combination.Drug
. O

Acute I-Effect
dystonic I-Effect
reaction I-Effect
with I-Adverse_event.Trigger
low I-Treatment.Dosage
- I-Treatment.Dosage
dose I-Treatment.Dosage
pimozide I-Treatment.Drug
. O

There O
are O
, O
however O
, O
case O
studies O
describing O
patients O
experiencing O
recurrences I-Effect
of I-Effect
tics I-Effect
following I-Adverse_event.Trigger
treatment I-Treatment
with I-Treatment
atomoxetine I-Treatment.Drug
. O

Nicotinic I-Treatment.Drug
acid I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
fulminant I-Effect
hepatic I-Effect
failure I-Effect
. O

Ketanserin O
in O
the O
treatment O
of O
protamine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
pulmonary I-Effect
hypertension I-Effect
. I-Effect

We O
have O
safely O
used O
recombinant I-Treatment.Drug
factor I-Treatment.Drug
VIIa I-Treatment.Drug
to O
treat I-Potential_therapeutic_event.Trigger
bleeding I-Treat_Disorder
in O
the O
immediate I-Time_elapsed
and I-Time_elapsed
long I-Time_elapsed
- I-Time_elapsed
term I-Time_elapsed
period I-Time_elapsed
following O
PCC I-Subject.Sub_Disorder
- I-Subject.Sub_Disorder
related I-Subject.Sub_Disorder
MI I-Subject.Sub_Disorder
. O

We O
have O
safely O
used O
recombinant O
factor O
VIIa O
to O
treat O
bleeding O
in O
the O
immediate O
and O
long O
- O
term O
period O
following O
PCC I-Treatment.Drug
- O
related I-Adverse_event.Trigger
MI I-Effect
. O

Lithium I-Treatment.Combination.Drug
and I-Treatment
venlafaxine I-Treatment.Combination.Drug
interaction I-Treatment
: O
a O
case I-Adverse_event.Trigger
of O
serotonin I-Effect
syndrome I-Effect
. O

The O
seizures I-Effect
were O
suspected O
to O
be O
caused I-Adverse_event.Trigger
by O
a O
reduced I-Treatment.Dosage
concentration I-Treatment.Dosage
of I-Treatment
VPA I-Treatment.Drug
in I-Treatment
the I-Treatment
blood I-Treatment
. O

D I-Treatment.Drug
- I-Treatment.Drug
penicillamine I-Treatment.Drug
induced I-Adverse_event.Trigger
crescentic I-Effect
glomerulonephritis I-Effect
: O
report O
and O
review O
of O
the O
literature O
. O

We O
offered O
several O
tentative O
explanations O
for O
this O
event O
, O
including O
an O
adverse I-Effect
interaction I-Effect
between I-Adverse_event.Trigger
paroxetine I-Treatment.Combination.Drug
and I-Treatment
other I-Treatment
agent(s I-Treatment
) I-Treatment
used O
in O
the O
course O
of O
the O
anaesthesia I-Combination.Drug
. O

Neuroleptic I-Effect
malignant I-Effect
syndrome I-Effect
is O
an O
uncommon O
and O
potentially O
fatal O
idiosynchratic O
reaction I-Adverse_event.Trigger
of O
antipsychotic I-Treatment.Drug
drugs I-Treatment
, O
in O
which O
the O
clinical O
scenario O
encompass O
muscular I-Effect
rigidity I-Effect
, I-Effect
hyperthermia I-Effect
, I-Effect
autonomic I-Effect
dysfunction I-Effect
, I-Effect
altered I-Effect
consciousness I-Effect
, I-Effect
high I-Effect
creatinine I-Effect
phosphokinase I-Effect
levels I-Effect
, I-Effect
and I-Effect
leukocytosis I-Effect
. O

Indinavir I-Treatment.Drug
- O
associated I-Adverse_event.Trigger
nephrolithiasis I-Effect
and I-Effect
chronic I-Effect
interstitial I-Effect
nephritis I-Effect
were O
the O
only O
possible O
causes O
identified O
in O
this O
patient O
. O

Gemcitabine I-Treatment.Drug
is O
a O
chemotherapy O
agent O
that O
may O
cause I-Adverse_event.Trigger
unpredictable I-Effect
side I-Effect
effects I-Effect
. O

Albendazole I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
pseudomembranous I-Effect
colitis I-Effect
. O

Tuberculous I-Effect
uveitis I-Effect
after I-Adverse_event.Trigger
treatment O
with O
etanercept I-Treatment.Drug
. O

Salicylate I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
hepatotoxicity I-Effect
is O
reviewed O
. O

To O
describe O
a I-Subject
case I-Subject
of O
flecainide I-Treatment.Combination.Drug
- O
induced I-Adverse_event.Trigger
delirium I-Effect
associated O
with O
a O
pharmacokinetic O
drug O
interaction I-Treatment
with I-Treatment
paroxetine I-Treatment.Combination.Drug
. O

We O
report O
on O
a I-Subject
patient I-Subject
who O
developed I-Adverse_event.Trigger
hypersensitivity I-Effect
pneumonitis I-Effect
during O
treatment O
with O
the O
beta O
- O
blocker O
, O
celiprolol I-Treatment.Drug
. O

dexmedetomidine I-Treatment.Drug
is O
used I-Potential_therapeutic_event.Trigger
to I-Potential_therapeutic_event.Trigger
provide I-Effect
sedation I-Effect
for O
pediatric I-Subject.Age
patients I-Subject
undergoing I-Subject
nonpainful I-Subject
radiological I-Subject
imaging I-Subject
studies I-Subject
. O

A I-Subject
71 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
woman I-Subject.Gender
developed I-Adverse_event.Trigger
serotonin I-Effect
syndrome I-Effect
while O
receiving O
treatment O
with O
moderate I-Treatment.Dosage
doses I-Treatment.Dosage
of I-Treatment
lithium I-Treatment.Combination.Drug
and I-Treatment
venlafaxine I-Treatment.Combination.Drug
for O
refractory I-Treat_Disorder
depression I-Treat_Disorder
. O

Four I-Treatment.Time_elapsed
years I-Treatment.Time_elapsed
after I-Treatment.Time_elapsed
the I-Treatment
beginning I-Treatment
of I-Treatment
IFN I-Treatment.Drug
therapy I-Treatment
, O
he I-Subject.Gender
acutely I-Effect
developed I-Effect
moderate I-Effect
hyperglycemia I-Effect
and I-Effect
severe I-Effect
ketonuria I-Effect
with I-Effect
positive I-Effect
islet I-Effect
cell I-Effect
antibody I-Effect
, O
and O
then O
28 O
units O
/ O
day O
of O
insulin O
injection O
was O
started O
. O

Tardive I-Effect
dyskinesia I-Effect
in I-Adverse_event.Trigger
2 I-Subject.Population
patients I-Subject
treated O
with O
ziprasidone I-Treatment.Drug
. O

The O
mean O
time O
from O
starting O
MMF I-Treatment.Drug
to O
the O
development I-Adverse_event.Trigger
of O
neutropenia I-Effect
was O
4 O
months O
. O

Fulminant I-Effect
hepatic I-Effect
failure I-Effect
associated I-Adverse_event.Trigger
with O
bicalutamide I-Treatment.Drug
. O

A O
complex O
pattern O
of O
melanonychia I-Effect
and I-Effect
onycholysis I-Effect
after O
treatment I-Adverse_event.Trigger
with O
pemetrexed I-Treatment.Drug
for I-Treatment
lung I-Treatment.Treat_Disorder
cancer I-Treatment.Treat_Disorder
. O

Hypernatraemia I-Effect
induced I-Adverse_event.Trigger
by I-Adverse_event.Trigger
sodium I-Treatment.Drug
polystyrene I-Treatment.Drug
sulphonate I-Treatment.Drug
( I-Treatment.Drug
Kayexalate I-Treatment.Drug
) I-Treatment
in O
two I-Subject.Population
extremely I-Subject
low I-Subject
birth I-Subject
weight I-Subject
newborns I-Subject.Age
. O

Hypoxia O
is O
a O
predisposing O
factor O
for O
premature I-Effect
ductal I-Effect
closure I-Effect
and O
often O
occurs O
after I-Adverse_event.Trigger
maternal I-Treatment.Route
indomethacin I-Treatment.Drug
therapy I-Treatment
. O

Severe O
histological I-Effect
osteomalacia I-Effect
developed I-Adverse_event.Trigger
in O
a I-Subject
woman I-Subject.Gender
with I-Subject
Crohn I-Treat_Disorder
's I-Treat_Disorder
disease I-Treat_Disorder
2 I-Treatment
years I-Treatment
after I-Treatment
ileal I-Treatment
resection I-Treatment
and I-Treatment
the I-Treatment
start I-Treatment.Time_elapsed
of I-Treatment
cholestyramine I-Treatment.Drug
therapy O
. O

Serotonin I-Effect
syndrome I-Effect
( I-Effect
SS I-Effect
) I-Effect
and I-Effect
neuroleptic I-Effect
malignant I-Effect
syndrome I-Effect
( I-Effect
NMS I-Effect
) I-Effect
are O
medical O
emergencies O
associated I-Adverse_event.Trigger
with O
psychotropic I-Treatment.Drug
administration I-Treatment
. O

Drug I-Effect
eruption I-Effect
caused I-Adverse_event.Trigger
by O
azathioprine I-Treatment.Drug
: O
value O
of O
using O
the O
drug O
- O
induced O
lymphocytes O
stimulation O
test O
for O
diagnosis O
. O

Continuous O
EEG O
monitoring O
is O
helpful O
in O
managing O
seizures I-Effect
that O
occur I-Adverse_event.Trigger
as O
a I-Treatment
complication I-Treatment
of I-Treatment
CBZ I-Treatment.Drug
OD I-Treatment.Drug
, O
after O
the O
course O
of O
recovery O
or O
worsening O
, O
and O
in O
providing O
assistance O
with O
prognosis O
. O

The O
fluorine I-Treatment.Drug
contained O
in O
niflumic I-Treatment.Drug
acid I-Treatment.Drug
induced I-Adverse_event.Trigger
a O
marked I-Effect
densification I-Effect
of I-Effect
trabecular I-Effect
bone I-Effect
in O
all I-Subject
3 I-Subject.Population
cases I-Subject
. O

A I-Subject
17 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
boy I-Subject.Gender
with I-Subject
refractory I-Treat_Disorder
psoriatic I-Treat_Disorder
arthritis I-Treat_Disorder
and I-Subject
alpha I-Subject.Sub_Disorder
- I-Subject.Sub_Disorder
1 I-Subject.Sub_Disorder
antitrypsin I-Subject.Sub_Disorder
deficiency I-Subject.Sub_Disorder
who O
developed I-Adverse_event.Trigger
a O
syringotropic I-Effect
hypersensitivity I-Effect
reaction I-Effect
after O
9 I-Treatment.Duration
months I-Treatment.Duration
of I-Treatment
therapy I-Treatment
with I-Treatment
infliximab I-Treatment.Combination.Drug
and I-Treatment
leflunomide I-Treatment.Combination.Drug
is O
described O
. O

Managing O
cardiovascular I-Effect
collapse I-Effect
in I-Adverse_event.Trigger
severe I-Treatment
flecainide I-Treatment.Drug
overdose I-Treatment.Dosage
without O
recourse O
to O
extracorporeal O
therapy O
. O

A O
53 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
Caucasian I-Subject.Race
male I-Subject.Gender
victim I-Subject
of I-Subject
suicide I-Subject
was O
suspected O
of O
overdose I-Treatment.Dosage
with I-Adverse_event.Trigger
sertraline I-Treatment.Combination.Drug
and I-Treatment
alprazolam I-Treatment.Combination.Drug
after O
death O
- O
scene O
investigation O
. O

Infliximab I-Treatment.Drug
therapy I-Treatment
may O
cause I-Adverse_event.Trigger
a O
lupus I-Effect
- I-Effect
like I-Effect
syndrome I-Effect
that O
is O
reversible O
upon O
discontinuing O
this O
agent O
. O

A I-Subject
7 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
with I-Subject
congenital I-Treat_Disorder
toxoplasmosis I-Treat_Disorder
who O
took O
pyrimethamine I-Treatment.Combination.Drug
and I-Treatment
sulfadiazine I-Treatment.Combination.Drug
for I-Treatment
reactivated I-Treatment.Treat_Disorder
chorioretinitis I-Treatment.Treat_Disorder
developed I-Adverse_event.Trigger
fever I-Effect
, I-Effect
severe I-Effect
cutaneous I-Effect
involvement I-Effect
, I-Effect
swelling I-Effect
, I-Effect
abdominal I-Effect
pain I-Effect
and I-Effect
transaminitis I-Effect
, O
persisting O
weeks O
after O
withholding O
medicines O
. O

Pain O
management O
discussion O
forum O
: O
serious I-Effect
interaction I-Effect
among I-Adverse_event.Trigger
frequently I-Treatment.Freq
used I-Treatment
drugs I-Treatment.Drug
for O
chronic I-Treat_Disorder
pain I-Treat_Disorder
. O

This I-Effect
kind I-Effect
of I-Effect
reaction I-Effect
is O
seldom O
mentioned O
as O
occurring I-Adverse_event.Trigger
during O
co I-Treatment
- I-Treatment
administration I-Treatment
with I-Treatment
tizanidine I-Treatment.Drug
. O

A O
retrospective O
epidemiological O
study O
of O
deaths O
from O
hepatic I-Effect
angiosarcoma I-Effect
( O
HAS O
) O
in O
the O
U.S. O
showed O
that O
during O
1964 O
- O
- O
74 O
there O
were O
168 O
such O
cases O
, O
of O
which O
37 I-Subject.Population
( I-Subject
22 I-Subject
% I-Subject
) I-Subject
were O
associated I-Adverse_event.Trigger
with O
previously O
known O
causes O
( O
vinyl I-Treatment.Combination.Drug
chloride I-Treatment.Combination.Drug
, I-Treatment
' I-Treatment
Thorotrast I-Treatment.Combination.Drug
' I-Treatment
, I-Treatment
and I-Treatment
inorganic I-Treatment.Combination.Drug
arsenic I-Treatment.Combination.Drug
) O
and O
4 O
( O
3.1 O
% O
) O
of O
the O
remaining O
131 O
cases O
with O
the O
use O
of O
androgenic O
- O
anabolic O
steroids O
. O

A O
retrospective O
epidemiological O
study O
of O
deaths O
from O
hepatic I-Effect
angiosarcoma I-Effect
( O
HAS O
) O
in O
the O
U.S. O
showed O
that O
during O
1964 O
- O
- O
74 O
there O
were O
168 O
such O
cases O
, O
of O
which O
37 O
( O
22 O
% O
) O
were O
associated O
with O
previously O
known O
causes O
( O
vinyl O
chloride O
, O
' O
Thorotrast O
' O
, O
and O
inorganic O
arsenic O
) O
and O
4 I-Subject.Population
( I-Subject
3.1 I-Subject
% I-Subject
) I-Subject
of O
the O
remaining O
131 O
cases O
with I-Adverse_event.Trigger
the O
use O
of O
androgenic I-Treatment.Drug
- I-Treatment.Drug
anabolic I-Treatment.Drug
steroids I-Treatment.Drug
. O

Progressive I-Effect
hypokalemia I-Effect
developed I-Adverse_event.Trigger
during O
phosphate I-Treatment.Drug
treatment O
. O

A I-Subject
69 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
man I-Subject.Gender
developed I-Adverse_event.Trigger
pure I-Effect
red I-Effect
cell I-Effect
aplasia I-Effect
after O
taking I-Treatment
fenoprofen I-Treatment.Drug
for I-Treatment
ten I-Treatment.Time_elapsed
months I-Treatment.Time_elapsed
. O

Introduction O
of O
etanercept I-Treatment.Drug
was O
also O
clinically O
effective O
but O
followed O
by O
development I-Adverse_event.Trigger
of O
severe I-Effect
heart I-Effect
failure I-Effect
. I-Effect

Minimal I-Effect
change I-Effect
nephrotic I-Effect
syndrome I-Effect
developing I-Adverse_event.Trigger
during O
postoperative I-Treatment.Drug
interferon I-Treatment.Drug
- I-Treatment.Drug
beta I-Treatment.Drug
therapy I-Treatment
for I-Treatment
malignant I-Treatment.Treat_Disorder
melanoma I-Treatment.Treat_Disorder
. O

She I-Subject.Gender
was I-Subject
admitted I-Subject
following I-Subject
a I-Subject
fall I-Subject.Sub_Disorder
and O
, O
after O
being O
given O
metoclopramide I-Treatment.Drug
, O
developed I-Adverse_event.Trigger
movement I-Effect
disorder I-Effect
and I-Effect
a I-Effect
period I-Effect
of I-Effect
unresponsiveness I-Effect
. O

We O
observed O
transient I-Effect
panhypogammaglobulinaemia I-Effect
in O
a I-Subject
patient I-Subject
with I-Subject
neuropsychiatric I-Treat_Disorder
SLE I-Treat_Disorder
after O
treatment I-Adverse_event.Trigger
with O
prednisolone I-Treatment.Combination.Drug
and I-Treatment
cyclophosphamide I-Treatment.Combination.Drug
. O

Isoniazid I-Treatment.Drug
inhibits O
the O
conversion O
of O
tryptophan O
to O
niacin O
and O
may O
induce I-Adverse_event.Trigger
pellagra I-Effect
, O
particularly O
in O
poorly I-Subject.Sub_Disorder
nourished I-Subject.Sub_Disorder
patients I-Subject
. O

The O
authors O
suggest O
that O
in O
patients I-Subject
with I-Subject
corneal I-Treat_Disorder
ulcers I-Treat_Disorder
refractory O
to O
conventional O
treatment O
who O
are O
receiving I-Potential_therapeutic_event.Trigger
colchicine I-Treatment.Drug
, O
cessation O
of O
colchicine O
therapy O
should O
be O
considered O
. O

After I-Potential_therapeutic_event.Trigger
the O
patient I-Treatment
discontinued I-Treatment
rifampicin I-Treatment.Drug
, O
the O
skin I-Treat_Disorder
lesions I-Treat_Disorder
cleared I-Effect
completely I-Effect
within I-Time_elapsed
5 I-Time_elapsed
weeks I-Time_elapsed
without O
any O
systemic O
medication O
. O

Ziprasidone I-Treatment.Drug
is O
an O
atypical O
antipsychotic I-Treat_Disorder
drug O
that O
is O
believed O
to O
have O
a O
low O
propensity O
for O
inducing I-Adverse_event.Trigger
extrapyramidal I-Effect
symptoms I-Effect
, I-Effect
including I-Effect
tardive I-Effect
dyskinesia I-Effect
( I-Effect
TD I-Effect
) I-Effect
. O

Acute I-Effect
ischaemia I-Effect
of I-Effect
the I-Effect
leg I-Effect
following I-Adverse_event.Trigger
accidental O
intra I-Treatment
- I-Treatment
arterial I-Treatment
injection I-Treatment.Route
of I-Treatment
dissolved I-Treatment
flunitrazepam I-Treatment.Drug
tablets I-Treatment
. O

These O
findings O
suggest O
that O
prophylactic I-Treatment.Drug
antibiotic I-Treatment.Drug
use I-Adverse_event.Trigger
is O
unlikely I-Effect
to I-Effect
have I-Effect
a I-Effect
major I-Effect
impact I-Effect
on I-Effect
the I-Effect
recovery I-Effect
time I-Effect
from O
rocuronium I-Treat_Disorder
- I-Treat_Disorder
induced I-Treat_Disorder
NMB I-Treat_Disorder
with I-Treat_Disorder
sugammadex I-Treat_Disorder
reversal I-Treat_Disorder
. O

These O
findings O
suggest O
that O
prophylactic O
antibiotic O
use O
is O
unlikely O
to O
have O
a O
major O
impact O
on O
the O
recovery O
time O
from O
rocuronium I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
NMB I-Effect
with I-Effect
sugammadex I-Effect
reversal I-Effect
. O

Emphasis O
is O
given O
to O
the O
differentiation O
of O
diphenylhydantoin I-Treatment.Drug
induced I-Adverse_event.Trigger
gingival I-Effect
hyperplasia I-Effect
from O
the I-Effect
angiomatous I-Effect
enlargement I-Effect
of I-Effect
the I-Effect
gingiva I-Effect
before O
any O
treatment O
is O
planned O
. O

Electro O
- O
oculography O
, O
electroretinography O
, O
visual O
evoked O
potentials O
, O
and O
multifocal O
electroretinography O
in O
patients I-Subject
with O
vigabatrin I-Treatment.Drug
- O
attributed I-Adverse_event.Trigger
visual I-Effect
field I-Effect
constriction I-Effect
. O

CASE O
SUMMARIES O
: O
Two I-Subject.Population
patients I-Subject
with I-Subject
stable I-Treat_Disorder
hypothyroidism I-Treat_Disorder
experienced O
symptoms O
of O
hypothyroidism I-Effect
with I-Effect
increased I-Effect
serum I-Effect
thyroid I-Effect
- I-Effect
stimulating I-Effect
hormone I-Effect
( O
TSH O
) O
concentrations O
after I-Adverse_event.Trigger
switching I-Treatment
from I-Treatment
1 I-Treatment
levothyroxine I-Treatment.Drug
product I-Treatment
to I-Treatment
another I-Treatment
. O

An O
objective O
causality O
assessment O
indicated O
a O
probable O
relationship I-Adverse_event.Trigger
between O
clotting I-Effect
abnormality I-Effect
and O
warfarin I-Treatment.Drug
administration O
, O
although O
the O
degree O
of O
elevation O
of O
the O
INR O
was O
unusual O
in O
the O
light O
of O
the O
daily O
warfarin O
dose O
and O
duration O
of O
its O
exposure O
. O

The O
pathophysiological O
mechanisms O
remain O
unknown O
, O
although O
the O
drug O
could O
act I-Adverse_event.Trigger
through O
massive I-Effect
cytokines I-Effect
liberation I-Effect
after O
destruction I-Effect
of I-Effect
CD20 I-Effect
positive I-Effect
cells I-Effect
by O
rituximab I-Treatment.Drug
. O

The O
more O
common O
grade O
3 O
or O
4 O
adverse I-Adverse_event.Trigger
effects I-Adverse_event.Trigger
of O
sunitinib I-Treatment.Drug
include O
hypertension I-Effect
, I-Effect
fatigue I-Effect
, I-Effect
hand I-Effect
- I-Effect
foot I-Effect
syndrome I-Effect
, I-Effect
elevated I-Effect
lipase I-Effect
and I-Effect
lymphopenia I-Effect
. O

We O
report O
a O
45 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
psoriasis I-Treat_Disorder
patient I-Subject
who O
developed I-Adverse_event.Trigger
eruptive I-Effect
mollusca I-Effect
contagiosa I-Effect
during O
an O
antipsoriatic I-Treatment
treatment I-Treatment
with I-Treatment
efalizumab I-Treatment.Drug
. O

Skin I-Effect
necrosis I-Effect
is O
a O
rare O
complication I-Adverse_event.Trigger
of O
subcutaneous I-Treatment.Route
heparin I-Treatment.Drug
therapy I-Treatment
that O
usually O
occurs O
at O
injection O
sites O
. O

Epsilon I-Treatment.Drug
- I-Treatment.Drug
aminocaproic I-Treatment.Drug
acid I-Treatment.Drug
and O
renal I-Effect
complications I-Effect
: O
case O
report O
and O
review O
of O
the O
literature O
. O

Ibuprofen I-Treatment.Drug
rarely O
causes O
lower O
gastrointestinal O
adverse O
reactions O
but O
has O
been O
implicated I-Adverse_event.Trigger
in I-Adverse_event.Trigger
systemic I-Effect
and I-Effect
local I-Effect
side I-Effect
effects I-Effect
in I-Effect
patients I-Effect
with I-Effect
lupus I-Effect
. O

CASE O
SUMMARIES O
: O
While O
conducting O
a O
protocol O
evaluating O
the O
efficacy O
of O
intraperitoneal I-Treatment.Route
cisplatin I-Treatment.Drug
and I-Treatment
hyperthermia I-Treatment
in O
the O
treatment O
of O
recurrent I-Treat_Disorder
ovarian I-Treat_Disorder
cancer I-Treat_Disorder
, O
3 I-Subject.Population
patients I-Subject
were O
noted O
to O
exhibit I-Adverse_event.Trigger
anaphylactoid I-Effect
reactions I-Effect
. O

Perinatal I-Effect
vasoconstrictive I-Effect
renal I-Effect
insufficiency I-Effect
associated I-Adverse_event.Trigger
with O
maternal I-Treatment
nimesulide I-Treatment.Drug
use I-Treatment
. O

Protease I-Treatment.Combination.Drug
inhibitors I-Treatment.Combination.Drug
( I-Treatment
ritonavir I-Treatment
and I-Treatment
saquinavir I-Treatment
) I-Treatment
were I-Treatment
added I-Treatment
to I-Treatment
the I-Treatment
treatment I-Treatment
and O
the I-Subject
patient I-Subject
developed I-Adverse_event.Trigger
progressive I-Effect
ataxia I-Effect
related I-Effect
to I-Effect
carbamazepine I-Treatment.Combination.Drug
toxicity I-Effect
. O

The O
medical O
examiner O
's O
report O
indicated O
death I-Effect
caused I-Adverse_event.Trigger
by O
fluoxetine I-Treatment.Drug
toxicity I-Treatment
. O

Hypertonic I-Treatment
sodium I-Treatment.Drug
bicarbonate I-Treatment.Drug
is O
recognized O
as O
effective I-Potential_therapeutic_event.Trigger
therapy O
for O
hypotension I-Treat_Disorder
and I-Treat_Disorder
arrhythmias I-Treat_Disorder
. O

Because O
toxicity I-Effect
may O
occur I-Adverse_event.Trigger
when O
flecainide I-Treatment.Combination.Drug
is I-Treatment
prescribed I-Treatment
with I-Treatment
paroxetine I-Treatment.Combination.Drug
and I-Treatment
other I-Treatment
potent I-Treatment
CYP2D6 I-Treatment
inhibitors I-Treatment
, O
flecainide O
plasma O
concentrations O
should O
be O
monitored O
closely O
with O
commencement O
of O
CYP2D6 O
inhibitors O
. O

Gentamicin I-Treatment.Drug
- O
associated I-Adverse_event.Trigger
acute I-Effect
renal I-Effect
failure I-Effect
. O

Sulfasalazine I-Treatment.Treat_Disorder
- O
induced I-Adverse_event.Trigger
lung I-Effect
disorder I-Effect
is O
an O
extremely O
rare O
entity O
which O
must O
be O
considered O
in O
all O
ulcerative O
colitis O
patients O
while O
on O
sulfasalazine O
therapy O
, O
despite O
the O
absence O
of O
pulmonary O
symptomatology O
. O

Suspected O
ciprofloxacin I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
interstitial I-Effect
nephritis I-Effect
. O

Tegaserod I-Treatment.Drug
- O
associated I-Adverse_event.Trigger
ischemic I-Effect
colitis I-Effect
. O

Clinicians O
should O
be O
aware O
of O
the O
signs O
and O
symptoms O
of O
neurotoxicity O
during O
treatment O
, O
as O
well O
as O
predisposing O
factors O
that O
put O
patients I-Subject
receiving O
methotrexate I-Treatment.Drug
at O
risk I-Adverse_event.Trigger
for O
neurotoxic I-Effect
effects I-Effect
. O

We O
report O
the O
first O
case O
of O
chlorambucil I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
DRESS I-Effect
syndrome I-Effect
in O
a I-Subject
70 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
man I-Subject.Gender
recently O
diagnosed O
with O
chronic I-Treat_Disorder
lymphocytic I-Treat_Disorder
leukaemia I-Treat_Disorder
. O

Are O
nasal O
decongestants O
safer O
than O
rhinitis O
? O
A O
case O
of O
oxymetazoline I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
syncope I-Effect
. O

Marked I-Effect
elevation I-Effect
of I-Effect
serum I-Effect
creatine I-Effect
kinase I-Effect
associated I-Adverse_event.Trigger
with O
olanzapine I-Treatment.Drug
therapy I-Treatment
. O

After I-Potential_therapeutic_event.Trigger
cessation I-Treatment
of I-Treatment
amantadine I-Treatment.Drug
, O
the I-Effect
edema I-Effect
resolved I-Effect
, I-Effect
and I-Effect
the I-Effect
endothelial I-Effect
cell I-Effect
densities I-Effect
were I-Effect
< I-Dosage
or=600/mm I-Dosage
. O

DISCUSSION O
: O
Olanzapine I-Treatment.Drug
, O
like O
other O
atypical I-Treatment
antipsychotic I-Treatment
drugs I-Treatment
, O
may O
cause I-Adverse_event.Trigger
muscle I-Effect
injury I-Effect
with I-Effect
concomitant I-Effect
elevations I-Effect
of I-Effect
serum I-Effect
CK I-Effect
of I-Effect
muscle I-Effect
origin I-Effect
. O

Study O
202 O
was O
an O
open O
- O
label O
, O
add O
- O
on O
study O
in O
patients I-Subject
with I-Subject
partial I-Subject
or I-Subject
generalized I-Subject
epilepsy I-Subject
treated I-Potential_therapeutic_event.Trigger
with O
valproic I-Treatment.Combination.Drug
acid I-Treatment.Combination.Drug
( I-Treatment
VPA I-Treatment
) I-Treatment
, I-Treatment
carbamazepine I-Treatment.Combination.Drug
( I-Treatment
CBZ I-Treatment
) I-Treatment
, I-Treatment
phenytoin I-Treatment.Combination.Drug
( I-Treatment
PHT I-Treatment
) I-Treatment
, I-Treatment
or I-Treatment
topiramate I-Treatment.Combination.Drug
( I-Treatment
TPM I-Treatment
) I-Treatment
as I-Treatment
monotherapy I-Treatment
. O

Dual O
antiplatelet O
therapy O
with O
aspirin I-Treatment.Combination.Drug
and I-Treatment
a I-Treatment
P2Y12 I-Treatment.Combination.Drug
receptor I-Treatment.Combination.Drug
antagonist I-Treatment.Combination.Drug
following I-Treatment
placement I-Treatment
of I-Treatment
coronary I-Treatment
stents I-Treatment
is O
critical O
to O
prevent I-Potential_therapeutic_event.Trigger
stent I-Treat_Disorder
thrombosis I-Treat_Disorder
and I-Treat_Disorder
subsequent I-Treat_Disorder
myocardial I-Treat_Disorder
infarction I-Treat_Disorder
. O

Organometals I-Treatment.Drug
also O
compromise I-Effect
the I-Effect
limbic I-Effect
system I-Effect
and O
result I-Adverse_event.Trigger
in O
deficits I-Effect
in I-Effect
learning I-Effect
and I-Effect
memory I-Effect
. O

Optic I-Effect
neuropathy I-Effect
associated I-Adverse_event.Trigger
with O
penicillamine I-Treatment.Drug
therapy O
in O
a I-Subject
patient I-Subject
with I-Subject
rheumatoid I-Treat_Disorder
arthritis I-Treat_Disorder
. O

We O
present O
the O
first O
case O
of O
ovarian I-Effect
endometrioid I-Effect
carcinoma I-Effect
and I-Effect
endometriosis I-Effect
in O
a O
postmenopausal I-Subject
patient I-Subject
who O
was O
treated I-Adverse_event.Trigger
with I-Adverse_event.Trigger
tamoxifen I-Treatment.Drug
for O
breast I-Treat_Disorder
cancer I-Treat_Disorder
. I-Subject

There O
was O
a O
good O
correlation I-Adverse_event.Trigger
between O
the O
total I-Treatment
dose I-Treatment
of I-Treatment
ACTH I-Treatment.Drug
and O
the O
percentage I-Effect
decrease I-Effect
of I-Effect
brain I-Effect
parenchyma I-Effect
. O

We O
noted O
that O
the O
delirium I-Effect
resembled I-Effect
serotonin I-Effect
toxicity I-Effect
and O
that O
the O
patient O
had O
been O
taking I-Adverse_event.Trigger
paroxetine I-Treatment.Drug
until I-Treatment
2 I-Treatment
days I-Treatment
before I-Treatment
surgery I-Treatment
. O

Primary I-Effect
central I-Effect
nervous I-Effect
system I-Effect
lymphoma I-Effect
in O
a I-Subject
patient I-Subject
treated I-Adverse_event.Trigger
with O
natalizumab I-Treatment.Drug
. O

We O
retrospectively O
reviewed O
the O
records O
of O
7 I-Subject.Population
pediatric I-Subject.Age
oncology I-Treat_Disorder
patients I-Subject
who O
received I-Potential_therapeutic_event.Trigger
low I-Treatment.Dosage
- I-Treatment.Dosage
dose I-Treatment.Dosage
ketamine I-Treatment.Combination.Drug
in I-Treatment
conjunction I-Treatment
with I-Treatment
propofol I-Treatment.Combination.Drug
for I-Treatment
total I-Treatment
intravenous I-Treatment
anesthesia I-Treatment
( I-Treatment
TIVA I-Treatment
) I-Treatment
repeatedly I-Treatment
for I-Treatment
radiation I-Treatment
therapy I-Treatment
. O

We O
presume O
the O
cause I-Adverse_event.Trigger
for O
multiple I-Effect
organ I-Effect
failure I-Effect
could O
be O
the O
result O
of O
drug O
- O
drug O
interaction I-Treatment
, I-Treatment
atorvastatin I-Treatment.Combination.Drug
and I-Treatment
verapamil I-Treatment.Combination.Drug
, O
as O
verapamil O
is O
known O
to O
increase O
the O
serum O
concentration O
of O
atorvastatin O
significantly O
. O

Hypersensitivity I-Effect
to I-Adverse_event.Trigger
zonisamide I-Treatment.Drug
was O
confirmed O
by O
the O
skin O
patch O
test O
. O

Pulmonary I-Effect
edema I-Effect
occurred I-Adverse_event.Trigger
24 I-Treatment.Time_elapsed
hours I-Treatment.Time_elapsed
after I-Treatment
intravenous I-Treatment.Route
ritodrine I-Treatment.Combination.Drug
therapy I-Treatment
and I-Treatment
10 I-Treatment.Time_elapsed
hours I-Treatment.Time_elapsed
after I-Treatment
subcutaneous I-Treatment.Route
terbutaline I-Treatment.Combination.Drug
therapy I-Treatment
. O

Transient I-Effect
acute I-Effect
myopia I-Effect
resulting I-Adverse_event.Trigger
from O
isotretinoin I-Treatment.Drug
( I-Treatment
accutane I-Treatment
) I-Treatment
therapy I-Treatment
. O

We O
report O
a O
case O
of O
fatal I-Effect
fulminant I-Effect
hepatitis I-Effect
caused I-Adverse_event.Trigger
by O
the O
use O
of O
disulfiram I-Treatment.Drug
in O
a I-Subject
man I-Subject.Gender
with O
previously O
normal O
hepatocellular O
function O
. O

OBJECTIVE O
: O
To O
describe O
two I-Subject.Population
cases I-Subject
of O
rhabdomyolysis I-Effect
in O
patients I-Subject
taking I-Adverse_event.Trigger
lovastatin I-Treatment.Drug
that I-Treatment
were I-Treatment
precipitated I-Treatment
by I-Treatment
the I-Treatment
use I-Treatment
of I-Treatment
the I-Treatment
newer I-Treatment
macrolide I-Treatment
antibiotics I-Treatment
clarithromycin I-Treatment.Combination.Drug
and I-Treatment
azithromycin I-Treatment.Combination.Drug
. O

Neutrophilic I-Effect
dermatoses I-Effect
in O
two I-Subject.Population
children I-Subject.Age
with I-Subject
idiopathic I-Treat_Disorder
neutropenia I-Treat_Disorder
: O
association I-Adverse_event.Trigger
with O
granulocyte I-Treatment.Drug
colony I-Treatment.Drug
- I-Treatment.Drug
stimulating I-Treatment.Drug
factor I-Treatment.Drug
( I-Treatment
G I-Treatment
- I-Treatment
CSF I-Treatment
) I-Treatment
therapy I-Treatment
. O

The O
zinc I-Treatment.Combination.Drug
/ I-Treatment
o I-Treatment.Combination.Drug
- I-Treatment.Combination.Drug
cymen I-Treatment.Combination.Drug
- I-Treatment.Combination.Drug
5 I-Treatment.Combination.Drug
- I-Treatment.Combination.Drug
ol I-Treatment.Combination.Drug
system I-Treatment
has O
direct O
antimicrobial I-Effect
effects I-Effect
and O
inhibits I-Effect
oral I-Effect
disease I-Effect
- I-Effect
related I-Effect
processes I-Effect
. O

Paroxetine I-Treatment.Drug
is O
a O
selective O
serotonin O
reuptake O
inhibitor O
possessing I-Potential_therapeutic_event.Trigger
anti I-Treat_Disorder
- I-Treat_Disorder
depressant I-Treat_Disorder
activity I-Treat_Disorder
. O

A I-Subject
case I-Subject
of O
polymyositis I-Effect
with I-Effect
dilated I-Effect
cardiomyopathy I-Effect
associated I-Adverse_event.Trigger
with O
interferon I-Treatment.Drug
alpha I-Treatment.Drug
treatment O
for O
hepatitis I-Treat_Disorder
B. I-Treat_Disorder

Phenytoin I-Treatment.Drug
toxicity O
: O
an O
easily O
missed O
cause I-Adverse_event.Trigger
of O
cerebellar I-Effect
syndrome I-Effect
. O

Successful O
treatment I-Potential_therapeutic_event.Trigger
of O
visceral I-Treatment.Treat_Disorder
leishmaniasis I-Treatment.Treat_Disorder
with I-Treatment
allopurinol I-Treatment.Combination.Drug
plus I-Treatment
ketoconazole I-Treatment.Combination.Drug
in O
an I-Subject
infant I-Subject.Age
who I-Subject
developed I-Subject
pancreatitis I-Subject.Sub_Disorder
caused I-Subject.Sub_Disorder
by I-Subject.Sub_Disorder
meglumine I-Subject.Sub_Disorder
antimoniate I-Subject.Sub_Disorder
. O

Successful O
treatment O
of O
visceral O
leishmaniasis O
with O
allopurinol O
plus O
ketoconazole O
in O
an O
infant O
who O
developed O
pancreatitis I-Effect
caused I-Adverse_event.Trigger
by O
meglumine I-Treatment.Drug
antimoniate I-Treatment.Drug
. O

Hepatotoxicity I-Effect
after I-Adverse_event.Trigger
high I-Treatment.Dosage
- I-Treatment.Dosage
dose I-Treatment.Dosage
methylprednisolone I-Treatment.Drug
for O
demyelinating I-Treat_Disorder
disease I-Treat_Disorder
. O

Interferon I-Treatment.Drug
- I-Treatment.Drug
alpha I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
focal I-Effect
segmental I-Effect
glomerulosclerosis I-Effect
in I-Effect
chronic I-Effect
myelogenous I-Effect
leukemia I-Effect
: O
a O
case O
report O
and O
review O
of O
the O
literature O
. O

Prior O
reports O
have O
emphasized O
the O
tubular I-Effect
and I-Effect
interstitial I-Effect
lesions I-Effect
associated I-Adverse_event.Trigger
with O
intermittent I-Treatment
or I-Treatment
discontinuous I-Treatment
rifampin I-Treatment.Drug
therapy I-Treatment
for O
tuberculosis I-Treat_Disorder
. O

Transtentorial I-Effect
herniation I-Effect
caused O
by O
an I-Effect
intracranial I-Effect
mass I-Effect
lesion I-Effect
following I-Adverse_event.Trigger
high I-Treatment.Dosage
- I-Treatment.Dosage
dose I-Treatment.Dosage
methotrexate I-Treatment.Drug
. O

A O
case O
of O
prolonged I-Effect
suxamethonium I-Drug
apnoea I-Effect
successfully O
terminated I-Potential_therapeutic_event.Trigger
by O
the I-Treatment
infusion I-Treatment.Route
of I-Treatment
a I-Treatment
commercial I-Treatment
preparation I-Treatment
of I-Treatment
serumcholinesterase I-Treatment.Drug
is O
reported O
. O

53 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
woman I-Subject.Gender
with I-Subject
a I-Subject
history I-Subject
of I-Subject
deep I-Treat_Disorder
vein I-Treat_Disorder
thrombosis I-Treat_Disorder
and I-Subject
pulmonary I-Treat_Disorder
embolism I-Treat_Disorder
was O
receiving O
warfarin I-Treatment.Drug
to O
prevent I-Potential_therapeutic_event.Trigger
thromboembolic I-Treat_Disorder
complications I-Treat_Disorder
; I-Treat_Disorder
her O
international O
normalized O
ratio O
( O
INR O
) O
had O
been O
stable O
for O
1 O
month O
. O

OBJECTIVE O
: O
To O
describe O
a I-Subject
patient I-Subject
with I-Subject
asymptomatic I-Subject.Sub_Disorder
bronchial I-Subject.Sub_Disorder
asthma I-Subject.Sub_Disorder
and I-Subject
hypertension I-Treat_Disorder
who O
developed O
an O
acute I-Effect
asthma I-Effect
attack I-Effect
after I-Adverse_event.Trigger
receiving O
sustained I-Treatment.Drug
- I-Treatment.Drug
release I-Treatment.Drug
verapamil I-Treatment.Drug
. O

Severe O
hepatotoxicity I-Effect
related I-Adverse_event.Trigger
to O
benzarone I-Treatment.Drug
: O
a O
report O
of O
three I-Subject.Population
cases I-Subject
with O
two O
fatalities O
. O

We O
report O
on O
a I-Subject
56 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
female I-Subject.Gender
who O
exhibited O
drug I-Effect
refractory I-Effect
paroxysmal I-Effect
atrial I-Effect
fibrillation I-Effect
, I-Effect
in I-Effect
which I-Effect
marked I-Effect
prolongation I-Effect
of I-Effect
the I-Effect
QT I-Effect
interval I-Effect
and I-Effect
T I-Effect
wave I-Effect
inversion I-Effect
on O
electrocardiogram O
was O
demonstrated O
reproducibly O
shortly O
after I-Adverse_event.Trigger
the O
administration O
of O
oral I-Route
pirmenol I-Treatment.Drug
therapy O
. O

Insulin I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
lipohypertrophy I-Effect
: O
report O
of O
a O
case O
with O
histopathology O
. O

OBJECTIVE O
: O
To O
study O
therapy I-Potential_therapeutic_event.Trigger
with O
indapamide I-Treatment.Drug
impairing O
carbohydrate I-Treat_Disorder
metabolism I-Treat_Disorder
in O
essential I-Subject
hypertension I-Treat_Disorder
patients I-Subject
and O
achieve O
earlier O
prevention O
, O
diagnoses O
and O
treatment O
of O
diabetes O
induced O
by O
indapamide O
. O

OBJECTIVE O
: O
To O
study O
therapy O
with O
indapamide O
impairing O
carbohydrate O
metabolism O
in O
essential O
hypertension O
patients O
and O
achieve O
earlier O
prevention O
, O
diagnoses O
and O
treatment O
of O
diabetes I-Effect
induced I-Adverse_event.Trigger
by O
indapamide I-Treatment.Drug
. O

We O
describe O
a I-Subject
patient I-Subject
with I-Subject
CREST I-Subject.Sub_Disorder
syndrome I-Subject.Sub_Disorder
( I-Subject.Sub_Disorder
calcinosis I-Subject.Sub_Disorder
, I-Subject.Sub_Disorder
Raynaud I-Subject.Sub_Disorder
's I-Subject.Sub_Disorder
phenomenon I-Subject.Sub_Disorder
, I-Subject.Sub_Disorder
esophageal I-Subject.Sub_Disorder
dysfunction I-Subject.Sub_Disorder
, I-Subject.Sub_Disorder
sclerodactyly I-Subject.Sub_Disorder
, I-Subject.Sub_Disorder
and I-Subject.Sub_Disorder
telangiectasia I-Subject.Sub_Disorder
) I-Subject.Sub_Disorder
who O
paradoxically O
experienced I-Adverse_event.Trigger
worsening I-Effect
of I-Effect
Raynaud I-Effect
's I-Effect
phenomenon I-Effect
when O
using O
yohimbine I-Treatment.Drug
for O
ED I-Treat_Disorder
. O

High I-Treatment.Dosage
- I-Treatment.Dosage
dose I-Treatment.Dosage
methotrexate I-Treatment.Drug
- O
associated I-Adverse_event.Trigger
acute I-Effect
renal I-Effect
failure I-Effect
may O
be O
an O
avoidable O
complication O
. O

Chronic O
myelogenous O
leukemia O
( O
CML O
) O
, O
hepatitis O
C O
, O
and O
interferon I-Treatment.Drug
alpha I-Treatment.Drug
( I-Treatment
IFNalpha I-Treatment
) I-Treatment
have O
all O
been O
associated I-Adverse_event.Trigger
with O
renal I-Effect
dysfunction I-Effect
. O

CONCLUSIONS O
: O
Infectious I-Effect
endophthalmitis I-Effect
is O
a O
potential O
complication I-Adverse_event.Trigger
of O
intravitreal I-Treatment.Route
bevacizumab I-Treatment.Drug
injection I-Treatment.Route
. O

RESULTS O
: O
One O
case O
of O
recurrent I-Treat_Disorder
primary I-Treat_Disorder
peritoneal I-Treat_Disorder
carcinoma I-Treat_Disorder
previously O
treated O
with O
a I-Treatment
carboplatin I-Treatment.Drug
- I-Treatment
based I-Treatment
regimen I-Treatment
, O
developed I-Adverse_event.Trigger
a I-Effect
platinum I-Effect
hypersensitivity I-Effect
. O

To O
our O
knowledge O
, O
these O
cases O
are O
the O
first O
published O
reports O
of O
lovastatin I-Treatment.Combination.Drug
- O
induced I-Adverse_event.Trigger
rhabdomyolysis I-Effect
associated I-Treatment
with I-Treatment
azithromycin I-Treatment.Combination.Drug
and I-Treatment
clarithromycin I-Treatment.Combination.Drug
. O

Prick O
tests O
and O
intradermal O
tests O
with O
a O
series O
of O
dilutions O
of O
carboplatin O
and O
cisplatin O
were O
performed O
on O
three I-Subject
patients I-Subject
who O
had O
exhibited I-Adverse_event.Trigger
medium I-Effect
and I-Effect
severe I-Effect
hypersensitivity I-Effect
reactions I-Effect
to O
carboplatin I-Treatment.Drug
. O

A O
case O
of O
sideroblastic I-Effect
anemia I-Effect
is O
presented I-Adverse_event.Trigger
in O
a I-Subject
patient I-Subject
with I-Subject
a I-Subject
left I-Subject.Sub_Disorder
ventricular I-Subject.Sub_Disorder
assist I-Subject.Sub_Disorder
device I-Subject.Sub_Disorder
drive I-Subject.Sub_Disorder
- I-Subject.Sub_Disorder
line I-Subject.Sub_Disorder
infection I-Subject.Sub_Disorder
who O
was O
receiving I-Treatment
linezolid I-Treatment.Drug
, O
an O
antibiotic O
used O
for O
serious I-Treat_Disorder
infections I-Treat_Disorder
with I-Treat_Disorder
gram I-Treat_Disorder
- I-Treat_Disorder
positive I-Treat_Disorder
organisms I-Treat_Disorder
. O

Development O
of O
nephrotic I-Effect
syndrome I-Effect
in O
a I-Subject
patient I-Subject
with I-Subject
acute I-Treat_Disorder
myeloblastic I-Treat_Disorder
leukemia I-Treat_Disorder
after I-Adverse_event.Trigger
treatment O
with O
macrophage I-Treatment.Drug
- I-Treatment.Drug
colony I-Treatment.Drug
- I-Treatment.Drug
stimulating I-Treatment.Drug
factor I-Treatment.Drug
. O

In O
patients O
with O
a O
known O
access O
to O
INH I-Treatment.Drug
, O
seizures I-Effect
should O
be O
considered O
to O
be O
caused I-Adverse_event.Trigger
by O
INH O
toxicity O
unless O
proved O
otherwise O
. O

To O
our O
knowledge O
, O
this O
is O
the I-Subject
first I-Subject
case I-Subject
reported O
in O
the O
English O
literature O
of O
a O
generalized I-Effect
exanthem I-Effect
due I-Adverse_event.Trigger
to O
subcutaneous I-Treatment.Route
injection I-Treatment.Route
of I-Treatment
enoxaparin I-Treatment.Drug
. O

This O
case O
illustrates I-Adverse_event.Trigger
the O
potential I-Effect
decoupling I-Effect
of I-Effect
PSA I-Effect
response I-Effect
from O
disease O
status O
in O
flutamide I-Treatment.Drug
withdrawal I-Treatment
. O

Upon O
discontinuation I-Treatment
of I-Treatment
MTX I-Treatment.Drug
, O
her I-Subject.Gender
ascites I-Treat_Disorder
resolved O
, O
and O
her O
arthritis I-Effect
became I-Effect
more I-Effect
active I-Effect
. O

Upon O
discontinuation I-Treatment
of I-Treatment
MTX I-Treatment.Drug
, O
her I-Subject.Gender
ascites I-Treat_Disorder
resolved I-Potential_therapeutic_event.Trigger
, O
and O
her O
arthritis I-Sub_Disorder
became O
more O
active O
. O

Colonic I-Effect
mucosal I-Effect
necrosis I-Effect
following O
administration I-Adverse_event.Trigger
of O
calcium I-Treatment.Drug
polystryrene I-Treatment.Drug
sulfonate I-Treatment.Drug
( I-Treatment
Kalimate I-Treatment
) I-Treatment
in O
a O
uremic I-Treat_Disorder
patient I-Subject
. O

Intracranial I-Effect
hemorrhage I-Effect
and I-Effect
focal I-Effect
seizures I-Effect
secondary I-Adverse_event.Trigger
to I-Adverse_event.Trigger
use O
of O
L I-Treatment.Drug
- I-Treatment.Drug
asparaginase I-Treatment.Drug
during O
induction O
therapy O
of O
acute O
lymphocytic O
leukemia O
. O

A I-Effect
fatal I-Effect
poisoning I-Effect
case I-Subject
involving I-Adverse_event.Trigger
etizolam I-Treatment.Drug
, I-Treatment
phenobarbital I-Treatment.Drug
, I-Treatment
promethazine I-Treatment.Drug
and I-Treatment
chlorpromazine I-Treatment.Drug
is O
presented O
. O

Rituximab O
- O
based O
therapy O
for O
gemcitabine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
hemolytic I-Effect
uremic I-Effect
syndrome I-Effect
in O
a O
patient I-Subject
with I-Subject
metastatic I-Treat_Disorder
pancreatic I-Treat_Disorder
adenocarcinoma I-Treat_Disorder
: O
a O
case O
report O
. O

Leukopenia I-Effect
due I-Adverse_event.Trigger
to O
parvovirus I-Subject.Sub_Disorder
B19 I-Subject.Sub_Disorder
in I-Subject
a I-Subject
Crohn I-Treat_Disorder
's I-Treat_Disorder
disease I-Treat_Disorder
patient I-Subject
using O
azathioprine I-Treatment.Drug
. O

Fixed I-Effect
drug I-Effect
eruption I-Effect
of I-Effect
the I-Effect
scrotum I-Effect
due I-Adverse_event.Trigger
to O
methylphenidate I-Treatment.Drug
. O

Cytarabine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
cerebellar I-Effect
syndrome I-Effect
: O
case O
report O
and O
literature O
review O
. O

We O
report O
a I-Subject
case I-Subject
of O
glaucoma I-Effect
induced I-Adverse_event.Trigger
by O
doxetaxel I-Treatment.Drug
therapy I-Treatment
for I-Treatment
metastatic I-Treatment.Treat_Disorder
breast I-Treatment.Treat_Disorder
cancer I-Treatment.Treat_Disorder
. O

Myoclonus I-Effect
was O
induced I-Adverse_event.Trigger
and I-Adverse_event.Trigger
enhanced I-Adverse_event.Trigger
by O
L I-Treatment.Drug
- I-Treatment.Drug
dopa I-Treatment.Drug
, O
developing I-Effect
into I-Effect
generalized I-Effect
seizures I-Effect
. O

During O
analysis O
of O
28 O
patients O
receiving O
CAP I-Treatment.Drug
with I-Treatment
concomitant I-Treatment.Route
radiation I-Treatment.Route
( I-Treatment
XRT I-Treatment
) I-Treatment
for O
pancreatic I-Treat_Disorder
cancer I-Treat_Disorder
( O
resected O
or O
locally O
advanced O
) O
, O
two I-Subject.Population
patients I-Subject
developed I-Adverse_event.Trigger
signs O
and O
symptoms O
consistent O
with O
peripheral I-Effect
neuropathy I-Effect
. O

A O
liver O
biopsy O
in O
2012 O
revealed O
marked O
fibrosis I-Treat_Disorder
, I-Subject
leading I-Subject
the I-Subject
patient I-Subject
to O
start O
hepatitis O
C O
treatment I-Potential_therapeutic_event.Trigger
with O
peginterferon I-Treatment.Combination.Drug
alfa I-Treatment.Combination.Drug
- I-Treatment.Combination.Drug
2a I-Treatment.Combination.Drug
, I-Treatment
ribavirin I-Treatment.Combination.Drug
and I-Treatment
boceprevir I-Treatment.Combination.Drug
. O

Knowledge O
regarding O
potential O
adverse I-Adverse_event.Trigger
effects I-Adverse_event.Trigger
of O
CAP I-Treatment.Drug
is O
paramount O
and O
dose O
modification O
is O
indicated O
with O
development O
of O
neurotoxicity I-Effect
. O

We O
present O
a O
case O
of O
significant O
over I-Adverse_event.Trigger
- I-Adverse_event.Trigger
anticoagulation I-Adverse_event.Trigger
temporally O
associated O
with O
a O
bout O
of O
protracted I-Effect
diarrhea I-Effect
in O
a O
patient O
on O
warfarin I-Treatment.Drug
therapy O
. O

New O
oral I-Treatment.Route
therapies I-Treatment
for I-Potential_therapeutic_event.Trigger
type I-Treat_Disorder
2 I-Treat_Disorder
diabetes I-Treat_Disorder
mellitus I-Treat_Disorder
: O

The O
case O
histories O
are O
presented O
of O
two I-Subject.Population
patients I-Subject
who O
developed I-Adverse_event.Trigger
lung I-Effect
disease I-Effect
associated O
with O
the I-Treatment
use I-Treatment
of I-Treatment
nitrofurantoin I-Treatment.Drug
with I-Effect
histological I-Effect
features I-Effect
of I-Effect
bronchiolitis I-Effect
obliterans I-Effect
organising I-Effect
pneumonia I-Effect
( I-Effect
BOOP I-Effect
) I-Effect
, O
a O
rare O
but O
recognised O
form O
of O
drug O
induced O
injury O
. O

A I-Subject
57 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
woman I-Subject.Gender
with I-Subject
right I-Subject.Sub_Disorder
bundle I-Subject.Sub_Disorder
branch I-Subject.Sub_Disorder
block I-Subject.Sub_Disorder
+ I-Subject.Sub_Disorder
LPH I-Subject.Sub_Disorder
and I-Subject
ventricular I-Subject.Sub_Disorder
premature I-Subject.Sub_Disorder
contractions I-Subject.Sub_Disorder
developed I-Adverse_event.Trigger
complete I-Effect
heart I-Effect
block I-Effect
( I-Effect
CHB I-Effect
) I-Effect
following O
administration O
of O
disopyramide I-Treatment.Drug
phosphate I-Treatment.Drug
( I-Treatment
Norpace I-Treatment
) I-Treatment
. O

METHODS O
: O
In O
an O
institutional O
practice O
setting O
, O
two I-Subject.Population
women I-Subject.Gender
, I-Subject
aged I-Subject.Age
25 I-Subject.Age
and I-Subject.Age
45 I-Subject.Age
, O
developed I-Adverse_event.Trigger
acute I-Effect
myopia I-Effect
after O
starting O
topiramate I-Treatment.Drug
for O
epilepsy I-Treat_Disorder
. O

Diffusion O
- O
weighted O
MRI O
correlates O
of O
subacute I-Effect
methotrexate I-Treatment.Drug
- O
related I-Adverse_event.Trigger
neurotoxicity I-Effect
. O

ARDS I-Effect
is O
rarely O
associated O
with O
rituximab O
infusion O
for O
lympho O
- O
proliferative O
disorders O
, O
but O
it O
should O
be O
considered O
by O
those O
administering O
rituximab I-Treatment.Drug
, O
especially O
when O
a I-Subject
patient I-Subject
develops O
severe I-Effect
pulmonary I-Effect
symptoms I-Effect
soon O
after I-Adverse_event.Trigger
infusion I-Treatment.Route
. O

Seven I-Subject
of I-Subject
the I-Subject
eight I-Subject.Population
cases I-Subject
of O
acute I-Effect
leukemia I-Effect
occurred I-Adverse_event.Trigger
in O
a O
series O
of O
553 O
patients O
treated O
with O
Treosulfan I-Treatment.Drug
for O
ovarian I-Treat_Disorder
cancer I-Treat_Disorder
in O
the O
period O
from O
1970 O
to O
1977 O
and O
followed O
closely O
for O
a O
total O
of O
1159 O
patient O
- O
years O
up O
to O
February O
1978 O
. O

Desipramine I-Treatment.Drug
- O
associated I-Adverse_event.Trigger
SIADH I-Effect
in O
an I-Subject
elderly I-Subject.Age
woman I-Subject.Gender
: O
case O
report O
. O

Can O
propofol I-Treatment.Drug
precipitate I-Adverse_event.Trigger
pancreatitis I-Effect
in O
patients I-Subject
with I-Subject
Cushing I-Treat_Disorder
's I-Treat_Disorder
syndrome I-Treat_Disorder
? I-Subject

This O
case O
presents O
the O
possibility O
of O
anaphylaxis I-Effect
to I-Adverse_event.Trigger
topical O
5 I-Treatment.Combination.Drug
- I-Treatment.Combination.Drug
FU I-Treatment.Combination.Drug
treatments O
and/or O
the O
interaction O
with O
angiotensin I-Treatment.Combination.Drug
converting I-Treatment.Combination.Drug
enzyme I-Treatment.Combination.Drug
inhibitors I-Treatment.Combination.Drug
. O

After O
stopping I-Potential_therapeutic_event.Trigger
indapamide I-Treatment.Drug
, I-Treatment
glucose I-Treatment.Treat_Disorder
tolerance I-Treatment.Treat_Disorder
impairing I-Treatment.Treat_Disorder
may O
be O
reversed O
. O

We O
describe O
a O
case O
of O
needle I-Effect
- I-Effect
track I-Effect
cutaneous I-Effect
seeding I-Effect
of I-Effect
hepatocellular I-Effect
carcinoma I-Effect
( O
HCC O
) O
after I-Adverse_event.Trigger
sonographically I-Treatment
guided I-Treatment
percutaneous I-Treatment
ethanol I-Treatment.Drug
injection I-Treatment.Route
( O
PEI O
) O
. O

Zidovudine I-Treatment.Drug
use O
in O
pregnancy O
: O
a O
report O
on O
104 O
cases O
and O
the O
occurrence I-Adverse_event.Trigger
of O
birth I-Effect
defects I-Effect
. O

A I-Subject
patient I-Subject
with I-Subject
seropositive I-Treat_Disorder
rheumatoid I-Treat_Disorder
arthritis I-Treat_Disorder
developed I-Adverse_event.Trigger
ascites I-Effect
while O
taking I-Treatment
weekly I-Treatment.Freq
doses I-Treatment
of I-Treatment
methotrexate I-Treatment.Drug
( I-Treatment
MTX I-Treatment
) I-Treatment
. O

High I-Effect
incidence I-Effect
of I-Effect
adverse I-Effect
events I-Effect
in O
healthy I-Subject
volunteers I-Subject
receiving I-Adverse_event.Trigger
rifampicin I-Treatment.Combination.Drug
and I-Treatment
adjusted I-Treatment.Dosage
doses I-Treatment.Dosage
of I-Treatment
lopinavir I-Treatment.Combination.Drug
/ I-Treatment
ritonavir I-Treatment.Combination.Drug
tablets I-Treatment.Route
. O

We O
report O
here O
a I-Subject
case I-Subject
of O
TEN I-Effect
after O
administration I-Adverse_event.Trigger
of O
ciprofloxacin I-Treatment.Drug
. O

Zidovudine I-Treatment.Drug
induced I-Adverse_event.Trigger
pure I-Effect
red I-Effect
cell I-Effect
aplasia I-Effect
: O
a I-Subject
case I-Subject
report O
. O

A I-Subject
case I-Subject
of O
recall I-Effect
pneumonitis I-Effect
induced I-Adverse_event.Trigger
by O
gemcitabine I-Treatment.Drug
is O
reported O
. O

Albuterol I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
hypokalemia I-Effect
and I-Effect
its I-Effect
potential I-Effect
cardiac I-Effect
toxicity I-Effect
are O
discussed O
briefly O
. O

In O
the O
absence O
of O
an O
ideal O
dose O
- O
intense O
FU O
monotherapy O
regimen O
, O
monthly I-Treatment.Freq
FU I-Treatment.Combination.Drug
with I-Treatment
low I-Treatment.Dosage
- I-Treatment.Dosage
dose I-Treatment.Dosage
LV I-Treatment.Combination.Drug
provides O
a O
simple O
and O
economical O
means O
by O
which O
to O
achieve O
adequate O
FU O
efficacy O
in O
the O
treatment I-Potential_therapeutic_event.Trigger
of O
advanced I-Treat_Disorder
colorectal I-Treat_Disorder
cancer I-Treat_Disorder
. O

OBJECTIVE O
: O
To O
report O
a I-Subject
patient I-Subject
developing O
fulminant I-Effect
liver I-Effect
failure I-Effect
while O
being O
treated I-Adverse_event.Trigger
with O
clarithromycin I-Treatment.Drug
for O
pneumonia I-Treat_Disorder
. O

The O
abnormal O
rhythm O
disappeared O
with O
the O
withdrawal O
of O
propranolol I-Treatment.Drug
and O
when O
the O
drug O
was O
restarted O
a O
2/1 I-Effect
S I-Effect
- I-Effect
A I-Effect
block I-Effect
was O
seen I-Adverse_event.Trigger
. O

The O
Naranjo O
probability O
scale O
indicated O
a I-Adverse_event.Trigger
probable I-Adverse_event.Trigger
relationship I-Adverse_event.Trigger
between O
apnea I-Effect
and O
exposure O
to O
lamotrigine I-Treatment.Drug
through I-Treatment
breast I-Treatment.Route
- I-Treatment.Route
feeding I-Treatment.Route
in I-Subject
this I-Subject
infant I-Subject.Age
. O

Listeria I-Effect
brain I-Effect
abscess I-Effect
, I-Effect
Pneumocystis I-Effect
pneumonia I-Effect
and I-Effect
Kaposi I-Effect
's I-Effect
sarcoma I-Effect
after I-Adverse_event.Trigger
temozolomide I-Treatment.Drug
. O

Since O
amiodarone I-Drug
was O
first O
marketed O
in O
1992 O
in O
Japan O
, O
the O
incidence O
of O
amiodarone I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
thyrotoxicosis I-Effect
( I-Effect
AIT I-Effect
) I-Effect
has O
been O
increasing O
. O

The O
occurrence O
of O
a O
myocardial I-Effect
infarction I-Effect
is O
reported O
after I-Adverse_event.Trigger
chemotherapy I-Treatment
containing I-Treatment
etoposide I-Treatment.Drug
, O
in O
a I-Subject
man I-Subject.Gender
with I-Subject
no I-Subject
risk I-Subject
factors I-Subject
for I-Subject
coronary I-Subject
heart I-Subject
disease I-Subject
. O

The O
use O
of O
beclomethasone I-Treatment.Drug
diproprionate I-Treatment.Drug
inhaler I-Treatment.Route
complicated O
by O
the O
development I-Adverse_event.Trigger
of O
an O
eosinophilic I-Effect
pneumonia I-Effect
reaction I-Effect
. O

Nephrotic I-Effect
syndrome I-Effect
related I-Effect
to I-Effect
systemic I-Effect
lupus I-Effect
erythematosus I-Effect
after I-Adverse_event.Trigger
griseofulvin I-Treatment.Drug
therapy O
. O

Theoretical O
basal O
ganglia O
toxicologic O
mechanisms I-Adverse_event.Trigger
of O
methanol I-Treatment.Drug
poisoning I-Effect
are O
reviewed O
, O
and O
the O
role O
of O
brain O
imaging O
studies O
will O
regard O
to O
diagnosis O
, O
prognosis O
and O
impact O
on O
management O
is O
discussed O
. O

We O
report O
a I-Subject
case I-Subject
of I-Subject
drug O
- O
induced I-Adverse_event.Trigger
Kaposi I-Effect
's I-Effect
sarcoma I-Effect
( I-Effect
KS I-Effect
) I-Effect
on O
the O
sole O
of O
the O
right O
foot O
in O
a I-Subject
71 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
man I-Subject.Gender
, O
treated O
for O
6 I-Treatment.Duration
months I-Treatment.Duration
with I-Treatment
corticosteroid I-Treatment
therapy I-Treatment
( I-Treatment
prednisolone I-Treatment.Drug
25 I-Treatment.Dosage
mg I-Treatment.Dosage
/ I-Treatment.Dosage
day I-Treatment.Dosage
) I-Treatment
for I-Subject
pericardial I-Treat_Disorder
effusion I-Treat_Disorder
. O

We O
present O
a O
case O
of O
acute I-Treatment
epinephrine I-Treatment.Drug
toxicity I-Adverse_event.Trigger
resulting O
in O
acute I-Effect
myocardial I-Effect
ischemia I-Effect
in O
a I-Subject
young I-Subject.Age
boy I-Subject.Gender
with I-Subject
combined I-Treat_Disorder
variable I-Treat_Disorder
immunodeficiency I-Treat_Disorder
syndrome I-Treat_Disorder
who O
developed O
severe I-Effect
allergic I-Effect
reaction I-Effect
to O
intravenous I-Treatment.Route
immunoglobulin I-Treatment.Drug
, I-Treatment
and I-Treatment
was I-Treatment
subsequently I-Treatment
given I-Treatment
epinephrine I-Treatment
by I-Treatment
mistake I-Treatment
intravenously I-Treatment.Route
rather I-Treatment
than I-Treatment
subcutaneously I-Treatment
. O

Albeit O
rare O
among O
Western O
patients O
, O
such O
lithium I-Treatment.Drug
- O
associated I-Adverse_event.Trigger
thyroid I-Effect
dysfunctions I-Effect
appeared O
to O
be O
more O
likely O
to O
occur O
in O
Hong I-Subject.Race
Kong I-Subject.Race
Chinese I-Subject.Race
. O

Metaxalone I-Treatment.Drug
has O
only O
recently O
been O
associated I-Adverse_event.Trigger
with O
serotonin I-Effect
syndrome I-Effect
. O

Bisphosphonate I-Drug
- O
related I-Adverse_event.Trigger
osteonecrosis I-Effect
of I-Effect
the I-Effect
jaw I-Effect
( I-Effect
BRONJ I-Effect
) I-Effect
is O
reported O
in O
up O
to O
18.6 I-Subject.Population
% I-Subject.Population
of I-Subject
patients I-Subject
treated O
with O
intravenous I-Treatment.Route
bisphosphonates I-Treatment.Drug
and O
can O
result O
in O
significant O
morbidity O
. O

Growth I-Effect
and I-Effect
adrenal I-Effect
suppression I-Effect
in I-Potential_therapeutic_event.Trigger
asthmatic I-Treat_Disorder
children I-Subject.Age
treated O
with O
high I-Treatment.Dosage
- I-Treatment.Dosage
dose I-Treatment.Dosage
fluticasone I-Treatment.Drug
propionate I-Treatment.Drug
. O

A O
diagnosis O
of O
infliximab I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
lupus I-Effect
was O
made O
and O
the O
drug O
treatment O
was O
withdrawn O
. O

AIMS O
: O
To O
identify O
the O
human O
cytochrome O
P450 O
enzyme O
( O
s O
) O
involved O
in O
the O
in O
vitro O
metabolism O
of O
rosiglitazone I-Treatment.Drug
, O
a O
potential I-Potential_therapeutic_event.Trigger
oral I-Route
antidiabetic O
agent O
for O
the O
treatment O
of O
type I-Treat_Disorder
2 I-Treat_Disorder
diabetes I-Treat_Disorder
- I-Treat_Disorder
mellitus I-Treat_Disorder
. I-Treat_Disorder

Neurotoxicity I-Effect
can O
occur I-Adverse_event.Trigger
at O
any O
time O
using O
high I-Treatment.Dosage
- I-Treatment.Dosage
dose I-Treatment.Dosage
cytosine I-Treatment.Drug
therapy O
. O

The O
possibility O
of O
phenytoin I-Effect
hypersensitivity I-Effect
reactions O
should O
be O
considered O
when O
patients O
receiving I-Adverse_event.Trigger
phenytoin I-Treatment.Drug
have O
unusual O
symptoms O
, O
particularly O
fever I-Effect
, I-Effect
rash I-Effect
, I-Effect
and I-Effect
lymphadenopathy I-Effect
. O

Magnesium I-Treatment.Drug
tocolysis I-Treatment
as O
the O
cause I-Adverse_event.Trigger
of O
urinary I-Effect
calculus I-Effect
during I-Effect
pregnancy I-Effect
. O

Ocular I-Treatment.Route
ethambutol I-Treatment.Drug
toxicity I-Effect
. O

Fatal I-Effect
intravascular I-Effect
autoimmune I-Effect
hemolytic I-Effect
anemia I-Effect
after I-Adverse_event.Trigger
fludarabine I-Treatment.Drug
treatment I-Treatment
for O
chronic I-Treat_Disorder
lymphocytic I-Treat_Disorder
leukemia I-Treat_Disorder
. O

A I-Subject
74 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
patient I-Subject
with I-Subject
idiopathic I-Treat_Disorder
Parkinson I-Treat_Disorder
's I-Treat_Disorder
disease I-Treat_Disorder
was O
evaluated O
for O
unintended I-Effect
sleep I-Effect
episodes I-Effect
that O
occurred O
after I-Adverse_event.Trigger
long I-Treatment.Duration
- I-Treatment.Duration
term I-Treatment.Duration
treatment I-Treatment.Duration
with I-Treatment
400 I-Treatment.Dosage
mg I-Treatment.Dosage
/ I-Treatment.Dosage
day I-Treatment.Dosage
of I-Treatment
L I-Treatment.Drug
- I-Treatment.Drug
dopa I-Treatment.Drug
. O

Thrombotic I-Effect
thrombocytopenic I-Effect
purpura I-Effect
( I-Effect
TTP I-Effect
) I-Effect
developed I-Adverse_event.Trigger
in O
a I-Subject
patient I-Subject
with I-Subject
seropositive I-Subject
rheumatoid I-Treat_Disorder
arthritis I-Treat_Disorder
( I-Subject
RA I-Subject
) I-Subject
after O
2 I-Treatment.Duration
1/2 I-Treatment.Duration
months I-Treatment.Duration
of I-Treatment
treatment I-Treatment
with I-Treatment
penicillamine I-Treatment.Drug
. O

Phenolphthalein I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
toxic I-Effect
epidermal I-Effect
necrolysis I-Effect
. O

We O
present O
a O
case O
of O
ethylenediamine O
- O
induced O
delayed O
hypersensitivity O
reaction O
in O
a I-Subject
46 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
woman I-Subject.Gender
who O
received I-Potential_therapeutic_event.Trigger
parenteral I-Treatment.Route
aminophylline I-Treatment.Drug
for O
an O
acute I-Treat_Disorder
asthma I-Treat_Disorder
exacerbation I-Treat_Disorder
. O

We O
present O
a O
case O
of O
ethylenediamine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
delayed I-Effect
hypersensitivity I-Effect
reaction I-Effect
in O
a I-Subject
46 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
woman I-Subject.Gender
who O
received O
parenteral O
aminophylline O
for O
an O
acute O
asthma O
exacerbation O
. O

Physicians O
should O
be O
aware O
of O
the O
potentially O
lethal I-Effect
side I-Effect
effects I-Effect
of I-Adverse_event.Trigger
dapsone I-Treatment.Drug
. O

Acute I-Effect
myocardial I-Effect
necrosis I-Effect
during I-Adverse_event.Trigger
administration O
of O
amsacrine I-Treatment.Drug
. O

Rapid O
identification O
of O
speech I-Effect
loss I-Effect
linked I-Adverse_event.Trigger
to O
FK506 I-Treatment.Drug
may O
be O
important O
because O
reduction O
or O
cessation O
of O
the O
drug O
may O
be O
associated O
with O
reverse O
of O
speech O
loss O
. O

Fatal O
pulmonary I-Effect
fibrosis I-Effect
following I-Adverse_event.Trigger
1,3 I-Treatment.Drug
- I-Treatment.Drug
bis(2 I-Treatment.Drug
- I-Treatment.Drug
chloroethyl) I-Treatment.Drug
- I-Treatment.Drug
1 I-Treatment.Drug
- I-Treatment.Drug
nitrosourea I-Treatment.Drug
( I-Treatment.Drug
BCNU I-Treatment.Drug
) I-Treatment.Drug
therapy I-Treatment
. O

The O
increasing O
prevalence O
of O
methamphetamine I-Treatment.Drug
abuse I-Treatment
and O
the O
severity O
of O
the O
associated I-Effect
ulcers I-Effect
should O
alert O
ophthalmologists O
to O
the O
problem O
of O
methamphetamine I-Treatment.Drug
- O
related I-Adverse_event.Trigger
keratitis I-Effect
. O

MDS I-Effect
was O
diagnosed I-Adverse_event.Trigger
8.4 I-Treatment.Time_elapsed
months I-Treatment.Time_elapsed
after I-Treatment
beginning I-Treatment
TMZ I-Treatment.Drug
. O

Uveitis I-Effect
associated I-Adverse_event.Trigger
with O
rifabutin I-Treatment.Drug
therapy I-Treatment
: O
a O
clinical O
alert O
. O

We O
report O
a O
case O
of O
a I-Subject
patient I-Subject
with O
ciprofloxacin I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
SJS I-Effect
and O
acute I-Effect
onset I-Effect
of I-Effect
VBDS I-Effect
, O
and O
reviewed O
the O
related O
literature O
. O

This O
case O
supports O
the O
assessment O
that O
MH O
and O
diabetes O
are O
associated O
diseases O
and O
that O
cresol I-Treatment.Drug
could O
possibly O
trigger I-Adverse_event.Trigger
MH I-Effect
. O

Neonatal I-Effect
mydriasis I-Effect
: O
intravenous O
lidocaine I-Treatment.Drug
adverse I-Adverse_event.Trigger
reaction I-Adverse_event.Trigger
. O

Acute I-Effect
renal I-Effect
failure I-Effect
in I-Adverse_event.Trigger
a I-Subject
patient I-Subject
treated O
by O
continuous I-Treatment
povidone I-Treatment.Combination.Drug
- I-Treatment
iodine I-Treatment.Combination.Drug
mediastinal I-Treatment
irrigation I-Treatment.Route
. O

To O
our O
knowledge O
, O
this O
is O
the I-Subject
first I-Subject
case I-Subject
of O
griseofulvin I-Treatment.Drug
- O
exacerbated I-Adverse_event.Trigger
lupus I-Effect
in O
which O
nephrotic I-Effect
syndrome I-Effect
has O
been O
observed O
. O

After O
reviewing O
the O
literature O
we O
suggest O
the O
CPM I-Effect
was O
a O
complication I-Adverse_event.Trigger
of O
lithium I-Treatment.Drug
toxicity I-Effect
which O
affected O
the O
lateral O
geniculate O
nucleus O
which O
produced O
blindness I-Effect
. O

A I-Subject
71 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
man I-Subject.Gender
, O
who O
had O
a O
history O
of O
a O
previous O
bullous I-Effect
drug O
reaction I-Adverse_event.Trigger
to O
a O
sulfonamide I-Treatment.Drug
, O
began O
receiving O
an O
ophthalmic O
preparation O
that O
contained O
sulfacetamide I-Drug
sodium I-Drug
. O

The O
authors O
report O
on O
two I-Subject.Population
patients I-Subject
with O
corneal I-Effect
ulcers I-Effect
refractory O
to O
conventional O
treatment O
while O
the O
patients O
were O
undergoing I-Adverse_event.Trigger
oral I-Treatment.Route
colchicine I-Treatment.Drug
therapy I-Treatment
. O

Vancomycin I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
vasculitis I-Effect
. O

Based O
on O
our O
findings O
, O
it O
is O
thus O
concluded O
that O
cisplatin I-Treatment.Drug
may O
cause I-Adverse_event.Trigger
C. I-Effect
difficile I-Effect
colitis I-Effect
. O

Nephrotic I-Effect
syndrome I-Effect
associated I-Adverse_event.Trigger
with O
lithium I-Treatment.Drug
therapy I-Treatment
. O

We O
report O
2 I-Subject.Population
patients I-Subject
who O
developed I-Adverse_event.Trigger
polyarteritis I-Effect
nodosa I-Effect
following O
vaccination I-Treatment.Drug
against I-Treatment.Drug
hepatitis I-Treatment.Drug
B. I-Treatment.Drug

We O
recommend O
the O
cautious O
use O
of O
ketorolac I-Treatment.Drug
in O
patients I-Subject
with I-Subject
underlying I-Subject.Sub_Disorder
illnesses I-Subject.Sub_Disorder
where I-Adverse_event.Trigger
NSAID I-Effect
- I-Effect
induced I-Effect
ototoxicity I-Effect
could I-Effect
result I-Effect
in I-Effect
adverse I-Effect
otologic I-Effect
consequences I-Effect
. O

Colitis I-Effect
as O
a O
manifestation O
of O
infliximab I-Treatment.Drug
- O
associated I-Adverse_event.Trigger
disseminated O
cryptococcosis O
. O

A I-Subject
15 I-Subject.Age
- I-Subject.Age
month I-Subject.Age
- I-Subject.Age
old I-Subject.Age
girl I-Subject.Gender
with I-Subject
rhinopharyngitis I-Treat_Disorder
was O
treated I-Potential_therapeutic_event.Trigger
with O
a I-Treatment
nasal I-Treatment
solution I-Treatment
containing I-Treatment
the I-Treatment
imidazoline I-Treatment.Drug
derivative I-Treatment.Drug
naphazoline I-Treatment.Route
. O

Three I-Subject.Population
diabetic I-Treat_Disorder
cases I-Subject
of O
acute I-Effect
dizziness I-Effect
due I-Adverse_event.Trigger
to O
initial I-Treatment
administration I-Treatment
of I-Treatment
voglibose I-Treatment.Drug
. O

Fatal I-Effect
cold I-Treatment.Drug
medication I-Treatment.Drug
intoxication I-Effect
in I-Adverse_event.Trigger
an O
infant I-Subject.Age
. O

Case O
study O
: O
a O
modified O
topical O
treatment O
regimen O
for O
sodium I-Treatment.Drug
warfarin I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
necrotizing I-Effect
fasciitis I-Effect
. O

Marked I-Effect
QT I-Effect
prolongation I-Effect
and I-Effect
torsades I-Effect
de I-Effect
pointes I-Effect
secondary I-Effect
to I-Effect
acute I-Effect
ischemia I-Effect
in O
an I-Subject
elderly I-Subject.Age
man I-Subject.Gender
taking I-Adverse_event.Trigger
dofetilide I-Treatment.Drug
for O
atrial I-Treat_Disorder
fibrillation I-Treat_Disorder
: O
a O
cautionary O
tale O
. O

Methylphenidate I-Treatment.Drug
and I-Treatment
dextroamphetamine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
peripheral I-Effect
vasculopathy I-Effect
. O

The I-Treatment
reversal I-Treatment
of I-Treatment
heparin I-Treatment.Combination.Drug
by I-Treatment
protamine I-Treatment.Combination.Drug
may O
cause I-Adverse_event.Trigger
severe I-Effect
hemodynamic I-Effect
deterioration I-Effect
, O
characterized O
by O
systemic I-Effect
hypotension I-Effect
, I-Effect
pulmonary I-Effect
hypertension I-Effect
, I-Effect
and I-Effect
bronchoconstriction I-Effect
. O

OBJECTIVE O
: O
To O
report O
a O
case O
of O
severe I-Effect
apnea I-Effect
in I-Adverse_event.Trigger
an I-Subject
infant I-Subject.Age
exposed I-Treatment
to I-Treatment
lamotrigine I-Treatment.Drug
through I-Treatment
breast I-Treatment.Route
- I-Treatment.Route
feeding I-Treatment.Route
. O

Hemodynamic I-Effect
collapse I-Effect
following I-Adverse_event.Trigger
labetalol I-Treatment.Drug
administration O
in O
preeclampsia I-Treat_Disorder
. O

We O
report O
a O
case O
of O
a O
35 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
old I-Subject.Age
female I-Subject.Gender
who O
developed I-Adverse_event.Trigger
new O
onset O
type I-Effect
II I-Effect
diabetes I-Effect
mellitus I-Effect
with I-Effect
hyperosmolar I-Effect
hyperglycaemic I-Effect
coma I-Effect
and I-Effect
acute I-Effect
renal I-Effect
failure I-Effect
following O
treatment I-Treatment
with I-Treatment
a I-Treatment
SGA I-Treatment.Drug
for O
a O
first O
manic O
episode O
. O

We O
report O
the O
occurrence I-Adverse_event.Trigger
of O
renal I-Effect
failure I-Effect
due I-Effect
to I-Effect
cholesterol I-Effect
crystal I-Effect
embolization I-Effect
following O
thrombolytic I-Treatment
therapy I-Treatment
with I-Treatment
intravenous I-Treatment.Route
recombinant I-Treatment.Drug
tissue I-Treatment.Drug
- I-Treatment.Drug
type I-Treatment.Drug
plasminogen I-Treatment.Drug
activator I-Treatment.Drug
( I-Treatment
t I-Treatment
- I-Treatment
PA I-Treatment
) I-Treatment
. O

The O
asthma I-Treat_Disorder
resolved I-Potential_therapeutic_event.Trigger
within I-Time_elapsed
24 I-Time_elapsed
hours I-Time_elapsed
following O
three I-Treatment.Dosage
albuterol I-Treatment.Drug
inhalations I-Treatment.Route
. O

Administration O
of O
amantadine I-Treatment.Combination.Drug
was O
associated I-Adverse_event.Trigger
with O
psychotic I-Effect
decompensations I-Effect
in O
two I-Subject.Population
schizophrenic I-Subject.Sub_Disorder
patients I-Subject
being O
maintained O
on O
concomitant I-Treatment
neuroleptic I-Treatment.Combination.Drug
medication I-Treatment
. O

Clinicians O
should O
be O
aware O
of O
fasting I-Effect
hypoglycemia I-Effect
as O
an O
unusual O
but O
potentially O
serious O
complication I-Adverse_event.Trigger
of O
disopyramide I-Treatment.Drug
therapy O
. O

To O
the O
best O
of O
our O
knowledge O
, O
this O
is O
the O
first O
reported O
patient I-Subject
with O
captopril I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
pemphigus I-Effect
in O
whom O
no O
new O
lesions O
developed O
after O
subsequent O
treatment O
with O
enalapril O
. O

Fortunately O
, O
a O
hypersensitivity I-Effect
reaction I-Effect
to I-Adverse_event.Trigger
one I-Treatment
formulation I-Treatment
of I-Treatment
cyclosporine I-Treatment.Drug
does O
not O
preclude O
use O
of O
a O
different O
formulation O
. O

She O
developed I-Adverse_event.Trigger
a O
severe O
urticarial I-Effect
rash I-Effect
3 I-Time_elapsed
weeks I-Time_elapsed
following I-Time_elapsed
initiation O
of O
therapy O
with O
Enoxaparin I-Treatment.Drug
. O

Fatal I-Effect
toxic I-Effect
epidermal I-Effect
necrolysis I-Effect
related I-Adverse_event.Trigger
to I-Adverse_event.Trigger
lamotrigine I-Treatment.Drug
administration I-Treatment
. O

OBJECTIVE O
: O
To O
document O
a I-Subject
case I-Subject
of O
serotonin I-Effect
syndrome I-Effect
( I-Effect
SS I-Effect
) I-Effect
associated I-Adverse_event.Trigger
with O
mirtazapine I-Treatment.Drug
monotherapy I-Treatment
, O
review O
the O
previously O
reported O
cases O
of O
SS O
associated O
with O
this O
tetracyclic O
antidepressant O
, O
and O
discuss O
the O
possible O
pathogenic O
mechanisms O
leading O
to O
this O
serious O
adverse O
drug O
reaction O
. O

CONCLUSION O
: O
Therapy O
with O
indapamide I-Treatment.Drug
may O
induce I-Adverse_event.Trigger
diabetes I-Effect
in O
essential I-Treat_Disorder
hypertension I-Treat_Disorder
patients I-Subject
. O

Placebo O
- O
controlled O
clinical O
trials O
of O
recombinant I-Treatment.Drug
human I-Treatment.Drug
interleukin I-Treatment.Drug
- I-Treatment.Drug
11 I-Treatment.Drug
( I-Treatment
rhIL I-Treatment
- I-Treatment
11 I-Treatment
, I-Treatment
also I-Treatment
known I-Treatment
as I-Treatment
oprelvekin I-Treatment
[ I-Treatment
Neumega I-Treatment
] I-Treatment
) I-Treatment
in O
patients I-Subject
with I-Subject
nonmyeloid I-Subject.Sub_Disorder
malignancies I-Subject.Sub_Disorder
have O
demonstrated O
significant O
efficacy O
in O
preventing I-Potential_therapeutic_event.Trigger
postchemotherapy I-Treat_Disorder
platelet I-Treat_Disorder
nadirs I-Treat_Disorder
of I-Treat_Disorder
< I-Treat_Disorder
or I-Treat_Disorder
= I-Treat_Disorder
20,000/microL I-Treat_Disorder
, O
and O
reducing O
the O
need O
for O
platelet O
transfusions O
while O
continuing O
chemotherapy O
without O
dose O
reductions O
. O

A I-Subject
patient I-Subject
with I-Subject
rheumatoid I-Treat_Disorder
arthritis I-Treat_Disorder
developed I-Adverse_event.Trigger
an O
acute I-Effect
intrahepatic I-Effect
cholestasis I-Effect
after O
100 I-Treatment.Dosage
mg I-Treatment.Dosage
of I-Treatment
sodium I-Treatment.Drug
aurothiomalate I-Treatment.Drug
. O

We O
concluded O
that O
the O
colonic I-Effect
ulcer I-Effect
and I-Effect
the I-Effect
sigmoidovesical I-Effect
fistula I-Effect
had O
been O
caused I-Adverse_event.Trigger
by O
the O
administration O
of O
calcium I-Treatment.Combination.Drug
polystyrene I-Treatment.Combination.Drug
sulfonate I-Treatment.Combination.Drug
and I-Treatment
sorbitol I-Treatment.Combination.Drug
. O

Rosiglitazone I-Treatment.Drug
, O
a I-Treatment
thiazolidinedione I-Treatment.Drug
antidiabetic I-Treatment.Drug
medication I-Treatment.Drug
used I-Potential_therapeutic_event.Trigger
in O
the O
treatment O
of O
Type I-Treat_Disorder
2 I-Treat_Disorder
diabetes I-Treat_Disorder
mellitus I-Treat_Disorder
, O
is O
predominantly O
metabolized O
by O
the O
cytochrome O
P450 O
( O
CYP O
) O
enzyme O
CYP2C8 O
. O

Interstitial I-Effect
lung I-Effect
disease I-Effect
( I-Effect
ILD I-Effect
) I-Effect
related I-Adverse_event.Trigger
to O
therapy I-Treatment
with I-Treatment
the I-Treatment
drug I-Treatment
gefitinib I-Treatment.Drug
has O
been O
well O
reported O
. O

According O
to O
the O
Naranjo O
adverse O
drug O
reaction O
probability O
scale O
, O
tigecycline I-Treatment.Drug
was O
the O
probable O
cause I-Adverse_event.Trigger
of O
her O
acute I-Effect
pancreatitis I-Effect
. O

We O
report O
a O
case O
of O
severe I-Effect
anemia I-Effect
, O
which O
responded O
well O
to O
steroid O
therapy O
, O
in O
a I-Subject
patient I-Subject
receiving I-Adverse_event.Trigger
IL I-Treatment.Combination.Drug
- I-Treatment.Combination.Drug
2 I-Treatment.Combination.Drug
plus I-Treatment
IFN I-Treatment.Combination.Drug
- I-Treatment.Combination.Drug
alpha I-Treatment.Combination.Drug
for O
metastatic I-Treat_Disorder
renal I-Treat_Disorder
cell I-Treat_Disorder
carcinoma I-Treat_Disorder
. O

We O
report O
a O
case O
of O
severe I-Treat_Disorder
anemia I-Treat_Disorder
, O
which O
responded I-Potential_therapeutic_event.Trigger
well O
to O
steroid I-Treatment.Drug
therapy O
, O
in O
a O
patient O
receiving O
IL O
- O
2 O
plus O
IFN O
- O
alpha O
for O
metastatic O
renal O
cell O
carcinoma O
. O

The O
patient O
's O
movements I-Treat_Disorder
resolved I-Potential_therapeutic_event.Trigger
following O
diphenhydramine I-Treatment.Drug
administration O
. O

The O
spectrum O
of O
nitrofurantoin I-Treatment.Drug
lung I-Effect
injury I-Effect
continues O
to O
widen I-Adverse_event.Trigger
. O

We O
describe O
a I-Subject
patient I-Subject
with O
a O
complex O
medication O
regimen O
who O
was O
admitted O
for O
rhabdomyolysis I-Effect
and I-Effect
accompanying I-Effect
acute I-Effect
renal I-Effect
failure I-Effect
, I-Effect
along I-Effect
with I-Effect
acute I-Effect
hepatitis I-Effect
, O
thought O
to O
be O
secondary I-Adverse_event.Trigger
to O
a O
drug O
interaction O
between O
atorvastatin I-Treatment.Combination.Drug
and O
diltiazem I-Treatment.Combination.Drug
. O

The O
current O
study O
investigated O
the O
visual O
fields O
and O
visual O
electrophysiology O
of O
eight I-Subject.Population
patients I-Subject
with O
known O
vigabatrin I-Treatment.Drug
- O
attributed I-Adverse_event.Trigger
visual I-Effect
field I-Effect
loss I-Effect
, O
three O
of O
whom O
were O
reported O
previously O
. O

Although O
the O
literature O
on O
the O
use I-Treatment
of I-Treatment
risperidone I-Treatment.Drug
in O
elderly I-Subject.Age
patients I-Subject
with I-Subject
dementia I-Treat_Disorder
consists O
largely O
of O
uncontrolled O
trials O
, O
case O
reports O
, O
and O
chart O
reviews O
, O
it O
appears O
that O
this O
agent O
is I-Potential_therapeutic_event.Trigger
effective O
for O
managing O
agitation O
in O
this O
population O
and O
does O
so O
with O
a O
low O
frequency O
of O
extrapyramidal O
symptoms O
( O
EPS O
) O
. O

Temozolomide I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
desquamative I-Effect
skin I-Effect
rash I-Effect
in O
a I-Subject
patient I-Subject
with I-Subject
metastatic I-Treat_Disorder
melanoma I-Treat_Disorder
. O

The O
calcium I-Treatment.Drug
channel I-Treatment.Drug
blockers I-Treatment.Drug
are O
a O
group O
of O
drugs O
that O
have O
recently O
become O
available O
for O
the O
treatment I-Potential_therapeutic_event.Trigger
of O
angina I-Treat_Disorder
. O

We O
report O
on O
a I-Subject
young I-Subject.Age
adolescent I-Subject.Age
with O
benign I-Effect
intracranial I-Effect
hypertension I-Effect
which O
we O
attribute I-Adverse_event.Trigger
to O
the O
use O
of O
minocycline I-Treatment.Drug
for O
acne I-Treat_Disorder
. O

A I-Subject
10 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
asthmatic I-Treat_Disorder
boy I-Subject.Gender
began O
to O
suffer O
from O
urticarial I-Effect
rash I-Effect
and I-Effect
moderately I-Effect
severe I-Effect
bronchospasm I-Effect
after I-Adverse_event.Trigger
8 I-Treatment.Time_elapsed
weeks I-Treatment.Time_elapsed
' I-Treatment.Time_elapsed
treatment I-Treatment
with I-Treatment
disodium I-Treatment.Drug
cromoglycate I-Treatment.Drug
. O

Panic I-Effect
anxiety I-Effect
after I-Adverse_event.Trigger
abrupt I-Treatment
discontinuation I-Treatment
of I-Treatment
mianserin I-Treatment.Drug
. O

This I-Subject
case I-Subject
and O
other O
published O
evidence O
should O
alert O
physicians O
to O
the O
possibility O
of O
fatal O
erlotinib I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
ILD I-Effect
. O

Recent O
reports O
suggest O
that O
concomitant I-Treatment
administration I-Treatment
of I-Treatment
CYP3A I-Treatment.Combination.Drug
inhibitors I-Treatment.Combination.Drug
with I-Treatment
fentanyl I-Treatment.Combination.Drug
may O
lead I-Adverse_event.Trigger
to O
dangerous O
drug I-Effect
interactions I-Effect
. O

Post O
- O
exposure O
prophylaxis I-Potential_therapeutic_event.Trigger
of O
H1N1 I-Treat_Disorder
with O
oseltamivir I-Treatment.Combination.Drug
was O
safe I-Effect
, I-Effect
effective I-Effect
and I-Effect
well I-Effect
tolerated I-Effect
to I-Effect
prevent I-Effect
H1N1 I-Effect
influenza I-Effect
A I-Effect
virus I-Effect
infection I-Effect
in O
newly I-Subject
transplanted I-Subject.Sub_Disorder
renal I-Subject.Sub_Disorder
allograft I-Subject.Sub_Disorder
recipient I-Subject
receiving O
triple O
immunosuppression O
without I-Treatment
any I-Treatment
interaction I-Treatment
with I-Treatment
tacrolimus I-Treatment.Combination.Drug
level I-Treatment
. O

DISCUSSION O
: O
Central I-Effect
nervous I-Effect
system I-Effect
( I-Effect
CNS I-Effect
) I-Effect
toxicity I-Effect
has O
been O
described I-Adverse_event.Trigger
with O
ifosfamide I-Treatment.Drug
, O
with O
most O
cases O
reported O
in I-Subject
the I-Subject
pediatric I-Subject.Age
population I-Subject
. O

Despite O
the O
underlying O
hepatitis O
C O
, O
this I-Subject
case I-Subject
represents O
renal I-Effect
abnormalities I-Effect
consistent I-Adverse_event.Trigger
with O
IFNalpha I-Treatment.Drug
therapy I-Treatment
for O
CML I-Treat_Disorder
. O

CONCLUSION O
: O
To O
the O
best O
of O
our O
knowledge O
, O
this O
is O
the O
first O
time O
colchicine I-Treatment.Drug
intoxication I-Effect
in O
this O
age O
group O
has O
been O
described O
in O
the O
English O
literature O
. O

We O
have O
seen O
a O
case O
of O
terminal I-Effect
malignant I-Effect
melanoma I-Effect
in I-Effect
which I-Effect
clinical I-Effect
manifestations I-Effect
, I-Effect
indicative I-Effect
of I-Effect
anterior I-Effect
spinal I-Effect
artery I-Effect
syndrome I-Effect
, O
developed I-Adverse_event.Trigger
following O
the I-Treatment
injection I-Treatment.Route
of I-Treatment
0.3 I-Treatment.Dosage
ml I-Treatment.Dosage
of I-Treatment
10 I-Treatment.Drug
% I-Treatment.Drug
phenol I-Treatment.Drug
- I-Treatment.Drug
glycerine I-Treatment.Drug
into I-Treatment
the I-Treatment
cervical I-Treatment.Route
subarachnoid I-Treatment.Route
space I-Treatment.Route
at I-Treatment.Route
the I-Treatment.Route
C4 I-Treatment.Route
- I-Treatment.Route
- I-Treatment.Route
C5 I-Treatment.Route
level I-Treatment.Route
for O
the O
control O
of O
severe I-Treat_Disorder
right I-Treat_Disorder
arm I-Treat_Disorder
pain I-Treat_Disorder
. O

Colchicine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
myopathy I-Effect
in O
renal I-Treat_Disorder
failure I-Treat_Disorder
. O

This O
report O
suggests O
that O
bleomycin I-Treatment.Drug
lung I-Effect
toxicity I-Effect
may O
be O
reversible O
if O
treated O
aggressively O
. O

DISCUSSION O
: O
NMS I-Effect
is O
a O
rare O
but O
potentially O
fatal O
reaction O
associated I-Adverse_event.Trigger
with O
neuroleptic I-Treatment.Drug
drugs I-Treatment
. O

Scleroderma I-Effect
in O
association I-Adverse_event.Trigger
with O
the O
use O
of O
bleomycin I-Treatment.Drug
: O
a O
report O
of O
3 I-Subject.Population
cases I-Subject
. O

Linezolid I-Treatment.Drug
- O
associated I-Adverse_event.Trigger
acute I-Effect
interstitial I-Effect
nephritis I-Effect
and I-Effect
drug I-Effect
rash I-Effect
with I-Effect
eosinophilia I-Effect
and I-Effect
systemic I-Effect
symptoms I-Effect
( I-Effect
DRESS I-Effect
) I-Effect
syndrome I-Effect
. O

A I-Subject
3 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
boy I-Subject.Gender
diagnosed I-Subject
with I-Subject
acute I-Treat_Disorder
lymphoblastic I-Treat_Disorder
leukemia I-Treat_Disorder
received I-Potential_therapeutic_event.Trigger
induction I-Treatment.Route
chemotherapy I-Treatment.Route
. O

Interferon I-Treatment.Drug
and I-Treatment
other I-Treatment
immunostimulatory I-Treatment
medications I-Treatment
can O
lead I-Adverse_event.Trigger
to O
an O
exacerbation I-Effect
of I-Effect
this I-Effect
preexisting I-Effect
low I-Effect
- I-Effect
grade I-Effect
chronic I-Effect
inflammation I-Effect
that O
is O
quite O
similar O
to O
interferon O
- O
triggered O
sarcoidosis O
. O

Intravenous I-Treatment.Route
cytarabine I-Treatment.Combination.Drug
and I-Treatment
methotrexate I-Treatment.Combination.Drug
appear O
to O
act O
synergistically O
to O
enhance I-Adverse_event.Trigger
the O
potential O
for O
central I-Effect
nervous I-Effect
system I-Effect
toxicity I-Effect
. O

We O
suggest O
adding O
this O
side I-Effect
effect I-Effect
to O
the O
list O
of O
untoward O
effects O
of O
lidocaine O
and O
to O
the O
differential O
diagnosis O
of O
fixed O
dilated O
pupils O
in O
neonates I-Subject.Age
treated I-Adverse_event.Trigger
with O
lidocaine I-Treatment.Drug
. O

CONCLUSIONS O
: O
Topical I-Treatment.Route
INF I-Treatment.Drug
alpha I-Treatment.Drug
2 I-Treatment.Drug
- I-Treatment.Drug
beta I-Treatment.Drug
is O
a I-Potential_therapeutic_event.Trigger
valid I-Potential_therapeutic_event.Trigger
choice I-Potential_therapeutic_event.Trigger
for O
the O
treatment O
of O
CIN I-Treat_Disorder
in O
patients I-Subject
for I-Subject
whom I-Subject
surgery I-Subject
is I-Subject
not I-Subject
possible I-Subject
. O

We O
report O
3 I-Subject.Population
patients I-Subject
who O
developed I-Adverse_event.Trigger
cutaneous I-Effect
vasculitis I-Effect
which O
is O
a O
rare O
and O
serious O
side O
- O
effect O
during I-Treatment
antithyroid I-Treatment.Drug
drug I-Treatment
therapy I-Treatment
. O

Prominent I-Effect
eye I-Effect
movements I-Effect
during I-Effect
NREM I-Effect
sleep I-Effect
and I-Effect
REM I-Effect
sleep I-Effect
behavior I-Effect
disorder I-Effect
associated I-Adverse_event.Trigger
with O
fluoxetine I-Treatment.Drug
treatment I-Treatment
of O
depression I-Treat_Disorder
and I-Subject
obsessive I-Treat_Disorder
- I-Treat_Disorder
compulsive I-Treat_Disorder
disorder I-Treat_Disorder
. O

Allergic I-Adverse_event.Trigger
reaction I-Adverse_event.Trigger
to O
gemfibrozil I-Treatment.Drug
manifesting O
as O
eosinophilic I-Effect
gastroenteritis I-Effect
. O

We O
suggest O
that O
sarcoidosis I-Effect
may O
develop I-Adverse_event.Trigger
in O
chronic I-Treat_Disorder
hepatitis I-Treat_Disorder
C I-Treat_Disorder
patients I-Subject
during O
interferon I-Treatment.Drug
alpha I-Treatment.Drug
and/or I-Treatment
ribavirin I-Treatment.Drug
treatment O
, O
and O
diagnostic O
tests O
for O
this O
adverse O
effect O
should O
be O
performed O
during O
the O
follow O
- O
ups O
. O

Azole I-Treatment.Combination.Drug
antifungals I-Treatment.Combination.Drug
, O
prescribed O
prophylactically O
to O
avoid O
severe I-Treat_Disorder
infections I-Treat_Disorder
in O
immunosuppressed I-Subject.Sub_Disorder
organ I-Subject.Sub_Disorder
transplant I-Subject.Sub_Disorder
recipients I-Subject
, O
can O
interact I-Adverse_event.Trigger
with O
drug I-Treatment.Combination.Drug
substrates I-Treatment.Combination.Drug
of I-Treatment.Combination.Drug
CYP3A4 I-Treatment.Combination.Drug
. O

We O
present O
the O
case O
of O
a I-Subject
5 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
girl I-Subject.Gender
who O
developed O
bilateral I-Effect
vocal I-Effect
cord I-Effect
paralysis I-Effect
following I-Adverse_event.Trigger
preoperative I-Treatment
peritonsillar I-Treatment.Route
bupivacaine I-Treatment.Drug
infiltration I-Treatment.Route
. O

One I-Subject.Population
patient I-Subject
suffered O
coronary I-Effect
artery I-Effect
vasospasm I-Effect
, O
attributed I-Adverse_event.Trigger
to O
the O
use O
of O
topical I-Treatment
1:1000 I-Treatment.Dosage
epinephrine I-Treatment.Drug
during I-Treatment
surgery I-Treatment
. O

Trimethoprim I-Treatment.Drug
- I-Treatment.Drug
sulfamethoxazole I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
aseptic I-Effect
meningitis I-Effect
. O

We O
describe O
a I-Subject
patient I-Subject
with I-Subject
metastatic I-Treat_Disorder
prostate I-Treat_Disorder
cancer I-Treat_Disorder
who O
developed O
nonoliguric I-Effect
renal I-Effect
failure I-Effect
during I-Adverse_event.Trigger
treatment O
with O
suramin I-Treatment.Drug
. O

In O
conclusion O
, O
this I-Subject
case I-Subject
strongly O
suggests O
that O
gliclazide I-Treatment.Drug
can O
induce I-Adverse_event.Trigger
acute I-Effect
icteric I-Effect
liver I-Effect
necro I-Effect
- I-Effect
inflammation I-Effect
which O
may O
be O
misdiagnosed O
clinically O
as O
acute O
viral O
hepatitis O
. O

After I-Adverse_event.Trigger
administration O
of O
Oxybutynin I-Treatment.Combination.Drug
concomitantly I-Treatment
with I-Treatment
an I-Treatment
increase I-Treatment
in I-Treatment
the I-Treatment
dose I-Treatment
of I-Treatment
Dantrolene I-Treatment.Combination.Drug
, O
she I-Subject.Gender
presented O
the O
clinical I-Effect
symptoms I-Effect
and I-Effect
laboratory I-Effect
finding I-Effect
of I-Effect
Carbamazepine I-Treatment.Drug
intoxication I-Effect
. O

A O
methotrexate I-Treatment.Drug
overdosage I-Effect
was I-Effect
shown I-Effect
at I-Effect
36 I-Effect
h I-Effect
after I-Effect
infusion I-Effect
associated I-Adverse_event.Trigger
with O
a O
severe I-Effect
renal I-Effect
failure I-Effect
. O

Ceftriaxone I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
fixed I-Effect
drug I-Effect
eruption I-Effect
: O
first O
report O
. O

We O
report O
the O
case O
of O
a O
20 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
female I-Subject.Gender
with I-Subject
polyarteritis I-Treat_Disorder
nodosa I-Treat_Disorder
( I-Subject
PAN I-Subject
) I-Subject
who O
developed I-Adverse_event.Trigger
bilateral I-Effect
sensorineural I-Effect
hearing I-Effect
loss I-Effect
25 I-Time_elapsed
minutes I-Time_elapsed
after I-Time_elapsed
receiving O
30 I-Treatment.Dosage
mg I-Treatment.Dosage
of I-Treatment
intravenous I-Treatment.Route
ketoralac I-Treatment.Drug
. O

We O
report O
an I-Subject
82 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
man I-Subject.Gender
who O
developed O
ventricular I-Effect
tachycardia I-Effect
and I-Effect
Torsades I-Effect
de I-Effect
Pointes I-Effect
( I-Effect
TdP I-Effect
) I-Effect
after I-Adverse_event.Trigger
oral I-Treatment.Route
administration I-Treatment
of I-Treatment
garenoxacin I-Treatment.Drug
, O
a O
novel O
quinolone O
antibiotic O
agent O
that O
differs O
from O
the O
third O
- O
generation O
quinolones O
, O
for O
pneumonia I-Treat_Disorder
. O

Lethargy I-Effect
in O
a I-Subject
newborn I-Subject.Age
: O
lithium I-Treatment.Drug
toxicity I-Adverse_event.Trigger
or O
lab O
error O
? O

Simultaneous I-Effect
toxicities I-Effect
in O
a I-Subject
child I-Subject.Age
on I-Adverse_event.Trigger
multiple I-Treatment
anticonvulsants I-Treatment.Drug
. I-Treatment

We O
report O
a I-Subject
71 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
male I-Subject.Gender
with I-Subject
castration I-Treat_Disorder
- I-Treat_Disorder
resistant I-Treat_Disorder
metastatic I-Treat_Disorder
prostate I-Treat_Disorder
cancer I-Treat_Disorder
who O
was O
treated O
with O
weekly I-Treatment.Freq
docetaxel I-Treatment.Drug
for I-Treatment
12 I-Treatment.Duration
weeks I-Treatment.Duration
and O
developed I-Adverse_event.Trigger
significant I-Effect
eye I-Effect
irritation I-Effect
and I-Effect
dryness I-Effect
during O
treatment O
. O

In O
addition O
, O
a I-Subject
31 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
man I-Subject.Gender
with I-Subject
obsessive I-Treat_Disorder
- I-Treat_Disorder
compulsive I-Treat_Disorder
disorder I-Treat_Disorder
developed I-Adverse_event.Trigger
RBD I-Effect
soon I-Time_elapsed
after I-Time_elapsed
starting I-Treatment.Time_elapsed
fluoxetine I-Treatment.Drug
therapy I-Treatment
, O
which I-Effect
persisted I-Effect
at I-Effect
PSG I-Effect
study I-Effect
19 I-Effect
months I-Effect
after I-Effect
fluoxetine I-Effect
discontinuation I-Effect
. O

Propafenone I-Treatment.Combination.Drug
associated O
severe O
central I-Effect
nervous I-Effect
system I-Effect
and I-Effect
cardiovascular I-Effect
toxicity I-Effect
due I-Adverse_event.Trigger
to I-Adverse_event.Trigger
mirtazapine I-Treatment.Combination.Drug
: O
a O
case O
of O
severe O
drug O
interaction O
. O

Neurotoxicity I-Effect
of I-Adverse_event.Trigger
intrathecal I-Treatment.Route
administration I-Treatment
of I-Treatment
amphotericin I-Treatment.Drug
B. I-Treatment.Drug

Parenteral O
pyridoxine O
, O
the O
specific O
antidote O
for O
INH I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
refractory I-Effect
seizures I-Effect
, O
should O
be O
readily O
available O
in O
every O
emergency O
department O
in O
the O
areas O
similarly O
experiencing O
increasing O
trends O
of O
TB O
. O

DISCUSSION O
: O
Rhabdomyolysis I-Effect
is I-Effect
a I-Effect
clinical I-Effect
syndrome I-Effect
resulting I-Effect
from I-Effect
the I-Effect
destruction I-Effect
of I-Effect
skeletal I-Effect
muscle I-Effect
that I-Effect
may I-Effect
progress I-Effect
to I-Effect
renal I-Effect
failure I-Effect
Several O
drugs O
have O
been O
associated I-Adverse_event.Trigger
with O
rhabdomyolysis O
, O
including O
lovastatin I-Treatment.Drug
, I-Treatment
a I-Treatment
hydroxymethylglutaryl I-Treatment
- I-Treatment
coenzyme I-Treatment
A I-Treatment
reductase I-Treatment
inhibitor I-Treatment
. O

Thrombocytosis I-Effect
associated I-Adverse_event.Trigger
with O
enoxaparin I-Treatment.Drug
: O
A O
very O
rare O
cause O
in O
newborns I-Subject.Age
. O

The I-Effect
spectrum I-Effect
of I-Effect
renal I-Effect
lesions I-Effect
occurring I-Effect
during I-Adverse_event.Trigger
antituberculous I-Treatment.Combination.Drug
therapy I-Treatment.Combination.Drug
, I-Treatment
particularly I-Treatment
in I-Treatment
association I-Treatment
with I-Treatment
rifampin I-Treatment.Combination.Drug
, O
may O
be O
wider O
than O
previously O
suspected O
. O

Native I-Effect
arterial I-Effect
thrombosis I-Effect
, O
though O
recognized O
as O
a O
severe O
complication I-Adverse_event.Trigger
of O
thrombin I-Treatment.Drug
injection I-Treatment.Route
, O
has O
not O
been O
well O
described O
in O
the O
literature O
. O

After O
treatment O
with O
levetiracetam O
, O
seizures I-Treat_Disorder
recurred O
and O
intravenous I-Treatment.Route
loading I-Treatment
with I-Treatment
valproic I-Treatment.Drug
acid I-Treatment.Drug
was O
administered I-Potential_therapeutic_event.Trigger
, O
but O
resulted O
in O
a O
rapid O
increase O
in O
international O
normalized O
ratio O
( O
INR O
) O
to O
7.6 O
. O

After O
treatment O
with O
levetiracetam I-Treatment.Drug
, O
seizures I-Effect
recurred I-Adverse_event.Trigger
and O
intravenous O
loading O
with O
valproic O
acid O
was O
administered O
, O
but O
resulted O
in O
a O
rapid O
increase O
in O
international O
normalized O
ratio O
( O
INR O
) O
to O
7.6 O
. O

Acute I-Effect
hepatitis I-Effect
with I-Effect
prolonged I-Effect
cholestasis I-Effect
and I-Effect
disappearance I-Effect
of I-Effect
interlobular I-Effect
bile I-Effect
ducts I-Effect
following I-Adverse_event.Trigger
tibolone I-Treatment.Drug
and I-Treatment
Hypericum I-Treatment.Drug
perforatum I-Treatment.Drug
( I-Treatment
St. I-Treatment
John I-Treatment
's I-Treatment
wort I-Treatment
) I-Treatment
. O

METHODS O
: O
Five I-Subject.Population
cases I-Subject
of O
contact I-Effect
dermatitis I-Effect
due I-Adverse_event.Trigger
to I-Adverse_event.Trigger
budesonide I-Treatment.Drug
, O
a O
nonhalogenated O
steroid O
, O
are O
described O
. O

This O
sulfonamide O
like O
nephropathy O
should O
be O
differentiated O
from O
acetazolamide I-Treatment.Drug
- O
related I-Adverse_event.Trigger
calcium I-Effect
phosphate I-Effect
nephrolithiasis I-Effect
. I-Effect

Aripiprazole I-Treatment.Drug
was O
subsequently O
discontinued O
secondary O
to O
its O
lack O
of O
efficacy O
for O
OCD I-Treat_Disorder
and O
the O
development I-Adverse_event.Trigger
of O
a I-Effect
movement I-Effect
disorder I-Effect
. O

Gigantomastia I-Effect
induced I-Adverse_event.Trigger
by O
bucillamine I-Treatment.Drug
. O

Hypersensitivity I-Effect
to I-Adverse_event.Trigger
carboplatin I-Treatment.Drug
has O
been O
reported O
in O
up O
to O
44 I-Subject
% I-Subject
of I-Subject
patients I-Subject
receiving O
this O
antineoplastic O
agent O
, O
usually O
occurring O
after I-Treatment
several I-Treatment
courses I-Treatment
of I-Treatment
treatment I-Treatment
. O

CONCLUSIONS O
: O
In O
our O
reported I-Subject
case I-Subject
, O
a O
local I-Effect
hyperproduction I-Effect
of I-Effect
TNF I-Effect
- I-Effect
alpha I-Effect
from I-Effect
macrophages I-Effect
that O
was O
induced I-Adverse_event.Trigger
by O
the O
injected I-Treatment.Route
insulin I-Treatment.Drug
could O
explain O
the O
dedifferentiation I-Effect
of I-Effect
the I-Effect
adipocytes I-Effect
of I-Effect
the I-Effect
subcutaneous I-Effect
tissue I-Effect
and O
the O
reversion O
that O
was O
induced O
by O
the O
local O
injection O
of O
dexamethasone O
. O

Both O
venlafaxine I-Treatment.Drug
and I-Treatment
trimipramine I-Treatment.Drug
have O
been O
associated I-Adverse_event.Trigger
with O
seizures I-Effect
, O
mainly O
after O
overdose I-Treatment.Dosage
. O

Thirty O
- O
six O
patients O
with O
AL O
received O
, O
in O
a O
three I-Duration
- I-Duration
month I-Duration
period O
, O
51 O
cycles O
of O
combined O
chemotherapy I-Treatment
which O
included O
, O
in O
all O
of O
them O
, O
cytosine I-Treatment.Drug
arabinoside I-Treatment.Drug
( I-Treatment
ARA I-Treatment
- I-Treatment
C I-Treatment
) I-Treatment
; O
among O
them O
, O
along O
with O
myelosuppression O
, O
five I-Subject.Population
experienced I-Adverse_event.Trigger
fever I-Effect
, I-Effect
infectious I-Effect
complications I-Effect
, I-Effect
gastrointestinal I-Effect
tract I-Effect
symptoms I-Effect
and I-Effect
severe I-Effect
myalgias I-Effect
. O

Infliximab I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
lupus I-Effect
in O
Crohn O
's O
disease O
: O
a I-Subject
case I-Subject
report O
. O

The O
infection I-Effect
tended I-Effect
to O
subside I-Potential_therapeutic_event.Trigger
with O
the O
AMPH I-Treatment.Drug
administration I-Treatment
. O

CONTEXT O
: O
Acute I-Effect
drug I-Effect
induced I-Effect
hepatitis I-Effect
has O
not O
been O
commonly O
associated I-Adverse_event.Trigger
with O
epidermal I-Treatment.Drug
growth I-Treatment.Drug
factor I-Treatment.Drug
receptor I-Treatment.Drug
( I-Treatment
EGFR I-Treatment
) I-Treatment
inhibitors I-Treatment.Drug
. O

We O
report O
a O
case O
of O
fatal O
pulmonary I-Effect
toxicity I-Effect
in O
a I-Subject
patient I-Subject
with I-Subject
advanced I-Treat_Disorder
non I-Treat_Disorder
- I-Treat_Disorder
small I-Treat_Disorder
cell I-Treat_Disorder
lung I-Treat_Disorder
cancer I-Treat_Disorder
who O
received I-Adverse_event.Trigger
erlotinib I-Treatment.Drug
. O

We O
describe O
a I-Subject
patient I-Subject
with I-Subject
idiopathic I-Treat_Disorder
RLS I-Treat_Disorder
who O
developed I-Adverse_event.Trigger
augmentation I-Effect
after I-Treatment
8 I-Treatment.Time_elapsed
months I-Treatment.Time_elapsed
of I-Treatment
levodopa I-Treatment.Drug
treatment I-Treatment
. O

This O
communication O
describes O
a I-Subject
patient I-Subject
who O
developed I-Adverse_event.Trigger
Schneiderian I-Effect
first I-Effect
- I-Effect
rank I-Effect
symptoms I-Effect
in O
the O
course O
of O
treatment O
with O
fluvoxamine I-Treatment.Drug
. O

In O
addition O
to O
the O
recognized O
arrhythmic O
complications O
, O
the O
authors O
emphasize O
myocardial I-Effect
necrosis I-Effect
as O
a O
possible O
further O
manifestation O
of O
amsacrine I-Treatment.Drug
- O
related I-Adverse_event.Trigger
cardiotoxicity I-Effect
. O

The O
authors O
caution O
that O
treatment I-Treatment
with I-Treatment
alprazolam I-Treatment.Drug
may O
be O
complicated O
by O
the O
induction I-Adverse_event.Trigger
of I-Adverse_event.Trigger
mania I-Effect
. O

The O
use O
of O
rituximab I-Treatment.Drug
has O
been O
uncommonly O
associated I-Adverse_event.Trigger
with O
delayed I-Effect
pulmonary I-Effect
toxicity I-Effect
. O

We O
believe O
that O
the O
acute I-Effect
renal I-Effect
failure I-Effect
in O
our O
patient I-Subject
was O
associated I-Adverse_event.Trigger
with O
anastrozole I-Treatment.Drug
. O

On I-Treatment
the I-Treatment.Duration
fifth I-Treatment.Duration
day I-Treatment.Duration
of I-Treatment
tocolysis I-Treatment
with I-Treatment
magnesium I-Treatment.Combination.Drug
sulfate I-Treatment.Combination.Drug
, I-Treatment
nifedipine I-Treatment.Combination.Drug
, I-Treatment
terbutaline I-Treatment.Combination.Drug
and I-Treatment
betamethasone I-Treatment.Combination.Drug
, O
edema I-Effect
developed I-Adverse_event.Trigger
in I-Effect
both I-Effect
labia I-Effect
. O

Two I-Subject.Population
patients I-Subject
with I-Subject
extrinsic I-Subject.Sub_Disorder
asthma I-Subject.Sub_Disorder
and I-Subject
coexistent I-Subject
insulin I-Subject.Sub_Disorder
- I-Subject.Sub_Disorder
dependent I-Subject.Sub_Disorder
diabetes I-Subject.Sub_Disorder
mellitus I-Subject.Sub_Disorder
sustained O
an O
anaphylactoid I-Effect
reaction I-Effect
after I-Adverse_event.Trigger
the O
intravenous I-Treatment.Route
administration I-Treatment
of I-Treatment
50 I-Treatment
% I-Treatment
solution I-Treatment
of I-Treatment
dextrose I-Treatment.Drug
. O

Cardiac I-Effect
arrest I-Effect
after I-Adverse_event.Trigger
esmolol I-Treatment.Drug
administration O
: O
a O
review O
of O
acute O
beta O
- O
blocker O
toxicity O
. O

We O
suggest O
that O
nicotinic I-Treatment.Drug
acid I-Treatment.Drug
was O
the O
cause I-Adverse_event.Trigger
of O
his O
liver I-Effect
disease I-Effect
, O
that O
this O
case O
is O
of O
particular O
note O
because O
of O
the O
rather O
short O
period O
of O
therapy O
before O
the O
onset O
of O
liver O
injury O
and O
the O
severity O
of O
the O
hepatic O
failure O
, O
and O
that O
the O
probable O
increased O
use O
of O
nicotinic O
acid O
for O
serum O
cholesterol O
control O
makes O
it O
especially O
important O
for O
physicians O
and O
their O
patients O
to O
be O
alert O
to O
the O
signs O
of O
hepatotoxicity O
. O

METHODS O
: O
Two I-Subject.Population
patients I-Subject
with O
exudative I-Treat_Disorder
age I-Treat_Disorder
- I-Treat_Disorder
related I-Treat_Disorder
macular I-Treat_Disorder
degeneration I-Treat_Disorder
were O
treated O
sequentially O
with O
an O
intravitreal I-Treatment.Route
injection I-Treatment.Route
of I-Treatment
bevacizumab I-Treatment.Drug
and O
developed I-Adverse_event.Trigger
signs O
of O
severe O
but O
painless O
infectious I-Effect
endophthalmitis I-Effect
2 I-Treatment.Time_elapsed
days I-Treatment.Time_elapsed
later I-Treatment.Time_elapsed
. I-Time_elapsed

Ibuprofen I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
meningitis I-Effect
: O
detection O
of O
intrathecal O
IgG O
synthesis O
and O
immune O
complexes O
. O

Tardive I-Effect
oculogyric I-Effect
crisis I-Effect
during O
treatment O
with I-Adverse_event.Trigger
clozapine I-Treatment.Drug
: O
report O
of O
three I-Subject.Population
cases I-Subject
. O

Myasthenia I-Effect
gravis I-Effect
during I-Adverse_event.Trigger
low I-Treatment.Dosage
- I-Treatment.Dosage
dose I-Treatment.Dosage
IFN I-Treatment.Drug
- I-Treatment.Drug
alpha I-Treatment.Drug
therapy I-Treatment
for O
chronic I-Treat_Disorder
hepatitis I-Treat_Disorder
C. I-Treat_Disorder

We O
herein O
report O
this O
rare O
case O
of O
acute I-Effect
onset I-Effect
of I-Effect
nephrotic I-Effect
syndrome I-Effect
during I-Adverse_event.Trigger
interferon I-Treatment.Drug
- I-Treatment.Drug
alpha I-Treatment.Drug
retreatment O
. O

Para I-Treatment.Drug
- I-Treatment.Drug
aminosalicylic I-Treatment.Drug
acid I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
hypoglycaemia I-Effect
in O
a I-Subject
patient I-Subject
with I-Subject
diabetic I-Subject.Sub_Disorder
nephropathy I-Subject.Sub_Disorder
. O

Ischaemia I-Effect
following I-Adverse_event.Trigger
selfadministered I-Treatment
intra I-Treatment.Route
- I-Treatment.Route
arterial I-Treatment.Route
injection I-Treatment.Route
of I-Treatment
methylphenidate I-Treatment.Combination.Drug
and I-Treatment
diamorphine I-Treatment.Combination.Drug
. O

Mitomycin I-Treatment.Drug
C I-Treatment.Drug
- O
related I-Adverse_event.Trigger
hemolytic I-Effect
uremic I-Effect
syndrome I-Effect
in O
cancer I-Treat_Disorder
patients I-Subject
. O

The O
second O
had O
acute O
cystitis O
and O
was O
treated O
by O
sulphonamide O
and O
the I-Subject
third I-Subject
developed I-Adverse_event.Trigger
myopia I-Effect
coincident O
with O
metronidazole I-Treatment.Drug
treatment I-Treatment
for O
trichomonas I-Treat_Disorder
vaginalis I-Treat_Disorder
. O

The O
second O
had O
acute I-Treat_Disorder
cystitis I-Treat_Disorder
and O
was O
treated I-Potential_therapeutic_event.Trigger
by O
sulphonamide I-Treatment.Drug
and O
the O
third O
developed O
myopia O
coincident O
with O
metronidazole O
treatment O
for O
trichomonas O
vaginalis O
. O

Acute I-Effect
bilateral I-Effect
phrenic I-Effect
neuropathy I-Effect
following I-Adverse_event.Trigger
treatment O
with O
adalimumab I-Treatment.Drug
. O

Hypoxemia I-Treatment.Treat_Disorder
improved I-Treatment
during I-Treatment
continuous I-Treatment
tolazoline I-Treatment.Drug
infusion I-Treatment.Route
, O
but O
gastrointestinal I-Effect
bleeding I-Effect
occurred I-Adverse_event.Trigger
. O

BACKGROUND O
: O
NVP I-Treatment.Drug
is O
a O
non O
- O
nucleoside O
reverse O
transcriptase O
inhibitor O
used I-Potential_therapeutic_event.Trigger
in O
the O
treatment O
of O
Human I-Treat_Disorder
Immunodeficiency I-Treat_Disorder
Virus I-Treat_Disorder
( I-Treat_Disorder
HIV I-Treat_Disorder
) I-Treat_Disorder
infection I-Treat_Disorder
. O

A O
62 O
- O
year O
- O
old O
Indian O
with O
diabetic O
nephropathy O
controlled O
with O
metformin O
, O
developed O
miliary I-Treat_Disorder
tuberculosis I-Treat_Disorder
for O
which O
he O
was O
treated I-Potential_therapeutic_event.Trigger
with O
rifampicin I-Treatment.Combination.Drug
, I-Treatment
isoniazid I-Treatment.Combination.Drug
and I-Treatment
ethambutol I-Treatment.Combination.Drug
. O

A I-Subject
62 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
Indian I-Subject.Race
with I-Subject
diabetic I-Treat_Disorder
nephropathy I-Treat_Disorder
controlled O
with O
metformin I-Treatment.Drug
, O
developed I-Adverse_event.Trigger
miliary I-Effect
tuberculosis I-Effect
for O
which O
he O
was O
treated O
with O
rifampicin O
, O
isoniazid O
and O
ethambutol O
. O

A I-Subject
patient I-Subject
with I-Subject
acute I-Treat_Disorder
esophageal I-Treat_Disorder
variceal I-Treat_Disorder
bleeding I-Treat_Disorder
developed O
fatal I-Effect
rhabdomyolysis I-Effect
during I-Adverse_event.Trigger
treatment O
with O
a O
continuous I-Treatment.Route
intravenous I-Treatment.Route
infusion I-Treatment.Route
of I-Treatment
vasopressin I-Treatment.Drug
. O

Preliminary O
results O
suggest O
that O
the O
higher I-Treatment.Dosage
concentrations I-Treatment.Dosage
of I-Treatment
dextrose I-Treatment.Drug
induce I-Adverse_event.Trigger
increased I-Effect
histamine I-Effect
release I-Effect
from I-Effect
blood I-Effect
cells I-Effect
, O
and O
that O
this O
phenomenon O
is O
more O
marked O
in O
diabetic I-Subject.Sub_Disorder
, I-Subject
and I-Subject
particularly I-Subject
diabetic I-Subject.Sub_Disorder
- I-Subject.Sub_Disorder
allergic I-Subject.Sub_Disorder
, I-Subject
individuals I-Subject
. O

All I-Subject
patients I-Subject
beginning O
HMG I-Treatment.Drug
- I-Treatment.Drug
CoA I-Treatment.Drug
reductase I-Treatment.Drug
inhibitor I-Treatment.Drug
therapy O
should O
be O
counseled O
regarding I-Adverse_event.Trigger
the I-Effect
signs I-Effect
and I-Effect
symptoms I-Effect
of I-Effect
muscle I-Effect
injury I-Effect
; O
particular O
attention O
should O
be O
paid O
to O
those O
patients O
who O
are O
taking O
medications O
that O
may O
interact O
. O

Interferon I-Treatment.Drug
- I-Treatment.Drug
alpha I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
hyperthyroidism I-Effect
: O
a O
three O
- O
stage O
evolution O
from O
silent O
thyroiditis O
towards O
Graves I-Effect
' I-Effect
disease I-Effect
. O

Acute I-Effect
severe I-Effect
intoxication I-Effect
with O
carbamazepine I-Treatment.Drug
is O
associated I-Adverse_event.Trigger
with O
seizures O
, O
coma O
and O
respiratory O
depression O
. O

CONCLUSION O
: O
We O
have O
introduced O
a I-Subject
case I-Subject
of O
anaphylaxis I-Effect
by I-Adverse_event.Trigger
calcitonin I-Treatment.Drug
that O
suggest O
an O
IgE O
mediated O
hypersensitivity O
reaction O
. O

PURPOSE O
: O
To O
describe O
transient I-Effect
structured I-Effect
visual I-Effect
hallucinations I-Effect
in O
a I-Subject
patient I-Subject
with I-Subject
vascular I-Treat_Disorder
age I-Treat_Disorder
- I-Treat_Disorder
related I-Treat_Disorder
macular I-Treat_Disorder
degeneration I-Treat_Disorder
( I-Treat_Disorder
AMD I-Treat_Disorder
) I-Treat_Disorder
, O
following I-Adverse_event.Trigger
an I-Treatment
intravitreal I-Treatment.Route
Avastin I-Treatment.Drug
- I-Treatment
injection I-Treatment.Route
. O

Bortezomib I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
paralytic I-Effect
ileus I-Effect
is O
a O
potential O
gastrointestinal O
side O
effect O
of O
this O
first O
- O
in O
- O
class O
anticancer O
proteasome O
inhibitor O
. O

Fatal O
gemcitabine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
pulmonary I-Effect
toxicity I-Effect
in O
metastatic I-Treat_Disorder
gallbladder I-Treat_Disorder
adenocarcinoma I-Treat_Disorder
. O

It O
is O
suggested O
that O
the O
fatal O
stroke I-Effect
may O
have O
resulted O
from O
arterial I-Effect
spasm I-Effect
caused I-Adverse_event.Trigger
by O
ergotamine I-Treatment.Drug
overdosage I-Treatment
and O
possibly O
complicated O
by O
thrombosis O
. O

During O
the O
anti O
- O
tuberculous O
therapy O
, O
visual I-Effect
loss I-Effect
can O
be O
related I-Adverse_event.Trigger
to O
ethambutol I-Treatment.Drug
toxicity O
or O
the O
tuberculosis I-Treat_Disorder
infection I-Treat_Disorder
itself O
. O

Elevated I-Effect
International I-Effect
Normalized I-Effect
Ratio I-Effect
in O
a I-Subject
patient I-Subject
concurrently O
using I-Adverse_event.Trigger
warfarin I-Treatment.Combination.Drug
and I-Treatment
vismodegib I-Treatment.Combination.Drug
. O

Occurrence O
of O
IDDM I-Effect
during I-Adverse_event.Trigger
interferon I-Treatment.Drug
therapy I-Treatment
for O
chronic I-Treat_Disorder
viral I-Treat_Disorder
hepatitis I-Treat_Disorder
. O

Pseudomembranous I-Effect
colitis I-Effect
readily O
occurs I-Adverse_event.Trigger
in O
at O
least O
certain I-Subject
population I-Subject
groups I-Subject
receiving O
trimethoprim I-Treatment.Combination.Drug
- I-Treatment
sulfamethoxazole I-Treatment.Combination.Drug
. O

RESULTS O
: O
Budesonide I-Treatment.Drug
use O
can O
cause I-Adverse_event.Trigger
contact I-Effect
dermatitis I-Effect
. O

Hypertension I-Effect
develops O
in O
most I-Subject.Population
patients I-Subject
after I-Treatment
transplantation I-Treatment
when I-Adverse_event.Trigger
immunosuppression I-Treatment
is I-Treatment
based I-Treatment
on I-Treatment
cyclosporine I-Treatment.Drug
and I-Treatment
prednisone I-Treatment.Drug
. O

It O
was O
concluded O
that O
potassium I-Effect
loss I-Effect
occurred O
by O
a O
non O
- O
renal O
( O
intestinal O
) O
route O
in O
phosphate I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
hypokalemia I-Effect
. O

We O
have O
described O
three I-Subject.Population
patients I-Subject
with I-Subject
hepatitis I-Treat_Disorder
C I-Treat_Disorder
for O
whom O
IFN I-Treatment.Drug
- I-Treatment.Drug
alpha I-Treatment.Drug
and I-Treatment
ribavirin I-Treatment.Drug
were O
prescribed O
and O
who O
developed I-Adverse_event.Trigger
two I-Effect
successive I-Effect
phases I-Effect
of I-Effect
silent I-Effect
thyroiditis I-Effect
followed I-Effect
by I-Effect
hyperthryroidism I-Effect
relapse I-Effect
due I-Effect
to I-Effect
Graves I-Effect
' I-Effect
disease I-Effect
. O

Hepatotoxicity I-Effect
associated I-Adverse_event.Trigger
with O
choline I-Treatment.Drug
magnesium I-Treatment.Drug
trisalicylate I-Treatment.Drug
: O
case I-Subject
report O
and O
review O
of O
salicylate O
- O
induced O
hepatotoxicity O
. O

CONCLUSIONS O
: O
The I-Subject
3 I-Subject.Population
cases I-Subject
presented O
here O
illustrate O
the O
development I-Adverse_event.Trigger
of O
reproductive I-Effect
endocrine I-Effect
disorders I-Effect
after I-Treatment
the I-Treatment
initiation I-Treatment
of I-Treatment
valproate I-Treatment.Drug
therapy I-Treatment
in O
women I-Subject.Gender
with I-Subject
epilepsy I-Treat_Disorder
. O

A I-Subject
43 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
white I-Subject.Race
man I-Subject.Gender
developed O
a O
shallow I-Effect
erosion I-Effect
of I-Effect
a I-Effect
psoriatic I-Treat_Disorder
plaque I-Treat_Disorder
after I-Adverse_event.Trigger
chronic I-Treatment.Duration
administration I-Treatment
of I-Treatment
methotrexate I-Treatment.Drug
. O

CONCLUSIONS O
: O
SD O
- O
OCT O
and O
AO O
detected O
abnormalities O
that O
correlate O
topographically O
with O
visual I-Effect
field I-Effect
loss I-Effect
from I-Adverse_event.Trigger
hydroxychloroquine I-Treatment.Drug
toxicity O
as O
demonstrated O
by O
HVF O
10 O
- O
2 O
and O
may O
be O
useful O
in O
the O
detection O
of O
subclinical O
abnormalities O
that O
precede O
symptoms O
or O
objective O
visual O
field O
loss O
. O

Leflunomide I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
toxic I-Effect
epidermal I-Effect
necrolysis I-Effect
in O
a I-Subject
patient I-Subject
with I-Subject
rheumatoid I-Treat_Disorder
arthritis I-Treat_Disorder
. O

Delayed I-Effect
bowel I-Effect
injury I-Effect
is O
an O
infrequently O
observed O
complication I-Adverse_event.Trigger
of O
chromic I-Treatment.Drug
phosphate I-Treatment.Drug
administration I-Treatment
. O

Therefore O
, O
amantadine I-Treatment.Drug
was I-Adverse_event.Trigger
permanently O
discontinued O
and O
the O
cornea I-Effect
cleared I-Effect
again O
. O

CONCLUSION O
: O
We O
believe O
that O
risperidone I-Treatment.Drug
is O
not O
a O
substitute O
for O
clozapine O
in O
treating I-Potential_therapeutic_event.Trigger
psychosis I-Treat_Disorder
in O
parkinsonian I-Subject.Sub_Disorder
patients I-Subject
and O
should O
be O
used O
with O
caution O
. O

CONCLUSION O
: O
We O
believe O
that O
risperidone O
is O
not O
a O
substitute O
for O
clozapine I-Treatment.Drug
in O
treating I-Potential_therapeutic_event.Trigger
psychosis O
in O
parkinsonian I-Subject.Sub_Disorder
patients I-Subject
and O
should O
be O
used O
with O
caution O
. O

Spontaneous I-Effect
splenic I-Effect
infarction I-Effect
associated I-Adverse_event.Trigger
with O
sumatriptan I-Treatment.Drug
use O
. O

DISCUSSION O
: O
Anaphylactoid I-Effect
reactions I-Effect
have O
been O
described O
previously O
with I-Adverse_event.Trigger
cisplatin I-Treatment.Drug
administration O
. O

The O
current O
report O
describes O
a I-Subject
man I-Subject.Gender
who O
was O
prescribed O
zonisamide I-Treatment.Drug
for I-Treatment
epilepsy I-Treatment.Treat_Disorder
and O
subsequently O
developed I-Adverse_event.Trigger
widespread I-Effect
skin I-Effect
rash I-Effect
, I-Effect
acute I-Effect
kidney I-Effect
injury I-Effect
, I-Effect
high I-Effect
- I-Effect
grade I-Effect
fever I-Effect
, I-Effect
eosinophilia I-Effect
, I-Effect
liver I-Effect
dysfunction I-Effect
, I-Effect
lymphadenopathy I-Effect
and I-Effect
an I-Effect
increase I-Effect
in I-Effect
antihuman I-Effect
herpesvirus I-Effect
- I-Effect
6 I-Effect
immunoglobulin I-Effect
G I-Effect
titer I-Effect
. O

The O
toxicity I-Effect
of I-Adverse_event.Trigger
cadmium I-Treatment.Drug
, I-Treatment
zinc I-Treatment.Drug
, I-Treatment
and I-Treatment
cadmium I-Treatment.Combination.Drug
/ I-Treatment
zinc I-Treatment.Combination.Drug
mixtures I-Treatment
at I-Treatment
concentrations I-Treatment
ranging I-Treatment
from I-Treatment.Dosage
10000 I-Treatment.Dosage
to I-Treatment.Dosage
10 I-Treatment.Dosage
microg I-Treatment.Dosage
/ I-Treatment.Dosage
l I-Treatment.Dosage
was O
investigated O
. O

We O
present O
a O
case O
of O
an I-Subject
elderly I-Subject.Age
woman I-Subject.Gender
with I-Subject
a I-Subject
pre I-Subject
- I-Subject
existing I-Subject
history I-Subject
of I-Subject
ischaemic I-Subject.Sub_Disorder
heart I-Subject.Sub_Disorder
disease I-Subject.Sub_Disorder
, O
who O
was O
treated O
with O
venlafaxine I-Treatment.Drug
, O
and O
developed I-Adverse_event.Trigger
acute I-Effect
myocardial I-Effect
ischaemia I-Effect
within I-Duration
the I-Duration
first I-Duration
week I-Duration
of I-Effect
treatment I-Effect
. O

Here O
, O
we O
describe O
a I-Subject
case I-Subject
of O
Vogt I-Effect
- I-Effect
Koyanagi I-Effect
- I-Effect
Harada I-Effect
disease I-Effect
occurring I-Adverse_event.Trigger
4 I-Treatment.Time_elapsed
months I-Treatment.Time_elapsed
after I-Treatment
the I-Treatment
start I-Treatment
of I-Treatment
interferon I-Treatment.Drug
alpha I-Treatment.Drug
treatment O
, O
probably O
induced O
by O
the O
immunomodulatory O
effects O
of O
interferon O
. O

Capecitabine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
headache I-Effect
responding O
to O
diltiazem O
. O

Serotonin I-Effect
syndrome I-Effect
after I-Adverse_event.Trigger
concomitant I-Treatment
treatment I-Treatment
with I-Treatment
linezolid I-Treatment.Combination.Drug
and I-Treatment
meperidine I-Treatment.Combination.Drug
. O

We O
report O
on O
a I-Subject
child I-Subject.Age
with O
fatal O
valproate I-Treatment.Drug
- O
related I-Adverse_event.Trigger
hepatotoxic I-Effect
effects I-Effect
despite O
this O
supplementation O
. O

Acute I-Effect
isoniazid I-Treatment.Drug
neurotoxicity I-Effect
in I-Adverse_event.Trigger
an O
urban O
hospital O
. O

In O
vitro I-Effect
inhibition I-Effect
of I-Effect
hematopoiesis I-Effect
in O
a I-Subject
patient I-Subject
with I-Subject
systemic I-Treat_Disorder
sclerosis I-Treat_Disorder
treated O
with O
D I-Treatment.Drug
- I-Treatment.Drug
penicillamine I-Treatment.Drug
. O

Rhabdomyolysis I-Effect
has O
been O
reported O
in O
patients I-Subject
receiving I-Adverse_event.Trigger
hydroxymethylglutaryl I-Treatment.Combination.Drug
coenzyme I-Treatment.Combination.Drug
A I-Treatment.Combination.Drug
( I-Treatment
HMG I-Treatment
- I-Treatment
CoA I-Treatment
) I-Treatment
reductase I-Treatment
inhibitors I-Treatment
when I-Treatment
coadministered I-Treatment
with I-Treatment
agents I-Treatment.Combination.Drug
that I-Treatment.Combination.Drug
may I-Treatment.Combination.Drug
inhibit I-Treatment.Combination.Drug
their I-Treatment.Combination.Drug
metabolism I-Treatment.Combination.Drug
. O

A I-Subject
55 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
woman I-Subject.Gender
presented I-Adverse_event.Trigger
an O
episode O
of O
acute I-Effect
urticaria I-Effect
and I-Effect
labial I-Effect
angioedema I-Effect
60 I-Time_elapsed
minutes I-Time_elapsed
after O
ingesting I-Treatment.Route
500 I-Treatment.Dosage
mg I-Treatment.Dosage
of I-Treatment
cloxacillin I-Treatment.Drug
for O
a I-Subject
skin I-Treat_Disorder
abscess I-Treat_Disorder
. O

Acne I-Effect
provoked I-Adverse_event.Trigger
by O
gold I-Treatment.Drug
seems O
not O
to O
have O
been O
described O
elsewhere O
. O

Taxanes I-Treatment.Drug
are O
widely O
used O
chemotherapeutic O
agents O
with O
the O
potential O
to O
induce I-Adverse_event.Trigger
pulmonary I-Effect
injury I-Effect
through O
a O
variety O
of O
mechanisms O
. O

PURPOSE O
: O
To O
report O
two I-Subject.Population
cases I-Subject
of O
acute I-Effect
endophthalmitis I-Effect
following I-Adverse_event.Trigger
intravitreal I-Treatment.Route
bevacizumab I-Treatment.Drug
injection I-Treatment.Route
. O

This O
is O
a O
case O
report O
of O
subtle O
, O
mild I-Effect
hypothermia I-Effect
in O
a I-Subject
54 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
old I-Subject.Age
female I-Subject.Gender
patient I-Subject
receiving I-Adverse_event.Trigger
risperidone I-Treatment.Drug
for O
schizophrenia I-Treat_Disorder
. O

Mycophenolate I-Treatment.Drug
mofetil I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
neutropenia I-Effect
in I-Effect
liver I-Effect
transplantation I-Effect
. O

Replicate O
brain O
magnetic O
resonance O
imaging O
examinations O
after O
six I-Treatment.Duration
weeks I-Treatment.Duration
and I-Treatment.Duration
11 I-Treatment.Duration
months I-Treatment.Duration
of I-Treatment
penicillamine I-Treatment.Drug
therapy I-Treatment
documented O
the O
development I-Adverse_event.Trigger
of O
new I-Effect
brain I-Effect
lesions I-Effect
during O
this O
period O
, O
while O
liver O
biopsy O
specimen O
data O
disclosed O
that O
excellent O
hepatic O
decoppering O
had O
occurred O
. O

Replicate O
brain O
magnetic O
resonance O
imaging O
examinations O
after O
six I-Treatment.Duration
weeks I-Treatment.Duration
and I-Treatment.Duration
11 I-Treatment.Duration
months I-Treatment.Duration
of I-Treatment
penicillamine I-Treatment.Drug
therapy I-Treatment
documented O
the O
development O
of O
new O
brain O
lesions O
during O
this O
period O
, O
while O
liver O
biopsy O
specimen O
data O
disclosed O
that O
excellent I-Effect
hepatic I-Effect
decoppering I-Effect
had O
occurred I-Potential_therapeutic_event.Trigger
. O

According O
to O
the O
literature O
, O
chlorambucil I-Treatment.Drug
central I-Effect
nervous I-Effect
toxicity I-Effect
is O
found I-Adverse_event.Trigger
almost O
exclusively O
in O
childhood I-Subject.Age
nephrotic I-Subject.Sub_Disorder
syndrome I-Subject.Sub_Disorder
. O

Administration I-Treatment
of I-Treatment
lamotrigine I-Treatment.Combination.Drug
, O
especially O
in O
combination O
with I-Treatment
valproic I-Treatment.Combination.Drug
acid I-Treatment.Combination.Drug
, O
may O
lead O
to O
the O
development I-Adverse_event.Trigger
of O
TEN I-Effect
. O

Docetaxel I-Treatment.Drug
induced I-Adverse_event.Trigger
Meibomian I-Effect
duct I-Effect
inflammation I-Effect
and I-Effect
blockage I-Effect
is O
the O
likely O
cause O
of O
this O
presentation O
in O
a I-Subject
patient I-Subject
with I-Subject
no I-Subject
history I-Subject
of I-Subject
eyelid I-Subject
masses I-Subject
in I-Subject
the I-Subject
past I-Subject
. O

We O
describe O
a O
unique O
case O
of O
disseminated O
cryptococcosis O
presenting O
as O
colitis O
that O
mimicked O
an I-Effect
exacerbation I-Effect
of I-Effect
Crohn I-Effect
's I-Effect
disease I-Effect
in I-Adverse_event.Trigger
a I-Treatment
TNF I-Treatment.Drug
- I-Treatment.Drug
alpha I-Treatment.Drug
inhibitor I-Treatment.Drug
recipient I-Subject
. O

Rhabdomyolysis I-Effect
associated I-Adverse_event.Trigger
with O
the O
use O
of O
intravenous I-Treatment
vasopressin I-Treatment.Drug
. O

Administration I-Adverse_event.Trigger
of O
intravenous I-Treatment.Route
nitroglycerin I-Treatment.Drug
in O
a I-Subject
patient I-Subject
with I-Subject
idiopathic I-Treat_Disorder
pulmonary I-Treat_Disorder
hypertension I-Treat_Disorder
resulted O
in O
an O
increase I-Effect
in I-Effect
pulmonary I-Effect
artery I-Effect
pressure I-Effect
associated I-Effect
with I-Effect
a I-Effect
decrease I-Effect
in I-Effect
blood I-Effect
flow I-Effect
that I-Effect
is I-Effect
best I-Effect
explained I-Effect
by I-Effect
an I-Effect
increase I-Effect
in I-Effect
pulmonary I-Effect
vascular I-Effect
resistance I-Effect
. O

The O
increased I-Effect
libido I-Effect
disappeared O
after I-Adverse_event.Trigger
fluvoxamine I-Treatment.Drug
was O
discontinued O
. O

Coadministration I-Treatment
of I-Treatment
antidepressant I-Treatment
agents I-Treatment
such I-Treatment
as I-Treatment
nefazodone I-Treatment.Combination.Drug
, I-Treatment
or I-Treatment
any I-Treatment
other I-Treatment
drug I-Treatment
that I-Treatment
inhibits I-Treatment
the I-Treatment
CYP3A4 I-Treatment
isoenzyme I-Treatment
subfamily I-Treatment
, O
should O
be O
anticipated O
to O
interfere I-Adverse_event.Trigger
with O
tacrolimus I-Treatment.Combination.Drug
metabolism I-Effect
. O

CONCLUSIONS O
: O
We O
conclude O
that O
a I-Treatment
high I-Treatment.Dosage
dose I-Treatment.Dosage
combined I-Treatment
with I-Treatment
a I-Treatment
short I-Treatment
infusion I-Treatment
time I-Treatment
increases O
the O
risk O
of O
anaphylactoid I-Effect
reactions I-Effect
with I-Adverse_event.Trigger
the O
administration I-Treatment
of I-Treatment
intraperitoneal I-Treatment.Route
cisplatin I-Treatment.Drug
. O

Human I-Treatment.Drug
insulin I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
lipoatrophy I-Effect
. O

Severe I-Effect
hepatotoxicity I-Effect
from I-Adverse_event.Trigger
phenobarbital I-Treatment.Drug
occurred O
in O
an I-Subject
infant I-Subject.Age
boy I-Subject.Gender
who I-Subject
had I-Subject
a I-Subject
complicated I-Subject
illness I-Subject
with I-Subject
chronic I-Treat_Disorder
bilateral I-Treat_Disorder
subdural I-Treat_Disorder
hematomas I-Treat_Disorder
and I-Subject
sepsis I-Treat_Disorder
. I-Subject

Cholestatic I-Effect
liver I-Effect
disease I-Effect
with I-Effect
ductopenia I-Effect
( I-Effect
vanishing I-Effect
bile I-Effect
duct I-Effect
syndrome I-Effect
) I-Effect
after I-Adverse_event.Trigger
administration O
of O
clindamycin I-Treatment.Combination.Drug
and I-Treatment
trimethoprim I-Treatment.Combination.Drug
- I-Treatment
sulfamethoxazole I-Treatment.Combination.Drug
. O

The O
authors O
suggest O
that O
in O
the O
absence O
of O
any O
proven O
benefit O
of O
itraconazole I-Treatment.Combination.Drug
prophylaxis O
, O
and O
given O
the O
interaction O
of O
this O
drug O
with O
vincristine I-Treatment.Combination.Drug
leading I-Adverse_event.Trigger
to O
severe I-Effect
and I-Effect
even I-Effect
potentially I-Effect
fatal I-Effect
toxicities I-Effect
, O
the O
combination O
use O
of O
these O
drugs O
should O
be O
avoided O
. O

The O
determinant O
role O
of O
individual O
pharmacogenetic O
profile O
in O
the O
occurrence I-Adverse_event.Trigger
of O
tacrolimus I-Treatment.Drug
nephrotoxicity I-Effect
is O
presented O
and O
discussed O
. O

These O
findings O
suggest O
that O
bicytopenia I-Effect
in O
this O
patient I-Subject
was O
caused I-Adverse_event.Trigger
by O
D I-Treatment.Drug
- I-Treatment.Drug
Pen I-Treatment.Drug
and O
may O
be O
due O
to O
different O
sensitivities O
in O
the O
hematopoietic O
lineage O
. O

We O
strongly O
suspect O
that O
this O
lethal I-Effect
anuria I-Effect
was O
mainly O
due O
to O
ifosfamide I-Treatment.Combination.Drug
, O
occurring I-Adverse_event.Trigger
in O
a I-Subject
patient I-Subject
having I-Treatment
received I-Treatment
previous I-Treatment
cisplatin I-Treatment.Combination.Drug
chemotherapy I-Treatment
and I-Subject
with I-Subject
poor I-Subject.Sub_Disorder
kidney I-Subject.Sub_Disorder
perfusion I-Subject.Sub_Disorder
due I-Subject
to I-Subject
transient I-Subject
hypotension I-Subject
. O

Clinicians O
have O
been O
aware O
of O
lithium O
toxicity O
for O
many O
years O
and O
traditionally O
have O
administered I-Potential_therapeutic_event.Trigger
thiazide I-Treatment.Drug
diuretics I-Treatment.Drug
for O
lithium O
- O
induced O
polyuria I-Treat_Disorder
and O
nephrogenic I-Treat_Disorder
diabetes I-Treat_Disorder
insipidus I-Treat_Disorder
. O

We O
report O
the O
first O
case O
of O
acute I-Effect
renal I-Effect
failure I-Effect
with I-Effect
hyperkalemia I-Effect
associated I-Adverse_event.Trigger
with O
the O
recently O
marketed O
direct O
renin I-Treatment
inhibitor I-Treatment
aliskiren I-Treatment.Drug
. O

The O
authors O
describe O
a I-Subject
patient I-Subject
with I-Subject
hemiparesis I-Subject.Sub_Disorder
who O
developed I-Adverse_event.Trigger
the O
syndrome O
of O
irreversible I-Effect
lithium I-Effect
- I-Effect
effectuated I-Effect
neurotoxicity I-Effect
( I-Effect
SILENT I-Effect
) I-Effect
while O
being O
treated O
with O
lithium I-Treatment.Drug
for I-Treatment
a I-Treatment
manic I-Treatment.Treat_Disorder
episode I-Treatment.Treat_Disorder
. O

over O
the O
past O
3 O
years O
there O
have O
been O
several O
reports O
of O
uveitis I-Effect
associated I-Adverse_event.Trigger
with O
rifabutin I-Treatment.Drug
therapy I-Treatment
. O

Propylthiouracil I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
cutaneous I-Effect
vasculitis I-Effect
. O

It O
has O
been O
reported O
that O
fluoroquinolone I-Treatment.Drug
antimicrobials I-Treatment
prolong I-Adverse_event.Trigger
the O
corrected I-Effect
QT I-Effect
interval I-Effect
but I-Effect
rarely I-Effect
cause I-Effect
torsade I-Effect
de I-Effect
pointes I-Effect
. O

Succinylcholine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
hyperkalemia I-Effect
in O
a I-Subject
patient I-Subject
with I-Subject
mucositis I-Subject.Sub_Disorder
secondary O
to O
chemotherapy O
. O

To O
our O
knowledge O
, O
this O
is O
the I-Subject
first I-Subject
case I-Subject
of O
spontaneous O
remission O
of O
MTX I-Treatment.Drug
- O
associated I-Adverse_event.Trigger
gastric I-Effect
LPD I-Effect
after O
discontinuation O
of O
MTX I-Drug
therapy O
. O

We O
describe O
a I-Subject
patient I-Subject
with I-Subject
acute I-Treat_Disorder
myeloblastic I-Treat_Disorder
leukemia I-Treat_Disorder
( I-Subject
AML I-Subject
) I-Subject
who O
developed O
nephrotic I-Effect
syndrome I-Effect
after I-Adverse_event.Trigger
receiving O
several I-Treatment
courses I-Treatment
of I-Treatment
chemotherapy I-Treatment.Route
, I-Treatment
including I-Treatment
macrophage I-Treatment.Drug
- I-Treatment.Drug
colony I-Treatment.Drug
- I-Treatment.Drug
stimulating I-Treatment.Drug
factor I-Treatment.Drug
( I-Treatment
M I-Treatment
- I-Treatment
CSF I-Treatment
) I-Treatment
. O

Actinomycin I-Treatment.Drug
D I-Treatment.Drug
associated I-Adverse_event.Trigger
hepatic I-Effect
veno I-Effect
- I-Effect
occlusive I-Effect
disease I-Effect
-- O
a O
report O
of O
2 O
cases O
. O

Our O
patient I-Subject
developed I-Adverse_event.Trigger
both O
nephrogenic I-Effect
diabetes I-Effect
insipidus I-Effect
and I-Effect
renal I-Effect
tubular I-Effect
acidosis I-Effect
with O
a O
temporal O
pattern O
that O
demonstrated O
a O
link O
between O
foscarnet I-Treatment.Drug
therapy O
and O
these O
abnormalities O
. O

We O
report O
a I-Subject
case I-Subject
of O
acne I-Effect
fulminans I-Effect
occurring I-Adverse_event.Trigger
during O
treatment O
with O
13 I-Treatment.Drug
- I-Treatment.Drug
cis I-Treatment.Drug
- I-Treatment.Drug
retinoic I-Treatment.Drug
acid I-Treatment.Drug
for O
cystic I-Treat_Disorder
acne I-Treat_Disorder
. O

Verapamil I-Treatment.Drug
is O
widely O
used O
for O
the O
termination O
of O
paroxysmal I-Treat_Disorder
supraventricular I-Treat_Disorder
tachycardia I-Treat_Disorder
( O
PSVT O
) O
with I-Adverse_event.Trigger
little O
proarrhythmic I-Effect
effect I-Effect
. O

Acute O
kidney O
injury O
caused O
by O
zonisamide I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
hypersensitivity I-Effect
syndrome I-Effect
. O

Our O
findings O
suggest O
that O
hyperkalemia I-Effect
can O
develop I-Adverse_event.Trigger
with O
the O
use O
of O
low I-Treatment.Dosage
- I-Treatment.Dosage
dose I-Treatment.Dosage
heparin I-Treatment.Drug
, I-Treatment
within I-Treatment.Time_elapsed
seven I-Treatment.Time_elapsed
days I-Treatment.Time_elapsed
of I-Treatment
initiating I-Treatment
heparin I-Treatment
therapy I-Treatment
, O
and O
that O
patients I-Subject
with I-Subject
diabetes I-Subject.Sub_Disorder
mellitus I-Subject.Sub_Disorder
or I-Subject
chronic I-Subject.Sub_Disorder
renal I-Subject.Sub_Disorder
insufficiency I-Subject.Sub_Disorder
are O
especially O
predisposed O
to O
this O
complication O
. O

We O
report O
a O
case O
of O
Zidovudine I-Treatment.Drug
induced I-Adverse_event.Trigger
anaemia I-Effect
and I-Effect
bone I-Effect
marrow I-Effect
aplasia I-Effect
in O
a I-Subject
patient I-Subject
infected I-Subject
with I-Subject
HIV I-Treat_Disorder
. O

We O
present O
the O
case O
of O
an O
adult I-Subject.Age
Crohn I-Treat_Disorder
's I-Treat_Disorder
disease I-Treat_Disorder
patient I-Subject
with O
a I-Effect
parvovirus I-Effect
B19 I-Effect
infection I-Effect
and I-Effect
leukopenia I-Effect
during I-Adverse_event.Trigger
long I-Treatment.Duration
- I-Treatment.Duration
term I-Treatment.Duration
AZA I-Treatment.Drug
therapy I-Treatment
. O

Pathogenesis O
of O
methotrexate I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
papular I-Effect
eruption I-Effect
in I-Effect
psoriasis I-Effect
may O
involve O
immune O
mechanisms O
other O
than O
those O
of O
methotrexate O
- O
induced O
cutaneous I-Effect
vasculitis I-Effect
in I-Effect
collagen I-Effect
vascular I-Effect
disease I-Effect
. O

CASES O
: O
Two I-Subject.Population
postmenopausal I-Subject
women I-Subject.Gender
treated O
with O
tamoxifen I-Treatment.Drug
and I-Treatment
progestational I-Treatment
agents O
for O
breast I-Treat_Disorder
carcinoma I-Treat_Disorder
developed I-Adverse_event.Trigger
uterine I-Effect
enlargement I-Effect
and I-Effect
intermittent I-Effect
spotting I-Effect
. O

Tumor I-Effect
lysis I-Effect
syndrome I-Effect
after I-Adverse_event.Trigger
transcatheter I-Treatment.Route
arterial I-Treatment.Route
infusion I-Treatment.Route
of I-Treatment
cisplatin I-Treatment.Drug
and I-Treatment
embolization I-Treatment
therapy O
for O
liver I-Treat_Disorder
metastases I-Treat_Disorder
of I-Treat_Disorder
melanoma I-Treat_Disorder
. O

Oxcarbazepine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
Drug O
Reaction O
with O
Eosinophilia I-Effect
and I-Effect
Systemic I-Effect
Symptoms I-Effect
( I-Effect
DRESS I-Effect
) I-Effect
. O

Worsening I-Effect
of I-Effect
neurologic I-Effect
syndrome I-Effect
in I-Adverse_event.Trigger
patients I-Subject
with I-Subject
Wilson I-Treat_Disorder
's I-Treat_Disorder
disease I-Treat_Disorder
with O
initial O
penicillamine I-Treatment.Drug
therapy I-Treatment
. O

Patient I-Subject
A I-Subject
reported O
right I-Effect
leg I-Effect
weakness I-Effect
( O
foot O
drop O
) O
during I-Adverse_event.Trigger
week I-Treatment.Duration
4 I-Treatment.Duration
of I-Treatment
CAP I-Treatment.Drug
- I-Treatment.Drug
XRT I-Treatment.Drug
( I-Treatment
1600 I-Treatment.Dosage
mg I-Treatment.Dosage
/ I-Treatment.Dosage
m2 I-Treatment.Dosage
) I-Treatment
. O

A I-Subject
child I-Subject.Age
in O
whom O
a O
phenobarbital I-Treatment.Drug
hypersensitivity I-Effect
drug I-Effect
reaction I-Effect
developed I-Adverse_event.Trigger
which I-Effect
consisted I-Effect
of I-Effect
fever I-Effect
, I-Effect
a I-Effect
pruritic I-Effect
desquamating I-Effect
erythrodermic I-Effect
rash I-Effect
, I-Effect
alopecia I-Effect
, I-Effect
icterus I-Effect
, I-Effect
protein I-Effect
- I-Effect
losing I-Effect
enteropathy I-Effect
, I-Effect
myositis I-Effect
, I-Effect
and I-Effect
nephritis I-Effect
, O
is O
described O
. O

Detection O
of O
activated O
eosinophils O
in O
nasal O
polyps O
of O
an O
aspirin I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
asthma I-Effect
patient O
. O

We O
recommend O
that O
clinicians O
monitor O
patients O
for O
signs O
and O
symptoms O
of O
pancreatitis I-Effect
, I-Effect
including I-Effect
abdominal I-Effect
pain I-Effect
, O
during O
treatment I-Potential_therapeutic_event.Trigger
with O
tigecycline I-Treatment.Drug
. O

We O
describe O
a I-Subject
patient I-Subject
who O
experienced O
a O
lichenoid I-Effect
eruption I-Effect
after I-Adverse_event.Trigger
the I-Treatment
initiation I-Treatment.Duration
of I-Treatment
salsalate I-Treatment.Drug
for O
relief O
of O
arthritic I-Treat_Disorder
pain I-Treat_Disorder
. O

Concomitant O
administration I-Adverse_event.Trigger
of O
lithium I-Treatment.Combination.Drug
with O
olanzapine I-Treatment.Combination.Drug
may O
place O
patients I-Subject
at O
risk O
for O
NMS I-Effect
. O

We O
report O
the O
case O
of O
an I-Subject
87 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
white I-Subject.Race
woman I-Subject.Gender
with I-Subject
myasthenia I-Treat_Disorder
gravis I-Treat_Disorder
who O
presented I-Adverse_event.Trigger
with O
nausea I-Effect
, I-Effect
shortness I-Effect
of I-Effect
breath I-Effect
, I-Effect
azotemia I-Effect
, I-Effect
and I-Effect
hyperkalemia I-Effect
shortly O
after O
completing O
a O
course O
of O
intravenous I-Treatment.Route
immunoglobulin I-Treatment.Drug
( O
IVIG O
) O
. O

Linezolid I-Treatment.Drug
should O
be O
discontinued I-Adverse_event.Trigger
immediately O
in O
patients I-Subject
experiencing O
these O
adverse I-Effect
effects I-Effect
. O

PURPOSE O
: O
Symptomatic I-Effect
visual I-Effect
field I-Effect
constriction I-Effect
thought O
to O
be O
associated I-Adverse_event.Trigger
with O
vigabatrin I-Treatment.Drug
has O
been O
reported O
. O

Clinically I-Effect
significant I-Effect
adverse I-Adverse_event.Trigger
events I-Adverse_event.Trigger
from O
a O
drug O
interaction I-Treatment
between I-Treatment
quetiapine I-Treatment.Combination.Drug
and I-Treatment
atazanavir I-Treatment.Combination.Drug
- I-Treatment.Combination.Drug
ritonavir I-Treatment.Combination.Drug
in O
two I-Subject.Population
patients I-Subject
. O

OBJECTIVE O
: O
To O
report O
two I-Subject.Population
cases I-Subject
of O
fixed I-Effect
drug I-Effect
eruption I-Effect
induced I-Adverse_event.Trigger
by O
methylphenidate I-Treatment.Drug
. O

Linezolid I-Treatment.Drug
is O
an O
oxazolidinone O
antibacterial O
agent O
indicated I-Potential_therapeutic_event.Trigger
for O
serious I-Treat_Disorder
gram I-Treat_Disorder
- I-Treat_Disorder
positive I-Treat_Disorder
infections I-Treat_Disorder
. O

A O
search O
of O
the O
United O
States O
Food O
and O
Drug O
Administration O
's O
Adverse O
Event O
Reporting O
System O
identified O
nine O
cases O
of O
oxcarbazepine I-Treatment.Drug
- O
associated I-Adverse_event.Trigger
angioedema I-Effect
in O
pediatric I-Subject.Sub_Disorder
patients I-Subject
aged I-Subject
16 I-Subject.Age
years I-Subject.Age
and I-Subject.Age
younger I-Subject.Age
. O

Monitoring O
of O
liver O
function O
tests O
should O
be O
mandatory O
in O
patients I-Subject
receiving I-Treatment
high I-Treatment.Dosage
doses I-Treatment.Dosage
of I-Treatment
cyproterone I-Treatment.Drug
acetate I-Treatment.Drug
; O
the O
drug O
should O
be O
withdrawn O
immediately O
if O
abnormal I-Effect
liver I-Effect
function I-Effect
tests O
are O
found O
. O

In O
six I-Subject.Population
cases I-Subject
CT I-Effect
scans I-Effect
did I-Effect
not I-Effect
return I-Effect
to I-Effect
their I-Effect
original I-Effect
state I-Effect
after I-Adverse_event.Trigger
ACTH I-Treatment.Drug
therapy O
. O

This O
report O
describes O
a O
probable O
case O
of O
infliximab I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
membranous I-Effect
nephropathy I-Effect
. O

Thrombotic I-Effect
thrombocytopenic I-Effect
purpura I-Effect
during I-Adverse_event.Trigger
penicillamine I-Treatment.Drug
therapy O
in O
rheumatoid I-Treat_Disorder
arthritis I-Treat_Disorder
. O

OBJECTIVE O
: O
The O
purpose O
of O
this O
study O
was O
to O
determine O
whether O
desensitization I-Treatment.Route
to I-Treatment
NPH I-Treatment.Combination.Drug
insulin I-Treatment.Combination.Drug
, I-Treatment
as I-Treatment
well I-Treatment
as I-Treatment
standard I-Treatment.Combination.Drug
insulin I-Treatment.Combination.Drug
desensitization I-Treatment.Route
, O
could O
control I-Potential_therapeutic_event.Trigger
allergic I-Treat_Disorder
symptoms I-Treat_Disorder
in I-Treat_Disorder
a I-Treat_Disorder
patient I-Treat_Disorder
allergic I-Treat_Disorder
to I-Treat_Disorder
both I-Treat_Disorder
NPH I-Treat_Disorder
and I-Treat_Disorder
regular I-Treat_Disorder
insulin I-Treat_Disorder
. O

Fulminant I-Effect
hepatic I-Effect
failure I-Effect
developed I-Adverse_event.Trigger
in O
a I-Subject
24 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
black I-Subject.Race
woman I-Subject.Gender
who O
had O
been O
treated O
with O
propylthiouracil I-Treatment.Combination.Drug
and I-Treatment
propranolol I-Treatment.Combination.Drug
for O
hyperthyroidism I-Treat_Disorder
. O

However O
, O
as O
the O
use O
of O
hepatitis I-Treatment.Drug
B I-Treatment.Drug
vaccination I-Treatment.Drug
is O
growing O
, O
adverse O
side O
effects O
, O
including O
mental I-Effect
nerve I-Effect
neuropathy I-Effect
, O
should O
be O
observed I-Adverse_event.Trigger
with O
an O
increased O
frequency O
. O

Acute I-Effect
coronary I-Effect
events I-Effect
following I-Adverse_event.Trigger
cisplatin I-Treatment.Drug
- I-Treatment
based I-Treatment
chemotherapy I-Treatment.Route
. O

Capecitabine O
( O
CAP O
) O
is O
a O
pro O
- O
drug O
of O
5 O
- O
FU O
and O
peripheral I-Effect
neuropathy I-Effect
associated I-Adverse_event.Trigger
with O
CAP I-Treatment
has O
not O
been O
reported O
. O

PURPOSE O
: O
To O
report O
a O
case I-Effect
of I-Effect
angiographically I-Effect
documented I-Effect
cystoid I-Effect
macula I-Effect
edema I-Effect
occurring O
after O
switching I-Adverse_event.Trigger
a I-Subject
pseudophakic I-Treat_Disorder
patient I-Subject
from I-Treatment
latanoprost I-Treatment.Drug
to I-Treatment
bimatoprost I-Treatment.Drug
. I-Treatment

The O
clinical O
picture O
was O
identical I-Adverse_event.Trigger
to O
that O
of O
chloroquine I-Treatment.Drug
and I-Treatment
hydroxychloroquine I-Treatment.Drug
maculopathy I-Effect
. O

CONCLUSION O
: O
A I-Subject
woman I-Subject.Gender
receiving O
enoxaparin I-Treatment.Drug
every I-Treatment.Freq
12 I-Treatment.Freq
hours I-Treatment.Freq
developed I-Adverse_event.Trigger
signs I-Effect
and I-Effect
symptoms I-Effect
of I-Effect
hepatotoxicity I-Effect
after I-Treatment
the I-Treatment.Dosage
second I-Treatment.Dosage
dose I-Treatment.Dosage
. I-Dosage

A O
case O
of O
liver I-Effect
damage I-Effect
following I-Adverse_event.Trigger
treatment O
with O
Danazol I-Treatment.Drug
for O
fibrocystic I-Treat_Disorder
breast I-Treat_Disorder
disease I-Treat_Disorder
is O
reported O
. O

Antacid I-Treatment.Drug
and I-Treatment
sucralfate I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
hypophosphatemic I-Effect
osteomalacia I-Effect
: O
a I-Subject
case I-Subject
report O
and O
review O
of O
the O
literature O
. O

We O
report O
a I-Subject
case I-Subject
of O
senna I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
cholestatic I-Effect
hepatitis I-Effect
which O
was O
not O
diagnosed O
at O
presentation O
. O

Five I-Subject.Population
patients I-Subject
are O
described O
in O
whom O
only O
gentamicin I-Treatment.Drug
sulfate I-Treatment.Drug
appeared O
responsible I-Adverse_event.Trigger
for O
acute I-Effect
renal I-Effect
failure I-Effect
. O

However O
, O
in O
order O
to O
avoid O
neuropathic I-Effect
side I-Effect
effects I-Effect
, O
patients I-Subject
under I-Adverse_event.Trigger
thalidomide I-Treatment.Drug
therapy I-Treatment
should O
be O
monitored O
every O
6 O
months O
with O
nerve O
conduction O
studies O
while O
taking O
the O
drug O
. O

Videopolysomnographic O
and O
pharmacokinetic O
studies O
with O
monitoring O
of O
plasma O
levodopa I-Treatment.Drug
levels O
demonstrated I-Adverse_event.Trigger
marked I-Effect
motor I-Effect
hyperactivity I-Effect
during I-Effect
augmentation I-Effect
, I-Effect
with I-Effect
anarchic I-Effect
discharges I-Effect
of I-Effect
motor I-Effect
unit I-Effect
potentials I-Effect
, I-Effect
tonic I-Effect
grouped I-Effect
discharges I-Effect
and I-Effect
flexor I-Effect
spasms I-Effect
, I-Effect
associated I-Effect
with I-Effect
painful I-Effect
dysesthesia I-Effect
. O

Antibiotic I-Effect
- I-Effect
associated I-Effect
colitis I-Effect
( I-Effect
pseudomembranous I-Effect
colitis I-Effect
) I-Effect
developed I-Adverse_event.Trigger
in O
four I-Subject.Population
patients I-Subject
with I-Subject
spinal I-Treat_Disorder
cord I-Treat_Disorder
injury I-Treat_Disorder
and O
taking O
oral I-Treatment.Route
trimethoprim I-Treatment.Combination.Drug
- I-Treatment
sulfamethoxazole I-Treatment.Combination.Drug
. O

We O
report O
the O
case O
of O
a I-Subject
27 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
Indian I-Subject.Race
woman I-Subject.Gender
who O
developed I-Adverse_event.Trigger
maculopapular I-Effect
rash I-Effect
and I-Effect
angioedema I-Effect
secondary O
to O
carbamazepine I-Treatment.Drug
administration I-Treatment.Route
. O

We O
reviewed O
the O
literature O
in O
an O
attempt O
to O
characterize O
the O
pattern O
and O
predictors O
of O
TMP I-Treatment.Combination.Drug
/ I-Treatment
SMX I-Treatment.Combination.Drug
- O
induced I-Adverse_event.Trigger
aseptic I-Effect
meningitis I-Effect
. O

Mean O
time O
between O
initiation O
of O
gemcitabine O
therapy O
and O
onset I-Adverse_event.Trigger
of O
HUS I-Effect
was O
7.4 I-Treatment.Time_elapsed
+ I-Treatment.Time_elapsed
/ I-Treatment.Time_elapsed
- I-Treatment.Time_elapsed
3.5 I-Treatment.Time_elapsed
months I-Treatment.Time_elapsed
, I-Treatment
or I-Treatment
21.9 I-Treatment.Dosage
+ I-Treatment.Dosage
/ I-Treatment.Dosage
- I-Treatment.Dosage
10.9 I-Treatment.Dosage
doses I-Treatment.Dosage
of I-Treatment
gemcitabine I-Treatment.Drug
. O

Aluminum I-Treatment.Drug
intoxication I-Treatment
, O
along O
with O
other O
factors O
, O
was O
considered O
to O
be O
the O
cause I-Adverse_event.Trigger
of O
TC I-Effect
development I-Effect
. O

Agranulocytosis I-Effect
during I-Adverse_event.Trigger
clozapine I-Treatment.Drug
therapy I-Treatment
. O

It O
was O
highly O
suspected O
that O
finasteride I-Treatment.Drug
was O
associated I-Adverse_event.Trigger
with O
the O
anterior I-Effect
subcapsular I-Effect
opacity I-Effect
on I-Effect
the I-Effect
lens I-Effect
, O
and O
the I-Subject
patient I-Subject
therefore O
discontinued O
use O
of O
finasteride O
. O

Life O
- O
threatening O
cranial I-Effect
dystonia I-Effect
following I-Adverse_event.Trigger
trihexyphenidyl I-Treatment.Drug
withdrawal I-Treatment
. O

The O
risk I-Adverse_event.Trigger
of O
cardiac I-Effect
decompensation I-Effect
in O
infants I-Subject.Age
with I-Subject
supraventricular I-Treat_Disorder
tachycardia I-Treat_Disorder
and I-Subject
congestive I-Subject.Sub_Disorder
cardiac I-Subject.Sub_Disorder
failure I-Subject.Sub_Disorder
should O
be O
kept O
in O
mind O
prior O
to O
administration O
of O
verapamil I-Treatment.Drug
. O

We O
describe O
serotonin I-Effect
syndrome I-Effect
after I-Adverse_event.Trigger
concomitant I-Treatment
use I-Treatment
of I-Treatment
linezolid I-Treatment.Combination.Drug
and I-Treatment
meperidine I-Treatment.Combination.Drug
in O
a I-Subject
27 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
man I-Subject.Gender
with I-Subject
acute I-Subject.Sub_Disorder
leukemia I-Subject.Sub_Disorder
. O

Recent O
studies O
have O
shown O
that O
under O
experimental O
conditions O
ferrous I-Treatment.Combination.Drug
sulfate I-Treatment.Combination.Drug
may O
reduce I-Effect
the I-Effect
gastrointestinal I-Effect
absorption I-Effect
of I-Effect
orally I-Treatment.Route
administered I-Treatment
levothyroxine I-Treatment.Combination.Drug
sodium I-Treatment.Combination.Drug
in O
patients I-Subject
with I-Subject
primary I-Subject.Sub_Disorder
hypothyroidism I-Subject.Sub_Disorder
. O

We O
report O
here O
a O
case O
of O
cardiovascular I-Effect
and I-Effect
neurological I-Effect
depression I-Effect
induced I-Adverse_event.Trigger
by O
oxymetalzoline I-Treatment.Drug
in O
a I-Subject
toddler I-Subject.Age
. O

The O
association I-Adverse_event.Trigger
between O
heparin I-Treatment.Drug
and O
priapism I-Effect
is O
often O
recognized O
; O
abnormal O
platelet O
aggregation O
could O
play O
a O
role O
in O
the O
pathogenesis O
of O
this O
side O
effect O
. O

Posterior I-Effect
leukoencephalopathy I-Effect
following I-Adverse_event.Trigger
cisplatin I-Treatment.Combination.Drug
, I-Treatment
bleomycin I-Treatment.Combination.Drug
and I-Treatment
vinblastine I-Treatment.Combination.Drug
therapy I-Treatment
for I-Treatment
germ I-Treatment.Treat_Disorder
cell I-Treatment.Treat_Disorder
tumor I-Treatment.Treat_Disorder
of I-Treatment.Treat_Disorder
the I-Treatment.Treat_Disorder
ovary I-Treatment.Treat_Disorder
. O

OBJECTIVE O
: O
To O
report O
a O
case I-Adverse_event.Trigger
of O
cutaneous I-Effect
and I-Effect
hematologic I-Effect
toxicity I-Effect
in O
a I-Subject
patient I-Subject
treated O
with O
IL I-Treatment.Drug
- I-Treatment.Drug
2 I-Treatment.Drug
. O

Flecainide I-Treatment.Drug
is O
a O
rare O
cause I-Adverse_event.Trigger
of O
hypersensitivity I-Effect
pneumonitis I-Effect
, O
and O
few O
cases O
have O
been O
reported O
. O

The O
patient O
developed O
grade O
3 O
capecitabine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
headache I-Effect
. O

We O
report O
a O
case O
of O
biopsy I-Effect
- I-Effect
proven I-Effect
acute I-Effect
tubulointerstitial I-Effect
nephritis I-Effect
associated I-Adverse_event.Trigger
with O
a I-Treatment
second I-Treatment.Freq
course I-Treatment.Freq
of I-Treatment
flurbiprofen I-Treatment.Drug
, O
a O
nonsteroidal O
anti O
- O
inflammatory O
drug O
of O
the O
propionic O
acid O
class O
. O

Although O
an O
association O
between O
exposure O
to O
bleomycin I-Treatment.Drug
and O
the O
development I-Adverse_event.Trigger
of O
scleroderma I-Effect
has O
been O
suspected O
, O
few I-Subject
cases I-Subject
are O
reported O
. O

A I-Subject
74 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
man I-Subject.Gender
received O
oral I-Treatment.Route
administration I-Treatment
of I-Treatment
pilsicainide I-Treatment.Drug
, O
a O
pure O
sodium O
channel O
blocker O
with O
slow O
recovery O
kinetics O
, O
to O
convert O
paroxysmal I-Treat_Disorder
atrial I-Treat_Disorder
fibrillation I-Treat_Disorder
to O
sinus O
rhythm O
and O
developed I-Adverse_event.Trigger
loss I-Effect
of I-Effect
consciousness I-Effect
two I-Treatment.Time_elapsed
days I-Treatment.Time_elapsed
later I-Treatment.Time_elapsed
. O

Aggressive I-Effect
endometrial I-Effect
carcinoma I-Effect
in O
a O
breast I-Treat_Disorder
cancer I-Treat_Disorder
patient I-Subject
treated I-Adverse_event.Trigger
with O
tamoxifen I-Treatment.Drug
with I-Subject
normal I-Subject
transvaginal I-Subject
ultrasonography I-Subject
. O

Less O
common O
adverse O
events O
to O
dapsone I-Treatment.Drug
include I-Adverse_event.Trigger
the I-Effect
idiosyncratic I-Effect
reactions I-Effect
of I-Effect
leukopenia I-Effect
and I-Effect
agranulocytosis I-Effect
, I-Effect
cutaneous I-Effect
eruptions I-Effect
, I-Effect
peripheral I-Effect
neuropathy I-Effect
, I-Effect
psychosis I-Effect
, I-Effect
toxic I-Effect
hepatitis I-Effect
, I-Effect
cholestatic I-Effect
jaundice I-Effect
, I-Effect
nephrotic I-Effect
syndrome I-Effect
, I-Effect
renal I-Effect
papillary I-Effect
necrosis I-Effect
, I-Effect
severe I-Effect
hypoalbuminemia I-Effect
without I-Effect
proteinuria I-Effect
, I-Effect
an I-Effect
infectious I-Effect
mononucleosis I-Effect
- I-Effect
like I-Effect
syndrome I-Effect
, I-Effect
and I-Effect
minor I-Effect
neurological I-Effect
and I-Effect
gastrointestinal I-Effect
complaints I-Effect
. O

The O
association I-Adverse_event.Trigger
of O
venlafaxine I-Treatment.Drug
treatment I-Treatment
with O
ischaemic I-Effect
events I-Effect
could O
be O
explained O
by O
its O
unique O
pharmacological O
and O
haemodynamic O
properties O
. O

This O
selective O
closure O
of O
the O
ductus O
arteriosus O
suggests O
that O
the O
affected O
twin O
was O
predisposed O
to O
hypoxia O
and O
thus O
was O
more O
susceptible O
to O
ductal I-Effect
closure I-Effect
in O
response I-Adverse_event.Trigger
to O
indomethacin I-Treatment.Drug
exposure I-Treatment.Route
. O

This O
pattern O
is O
suggestive O
of O
renal I-Effect
toxicity I-Effect
due I-Adverse_event.Trigger
to I-Adverse_event.Trigger
tobramycin I-Treatment.Drug
. O

OBJECTIVE O
: O
To O
evaluate O
the O
efficacy O
of O
the O
administration O
of O
insulin O
by O
a O
jet O
- O
injector O
device O
in O
stopping O
and O
reversing O
severe I-Effect
human I-Effect
insulin I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
lipoatrophy I-Effect
. O

This O
is O
a I-Subject
unique I-Subject
autopsy I-Subject
case I-Subject
of O
hepatocellular I-Effect
carcinoma I-Effect
closely O
related I-Adverse_event.Trigger
to O
diethylstilbestrol I-Treatment.Drug
( I-Treatment
DES I-Treatment
) I-Treatment
therapy O
for O
prostatic I-Treat_Disorder
cancer I-Treat_Disorder
. O

Argatroban I-Treatment.Drug
for I-Potential_therapeutic_event.Trigger
heparin O
- O
induced O
thrombocytopenia O
in O
hepato I-Treat_Disorder
- I-Treat_Disorder
renal I-Treat_Disorder
failure I-Treat_Disorder
and O
CVVHD O
. O

Falling I-Effect
backward I-Effect
in O
two I-Subject.Population
elderly I-Subject.Age
patients I-Subject
taking I-Adverse_event.Trigger
bupropion I-Treatment.Drug
. O

METHODS O
: O
Three I-Subject.Population
patients I-Subject
with O
apparent O
itraconazole I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
liver I-Effect
injury I-Effect
were O
studied O
. O

Six O
patients O
developed O
peripheral O
neuropathy O
and O
five O
patients O
bone I-Treat_Disorder
marrow I-Treat_Disorder
depression I-Treat_Disorder
, O
blood O
transfusions O
were O
given O
to O
three O
patients O
and O
in O
all I-Subject
five I-Subject.Population
patients I-Subject
bone O
marrow O
function O
normalized I-Potential_therapeutic_event.Trigger
after O
cessation I-Treatment
of I-Treatment
linezolid I-Treatment.Drug
. O

Six I-Subject.Population
patients I-Subject
developed I-Adverse_event.Trigger
peripheral I-Effect
neuropathy I-Effect
and O
five O
patients O
bone O
marrow O
depression O
, O
blood O
transfusions O
were O
given O
to O
three O
patients O
and O
in O
all O
five O
patients O
bone O
marrow O
function O
normalized O
after O
cessation O
of O
linezolid I-Treatment.Drug
. O

Six O
patients O
developed I-Adverse_event.Trigger
peripheral O
neuropathy O
and O
five I-Subject.Population
patients I-Subject
bone I-Effect
marrow I-Effect
depression I-Effect
, O
blood O
transfusions O
were O
given O
to O
three O
patients O
and O
in O
all O
five O
patients O
bone O
marrow O
function O
normalized O
after O
cessation O
of O
linezolid I-Treatment.Drug
. O

Six O
patients O
developed O
peripheral O
neuropathy O
and O
five O
patients O
bone O
marrow O
depression O
, O
blood I-Treatment
transfusions I-Treatment
were O
given I-Potential_therapeutic_event.Trigger
to O
three I-Subject.Population
patients I-Subject
and O
in O
all O
five O
patients O
bone O
marrow O
function O
normalized O
after O
cessation I-Treatment
of I-Treatment
linezolid I-Treatment.Drug
. O

To O
our O
knowledge O
, O
four O
cases O
of O
interstitial I-Effect
pneumonitis I-Effect
associated I-Adverse_event.Trigger
with O
fludarabine I-Treatment.Drug
have O
been O
reported O
in O
medical O
literature O
. O

Normalization I-Effect
of I-Effect
generalized I-Effect
retinal I-Effect
function I-Effect
and I-Effect
progression I-Effect
of I-Effect
maculopathy I-Effect
after I-Potential_therapeutic_event.Trigger
cessation I-Treatment
of I-Treatment
therapy I-Treatment
in O
a I-Subject
case I-Subject
of I-Subject
severe I-Subject
hydroxychloroquine I-Treatment.Drug
retinopathy I-Treat_Disorder
with O
19 I-Time_elapsed
years I-Time_elapsed
follow O
- O
up O
. O

Interferon I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
psychosis I-Effect
as O
a O
" O
psychiatric O
contraindication O
" O
to O
hepatitis I-Treat_Disorder
C I-Treat_Disorder
treatment O
: O
a O
review O
and O
case O
- O
based O
discussion O
. O

Prolongation I-Effect
of I-Effect
the I-Effect
QT I-Effect
interval I-Effect
and I-Effect
ventricular I-Effect
tachyarrhymias I-Effect
have O
been O
described I-Adverse_event.Trigger
in O
patients I-Subject
on O
amiodarone I-Treatment.Drug
therapy I-Treatment
. O

Aripiprazole I-Treatment.Drug
, O
5 I-Treatment.Dosage
mg I-Treatment.Dosage
daily I-Treatment.Freq
, O
was O
initiated O
in O
November O
2004 O
as O
an O
augmentation I-Potential_therapeutic_event.Trigger
strategy O
for O
the O
diagnosis O
of O
OCD I-Treat_Disorder
. O

Serious I-Effect
adverse I-Effect
events I-Effect
experienced I-Adverse_event.Trigger
by O
patients I-Subject
with I-Subject
chronic I-Subject.Sub_Disorder
heart I-Subject.Sub_Disorder
failure I-Subject.Sub_Disorder
taking O
spironolactone I-Treatment.Drug
. O

Review O
of O
the O
literature O
relating O
to O
methicillin I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
nephropathy I-Effect
suggests O
a O
hypersensitivity I-Effect
origin O
for O
this O
disorder O
, O
but O
immunologic O
and O
ultrastructural O
investigation O
to O
date O
has O
failed O
to O
elucidate O
pathogenesis O
. O

ARDS I-Effect
has O
been O
associated I-Adverse_event.Trigger
with O
the I-Treatment
administration I-Treatment
of I-Treatment
other I-Treatment
monoclonal I-Treatment
antibodies I-Treatment
, I-Treatment
such I-Treatment
as I-Treatment
infliximab I-Treatment.Drug
, I-Treatment
gemtuzumab I-Treatment.Drug
ozogamicin I-Treatment.Drug
, I-Treatment
and I-Treatment
OKT3 I-Treatment.Drug
and O
is O
believed O
to O
be O
directly O
mediated O
by O
release O
of O
proinflammatory O
cytokines O
. O

CASE O
REPORT O
: O
Soon O
after I-Adverse_event.Trigger
initiation I-Adverse_event.Trigger
of O
amiodarone I-Treatment.Drug
HCl I-Treatment.Drug
( I-Dosage
200 I-Dosage
mg I-Dosage
/ O
day I-Freq
) O
, O
a I-Subject
76 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
man I-Subject.Gender
came O
to O
us O
with O
symptoms I-Effect
of I-Effect
visual I-Effect
" I-Effect
shining I-Effect
, I-Effect
" I-Effect
glare I-Effect
, I-Effect
color I-Effect
vision I-Effect
anomalies I-Effect
, I-Effect
and I-Effect
gradually I-Effect
decreased I-Effect
vision I-Effect
. O

An I-Subject
insulin I-Subject
- I-Subject
dependent I-Subject
diabetic I-Subject.Sub_Disorder
patient I-Subject
with I-Subject
nephropathy I-Subject.Sub_Disorder
developed I-Adverse_event.Trigger
severe I-Effect
acidosis I-Effect
after O
treatment O
with O
acetazolamide I-Treatment.Drug
for I-Treatment
glaucoma I-Treatment.Treat_Disorder
. O

Severe O
hypo I-Effect
- I-Effect
alpha I-Effect
- I-Effect
lipoproteinemia I-Effect
during I-Adverse_event.Trigger
treatment O
with O
rosiglitazone I-Treatment.Drug
. O

Peripheral I-Effect
neuropathy I-Effect
and I-Effect
cerebellar I-Effect
syndrome I-Effect
associated I-Adverse_event.Trigger
with O
amiodarone I-Treatment.Drug
therapy O
. O

CONCLUSIONS O
: O
We O
report O
this O
case I-Subject
of O
the O
concomitant O
appearance O
of O
multiple I-Effect
skin I-Effect
cancers I-Effect
and I-Effect
nail I-Effect
changes I-Effect
associated I-Adverse_event.Trigger
with O
hydroxyurea I-Treatment.Drug
use O
. O

As O
this O
relapse O
coincided O
with O
development I-Adverse_event.Trigger
of O
a I-Effect
strong I-Effect
delayed I-Effect
- I-Effect
type I-Effect
hypersensitivity I-Effect
response I-Effect
to O
tuberculin I-Treatment.Drug
and O
improved O
after O
treatment O
with O
the O
anti O
- O
inflammatory O
agent O
oxpentifylline O
, O
it O
was O
probably O
caused O
by O
restoration O
of O
pathogen O
- O
specific O
cellular O
immunity O
. O

As O
this I-Treat_Disorder
relapse I-Treat_Disorder
coincided O
with O
development O
of O
a O
strong O
delayed O
- O
type O
hypersensitivity O
response O
to O
tuberculin O
and O
improved I-Potential_therapeutic_event.Trigger
after O
treatment O
with O
the O
anti I-Treatment
- I-Treatment
inflammatory I-Treatment
agent I-Treatment
oxpentifylline I-Treatment.Drug
, O
it O
was O
probably O
caused O
by O
restoration O
of O
pathogen O
- O
specific O
cellular O
immunity O
. O

Itraconazole I-Treatment.Combination.Drug
- O
related I-Adverse_event.Trigger
increased I-Effect
vincristine I-Combination.Drug
neurotoxicity I-Effect
: O
case O
report O
and O
review O
of O
literature O
. O

A I-Subject
62 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
Caucasian I-Subject.Race
man I-Subject.Gender
with I-Subject
atrial I-Treat_Disorder
fibrillation I-Treat_Disorder
who O
was O
taking O
warfarin I-Treatment.Drug
reported O
an O
episode I-Adverse_event.Trigger
of O
hematochezia I-Effect
; O
his O
international O
normalized O
ratio O
( O
INR O
) O
was O
1.74 O
. O

Severe O
anaemia I-Effect
related I-Adverse_event.Trigger
to O
oseltamivir I-Treatment.Drug
during I-Treatment
treatment I-Treatment
of I-Treatment
chronic I-Treatment.Treat_Disorder
hepatitis I-Treatment.Treat_Disorder
C I-Treatment.Treat_Disorder
: O
a O
new O
drug O
interaction O
? O

BACKGROUND O
: O
How O
to O
best O
treat O
psychotic I-Treat_Disorder
patients I-Subject
who O
have O
had O
past O
clozapine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
agranulocytosis I-Effect
or I-Effect
granulocytopenia I-Effect
remains O
a O
problem O
. O

Cystoid I-Effect
macular I-Effect
edema I-Effect
in I-Adverse_event.Trigger
a O
low I-Subject
- I-Subject
risk I-Subject
patient I-Subject
after O
switching I-Treatment
from I-Treatment
latanoprost I-Treatment.Combination.Drug
to I-Treatment
bimatoprost I-Treatment.Combination.Drug
. O

Physicians O
should O
therefore O
be O
aware O
of O
its O
occurrence O
and O
carefully O
monitor O
serum O
levels O
of O
CPK O
, O
GOT O
and O
GPT O
during O
the O
treatment O
of O
diabetes I-Treat_Disorder
insipidus I-Treat_Disorder
with O
clofibrate I-Treatment.Drug
, O
especially O
in O
patients I-Subject
with I-Subject
associated I-Subject
hypothyroidism I-Subject.Sub_Disorder
, I-Subject
latent I-Subject.Sub_Disorder
or I-Subject
overt I-Subject.Sub_Disorder
, O
which O
possibly O
favors O
the O
development I-Adverse_event.Trigger
of O
myopathy I-Effect
. I-Effect

Flurbiprofen I-Treatment.Drug
- O
associated I-Adverse_event.Trigger
acute I-Effect
tubulointerstitial I-Effect
nephritis I-Effect
. O

CONCLUSION O
: O
We O
believe O
this O
to O
be O
the O
first O
reported O
case O
of O
rhGH I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
hypercalcemia I-Effect
in O
an I-Subject
HIV I-Treat_Disorder
- I-Subject
infected I-Subject
patient I-Subject
. O

A O
case O
of O
basilar I-Effect
invagination I-Effect
which O
is O
thought O
to O
have O
arisen O
from O
the O
patient O
's O
intrauterine I-Route
exposure I-Adverse_event.Trigger
to O
phenytoin I-Treatment.Drug
is O
presented O
. O

Methotrexate I-Effect
pneumonitis I-Effect
in I-Adverse_event.Trigger
nonsurgical I-Treatment
treatment I-Treatment
of O
ectopic I-Treat_Disorder
pregnancy I-Treat_Disorder
. O

Two I-Subject.Population
patients I-Subject
who O
were O
receiving I-Treatment
Tolazoline I-Treatment.Drug
by I-Treatment
infusion I-Treatment.Route
developed I-Adverse_event.Trigger
duodenal I-Effect
ulceration I-Effect
and I-Effect
subsequent I-Effect
intestinal I-Effect
perforation I-Effect
. O

We O
report O
the O
case O
of O
a I-Subject
14 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
female I-Subject.Gender
with I-Subject
acute I-Treat_Disorder
promyelocytic I-Treat_Disorder
leukemia I-Treat_Disorder
who O
developed I-Adverse_event.Trigger
symptomatic I-Effect
cardiomyopathy I-Effect
only O
4 I-Treatment.Time_elapsed
months I-Treatment.Time_elapsed
into I-Treatment
treatment I-Treatment
with I-Treatment
a I-Treatment
combination I-Treatment
of I-Treatment
daunomycin I-Treatment.Combination.Drug
and I-Treatment
all I-Treatment.Combination.Drug
- I-Treatment.Combination.Drug
trans I-Treatment.Combination.Drug
retinoic I-Treatment.Combination.Drug
acid I-Treatment.Combination.Drug
( I-Treatment
ATRA I-Treatment
) I-Treatment
. O

Hepatotoxicity I-Effect
seen I-Adverse_event.Trigger
with O
erlotinib I-Treatment.Drug
, O
a O
small O
molecule O
tyrosine O
kinase O
inhibitor O
to O
EGFR O
, O
is O
usually O
transient I-Effect
with I-Effect
mild I-Effect
elevation I-Effect
of I-Effect
transaminases I-Effect
. O

RESULTS O
: O
A I-Subject
previously I-Subject
healthy I-Subject
42 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
woman I-Subject.Gender
presented O
with O
acute I-Effect
- I-Effect
onset I-Effect
delirium I-Effect
with I-Effect
psychotic I-Effect
features I-Effect
as I-Adverse_event.Trigger
a I-Adverse_event.Trigger
consequence I-Adverse_event.Trigger
of I-Adverse_event.Trigger
levofloxacin I-Treatment.Drug
therapy I-Treatment
. O

Although O
limb O
dyskinesia O
after O
methylphenidate I-Drug
is O
a O
commonly O
reported O
side O
effect O
, O
to O
the O
authors O
' O
knowledge O
this O
is O
only O
the I-Subject
second I-Subject
reported I-Subject
case I-Subject
to O
develop I-Adverse_event.Trigger
both O
orofacial I-Effect
and I-Effect
limb I-Effect
dyskinesia I-Effect
in O
the O
acute O
period O
after O
the O
first O
dose O
of O
methylphenidate I-Treatment.Drug
. O

Phenylpropanolamine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
psychosis I-Effect
. O

Graft I-Effect
versus I-Effect
host I-Effect
- I-Effect
like I-Effect
illness I-Effect
in O
a I-Subject
child I-Subject.Age
with O
phenobarbital I-Treatment.Drug
hypersensitivity I-Effect
. O

The O
wide O
use O
of O
phenytoin I-Treatment.Drug
during O
the O
recent O
tuberculosis I-Duration
epidemic O
makes O
it O
imperative O
to O
suspect I-Adverse_event.Trigger
this O
drug O
interaction O
in O
patients I-Subject
exhibiting O
clinical O
features O
that O
might O
be O
related O
to O
phenytoin I-Effect
toxicity I-Effect
. O

We O
report O
a O
case O
of O
MMC I-Treatment.Drug
- O
related I-Adverse_event.Trigger
hemolytic I-Effect
uremic I-Effect
syndrome I-Effect
, O
and O
discuss O
the O
etiologic O
parameters O
, O
clinical O
aspects O
, O
prognosis O
and O
treatment O
modalities O
of O
this O
severe O
syndrome O
. O

Myasthenic I-Treat_Disorder
patients I-Subject
receiving I-Adverse_event.Trigger
ampicillin I-Treatment.Drug
should O
be O
closely O
monitored O
for O
possible O
acute I-Effect
exacerbations I-Effect
. O

The I-Subject
male I-Subject.Gender
patient I-Subject
was O
treated O
with O
225 I-Treatment.Dosage
- I-Treatment.Dosage
mg I-Treatment.Dosage
/ I-Treatment.Dosage
day I-Treatment.Dosage
clozapine I-Treatment.Drug
and O
the O
time O
to O
the O
diagnosis I-Adverse_event.Trigger
of O
agranulocytosis I-Effect
was O
6 I-Duration
weeks I-Duration
. O

Alprazolam I-Treat_Disorder
withdrawal I-Treat_Disorder
delirium I-Treat_Disorder
unresponsive O
to I-Potential_therapeutic_event.Trigger
diazepam I-Treatment.Drug
: O
case O
report O
. O

These O
findings O
support O
previous O
studies O
that O
showed O
that O
the O
use O
of O
aspirin I-Treatment.Drug
during O
the I-Treat_Disorder
antecedent I-Treat_Disorder
illness I-Treat_Disorder
may O
be O
a O
risk O
factor O
for O
the O
development I-Adverse_event.Trigger
of O
RS I-Effect
. O

Chloroquine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
bilateral I-Effect
ptosis I-Effect
. O

DISCUSSION O
: O
To O
our O
knowledge O
this O
is O
the O
first O
reported O
case O
of O
tuberculous I-Effect
uveitis I-Effect
following O
treatment O
with I-Adverse_event.Trigger
etanercept I-Treatment.Drug
. O

Hyponatremia I-Effect
is O
a O
known O
adverse I-Adverse_event.Trigger
effect O
of O
duloxetine I-Treatment.Drug
, O
and O
it O
can O
lead O
to O
potentially I-Effect
life I-Effect
- I-Effect
threatening I-Effect
complications I-Effect
. O

A I-Subject
22 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
drug I-Subject.Sub_Disorder
- I-Subject.Sub_Disorder
abuser I-Subject.Sub_Disorder
injected I-Treatment.Route
flunitrazepam I-Treatment.Drug
tablets I-Treatment.Route
dissolved I-Treatment.Route
in I-Treatment.Route
tap I-Treatment.Route
water I-Treatment.Route
into I-Treatment
her I-Treatment
left I-Treatment
femoral I-Treatment
artery I-Treatment
and O
presented I-Adverse_event.Trigger
with O
clinical O
signs O
of O
acute I-Effect
ischaemia I-Effect
of I-Effect
the I-Effect
left I-Effect
leg I-Effect
. O

A I-Subject
patient I-Subject
with I-Subject
Parkinson I-Treat_Disorder
's I-Treat_Disorder
disease I-Treat_Disorder
, O
initially I-Treatment
treated I-Treatment
with I-Treatment
bromocriptine I-Treatment.Drug
and I-Treatment
subsequently I-Treatment
with I-Treatment
cabergoline I-Treatment.Drug
, O
developed I-Adverse_event.Trigger
progressive I-Effect
pleuropulmonary I-Effect
abnormalities I-Effect
during I-Effect
the I-Effect
latter I-Effect
therapy I-Effect
. O

Although O
interferon I-Treatment.Drug
gamma I-Treatment.Drug
has O
been O
implicated O
in O
the O
pathogenesis I-Adverse_event.Trigger
of O
sarcoidosis I-Effect
, O
only O
a O
few O
cases O
of O
sarcoidosis O
associated O
with O
interferon O
alpha O
therapy O
have O
been O
reported O
. O

Although O
interferon O
gamma O
has O
been O
implicated O
in O
the O
pathogenesis O
of O
sarcoidosis O
, O
only O
a O
few O
cases O
of O
sarcoidosis I-Effect
associated I-Adverse_event.Trigger
with O
interferon I-Treatment.Drug
alpha I-Treatment.Drug
therapy O
have O
been O
reported O
. O

Camptocormia I-Effect
, O
a O
new O
side O
effect O
of I-Adverse_event.Trigger
sodium I-Treatment.Drug
valproate I-Treatment.Drug
. O

Many I-Subject
patients I-Subject
with I-Subject
cardiac I-Treat_Disorder
arrhythmias I-Treat_Disorder
require I-Potential_therapeutic_event.Trigger
concomitant I-Treatment
therapy I-Treatment
with I-Treatment
warfarin I-Treatment.Combination.Drug
and I-Treatment
amiodarone I-Treatment.Combination.Drug
. O

We O
report O
the O
case O
histories O
of O
two I-Subject.Population
patients I-Subject
with I-Subject
histologically I-Subject
confirmed I-Subject
adenocarcinoma I-Treat_Disorder
of I-Treat_Disorder
the I-Treat_Disorder
prostate I-Treat_Disorder
, O
both O
of O
whom O
had O
been O
treated I-Adverse_event.Trigger
with O
steroidal I-Treatment
anti I-Treatment
- I-Treatment
androgen I-Treatment
therapy I-Treatment
in I-Treatment
the I-Treatment
form I-Treatment
of I-Treatment
cyproterone I-Treatment.Drug
acetate I-Treatment.Drug
prior I-Treatment
to I-Treatment
radical I-Treatment
or I-Treatment
palliative I-Treatment
pelvic I-Treatment
irradiation I-Treatment
, O
and O
who O
subsequently O
developed O
femoral I-Effect
head I-Effect
avascular I-Effect
necrosis I-Effect
. I-Effect

Thus O
, O
the O
possible O
in O
vivo O
effects O
of O
insulin O
on O
adipocytes O
were O
clearly O
observed O
in O
this O
case O
of O
insulin I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
lipohypertrophy I-Effect
. O

After I-Adverse_event.Trigger
the O
addition O
of O
citalopram I-Treatment.Drug
, O
a O
desmethylclomipramine I-Effect
plasma I-Effect
level I-Effect
increase I-Effect
and I-Effect
an I-Effect
8 I-Effect
- I-Effect
hydroacy I-Effect
- I-Effect
desmethylclomipramine I-Effect
plasma I-Effect
level I-Effect
decrease I-Effect
were O
observed O
. O

Here O
we O
present O
the O
case O
of O
a I-Subject
woman I-Subject.Gender
who O
received I-Adverse_event.Trigger
high I-Treatment
doses I-Treatment
of I-Treatment
methylprednisolone I-Treatment.Drug
( I-Treatment
1 I-Treatment.Dosage
g I-Treatment.Dosage
iv I-Treatment.Route
daily I-Treatment.Freq
) I-Treatment
for O
active I-Treat_Disorder
Graves I-Treat_Disorder
' I-Treat_Disorder
ophthalmopathy I-Treat_Disorder
, O
and O
developed O
severe I-Effect
hypertension I-Effect
followed I-Effect
by I-Effect
myocardial I-Effect
infarction I-Effect
on I-Effect
the I-Effect
fifth I-Effect
day I-Effect
of I-Effect
treatment I-Effect
. I-Effect

Severe O
cardiomyopathy I-Effect
following I-Adverse_event.Trigger
treatment I-Treatment
with I-Treatment
the I-Treatment
tumour I-Treatment
necrosis I-Treatment
factor I-Treatment
- I-Treatment
alpha I-Treatment
inhibitor I-Treatment
adalimumab I-Treatment.Drug
for O
Crohn I-Treat_Disorder
's I-Treat_Disorder
disease I-Treat_Disorder
. O

There O
are O
now O
reports O
of O
liver I-Effect
failure I-Effect
following I-Adverse_event.Trigger
treatment O
of O
childhood I-Subject.Age
cancers I-Treat_Disorder
with O
AMD I-Treatment.Drug
. O

Imatinib I-Treatment.Drug
mesylate I-Treatment.Drug
- O
related I-Adverse_event.Trigger
fatal I-Effect
acute I-Effect
hepatic I-Effect
failure I-Effect
in O
a I-Subject
patient I-Subject
with I-Subject
chronic I-Treat_Disorder
myeloid I-Treat_Disorder
leukaemia I-Treat_Disorder
and I-Subject
chronic I-Subject.Sub_Disorder
hepatitis I-Subject.Sub_Disorder
B I-Subject.Sub_Disorder
infection I-Subject.Sub_Disorder
. O

This O
phase O
3 O
, O
randomized O
, O
double O
- O
blind O
1 O
- O
yr O
study O
assessed O
the O
effects I-Potential_therapeutic_event.Trigger
of O
combined I-Treatment
RLX I-Treatment.Combination.Drug
and I-Treatment
ALN I-Treatment.Combination.Drug
in O
331 I-Subject.Population
postmenopausal I-Subject.Age
women I-Subject.Gender
with I-Subject
osteoporosis I-Treat_Disorder
( I-Subject
femoral I-Subject
neck I-Subject
BMD I-Subject
T I-Subject
- I-Subject
score I-Subject
, I-Subject
less I-Subject
than I-Subject
-2 I-Subject
) I-Subject
. O

Phenytoin I-Combination.Drug
toxicity I-Effect
due I-Adverse_event.Trigger
to O
concomitant I-Treatment
antituberculosis I-Treatment.Combination.Drug
therapy I-Treatment
. I-Treatment

Hemodialysis O
should O
be O
performed O
for O
rapid O
reversal O
of O
mannitol I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
ARF I-Effect
. O

Hemodialysis I-Treatment.Drug
should O
be O
performed I-Potential_therapeutic_event.Trigger
for O
rapid O
reversal O
of O
mannitol I-Treat_Disorder
- I-Treat_Disorder
induced I-Treat_Disorder
ARF I-Treat_Disorder
. O

Amiodarone I-Treatment.Drug
is O
well O
recognized I-Adverse_event.Trigger
as O
an O
anti O
- O
arrhythmic O
drug O
containing O
a O
high O
dose O
of O
iodine O
with O
considerable O
potential I-Effect
to I-Effect
cause I-Effect
thyroid I-Effect
dysfunction I-Effect
. O

Pulmonary I-Effect
infiltrates I-Effect
and I-Effect
skin I-Effect
pigmentation I-Effect
associated I-Adverse_event.Trigger
with O
sulfasalazine I-Treatment.Drug
. O

Lithium I-Treatment.Drug
treatment I-Treatment
was O
terminated O
in O
1975 O
because I-Adverse_event.Trigger
of O
lithium I-Effect
intoxication I-Effect
with I-Effect
a I-Effect
diabetes I-Effect
insipidus I-Effect
- I-Effect
like I-Effect
syndrome I-Effect
. O

The O
authors O
report O
a O
longitudinal O
case O
study O
of O
a I-Subject
woman I-Subject.Gender
with I-Subject
a I-Subject
history I-Subject
of I-Subject
bipolar I-Subject.Sub_Disorder
affective I-Subject.Sub_Disorder
disorder I-Subject.Sub_Disorder
in O
which O
L I-Treatment.Drug
- I-Treatment.Drug
dopa I-Treatment.Drug
shortened I-Effect
the I-Effect
manic I-Effect
- I-Effect
depressive I-Effect
cycle I-Effect
length I-Effect
when O
administered O
in O
a O
double O
- O
blind O
trial O
. O

Isoniazid I-Treatment.Drug
causing I-Adverse_event.Trigger
breast I-Effect
tissue I-Effect
enlargement I-Effect
has O
been O
very O
rarely O
reported O
. O

The O
induction I-Adverse_event.Trigger
of O
hypoglycaemia I-Effect
with O
PAS I-Treatment.Drug
in O
this I-Subject
patient I-Subject
suggests O
a O
potential O
role O
for O
PAS O
in O
the O
treatment O
of O
diabetes I-Treat_Disorder
mellitus I-Treat_Disorder
. O

Although O
both I-Subject.Population
patients I-Subject
recovered I-Potential_therapeutic_event.Trigger
from O
the O
colitis I-Treat_Disorder
after O
the O
administration O
of O
vancomycin I-Treatment.Drug
, O
the O
first O
case O
demonstrated O
a O
relapse O
of O
the O
colitis O
after O
receiving O
a O
subsequent O
course O
of O
the O
same O
chemotherapy O
with O
cisplatin O
. O

Although O
both O
patients O
recovered O
from O
the O
colitis O
after O
the O
administration O
of O
vancomycin O
, O
the O
first O
case O
demonstrated O
a I-Effect
relapse I-Effect
of I-Effect
the I-Effect
colitis I-Effect
after O
receiving I-Adverse_event.Trigger
a I-Treatment
subsequent I-Treatment
course I-Treatment
of I-Treatment
the I-Treatment
same I-Treatment
chemotherapy I-Treatment.Route
with I-Treatment
cisplatin I-Treatment.Drug
. O

Acute I-Effect
dystonia I-Effect
during O
pegylated I-Treatment.Drug
interferon I-Treatment.Drug
alpha I-Treatment.Drug
therapy I-Adverse_event.Trigger
in O
a O
case O
with O
chronic I-Treat_Disorder
hepatitis I-Treat_Disorder
B I-Treat_Disorder
infection I-Treat_Disorder
. O

I O
saw O
two I-Subject.Population
patients I-Subject
with I-Subject
kala I-Treat_Disorder
- I-Treat_Disorder
azar I-Treat_Disorder
resistant I-Subject.Sub_Disorder
to I-Subject.Sub_Disorder
sodium I-Subject.Sub_Disorder
stibogluconate I-Subject.Sub_Disorder
who O
developed I-Adverse_event.Trigger
cardiac I-Effect
arrest I-Effect
after O
amphotericin I-Treatment.Drug
infusion I-Treatment.Route
( O
in O
spite O
of O
tolerating O
a O
test O
dose O
) O
. O

CONCLUSIONS O
: O
Anastrozole I-Treatment.Drug
may O
be O
the O
causative I-Adverse_event.Trigger
factor O
in O
patients I-Subject
with O
sclerosing I-Effect
glomerulonephritis I-Effect
. O

We O
describe O
two I-Subject
cases I-Subject
of O
acute I-Effect
pancreatitis I-Effect
that O
occurred I-Adverse_event.Trigger
after O
long O
term O
mesalamine I-Treatment.Drug
therapy O
for O
ulcerative I-Treat_Disorder
colitis I-Treat_Disorder
. O

Amphotericin I-Treatment.Drug
B I-Treatment.Drug
( I-Treatment
AmB I-Treatment
) I-Treatment
is O
effective O
, O
but O
its O
use O
is O
limited O
by I-Adverse_event.Trigger
toxicity I-Effect
: I-Effect
renal I-Effect
impairment I-Effect
, I-Effect
anaemia I-Effect
, I-Effect
fever I-Effect
, I-Effect
malaise I-Effect
, I-Effect
and I-Effect
hypokalaemia I-Effect
are O
common O
. O

We O
believe O
that O
a I-Treatment
drug I-Treatment
interaction I-Treatment
between I-Treatment
terfenadine I-Treatment.Combination.Drug
and I-Treatment
ketoconazole I-Treatment.Combination.Drug
resulted I-Adverse_event.Trigger
in O
the I-Effect
elevated I-Effect
terfenadine I-Effect
levels I-Effect
in I-Effect
plasma I-Effect
and I-Effect
in I-Effect
the I-Effect
cardiotoxicity I-Effect
previously O
seen O
only O
in O
cases O
of O
terfenadine O
overdose O
. O

A O
case O
of O
halothane I-Treatment.Drug
induced I-Adverse_event.Trigger
hepatitis I-Effect
is O
reported O
in O
a I-Subject
middle I-Subject.Age
aged I-Subject.Age
woman I-Subject.Gender
who O
underwent O
gastric I-Treatment
surgery I-Treatment
for I-Treatment
morbid I-Treatment.Treat_Disorder
obesity I-Treatment.Treat_Disorder
. O

Carbonic I-Treatment.Drug
anhydrase I-Treatment.Drug
inhibitors I-Treatment.Drug
used O
in O
the O
treatment O
of O
glaucoma I-Treat_Disorder
, I-Treat_Disorder
seizure I-Treat_Disorder
disorders I-Treat_Disorder
, I-Treat_Disorder
and I-Treat_Disorder
hypertension I-Treat_Disorder
are O
rarely I-Potential_therapeutic_event.Trigger
associated I-Potential_therapeutic_event.Trigger
with O
blood I-Effect
dyscrasias I-Effect
. O

Administration I-Treatment
of I-Treatment
intrathecal I-Treatment.Route
Ara I-Treatment.Drug
- I-Treatment.Drug
C I-Treatment.Drug
in I-Treatment
the I-Treatment
same I-Treatment
dose I-Treatment
over I-Treatment
longer I-Treatment.Freq
intervals I-Treatment.Freq
within I-Treatment.Freq
3 I-Treatment.Freq
- I-Treatment.Freq
5 I-Treatment.Freq
days I-Treatment.Freq
between I-Treatment.Freq
consecutive I-Treatment.Freq
doses I-Treatment.Freq
resulted I-Adverse_event.Trigger
in O
mild O
, O
transient O
neurological I-Effect
symptoms I-Effect
( O
paresthesias O
) O
in O
only O
one I-Subject.Population
of I-Subject.Population
30 I-Subject.Population
patients I-Subject
so O
treated O
. O

Anaphylaxis I-Effect
from O
isoniazid I-Treatment.Drug
is I-Adverse_event.Trigger
a O
possible O
side O
effect O
to O
this O
commonly I-Treatment
prescribed I-Treatment
antibiotic I-Treatment
. O

Among O
12 O
thyrotoxic O
patients O
, O
a I-Subject
patient I-Subject
with I-Subject
arrhythmogenic I-Treat_Disorder
right I-Treat_Disorder
ventricular I-Treat_Disorder
dysplasia I-Treat_Disorder
, O
who O
had O
been O
taking O
amiodarone I-Treatment.Drug
for I-Treatment
4 I-Treatment.Duration
years I-Treatment.Duration
, O
developed I-Adverse_event.Trigger
thyrotoxicosis I-Effect
with I-Effect
subacute I-Effect
onset I-Effect
, I-Effect
accompanied I-Effect
by I-Effect
transiently I-Effect
positive I-Effect
thyrotropin I-Effect
( I-Effect
TSH I-Effect
) I-Effect
receptor I-Effect
antibody I-Effect
( I-Effect
TRAb I-Effect
) I-Effect
, I-Effect
or I-Effect
thyrotropin I-Effect
- I-Effect
binding I-Effect
inhibiting I-Effect
immunoglobulin I-Effect
( I-Effect
TBII I-Effect
) I-Effect
. O

Methotrexate I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
papular I-Effect
eruption I-Effect
following O
treatment O
of O
psoriasis I-Treat_Disorder
. O

Sexual I-Effect
dysfunction I-Effect
associated I-Adverse_event.Trigger
with O
intrathecal I-Treatment.Route
baclofen I-Treatment.Drug
use O
: O
a O
report O
of O
two I-Subject.Population
cases I-Subject
. O

Patients I-Subject
treated O
with O
L I-Treatment.Drug
- I-Treatment.Drug
asparaginase I-Treatment.Drug
may O
present I-Adverse_event.Trigger
with O
hemorrhagic I-Effect
and I-Effect
thrombotic I-Effect
cerebrovascular I-Effect
events I-Effect
. O

Since O
imiquimod I-Treatment.Drug
induces I-Adverse_event.Trigger
large I-Effect
amounts I-Effect
of I-Effect
type I-Effect
I I-Effect
interferon I-Effect
production I-Effect
from O
TLR7 O
- O
expressing O
plasmacytoid O
dendritic O
cell O
precursors O
( O
PDCs O
) O
, O
the O
natural O
interferon O
- O
producing O
cells O
of O
the O
peripheral O
blood O
, O
we O
asked O
whether O
PDCs O
are O
present O
in O
psoriatic O
skin O
. O

Ptosis I-Effect
occurring I-Adverse_event.Trigger
24 I-Time_elapsed
h I-Time_elapsed
after O
chloroquine I-Treatment.Drug
therapy I-Treatment
, O
with O
full I-Effect
recovery I-Effect
48 I-Effect
h I-Effect
after I-Effect
cessation I-Effect
of I-Effect
chloroquine I-Effect
, O
has O
not O
been O
described O
previously O
. O

Hypersensitivity I-Effect
pneumonitis I-Effect
- I-Effect
like I-Effect
syndrome I-Effect
associated I-Adverse_event.Trigger
with O
the O
use O
of O
lenalidomide I-Treatment.Drug
. O

Incidence O
of O
seizures I-Effect
in O
pediatric I-Subject.Age
cancer I-Subject.Sub_Disorder
patients I-Subject
treated I-Adverse_event.Trigger
with O
imipenem I-Treatment.Combination.Drug
/ I-Treatment
cilastatin I-Treatment.Combination.Drug
. O

One O
of O
these O
was O
clofazimine I-Treatment.Drug
, O
an O
aniline O
aposafranine O
derivative O
known O
to O
produce I-Adverse_event.Trigger
a I-Effect
ceroid I-Effect
- I-Effect
like I-Effect
pigment I-Effect
in O
the O
tissues O
of O
patients I-Subject
treated I-Subject
with I-Subject
this I-Subject
drug I-Subject
or I-Subject
lepromatous I-Treat_Disorder
leprosy I-Treat_Disorder
. O

Deposits I-Effect
of I-Effect
plasma I-Effect
proteins I-Effect
in I-Effect
the I-Effect
skin I-Effect
during O
treatment I-Adverse_event.Trigger
with O
carbamazepine I-Treatment.Combination.Drug
and I-Treatment
diphenylhydantoin I-Treatment.Combination.Drug
. O

2 I-Treatment.Drug
- I-Treatment.Drug
Chloro I-Treatment.Drug
- I-Treatment.Drug
deoxyadenosine I-Treatment.Drug
induces O
durable O
complete O
remission O
in O
Castleman I-Treat_Disorder
's I-Treat_Disorder
disease I-Treat_Disorder
but O
may O
accelerate I-Adverse_event.Trigger
its O
transformation O
to O
non I-Effect
- I-Effect
Hodgkin I-Effect
's I-Effect
lymphoma I-Effect
. O

Hypersensitivity I-Effect
to O
aspirin I-Treatment.Drug
can O
be O
manifested I-Adverse_event.Trigger
as O
acute I-Effect
asthma I-Effect
, O
urticaria I-Effect
and/or O
angioedema I-Effect
, O
or O
a O
systemic I-Effect
anaphylactoid I-Effect
reaction I-Effect
. O

An O
exaggerated O
hypertensive O
response O
to O
glycopyrrolate O
therapy O
for O
bradycardia I-Effect
associated I-Adverse_event.Trigger
with O
high I-Treatment.Dosage
- I-Treatment.Dosage
dose I-Treatment.Dosage
dexmedetomidine I-Treatment.Drug
. O

An O
exaggerated I-Effect
hypertensive I-Effect
response I-Adverse_event.Trigger
to O
glycopyrrolate I-Treatment.Drug
therapy O
for O
bradycardia I-Treat_Disorder
associated O
with O
high O
- O
dose O
dexmedetomidine O
. O

Only O
one O
patient O
, O
the I-Subject
youngest I-Subject
, O
did I-Potential_therapeutic_event.Trigger
well I-Potential_therapeutic_event.Trigger
on O
risperidone I-Treatment.Drug
therapy O
. O

Two I-Subject.Population
elderly I-Subject.Age
women I-Subject.Gender
suffered O
an O
acute I-Effect
deterioration I-Effect
of I-Effect
renal I-Effect
function I-Effect
after I-Adverse_event.Trigger
treatment I-Treatment
with I-Treatment
cefoxitin I-Treatment.Drug
sodium I-Treatment.Drug
. O

Physicians O
should O
suspect O
pulmonary I-Effect
toxicity I-Effect
in O
patients I-Subject
with I-Subject
respiratory I-Treat_Disorder
distress I-Treat_Disorder
after I-Adverse_event.Trigger
gemcitabine I-Treatment.Drug
chemotherapy I-Treatment.Route
, O
mainly I-Subject
in I-Subject
elderly I-Subject
patients I-Subject
. O

Delay I-Effect
of I-Effect
corneal I-Effect
wound I-Effect
healing I-Effect
in O
patients I-Subject
treated I-Adverse_event.Trigger
with O
colchicine I-Treatment.Drug
. O

Amiodarone I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
thyrotoxicosis I-Effect
associated O
with O
thyrotropin O
receptor O
antibody O
. O

CONCLUSION O
: O
All O
doctors O
need O
to O
be O
aware O
of O
the O
need O
to O
review O
the O
indications O
for O
gabapentin I-Treatment.Drug
use O
during O
periods O
of O
acute I-Treat_Disorder
illness I-Treat_Disorder
, O
especially O
with O
regard I-Adverse_event.Trigger
to O
renal I-Effect
impairment I-Effect
. O

EA I-Effect
signs I-Effect
were O
observed I-Adverse_event.Trigger
in O
all I-Subject
7 I-Subject.Population
patients I-Subject
in O
association O
with O
propofol I-Treatment.Drug
TIVA I-Treatment.Route
but O
did O
not O
recur O
in O
any O
of O
123 O
subsequent O
anesthetics O
sessions O
during O
which O
low I-Treatment.Dosage
- I-Treatment.Dosage
dose I-Treatment.Dosage
ketamine I-Treatment.Combination.Drug
was I-Treatment
added I-Treatment
to I-Treatment
propofol I-Treatment.Combination.Drug
. O

The O
cause O
of O
death O
was O
multiple I-Effect
drug I-Effect
intoxication I-Effect
following I-Adverse_event.Trigger
acute O
use O
of O
sertraline I-Treatment.Drug
, O
the O
manner O
of O
death O
was O
suicide O
, O
and O
the O
mechanism O
of O
death O
is O
an O
unexplained O
drug O
interaction O
and/or O
toxicity O
. O

On I-Treatment
the I-Treatment
next I-Treatment
day I-Treatment
, I-Treatment
after I-Treatment
a I-Treatment.Dosage
total I-Treatment.Dosage
dose I-Treatment.Dosage
of I-Treatment.Dosage
only I-Treatment.Dosage
600 I-Treatment.Dosage
mg I-Treatment.Dosage
of I-Treatment
danazol I-Treatment.Drug
, O
gingival I-Effect
bleeding I-Effect
and I-Effect
purpura I-Effect
occurred I-Adverse_event.Trigger
. O

SLE I-Treat_Disorder
receded O
after I-Potential_therapeutic_event.Trigger
withdrawal I-Treatment
of I-Treatment
carbamazepine I-Treatment.Drug
and I-Treatment
treatment I-Treatment
with I-Treatment
anti I-Treatment.Drug
- I-Treatment.Drug
inflammatory I-Treatment.Drug
drugs I-Treatment
. O

a I-Subject
67 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
man I-Subject.Gender
with I-Subject
bipolar I-Treat_Disorder
disorder I-Treat_Disorder
developed O
a O
Creutzfeldt I-Effect
- I-Effect
Jakob I-Effect
like I-Effect
syndrome I-Effect
during I-Adverse_event.Trigger
lithium I-Treatment.Drug
carbonate I-Treatment.Drug
treatment O
. O

A O
42 I-Subject.Age
year I-Subject.Age
old I-Subject.Age
man I-Subject.Gender
, O
treated O
for O
testicular I-Treat_Disorder
carcinoma I-Treat_Disorder
with O
combination I-Treatment
chemotherapy I-Treatment
that I-Treatment
included I-Treatment
bleomycin I-Treatment.Drug
, I-Treatment
developed I-Adverse_event.Trigger
life O
threatening O
interstitial I-Effect
pneumonitis I-Effect
. O

Disseminated I-Effect
eruptive I-Effect
giant I-Effect
mollusca I-Effect
contagiosa I-Effect
in O
an I-Subject
adult I-Subject.Age
psoriasis I-Treat_Disorder
patient I-Subject
during I-Adverse_event.Trigger
efalizumab I-Treatment.Drug
therapy I-Treatment
. O

Significant O
clinical O
improvement I-Potential_therapeutic_event.Trigger
of O
the O
porphyria I-Treat_Disorder
followed O
withdrawal I-Treatment
of I-Treatment
the I-Treatment
diphenylhydantoin I-Treatment.Drug
. O

Temozolomide I-Treatment.Drug
was O
restarted O
2 O
months O
later O
; O
the I-Subject
patient I-Subject
again O
developed I-Adverse_event.Trigger
a O
fever I-Effect
. O

The I-Subject
patient I-Subject
's I-Subject
previous I-Subject
rash I-Subject.Sub_Disorder
and O
the O
temporal O
relation O
of O
this O
event O
and O
the O
ingestion I-Treatment.Route
of I-Treatment
phenolphthalein I-Treatment.Drug
, O
as O
well O
as O
the O
similarity O
of O
this O
case O
to O
other O
reports O
, O
point O
to O
phenolphthalein O
as O
the O
cause I-Adverse_event.Trigger
of O
TEN I-Effect
in O
this O
patient O
. O

Ciprofloxacin I-Treatment.Drug
greatly O
elevates I-Potential_therapeutic_event.Trigger
plasma I-Effect
concentrations I-Effect
of I-Effect
tizanidine I-Drug
and I-Effect
dangerously I-Effect
potentiates I-Effect
its I-Effect
hypotensive I-Effect
and I-Effect
sedative I-Effect
effects I-Effect
, O
mainly O
by O
inhibiting O
its O
CYP1A2 O
- O
mediated O
metabolism O
, O
at O
least O
when O
administered O
1 O
hour O
before O
tizanidine I-Drug
. O

RESULTS O
: O
The I-Subject
patient I-Subject
, I-Subject
a I-Subject
27 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
married I-Subject
Japanese I-Subject.Race
woman I-Subject.Gender
with I-Subject
borderline I-Treat_Disorder
personality I-Treat_Disorder
disorder I-Treat_Disorder
, O
developed I-Adverse_event.Trigger
an O
increased I-Effect
libido I-Effect
with O
the O
administration I-Treatment
of I-Treatment
fluvoxamine I-Treatment.Drug
. O

Acute I-Effect
renal I-Effect
failure I-Effect
with I-Effect
severe I-Effect
tubulointerstitial I-Effect
changes I-Effect
in I-Adverse_event.Trigger
a I-Subject
patient I-Subject
with I-Subject
minimal I-Treat_Disorder
change I-Treat_Disorder
nephrotic I-Treat_Disorder
syndrome I-Treat_Disorder
treated O
with O
enalapril I-Treatment.Drug
. O

PURPOSE O
: O
A I-Subject
case I-Subject
of O
carbamazepine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
hyperammonemia I-Effect
is O
presented O
. O

The O
cough I-Effect
continued I-Adverse_event.Trigger
for O
the O
duration O
of O
therapy O
with O
quinapril I-Treatment.Drug
. O

OBJECTIVE O
: O
To O
report O
a O
case O
of O
Carbamazepine I-Treatment.Combination.Drug
toxicity I-Effect
following I-Adverse_event.Trigger
the O
administration O
of O
Oxybutynin I-Treatment.Combination.Drug
and I-Treatment
Dantrolene I-Treatment.Combination.Drug
. O

Danazol I-Treatment.Drug
induced I-Adverse_event.Trigger
thrombocytopenia I-Effect
. O

Four I-Subject.Population
elderly I-Subject.Age
LTCF I-Treat_Disorder
residents I-Subject
treated I-Potential_therapeutic_event.Trigger
with O
serotonergic I-Treatment
antidepressants I-Treatment
including I-Treatment
selective I-Treatment.Drug
serotonin I-Treatment.Drug
reuptake I-Treatment.Drug
inhibitor I-Treatment.Drug
( I-Treatment
SSRI I-Treatment
) I-Treatment
or I-Treatment
mirtazapine I-Treatment.Combination.Drug
and I-Treatment
opioids I-Treatment.Combination.Drug
. O

Detection O
of O
antineutrophil O
cytoplasmic O
antibody O
in O
a O
patient I-Subject
with O
L I-Treatment.Drug
- I-Treatment.Drug
tryptophan I-Treatment.Drug
induced I-Adverse_event.Trigger
eosinophilia I-Effect
- I-Effect
myalgia I-Effect
syndrome I-Effect
. O

His O
impaired I-Effect
memory I-Effect
was O
found O
to O
be O
due I-Adverse_event.Trigger
to O
the O
atenolol I-Treatment.Drug
he I-Subject.Gender
was O
on O
and O
he O
made O
a O
complete O
recovery O
on O
withdrawing O
the O
beta O
- O
blocker O
. O

Tiagabine I-Treatment.Drug
overdose I-Treatment.Dosage
causes I-Adverse_event.Trigger
an I-Effect
unusual I-Effect
array I-Effect
of I-Effect
neurological I-Effect
symptoms I-Effect
, O
many O
similar O
to O
reported O
adverse O
effects O
during O
therapeutic O
use O
. O

This O
paper O
reports O
on O
a O
6.9 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
autistic I-Subject.Sub_Disorder
male I-Subject.Gender
who O
developed O
repeated I-Effect
episodes I-Effect
of I-Effect
acute I-Effect
dystonic I-Effect
reactions I-Effect
associated I-Adverse_event.Trigger
with O
pimozide I-Treatment.Drug
administration I-Treatment
at I-Treatment
the I-Treatment
doses I-Treatment
of I-Treatment
0.096 I-Treatment.Dosage
mg I-Treatment.Dosage
/ I-Treatment.Dosage
kg I-Treatment.Dosage
/ I-Treatment
day I-Treatment.Freq
and I-Treatment
0.032 I-Treatment.Dosage
mg I-Treatment.Dosage
/ I-Treatment.Dosage
kg I-Treatment.Dosage
/ I-Treatment
day I-Treatment.Freq
and I-Treatment
32 I-Treatment
hours I-Treatment
following I-Treatment
pimozide I-Treatment.Drug
withdrawal I-Treatment
, I-Treatment
as I-Treatment
well I-Treatment
as I-Treatment
during I-Treatment
subsequent I-Treatment
thioridazine I-Treatment.Drug
administration I-Treatment
. O

Cephalexin I-Treatment.Drug
rash I-Effect
in I-Adverse_event.Trigger
infectious I-Treat_Disorder
mononucleosis I-Treat_Disorder
. O

He O
developed I-Adverse_event.Trigger
recurrent I-Effect
skin I-Effect
rash I-Effect
, I-Effect
fever I-Effect
, I-Effect
hypereosinophilia I-Effect
, I-Effect
and I-Effect
acute I-Effect
renal I-Effect
failure I-Effect
after O
rechallenge I-Treatment
with I-Treatment
chlorambucil I-Treatment.Drug
. O

Lower I-Effect
extremity I-Effect
arterial I-Effect
insufficiency I-Effect
after I-Adverse_event.Trigger
long I-Treatment.Duration
- I-Treatment.Duration
term I-Treatment.Duration
methysergide I-Treatment.Drug
maleate I-Treatment.Drug
therapy I-Treatment
. O

Hepatolithiasis I-Effect
( I-Effect
intrahepatic I-Effect
stone I-Effect
) I-Effect
during I-Adverse_event.Trigger
octreotide I-Treatment.Drug
therapy O
for O
acromegaly I-Treat_Disorder
: O
a O
case O
report O
. O

Acute I-Effect
unilateral I-Effect
total I-Effect
visual I-Effect
loss I-Effect
after I-Adverse_event.Trigger
retrogasserian I-Treatment.Drug
phenol I-Treatment.Drug
injection I-Treatment.Route
for O
the O
treatment O
of O
trigeminal I-Treat_Disorder
neuralgia I-Treat_Disorder
: O
a O
case O
report O
. O

OBJECTIVE O
: O
Clozapine I-Treatment.Drug
causes I-Adverse_event.Trigger
few I-Effect
extrapyramidal I-Effect
symptoms I-Effect
and O
is O
recommended O
as O
a O
treatment O
drug O
for O
severe O
tardive O
dyskinesia O
( O
TD O
) O
. O

Methylphenidate I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
acute I-Effect
orofacial I-Effect
and I-Effect
extremity I-Effect
dyskinesia I-Effect
. O

Basilar I-Effect
invagination I-Effect
and I-Effect
mid I-Effect
- I-Effect
line I-Effect
skeletal I-Effect
abnormalities I-Effect
due I-Adverse_event.Trigger
to O
in O
utero I-Treatment
exposure I-Treatment
to I-Treatment
phenytoin I-Treatment.Drug
. O

DISCUSSION O
: O
To O
our O
knowledge O
, O
this O
is O
the O
first O
case O
report O
illustrating O
neuralgic I-Effect
amyotrophy I-Effect
triggered I-Adverse_event.Trigger
by O
exposure O
to O
the O
antibiotics I-Treatment
vancomycin I-Treatment.Combination.Drug
, I-Treatment
tobramycin I-Treatment.Combination.Drug
, I-Treatment
and I-Treatment
piperacillin I-Treatment.Combination.Drug
/ I-Treatment
tazobactam I-Treatment.Combination.Drug
. O

Alveolar I-Effect
- I-Effect
interstitial I-Effect
pneumopathy I-Effect
after I-Adverse_event.Trigger
gold I-Treatment.Drug
- I-Treatment.Drug
salts I-Treatment.Drug
compounds I-Treatment.Drug
administration I-Treatment
, O
requiring O
mechanical O
ventilation O
. O

This O
study O
revealed O
that O
ketoconazole I-Treatment.Drug
affected O
the O
disposition O
of O
rosiglitazone O
in O
humans I-Subject
, O
probably O
by O
the O
inhibition O
of O
CYP2C8 O
and O
CYP2C9 O
, O
leading I-Adverse_event.Trigger
to I-Adverse_event.Trigger
increasing I-Effect
rosiglitazone I-Effect
concentrations I-Effect
that I-Effect
could I-Effect
increase I-Effect
the I-Effect
efficacy I-Effect
of I-Effect
rosiglitazone I-Effect
or I-Effect
its I-Effect
adverse I-Effect
events I-Effect
. O

We O
report O
a O
case O
of O
duloxetine I-Treatment.Combination.Drug
- O
induced I-Adverse_event.Trigger
hyponatremia I-Effect
in O
an I-Subject
elderly I-Subject.Age
patient I-Subject
treated O
with O
thiazide I-Treatment.Combination.Drug
diuretics I-Treatment.Combination.Drug
. O

Protamine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
fatal O
anaphylaxis I-Effect
. O

We O
diagnosed O
this I-Subject
case I-Subject
as O
danazol I-Treatment.Drug
induced I-Adverse_event.Trigger
thrombocytopenia I-Effect
. O

One I-Subject.Population
patient I-Subject
required O
nursing O
home O
placement O
and O
a O
feeding O
gastrostomy O
as O
a O
result O
of O
the O
worsening I-Treat_Disorder
parkinsonism I-Treat_Disorder
during O
risperidone O
treatment O
, O
but O
was I-Effect
able I-Effect
to I-Effect
return I-Effect
home I-Effect
and I-Effect
have I-Effect
the I-Effect
gastrostomy I-Effect
removed I-Effect
after I-Potential_therapeutic_event.Trigger
switching I-Treatment
from I-Treatment
risperidone I-Treatment.Drug
to I-Treatment
clozapine I-Treatment.Drug
. O

One I-Subject.Population
patient I-Subject
required I-Effect
nursing I-Effect
home I-Effect
placement I-Effect
and I-Effect
a I-Effect
feeding I-Effect
gastrostomy I-Effect
as I-Effect
a I-Effect
result I-Effect
of I-Effect
the I-Effect
worsening I-Effect
parkinsonism I-Effect
during O
risperidone I-Treatment.Drug
treatment I-Adverse_event.Trigger
, O
but O
was O
able O
to O
return O
home O
and O
have O
the O
gastrostomy O
removed O
after O
switching O
from O
risperidone O
to O
clozapine O
. O

NMS I-Effect
is O
a O
drug O
- O
related O
response I-Adverse_event.Trigger
to O
various O
medications O
, O
such O
as O
Haloperidol I-Treatment.Drug
, O
which O
the O
patient I-Subject
was O
receiving O
. O

In O
addition O
, O
ethambutol I-Treatment.Drug
rarely O
causes I-Adverse_event.Trigger
visual I-Effect
loss I-Effect
during I-Treatment
the I-Treatment
early I-Treatment.Time_elapsed
period I-Treatment.Time_elapsed
or I-Treatment
when I-Treatment
given I-Treatment
at I-Treatment
lower I-Treatment.Dosage
doses I-Treatment.Dosage
. O

The O
day I-Treatment
after I-Treatment
clozapine I-Treatment.Drug
was I-Treatment
stopped I-Treatment
, I-Treatment
while I-Treatment
he I-Treatment
was I-Treatment
still I-Treatment
receiving I-Treatment
clomipramine I-Treatment.Drug
150 I-Treatment.Dosage
mg I-Treatment.Dosage
/ I-Treatment.Dosage
d I-Treatment.Dosage
, O
he I-Subject.Gender
began O
behaving I-Effect
oddly I-Effect
, I-Effect
started I-Effect
sweating I-Effect
profusely I-Effect
, I-Effect
shivering I-Effect
, I-Effect
and I-Effect
became I-Effect
tremulous I-Effect
, I-Effect
agitated I-Effect
, I-Effect
and I-Effect
confused I-Effect
. O

CONCLUSIONS O
: O
Hypersensitivity I-Effect
reactions I-Effect
to I-Effect
cyclosporine I-Effect
are O
due I-Adverse_event.Trigger
to O
Cremophor I-Treatment.Drug
EL I-Treatment.Drug
. O

There O
are O
few O
reports O
in O
the O
literature O
related O
to O
sulfonylurea I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
hepatotoxicity I-Effect
. O

Radiation I-Effect
recall I-Effect
pneumonitis I-Effect
induced I-Adverse_event.Trigger
by O
gemcitabine I-Treatment.Drug
. O

Four O
days O
after O
the O
initial O
injection I-Treatment.Route
of I-Treatment
3.6 I-Treatment.Dosage
mg I-Treatment.Dosage
of I-Treatment
goserelin I-Treatment.Drug
acetate I-Treatment.Drug
, O
severe I-Effect
dyspnea I-Effect
developed I-Adverse_event.Trigger
due O
to O
worsening I-Effect
pleuritis I-Effect
carcinomatosa I-Effect
, O
which O
was O
considered O
as O
a O
flare O
- O
up O
. O

Ropinirole I-Treatment.Combination.Drug
was O
added I-Potential_therapeutic_event.Trigger
to O
his O
current O
therapy O
for O
Parkinson I-Treat_Disorder
disease I-Treat_Disorder
, O
with O
a I-Treatment
corresponding I-Treatment
decrease I-Treatment
in I-Treatment
the I-Treatment
dose I-Treatment
of I-Treatment
levodopa I-Treatment.Combination.Drug
/ I-Treatment
carbidopa I-Treatment.Combination.Drug
to I-Treatment
allow I-Treatment
levodopa I-Treatment
sparing I-Treatment
. O

Recognizing O
early O
signs O
of O
HMSN I-Treat_Disorder
, O
such O
as O
areflexia O
and O
pes O
cavus O
deformity O
, O
can O
prevent O
severe I-Effect
neurotoxicity I-Effect
of I-Effect
polychemotherapy I-Effect
by I-Adverse_event.Trigger
avoiding O
vincristine I-Treatment.Drug
. O

This O
is O
the O
first O
report O
of O
pulmonary I-Effect
hypertension I-Effect
in O
an I-Subject
adult I-Subject.Age
patient I-Subject
during I-Adverse_event.Trigger
lithium I-Treatment.Drug
therapy I-Treatment
. I-Treatment

In O
this O
report O
, O
we O
present O
a O
case O
of O
hypoglycaemic I-Effect
coma I-Effect
associated I-Adverse_event.Trigger
with O
SP I-Treatment.Drug
, O
an I-Effect
adverse I-Effect
reaction I-Effect
that I-Effect
is I-Effect
likely I-Effect
to I-Effect
be I-Effect
underreported I-Effect
and I-Effect
expected I-Effect
to I-Effect
occur I-Effect
with I-Effect
greater I-Effect
frequency I-Effect
as I-Effect
the I-Effect
use I-Effect
of I-Effect
SP I-Effect
increases I-Effect
. O

However O
, O
we O
have O
recently O
had O
four I-Subject.Population
cases I-Subject
of O
clofibrate I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
myopathy I-Effect
in O
patients O
with O
diabetes I-Treat_Disorder
insipidus I-Treat_Disorder
due I-Subject
to I-Subject
hypothalamic I-Subject
lesions I-Subject
. O

One I-Subject.Population
patient I-Subject
had I-Adverse_event.Trigger
MRI I-Effect
T2 I-Effect
abnormalities I-Effect
compatible O
with O
cyclosporin I-Treatment.Drug
neurotoxicity I-Effect
. O

Post I-Potential_therapeutic_event.Trigger
- I-Potential_therapeutic_event.Trigger
exposure I-Potential_therapeutic_event.Trigger
prophylaxis I-Potential_therapeutic_event.Trigger
for O
H1N1 I-Treat_Disorder
with O
oseltamivir I-Treatment.Drug
in O
renal I-Subject.Sub_Disorder
allograft I-Subject.Sub_Disorder
recipient I-Subject
-- O
safe I-Effect
and I-Effect
effective I-Effect
without I-Effect
any I-Effect
immunosuppresive I-Effect
drug I-Effect
interaction I-Effect
. O

Seven I-Treatment.Time_elapsed
days I-Treatment.Time_elapsed
after I-Treatment.Time_elapsed
the I-Treatment
introduction I-Treatment
of I-Treatment
amoxycillin I-Treatment.Drug
( I-Treatment
500 I-Treatment.Dosage
mg/8 I-Treatment.Dosage
h I-Treatment.Dosage
) I-Treatment
for O
a I-Treat_Disorder
probable I-Treat_Disorder
respiratory I-Treat_Disorder
infection I-Treat_Disorder
, O
the I-Subject
patient I-Subject
developed I-Adverse_event.Trigger
spontaneous I-Effect
bruising I-Effect
, I-Effect
with I-Effect
an I-Effect
INR I-Effect
of I-Effect
7.1 I-Effect
. O

To O
report O
a I-Subject
case I-Subject
in O
which O
significant O
hypotension I-Effect
occurred O
after I-Adverse_event.Trigger
initiation I-Treatment
of I-Treatment
tizanidine I-Treatment.Drug
in O
a I-Subject
patient I-Subject
using O
the O
antihypertensive O
agent O
lisinopril I-Treatment.Drug
. O

We O
herein O
describe O
a O
case O
of O
severe I-Effect
hyponatremia I-Effect
complicated O
by O
seizure I-Effect
and I-Effect
coma I-Effect
due I-Adverse_event.Trigger
to I-Adverse_event.Trigger
the O
intake I-Treatment
of I-Treatment
non I-Treatment.Combination.Drug
- I-Treatment.Combination.Drug
steroidal I-Treatment.Combination.Drug
anti I-Treatment.Combination.Drug
- I-Treatment.Combination.Drug
inflammatory I-Treatment.Combination.Drug
drugs I-Treatment.Combination.Drug
( I-Treatment
NSAIDs I-Treatment
) I-Treatment
in O
a I-Subject
patient I-Subject
on I-Treatment
DDAVP I-Treatment.Combination.Drug
replacement I-Treatment
therapy I-Treatment
for I-Subject
central I-Treat_Disorder
diabetes I-Treat_Disorder
insipidus I-Treat_Disorder
( I-Subject
DI I-Subject
) I-Subject
. O

Each I-Subject
subject I-Subject
was O
treated I-Potential_therapeutic_event.Trigger
according O
to O
the O
following O
sequence O
: O
baseline I-Treatment
; I-Treatment
phase I-Treatment
1 I-Treatment
( I-Treatment
days I-Treatment
1 I-Treatment
- I-Treatment
6 I-Treatment
) I-Treatment
: I-Treatment
cisapride I-Treatment.Drug
10 I-Treatment.Dosage
mg I-Treatment.Dosage
4 I-Treatment.Freq
times I-Treatment.Freq
/ I-Treatment.Freq
day I-Treatment.Freq
; I-Treatment
washout I-Treatment
( I-Treatment
days I-Treatment
7 I-Treatment
- I-Treatment
13 I-Treatment
) I-Treatment
; I-Treatment
phase I-Treatment
2 I-Treatment
( I-Treatment
days I-Treatment
14 I-Treatment
- I-Treatment
44 I-Treatment
) I-Treatment
: I-Treatment
fluoxetine I-Treatment.Drug
20 I-Treatment.Dosage
mg I-Treatment.Dosage
/ I-Treatment.Dosage
day I-Treatment.Dosage
; I-Treatment
and I-Treatment
phase I-Treatment
3 I-Treatment
( I-Treatment
days I-Treatment
45 I-Treatment
- I-Treatment
52 I-Treatment
) I-Treatment
: I-Treatment
cisapride I-Treatment.Combination.Drug
10 I-Treatment.Dosage
mg I-Treatment.Dosage
4 I-Treatment.Freq
times I-Treatment.Freq
/ I-Treatment.Freq
day I-Treatment.Freq
( I-Treatment
days I-Treatment
45 I-Treatment
- I-Treatment
51 I-Treatment
) I-Treatment
plus I-Treatment
fluoxetine I-Treatment.Combination.Drug
20 I-Treatment.Dosage
mg I-Treatment.Dosage
/ I-Treatment.Dosage
day I-Treatment.Dosage
( I-Treatment
days I-Treatment
45 I-Treatment
- I-Treatment
52 I-Treatment
) I-Treatment
. O

These O
findings O
are O
consistent O
with O
an O
immune O
- O
complex O
form O
of O
glomerulopathy O
in O
which O
gold O
is O
neither O
the O
antigen O
nor O
a O
hapten O
in O
the O
glomerular O
deposits O
, O
and O
they O
suggest O
the O
hypothesis O
that O
antibodies O
to O
tubular O
epithelial O
antigens O
induced O
by O
gold O
therapy O
may O
be O
a O
causative O
factor O
in O
the O
renal I-Effect
disease I-Effect
associated I-Adverse_event.Trigger
with O
gold I-Treatment.Drug
therapy I-Treatment
in I-Treatment
rheumatoid I-Treatment.Treat_Disorder
arthritis I-Treatment.Treat_Disorder
. O

Induction O
of O
rapid I-Effect
mood I-Effect
cycling I-Effect
during I-Adverse_event.Trigger
L I-Treatment.Drug
- I-Treatment.Drug
dopa I-Treatment.Drug
treatment O
in O
a I-Subject
bipolar I-Treat_Disorder
patient I-Subject
. O

To O
report O
a O
patient I-Subject
having O
a O
first O
- O
time O
seizure I-Effect
after O
receiving I-Adverse_event.Trigger
venlafaxine I-Treatment.Combination.Drug
and I-Treatment
trimipramine I-Treatment.Combination.Drug
for O
depression I-Treat_Disorder
. O

Paraplegia I-Effect
following I-Adverse_event.Trigger
prophylactic I-Treatment
intrathecal I-Treatment.Route
cytosine I-Treatment.Drug
arabinoside I-Treatment.Drug
( I-Treatment
Ara I-Treatment
- I-Treatment
C I-Treatment
) I-Treatment
is O
described O
in O
a I-Subject
patient I-Subject
with I-Subject
acute I-Treat_Disorder
myelogenous I-Treat_Disorder
leukemia I-Treat_Disorder
in I-Treat_Disorder
remission I-Treat_Disorder
who O
received O
doses I-Treatment
of I-Treatment
100 I-Treatment.Dosage
mg I-Treatment.Dosage
/ I-Treatment.Dosage
m2/d I-Treatment.Dosage
for I-Treatment
5 I-Treatment.Duration
consecutive I-Treatment.Duration
days I-Treatment.Duration
. O

Isoniazid I-Treatment.Drug
induced I-Adverse_event.Trigger
gynaecomastia I-Effect
: O
a O
case O
report O
. O

One O
previous O
study O
of O
four I-Subject.Population
transplant I-Subject.Sub_Disorder
patients I-Subject
whose O
immediate I-Treatment
post I-Treatment.Treat_Disorder
- I-Treatment.Treat_Disorder
transplantation I-Treatment.Treat_Disorder
immunosuppression I-Treatment.Treat_Disorder
utilized I-Treatment
corticosteroids I-Treatment.Combination.Drug
, I-Treatment
cyclosporine I-Treatment.Combination.Drug
, I-Treatment
MMF I-Treatment.Combination.Drug
, I-Treatment
and I-Treatment
anti I-Treatment.Combination.Drug
- I-Treatment.Combination.Drug
T I-Treatment.Combination.Drug
- I-Treatment.Combination.Drug
lymphocyte I-Treatment.Combination.Drug
globulin I-Treatment.Combination.Drug
noted I-Adverse_event.Trigger
anemia I-Effect
in O
13 O
% O
of O
them O
. O

Pleuropulmonary I-Effect
changes I-Effect
during I-Adverse_event.Trigger
treatment O
of O
Parkinson I-Treat_Disorder
's I-Treat_Disorder
disease I-Treat_Disorder
with O
a O
long O
- O
acting O
ergot O
derivative O
, O
cabergoline I-Treatment.Drug
. O

However O
, O
each I-Subject
infant I-Subject.Age
demonstrated I-Adverse_event.Trigger
hemodynamic I-Effect
decompensation I-Effect
shortly O
after O
verapamil I-Treatment.Drug
administration O
and O
required O
cardiopulmonary O
resuscitation O
. O

Long O
- O
term O
studies O
are O
needed O
to O
determine O
whether O
the O
insulin O
- O
sensitizing O
effects O
of O
the O
glitazones I-Treatment.Drug
can O
prevent I-Potential_therapeutic_event.Trigger
or O
delay O
premature I-Treat_Disorder
atherosclerotic I-Treat_Disorder
cardiovascular I-Treat_Disorder
disease I-Treat_Disorder
, I-Treat_Disorder
morbidity I-Treat_Disorder
, I-Treat_Disorder
and I-Treat_Disorder
death I-Treat_Disorder
. O

Probable O
propafenone I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
transient I-Effect
global I-Effect
amnesia I-Effect
. O

The O
patient O
continued O
to O
have I-Adverse_event.Trigger
fever I-Effect
and I-Effect
autonomic I-Effect
instability I-Effect
without I-Effect
evidence I-Effect
of I-Effect
infection I-Effect
which I-Effect
entirely I-Effect
resolved I-Effect
within O
24 I-Treatment.Time_elapsed
hours I-Treatment.Time_elapsed
of I-Treatment
reinstitution I-Treatment
of I-Treatment
full I-Treatment
preadmission I-Treatment
dosing I-Treatment
of I-Treatment
oral I-Treatment.Route
baclofen I-Treatment.Drug
. O

Traumatic I-Effect
late I-Effect
flap I-Effect
dehiscence I-Effect
and I-Effect
Enterobacter I-Effect
keratitis I-Effect
following I-Adverse_event.Trigger
LASIK I-Treatment.Drug
. O

We O
report O
on O
a O
patient I-Subject
with I-Subject
subarachnoid I-Treat_Disorder
haemorrhage I-Treat_Disorder
who O
developed I-Adverse_event.Trigger
an O
acute O
life O
- O
threatening O
pseudo I-Effect
- I-Effect
obstruction I-Effect
of I-Effect
the I-Effect
colon I-Effect
, O
a O
variant O
of O
adynamic O
ileus O
, O
while O
being O
treated O
with O
intravenous I-Treatment.Route
nimodipine I-Treatment.Drug
. O

A I-Subject
73 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
woman I-Subject.Gender
presented I-Adverse_event.Trigger
with O
fever I-Effect
and I-Effect
cough I-Effect
2 I-Treatment.Time_elapsed
weeks I-Treatment.Time_elapsed
after I-Treatment
completing I-Treatment
the I-Treatment
third I-Treatment
cycle I-Treatment
of I-Treatment
fludarabine I-Treatment.Drug
for I-Treatment
chronic I-Treatment.Treat_Disorder
lymphocytic I-Treatment.Treat_Disorder
leukemia I-Treatment.Treat_Disorder
( I-Treatment.Treat_Disorder
CLL I-Treatment.Treat_Disorder
) I-Treatment.Treat_Disorder
. O

We O
report O
a I-Subject
case I-Subject
of O
myoclonus I-Effect
induced I-Adverse_event.Trigger
by O
quetiapine I-Treatment.Drug
. O

A I-Subject
21 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
woman I-Subject.Gender
suffering I-Subject
from I-Subject
bipolar I-Treat_Disorder
affective I-Treat_Disorder
disorder I-Treat_Disorder
developed I-Adverse_event.Trigger
systemic I-Effect
lupus I-Effect
erythematosus I-Effect
( I-Effect
SLE I-Effect
) I-Effect
with O
characteristic O
laboratory O
findings O
, O
18 I-Treatment.Time_elapsed
months I-Treatment.Time_elapsed
after I-Treatment
starting I-Treatment
carbamazepine I-Treatment.Drug
maintenance I-Treatment
treatment I-Treatment
. O

Acyclovir I-Treatment.Drug
produces I-Adverse_event.Trigger
neurologic I-Effect
symptoms I-Effect
that O
resemble O
extension O
of O
viral O
infection O
into O
the O
central O
nervous O
system O
. O

Subcutaneous I-Treatment.Route
IL I-Treatment.Drug
- I-Treatment.Drug
2 I-Treatment.Drug
is O
safe O
and O
well O
tolerated O
, O
with I-Adverse_event.Trigger
a O
mortality I-Effect
rate I-Effect
< I-Effect
3 I-Effect
% I-Effect
. O

Two I-Subject.Population
patients I-Subject
with I-Subject
HLH I-Treat_Disorder
developed O
etoposide I-Treatment.Drug
- O
related I-Adverse_event.Trigger
secondary I-Effect
acute I-Effect
myeloid I-Effect
leukemia I-Effect
( I-Effect
sAML I-Effect
) I-Effect
following O
therapy O
for O
HLH O
. O

We O
report O
a O
case O
of O
secondary I-Effect
glaucoma I-Effect
caused I-Adverse_event.Trigger
by O
epithelial I-Effect
downgrowth I-Effect
in O
which O
filtration I-Treatment
surgery I-Treatment
was I-Treatment
performed I-Treatment
with I-Treatment
adjunctive I-Treatment
use I-Treatment
of I-Treatment
subconjunctival I-Treatment.Route
5 I-Treatment.Drug
- I-Treatment.Drug
fluorouracil I-Treatment.Drug
. O

Mild O
serotonin I-Effect
syndrome I-Effect
associated I-Adverse_event.Trigger
with O
concurrent I-Treatment
linezolid I-Treatment.Combination.Drug
and I-Treatment
fluoxetine I-Treatment.Combination.Drug
. O

Risperidone I-Treatment.Drug
versus I-Treatment
clozapine I-Treatment.Drug
in O
the O
treatment I-Potential_therapeutic_event.Trigger
of O
psychosis I-Treat_Disorder
in O
six I-Subject.Population
patients I-Subject
with I-Subject
Parkinson I-Subject.Sub_Disorder
's I-Subject.Sub_Disorder
disease I-Subject.Sub_Disorder
and I-Subject
other I-Subject
akinetic I-Subject.Sub_Disorder
- I-Subject.Sub_Disorder
rigid I-Subject.Sub_Disorder
syndromes I-Subject.Sub_Disorder
. O

Hydroxyurea I-Treatment.Drug
associated I-Adverse_event.Trigger
with O
concomitant I-Effect
occurrence I-Effect
of I-Effect
diffuse I-Effect
longitudinal I-Effect
melanonychia I-Effect
and I-Effect
multiple I-Effect
squamous I-Effect
cell I-Effect
carcinomas I-Effect
in O
an I-Subject
elderly I-Subject.Age
subject I-Subject
. O

Women I-Subject.Gender
( I-Subject
aged I-Subject.Age
< I-Subject.Age
or I-Subject.Age
= I-Subject.Age
75 I-Subject.Age
yr I-Subject.Age
; I-Subject.Age
> I-Subject.Age
or I-Subject.Age
= I-Subject.Age
2 I-Subject.Age
yr I-Subject.Age
since I-Subject
their I-Subject
last I-Subject
menstrual I-Subject
period I-Subject
) I-Subject
received I-Potential_therapeutic_event.Trigger
placebo O
, O
RLX I-Treatment.Drug
60 I-Treatment.Dosage
mg I-Treatment.Dosage
/ I-Treatment.Dosage
d I-Treatment.Dosage
, I-Treatment
ALN I-Treatment.Drug
10 I-Treatment.Dosage
mg I-Treatment.Dosage
/ I-Treatment.Dosage
d I-Treatment.Dosage
, I-Treatment
or I-Treatment
RLX I-Treatment.Combination.Drug
60 I-Treatment.Dosage
mg I-Treatment.Dosage
/ I-Treatment.Dosage
d I-Treatment.Dosage
and I-Treatment
ALN I-Treatment.Combination.Drug
10 I-Treatment.Dosage
mg I-Treatment.Dosage
/ I-Treatment.Dosage
d I-Treatment.Dosage
combined I-Treatment
. O

Myoclonus I-Effect
and I-Effect
seizures I-Effect
in O
a I-Subject
patient I-Subject
with I-Subject
parkinsonism I-Treat_Disorder
: O
induction I-Adverse_event.Trigger
by O
levodopa I-Treatment.Drug
and O
its O
confirmation O
on O
SEPs O
. O

OBJECTIVE O
: O
To O
describe O
a O
probable O
case O
of O
transient I-Effect
global I-Effect
amnesia I-Effect
caused I-Adverse_event.Trigger
by O
propafenone I-Treatment.Drug
. O

We O
report O
the O
development O
of O
squamous I-Effect
- I-Effect
cell I-Effect
carcinoma I-Effect
within I-Effect
a I-Effect
basal I-Effect
- I-Effect
cell I-Effect
epithelioma I-Effect
that O
was O
treated I-Potential_therapeutic_event.Trigger
with O
intralesional I-Treatment.Route
injections I-Treatment.Route
of I-Treatment
5 I-Treatment.Drug
- I-Treatment.Drug
FU I-Treatment.Drug
. O

This O
case O
report O
illustrates O
the O
use I-Treatment
of I-Treatment
continuous I-Treatment
high I-Treatment.Dosage
- I-Treatment.Dosage
dose I-Treatment.Dosage
intracoronary I-Treatment.Drug
nitroglycerin I-Treatment.Drug
infusion I-Treatment.Route
through I-Treatment.Route
a I-Treatment.Route
6 I-Treatment.Route
French I-Treatment.Route
coronary I-Treatment.Route
guiding I-Treatment.Route
catheter I-Treatment.Route
in O
the O
treatment I-Potential_therapeutic_event.Trigger
of O
a O
patient O
with O
cocaine I-Treat_Disorder
- I-Treat_Disorder
induced I-Treat_Disorder
refractory I-Treat_Disorder
coronary I-Treat_Disorder
vasospasm I-Treat_Disorder
. O

This O
case O
report O
illustrates O
the O
use O
of O
continuous O
high O
- O
dose O
intracoronary O
nitroglycerin O
infusion O
through O
a O
6 O
French O
coronary O
guiding O
catheter O
in O
the O
treatment O
of O
a O
patient O
with O
cocaine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
refractory I-Effect
coronary I-Effect
vasospasm I-Effect
. O

Here O
, O
we O
describe O
levofloxacin I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
delirium I-Effect
with I-Effect
psychotic I-Effect
features I-Effect
in O
a O
relatively I-Subject
young I-Subject
, I-Subject
otherwise I-Subject
healthy I-Subject
female I-Subject
. O

Ticlopidine I-Treatment.Combination.Drug
- O
induced I-Adverse_event.Trigger
phenytoin I-Combination.Drug
toxicity I-Effect
. O

Pancreatitis O
has O
been O
associated O
with O
the O
tetracycline O
class O
of O
antibiotics O
and O
concerns O
about O
tigecycline I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
acute I-Effect
pancreatitis I-Effect
have O
recently O
been O
raised O
. O

Abrupt I-Treatment
, I-Treatment
accidental I-Treatment
withdrawal I-Treatment
of I-Treatment
trihexyphenidyl I-Treatment.Drug
triggered I-Adverse_event.Trigger
severe O
exacerbation I-Effect
of I-Effect
the I-Effect
cranial I-Effect
dystonia I-Effect
associated I-Effect
with I-Effect
inspiratory I-Effect
stridor I-Effect
and I-Effect
acute I-Effect
respiratory I-Effect
difficulties I-Effect
, O
prompting O
emergency O
admission O
. O

We O
report O
two I-Subject.Population
patients I-Subject
with O
anhedonic I-Effect
ejaculation I-Effect
( I-Effect
ejaculation I-Effect
without I-Effect
orgasm I-Effect
) I-Effect
associated I-Adverse_event.Trigger
with O
initiation O
of O
treatment O
with O
desipramine I-Treatment.Drug
. O

We O
describe O
longitudinal O
diffusion O
- O
weighted O
MRI O
findings O
of O
sub O
- O
acute O
leukoencephalopathy O
following O
methotrexate O
therapy O
in O
a I-Subject
24 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
man I-Subject.Gender
diagnosed O
with O
pre I-Treat_Disorder
- I-Treat_Disorder
B I-Treat_Disorder
- I-Treat_Disorder
cell I-Treat_Disorder
acute I-Treat_Disorder
lymphoblastic I-Treat_Disorder
leukemia I-Treat_Disorder
( I-Treat_Disorder
ALL I-Treat_Disorder
) I-Treat_Disorder
, O
presenting I-Effect
with I-Effect
right I-Effect
- I-Effect
sided I-Effect
paralysis I-Effect
and I-Effect
aphasia I-Effect
after I-Adverse_event.Trigger
second I-Treatment
consolidation I-Treatment
with I-Treatment
intrathecal I-Treatment
triple I-Treatment
- I-Treatment
drug I-Treatment
therapy I-Treatment
given I-Treatment
intrathecally I-Treatment.Route
. O

We O
describe O
longitudinal I-Effect
diffusion I-Effect
- I-Effect
weighted I-Effect
MRI I-Effect
findings I-Effect
of I-Effect
sub I-Effect
- I-Effect
acute I-Effect
leukoencephalopathy I-Effect
following I-Adverse_event.Trigger
methotrexate I-Treatment.Drug
therapy O
in O
a I-Subject
24 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
man I-Subject.Gender
diagnosed O
with O
pre O
- O
B O
- O
cell O
acute O
lymphoblastic O
leukemia O
( O
ALL O
) O
, O
presenting O
with O
right O
- O
sided O
paralysis O
and O
aphasia O
after O
second O
consolidation O
with O
intrathecal O
triple O
- O
drug O
therapy O
given O
intrathecally O
. O

Therefore O
, O
although O
garenoxacin I-Treatment.Drug
reportedly O
causes O
fewer O
adverse O
reactions O
for O
cardiac O
rhythms O
than O
third O
- O
generation O
quinolone O
antibiotics O
, O
one O
must O
be O
cautious O
of O
the O
interference O
of O
other O
drugs O
during O
hypokalemia I-Subject.Sub_Disorder
in O
order O
to O
prevent I-Adverse_event.Trigger
TdP. I-Effect

Therefore O
, O
although O
garenoxacin I-Treatment.Drug
reportedly O
causes I-Adverse_event.Trigger
fewer O
adverse I-Effect
reactions I-Effect
for I-Effect
cardiac I-Effect
rhythms I-Effect
than O
third O
- O
generation O
quinolone O
antibiotics O
, O
one O
must O
be O
cautious O
of O
the O
interference O
of O
other O
drugs O
during O
hypokalemia O
in O
order O
to O
prevent O
TdP. O

A I-Subject
45 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
woman I-Subject.Gender
with I-Subject
steroid I-Treat_Disorder
- I-Treat_Disorder
dependent I-Treat_Disorder
Crohn I-Treat_Disorder
's I-Treat_Disorder
colitis I-Treat_Disorder
, O
successfully O
managed O
with O
maintenance I-Treatment
infliximab I-Treatment.Combination.Drug
infusions I-Treatment.Route
and I-Treatment
methotrexate I-Treatment.Combination.Drug
, O
developed I-Adverse_event.Trigger
a O
lupus I-Effect
- I-Effect
like I-Effect
syndrome I-Effect
eight I-Treatment.Time_elapsed
months I-Treatment.Time_elapsed
after I-Treatment
her I-Treatment
initial I-Treatment
infusion I-Treatment
. O

Severe O
neurotoxicity I-Effect
with I-Adverse_event.Trigger
methyl I-Treatment.Drug
G I-Treatment.Drug
: O
CALGB O
experience O
. O

We O
report O
a O
case O
of O
a O
60 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
woman I-Subject.Gender
affected I-Subject
by I-Subject
squamous I-Treat_Disorder
lung I-Treat_Disorder
carcinoma I-Treat_Disorder
, I-Treat_Disorder
who O
developed I-Adverse_event.Trigger
paroxysmal I-Effect
supraventricular I-Effect
tachycardia I-Effect
during O
cisplatin I-Treatment.Combination.Drug
and I-Treatment
etoposide I-Treatment.Combination.Drug
combination I-Treatment
chemotherapy O
. O

The O
authors O
report O
a O
case O
of O
acute I-Effect
pancreatitis I-Effect
( O
AP O
) O
occurring I-Adverse_event.Trigger
in O
a I-Subject
patient I-Subject
under O
treatment O
with O
carbamazepine I-Treatment.Drug
( O
CBZ O
) O
for O
post I-Treat_Disorder
- I-Treat_Disorder
traumatic I-Treat_Disorder
petit I-Treat_Disorder
mal I-Treat_Disorder
epilepsy I-Treat_Disorder
, O
and O
review O
the O
current O
literature O
of O
drug O
- O
induced O
AP O
. O

Acute I-Effect
ocular I-Effect
ischemic I-Effect
change I-Effect
may O
be O
associated I-Adverse_event.Trigger
with O
intravitreal I-Treatment.Dosage
injection I-Treatment.Dosage
of I-Treatment
bevacizumab I-Treatment.Drug
in O
patients I-Subject
with I-Subject
vascular I-Subject.Sub_Disorder
compromised I-Subject.Sub_Disorder
diabetic I-Subject.Sub_Disorder
retinopathy I-Subject.Sub_Disorder
and/or I-Subject
underlying I-Subject.Sub_Disorder
stenosis I-Subject.Sub_Disorder
of I-Subject.Sub_Disorder
the I-Subject.Sub_Disorder
carotid I-Subject.Sub_Disorder
artery I-Subject.Sub_Disorder
. O

All I-Treatment.Drug
- I-Treatment.Drug
trans I-Treatment.Drug
- I-Treatment.Drug
retinoic I-Treatment.Drug
acid I-Treatment.Drug
( I-Treatment
ATRA I-Treatment
) I-Treatment
has O
been O
proved I-Potential_therapeutic_event.Trigger
to O
be O
an O
effective O
treatment O
for O
acute I-Treat_Disorder
promyelocytic I-Treat_Disorder
leukemia I-Treat_Disorder
( I-Treat_Disorder
APL I-Treat_Disorder
) I-Treat_Disorder
, O
inducing O
remission O
in O
more I-Subject.Population
than I-Subject.Population
90 I-Subject.Population
% I-Subject.Population
of I-Subject
cases I-Subject
. O

Vanishing I-Effect
bile I-Effect
duct I-Effect
and I-Effect
Stevens I-Effect
- I-Effect
Johnson I-Effect
syndrome I-Effect
associated I-Adverse_event.Trigger
with O
ciprofloxacin I-Treatment.Drug
treated O
with O
tacrolimus O
. O

Antiasthmatic I-Treatment.Drug
medications I-Treatment.Drug
were I-Treatment
prescribed I-Treatment
, O
but O
the O
asthma I-Treat_Disorder
symptoms O
did O
not O
improve I-Potential_therapeutic_event.Trigger
. O

Both O
6 I-Treatment.Combination.Drug
- I-Treatment.Combination.Drug
MP I-Treatment.Combination.Drug
and I-Treatment
AZA I-Treatment.Combination.Drug
are O
widely O
used I-Adverse_event.Trigger
and O
are O
known O
to O
cause O
hepatotoxicity I-Effect
in O
a I-Subject
proportion I-Subject
of I-Subject
patients I-Subject
. O

Both I-Treatment
raloxifene I-Treatment.Drug
( I-Treatment
RLX I-Treatment
) I-Treatment
and I-Treatment
alendronate I-Treatment.Drug
( I-Treatment
ALN I-Treatment
) I-Treatment
can O
treat I-Potential_therapeutic_event.Trigger
and O
prevent O
new O
vertebral I-Treat_Disorder
fractures I-Treat_Disorder
, O
increase I-Effect
bone I-Effect
mineral I-Effect
density I-Effect
( I-Effect
BMD I-Effect
) I-Effect
, O
and O
decrease I-Effect
biochemical I-Effect
markers I-Effect
of I-Effect
bone I-Effect
turnover I-Effect
in O
postmenopausal I-Subject
women I-Subject
with I-Subject
osteoporosis I-Subject.Sub_Disorder
. O

We O
report O
a O
case O
of O
severe O
respiratory I-Effect
failure I-Effect
due I-Adverse_event.Trigger
to O
gold I-Treatment.Drug
salt I-Treatment
toxicity O
in O
a I-Subject
patient I-Subject
suffering I-Subject
from I-Subject
rheumatoid I-Treat_Disorder
arthritis I-Treat_Disorder
requiring O
mechanical O
ventilation O
. O

We O
describe O
rupture I-Effect
of I-Effect
a I-Effect
cerebral I-Effect
arterial I-Effect
aneurysm I-Effect
in O
a I-Subject
32 I-Subject.Age
year I-Subject.Age
old I-Subject.Age
hypertensive I-Treat_Disorder
woman I-Subject.Gender
following I-Adverse_event.Trigger
the O
introduction O
of O
nifedipine I-Treatment.Drug
treatment I-Treatment
. O

Factors O
that O
suggested O
an O
association I-Adverse_event.Trigger
between O
the O
severe I-Effect
angioedematous I-Effect
reaction I-Effect
and O
BP I-Treatment.Drug
topical I-Treatment.Drug
application I-Treatment.Drug
include O
the O
strong O
reaction O
to O
BP O
in O
the O
patch O
- O
test O
, O
the O
temporal O
relationship O
, O
the O
complete O
resolution O
of O
symptoms O
after O
the O
drug O
was O
withdrawn O
and O
the O
absence O
of O
other O
identified O
explanations O
. O

RLX+ALN I-Treatment.Combination.Drug
reduced I-Potential_therapeutic_event.Trigger
bone I-Effect
turnover I-Effect
more I-Effect
than I-Effect
either I-Effect
drug I-Effect
alone I-Effect
, I-Effect
resulting I-Effect
in I-Effect
greater I-Effect
BMD I-Effect
increment I-Effect
, O
but O
whether O
this O
difference O
reflects O
better O
fracture O
risk O
reduction O
was O
not O
assessed O
in O
this O
study O
. O

Hepatotoxicity I-Effect
related I-Adverse_event.Trigger
to O
itraconazole I-Treatment.Drug
: O
report O
of O
three I-Subject.Population
cases I-Subject
. O

This O
report O
presents O
a O
case O
of O
colon I-Effect
perforation I-Effect
which O
occurred I-Adverse_event.Trigger
4 I-Time_elapsed
months I-Time_elapsed
after O
treatment O
with O
intraperitoneal I-Treatment.Route
chromic I-Treatment.Drug
phosphate I-Treatment.Drug
for O
stage I-Treat_Disorder
IB I-Treat_Disorder
ovarian I-Treat_Disorder
papillary I-Treat_Disorder
serous I-Treat_Disorder
cystadenocarcinoma I-Treat_Disorder
. O

Flutamide O
withdrawal O
syndrome O
is O
characterized O
by O
a O
decrease I-Effect
in I-Effect
prostate I-Effect
- I-Effect
specific I-Effect
antigen I-Effect
( I-Effect
PSA I-Effect
) I-Effect
after O
flutamide I-Treatment.Drug
withdrawal I-Adverse_event.Trigger
in O
a O
subset I-Subject
of I-Subject
patients I-Subject
with I-Subject
progressing I-Treat_Disorder
metastatic I-Treat_Disorder
carcinoma I-Treat_Disorder
of I-Treat_Disorder
the I-Treat_Disorder
prostate I-Treat_Disorder
. O

Bradycardia I-Effect
and I-Effect
congestive I-Effect
heart I-Effect
failure I-Effect
associated I-Adverse_event.Trigger
with O
ocular I-Treatment.Route
timolol I-Treatment.Drug
maleate I-Treatment.Drug
. O

CONCLUSIONS O
: O
Patients O
receiving O
intravitreal I-Treatment.Route
injections I-Treatment.Route
of I-Treatment
bevacizumab I-Treatment.Drug
should O
be O
evaluated O
for O
potential O
systemic O
risk I-Adverse_event.Trigger
factors O
such O
as O
carotid I-Effect
insufficiency I-Effect
, I-Effect
coagulopathy I-Effect
and I-Effect
poorly I-Effect
controlled I-Effect
diabetes I-Effect
mellitus I-Effect
. O

Severe O
serotonin I-Effect
toxicity I-Effect
may O
result I-Adverse_event.Trigger
from O
metaxalone I-Treatment.Combination.Drug
abuse I-Treatment.Dosage
in O
individuals O
using I-Treatment
a I-Treatment
selective I-Treatment.Combination.Drug
serotonin I-Treatment.Combination.Drug
reuptake I-Treatment.Combination.Drug
inhibitor I-Treatment.Combination.Drug
therapeutically I-Treatment
. O

The O
purpose O
of O
this O
article O
is O
to O
present O
the O
first O
case O
- O
series O
of O
posterior I-Effect
reversible I-Effect
encephalopathy I-Effect
syndrome I-Effect
( I-Effect
PRES I-Effect
) I-Effect
associated I-Adverse_event.Trigger
with O
L I-Treatment.Drug
- I-Treatment.Drug
asparaginase I-Treatment.Drug
treatment I-Treatment
. O

Eruptive I-Effect
epidermoid I-Effect
cysts I-Effect
resulting I-Adverse_event.Trigger
from O
treatment O
with O
imiquimod I-Treatment.Drug
. O

Carbamazepine I-Treatment.Drug
- O
related I-Adverse_event.Trigger
hyponatremia I-Effect
following O
cardiopulmonary O
bypass O
. O

Fulminant I-Effect
hepatic I-Effect
failure I-Effect
is O
a O
rare O
complication I-Adverse_event.Trigger
of O
disulfiram I-Treatment.Drug
treatment O
for O
alcoholism I-Treat_Disorder
. O

Implications O
: O
Clinicians O
should O
be O
aware O
of O
the O
possibility O
of O
increased I-Adverse_event.Trigger
toxicity I-Effect
of O
ropivacaine I-Treatment.Combination.Drug
when O
used O
together O
with O
inhibitors I-Treatment.Combination.Drug
of I-Treatment.Combination.Drug
CYP1A2 I-Treatment.Combination.Drug
. O

Evidence O
obtained O
indicated O
that O
the O
Reye I-Effect
- I-Effect
like I-Effect
syndrome I-Effect
might O
be O
caused I-Adverse_event.Trigger
by O
calcium I-Treatment.Drug
hopantenate I-Treatment.Drug
possibly O
due O
to O
the O
induction O
of O
pantothenic O
acid O
deficiency O
. O

Hepatopathy I-Effect
subsided I-Effect
after I-Adverse_event.Trigger
the O
cessation I-Dosage
of O
carbamazepine I-Treatment.Combination.Drug
and O
lynestrenol I-Treatment.Combination.Drug
. O

This O
article O
presents O
a I-Subject
patient I-Subject
with I-Subject
hypoparathyroidism I-Treat_Disorder
who O
was O
treated O
with O
calcium I-Treatment.Combination.Drug
carbonate I-Treatment.Combination.Drug
and I-Treatment
calcitriol I-Treatment.Combination.Drug
resulting I-Adverse_event.Trigger
in O
two I-Effect
admissions I-Effect
to I-Effect
the I-Effect
hospital I-Effect
for I-Effect
milk I-Effect
- I-Effect
alkali I-Effect
syndrome I-Effect
. O

Recurrent I-Effect
hyponatremia I-Effect
associated I-Adverse_event.Trigger
with O
citalopram I-Treatment.Drug
and I-Treatment
mirtazapine I-Treatment.Drug
. O

A O
case O
report O
of O
a I-Effect
sharp I-Effect
rise I-Effect
in I-Effect
International I-Effect
Normalized I-Effect
Ratio I-Effect
( I-Effect
INR I-Effect
) I-Effect
values I-Effect
during I-Adverse_event.Trigger
a I-Subject
patient I-Subject
's O
concomitant I-Treatment
use I-Treatment
of I-Treatment
warfarin I-Treatment.Combination.Drug
and I-Treatment
the I-Treatment
antineoplastic I-Treatment
agent I-Treatment
vismodegib I-Treatment.Combination.Drug
is O
presented O
. O

In O
this O
report O
we O
described O
a I-Subject
case I-Subject
of I-Subject
juvenile I-Subject.Age
idiopathic I-Treat_Disorder
arthritis I-Treat_Disorder
patient I-Subject
who O
developed I-Adverse_event.Trigger
thymic I-Effect
enlargement I-Effect
( I-Effect
true I-Effect
thymic I-Effect
hyperplasia I-Effect
) I-Effect
, I-Effect
mediastinal I-Effect
lymphadenopathy I-Effect
and I-Effect
pleurisy I-Effect
associated I-Effect
with I-Effect
systemic I-Effect
symptoms I-Effect
under O
Etanercept I-Treatment.Drug
treatment O
. O

A I-Subject
52 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
woman I-Subject.Gender
developed I-Adverse_event.Trigger
symmetric I-Effect
sensorimotor I-Effect
polyneuropathy I-Effect
and O
cerebellar I-Effect
syndrome I-Effect
after O
24 I-Time_elapsed
months I-Time_elapsed
of O
amiodarone I-Treatment.Drug
treatment O
. O

The O
case O
of O
a I-Subject
patient I-Subject
under I-Treatment
tibolone I-Treatment.Combination.Drug
therapy I-Treatment
for O
two O
years O
who O
developed I-Adverse_event.Trigger
a I-Effect
mixed I-Effect
- I-Effect
type I-Effect
liver I-Effect
injury I-Effect
with I-Effect
prolonged I-Effect
cholestasis I-Effect
and I-Effect
features I-Effect
of I-Effect
the I-Effect
vanishing I-Effect
bile I-Effect
duct I-Effect
syndrome I-Effect
following O
a I-Treatment
ten I-Treatment.Duration
weeks I-Treatment.Duration
treatment I-Treatment
with I-Treatment
St. I-Treatment
John I-Treatment
wort I-Treatment
( I-Treatment
Hypericum I-Treatment.Combination.Drug
Perforatum I-Treatment.Combination.Drug
) I-Treatment
infusions I-Treatment.Route
is O
reported O
. O

OBJECTIVE O
: O
To O
report O
a O
case O
of O
a O
diffuse I-Effect
papular I-Effect
eruption I-Effect
following I-Adverse_event.Trigger
treatment O
of O
psoriasis I-Treat_Disorder
with O
methotrexate I-Treatment.Drug
injections I-Treatment.Route
. O

Prolonged O
severe O
5 I-Treatment.Drug
- I-Treatment.Drug
fluorouracil I-Treatment.Drug
- O
associated I-Adverse_event.Trigger
neurotoxicity I-Effect
in O
a I-Subject
patient I-Subject
with I-Subject
dihydropyrimidine I-Treat_Disorder
dehydrogenase I-Treat_Disorder
deficiency I-Treat_Disorder
. O

Life I-Effect
- I-Effect
threatening I-Effect
interstitial I-Effect
lung I-Effect
disease I-Effect
associated I-Adverse_event.Trigger
with O
trastuzumab I-Treatment.Drug
: O
case I-Subject
report O
. O

Thalidomide I-Treatment.Drug
neuropathy I-Effect
is O
often O
associated I-Adverse_event.Trigger
with O
proximal I-Effect
weakness I-Effect
and O
may O
progress O
even O
after O
discontinuation O
of O
treatment O
, O
in O
the O
phenomenon O
of O
' O
coasting O
' O
. O

RESULTS O
: O
Our O
patient I-Subject
developed I-Adverse_event.Trigger
Crohn I-Effect
's I-Effect
disease I-Effect
while O
on O
Copaxone I-Treatment.Drug
treatment O
as O
a O
consequence O
of O
long I-Effect
- I-Effect
term I-Effect
immunosuppression I-Effect
. O

Acute I-Effect
vision I-Effect
loss I-Effect
after I-Adverse_event.Trigger
intravitreal I-Treatment.Route
injection I-Treatment.Route
of I-Treatment
bevacizumab I-Treatment.Drug
( I-Treatment
avastin I-Treatment
) I-Treatment
associated O
with O
ocular I-Effect
ischemic I-Effect
syndrome I-Effect
. O

Development O
of O
persistent I-Effect
late I-Effect
onset I-Effect
asthma I-Effect
following I-Adverse_event.Trigger
treatment O
with O
captopril I-Treatment.Drug
. O

Herein O
, O
we O
describe O
a I-Subject
patient I-Subject
with I-Subject
AIDS I-Subject.Sub_Disorder
who O
presented I-Adverse_event.Trigger
to O
medical I-Effect
attention I-Effect
with I-Effect
pancytopenia I-Effect
48 I-Treatment.Duration
months I-Treatment.Duration
postchemotherapy I-Treatment
with I-Treatment
etoposide I-Treatment.Combination.Drug
, I-Treatment
prednisone I-Treatment.Combination.Drug
, I-Treatment
vincristine I-Treatment.Combination.Drug
, I-Treatment
cyclophosphamide I-Treatment.Combination.Drug
, I-Treatment
doxorubicin I-Treatment.Combination.Drug
, I-Treatment
and I-Treatment
rituximab I-Treatment.Combination.Drug
( I-Treatment
R I-Treatment
- I-Treatment
EPOCH I-Treatment
) I-Treatment
for O
diffuse I-Treat_Disorder
large I-Treat_Disorder
B I-Treat_Disorder
- I-Treat_Disorder
cell I-Treat_Disorder
lymphoma I-Treat_Disorder
. O

However O
, O
prolongation I-Effect
of I-Effect
5 I-Effect
- I-Effect
FU I-Effect
half I-Effect
- I-Effect
life I-Effect
and I-Effect
an I-Effect
increase I-Effect
in I-Effect
INR I-Effect
have O
been O
reported I-Adverse_event.Trigger
with O
the I-Treatment
concurrent I-Treatment
use I-Treatment
of I-Treatment
5 I-Treatment.Combination.Drug
- I-Treatment.Combination.Drug
FU I-Treatment.Combination.Drug
and I-Treatment
warfarin I-Treatment.Combination.Drug
. O

Graves I-Effect
' I-Effect
hyperthyroidism I-Effect
following I-Effect
transient I-Effect
thyrotoxicosis I-Effect
during I-Adverse_event.Trigger
interferon I-Treatment.Drug
therapy O
for O
chronic I-Treat_Disorder
hepatitis I-Treat_Disorder
type I-Treat_Disorder
C. I-Treat_Disorder

We O
report O
a O
case O
of O
acute I-Effect
generalized I-Effect
exanthematous I-Effect
pustulosis I-Effect
( I-Effect
AGEP I-Effect
) I-Effect
in O
a I-Subject
50 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
woman I-Subject.Gender
that O
was O
attributed I-Adverse_event.Trigger
to O
the O
ingestion I-Treatment.Route
of I-Treatment
nimesulide I-Treatment.Drug
. O

This O
case O
demonstrates O
the O
value O
of O
DWI O
in O
evaluation O
and O
diagnosis O
of O
sub I-Effect
- I-Effect
acute I-Effect
toxic I-Effect
leukoencephalopathy I-Effect
in I-Adverse_event.Trigger
patients I-Subject
being O
treated O
with O
methotrexate I-Treatment.Drug
. O

We O
report O
the O
first O
histopathologically O
documented O
case O
of O
oral I-Effect
mucosa I-Effect
pigmentation I-Effect
after O
OLP I-Treat_Disorder
treatment I-Adverse_event.Trigger
with O
topical I-Treatment.Route
tacrolimus I-Treatment.Drug
. O

Progressive I-Effect
hypoxemia I-Effect
mandated O
endotracheal O
intubation O
1 I-Time_elapsed
week I-Time_elapsed
after I-Adverse_event.Trigger
rituximab I-Treatment.Drug
administration I-Treatment
and O
led I-Effect
to I-Effect
death I-Effect
4 O
weeks O
after O
admission O
. O

Angiotensin I-Treatment.Drug
converting I-Treatment.Drug
enzyme I-Treatment.Drug
blockers I-Treatment.Drug
and O
their O
influence O
on O
the O
endothelial O
dysfunction O
, O
but O
the O
risk O
of O
hyperpotassemia I-Effect
are O
showed I-Adverse_event.Trigger
. O

This O
is O
the O
first O
report O
of O
a O
fatal O
outcome O
from O
serotonin I-Effect
toxicity I-Effect
, O
precipitated I-Adverse_event.Trigger
by O
an O
interaction O
between O
methylene I-Treatment.Combination.Drug
blue I-Treatment.Combination.Drug
and O
venlafaxine I-Treatment.Combination.Drug
. O

A O
helicoidal O
CT O
scan O
showed O
diffuse I-Effect
and I-Effect
severe I-Effect
interstitial I-Effect
pneumonitis I-Effect
, O
and O
lung O
biopsy O
confirmed O
accelerated I-Effect
usual I-Effect
interstitial I-Effect
pneumonia I-Effect
consistent O
with O
drug I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
toxicity I-Effect
. O

We O
report O
a O
case O
of O
severe O
hypotension I-Effect
associated I-Adverse_event.Trigger
with O
intravenous I-Treatment.Route
valproate I-Treatment.Drug
used O
to O
treat O
status I-Treat_Disorder
epilepticus I-Treat_Disorder
in O
an I-Subject
11 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
girl I-Subject.Gender
. O

Relief I-Potential_therapeutic_event.Trigger
by O
naloxone I-Treatment.Drug
of O
morphine I-Treat_Disorder
- I-Treat_Disorder
induced I-Treat_Disorder
spasm I-Treat_Disorder
of I-Treat_Disorder
the I-Treat_Disorder
sphincter I-Treat_Disorder
of I-Treat_Disorder
Oddi I-Treat_Disorder
in O
a O
post I-Subject
- I-Subject
cholecystectomy I-Subject
patient I-Subject
. I-Subject

Relief O
by O
naloxone O
of O
morphine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
spasm I-Effect
of I-Effect
the I-Effect
sphincter I-Effect
of I-Effect
Oddi I-Effect
in O
a O
post I-Subject
- I-Subject
cholecystectomy I-Subject
patient I-Subject
. I-Subject

The O
results O
of O
the O
ultrasound O
examination O
combined O
with O
clinical O
anamnesis O
allowed O
diagnosis O
of O
gastric I-Effect
mucosa I-Effect
foveolar I-Effect
hyperplasia I-Effect
due I-Adverse_event.Trigger
to O
prolonged I-Treatment.Duration
PGE1 I-Treatment.Drug
therapy I-Treatment
. O

To O
our O
knowledge O
, O
no O
prior O
cases O
of O
penicillamine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
TTP I-Effect
in O
RA O
have O
been O
reported O
. O

Alternating I-Effect
sinus I-Effect
rhythm I-Effect
and I-Effect
intermittent I-Effect
sinoatrial I-Effect
block I-Effect
induced I-Adverse_event.Trigger
by O
propranolol I-Treatment.Drug
. O

The O
noted O
increase I-Effect
in I-Effect
the I-Effect
theophylline I-Effect
level I-Effect
after I-Adverse_event.Trigger
zafirlukast I-Treatment.Drug
administration I-Treatment
is O
in O
contrast O
to O
the O
original O
reports O
by O
the O
manufacturer O
. O

The O
cause O
is O
presumed O
to O
be O
secondary O
to O
hypercoagulability O
due O
to O
asparaginase I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
antithrombin I-Effect
III I-Effect
deficiency I-Effect
. O

Troglitazone I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
fulminant I-Effect
hepatic I-Effect
failure I-Effect
. O

A I-Subject
sixty I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
woman I-Subject.Gender
with I-Subject
advanced I-Treat_Disorder
breast I-Treat_Disorder
cancer I-Treat_Disorder
, I-Subject
previously I-Subject
treated I-Subject
with I-Subject
cisplatin I-Subject
, O
developed I-Adverse_event.Trigger
an I-Effect
irreversible I-Effect
lethal I-Effect
renal I-Effect
failure I-Effect
with I-Effect
anuria I-Effect
, O
the I-Treatment.Time_elapsed
day I-Treatment.Time_elapsed
after I-Treatment.Time_elapsed
5 I-Treatment.Dosage
g I-Treatment.Dosage
/ I-Treatment.Dosage
m2 I-Treatment.Dosage
bolus I-Treatment
ifosfamide I-Treatment.Drug
. O

With O
the O
negative O
viral O
serologies O
, O
the O
clinical O
picture O
was O
most O
consistent O
with O
an O
infectious I-Effect
mononucleosis I-Effect
- I-Effect
like I-Effect
syndrome I-Effect
produced I-Adverse_event.Trigger
by O
the O
minocycline I-Treatment.Drug
ingestion I-Treatment.Route
. O

High I-Effect
- I-Effect
grade I-Effect
endometrial I-Effect
stromal I-Effect
sarcoma I-Effect
after I-Adverse_event.Trigger
tamoxifen I-Treatment.Drug
therapy O
for O
breast I-Treat_Disorder
cancer I-Treat_Disorder
. O

We O
report O
here O
two O
cases O
of O
dyserythropoietic I-Effect
anaemia I-Effect
associated I-Adverse_event.Trigger
with O
long I-Treatment.Duration
- I-Treatment.Duration
term I-Treatment.Duration
linezolid I-Treatment.Drug
use O
that O
share O
striking O
similarities O
to O
chloramphenicol O
- O
associated O
myelotoxicity O
. O

Dipyrone I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
granulocytopenia I-Effect
: O
a I-Subject
case I-Subject
for O
awareness O
. O

We O
report O
the O
case O
of O
a I-Subject
patient I-Subject
with I-Subject
chronic I-Treat_Disorder
hepatitis I-Treat_Disorder
C I-Treat_Disorder
infection I-Treat_Disorder
who O
developed I-Adverse_event.Trigger
severe I-Effect
anaemia I-Effect
during O
antiviral O
treatment O
with O
peginterferon I-Treatment.Combination.Drug
alfa I-Treatment.Combination.Drug
/ I-Treatment
ribavirin I-Treatment.Combination.Drug
when O
oseltamivir I-Treatment.Combination.Drug
was O
added O
to O
treat O
influenza I-Treat_Disorder
. O

Both I-Subject
patients I-Subject
were O
then O
treated O
with O
a O
carboplatin I-Treatment.Drug
alternative O
to O
cisplatin O
in O
the O
following O
courses O
, O
which O
resulted I-Potential_therapeutic_event.Trigger
in O
neither I-Effect
a I-Effect
relapse I-Effect
of I-Effect
the I-Effect
colitis I-Treat_Disorder
nor I-Effect
a I-Effect
recurrence I-Effect
of I-Effect
the I-Effect
malignancies I-Treat_Disorder
up O
to O
this O
time O
. O

It O
is O
rare O
to O
develop I-Adverse_event.Trigger
simultaneous O
toxicities I-Effect
while O
on O
anticonvulsants I-Treatment.Drug
. O

Because O
of O
serious O
side O
effects O
of O
an O
increase I-Adverse_event.Trigger
in O
the O
QT I-Effect
interval I-Effect
causing I-Effect
torsades I-Effect
de I-Effect
pointes I-Effect
, O
dofetilide I-Treatment.Drug
must O
be O
initiated O
with O
close O
monitoring O
of O
the O
QT O
interval O
in O
an O
inpatient O
setting O
. O

It O
should O
be O
emphasized O
that O
the O
recurrence O
of O
nephrotic I-Effect
syndrome I-Effect
was O
observed O
after I-Adverse_event.Trigger
the O
following O
chemotherapy I-Treatment
, I-Treatment
including I-Treatment
M I-Treatment.Drug
- I-Treatment.Drug
CSF I-Treatment.Drug
, O
whereas O
the I-Effect
bone I-Effect
marrow I-Effect
still I-Effect
remained I-Effect
completely I-Effect
remitted I-Effect
. O

We O
present O
a I-Subject
patient I-Subject
with I-Subject
human I-Subject.Sub_Disorder
immunodeficiency I-Subject.Sub_Disorder
virus I-Subject.Sub_Disorder
infection I-Subject.Sub_Disorder
under O
treatment O
with O
foscarnet I-Treatment.Drug
for O
CMV I-Treat_Disorder
retinitis I-Treat_Disorder
who O
complained I-Adverse_event.Trigger
of O
thirst I-Effect
and I-Effect
polyuria I-Effect
. O

This O
represents O
the O
first O
report O
of O
nonconvulsive I-Effect
status I-Effect
epilepticus I-Effect
induced I-Adverse_event.Trigger
by O
ifosfamide I-Treatment.Drug
. O

BACKGROUND O
: O
Headaches I-Effect
have O
been O
reported O
as O
a O
potential O
side O
effect O
of I-Adverse_event.Trigger
capecitabine I-Treatment.Drug
therapy O
. O

When O
DSCG I-Treatment.Drug
was I-Treatment
withdrawn I-Treatment
, O
urticaria I-Effect
vanished I-Effect
and O
the I-Subject
child I-Subject.Age
remained I-Potential_therapeutic_event.Trigger
symptom I-Effect
- I-Effect
free I-Effect
. O

Hepatotoxic I-Effect
effects I-Effect
in O
a I-Subject
child I-Subject.Age
receiving I-Adverse_event.Trigger
valproate I-Treatment.Combination.Drug
and I-Treatment
carnitine I-Treatment.Combination.Drug
. O

We O
report O
a I-Subject
case I-Subject
of O
Graves I-Effect
' I-Effect
hyperthyroidism I-Effect
induced I-Adverse_event.Trigger
by O
long I-Treatment.Time_elapsed
- I-Treatment.Time_elapsed
term I-Treatment.Time_elapsed
interferon I-Treatment.Drug
( I-Treatment
IFN I-Treatment
) I-Treatment
therapy I-Treatment
. O

Bleomycin I-Treatment.Combination.Drug
and I-Treatment
cyclophosphamide I-Treatment.Combination.Drug
toxicity I-Treatment
simulating I-Adverse_event.Trigger
metastatic I-Effect
nodules I-Effect
to I-Effect
the I-Effect
lungs I-Effect
in O
childhood I-Subject.Age
cancer I-Treat_Disorder
. O

The I-Subject
patient I-Subject
presented I-Adverse_event.Trigger
with O
fulminant I-Effect
microangiopathic I-Effect
hemolytic I-Effect
anemia I-Effect
and I-Effect
thrombocytopenia I-Effect
within I-Treatment
48 I-Treatment.Time_elapsed
hr I-Treatment.Time_elapsed
of I-Treatment
initiating I-Treatment
therapy I-Treatment
with I-Treatment
trimethoprim I-Treatment.Combination.Drug
- I-Treatment
sulfamethoxazole I-Treatment.Combination.Drug
. O

Pneumocystis I-Effect
pneumonia I-Effect
should O
be O
considered O
in O
asthmatic I-Treat_Disorder
patients I-Subject
taking I-Adverse_event.Trigger
methotrexate I-Treatment.Drug
who O
present O
with O
fever I-Effect
, I-Effect
pulmonary I-Effect
infiltrates I-Effect
, I-Effect
and I-Effect
hypoxia I-Effect
. O

Acute I-Effect
respiratory I-Effect
distress I-Effect
syndrome I-Effect
after I-Adverse_event.Trigger
rituximab I-Treatment.Drug
infusion I-Treatment.Route
. O

CONCLUSION O
: O
Gemcitabine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
recall I-Effect
pneumonitis I-Effect
is O
a O
rarely O
reported O
phenomenon O
and O
should O
be O
taken O
into O
account O
even O
after O
extended O
time O
interval O
to O
the O
previous O
radiotherapy O
. O

In O
a I-Subject
61 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
man I-Subject.Gender
receiving O
chronic I-Treatment
low I-Treatment.Dosage
- I-Treatment.Dosage
dosage I-Treatment.Dosage
amiodarone I-Treatment.Drug
an O
interstitial I-Effect
pneumopathy I-Effect
was O
observed I-Adverse_event.Trigger
. O

A I-Subject
75 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
man I-Subject.Gender
developed I-Adverse_event.Trigger
bilateral I-Effect
lower I-Effect
leg I-Effect
edema I-Effect
6 I-Treatment.Drug
months I-Treatment.Drug
after I-Treatment
switching I-Treatment
from I-Treatment
troglitazone I-Treatment.Drug
to I-Treatment
pioglitazone I-Treatment.Drug
. O

An I-Effect
acute I-Effect
ischaemic I-Effect
event I-Effect
associated I-Adverse_event.Trigger
with O
the O
use O
of O
venlafaxine I-Treatment.Drug
: O
a I-Subject
case I-Subject
report O
and O
proposed O
pathophysiological O
mechanisms O
. O

Oseltamivir I-Treatment.Drug
was O
effective O
for O
post I-Potential_therapeutic_event.Trigger
- I-Potential_therapeutic_event.Trigger
exposure I-Potential_therapeutic_event.Trigger
prophylaxis I-Potential_therapeutic_event.Trigger
of O
H1N1 I-Treat_Disorder
in O
close O
contact O
. O

Herein O
, O
we O
present O
a I-Subject
patient I-Subject
with O
severe I-Effect
and I-Effect
prolonged I-Effect
hypoglycemia I-Effect
after I-Adverse_event.Trigger
long I-Treatment
- I-Treatment
acting I-Treatment
octreotide I-Treatment.Drug
treatment I-Treatment
. O

Worsening I-Effect
pneumonitis I-Effect
due I-Adverse_event.Trigger
to I-Adverse_event.Trigger
a O
pharmacokinetic I-Treatment
drug I-Treatment
- I-Treatment
drug I-Treatment
interaction I-Treatment
between I-Treatment
everolimus I-Treatment.Combination.Drug
and I-Treatment
voriconazole I-Treatment.Combination.Drug
in O
a I-Subject
renal I-Treat_Disorder
transplant I-Treat_Disorder
patient I-Subject
. O

Vocal I-Effect
cord I-Effect
paralysis I-Effect
as O
a O
consequence I-Adverse_event.Trigger
of O
peritonsillar I-Treatment.Route
infiltration I-Treatment.Route
with I-Treatment
bupivacaine I-Treatment.Drug
. O

The O
sulfonamides I-Treatment.Drug
are O
the O
best O
verified O
drug I-Adverse_event.Trigger
- I-Adverse_event.Trigger
trigger I-Adverse_event.Trigger
for O
erythema I-Effect
multiforme I-Effect
and I-Effect
Stevens I-Effect
- I-Effect
Johnson I-Effect
syndrome I-Effect
. O

Edema I-Effect
associated I-Adverse_event.Trigger
with O
ibuprofen I-Treatment.Drug
therapy O
. O

A I-Subject
patient I-Subject
is I-Subject
presented I-Subject
with I-Subject
typical I-Treat_Disorder
hyperthyroidism I-Treat_Disorder
, O
who O
developed O
a O
severe I-Effect
proximal I-Effect
muscle I-Effect
weakness I-Effect
and I-Effect
a I-Effect
raised I-Effect
creatine I-Effect
phosphokinase I-Effect
after I-Adverse_event.Trigger
treatment I-Treatment
for I-Treatment
hyperthyroidism I-Treatment.Treat_Disorder
with I-Treatment
propylthiouracil I-Treatment.Drug
( I-Treatment
100 I-Treatment.Dosage
mg I-Treatment.Dosage
orally I-Treatment.Route
, I-Treatment
three I-Treatment.Freq
times I-Treatment.Freq
a I-Treatment.Freq
day I-Treatment.Freq
) I-Treatment
. O

Atorvastatin I-Treatment.Drug
is O
the O
most I-Effect
potent I-Effect
of O
this O
class O
of O
agents O
currently O
available O
and O
is O
commonly O
used O
in O
the O
treatment I-Potential_therapeutic_event.Trigger
of O
hyperlipidemia I-Treat_Disorder
. O

However O
, O
there O
are O
few O
reports O
in O
the O
literature O
of O
ampicillin I-Treatment.Drug
as O
a O
cause I-Adverse_event.Trigger
of O
acute I-Effect
interstitial I-Effect
nephritis I-Effect
. O

Optic I-Effect
neuropathy I-Effect
in O
ethambutol I-Treatment.Drug
- O
treated I-Adverse_event.Trigger
renal I-Treat_Disorder
tuberculosis I-Treat_Disorder
. O

This O
case O
study O
describes O
an O
atypical O
case O
of O
refractory O
, O
sodium I-Treatment.Drug
warfarin I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
necrotizing I-Effect
fasciitis I-Effect
and I-Effect
myonecrosis I-Effect
. O

OBJECTIVE O
: O
To O
report O
a I-Subject
case I-Subject
of O
possible O
foscarnet I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
severe I-Effect
hypomagnesemia I-Effect
and I-Effect
other I-Effect
electrolyte I-Effect
disorders I-Effect
. O

However O
, O
the O
occurrence O
and O
management O
of O
akathisia I-Effect
induced I-Adverse_event.Trigger
by O
fluvoxamine I-Treatment.Drug
have O
not O
been O
described O
. O

Nephrotic I-Effect
syndrome I-Effect
associated I-Adverse_event.Trigger
with I-Adverse_event.Trigger
interferon I-Treatment.Drug
- I-Treatment.Drug
beta I-Treatment.Drug
- I-Treatment.Drug
1b I-Treatment.Drug
therapy I-Treatment
for O
multiple I-Treat_Disorder
sclerosis I-Treat_Disorder
. I-Treat_Disorder

OBSERVATIONS O
: O
A I-Subject
48 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
woman I-Subject.Gender
presented O
with O
disfiguring I-Effect
facial I-Effect
edema I-Effect
10 I-Treatment.Time_elapsed
weeks I-Treatment.Time_elapsed
after I-Adverse_event.Trigger
she O
began O
antiviral I-Treatment
therapy I-Treatment
with I-Treatment
peginterferon I-Treatment.Combination.Drug
alfa I-Treatment.Combination.Drug
- I-Treatment.Combination.Drug
2a I-Treatment.Combination.Drug
and I-Treatment
ribavirin I-Treatment.Combination.Drug
for O
chronic I-Treat_Disorder
hepatitis I-Treat_Disorder
C I-Treat_Disorder
infection I-Treat_Disorder
. O

Two I-Subject.Population
of I-Subject
these I-Subject
patients I-Subject
, O
who O
also O
received O
the O
anti I-Treatment
- I-Treatment
emetic I-Treatment
prochlorperazine I-Treatment.Drug
, O
lost I-Effect
consciousness I-Effect
for I-Effect
48 I-Effect
- I-Effect
72 I-Effect
h I-Effect
and I-Effect
then I-Effect
fully I-Effect
recovered I-Effect
. O

We O
present O
a O
depressive I-Treat_Disorder
patient I-Subject
who O
developed I-Adverse_event.Trigger
mild I-Effect
parkinsonian I-Effect
signs I-Effect
and I-Effect
camptocormia I-Effect
after O
the O
introduction I-Treatment
of I-Treatment
olanzapine I-Treatment.Drug
. O

The O
case O
report O
discussed O
is O
, O
to O
our O
knowledge O
, O
the O
third O
of O
its O
kind O
regarding O
bone I-Effect
fluorosis I-Effect
resulting O
from O
use I-Adverse_event.Trigger
of O
this O
nicotinic I-Treatment.Drug
derivative I-Treatment.Drug
. O

We O
report O
a O
case O
of O
Thrombotic I-Effect
Thrombocytopenic I-Effect
Purpura I-Effect
occurring O
as O
an O
allergic I-Effect
response I-Effect
to I-Adverse_event.Trigger
trimethoprim I-Treatment.Combination.Drug
- I-Treatment
sulfamethoxazole I-Treatment.Combination.Drug
therapy O
( O
Bactrim O
, O
Septra O
) O
in O
a O
Jehovah I-Subject
's I-Subject
Witness I-Subject
patient I-Subject
. O

A I-Subject
25 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
white I-Subject.Race
woman I-Subject.Gender
with I-Subject
chronic I-Treat_Disorder
depression I-Treat_Disorder
was O
treated I-Potential_therapeutic_event.Trigger
with O
venlafaxine I-Treatment.Combination.Drug
150 I-Treatment.Dosage
mg I-Treatment.Dosage
/ I-Treatment.Dosage
d I-Treatment.Dosage
and I-Treatment
trimipramine I-Treatment.Combination.Drug
50 I-Treatment.Dosage
mg I-Treatment.Dosage
/ I-Treatment.Dosage
d I-Treatment.Dosage
. O

A I-Subject
31 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
female I-Subject.Gender
developed I-Adverse_event.Trigger
multiple I-Effect
episodes I-Effect
of I-Effect
grand I-Effect
mal I-Effect
seizures I-Effect
after O
combination I-Treatment
chemotherapy I-Treatment
with I-Treatment
cisplatin I-Treatment.Combination.Drug
, I-Treatment
vinblastine I-Treatment.Combination.Drug
and I-Treatment
bleomycin I-Treatment.Combination.Drug
for O
germ I-Treat_Disorder
cell I-Treat_Disorder
ovarian I-Treat_Disorder
cancer I-Treat_Disorder
stage I-Treat_Disorder
Ic I-Treat_Disorder
. O

Nephrogenic I-Effect
diabetes I-Effect
insipidus I-Effect
and I-Effect
renal I-Effect
tubular I-Effect
acidosis I-Effect
secondary I-Adverse_event.Trigger
to O
foscarnet I-Treatment.Drug
therapy O
. O

PURPOSE O
: O
Topiramate I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
angle I-Effect
- I-Effect
closure I-Effect
glaucoma I-Effect
( I-Effect
TiACG I-Effect
) I-Effect
is O
believed O
to O
be O
related O
to O
its O
sulfonamide O
moiety O
. O

These O
toxicities O
resolved O
after O
the O
cessation O
of O
anticonvulsants O
, O
and O
her O
seizures I-Treat_Disorder
were O
managed I-Potential_therapeutic_event.Trigger
acutely O
with O
scheduled O
lorazepam I-Treatment.Drug
. O

This O
article O
reports O
the O
occurrence O
of O
rifampin I-Treatment.Drug
- O
associated I-Adverse_event.Trigger
thrombocytopenia I-Effect
in O
an I-Subject
indigent I-Subject
patient I-Subject
after I-Treatment
a I-Treatment
four I-Treatment.Time_elapsed
- I-Treatment.Time_elapsed
month I-Treatment.Time_elapsed
lapse I-Treatment
in I-Treatment
therapy I-Treatment
for I-Treatment
pulmonary I-Treatment.Treat_Disorder
tuberculosis I-Treatment.Treat_Disorder
. O

Drug O
- O
induced I-Adverse_event.Trigger
psychosis I-Effect
resulted I-Effect
from O
the O
administration I-Treatment
of I-Treatment
quinacrine I-Treatment.Drug
hydrochloride I-Treatment.Drug
at I-Treatment
a I-Treatment
dosage I-Treatment
of I-Treatment
100 I-Treatment.Dosage
mg I-Treatment.Dosage
twice I-Treatment.Freq
daily I-Treatment.Freq
for O
the O
treatment O
of O
discoid I-Treat_Disorder
lupus I-Treat_Disorder
. O

We O
report O
a I-Subject
case I-Subject
of O
a I-Effect
scleroderma I-Effect
- I-Effect
like I-Effect
reaction I-Effect
induced I-Adverse_event.Trigger
by O
long I-Treatment.Duration
- I-Treatment.Duration
term I-Treatment.Duration
administration I-Treatment
of I-Treatment
UFT I-Treatment.Drug
. O

We O
report O
four I-Population
cases O
of O
hemodynamically I-Effect
significant I-Effect
pericardial I-Effect
effusion I-Effect
in I-Adverse_event.Trigger
patients O
with O
refractory I-Treat_Disorder
lymphoma I-Treat_Disorder
who O
were O
receiving O
gemcitabine I-Treatment.Drug
, O
all O
of O
whom O
had I-Subject
a I-Subject
history I-Subject
of I-Subject
mediastinal I-Subject.Sub_Disorder
radiation I-Subject.Sub_Disorder
without I-Subject.Sub_Disorder
subcarinal I-Subject.Sub_Disorder
blocking I-Subject.Sub_Disorder
. O

Both I-Subject.Population
had I-Subject
impaired I-Treat_Disorder
lung I-Treat_Disorder
function I-Treat_Disorder
and I-Subject
abnormal I-Subject.Sub_Disorder
computed I-Subject.Sub_Disorder
tomographic I-Subject.Sub_Disorder
scans I-Subject.Sub_Disorder
, O
and O
their O
condition O
improved I-Potential_therapeutic_event.Trigger
when O
nitrofurantoin I-Treatment.Drug
was I-Treatment
withdrawn I-Treatment
and I-Treatment
corticosteroid I-Treatment.Drug
treatment I-Treatment
commenced I-Treatment
. O

OBJECTIVE O
: O
The O
purpose O
of O
this O
study O
was O
to O
report O
the O
concomitant O
occurrence O
of O
multiple I-Effect
squamous I-Effect
cell I-Effect
carcinomas I-Effect
and I-Effect
diffuse I-Effect
nail I-Effect
hyperpigmentation I-Effect
associated I-Adverse_event.Trigger
with O
hydroxyurea I-Treatment.Drug
treatment O
, O
and O
to O
describe O
a O
successful O
therapeutic O
approach O
using O
imiquimod O
5 O
% O
. O

We O
present O
a O
case O
report O
of O
a I-Subject
patient I-Subject
who O
developed O
a O
prolonged I-Effect
QT I-Effect
while O
being O
treated I-Adverse_event.Trigger
with O
oral I-Treatment.Route
methadone I-Treatment.Drug
for O
a O
chronic I-Treat_Disorder
pain I-Treat_Disorder
syndrome I-Treat_Disorder
. O

In O
this O
article O
, O
we O
describe O
a I-Subject
Japanese I-Subject.Race
patient I-Subject
with O
severe I-Effect
interstitial I-Effect
pneumonia I-Effect
probably O
caused I-Adverse_event.Trigger
by O
sorafenib I-Treatment.Drug
treatment O
for O
metastatic I-Treat_Disorder
renal I-Treat_Disorder
cell I-Treat_Disorder
carcinoma I-Treat_Disorder
. O

Neurotoxicity I-Effect
occurs I-Adverse_event.Trigger
most O
often O
with O
intermittent I-Treatment
high I-Treatment.Dosage
dose I-Treatment.Dosage
5 I-Treatment.Drug
- I-Treatment.Drug
FU I-Treatment.Drug
as I-Treatment
bolus I-Treatment
injection I-Treatment.Route
or I-Treatment
24 I-Treatment
- I-Treatment
to I-Treatment
48 I-Treatment
- I-Treatment
h I-Treatment
infusions I-Treatment.Route
. O

Lovastatin I-Treatment.Drug
also O
reportedly O
has O
caused I-Adverse_event.Trigger
increases I-Effect
in I-Effect
INR I-Effect
when O
coadministered O
with O
warfarin O
. O

Pravastatin I-Treatment.Combination.Drug
does O
not O
appear O
to O
interact O
with O
warfarin O
but O
has O
caused I-Adverse_event.Trigger
an O
increased I-Effect
INR I-Effect
when O
combined I-Treatment
with I-Treatment
the I-Treatment
anticoagulant I-Treatment.Combination.Drug
fluindione I-Treatment.Combination.Drug
. O

Bromocriptine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
schizophrenia I-Effect
. O

Pulmonary I-Effect
toxicity I-Effect
associated I-Adverse_event.Trigger
with O
erlotinib I-Treatment.Drug
. O

Multicentric I-Effect
hepatocellular I-Effect
carcinoma I-Effect
following I-Adverse_event.Trigger
phosphate I-Treatment.Drug
diethylstilbestrol I-Treatment.Drug
therapy O
for O
prostatic I-Treat_Disorder
cancer I-Treat_Disorder
. O

Rapid O
onset O
of O
quetiapine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
diabetic I-Effect
ketoacidosis I-Effect
in O
an I-Subject
elderly I-Subject.Age
patient I-Subject
: O
a O
case O
report O
. O

A O
57 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
woman I-Subject.Gender
developed I-Adverse_event.Trigger
pulmonary I-Effect
sarcoidosis I-Effect
during O
therapy O
with O
interferon I-Treatment.Drug
beta I-Treatment.Drug
for I-Treatment
advanced I-Treatment.Treat_Disorder
renal I-Treatment.Treat_Disorder
cell I-Treatment.Treat_Disorder
carcinoma I-Treatment.Treat_Disorder
metastatic I-Treatment.Treat_Disorder
to I-Treatment.Treat_Disorder
mediastinal I-Treatment.Treat_Disorder
lymph I-Treatment.Treat_Disorder
nodes I-Treatment.Treat_Disorder
. O

Mesalamine I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
hypersensitivity I-Effect
pneumonitis I-Effect
. O

A I-Subject
girl I-Subject.Gender
with I-Subject
cystic I-Subject.Sub_Disorder
fibrosis I-Subject.Sub_Disorder
and I-Subject
cyclic I-Treat_Disorder
neutropenia I-Treat_Disorder
developed I-Adverse_event.Trigger
an O
erythematous I-Effect
papular I-Effect
eruption I-Effect
without I-Effect
fever I-Effect
or I-Effect
neutrophilia I-Effect
7 I-Treatment.Time_elapsed
months I-Treatment.Time_elapsed
after I-Treatment
commencing I-Treatment
therapy I-Treatment
with I-Treatment
G I-Treatment.Drug
- I-Treatment.Drug
CSF I-Treatment.Drug
. I-Treatment

Lichen I-Effect
planus I-Effect
and I-Effect
acne I-Effect
provoked I-Adverse_event.Trigger
by O
gold I-Treatment.Drug
. O

To O
the O
best O
of O
our O
knowledge O
only O
two O
previous O
cases O
of O
AML I-Effect
have O
been O
linked I-Adverse_event.Trigger
to O
treatment O
of O
HCL I-Treat_Disorder
with O
purine I-Treatment
analogs I-Treatment
, I-Treatment
both I-Treatment
with I-Treatment
2 I-Treatment.Drug
- I-Treatment.Drug
chlorodeoxyadenosine I-Treatment.Drug
. O

There O
are O
no O
previous O
reports O
in O
the O
literature O
about O
the O
emergence O
of O
CML I-Effect
during I-Adverse_event.Trigger
treatment I-Treatment
with I-Treatment
hydroxyurea I-Treatment.Drug
. O

Intravenous I-Treatment.Route
valproate I-Treatment.Drug
associated I-Adverse_event.Trigger
with O
significant I-Effect
hypotension I-Effect
in O
the O
treatment O
of O
status I-Treat_Disorder
epilepticus I-Treat_Disorder
. O

Torsade I-Effect
de I-Effect
pointes I-Effect
associated I-Adverse_event.Trigger
with O
moxifloxacin I-Treatment.Drug
: O
a O
rare O
but O
potentially O
fatal O
adverse O
event O
. O

We O
report O
serious I-Effect
adverse I-Effect
effects I-Effect
due I-Adverse_event.Trigger
to I-Adverse_event.Trigger
interaction I-Treatment
between I-Treatment
orally I-Treatment.Route
administered I-Treatment
voriconazole I-Treatment.Combination.Drug
and I-Treatment
everolimus I-Treatment.Combination.Drug
in O
a I-Subject
renal I-Subject.Sub_Disorder
transplant I-Subject.Sub_Disorder
recipient I-Subject
. O

Horner I-Effect
's I-Effect
syndrome I-Effect
and I-Effect
demyelinating I-Effect
peripheral I-Effect
neuropathy I-Effect
caused I-Adverse_event.Trigger
by O
high I-Treatment.Dosage
- I-Treatment.Dosage
dose I-Treatment.Dosage
cytosine I-Treatment.Drug
arabinoside I-Treatment.Drug
. O

Fatal O
radiation I-Effect
myelopathy I-Effect
after I-Adverse_event.Trigger
high I-Treatment.Dosage
- I-Treatment.Dosage
dose I-Treatment.Dosage
busulfan I-Treatment.Combination.Drug
and O
melphalan I-Treatment.Combination.Drug
chemotherapy O
and O
radiotherapy O
for O
Ewing I-Treat_Disorder
's I-Treat_Disorder
sarcoma I-Treat_Disorder
: I-Treat_Disorder
a O
review O
of O
the O
literature O
and O
implications O
for O
practice O
. O

This O
is O
the O
first O
description O
, O
to O
our O
knowledge O
, O
of O
ductopenia I-Effect
apparently O
caused I-Adverse_event.Trigger
by O
clindamycin I-Treatment.Drug
. O

Mefloquine I-Treatment.Drug
- O
associated I-Adverse_event.Trigger
hypoglycaemia I-Effect
in O
a O
cachectic I-Subject.Sub_Disorder
AIDS I-Subject.Sub_Disorder
patient I-Subject
. O

Patients I-Subject
who O
commonly O
require I-Potential_therapeutic_event.Trigger
linezolid I-Treatment.Drug
as I-Treatment
an I-Treatment
antimicrobial I-Treatment
are O
those O
with O
complex I-Treat_Disorder
infections I-Treat_Disorder
where O
other O
antibiotic O
treatment O
has O
failed O
. O

In O
three I-Subject.Population
of I-Subject
these I-Subject
patients I-Subject
the O
infection O
was O
clinically O
unsuspected O
; O
in O
the O
fourth O
, O
cutaneous I-Effect
herpes I-Effect
zoster I-Effect
developed I-Adverse_event.Trigger
after O
administration O
of O
300 I-Treatment.Dosage
mg I-Treatment.Dosage
of I-Treatment
cytarabine I-Treatment.Drug
daily I-Treatment.Freq
for I-Treatment
the I-Treatment
preceding I-Treatment.Duration
five I-Treatment.Duration
days I-Treatment.Duration
. O

Patients I-Subject
receiving O
linezolid I-Treatment.Drug
for I-Treatment
more I-Treatment
than I-Treatment
28 I-Treatment.Duration
days I-Treatment.Duration
should O
be O
monitored I-Adverse_event.Trigger
for O
signs O
of O
peripheral I-Effect
and I-Effect
optic I-Effect
neuropathy I-Effect
. O

Atrioventricular I-Sub_Disorder
block I-Sub_Disorder
complicating O
amiodarone I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
hypothyroidism I-Effect
in O
a I-Subject
patient I-Subject
with I-Subject
pre I-Subject.Sub_Disorder
- I-Subject.Sub_Disorder
excitation I-Subject.Sub_Disorder
and I-Subject
rate I-Subject.Sub_Disorder
- I-Subject.Sub_Disorder
dependent I-Subject.Sub_Disorder
bilateral I-Subject.Sub_Disorder
bundle I-Subject.Sub_Disorder
branch I-Subject.Sub_Disorder
block I-Subject.Sub_Disorder
. O

Lithium I-Treatment.Drug
is O
known O
to O
cause O
acute I-Effect
renal I-Effect
failure I-Effect
and I-Effect
tubulo I-Effect
- I-Effect
interstitial I-Effect
disease I-Effect
, O
but O
the O
recently O
described O
association I-Adverse_event.Trigger
with O
proteinuria I-Effect
or I-Effect
nephrotic I-Effect
syndrome I-Effect
is O
little O
recognized O
. O

A O
40 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
man I-Subject.Gender
with I-Subject
advanced I-Subject
HIV I-Treat_Disorder
infection I-Treat_Disorder
and I-Subject
Mycobacterium I-Treat_Disorder
avium I-Treat_Disorder
complex I-Treat_Disorder
infection I-Treat_Disorder
experienced O
rapid I-Effect
cognitive I-Effect
decline I-Effect
after I-Adverse_event.Trigger
commencement I-Treatment
of I-Treatment
ethambutol I-Treatment.Drug
, O
and O
symptoms O
fully O
resolved O
with O
cessation O
. O

Ciprofloxacin I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
hemorrhagic I-Effect
vasculitis I-Effect
is O
a O
rare O
side O
effect O
. O

Given O
that O
significant I-Effect
thyroid I-Effect
disorders I-Effect
may O
be O
only O
mildly O
symptomatic O
and O
thus O
may O
escape O
clinical O
detection O
, O
we O
suggest O
that O
thyroid O
function O
should O
be O
tested O
in O
any O
patient O
with O
otherwise O
unexplained O
changes I-Adverse_event.Trigger
in O
warfarin I-Treatment.Combination.Drug
dose O
requirements O
, O
particularly O
if O
concomitantly O
treated O
with I-Treatment
amiodarone I-Treatment.Combination.Drug
. O

Myotonia I-Effect
associated I-Adverse_event.Trigger
with O
sarcoidosis I-Subject.Sub_Disorder
: O
marked O
exacerbation I-Effect
with O
pravastatin I-Treatment.Drug
. O

This O
observation O
questions O
the O
suitability O
of O
aspirin I-Treatment.Drug
as O
prophylaxis I-Potential_therapeutic_event.Trigger
for O
vascular I-Treat_Disorder
disease I-Treat_Disorder
in O
patients I-Subject
with I-Subject
meningiomas I-Subject.Sub_Disorder
. O

Delayed I-Effect
neurotoxicity I-Effect
of I-Adverse_event.Trigger
intraventricular I-Treatment.Route
interleukin I-Treatment.Drug
- I-Treatment.Drug
2 I-Treatment.Drug
: O
a I-Subject
case I-Subject
report I-Subject
. O

We O
stress O
the O
potential O
of O
benzarone I-Treatment.Drug
to O
cause I-Adverse_event.Trigger
hepatotoxicity I-Effect
, O
which O
usually O
resembles O
severe I-Effect
chronic I-Effect
active I-Effect
hepatitis I-Effect
. O

We O
describe O
a I-Subject
patient I-Subject
with I-Subject
Wilson I-Treat_Disorder
's I-Treat_Disorder
disease I-Treat_Disorder
who I-Subject
presented I-Subject
with I-Subject
neurologic I-Subject.Sub_Disorder
disease I-Subject.Sub_Disorder
, O
was O
treated O
with O
D I-Treatment.Drug
- I-Treatment.Drug
penicillamine I-Treatment.Drug
, O
and O
suffered I-Adverse_event.Trigger
sudden I-Effect
neurologic I-Effect
deterioration I-Effect
coincident O
with O
therapy O
. O

We O
report O
the O
case O
of O
a I-Subject
21 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
female I-Subject.Gender
patient I-Subject
with I-Adverse_event.Trigger
dapsone I-Treatment.Drug
hypersensitivity I-Effect
syndrome I-Effect
. O

The O
adverse I-Effect
events I-Effect
related I-Adverse_event.Trigger
to O
ribavirin I-Treatment.Drug
and O
drug O
- O
drug O
interactions O
during O
therapy O
for O
hepatitis I-Treat_Disorder
C I-Treat_Disorder
are O
discussed O
. O

Insulin I-Effect
- I-Effect
dependent I-Effect
diabetes I-Effect
mellitus I-Effect
developed O
in O
a I-Subject
young I-Subject.Age
woman I-Subject.Gender
8 I-Treatment.Time_elapsed
weeks I-Treatment.Time_elapsed
after I-Treatment
the I-Treatment
initiation I-Treatment
of I-Treatment
danazol I-Treatment.Drug
for O
treatment O
of O
pelvic I-Treat_Disorder
endometriosis I-Treat_Disorder
. O

Four I-Subject.Age
cases I-Subject
of O
fat I-Effect
embolism I-Effect
are O
described O
in O
infants I-Subject.Age
receiving I-Adverse_event.Trigger
prolonged I-Treatment
intravenous I-Treatment.Route
infusion I-Treatment.Route
of I-Treatment
fat I-Treatment
( I-Treatment
Intralipid I-Treatment.Drug
20 I-Treatment
% I-Treatment
) I-Treatment
. O

Oral I-Route
adverse I-Effect
effects I-Effect
due I-Adverse_event.Trigger
to O
the O
use O
of O
Nevirapine I-Treatment.Drug
. O

PURPOSE O
: O
A O
case O
of O
probable O
enoxaparin I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
hepatotoxicity I-Effect
is O
described O
. O

Tizanidine I-Treatment.Drug
was O
used O
again O
after O
her O
BP O
had O
stabilized O
, O
but O
did O
not O
produce I-Adverse_event.Trigger
similar O
problems I-Effect
. O

It O
is O
suggested O
therefore O
that O
methotrexate I-Treatment.Drug
be O
added O
to O
the O
list O
of O
agents O
capable O
of O
inducing I-Adverse_event.Trigger
diffuse I-Effect
interstitial I-Effect
pulmonary I-Effect
fibrosis I-Effect
. O

The O
delayed I-Effect
encephalopathy I-Effect
developed I-Adverse_event.Trigger
9 I-Time_elapsed
and I-Time_elapsed
22 I-Time_elapsed
months I-Time_elapsed
respectively O
after O
the O
first O
dose O
of O
intrathecal I-Treatment.Route
methotrexate I-Treatment.Dosage
. O

Severe I-Effect
systemic I-Effect
hypersensitivity I-Effect
reaction I-Effect
to O
ibuprofen I-Treatment.Drug
occurring O
after I-Adverse_event.Trigger
prolonged I-Treatment.Time_elapsed
therapy I-Treatment.Time_elapsed
. O

In O
patients I-Subject
with I-Subject
chronic I-Subject.Sub_Disorder
heart I-Subject.Sub_Disorder
failure I-Subject.Sub_Disorder
, O
spironolactone I-Treatment.Drug
added O
to O
conventional O
treatment O
may O
lead I-Adverse_event.Trigger
to O
serious I-Effect
and I-Effect
, I-Effect
occasionally I-Effect
, I-Effect
fatal I-Effect
hyperkalaemia I-Effect
. O

We O
report O
a O
case O
of O
acute I-Effect
hyperphosphatemia I-Effect
secondary I-Adverse_event.Trigger
to O
rectal I-Treatment.Route
administration I-Treatment
of I-Treatment
sodium I-Treatment.Combination.Drug
phosphate I-Treatment.Combination.Drug
and I-Treatment
sodium I-Treatment.Combination.Drug
biphosphate I-Treatment.Combination.Drug
( I-Treatment
Fleet I-Treatment
enema I-Treatment
) I-Treatment
. O

Visual I-Effect
changes I-Effect
secondary I-Adverse_event.Trigger
to O
initiation O
of O
amiodarone I-Treatment.Drug
: O
a I-Subject
case I-Subject
report O
and O
review O
involving O
ocular O
management O
in O
cardiac O
polypharmacy O
. O

This O
is O
the O
first O
case O
, O
to O
our O
knowledge O
, O
of O
onset O
of O
prolonged I-Duration
infliximab I-Treatment.Drug
- O
induced I-Adverse_event.Trigger
lupus I-Effect
. O

A I-Subject
patient I-Subject
with I-Subject
developmental I-Subject.Sub_Disorder
disabilities I-Subject.Sub_Disorder
who I-Subject
had I-Subject
no I-Subject
history I-Subject
of I-Subject
movement I-Subject
disorders I-Subject
developed O
EPS I-Effect
following I-Adverse_event.Trigger
initiation I-Treatment
of I-Treatment
aripiprazole I-Treatment.Drug
. O

Case I-Subject
report O
: O
life I-Effect
- I-Effect
threatening I-Effect
hypoglycaemia I-Effect
associated I-Adverse_event.Trigger
with O
sulfadoxine I-Treatment.Drug
- I-Treatment.Drug
pyrimethamine I-Treatment.Drug
, O
a O
commonly O
used O
antimalarial O
drug O
. O

Diphenhydramine I-Drug
- I-Treat_Disorder
induced I-Treat_Disorder
wide I-Treat_Disorder
complex I-Treat_Disorder
dysrhythmia I-Treat_Disorder
responds O
to I-Potential_therapeutic_event.Trigger
treatment I-Treatment
with I-Treatment
sodium I-Treatment.Drug
bicarbonate I-Treatment.Drug
. O

Prenatal I-Effect
cytomegalovirus I-Effect
( I-Effect
CMV I-Effect
) I-Effect
infection I-Effect
associated I-Effect
with I-Effect
severe I-Effect
brain I-Effect
damage I-Effect
was O
detected O
in O
an I-Subject
infant I-Subject.Age
whose I-Subject
mother I-Subject
had I-Subject
been I-Subject
treated I-Subject
with I-Subject
prednisolone I-Treatment.Combination.Drug
and I-Treatment
azathioprine I-Treatment.Combination.Drug
for I-Subject
systemic I-Subject
lupus I-Subject
erythematosus I-Subject
( I-Subject
SLE I-Subject
) I-Subject
. O

Methotrexate I-Treatment.Drug
may O
rarely O
provoke I-Adverse_event.Trigger
serositis I-Effect
, O
even O
with O
low O
doses O
and O
after O
just O
a O
few O
weeks O
of O
therapy O
. O

Prescription O
analyses O
by O
pharmacists O
and O
literature O
research O
have O
permitted O
us O
to O
suggest O
that O
a O
drug O
- O
drug O
interaction O
between O
methotrexate I-Treatment.Combination.Drug
and I-Treatment
proton I-Treatment.Combination.Drug
pump I-Treatment.Combination.Drug
inhibitors I-Treatment.Combination.Drug
( I-Treatment.Combination.Drug
PPI I-Treatment.Combination.Drug
) I-Treatment.Combination.Drug
was O
responsible I-Adverse_event.Trigger
for O
this O
renal I-Effect
failure I-Effect
. O

Asthma I-Effect
and I-Effect
urticaria I-Effect
during I-Adverse_event.Trigger
disodium I-Treatment.Drug
cromoglycate I-Treatment.Drug
treatment I-Treatment
. O

We O
suggest O
that O
the O
previous O
classification O
of O
nitrofurantoin I-Treatment.Drug
induced I-Adverse_event.Trigger
lung I-Effect
injury I-Effect
into O
" O
acute O
" O
and O
" O
chronic O
" O
injury O
is O
an O
oversimplification O
in O
view O
of O
the O
wide O
variety O
of O
pathological O
entities O
that O
have O
subsequently O
emerged O
. O

Hepatitis I-Effect
with I-Effect
bridging I-Effect
fibrosis I-Effect
and I-Effect
reversible I-Effect
hepatic I-Effect
insufficiency I-Effect
in O
a I-Subject
woman I-Subject.Gender
with I-Subject
rheumatoid I-Treat_Disorder
arthritis I-Treat_Disorder
taking I-Adverse_event.Trigger
methotrexate I-Treatment.Drug
. O

Primary I-Effect
CNS I-Effect
lymphoma I-Effect
regressed I-Potential_therapeutic_event.Trigger
on O
withdrawal I-Treatment
of I-Treatment
MM I-Treatment.Drug
. O

Pemphigus I-Effect
foliaceus I-Effect
induced I-Adverse_event.Trigger
by O
rifampicin I-Treatment.Drug
. O

L I-Treatment.Drug
- I-Treatment.Drug
T4 I-Treatment.Drug
stimulated I-Adverse_event.Trigger
lymphocyte I-Effect
transformation I-Effect
in O
this I-Subject
patient I-Subject
. O

A I-Subject
53 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
man I-Subject.Gender
developed O
lower I-Effect
leg I-Effect
edema I-Effect
4 I-Treatment.Time_elapsed
weeks I-Treatment.Time_elapsed
after I-Treatment
rosiglitazone I-Treatment.Drug
was I-Treatment
increased I-Treatment
from I-Treatment
4 I-Treatment
mg I-Treatment
once I-Treatment
/ I-Treatment
day I-Treatment
to I-Treatment
4 I-Treatment.Dosage
mg I-Treatment.Dosage
twice I-Treatment.Freq
/ I-Treatment.Freq
day I-Treatment.Freq
. O

A I-Subject
mentally I-Subject.Sub_Disorder
retarded I-Subject.Sub_Disorder
23 I-Subject.Age
- I-Subject.Age
year I-Subject.Age
- I-Subject.Age
old I-Subject.Age
woman I-Subject
with I-Subject
myoclonic I-Treat_Disorder
astatic I-Treat_Disorder
epilepsy I-Treat_Disorder
developed O
an O
abnormal I-Effect
posture I-Effect
of I-Effect
extreme I-Effect
forward I-Effect
flexion I-Effect
, I-Effect
called I-Effect
camptocormia I-Effect
, I-Effect
during I-Adverse_event.Trigger
valproate I-Treatment.Drug
monotherapy O
. O

After I-Time_elapsed
5 I-Treatment.Time_elapsed
days I-Treatment.Time_elapsed
of I-Treatment
treatment I-Treatment
with I-Treatment
IL I-Treatment.Drug
- I-Treatment.Drug
2 I-Treatment.Drug
, O
the O
patient I-Subject
developed I-Adverse_event.Trigger
a I-Effect
hemorrhagic I-Effect
lesion I-Effect
that I-Effect
progressed I-Effect
to I-Effect
toxic I-Effect
epidermal I-Effect
necrolysis I-Effect
, I-Effect
as I-Effect
well I-Effect
as I-Effect
grade I-Effect
4 I-Effect
pancytopenia I-Effect
. O

Acute I-Effect
pancreatitis I-Effect
after I-Adverse_event.Trigger
long I-Treatment.Time_elapsed
- I-Treatment.Time_elapsed
term I-Treatment.Time_elapsed
5 I-Treatment.Drug
- I-Treatment.Drug
aminosalicylic I-Treatment.Drug
acid I-Treatment.Drug
therapy I-Treatment
. O
